<SEC-DOCUMENT>0001590750-23-000002.txt : 20230309
<SEC-HEADER>0001590750-23-000002.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309072403
ACCESSION NUMBER:		0001590750-23-000002
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viridian Therapeutics, Inc.\DE
		CENTRAL INDEX KEY:			0001590750
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				471187261
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36483
		FILM NUMBER:		23718184

	BUSINESS ADDRESS:	
		STREET 1:		203 CRESCENT STREET
		STREET 2:		BLDG. 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		617.272.4600

	MAIL ADDRESS:	
		STREET 1:		203 CRESCENT STREET
		STREET 2:		BLDG. 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIRAGEN THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20170213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIRAGEN THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20170213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SIGNAL GENETICS, INC.
		DATE OF NAME CHANGE:	20140710
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vrdn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a,d:d5b8a3a67e4b4120aef8023d2c3721ae--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:vrdn="http://www.viridiantherapeutics.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrdn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF80LTEtMS0xLTY0NjE0_44d08031-211a-433a-95ad-2c9d58ece6b1">0001590750</ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF82LTEtMS0xLTY0NjE0_ada5add7-149e-4f15-93b2-a51b69f27e65">false</ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF83LTEtMS0xLTY0NjE0_271b5101-b436-4710-b389-a85b58b8cfe5">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF84LTEtMS0xLTY0NjE0_674f5e5d-74d5-4be9-b1e5-c0b6a433770a">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF85LTEtMS0xLTY0NjE0_7ad0a5c4-0e08-4834-a219-cb6a5b64b49f">Viridian Therapeutics, Inc./DE</ix:nonNumeric><ix:nonNumeric contextRef="iecdf32196c3b49e9a21b4456f68dc18a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i369f8afef8e64303909112080068f0af_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjM_e8ea74a0-3f88-44a4-a851-a40562034c1a">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMzg_22c5afc1-2efb-427c-a693-1ae037736565">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrdn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b03f6820f64be1a5cf5d792fdee0ec_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4bddb80bbec7433dba39aa163dc3a5dd_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369f8afef8e64303909112080068f0af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if05bfdb09f134543bd371b54e8ca91a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9442e34fd9c44319d656358b37cacf1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d116b0d685d4c0892407cdf68ea7473_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i778249cf6ce9418b9ad4f911c7d378a8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0d47b55d5c4d7a86368dd7a7fe9210_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f4e2c253814d9993e96053bae40a2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33717d39c2943d388f869ebe747c1e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1bba44fa4d4b6e9380aceefcb77a8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i895af20035af46daa806cd54af1820ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa992c0e8b04d0ba561866e5ddc5c70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae0b71a3dbf4614b433002bcd8498cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie244e1d6bb534436961dc38a043ef711_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9fcc60a60e445c8f1795104a6c46f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib443f38e5cd2438c9634efcd8b2278ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6c2ed89fed4622a2d2aa7172d7f416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aed7cceb62b4b92bc8ed6ec984f2319_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39fb3692ca914421afc3d247f7d8cca4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35723f52a2d4347be6c1269abb323a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb583c45106b4818a232ee9c4ad39c58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86c28f6cc424ce98bea0a4a97eddb90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d6b724a9464b29ae68552713b5ed42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id337e30fdc0349c4816ac5a494a9223d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2d086c62db415b86b0a9d226c455d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4425cde974494cabb81ce893b56b8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e57058fb77d4e7fbf5cb93719753578_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2267406c415407baff04941844c5d1b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i508999d2a2594110b99007f534be4af5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25983ef470214368ab0eea4aa4373a8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789f9857a6f441e3aa1e17f4094afaf7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2335da7e52874d249a90521b0fd87ab1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0451fea21364299a740c764817cf380_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0397e407cad54193ab35946350fff184_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ab3fa116a44b7da15ac250754235b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id58d19c7f26d4ebd88665ae0a8aa7f16_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e66c30a3694f1299adfc4cecaa2744_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c84830c57044151be9237f1a7dd891b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca19cad32d5468a88da45e616c993ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14703c6fcd204cf4bb4d52313293b090_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c66a163e074d75953188a31b49a161_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d69f24ee32425883b5fb4906e7848c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6153c8d6ca7244fcaaa83b242bba2e18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95cffa740f64b68af86df3f770a0b25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0697651628c4404996864ee40e782d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a876722929249349e7f7da5272ce756_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdf32196c3b49e9a21b4456f68dc18a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14e5a6aafc64ee685e4abf45a236d64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vrdn:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib6eb1090043441ef956275d1fb66e81c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cdd597646b44d52894aecdbad5728ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28384390d13f43e5b84481e6b9381841_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319fa86bec5d4b28816c65ae30472b0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib504c0d9b1b1464ca139986003bd5108_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cdcc30d49604c4f8a177a5ad2200579_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9356ff5b031a4687b1c762d67b77aa89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i138932474f284b93a8c0a3f2ea051590_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f9db3f0dd54baab1199f7f903a42f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf415c64ea54fffaef87bbacbad114c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17544d63b7e4808a4b8208d12cb2e71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d2676e80164d798e781f7504896a1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie994cb889acc4540af7bc488619bb148_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68f4338d1f44253b074041654004af8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2795e5bc63324d8692234b45f12d6e89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495cfb882143496ab5fafbfd845fc230_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7a54bdbf734a5f8559bb31501853dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1ec5d1cd14648b2a0cb3409d8481901_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb2d53f432d49a28a93868e1b8234d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e890918a65f47ea962c20bc52a3a589_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718d62966309427ab5d15be792791b49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f92b6bed324e2ba85a9852abf1b187_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a6d117211af41a28fb359bb1d81d933_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie418b540ddec4d8f9a908bc68dd410e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39731739ccb24de699b33ec24511466f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife91bebf75fa462f9dc8efd8e9e15192_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00032c150d7b4b26b67be5b777d07453_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb7acaf82d94261b8bbef9198fb5b9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397518dae3854f5aaf22291b12e28fbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0e75e0c7604e9682a93b1b039078c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b087108fec4701a4a2c61e0717f2a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e20b79c6ce409d9f6ade1210e3b210_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c21147b36794bedbd9fc27467dd2076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569d7eb69fb147f7a599cb9ed5033a75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica72868174974c239b1ad5f7a2786253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa2353ccf1b493a906749cc46971b22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd00d8f83ece4bb8bf16db7bf032c030_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf96050c9b204ae3a4dc0d09a8f89a45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2493b7d3e6f54fc4aca64c1b7e756944_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7237ef7f504c42ac91f4cd23a2e8f7d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic661c528426d40a4a7f6ff953d525bbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962c21f5667a48bead2b497aa2cc2efb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f6583aa4bf42c9b1b52633f83d14a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia25cc2ffa9f144a88bb763f938333daf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a117538c9041aebcee41fd26d43947_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558bf4d01982457597bb849567a66261_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia959ee789f0d49838e929580701a3357_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2828cb09ac024bbeb97dcdad08208d79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad844ce133a4439b89b3b712bcebe2fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb8a885c6c2471aac42e78a2b6716e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>vrdn:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iee91adf567604cd2aa42b110e5fac7af_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5068b8f88948444a8959f2c27cf864e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5106586991db467b98afa08d33f637c0_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bf3ab4aa3946a18532afb870802102_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ae605e448441d3a3f0ac5f55eca328_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0659d7dc0d044cddb185ec3b557387ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5e9943af7844ce9cf70397131daf9b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a42fb2ee584e7ca4c08ef5f57c78d4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50bf97251614e40ab675969431f996b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i021c11dfe09a4127921884ad1fc46e9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84d62946a994027b63085a509c4d878_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b67fa0e69554ec68418419f8b40c77e_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i124a3275b5a440f5acff5df5308106be_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf8bb4484b14487a716974ff915120a_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0808833c084902820bea4f3472d32b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa3a835940b42d39eb93c3ed98a799e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46a9b2c111841f28563bace994e0980_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf6615de6694ae69368169bef73730a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_term"><xbrli:measure>vrdn:renewal_term</xbrli:measure></xbrli:unit><xbrli:context id="ic802c0b9ae6945e4a39732c93b32f251_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f669c23fa44047a98623dceb3ec78b_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0728b5d899440094213edef06f750b_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1aef7c7506834b01bc927bc477344c11_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8403d7b138f480f8845cd9631fed10a_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id838e3d9eb3e439aae39d4378ce4ba61_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>vrdn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i3b72d2965ee0434c841cfb9e8258e086_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8b414d79224c589b4f8171dc32086e_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7803c980e7e94395b6662e71bdb21d08_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia279525ba3464bb3bd46c39083223a69_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if928b497323f4aa09bdc2a799e98f2d8_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0137f42d4153427eba19af3131416b54_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfedb0c338d24c7fb89b19d4dc8f497d_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60581c1fe5a94b06a7f4dbec809547b3_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf90d2e59564c068859bfb9affa9e2d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79b5053076944fa8214003d886b1ba3_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd1e3cfaeeb44ec8b6e9c11e444058e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af72201586744fbb2c99adcce15b017_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb9991b56694a0faf0dc09579f73d81_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4be6ccd9ad4885a999915b4b0caed6_D20211101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe4499fee034827abde9a07a164e945_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86483928bea44016893e50c31509dba0_D20191201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eac05f69eb14abb936aff1bddd334b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad687f93f544b899dde34ad1e484822_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sale_price"><xbrli:measure>vrdn:sale_price</xbrli:measure></xbrli:unit><xbrli:context id="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba8d787738a4d90b399133c72c646a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b9550134c5468b8fd0e59a39c182ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128e797bb49d4cd88ed84383f99ec141_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i606007a11a244c8c8b02f58f219ee3cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb45543c55a341d59828621ace35f8e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d5a529d15d48ca9f86845a914722f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ef63c34dae44f0853d1416aa2f882e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife09cc8c10c94dc8996beb13848ad137_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaeea194517f4499b35939e81a5d9621_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d62a34b1b4a4f5e9b01227f00998027_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd6f20f151aa4c638e38a93431710146_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89382e3a327947c289b5183a9f74f852_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied23b327864a44a984dcfb100731b721_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3974d6a34a904cfb85456eb0420ddb31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc204ff96984e1783d7a194c6f1ac47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f880652d2a4b6798eccdac2488595d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdadfb509ff40919c0cab248bd849e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b41fe046b334a039198964438e80c98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d7ad7937f2e4f1a815947ffda355a35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0930912c457940afaf6c32b75e459522_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id35aece8bbc142a1911840a29f94d84d_D20160101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35dd0d5868d3450181c2d16f2687ac92_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6738e86aeb641cfb7e9e094c2fc4c6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b73a1e80a44f5590d1cc32f390331b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6eac4ba1e8146d09bc0d4159bb00c0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65916045213f4b35b8eaac7d9d7c38f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49abc6a01de84a36bc043c40f8227f10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29536a69b2634ac49eb9828516064751_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a030fb15c14da49fde0862e7c27a2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697a762fdb594a17ba1c80bc48028a56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e4eeddfa014778a51d0845f779bd05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd090a1fac43479584a8c5f526d77264_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087f0a8b9f354a148b61f301862025db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie575904542f4433e911075dd3974f021_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd65cfed6004a6e9be4b0f521ae67ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041bd935d0394bcb91d5976137df8830_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA4_6bf13a90-0ac6-4200-a3ce-6bf511ce2a83">10-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk0_8ab359c8-b38b-4978-9526-4ac82f56855a">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yMTM_83c6db10-cd71-4fc3-9bad-60e5447de495"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yMTM_d63f5aba-e3bd-4984-8395-b6050a8f2261">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzkw_9842e365-9405-47d8-bb69-a16f290bd7ab">&#9744;</ix:nonNumeric> &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from&#160;to </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number&#160;<ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzkx_7155c7be-f41b-448d-8fda-bbe858b6c162">001-36483</ix:nonNumeric></span></div><div style="text-align:center"><img src="vrdn-20221231_g1.jpg" alt="vrdn-20221231_g1.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OWQxOThkZGY1NGY0NGNkMGJiMjdmNzI3OTI3YjNmNDAvdGFibGVyYW5nZTo5ZDE5OGRkZjU0ZjQ0Y2QwYmIyN2Y3Mjc5MjdiM2Y0MF8wLTAtMS0xLTY0NjE0_60a1241d-5990-410e-821f-6a7e526c0cee">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OWQxOThkZGY1NGY0NGNkMGJiMjdmNzI3OTI3YjNmNDAvdGFibGVyYW5nZTo5ZDE5OGRkZjU0ZjQ0Y2QwYmIyN2Y3Mjc5MjdiM2Y0MF8wLTItMS0xLTY0NjE0_f99c18ff-ba51-4608-867f-70efadad26e4">47-1187261</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA5_76e03e4c-b407-4554-b081-884e00aad615">221 Crescent Street, Suite 401</ix:nonNumeric>, <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODEw_f44cca91-25be-4f12-98a0-1a24decbfbe3">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODEz_67023e9e-c51d-44e1-8dae-224878299f99">MA</ix:nonNumeric> <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk1_b9ec36ff-b1ee-4c23-b7f3-c32cd2a0a2a2">02453</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODE0_ade761dd-66ab-4aca-8ca9-97a32f37501b">(617)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODE1_d58cb2ab-4d56-4797-acab-e5ce3278d074">272-4600</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTAtMS0xLTY0NjE0_699535da-3d4e-4ab1-b0e3-81261a0208ea">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTEtMS0xLTY0NjE0_0d28555d-b32e-4326-a152-2330c795ad28">VRDN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTItMS0xLTY0NjE0_8556dfc1-5754-4cc0-8961-bc2c7adf84b3">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section&#160;12(g) of the Act: None</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk2_e62c1729-9fbd-419b-9677-c9ea62718cf1">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODAx_5b77d173-e73e-4571-b352-880013107450">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA2_d9d8cd4f-e08a-4f13-a22b-288dd5505e3b">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744; </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk3_6edaca73-93c3-4092-82a3-07591f73f49f">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No &#9744; </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18xLTAtMS0xLTY0NjE0_a118754a-0928-4a50-9785-58dfcaf66944">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18xLTMtMS0xLTY0NjE0_80641ea0-3af3-4c79-a57d-082d44bf30cd">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18yLTMtMS0xLTY0NjE0_e021b5d7-db43-4eb3-99cf-4ab9b393c225">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:7pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODAy_7f86306c-3738-42f6-84fc-e2564aeabc5e">&#9744;</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).  Yes <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk5_4206095d-8c35-4731-9df0-227c7723783b">&#9744;</ix:nonNumeric> No</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> x</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based upon the closing sale price of the registrant&#8217;s common stock on June&#160;30, 2022, as reported on The Nasdaq Capital Market, was $<ix:nonFraction unitRef="usd" contextRef="i33b03f6820f64be1a5cf5d792fdee0ec_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yOTg5_4d785ad6-5513-4ce5-844c-597dd64a5ddd">329.3</ix:nonFraction>&#160;million. Shares of common stock held by each executive officer and director and by each person who owns 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;3, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i4bddb80bbec7433dba39aa163dc3a5dd_I20230303" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zMzMw_41368f4c-6d14-46c8-85f0-7128c931e156">42,897,951</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA3_94e42c29-7bf2-4c3a-a1b0-bb7561cb77bc" escape="true">Portions of the registrant&#8217;s definitive proxy statement for the 2023 annual meeting of shareholders (the &#8220;2023 Proxy Statement&#8221;) are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_16">ITEM 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_16">BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_19">ITEM 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_19">RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_19">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_22">ITEM 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_22">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_25">ITEM 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_25">PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_25">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_28">ITEM 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_28">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_31">ITEM 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_31">59</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_37">ITEM 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_37">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_40">ITEM 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_40">RESERVED</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_40">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_43">ITEM 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_43">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_55">ITEM 7A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_55">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_55">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_58">ITEM 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_58">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_58">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_61">ITEM 9.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_61">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_61">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_64">ITEM 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_64">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_64">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_67">ITEM 9B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_67">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_67">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_70">ITEM 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_70">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_67">68</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_76">ITEM 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_76">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_76">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_79">ITEM 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_79">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_79">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_82">ITEM 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_82">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_82">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_85">ITEM 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_85">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_85">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_88">ITEM 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_88">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_88">69</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_94">ITEM 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_94">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_94">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_100">ITEM 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_100">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_100">72</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_175">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;preliminary,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;opportunity,&#8221; &#8220;goals,&#8221; or &#8220;should,&#8221; and similar expressions are intended to identify forward-looking statements. All statements contained in this Annual Report, other than statements of historical fact are forward-looking statements. You should not unduly rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, statements relating to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future research and development activities, including clinical testing and the costs and timing thereof;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy, including clinical development of VRDN-001, VRDN-002, VRDN-003 and other product candidates, and the clinical and commercial potential of our product candidates, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our cash resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional funding when needed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any statements concerning anticipated regulatory activities or licensing or collaborative arrangements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from pandemics or other public health crises, which could cause a disruption in the development of our product candidates and adversely impact our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operations and legal risks;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any statement of assumptions underlying any of the foregoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, as described in greater detail in Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report, and under a similar heading in any other periodic or current report we may file with the Securities and Exchange Commission (&#8220;SEC&#8221;) in the future. You are advised to consult any further disclosures we make on related subjects in our Annual Reports, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our website. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Annual Report, may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise mentioned or unless the context requires otherwise, all references in this Annual Report, to &#8220;Viridian,&#8221; &#8220;Viridian Therapeutics,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar references refer to Viridian Therapeutics, Inc., and our consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_16"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Company Overview</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. We target under-competitive disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience. We believe that first-generation medicines rarely represent optimal solutions, especially in rare disease areas, and that there is potential to develop differentiated, best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, expanded market access, and augmented market competition. Our business model is designed to identify and evaluate product opportunities in disease areas where trial data establishes proof-of-concept for a drug target in the clinic, but the competitive evolution of the product life cycle management and number of entrants appears incomplete. We intend to prioritize indications where a fast-follower and a potentially differentiated drug candidate, or overall product profile, could create significant medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to identify and evaluate product concepts leveraging clinically validated molecular targets using established therapeutic modalities. We prioritize product concepts that are aligned with clinical and commercial hypotheses, which we expect will provide an attractive balance of risk and opportunity, thereby representing a compelling allocation of our resources. We focus on advancing therapeutic antibodies that we either in-license or discover internally, incorporating proprietary monoclonal antibody discovery and optimization platforms to advance clinical candidates with unique characteristics. We have built relevant expertise in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (&#8220;TED&#8221;) and other undisclosed target indications in rare and autoimmune diseases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to rapidly discovering and developing novel therapeutics relies on our scientific expertise in evaluating pre-existing clinical proof-of-concept data for the drug targets we are pursuing, and opportunities to improve upon existing investigational and/or approved therapies. This approach informs how we design, select, and develop our product candidates, including in critical areas such as pharmacokinetics, pharmacodynamics, clinical trial design, trial endpoints, and the selection and recruitment of patients. We believe this strategy reduces the risks associated with discovering and developing novel therapeutics.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initially prioritized the development of therapies for the treatment of TED, a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness. TED significantly impacts quality of life, imposing a high burden on activities of daily living and mental health for patients suffering from the disease. TED is a progressive disease consisting of an initial active phase, followed by a transition to a secondary chronic phase. The only medicine approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for TED is Tepezza&#174; (teprotumumab), which is an intravenously administered monoclonal antibody that targets insulin-like growth factor 1 receptor (&#8220;IGF-1R&#8221;). Tepezza&#174; is marketed in the United States by Horizon Therapeutics plc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results from clinical trials of teprotumumab conducted by Horizon provide strong clinical validation linking the targeting of IGF-1R to clinical benefit in patients with TED. However, clinical trials evaluating teprotumumab in patients with TED reported to date used a single dosing regimen, providing little guidance as to the optimal dosing required for clinical activity in TED. We believe that there are multiple opportunities to develop fast-follower therapeutics that improve on teprotumumab&#8217;s features, including dosing schedule and route of administration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous (&#8220;IV&#8221;) or subcutaneous administration to treat patients who suffer from TED. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment for TED. In October 2022, we presented preclinical data from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in-vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies demonstrating that VRDN-001 is a potentially differentiated full antagonist of IGF-1R, compared to teprotumumab&#8217;s incomplete antagonism of IGF-1R. In addition, the Phase 1/2 clinical data reported from all three dose cohorts of VRDN-001 in patients with active TED (n=21), showed significant and rapid improvement in both signs and symptoms of TED after two infusions of VRDN-001. Across all VRDN-001 treated patients in the trial, 71% were proptosis responders, 67% were overall responders, 62% achieved a clinical activity score (&#8220;CAS&#8221;) of 0 or 1, and 54% had complete resolution of their diplopia. VRDN-001 had a favorable safety profile and was well-tolerated by all patients treated in the three dose cohorts. We believe the data further validate the differentiated and potentially best-in-class clinical activity of VRDN-001.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we announced that we enrolled our first patient in our ongoing THRIVE Phase 3 trial (&#8220;THRIVE&#8221;) evaluating the safety and efficacy of VRDN-001 in patients with active TED. THRIVE is a double-blind, placebo-controlled, randomized study enrolling approximately 120 patients with active TED. The study participants will be randomized 1:1:1 across three arms: (1) VRDN-001 10 mg/kg administered once every three weeks for eight cycles, (2) a shortened course of VRDN-001 10 mg/kg administered once every three weeks for five cycles, and (3) a placebo arm. THRIVE will be conducted in approximately 50 centers across North America and Europe. We expect to report topline results for the THRIVE trial in the middle of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the proof-of-concept Phase 1/2 trial evaluating the safety and efficacy of VRDN-001 in patients with chronic TED is expected in the second quarter of 2023. Following the release of the data, we are planning to initiate a global Phase 3 trial in patients with chronic TED called THRIVE-2. We expect that the THRIVE and THRIVE-2 Phase 3 trials will support global health authority registration for marketing approval in both active and chronic TED, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The low-dose data of VRDN-001 in patients with active TED support the potential for VRDN-001 to also be administered as a convenient, low volume, subcutaneous pen. We plan to initiate a Phase 1 trial of subcutaneously administered VRDN-001 in healthy volunteers, with results expected in the fourth quarter of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-002, a distinct IGF-1R antibody that incorporates half-life extension technology, is designed to support administration as a convenient, low volume, subcutaneous pen injection to treat patients who suffer from TED. Data reported from the Phase 1 trial in healthy volunteers, showed that VRDN-002 achieved an extended half-life of up to 43 days. VRDN-002 had a favorable safety profile and was well-tolerated. We are currently planning a Phase 2 trial to evaluate the safety and efficacy of a low volume subcutaneous injection of VRDN-002 in patients with active TED.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001, except for the addition of the same half-life extension technology that has been incorporated into VRDN-002. We plan to submit an investigational new drug (&#8220;IND&#8221;) application for VRDN-003 with the FDA in the second quarter of 2023. Following FDA acceptance of the IND, we plan to initiate a Phase 1 trial of VRDN-003 in healthy volunteers, with results expected in the fourth quarter of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent pharmacokinetic (&#8220;PK&#8221;) modeling supports the feasibility of ongoing development of a self-administered pen for subcutaneous administration, and a planned dosing interval of up to once-monthly for VRDN-001, VRDN-002 and VRDN-003. Following clinical results expected by year-end 2023, we expect to select VRDN-001, VRDN-002 or VRDN-003 as our lead subcutaneous program to advance to a pivotal Phase 3 trial in the middle of 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developing therapies for TED, we are executing a similar strategic approach to identify opportunities to develop more convenient, better performing therapeutic candidates in other rare and/or serious disease indications. We are currently advancing three preclinical programs, VRDN-004, VRDN-005, and VRDN-006. We plan to disclose additional details around at least one of these preclinical programs in 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to create and advance new biologic medicines for patients suffering from serious and rare diseases that are underserved by today&#8217;s therapies. Key elements of our business strategy are to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Evaluate opportunities to identify, engineer, and develop potential best-in-class monoclonal antibodies that optimize patient care. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline of therapeutic programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents a patient-centric model of innovation that leverages proven biology and antibody technology to reduce research and development risk, while striving to address strategic gaps related to access, delivery, quality of life, efficacy, and/or safety and tolerability in targeted therapeutic areas. Our multidisciplinary search process evaluates scientific and clinical validation of therapeutic targets, market potential, and feasibility of efficiently developing a competitive product.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Initial clinical development and commercial focus on thyroid eye disease (TED)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Rapidly advance VRDN-001 clinical development to enter the TED market quickly. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing THRIVE Phase 3 clinical trial is a double-blind, placebo-controlled, randomized study evaluating the safety and efficacy of VRDN-001 in patients with active TED. We expect data from the ongoing Phase 1/2 proof-of concept trial evaluating VRDN-001 in patients with chronic TED in the second quarter of 2023. Following the release of the data, we are planning to initiate a global Phase 3 trial in patients with chronic TED called </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THRIVE-2. We expect that the THRIVE and THRIVE-2 Phase 3 trials will support global health authority registration for marketing approval in active and chronic TED, respectively.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Offer patients suffering from TED improved convenience and broader settings of care. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next generation IGF-1R antibodies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-002 and VRDN-003, are humanized monoclonal antibodies that incorporate half-life extension technology and are designed as a self-administered low-volume, subcutaneous pen injection for the treatment of TED. Low-dose data of VRDN-001 administered intravenously support its potential as a subcutaneous candidate. Our most recent PK modeling for VRDN-001, VRDN-002, and VRDN-003 supports a planned dosing interval of up to once-monthly. Following data expected by the end of 2023 from the ongoing clinical trials of VRDN-001, VRDN-002 and VRDN-003, we expect to select one of the programs as our lead subcutaneous product candidate by year-end 2023. We plan to advance our selected lead subcutaneous program into a pivotal Phase 3 trial in the middle of 2024.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Be a trusted partner in the care of TED patients. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to cultivate a network across TED stakeholders to inform our patient-centric</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approach, including with patients and advocacy groups, key opinion leaders, research institutions, healthcare professionals and payers.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Prepare for commercialization of the intravenously administered VRDN-001 and one of our subcutaneously administered candidates, VRDN-001, VRDN-002, or VRDN-003, for the treatment of patients with TED. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold worldwide commercialization rights, excluding the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">greater area of China, to VRDN-001, VRDN-002, and VRDN-003. As a result, we have the flexibility to develop and potentially commercialize products ourselves, or alternatively to enter collaborations with industry partners.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand our portfolio beyond TED with strategically aligned opportunities in rare and autoimmune diseases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are significant opportunities to provide more</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convenient, better performing products compared to therapeutics approved or in development for several diseases. To that end, we continue to invest in portfolio expansion and have dedicated resources to seek additional opportunities to develop best-in-class therapeutics for newly validated targets. VRDN-004, VRDN-005, and VRDN-006 are preclinical-stage therapeutic antibody programs for undisclosed rare and autoimmune diseases. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leverage our therapeutic antibody and multi-disciplinary search expertise to continue discovering and developing novel, best-in class product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to identify and advance novel product candidates and technologies to generate potential best-in-class antibody therapeutics, either internally or through in-licensing. We continue to identify and evaluate several disease targets and therapeutic candidates with the aim of advancing a steady pipeline of best-in-class product candidates from discovery and preclinical research into clinical trials.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><img src="vrdn-20221231_g2.jpg" alt="vrdn-20221231_g2.jpg" style="height:422px;margin-bottom:5pt;vertical-align:text-bottom;width:543px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Thyroid Eye Disease (TED)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TED, commonly associated with Graves&#8217; Disease, and in some cases referred to as Graves&#8217; orbitopathy, is a serious and rare autoimmune disorder affecting the eye and its adjacent tissue. It is characterized by inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness. TED is a progressive disease consisting of an initial active phase, followed by a transition to a secondary chronic phase. In the active phase of TED, patients present with several inflammatory signs and symptoms such as pain, redness, swelling, proptosis, diplopia, and eyelid retraction. The active phase is generally defined as the first 18 to 24 months of disease onset, and is typically when inflammatory signs and symptoms reach their peak levels. The second, chronic phase of TED is characterized by a reduction in some of the inflammatory signs, such as redness and swelling in the area surrounding the eye, compared to the active phase of the disease. However, proptosis, pain, diplopia, and eyelid retraction often persist throughout life for patients with chronic TED. Patients with active and chronic TED experience significant impairment to their quality of life, including difficulties activities of daily living, trouble functioning in social situations, and decreased psychological well-being. About one in every three patients experience anxiety and depression.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pathologies Leading to the Development of TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TED develops in parallel with Graves&#8217; Disease, an autoimmune disease in which antibodies form against the thyroid-stimulating hormone receptor (&#8220;TSHR&#8221;), which is present in the thyroid and other cells such as adipocytes and fibroblasts. A close temporal relationship exists between the onset of Graves&#8217; Disease and the onset of TED. Regardless of which condition occurs first, the other condition develops within 18 months in 80% of patients. In addition to antibodies against TSHR, patients with TED also develop antibodies against IGF-1R.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insulin-like growth factor 1 (&#8220;IGF-1&#8221;) is a hormone similar in molecular structure to insulin with higher growth-promoting activity. IGF-1R, the receptor for IGF-1, is highly expressed in fibrocytes, cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat cells. IGF-1R and TSHR function in concert to regulate the proliferation and differentiation of fibrocytes in the orbital socket.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One potential cause of TED is autoimmune antibodies against IGF-1R that lead to the activation of IGF-1R, resulting in increased proliferation, secretion of extracellular complex carbohydrates, and differentiation into fat cells. These antibodies, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">autoimmune antibodies to TSHR, can elicit an immune attack against the fibrocytes that surround the eye triggering the development of TED. Inflammation associated with this attack combined with activation of IGF-1R leads to the wide spectrum of pathologies seen with this disease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exposure to other inflammatory agents, such as cigarette smoke, leads to exacerbation of the disease resulting in more severe symptoms.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Treatments for TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, moderate to severe cases of TED were treated off-label with steroids as daily doses of oral prednisone, or in more severe cases, weekly doses of IV methylprednisolone. Treatment with steroids is associated with a wide range of serious complications including high blood pressure, diabetes, psychological effects, personality change, insomnia, skin thinning, immunosuppression, hyperglycemia, and increased risks of infections. Systemic steroids showed limited efficacy for most of the signs and symptoms of TED and are not a sustainable long-range intervention given the side effects. If steroid treatment proved to be inadequate, or could not be tolerated, the only remaining options for patients were orbital radiation or surgery to reduce swelling, decompress orbital contents, and protect the vision. Again, each of these therapies was incomplete and inadequate from the perspective of both patient and treating physician.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, teprotumumab, an antibody that blocks the activation of IGF-1R, was approved by the FDA for the treatment of TED. In two randomized, double-blind placebo-controlled trials, infusions of teprotumumab every three weeks, for a total of eight doses, led to a greater than 2 mm decrease in proptosis in 71% and 83% of patients, respectively, compared to 20% and 10% with placebo. Treatment with teprotumumab also led to a 53% decrease in diplopia compared to a 25% decrease when patients were treated with placebo control. Thus, the defined target and its successful blockade has been de-risked and shown to provide a clinically meaningful improvement in the quality of life for these patients, allowing them to return to the workforce and to avoid radiation therapy or orbital decompressive surgeries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Potential</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TED has an annual incidence of approximately 19 in 100,000 people, which corresponds to over 60,000 patients in the United States. Of these, it is estimated that more than 20,000 patients in the United States have moderate to severe active disease that requires IV treatment, either with teprotumumab or steroids. In the secondary chronic phase of the disease, it is estimated that more than 75,000 patients in the United States are living with moderate to severe disease. At launch, Horizon Therapeutics plc announced a price of approximately $16,300 per vial of Tepezza&#174; which translates to a list price of approximately $375,000 based on patient weight for a six-month course of therapy. In the first three years following launch, Horizon Therapeutics plc reported full-year 2020, 2021, and 2022 net sales for Tepezza&#174; of $820.0 million, $1.66 billion, and $2.0 billion, respectively, in the first three years of launch. This demonstrates that TED is a multi-billion-dollar market in the United States alone, with the potential for additional revenue in the United States with indication expansion to chronic TED and more convenient routes of administration. There is also potential for additional revenue following regulatory approvals and commercial expansion outside of the United States, which will accommodate multiple entrants.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VRDN-001, a potential best-in-class intravenously administered IGF-1R antibody</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-001 is a monoclonal antibody that binds to and is believed to act as a full antagonist of IGF-1R signaling pathway. This mechanism of action is clinically and commercially validated by the only FDA product approved for the treatment of TED, Tepezza&#174;. Based on our ongoing THRIVE trial, our goal is for VRDN-001 to be second to market in this class of medicine, with the opportunity to offer a differentiated IV product.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license to the worldwide rights to develop and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of patients with TED, from ImmunoGen. The antibody sequence that we are developing as VRDN-001 in TED had previously been developed in oncology as AVE-1642 and studied in over 100 patients. However, development in oncology was stopped in 2009 due to its failure to meet the primary efficacy endpoints in multiple myeloma. As described below, we have sublicensed the right to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China to Zenas BioPharma (Cayman) Limited.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials for VRDN-001</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 Trial of VRDN-001 in Patients with Active TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second half of 2022 and early 2023, we announced data from our Phase 1/2 clinical trial evaluating the safety and efficacy of VRDN-001 in patients with active TED. The proof-of-concept portion of this double-blind, placebo-controlled Phase 1/2 trial evaluated two infusions of VRDN-001 administered intravenously, three weeks apart, with efficacy measured six weeks after the first dose. VRDN-001 was evaluated at doses of 3, 10, and 20 mg/kg, with each cohort designed to include six patients randomized to drug, and two patients randomized to placebo. We previously announced positive results from the first two dose cohorts, which demonstrated a favorable safety profile. In January 2023, we announced results from the third cohort, which evaluated a VRDN-001 dose of 3 mg/kg with 6-week data. In the 3 mg/kg dose cohort, nine patients were randomized to receive VRDN-001 to enable all consented patients who were eligible following screening to participate in the trial, and two patients were randomized to receive placebo. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following activity was observed across all three dose groups (n=21) at week six:</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proptosis</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">71% proptosis responder rate, defined as a &#8805;2-millimeter (mm) reduction in proptosis from baseline as measured by exophthalmometry</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2.3 mm mean reduction in proptosis from baseline as measured by exophthalmometry</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2.76 mm mean reduction in proptosis from baseline as measured by blinded, centrally reviewed magnetic resonance imaging (&#8220;MRI&#8221;, preliminary data available for 16 of the 21 patients)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Activity Score (&#8220;CAS&#8221;)</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4.1 point mean reduction in CAS from baseline on a 7-point measure of signs and symptoms of TED</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">62% maximal or near-maximal therapeutic effect on CAS, defined as reaching a CAS of 0 or 1 on the 7-point composite measure of signs and symptoms of TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall response</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">67% overall responder rate, defined as a &#8805;2 mm reduction in proptosis and a &#8805;2 point reduction in CAS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diplopia</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">54% complete resolution of diplopia, defined as patients with baseline diplopia who achieved a score of 0 on the Gorman subjective diplopia scale (13 patients with diplopia at baseline)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-001 had a favorable safety profile and was well-tolerated by all patients treated in the three dose cohorts. There were no reported serious adverse events (&#8220;SAEs&#8221;), no discontinuations, and no infusion reactions in patients treated with VRDN-001 as of December 19, 2022, the most recent cut-off date for follow-up observation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Trial (THRIVE) of VRDN-001 in Patients with Active TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we enrolled our first patient in our ongoing Phase 3 THRIVE trial evaluating the safety and efficacy of VRDN-001 in patients with active TED. The THRIVE trial is a double-blind, placebo-controlled, randomized trial enrolling approximately 120 patients with active TED. The trial participants will be randomized 1:1:1 across three arms: (1) VRDN-001 10 mg/kg administered once every three weeks for eight cycles, (2) a shortened course of VRDN-001 10 mg/kg administered once every three weeks for five cycles, and (3) a placebo arm. The global THRIVE trial is expected to be conducted in approximately 50 centers across North America and Europe. We expect to report topline results for the THRIVE trial in the middle of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 Trial of VRDN-001 in Patients with Chronic TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the Phase 1/2 proof-of-concept trial evaluating the safety and efficacy of VRDN-001 in patients with chronic TED is expected in the second quarter of 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Trial (THRIVE-2) of VRDN-001 in Patients with Chronic TED</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the release of the data from our proof-of-concept trial in chronic TED, we plan to initiate a global Phase 3 trial in patients with chronic TED called THRIVE-2. We expect that the THRIVE and THRIVE-2 Phase 3 trials will support global health authority registration for marketing approval in active and chronic TED, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VRDN-001, VRDN-002 and VRDN-003, potential best-in-class subcutaneously administered IGF-1R antibodies</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-002 and VRDN-003 are next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology, designed to support administration as a self-administered low-volume, subcutaneous pen injection for the treatment of TED. The low-dose data of VRDN-001 in patients with active TED support the potential for VRDN-001 to also be administered as a convenient, low volume, subcutaneous pen. We plan to initiate a Phase 1 trial of subcutaneously administered VRDN-001 in healthy volunteers, with results expected in the fourth quarter of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-002 is a distinct antibody that acts as a partial antagonist of the IGF-1R. In 2022, we reported data from the Phase 1 trial in healthy volunteers, showing that VRDN-002 achieved a half-life of up to 43 days compared to the half-life of 10 to 11 days achieved by VRDN-001 and Tepezza in separate trials. VRDN-002 had a favorable safety profile and was well tolerated. We are currently planning to evaluate the safety and efficacy of a low-volume subcutaneous injection of VRDN-002 in patients with active TED. Results from the trial are expected by year-end 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001, except for the addition of the half-life extension technology that is incorporated in VRDN-002. We plan to submit the IND with the FDA in the second quarter of 2023. Following FDA acceptance of the IND, we plan to initiate a Phase 1 trial of VRDN-003 in healthy volunteers, we results expected in the fourth quarter of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent PK modeling supports the feasibility of ongoing development of a self-administered pen for subcutaneous administration, and a planned dosing interval of up to once-monthly for VRDN-001, VRDN-002, and VRDN-003. We expect to select VRDN-001, VRDN-002, or VRDN-003 as our lead subcutaneous program by year-end 2023. We plan to advance our selected lead subcutaneous program into a pivotal Phase 3 trial in the middle of 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, with regard to our VRDN-001, VRDN-002 and VRDN-003 product candidates, we have five pending U.S. non- provisional patent applications, three PCT applications, two foreign applications, and one provisional application directed to compositions and directed to methods of using VRDN-001, VRDN-002 and/or VRDN-003 for the treatment of TED. We wholly own one issued patent, U.S. Patent No. 11,548,951, which issued on January 10, 2023. The patent claims, among other things, are directed to methods of treating thyroid eye disease by inhibiting IGF-1R activity in a subject in need thereof with VRDN-001 or VRDN-003. The &#8216;951 patent is expected to expire no earlier than 2041, subject to any disclaimers or extensions. Any patents to issue from any pending non-provisional applications would be expected to expire no earlier than 2041, without taking potential patent term extensions or disclaimers into account.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by intense and rapidly changing competition to develop new technologies and proprietary products. Our product candidates may address multiple markets. Ultimately, the diseases our product candidates target, and for which product candidates we may receive marketing authorization, will determine our competition. We believe that for most or all of our product development programs, there will be one or more competing programs under development by other companies. Any products that we may commercialize will have to compete with existing therapies and new therapies that may become available in the future. We face potential competition from many different sources, including larger and better-funded biotechnology and pharmaceutical companies. In many cases, the companies with competing programs will have access to greater resources and expertise than we do and may be more advanced in those programs. Horizon Therapeutics plc&#8217;s Tepezza&#174; is the only FDA-approved medication for TED. Other therapies, such as corticosteroids, have been used on an off-label basis to alleviate some of the symptoms of TED. Other companies that are advancing therapies for the treatment of TED in clinical development include ACELYRIN, Inc., argenx, Harbour BioMed, Immunovant, Inc., and Sling Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ACELYRIN, INC. is developing Lonigutamab (VB-421), a subcutaneously delivered anti-IGF-1R currently being evaluated in a Phase 1 study for TED.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">argenx is developing efgartigimod (Vyvgart&#174;), an antibody fragment to target the neonatal Fc receptor (FcRn) expected to be evaluated in a registrational Phase 3 trial in patients with TED.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunovant and Harbour BioMed are developing batoclimab (IMVT-1401/HBM9161), a monoclonal antibody targeting FcRn currently being evaluated in an ongoing Phase 3 trial in patients with TED.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Sling Therapeutics, Inc. is developing linsitinib, a small molecule IGF-1R inhibitor currently be evaluated in an ongoing Phase 2b LIDS clinical trial in patients with active, moderate-to-severe TED.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Zenas BioPharma</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Viridian Therapeutics, Inc. (&#8220;Private Viridian&#8221;) entered a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. On October 27, 2020, in connection with the closing of the Private Viridian acquisition, we became party to the license agreement with Zenas BioPharma. Since February 2021, we have entered into several letter agreements with Zenas BioPharma in which we agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. The license agreement, as amended, and letter agreements (collectively, the &#8220;Zenas Agreements&#8221;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, we granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for our goods and services provided and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, we are eligible to receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, we are eligible to receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to us for the royalty term in the Zenas Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ImmunoGen, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2020, Private Viridian entered into a license agreement with ImmunoGen (the &#8220;ImmunoGen License Agreement&#8221;), under which we obtained rights to an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, we are obligated to make certain development milestone payments of up to $48.0 million. Additionally, if we successfully commercialize any product candidate subject to the ImmunoGen License Agreement, we are responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $95.0 million. We assumed the ImmunoGen License Agreement in connection with the merger with Private Viridian in 2020.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements with Xencor, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a license agreement with Xencor, Inc. (&#8220;Xencor&#8221;) (the &#8220;Xencor License Agreement&#8221;), under which Xencor granted us rights to an exclusive, worldwide, sublicensable, non-transferable, royalty-bearing license to use specified Xencor technology for the research, development, manufacturing, and commercialization of therapeutic antibodies targeting IGF-1R. In consideration for rights granted by Xencor, we issued 322,407 shares of our common stock to Xencor in December 2020. The shares were valued at $6.0&#160;million and recorded as research and development expense in 2020. Under the terms of the Xencor License Agreement, we are obligated to make future development milestone payments of up to $30.0&#160;million. Additionally, if we successfully commercialize any product candidate subject to the Xencor License Agreement, we are responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $25.0&#160;million. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a subsequent technology license agreement with Xencor (the &#8220;2021 Xencor License Agreement&#8221;) for a non-exclusive license to certain antibody libraries developed by Xencor. Under the 2021 Xencor License Agreement, we received a one-year research license to review the antibodies and the right to select up to three antibodies for further development. In consideration for rights granted by Xencor, we issued 394,737 shares of our common stock to Xencor in December 2021. The shares were valued at $7.5 million and recorded as research and development expense during the year </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December 31, 2021. Under the terms of the 2021 Xencor License Agreement, for each licensed product, we are obligated to make future milestone payments of up to $27.75 million, which includes development and regulatory milestone payments of up to $4.75 million, special milestone payments of up to $3.0 million, and commercial milestone payments of up to $20.0 million. Additionally, for each licensed product that we successfully commercialize, we are responsible for royalty payments equal to a percentage in the mid-single digits of net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an antibody and discovery option agreement with Therapeutics, Inc. (&#8220;Paragon&#8221;)  (the &#8220;Paragon Agreement&#8221;) under which we and Paragon will cooperate to develop one or more antibodies. Under the terms of the Paragon Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and we will pay Paragon agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. The Paragon Agreement stipulates a final deliverable to us comprising of a report summarizing the experiments and processes performed under the research plan (the &#8220;Final Deliverable&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Paragon agreed to grant us an option for an exclusive license to all of Paragon&#8217;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#8220;Option&#8221; and together, the &#8220;Options&#8221;). Paragon also granted us a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing us to determine whether to exercise the Option with respect to certain programs. We may, at our sole discretion, exercise the Option with respect to specified programs at any time until the date that is 90 days after the Company&#8217;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#8220;Option Period&#8221;) by delivering written notice of such exercise to Paragon. If we fail to exercise an Option prior to expiration of the applicable Option Period, such Option for such Program will terminate. In consideration for Paragon&#8217;s grant of the Options to us, we paid to Paragon a non-refundable, non-creditable one-time fee of $2.5&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, we and Paragon entered into a first amendment to the Paragon Agreement, under which we obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of $2.3&#160;million (the &#8220;First Amendment Payment&#8221;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program. During the year ended December 31, 2022, the Company recorded $5.6&#160;million in research and development costs related to the Paragon Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biologics Regulation </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the trial is commenced;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture of the proposed biologic candidate in accordance with cGMPs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;) after completion of all pivotal clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA Submission and Review </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan (&#8220;PSA&#8221;), within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Orphan Drug Designation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an New Drug Application (&#8220;NDA&#8221;) or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the marketing application fee.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the FDA established a new regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (i) the drug qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through: the submission of clinical evidence, preclinical studies, clinical trials, patient registries or other sources of real world evidence such as electronic health records; the collection of larger confirmatory datasets; or post-approval monitoring of all patients treated with the therapy prior to approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, breakthrough therapy designation, priority review and RMAT designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In May 2018, the Right to Try Act established a new regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pathway to increase access to unapproved, investigational treatments for patients diagnosed with life-threatening diseases or conditions who have exhausted approved treatment options and who are unable to participate in a clinical trial. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, 2023 strengthens the FDA&#8217;s authority to require and regulate post-approval studies of accelerated approval drugs and to expedite the rescission of accelerated approval based on these post-approval studies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Reference Product Exclusivity </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act (&#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. As of March 2020, certain products previously approved as drugs under the FDCA, such as insulin and human growth hormone, are now deemed to be biologics under the PHSA, which means they may face competition through the biosimilars pathway and are not be eligible for the twelve-year period of exclusivity granted to new BLAs. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Data Laws</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal data in the European Union (&#8220;EU&#8221;) is governed by the provisions of the European General Data Protection Regulation 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EU/European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection (including the United States). Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). On March 25, 2022, the EC and the United States announced that they have agreed in principle on a new Trans-Atlantic Data Privacy Framework. Following this statement, on October 7, 2022, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Signals Intelligence Activities&#8217;, which implemented the agreement in principle. On that basis, the EC prepared a draft adequacy decision and launched its adoption procedure. While this new EU-U.S. privacy framework is expected to enter into force in 2023, there is still some uncertainty around the new framework. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation No.536/2014 (&#8220;CTR&#8221;), European Medicines Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the EU to the United Kingdom, personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force. Additionally, following </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the GDPR, as incorporated into UK national law), the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug and Biologic Development Process</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the European EU / EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU / EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU / EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (Clinical Trials Directive) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period. EU Member States will work in CTIS immediately after the system has gone live. On January 31, 2023, submission of initial clinical trial applications via CTIS became mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new CTR, national laws, regulations, and the applicable Good Clinical Practice, or GCP, and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the European Medical Agency, or EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Marketing Authorization </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medicinal products, including advanced therapy medicinal products (&#8220;ATMPs&#8221;) are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs manufacturing and control information that should be submitted in a In the EU and EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA, through, amongst others, a centralized or decentralized procedure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Centralized Authorization Procedure</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA that is issued by the EC, following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA Member States. The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, ATMP, and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the Committee for Medicinal Products for Human Use established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Decentralized Authorization Procedure</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submitted: (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (&#8220;PSURs&#8221;) are routinely available to third parties requesting access, subject to limited redactions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MA Validity Period</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exceptional Circumstances/Conditional Approval </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Designation and Exclusivity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;), addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRIME Designation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. The FCA imposes mandatory treble damages and per-violation civil penalties up to approximately $25,000.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of Open Payments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy and Security</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, state laws govern the privacy and security of personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the CCPA, which went into effect on January 1, 2020, creates new data privacy obligations for covered companies and provides new privacy rights to California residents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Reform</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through December 31, 2020, unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. These price negotiations will begin in 2023. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that will take effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate clinical or commercial manufacturing facilities for the production of our product candidates that we develop, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all of our required raw materials, active pharmaceutical ingredients, and finished product candidates for our clinical trials. We do not have any current contractual arrangements for the manufacture of commercial supplies of our product candidates that we develop. We currently employ internal resources and third-party consultants to manage our manufacturing contractors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have relied on third-party contract development and manufacturing organizations (&#8220;CDMOs&#8221;), to manufacture and supply our preclinical and clinical materials used during the development of our product candidates. We initially pursued three separate manufacturing paths to supply investigational product for our planned clinical trials in order to mitigate delays and uncertainties. We currently rely on a single multi-site CDMO for such manufacturing, although other avenues remain available if our current manufacturer were to be negatively impacted. We maintain a long-term master services agreement with our CDMO pursuant to which the CDMO provides biologics development and manufacturing services on a per-project basis and a related cell line license. We may terminate the master services agreement at any time for convenience in accordance with the terms of the agreement. We may also terminate the master services agreement in the event that the CDMO does not obtain or maintain any material governmental license or approval in accordance with the terms of the agreement. The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We do not currently have arrangements in place for redundant supply. While any reduction or halt in supply from the CDMO could limit our ability to develop our product candidates until a replacement CDMO is found and qualified, we believe that we have sufficient supply to support our current clinical trial programs. Any reduction or halt in supply from the CDMO could limit our ability to develop our product candidates until a replacement CDMO is found and qualified, although we believe that we have supply on hand that can partially support our current clinical trial programs until a replacement CDMO is secured.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet defined our sales, marketing, or product distribution strategy for our product candidates because our product candidates are still in preclinical or early-stage clinical development. Our commercial strategy may include the use of strategic partners, distributors, a contract sale force, or the establishment of our own commercial and specialty sales force. We plan to further evaluate these alternatives as we continue to advance into later stages of development for each one of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital Management</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we employed 86 full-time employees located in the United States. During 2022, we expanded our capabilities in the organization by hiring 49 new employees. These employees were hired to support our clinical development, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical research and development, and efforts associated with operating as a public company. We consider our relationship with our employees to be good. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective bargaining arrangements. We consider our employee relations to be good. We track and report internally on key talent metrics including workforce demographics, diversity data and the status of open positions. We are committed to equality, inclusion and diversity in the workplace. As of December 31, 2022, nearly 35% of our workforce identify as members of underrepresented ethnic communities and 55% identify as female. We strive to interview diverse candidates for our open positions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attracting, developing and retaining talented employees to support the growth of our business is an integral part of our human capital strategy and critical to our long-term success. We continue to seek additions to our staff, although the competition in our industry and in the Greater Boston area, where our headquarters is located, is significant. The principal purpose of our equity incentive and annual bonus programs is to attract, retain and motivate personnel through the granting of stock-based compensation awards and cash-based performance bonus awards. As a biopharmaceutical company, we recognize the importance of access to high quality healthcare and as such we cover 100% of our employees&#8217; monthly healthcare premiums. We offer a package of competitive employee benefits, including 401(k) plan matching contributions and an employee stock purchase plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a performance development review process in which managers provide regular feedback to assist with the development of our employees, including the use of individual plans to assist with career development. We also invest in the growth and development of our employees through various training and development programs that help build and strengthen our employees&#8217; leadership and professional skills. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our management team has the experience necessary to effectively execute our strategy and advance our product and technology leadership. A large majority of our employees have obtained advanced degrees in their professions. We support our employees&#8217; further development with individualized development plans, mentoring, coaching, group training and conference attendance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were initially founded as a Delaware limited liability company in January 2010 and subsequently incorporated as a Delaware corporation in June 2014. On January 20, 2021, pursuant to a merger agreement under which miRagen Therapeutics, Inc. acquired Viridian Therapeutics, Inc., we changed our name from Miragen Therapeutics, Inc. to Viridian Therapeutics, Inc. Our common stock currently trades on The Nasdaq Capital Market under the ticker symbol &#8220;VRDN.&#8221; Our principal executive office is located at 221 Crescent Street, Suite 401, Waltham, MA 02453, and our telephone number is (617) 272-4600. Our website address is www.viridiantherapeutics.com. The information contained on, or that can be accessed through, our website is not part of this Annual Report. We have included our website in this Annual Report solely as an inactive textual reference. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are available free of charge on our website located at www.viridiantherapeutics.com as soon as reasonably practicable after they are filed with the SEC. The reports are also available at the SEC&#8217;s internet website at www.sec.gov. A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics, and the charters of the Audit Committee, Compensation Committee, and Nominative and Corporate Governance Committee are posted on our website, www.viridiantherapeutics.com, under &#8220;Corporate Governance.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_19"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. The following information should be read in conjunction with Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and related notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock risky include, among others</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. Some of our product candidates have produced results only in non-clinical settings, or for other indications than those for which we contemplate conducting development and seeking FDA approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $424.6&#160;million of cash, cash equivalents, and short-term investments. We believe that our current cash, cash equivalents and short-term investments, including the Term Loan, will be sufficient to fund our operations, including our clinical development plan described elsewhere in this Annual Report, into the second half of 2025. We will need to raise additional capital to continue to fund our operations and service our obligations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developing our product candidates requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back, or discontinue the development or commercialization of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek strategic alliances, or amend existing alliances, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">file for bankruptcy or cease operations altogether.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, operating results, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a limited operating history. We have historically incurred net losses. During the years ended December&#160;31, 2022 and 2021, net loss was $129.9&#160;million and $79.4&#160;million, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $488.2 million and cash, cash equivalents, and short-term investments of $424.6 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current cash, cash equivalents and short-term investments, including the Term Loan, will be sufficient to fund our operations, including our clinical development plan described elsewhere in this Annual Report, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We will need to raise substantial additional capital to continue to fund our operations in the future. The amount and timing of our future funding requirements will depend on many factors, including the pace, results and costs of our clinical development efforts and macroeconomic conditions affecting our business and industry. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities and convertible promissory notes and the Hercules Loan and Security Agreement. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter more advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, coverage, and adequate reimbursement from third-party payors, and adequate market share for our product candidates in those markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">continue the development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue efforts to discover and develop new product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the manufacturing of our product candidates or increase volumes manufactured by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our programs into large expensive clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional preclinical studies or clinical trials for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals and reimbursement for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire, and/or develop other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone, royalty, or other payments under third-party license agreements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain skilled personnel; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research and development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory and marketing approvals for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gaining market acceptance of our product candidates as treatment options;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for our product candidates that supports profitability; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Portions of our current pipeline of product candidates have been in-licensed from third parties, which make the commercial sale of such in-licensed products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, if the costs of manufacturing our drug product are not commercially feasible, we will need to develop or procure our drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings, and license and development agreements. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under the Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into in September 2022 (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), convertible debt, or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. In December 2019, the Company entered into a common stock purchase agreement (the &#8220;Aspire Stock Purchase Agreement&#8221;) with Aspire Capital, LLC (&#8220;Aspire Capital&#8221;). Any additional sales of our common stock under the September 2022 ATM Agreement and the Aspire Common Stock Purchase Agreement will dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease. In addition, any exercise of outstanding warrants will dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing, including under our Hercules Loan and Security Agreement, may include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our third-party research institution collaborators, contract research organizations (&#8220;CROs&#8221;), contract manufacturing operations (&#8220;CMOs&#8221;), and other contractors and consultants, could be subject to acts of war, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical pandemics or epidemics, such as the novel coronavirus, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is expensive, time consuming, and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, clinical trial sites, and in countries or regions where our trials are conducted;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining required approvals from institutional review boards or independent ethics committees at each clinical trial site;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to permit the conduct of a clinical trial by regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting eligible patients and/or subjects in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by clinical sites, CROs, or other third parties to adhere to clinical trial requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our clinical sites, CROs, or other third parties to perform in accordance with the good clinical practices requirements of the FDA or applicable foreign regulatory guidelines;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients and/or subjects dropping out of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse events or tolerability or animal toxicology issues significant enough for the FDA or other regulatory agencies to put any or all clinical trials on hold;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of adverse events associated with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs of clinical trials of our product candidates, including manufacturing activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs in other ongoing or planned indications for a product candidate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with third-party manufacturers and the time to manufacture sufficient quantities of our product candidates acceptable for use in clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, or holds on post-approval clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete clinical development and obtain regulatory approval for our product candidates could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional nonclinical studies and the results obtained from studying such new formulation may not be consistent with previous results obtained. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or terminate clinical trials. They additionally may result in a delay of regulatory approval by the FDA or comparable foreign authorities, or, even in the instance that an affected product candidate is approved, may result in a restrictive drug label.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the drug label;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a REMS, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients or subjects; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product development program may not uncover all possible adverse events that patients or subjects who take our product candidates may experience. The number of patients or subjects exposed to our product candidates and the average exposure time in the clinical development program may be inadequate to detect rare adverse events that may only be detected once the product is administered to more patients or subjects and for greater periods of time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of our product candidates will be uncovered. Such rare and severe side effects may only be uncovered with a significantly larger number of patients or subjects exposed to the drug. If such safety problems occur or are identified after our product candidates reach the market, the FDA may require that we amend the labeling of the product or recall the product or may even withdraw approval for the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our product candidates and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested substantially all of our effort and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate. We continue to evaluate and pursue additional opportunities to expand our product pipeline, either by discovering novel antibodies internally, or by acquiring rights to existing antibodies or antibody sequences. Our goal is to build a sustainable portfolio of investigational monoclonal antibody therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a limited number of product candidates. There can be no assurance that the data that we may or may not develop for our product candidates in our planned indications will be sufficiently supportive to obtain regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to market or promote any of our product candidates before they receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct well-controlled trials in our proposed indications to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety of our product candidates, with respect to the proposed indication for use, sufficient to receive regulatory approval to market our drug candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and human resources, we may forgo or delay pursuit of opportunities with some programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into additional strategic collaboration agreements to develop and commercialize some of our programs and potential product candidates in indications with potentially large commercial markets. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll and maintain patients or subjects in our clinical trials, in part due to the limited number of patients or subjects who have the diseases for which our product candidates are being studied. We cannot predict if we will have difficulty enrolling and maintaining patients or subjects in our future clinical trials. Difficulty in enrolling and maintaining patients or subjects could delay or prevent clinical trials of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients or subjects to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients or subjects to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enrollment. In addition, our enrollment has been and may in the future be delayed due to supply chain delays and difficulties in site activation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The eligibility criteria of our clinical trials may further limit the available eligible trial participants as we expect to require that patients or subjects have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical trials. Accordingly, we may not be able to identify, recruit, enroll, and maintain a sufficient number of patients or subjects to complete our future clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, the option for patients to choose alternate existing approved therapies, and the willingness of physicians to participate in our planned clinical trials. Our ability to enroll patients in our planned clinical trials may be impacted by the COVID-19 pandemic, or any future disease pandemic. If patients or subjects are unwilling or unable to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product candidates may be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trials of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product candidate development, and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our approved products, if any, or product candidates harm patients or subjects, or is perceived to harm patients or subjects even when such harm is unrelated to our approved products, if any, or product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, a material liability claim could adversely affect our financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use or misuse of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval exposes us to the risk of potential product liability claims. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. Patients with the diseases targeted by our product candidates may already be in severe and advanced stages of disease and have both known and unknown significant preexisting and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact, or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have product liability insurance, which covers our historical clinical trials in the United States, for up to $5.0 million per occurrence, up to an aggregate limit of $5.0 million, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer. We will also likely be required to increase our product liability insurance coverage for any future clinical trials that we may initiate. If we obtain marketing approval for any of our product candidates, we will need to expand our insurance coverage to include the sale of commercial products. There is no way to know if we will be able to continue to obtain product liability coverage and obtain expanded coverage, if we require it, in sufficient amounts to protect us against losses due to liability, on acceptable terms, or at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. Any product liability claim brought against us, with or without merit, could result in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial volunteers, investigators, patients or subjects, or trial sites, or limitations on approved indications;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize, or if commercialized, decreased demand for, our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if commercialized, product recalls, labeling, marketing or promotional restrictions, or the need for product modification;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial costs of litigation, including monetary awards to patients or other claimants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from our business; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation and the reputation of our products and our technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a Biologics License Application (&#8220;BLA&#8221;). The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the approval of a biologic product biosimilar to one of our product candidates could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are seeking Orphan drug designation for VRDN-001 from the FDA and may seek Orphan drug designation for future product candidates, but we might not receive such designation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed an amended application for Orphan drug designation for VRDN-001 based on clinical data. In response, the FDA has indicated that further review of the application is suspended pending receipt of additional information. There is no guarantee that upon submission of this additional data information the FDA will grant us Orphan drug designation. See &#8220;Business&#8212;Government Regulation and Product Approvals&#8212;Orphan Drug Designation.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek Breakthrough Therapy designation for one or more of our product candidates from the FDA, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation from the FDA for some of our product candidates. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one of our product candidates is designated as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for designation and the designation may be rescinded. See &#8220;Business&#8212;Government Regulation and Product Approvals&#8212;Expedited Development and Review Programs.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval in any particular timeframe or at all. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. See &#8220;Business&#8212;Government Regulation and Product Approvals&#8212;Expedited Development and Review Programs.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to obtain accelerated approval of our product candidates. If we are unable to obtain accelerated approval, we may be required to conduct clinical trials beyond those that we contemplate, or the size and duration of our pivotal clinical trials could be greater than currently planned, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining necessary marketing approvals. Even if we receive accelerated approval from the FDA, the FDA may require that we conduct confirmatory trials to verify clinical benefit. If our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-approval requirements, the FDA may seek to withdraw accelerated approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek accelerated approval for our product candidates. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. If granted, accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug&#8217;s clinical benefits relative to its risks, the FDA may withdraw its approval of the drug. If we choose to pursue accelerated approval, there can be no assurance that the FDA will agree that our proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that we will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if we initially decide to do so. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA may require us to conduct a confirmatory study to verify the predicted clinical benefit. The FDA could withdraw accelerated approval for multiple reasons, including our failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the predicted clinical benefit. A failure to obtain accelerated approval or any other form of expedited review or approval for a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm our competitive position in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, we will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials, and submission of safety, efficacy, and other post-approval information, including both federal and state requirements in the United States, and requirements of comparable foreign regulatory authorities. See &#8220;Business&#8212;Government Regulation and Product Approvals&#8212;Expedited Development and Review Programs.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the marketed product. We will be required to report adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was granted accelerated approval by the FDA, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit of our products. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval. Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products, and the value of the company and our operating results would be adversely affected. In addition, if we were able to obtain accelerated approval of any of our drug candidates, the FDA may require us to conduct a confirmatory study to verify the predicted clinical benefit. Other regulatory authorities outside of the United States may have similar requirements. The results from the confirmatory study may not support the clinical benefit, which could result in the approval being withdrawn. While operating under accelerated approval, we will be subject to certain restrictions that we would not be subject to upon receiving regular approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition, or results of operations, and current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continues to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act was passed, which was intended to substantially change the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. More recently, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), which, among other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. See &#8220;Business&#8212;Health Reform.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to foreign, federal, and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions, or other liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations may be subject to various foreign, federal, and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and Physician Payments Sunshine Act, the EU&#8217;s GDPR, and other regulations. These laws may impact, among other things, our relationships with healthcare professionals and our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. See &#8220;Business&#8212;Other Regulations.&#8221; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, disgorgement, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts, and business operations, and cause environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of personal data or personal information processing is evolving, as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of such data. We, our collaborators, and our service providers may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (e.g., laws and regulations that address data privacy and data security, including, without limitation, health data). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our collaborators to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our collaborators&#8217; ability to process or use data in order to support the provision of our products or services, affect our or our collaborators&#8217; ability to offer our products and services or operate in certain locations, cause regulators to reject, limit, or disrupt our clinical trial activities, result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or collaborators. See &#8220;Business&#8212;Other Regulations.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties, fines, or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients or subjects about whom we or our collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Any failure by our third-party collaborators, service providers, contractors, or consultants to comply with applicable law, regulations, or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities or others.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publish privacy policies and other documentation regarding our collection, processing, use, and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to potential foreign, local, state, and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Any of these matters could materially adversely affect our business, financial condition, or operational results.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our preclinical development activities and clinical trials, manufacture our product candidates, and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor, and manage preclinical and clinical programs. We rely on these parties for execution of clinical trials, and we manage and control only some aspects of their activities. We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations, and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs or vendors fail to comply with applicable laws, regulations, and guidelines, the results generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot be assured that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical trials, comply with applicable requirements. Our failure to comply with these laws, regulations, and guidelines may require us to repeat clinical trials, which would be costly and delay the regulatory approval process.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers, and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. Additionally, regional disruptions, including natural disasters or health emergencies (such as novel viruses or pandemics), could significantly disrupt the timing of clinical trials. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortages and governmental restrictions resulting from the COVID-19 pandemic may disrupt the ability of or increase the cost for our clinical trial sites and other CROs to procure items that are essential for our research and development activities, including animals that are used for preclinical studies. For example, there have been shortages of various animals used in research studies, such as several types of monkeys, which are typically sourced from China, due to the COVID-19 pandemic and disruptions to the global supply chain.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not currently have, nor do we currently plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical trials and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing process is complex and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient supply of our product candidates for future clinical trials or commercialization, if approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our biologic product candidates is complex, highly regulated, variable, and subject to numerous risks. Our manufacturing process is susceptible to product loss or failure, or product variation that may negatively impact patient outcomes, due to logistical issues associated with preparing the product for administration, infusing the patient with the product, manufacturing issues, or different product characteristics resulting from the inherent differences in starting materials, variations between reagent lots, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation or operation of equipment and/or programs, vendor or operator error and variability in product characteristics.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even minor variations in starting reagents and materials, or deviations from normal manufacturing processes could result in reduced production yields, product defects, manufacturing failure, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in any of the manufacturing facilities in which products or other materials are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure in the foregoing processes could render a batch of product unusable, could affect the regulatory approval of such product candidate, could cause us to incur fines or penalties, or could harm our reputation and that of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may make changes to our manufacturing process for various reasons, such as to control costs, increase yield or dose, achieve scale, decrease processing time, increase manufacturing success rate, or for other reasons. Changes to our process made during the course of clinical development could require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. Other changes to our manufacturing process made before or after commercialization could require us to show the comparability of the resulting product to the product candidate used in the clinical trials using earlier processes. Such showings could require us to collect additional nonclinical or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If such data are not ultimately comparable to that seen in the earlier trials or earlier in the same trial in terms of safety or efficacy, we may be required to make further changes to our process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate, which would materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and we intend to rely on third parties to produce and process our product candidates, if approved, and our commercialization of any of our product candidates could be stopped, delayed, or made less profitable if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we currently plan to develop, the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates and our current cost to manufacture our drug products may not be commercially feasible. Additionally, the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to identify manufacturers of our product candidates on acceptable terms or at all.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and some state agencies to ensure strict compliance with cGMPs and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience labor disputes or shortages, including from the effects of health emergencies (such as novel viruses or pandemics) and natural disasters.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers may be impacted by global conflicts, including any potential conflict involving China and Taiwan, and any resulting trade sanctions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, as well as the approval, if any, of our product candidates by the FDA, or the commercialization of our product candidates, or could result in higher costs, or could deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm, and this could result in product liability suits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of medical products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with production costs and yields, quality control, stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state, and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot be assured that any stability issue or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes, shortages, including from the effects of heath emergencies (such as novel viruses or pandemics) and natural disasters, or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients or subjects in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to realize the potential benefits of any collaboration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in entering into additional future collaborations with respect to the development and/or commercialization of one or more product candidates, there is no guarantee that the collaboration will be successful. Collaborations may pose a number of risks, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators often have significant discretion in determining the efforts and resources that they will apply to the collaboration and may not commit sufficient resources to the development, marketing, or commercialization of the product or products that are subject to the collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any such collaboration may significantly limit our share of potential future profits from the associated program and may require us to relinquish potentially valuable rights to our current product candidates, potential products, proprietary technologies, or grant licenses on terms that are not favorable to us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may cease to devote resources to the development or commercialization of our product candidates if the collaborators view our product candidates as competitive with their own products or product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time consuming, distracting, and expensive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the collaborations may not result in us achieving revenue to justify such transactions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for us to raise additional capital to pursue further development or commercialization of the applicable product candidate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, a collaboration may not result in the successful development or commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, we could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into commercial, service, licensing, consulting, and other agreements that contain indemnification provisions. With respect to our research agreements, we typically indemnify the party and related parties from losses arising from claims relating to the products, processes, or services made, used, sold, or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to future collaboration agreements, we may indemnify our collaborators from any third-party product liability claims that could result from the production, use, or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition, and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on patent rights, trade secret protections, and confidentiality agreements to protect the intellectual property related to our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#8217; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technologies and product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought to protect our proprietary position by filing and licensing the rights to patent applications in the United States and abroad related to our technologies and product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unresolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in such patents being narrowed, found unenforceable, or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, independently or together with our licensors, have filed patent applications covering various aspects of our product candidates and their methods of use. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection or data exclusivity, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have sufficient patent term protections for our product candidates to effectively protect our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Additional patent terms may be available through a patent term adjustment (&#8220;PTA&#8221;) process, resulting from the United States Patent and Trademark Office (&#8220;USPTO&#8221;) delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from generic medications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term extensions (&#8220;PTEs&#8221;) under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations, and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, in 2011 the United States enacted the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) and is still currently implementing wide-ranging patent reform legislation. Recent rulings from the U.S. Supreme Court and the Court of Appeals for the Federal Circuit have narrowed the scope of patent protection available in specified circumstances and weakened the rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO has issued subject matter eligibility guidance instructing USPTO examiners on the ramifications of the Supreme Court rulings in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics, Inc., and applied the Myriad ruling to natural products and principles including all naturally occurring molecules. In addition, the USPTO continues to provide updates to its guidance continues to be a developing area. The USPTO guidance may make it impossible for us to obtain similar patent claims in future patent applications. Currently, our patent portfolio contains claims of various types and scope, including methods of medical treatment. The presence of varying types of claims in our patent portfolio significantly reduces, but may not eliminate, our exposure to potential validity challenges.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our U.S. patent applications, which contain claims entitled to priority after March 16, 2013, there is a greater level of uncertainty due to the the Leahy-Smith Act mentioned above. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation. The USPTO has promulgated regulations and developed procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not come into effect until March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the Leahy-Smith Act is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either: (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit and new procedures providing opportunities for third parties to challenge any issued patent in the USPTO. Included in these new procedures is a process known as Inter Partes Review (&#8220;IPR&#8221;), which has been generally used by many third parties since the enactment of the Leahy-Smith Act to invalidate patents. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Additionally, the rights of review and appeal for IPR decisions is an area of law that is still developing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, such as processes for which patents are difficult to enforce other elements of our product candidate discovery and/or development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business, financial condition, or results of operations. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technology without infringing the patent rights of third parties. Numerous third-party U.S. and non-U.S. issued patents and pending applications exist in the area of our product candidates. From time to time, we may also monitor these patents and patent applications. We may in the future pursue available proceedings in the U.S. and foreign patent offices to challenge the validity of these patents and patent applications. In addition, or alternatively, we may consider whether to seek to negotiate a license of rights to technology covered by one or more of such third-party patents and patent applications. If any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 remain confidential until patents issue, and applications filed after that date that will not be filed outside the United States can elect to remain confidential until patents issue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable, or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to specified limitations, be later amended in a manner that could cover our technologies, our product candidates, or the use of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits in federal courts, and interferences, oppositions, inter partes reviews, post-grant reviews, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign-issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in meeting our obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to the intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license their patent rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. If any of our licensors fail to appropriately follow our instructions with regard to the prosecution and maintenance of patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected, and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to intellectual property licenses and supply agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future license agreements will impose, various diligence, milestone payments, royalties, purchasing, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture, or market products covered by the license or subject to supply commitments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. If we, or one of our licensing partners, were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, clarity, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants, and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and therapeutic products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell our product candidates, we may be unable to generate any revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although some of our employees may have been employed at companies that have launched pharmaceutical products in the past, we have no experience establishing commercial manufacturing relationships for or selling and marketing our product candidates and we currently have no commercial manufacturing relationships or marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to find one or more collaborators to commercialize our products or invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult, and time consuming. Any failure or delay in entering into agreements with third parties to market or sell our product candidates or in the timely development of our internal commercialization capabilities could adversely impact the potential for the launch and success of our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If commercialization collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, particularly in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may attempt to form strategic collaborations, create joint ventures, or enter into licensing arrangements with third parties with respect to our programs that we believe will complement or augment our existing business. We may face significant competition in seeking appropriate strategic collaborators, and the negotiation process to secure appropriate terms is time consuming and complex. We may not be successful in our efforts to establish such a strategic collaboration for any product candidates and programs on terms that are acceptable to us, or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, the competitive or intellectual property landscape may be viewed as too intense or risky, and/or third parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully enter into a collaboration regarding the development or commercialization of our product candidates, we cannot guarantee that such a collaboration will be successful. Any delays in identifying suitable collaborators and entering into agreements to develop and/or commercialize our product candidates could delay the development or commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Absent a strategic collaborator, we would need to undertake development and/or commercialization activities at our own expense. If we elect to fund and undertake development and/or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition and our competitors may discover, develop, or commercialize products faster or more successfully than us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions worldwide with respect to our product candidates that we may seek to develop or commercialize in the future. We are aware that the following companies have therapeutics marketed or in development for TED: Horizon Therapeutics plc and Immunovant, Inc., Harbour BioMed, Valenza Bio, Inc. and Sling Therapeutics, Inc. If approved, VRDN-001 will also compete against generic medications, such as corticosteroids, that are prescribed for and surgical procedures for the treatment of TED.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may succeed in developing, acquiring, or licensing technologies and drug products that are more effective or less costly than our product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. Our competitors may also adopt a similar licensing and development strategy as ours with regard to the development of an existing anti-IGF-1R monoclonal antibody for the treatment of TED. If any competitor was able to effect this strategy in a more efficient manner, there may be less demand for our product candidates if any are approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Third-party payors, including governmental and private insurers, may also encourage the use of generic products. For example, if VRDN-001 is approved, it may be priced at a significant premium over other competitive products. This may make it difficult for VRDN-001 or any other future products to compete with these products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research, and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. For example, in December 2022, Amgen Inc. announced that it intends to acquire Horizon Therapeutics plc, which could have a significant impact on the competitive landscape for therapeutics for TED. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. Failure of VRDN-001, VRDN-002 or our other product candidates to effectively compete against established treatment options or in the future with new products currently in development would harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the healthcare providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, and third-party payors. The degree of market acceptance of any of our products will depend on a number of factors, including but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy of the product as demonstrated in clinical trials and potential advantages over competing treatments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease and any side effects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which approval is granted, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the patients and physicians to accept these therapies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived ratio of risk and benefit of these therapies by physicians and the willingness of physicians to recommend these therapies to patients based on such risks and benefits;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the marketing, sales, and distribution support for the product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the publicity concerning our products or competing products and treatments; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and availability of third-party payor coverage and adequate reimbursement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other healthcare providers, we will not be able to generate sufficient revenue to become or remain profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our effort will focus on clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not succeed in preclinical or clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business, financial condition, or results of operations and could potentially cause us to cease operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain adequate reimbursement or insurance coverage for our products, if any, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, as well as the coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs, and the availability of coverage and adequacy of reimbursement by third-party payors, including government healthcare programs, health maintenance organizations, private insurers, and other healthcare management organizations, are essential for most patients to be able to afford expensive treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by third-party payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free, or we may not be able to successfully commercialize our products. See &#8220;Business&#8212;Coverage and Reimbursement.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has increased and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if they receive regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, are critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense, and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel may impede the progress of our research, development, and commercialization objectives and would negatively impact our ability to succeed in our product development strategy.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, may have serious adverse consequences on our business and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, have experienced extreme volatility and disruptions at various points over the last few decades, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and the rising tensions between China and Taiwan have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Hercules Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan and Security Agreement, we have pledged substantially all of our assets, other than our intellectual property rights. Additionally, the Hercules Loan and Security Agreement contains certain affirmative and negative covenants that could prevent us from taking certain actions without the consent of our lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders. The Hercules Loan and Security Agreement also contains customary affirmative and negative covenants that, among other things, limit our ability, subject to certain exceptions, to incur indebtedness, grant liens, enter into a merger or consolidation, enter into transactions with affiliates, or sell all or a portion of our property, business or assets. The Hercules Loan and Security Agreement contains customary events of default. Upon the occurrence and continuation of an event of default, all amounts due under the Hercules Loan and Security Agreement become (in the case of an insolvency or bankruptcy event), or may become (in the case of all other events of default and at the option of Hercules), immediately due and payable. If an event of default under the Hercules Loan and Security Agreement should occur, we could be required to immediately repay any outstanding indebtedness. If we are unable to repay such debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Hercules Loan and Security Agreement. Even if we are able to repay any indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology and storage systems or those of third parties upon whom we rely could significantly disrupt the operation of our business and adversely impact our financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our information technology (&#8220;IT&#8221;) systems or those of third parties upon whom we rely. IT systems are vulnerable to risks and damages from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters (such as a tornado, an earthquake, or a fire). Moreover, despite network security and back-up measures, some of our and our vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, including cyber-attacks, computer viruses, and similar disruptive problems. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently, and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If the IT systems are compromised, we could be subject to fines, damages, litigation, and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. Despite precautionary measures designed to prevent unanticipated problems that could affect the IT systems, sustained or repeated system failures that interrupt our ability to generate and maintain data could adversely affect our ability to operate our business. In addition, the failure of our systems, maintenance problems, upgrading or transitioning to new platforms, or a breach in security could result in delays and reduce efficiency in our operations. Remediation of such problems could result in significant, unplanned capital investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A network or data security incident may allow unauthorized access to our network or data, which could result in a material disruption of our clinical trials, harm our reputation, harm our business, create additional liability and adversely impact our financial results or operational results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, we are subject to a wide variety of threats on our information networks, and systems and those of our service providers or collaborators. In addition to threats from natural disasters, telecommunications and electrical failures, traditional computer hackers, malicious code (such as malware, viruses, worms, and ransomware), employee error, theft or misuse, password spraying, phishing, and distributed denial-of-service (&#8220;DDOS&#8221;) attacks, we now also face threats from sophisticated nation-state and nation-state supported actors who engage in attacks (including advanced persistent threat intrusions) that add to the risks to our internal networks, our third-party service providers, our collaborators and the information that they store and process. Despite significant efforts to create security barriers to safeguard against such threats, it is virtually impossible for us to entirely mitigate these risks. The security measures we have integrated into our internal networks and systems, which are designed to detect unauthorized activity and prevent or minimize security incidents or breaches, may not function as expected or may not be sufficient to protect our internal networks and platform against certain threats. In addition, techniques used to obtain unauthorized access to networks in which data is stored or through which data is transmitted change frequently and generally are not recognized until launched against a target. As a result, we may be unable to anticipate these techniques or implement adequate preventative measures to prevent an electronic intrusion.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, security incidents or breaches or those of our current or future collaborators or third-party service providers could result in a risk of loss or unauthorized access to or disclosure of the information we process. This, in turn, could require notification under applicable data privacy regulations or contracts, and could lead to litigation, governmental audits, investigations, fines, penalties, and other possible liability, damage our relationships with our collaborators, trigger indemnification and other contractual obligations, cause us to incur investigation, mitigation and remediation expenses, and have a negative impact on our ability to conduct clinical trials. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have adequate insurance coverage for security incidents or breaches or information system failures. The successful assertion of one or more large claims against us that exceeds our available insurance coverage or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that any existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or perceived failure by us or any collaborators, service providers, or others to comply with our privacy, confidentiality, data security or similar obligations to third parties, or any data security incidents or other security breaches that result in the unauthorized access, acquisition, or disclosure of sensitive information (including, without limitation personally identifiable information), may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us, could cause third parties to lose trust in us or result in claims against us. Any of these events could cause harm to our reputation, business, financial condition, or operational results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss (&#8220;NOL&#8221;) carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited. It is uncertain if and to what extent various states will conform to the Tax Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Our most recent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analysis of possible ownership changes was completed for certain tax periods ending through December 31, 2022. It is possible that we have in the past undergone and may in the future undergo, additional ownership changes that could result in additional limitations on our NOL and tax credit carryforwards. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use, or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in numerous U.S. states and territories and non-U.S. jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors including the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes, and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Certificate of Incorporation and Bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue Preferred Stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, he Certificate of Designation of our Series A Preferred Stock and the provisions of our warrants issued in 2020 may delay or prevent a change in control of our company. At any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, we may not consummate a Fundamental Transaction (as defined in the Certificate of Designation of the Series A Preferred Stock) or any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock. As of December 31, 2022, a majority of the then outstanding shares of Series A Preferred Stock was held by entities affiliated with one stockholder. This provision of the Certificate of Designation may make it more difficult for us to enter into any of the aforementioned transactions. In addition, pursuant to such warrants, under certain circumstances each warrant holder has the right to demand that we redeem the warrant for a cash amount equal to the Black-Scholes value of a portion of the warrant upon the occurrence of specified events, including a merger, an asset sale or certain other change of control transactions. A takeover of us may trigger the requirement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we redeem the warrants, which could make it more costly for a potential acquirer to engage in a business combination transaction with us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. While these choice of forum provisions do not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction, the choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against our and our directors, officers, and other employees. If a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of equity and debt could result in additional dilution to our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will need significant additional capital to fund our current and future operations, including to complete potential clinical trials for our product candidates. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. As a result, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to our Equity Incentive Plans, we may grant equity awards and issue additional shares of our common stock to our employees, directors, and consultants, and the number of shares of our common stock reserved for future issuance under certain of these plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that new options are granted and exercised, or we issue additional shares of common stock in the future, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a substantial portion of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has historically been volatile, and the market price of our common stock may drop in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. In addition to the factors described elsewhere in this &#8220;Risk Factors,&#8221; some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public and the investment community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with our potential products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including volatility resulting from the COVID-19 pandemic and general global macroeconomic conditions. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting, and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). These rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> may be negatively affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. This requires that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner for each period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, it could result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis, which could require a restatement, cause us to be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, cause investors to lose confidence in our financial information, or cause our stock price to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company. We also anticipate that these costs and compliance initiatives will continue to increase as a result of ceasing to be an &#8220;emerging growth company,&#8221; as defined in the in the Jumpstart Our Business Startups Act of 2012.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_22"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_25"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a multi-year, non-cancelable lease agreement for our office space in Waltham, Massachusetts (the &#8220;Original Lease&#8221;). In July 2021, we entered into an amendment to the Original Lease to increase our Massachusetts-based office space (the &#8220;First Amendment&#8221;). In April 2022, we entered into a second amendment to the Original Lease (the &#8220;Second Amendment&#8221;). The Second Amendment made certain modifications to both the Original Lease and First Amendment, including (i) the addition of 2,432 square feet of office space in the same building (the &#8220;April 2022 Expansion Premises&#8221;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease seven days after the delivery of the April 2022 Expansion Premises, which occurred in the fourth quarter of 2022, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment from October 2024 through November 2026. Under the Second Amendment, we have the option to extend the lease term for an additional period of three years upon notice to the landlord. In July 2022, we entered into a third amendment to the Original Lease (the &#8220;Third Amendment&#8221;). The Third Amendment makes certain modifications to the Original Lease, including (i) the addition of 5,240 square feet of office space in the same building (the &#8220;July 2022 Expansion Premises&#8221;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment to four years from the delivery of the July 2022 Expansion Premises. Under the Third Amendment, we have the option to extend the lease term for an additional period of three years upon notice to the landlord.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we lease approximately 27,128 sq. ft. of office and laboratory space in Boulder, Colorado under a lease that expires in December 2024, subject to two three-year renewal options prior to the expiration, and that includes rent escalation clauses through the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings in the ordinary course of business. We are currently not a party to any legal proceedings that we believe would have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_31"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_37"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Capital Market under the symbol &#8220;VRDN.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 3, 2023, we had 20 registered holders of record of our common stock. A substantially greater number of holders of our common stock are in &#8220;street name&#8221; or beneficial holders, whose shares of record are held by banks, brokers, other financial institutions, and registered clearing agencies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically have not paid, and do not anticipate in the future paying, dividends on our common stock. We currently intend to retain all of our future earnings, as applicable, to finance the growth and development of our business. In addition to legal restrictions under applicable law, we are subject to certain dividend-related limitations under the Hercules Loan and Security Agreement. Subject to these limitations, any future determination as to the payment of cash dividends on our common stock will be at our board of directors&#8217; discretion and will depend on our financial condition, operating results, capital requirements, and other factors that our board of directors considers to be relevant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_40"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. RESERVED</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_43"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read together with our consolidated financial statements and the related notes thereto included elsewhere in this Annual Report. This discussion and other parts of this report contain forward-looking statements reflecting our current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, intentions, and beliefs. See &#8220;Forward-Looking Statements&#8221; for a discussion of the uncertainties, risks, and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. We target under-competitive disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience. We believe that first-generation medicines rarely represent optimal solutions, especially in rare disease areas, and that there is potential to develop differentiated, best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, expanded market access, and augmented market competition. Our business model is designed to identify and evaluate product opportunities in disease areas where trial data establishes proof-of-concept for a drug target in the clinic, but the competitive evolution of the product life cycle management and number of entrants appears incomplete. We intend to prioritize indications where a fast-follower and a potentially differentiated drug candidate, or overall product profile, could create significant medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing three product candidates, VRDN-001, VRDN-002 and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from thyroid eye disease (&#8220;TED&#8221;). Our most advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue has historically consisted primarily of up-front payments for licenses, milestone payments, and payments for other research and development services earned under license and collaboration agreements as well as for amounts earned under certain grants we have been awarded.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we became party to a license agreement with Zenas BioPharma. Since February 2021, we have entered into several letter agreements with Zenas BioPharma in which we agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing (collectively with the license agreement, the &#8220;Zenas Agreements&#8221;). Under the terms of the Zenas Agreements, we granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China in exchange for upfront non-cash consideration and non-refundable milestone payments upon achieving specific milestone events during the contract term. Zenas BioPharma announced that it had obtained IND approval in China in July 2022. Under the license agreement, we received a $1.0 million milestone payment from Zenas BioPharma. Additionally, we are eligible to receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to us for the royalty term in the Zenas Agreements. In May 2022, we entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical drug product for development purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to continue to generate revenue from a combination of license fees and other up-front payments, payments for research and development services, milestone payments, product sales, and royalties in connection with strategic alliances. We expect that any revenue we generate could fluctuate from quarter to quarter as a result of the timing of our achievement of development and commercial milestones, the timing and amount of payments relating to such milestones, and the extent to which any of our product candidates are approved and successfully commercialized by us or our strategic alliance collaborators, if any. If we or our strategic alliance collaborators, if any, fail to develop product candidates in a timely manner or to obtain regulatory approval for them, then our ability to generate future revenue, and our results of operations and financial position would be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred for the research and development of our therapeutic programs and product candidates, which include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, severance, retention, benefits, insurance, and share-based compensation expense;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with clinical research organizations (&#8220;CROs&#8221;), investigative sites that conduct our clinical trials, and other clinical trial-related vendors, and consultants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with contract manufacturing organizations (&#8220;CMOs&#8221;);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with non-clinical activities and regulatory operations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and milestone payments related to the acquisition and retention of certain licensed technology and intellectual property rights; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation, market research, and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make non-refundable advance payments for goods and services that will be used in future research and development activities. These payments are recorded as expense in the period in which we receive or take ownership of the goods or when the services are performed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record up-front and milestone payments to acquire and retain contractual rights to in-licensed technology and intellectual property rights as research and development expenses when incurred if there is uncertainty in our receiving future economic benefit from the acquired contractual rights. We consider future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase as we expand our clinical development programs and initiate new clinical trials. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic alliance collaborators, if any, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including clinical data, preclinical data, competition, manufacturability, and commercial viability of our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, and ongoing assessments as to each future product candidate&#8217;s commercial potential. For example, upon receipt of topline data from our planned proof of concept trial of VRDN-002 by the end of 2023, we expect to determine which of VRDN-002 or VRDN-003 to advance into a pivotal Phase 3 trial in the first half of 2024. We will need to raise additional capital and may seek additional strategic alliances in the future in order to advance the various clinical trials that are part of our clinical development program described above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation, and severance and retention benefits related to our finance, accounting, human resources, legal, business development, and other support functions, professional fees for auditing, tax, and legal services, as well as insurance, board of director compensation, consulting, and other administrative expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income, net of fees, and various income items of a non-recurring nature. Interest expense consists of cash and non-cash interest expense on our long-term debt. We earn interest income from interest-bearing accounts, money market funds, and short-term investments. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policy discussed below is critical to understanding our historical and future performance, as this policy relates to the more significant areas involving our judgments and estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on certain facts and circumstances at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred for services provided by external service providers and for other trial-related activities. The timing and amount of expenses we incur through our external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, we obtain information from various sources and estimate the level of effort or expense allocated to each period. Adjustments to our research and development expenses may be necessary in future periods as our estimates change.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_46"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,874)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,413)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was $1.8 million for the year ended December 31, 2022, as compared to $3.0 million for the year ended December 31, 2021. Revenue for both periods was attributable to our collaboration agreement with Zenas BioPharma. The $1.2 million decrease in revenue is due to the timing of activities performed under the collaboration agreement. During the year ended December 31, 2022, the Company recognized $1.0 million upon Zenas BioPharma&#8217;s achievement of a certain development milestone.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $100.9 million during the year ended December 31, 2022, compared to $56.9 million during the year ended December 31, 2021. The $44.0 million increase in research and development expenses is primarily attributable to an increase of $8.9 million in clinical trial expenses related to our lead product candidates, VRDN-001 and VRDN-002; an increase of $8.7 million in costs associated with our preclinical programs; an increase of $7.8 million in personnel related costs, including share-based compensation, due to an increase in headcount; an increase of $7.6 million in milestone, license and option fees due to milestone and upfront payments to ImmunoGen and Paragon Therapeutics, Inc.; an increase of $6.5 million in chemistry, manufacturing and controls costs; and an increase of $2.4 million in consulting expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we work to progress our clinical and preclinical programs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $35.2 million during the year ended December 31, 2022, compared to $25.8 million during the year ended December 31, 2021. The $9.4 million increase in general and administrative expenses is due primarily to an increase of $6.0 million in personnel costs, including share based compensation, due to an increase in headcount, as well as an increase of $3.1 million in consulting, professional and license fees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $4.4 million during the year ended December 31, 2022 compared to $0.3 million during the year ended December 31, 2021. Other income, net for the year ended December 31, 2022, is comprised of $4.9 million of interest income earned on short-term investments as well as sub-lease income, offset by $0.5 million in interest expense related to our Hercules </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan and Security Agreement. Other income, net for the year ended December 31, 2021, is comprised of interest income earned on short-term investments as well as sub-lease income.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have funded our operations to date principally through proceeds received from the sale of our common stock, our Series A Preferred Stock, our Series B Preferred Stock and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. As of December&#160;31, 2022, we had $424.6 million in cash, cash equivalents, and short-term investments. We expect that our current resources will enable us to fund our planned operations into the second half of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. Since our inception and through December&#160;31, 2022, we have generated an accumulated deficit of $488.2 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to require substantial additional capital to continue the development of our product candidates, and potential commercialization activities, and to fund our ongoing operations, including our clinical development plan described above. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our clinical development efforts, equity financings, securing additional license and collaboration agreements, and issuing debt or other financing vehicles. Our ability to secure capital is dependent upon a number of factors, including success in developing our technology and product candidates. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances, such as changes in the scope and timing of our clinical studies, may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material cash requirements include obligations as of December&#160;31, 2022, as well as resources required to fulfill our research and development activities and the effects that such obligations and activities are expected to have on our liquidity and cash flows in future periods. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of our development activities and efforts to achieve regulatory approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through the issuance of debt, the obligations related to such debt could be senior to rights of holders of our capital stock and could contain covenants that may restrict our operations. Should additional capital not be available to us in the near term, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business, which may, among other alternatives, cause us to further delay, substantially reduce, or discontinue operational activities to conserve our cash resources.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of our subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders party thereto (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided us with access to a term loan with an aggregate principal amount of up to $75.0 million, in four tranches (collectively the &#8220;Term Loan&#8221;), consisting of: (1) an initial tranche of $25.0 million, available through June 15, 2023; (2) a second tranche of $10.0 million, subject to the achievement of certain regulatory milestones, available through June 15, 2023; (3) a third tranche of $15.0 million, subject to the achievement of certain regulatory milestones, available through March 15, 2024; and (4) a fourth tranche of $25.0 million, subject to approval by the Lenders&#8217; investment committee(s), available through December 15, 2024. The first tranche of $25.0 million will be available to us through June 15, 2023. Upon signing we drew an initial principal amount of $5.0 million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bears interest at a floating per annum rate equal to the greater of (1) 7.45% and (2) 4.2% above the Prime Rate, provided that the Term Loan interest rate shall not exceed a per annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. Per the terms of the Hercules Loan and Security Agreement, we were originally obligated to make interest-only payments through April 1, 2024. However, upon the achievement of a development milestone the interest-only </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period was extended to October 1, 2024. If additional development milestones are met, the interest-only period will be extended to April 1, 2025 pursuant to a second extension. We are required to repay the Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, we are required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan Advances at maturity, which are being accreted as additional interest expense over the term of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies, LLC (&#8220;Jeffries&#8221;) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $175.0 million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as the sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. As of December&#160;31, 2022, 964,357 shares were sold under the September 2022 ATM Agreement at a weighted average price of $26.01 per share, for aggregate net proceeds of approximately $24.2 million, including commissions to Jefferies as a sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;November 2021 ATM Agreement&#8221;) with Jefferies, pursuant to which we could offer and sell shares of our common stock having an aggregate offering price of up to $75.0 million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as sales agent. The November 2021 ATM Agreement was terminated in connection with the September 2022 ATM Agreement. No shares were sold under the November 2021 ATM Agreement prior to its termination. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;April 2021 ATM Agreement&#8221;) with Jefferies pursuant to which we could offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as sales agent. Jefferies received a commission equal to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the April 2021 ATM Agreement. The April 2021 ATM Agreement was terminated in connection with the November 2021 ATM Agreement. An aggregate of 2,551,269 shares of common stock were sold pursuant to the April 2021 ATM Agreement prior to its termination, at a volume weighted-average price of $13.13 per share, for aggregate net proceeds of approximately $32.4 million, including commissions to Jefferies as sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Underwritten Public Offerings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into an underwriting agreement (the &#8220;2022 Underwriting Agreement&#8221;) with Jefferies, SVB Securities LLC and Evercore Group LLC relating to the offer and sale (the &#8220;2022 Offering&#8221;) of 11,352,640 shares of our common stock, which includes 1,725,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $23.50 per share, and 28,084 shares of the Company&#8217;s Series B Non-Voting Convertible Preferred Stock, at a public offering price of $1,566.745 per share (collectively, the &#8220;2022 Public Offering&#8221;). The aggregate gross proceeds to us from the 2022 Public Offering, including the exercise of the option, were approximately $311.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by us. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into an underwriting agreement (the &#8220;2021 Underwriting Agreement&#8221;) with Jeffries, SVB Leerink LLC and Evercore Group, LLC for the sale and issuance of 7,344,543 shares of common stock, which include 1,159,089 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $11.00 per share, and 23,126 shares of Series B Non-Voting Convertible Preferred Stock at a public offering price of $733.37 per share (the &#8220;2021 Public Offering&#8221;). Our aggregate gross proceeds from the 2021 Public Offering, including the exercise of the option, were approximately $97.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, we agreed to sell an aggregate of approximately 195,290 shares of Series A Preferred Stock for an aggregate purchase price of approximately $91.0 million. Each share of Series A Preferred Stock is convertible into 66.67 shares of our common stock, subject to specified conditions. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series A Preferred Stock are set forth in the applicable certificate of designations. During the year ended December 31, 2021, 138,050 shares of Series A Preferred Stock were converted into 9,203,732 shares of common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a common stock purchase agreement (the &#8220;Aspire Stock Purchase Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;), which provides that, subject to the terms, conditions, and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20.0 million of shares of our common stock over the 30-month term of the Aspire Stock Purchase Agreement. Upon execution of the Aspire Stock Purchase Agreement, we sold to Aspire Capital 106,564 shares of common stock at $9.38 per share for proceeds of $1.0 million as the Initial Purchase Shares (as defined in the Aspire Stock Purchase Agreement). During the year ended December 31, 2020, we sold to Aspire Capital 412,187 shares of our common stock at a weighted-average price of $21.35 per share for aggregate net proceeds of $8.8 million. As of December 31, 2022, we have the ability to sell an additional $10.2 million of shares of our common stock to Aspire Capital. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized cash flows for the year ended December 31, 2022 and 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,598)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $93.8 million for the year ended December 31, 2022, and primarily consisted of a net loss of $129.9 million, adjusted for non-cash items of $20.1 million (primarily share-based compensation of $19.8 million) and working capital adjustments of $16.0 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $54.6 million for the year ended December 31, 2021, and primarily consisted of a net loss of $79.4 million, adjusted for non-cash items of $23.1 million (primarily share-based compensation of $14.5 million and a $7.5 million non-cash charge related to the issuance of common stock as payment for licensing fees to Xencor, Inc.) and working capital adjustments of $1.7 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $115.1 million during the year ended December 31, 2022. Net cash used in investing activities in 2022 primarily consisted of net purchases of investments of $114.3 million and property and equipment purchases of $0.8 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $74.3 million during the year ended December 31, 2021. Net cash used in investing activities in 2021 primarily consisted of net purchases of investments of $74.0 million and property and equipment purchases of $0.3 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $322.2 million for the year ended December 31, 2022. Net cash provided by financing activities in 2022 was primarily driven by net proceeds of $313.8 million in net proceeds from the 2022 Public Offering and the September 2022 ATM Agreement, $4.6 million in net proceeds from the Hercules Loan and Security Agreement, as well as $2.8 million in proceeds from the exercise of stock options, $0.9 million in proceeds from the exercise of warrants and $0.2 million in proceeds from the issuance of common stock under our employee stock purchase plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $125.3 million for the year ended December 31, 2021. Net cash provided by financing activities in 2021 was primarily driven by net proceeds of $107.3 million from the sale of common stock in 2021 through the 2021 Public Offering and the April 2021 ATM Agreement, $15.7 million in net proceeds from the sale of our Series B Preferred Stock, $1.3 million from the exercise of common stock warrants, and $1.0 million in proceeds from employee stock option exercises.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_52"></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_55"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_58"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplemental data required by this item are set forth on the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.&#160;</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_61"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A. CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Under the supervision and with the participation of our principal executive officer, principal financial officer, and other senior management personnel, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based on this evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting refers to the process designed by, or under the supervision of, our principal officer and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets, (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report. Management used the framework set forth in the report entitled &#8220;Internal Control &#8212; Integrated Framework (2013 Framework)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management concluded that our internal control over financial reporting was effective at a reasonable level of assurance as of December&#160;31, 2022, the end of our most recent fiscal year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially effect, our internal control over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_67"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to our 2023 Proxy Statement to be filed with the SEC within 120 days after December&#160;31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on our website, which is located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.viridiantherapeutics.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a Current Report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_79"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11 is incorporated herein by reference to our 2023 Proxy Statement, including under headings &#8220;Executive Compensation&#8221; and &#8220;Directors, Executive Officers and Corporate Governance.&#8221;</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_82"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item 12 is incorporated herein by reference to our 2023 Proxy Statement, including under headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_85"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item 13 is incorporated herein by reference to our 2023 Proxy Statement, including under headings &#8220;Directors, Executive Officers and Corporate Governance&#8221; and &#8220;Transactions with Related Persons.&#8221;</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_88"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 is incorporated herein by reference to our 2023 Proxy Statement, including under the heading &#8220;Ratification of Selection of Independent Registered Accounting Firm.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_94"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(1) Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required by this item are submitted in a separate section beginning on page F-1 of this Annual Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(2)&#160;Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have been omitted because they are either not required, not applicable, or the information is otherwise included.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)(3)&#160;Exhibits</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Exhibit Index, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_97"></div><div style="-sec-extract:summary;margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the Exhibit Index are required by Item 601 of Regulation S-K. The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36483.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#94;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312520279263/d49501dex21.htm">Agreement and Plan of Merger, dated October 27, 2020, by and among the Registrant, Oculus Merger Sub I, Inc., Oculus Merger Sub II, LLC, and Viridian Therapeutics, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/ex31_vrdnxsecondrestatedce.htm">Second Restated Certificate of Incorporation of the Registrant, effective as of March 9, 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/11/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000007/vrdn_amendedandrestatedbyl.htm">Amended and Restated Bylaws of the Registrant, effective as of May 11, 2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/13/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312520279263/d49501dex31.htm">Certificate of Designation of Series A Non-Voting Convertible Preferred Stock.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521280729/d208955dex31.htm">Certificate of Designation of Series B Non-Voting Convertible Preferred Stock.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/23/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000114420414016510/v369400_ex4-1.htm">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/19/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-12312017xex42new.htm">Warrant to Purchase Stock between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated April 30, 2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/14/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517344143/d494730dex102.htm">Warrant to Purchase Stock between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated November&#160;14, 2017.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/15/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312520027538/d879847dex41.htm">Form of Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/07/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit45_descriptionofsec.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#94;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001590750/000119312520313403/d75325dex101.htm">License Agreement, by and between the Registrant and ImmunoGen, dated as of October 12, 2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/09/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#94;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001590750/000159075021000029/fy202010kex102.htm">Technology License Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/26/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001590750/000159075021000029/fy202010kex103.htm">Subscription Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/26/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/ex104subscriptionagreement.htm">Subscription Agreement, by and between the Registrant and Xencor, dated as of December 2, 2021.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/11/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex1032.htm">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">Barre</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">t Katz, M.D. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">Employment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1014.htm">January&#160;18,&#160;2021.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/26/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/d182412dex101.htm">Kristian Humer Employment Agreement, dated June 9, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/26/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/d318381dex101.htm">Carrie Melvin Employment Agreement, dated May 25, 2022.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/23/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/d406212dex101.htm">Scott Myers Employment Agreement, dated December 29, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/06/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/d406212dex102.htm">Jonathan Violin General Release and Separation and Consulting Agreement, dated February 6, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/06/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000009/ex10_3amendedandrestated20.htm">Viridian Therapeutics, Inc. Amended &amp; Restated 2016 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/15/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex1038.htm">Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517166522/d372009dex1012.htm">Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/11/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687ds4.htm#toc238687_132">2016 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075020000114/a20201124s8exhibit991.htm">Viridian Therapeutics, Inc. 2020 Stock Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/24/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/fy202010kex1023.htm">Form of 2020 Incentive Stock Option Grant Notice under Viridian Therapeutics, Inc. 2020 Stock Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/26/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex1048.htm">Form of 2008 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex1049.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Registrant 2008 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex1040.htm">Lease by and between Registrant and Crestview, LLC, dated as of December 16, 2010.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex10401.htm">First Addendum to Lease by and between Registrant and Crestview, LLC, dated as of February 18, 2015.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex10402.htm">Second Addendum to Lease by and between Registrant and Crestview, LLC, dated as of October 23, 2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/02/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-fy2019xex10123.htm">Third Addendum to Lease by and between Registrant and Crestview, LLC, dated as of January 17, 2020.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/13/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075020000053/mgen-q12020xex102.htm">Fourth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of April 7, 2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/08/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000070/a2021063010qex104.htm">Fifth Addendum to Lease by and between Registrant and Crestview LLC, dated as of March 26, 2021.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000075/watchcityventures-viridi.htm">Waltham Lease between Registrant and Watch City Ventures MT, LLC dated as of January 13, 2020</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000075/watchcityventures-viridi.htm">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/05/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075021000075/a2021-07x01bixwatchfacto.htm">First Amendment to Waltham Lease between Registrant and Watch City Ventures MT, LLC dated as of July 6, 2021.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/05/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000009/ex102_bi-watchfactoryxviri.htm">Second Amendment to Lease by and between the Registrant and Watch City Ventures MT, LLC dated as of April 13, 2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/15/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000012/a2022-07x29bixwatchfactory.htm">Third Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of July 29, 2022.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/14/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075019000063/a201912118kexhibit41.htm">Registration Rights Agreement, dated December 11, 2019, by and between the Registrant and Aspire Capital Fund, LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#94;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312520279263/d49501dex101.htm">Securities Purchase Agreement, dated as of October 27, 2020, by and among the Registrant and each purchaser identified on Annex A thereto.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#94;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1590750/000159075020000106/mgen-q32020xex108.htm">Registration Rights Agreement, dated as of October 30, 2020, by and among the Registrant and certain purchasers.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521322455/d254246dex12.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.48pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.48pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521322455/d254246dex12.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521322455/d254246dex12.htm">, dated as of November 8, 2021, by and among the Registrant and Jefferies LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/08/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312522241939/d347132dex12.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312522241939/d347132dex12.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312522241939/d347132dex12.htm">, dated as of September 9, 2022 by and between the Registrant and Jefferies LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/09/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#94;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312522095676/d324074dex101.htm">Loan and Security Agreement, dated as of April 1, 2022, among the Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to time party thereto and Hercules Capital, Inc., as Agent.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/05/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fy202210kex211.htm">Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23_1xfinalconsentx2022.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_175">Power of Attorney (included on signature page hereto).</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fy202210kex311.htm">Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fy202210kex312.htm">Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fy202210kex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Viridian agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Viridian may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, &#8220;[***],&#8221; may have been omitted because such portions contained information that is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act are deemed not filed for purposes of Section 18 of the Exchange Act and otherwise are not subject to liability under these sections.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed/furnished herewith.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_106">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (KPMG LLP, Boulder CO, Auditor Firm ID: <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDMvZnJhZzplMmE0Zjg5YmRhNzE0YmQ1OGQ4NmY5NmJiMDllOTAyZi90YWJsZTo5NDIyMGJmZmZhY2M0NjJmOGU2YzhhOTE0ZTkxYjcyYi90YWJsZXJhbmdlOjk0MjIwYmZmZmFjYzQ2MmY4ZTZjOGE5MTRlOTFiNzJiXzEtMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjpjYWVhOTkwZDc1Mjk0OTIxYTMyZDdiMTJiYmQ1Y2FjMV8xMDE_1beb501d-2a47-4d3d-b304-390323e4f468">185</ix:nonNumeric> )</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_106">2</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_112">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_112">4</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_115">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_115">5</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_118">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_118">6</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_121">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_121">7</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_124">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5b8a3a67e4b4120aef8023d2c3721ae_124">9</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viridian Therapeutics, Inc.:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Viridian Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued outsourced clinical trials and preclinical studies</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 2 and 5 to the consolidated financial statements, accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. The estimates consider a number of factors such as site initiation, patient screening, enrollment, delivery of reports, and other events. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities for outsourced clinical trials and preclinical studies were $12.6 million as of December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of accrued outsourced clinical trials and preclinical studies as a critical audit matter. Specifically, evaluating the sufficiency of audit evidence obtained over the estimates of costs incurred by third </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties, including the factors described above, required subjective auditor judgment due to the nature of available evidence. Such evidence included communications from third parties regarding tasks completed, invoices received from third parties, and management&#8217;s analysis of expenses incurred against budgeted and contractual amounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. For a selection of accrued liabilities for outsourced clinical trials and preclinical studies, we compared the relevant factors used by management to estimate the accrued expenses to contracts, invoices and third-party confirmations of contractual milestones and project status. We compared the Company&#8217;s estimate of costs accrued as of year-end to a selection of third-party invoices received after year-end, but prior to the issuance of the Company&#8217;s financial statements. We assessed the sufficiency of audit evidence obtained related to accrued outsourced clinical trials and preclinical studies by assessing the cumulative results of the audit procedures.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDYvZnJhZzo4ZjU4NzA1YzVmYjQ0NGUyOWRmMTZmMWMwZmE4MzdkMC90ZXh0cmVnaW9uOjhmNTg3MDVjNWZiNDQ0ZTI5ZGYxNmYxYzBmYTgzN2QwXzU3MjA_ef3dad55-2611-4654-9f81-1a5c7308d32c">KPMG LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:245.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2009.</span></div><div style="padding-left:4.5pt;padding-right:245.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDYvZnJhZzo4ZjU4NzA1YzVmYjQ0NGUyOWRmMTZmMWMwZmE4MzdkMC90ZXh0cmVnaW9uOjhmNTg3MDVjNWZiNDQ0ZTI5ZGYxNmYxYzBmYTgzN2QwXzU3MjE_ec6a1a52-4866-4b47-a06d-7ed82ce990a7">Boulder, Colorado</ix:nonNumeric></span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;9, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_112"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzYtMS0xLTEtNjQ2MTQ_74691384-28ca-4b60-8770-fa950d59e026">155,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzYtMy0xLTEtNjQ2MTQ_fdbdd8e6-eeb8-4603-bb41-6e9948be6d33">42,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzctMS0xLTEtNjQ2MTQ_936450a0-7601-4b29-b270-cf2bc4cfb477">268,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzctMy0xLTEtNjQ2MTQ_9ce888f0-a386-489f-95ef-ef52562daa8d">154,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzgtMS0xLTEtNjQ2MTQ_d307ea6a-3e4e-4bad-91e2-c4c2389de5c9">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzgtMy0xLTEtNjQ2MTQ_c4d36887-8458-4ee3-82d2-411403d4e51c">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unbilled revenue - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzktMS0xLTEtNjQ2MTQ_fe23be44-9230-4674-9f90-c1f76c64e6a6">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzktMy0xLTEtNjQ2MTQ_b6dc5abc-9285-435a-a434-af1f7f18378e">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEwLTEtMS0xLTY0NjE0_b3868102-7018-4ad7-9288-04b0f931e82d">431,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEwLTMtMS0xLTY0NjE0_0b3fcdc5-b36a-499a-a003-4d75727ab5cd">200,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzExLTEtMS0xLTY0NjE0_01642c03-90b3-4eea-b38e-f1104007bf8a">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzExLTMtMS0xLTY0NjE0_87d95dc0-6626-434a-bb4c-28c4a23f689f">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEyLTEtMS0xLTY0NjE0_5f3abf38-85a4-4d08-aff9-6a88451d007c">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEyLTMtMS0xLTY0NjE0_f313d895-92ee-40b9-9bba-b2fa31a055bf">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE0LTEtMS0xLTY0NjE0_02a95f28-9d98-496c-abab-030a2686eb46">982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE0LTMtMS0xLTY0NjE0_9df4b492-d5fd-4d84-846a-966108ebd42c">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE1LTEtMS0xLTY0NjE0_7387a12f-4b36-4831-97d1-a7e2b7c3cfb6">435,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE1LTMtMS0xLTY0NjE0_81dd6b3d-5625-4563-ae1c-ba6719c3d28a">203,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE5LTEtMS0xLTY0NjE0_8841f891-7cc6-45df-86b4-ceb4e3aa7b47">14,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE5LTMtMS0xLTY0NjE0_a1180b4c-88bb-4913-93b6-c747c21ef541">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIwLTEtMS0xLTY0NjE0_f1ba25ed-dbbb-4663-b283-f5e242de003f">18,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIwLTMtMS0xLTY0NjE0_ca608e91-987f-4fac-963b-7f040548ec21">11,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of deferred revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIxLTEtMS0xLTY0NjE0_cb531315-ee6a-44ab-8f09-8811850f8467">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIxLTMtMS0xLTY0NjE0_68fe7d53-803a-4c3d-b771-b693c254f3a3">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIyLTEtMS0xLTY0NjE0_2e7d84fe-9c34-4994-92cf-c3e236a843ec">33,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIyLTMtMS0xLTY0NjE0_d42c51a7-b64c-4766-98e5-652b136f0b41">13,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI1LTEtMS0xLTY0NjE0_98c4c3a2-412b-4b9c-874d-07db62b4b099">4,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI1LTMtMS0xLTY0NjE0_af774922-2882-407c-80b7-c1b1a50cd759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue  - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI2LTEtMS0xLTY0NjE0_d4403f77-5849-40cc-b465-098004c5d47c">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI2LTMtMS0xLTY0NjE0_a86afa25-3404-4ce0-a33b-7a8170966673">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI3LTEtMS0xLTY0NjE0_5ef1294b-9f55-44c5-a871-ff185bad88e2">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI3LTMtMS0xLTY0NjE0_b4168c5e-97e5-45fa-a862-45c0c3d6ccaa">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI4LTEtMS0xLTY1MDY5_4362a842-ef54-4fa5-811a-2d8cb0b28624">40,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI4LTMtMS0xLTY1MTI2_df6ac238-7db8-498b-80e5-1fe8c0c43c31">15,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI5LTEtMS0xLTY0NjE0_b820f1cc-5ecc-4399-a54a-832e13ba55cc"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI5LTMtMS0xLTY0NjE0_b4b25095-0e2c-4ab2-95bd-29acb0dd9dc1"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, series A non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTAz_6e794f9d-0f2a-4742-8ccc-ab8aea75077c"><ix:nonFraction unitRef="usdPerShare" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTAz_87d36551-c588-4976-aced-ccc185db5e5f">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfOTM0NTg0ODgzNjM0MQ_5767909d-db36-4382-99e8-bb4f45e5dbd6"><ix:nonFraction unitRef="shares" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfOTM0NTg0ODgzNjM0MQ_9cb87110-1193-451e-ab05-01a0decc2240">435,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTEz_01677419-b40b-469e-aa94-42a8335c019c"><ix:nonFraction unitRef="shares" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTEz_96193cb8-89b5-4611-8356-0128e958be88">188,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTIz_1b6672fe-6cb5-4746-80a3-f8cbc541f52e"><ix:nonFraction unitRef="shares" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTIz_435e5a36-7aff-4df5-a6d0-87333996aa42">260,437</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTEtMS0xLTY0NjE0_abc73415-5980-4667-920c-20e1052aaac9">85,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTMtMS0xLTY0NjE0_039109ef-5f51-4869-8b52-394e967808e5">118,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, series B non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTAx_ea4d14e3-a8cf-447c-8638-2504b240d806"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTAx_ee367e0e-a888-452c-a0b9-f0511bd0ab15">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfOTM0NTg0ODgzNjMzNw_380d3918-f691-473a-96a6-0ffa4b36b449"><ix:nonFraction unitRef="shares" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfOTM0NTg0ODgzNjMzNw_d8b2401b-0949-4cb1-8ee2-784d78536653">500,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTEw_9733476f-3ecd-49b5-b7e4-36c172109d2a"><ix:nonFraction unitRef="shares" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTEw_cc8f2657-6c4f-403c-b158-344fa0470d96">51,210</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTE5_0c49d8f5-6246-4562-8778-7372b8a5186d"><ix:nonFraction unitRef="shares" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTE5_a9f049b6-585c-4c5b-b8fc-bd20c3d545dd">23,126</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTEtMS0xLTY0NjE0_1e4db0e0-4829-4ac0-9dd6-b96bb25d9d97">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTMtMS0xLTY0NjE0_04c8daba-3342-407e-82de-9f7dbba40ef8">15,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTAw_357e2dd4-1b3e-4fb8-a98f-9e5e1a70af0c"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTAw_eb19e01b-8408-410b-9637-e806f3b66f57">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfOTM0NTg0ODgzNjMzNQ_35af0906-4e5d-4008-99dc-07987ed07774"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfOTM0NTg0ODgzNjMzNQ_f5fec42b-5a3d-42f0-bbcf-24b0092b29af">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MDU5_698dcf45-fbec-4daa-a7d4-8ac7702b186b"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MDU5_b9c21dfa-4835-4f7e-b81a-3ed3236f50e2">41,305,947</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTEz_5ab62ba7-6930-4e3f-9b9d-95914c77ff15"><ix:nonFraction unitRef="shares" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTEz_b106d214-fc21-4252-9ec2-0e3651a7024f">23,924,004</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTEtMS0xLTY0NjE0_79917fcc-4478-461c-98dd-5b4945fccc80">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTMtMS0xLTY0NjE0_26756916-aaa3-4885-83a3-64c9e7fe2b49">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM0LTEtMS0xLTY0NjE0_c653c63d-e72e-4ce4-a17f-9da47bda190b">741,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM0LTMtMS0xLTY0NjE0_5e6c9589-f362-43dd-833d-904b02b31f4d">412,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM1LTEtMS0xLTY0NjE0_4e6cdbb4-cd8e-406a-8f40-8599e619d2fb">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM1LTMtMS0xLTY0NjE0_f3919149-c0c7-45ff-a043-550464de0216">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM2LTEtMS0xLTY0NjE0_955e9249-3f20-4d2d-bfb4-5be4f8d051d7">488,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM2LTMtMS0xLTY0NjE0_570124e4-a4bc-450e-80f5-17c252205754">358,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM3LTEtMS0xLTY1MDY5_04b4c5c7-ee1d-4022-88a6-897321a1bdb1">395,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM3LTMtMS0xLTY1MTI2_fa09458f-ae73-4773-90ba-921f22ae714b">187,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM4LTEtMS0xLTY1MDY5_ea3cce98-60b3-4f81-b040-059a446a0b4a">435,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM4LTMtMS0xLTY1MTI2_ee6ccb8c-8d14-4ed9-82a3-9353f53fcc07">203,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzMtNS0xLTEtNjQ2MTQ_c8177af4-f5c0-4e38-8a6d-392481696d9d">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzMtNy0xLTEtNjQ2MTQ_886aea6a-a79c-4aa9-bc12-8ac9277e0ec2">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 37pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (related party - $<ix:nonFraction unitRef="usd" contextRef="i778249cf6ce9418b9ad4f911c7d378a8_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjowN2JhNDY0MzU2YzU0MjJhODYyMjUwNmI5NDQ3Y2ZhMF81NDk3NTU4MTM5MzQ_6f7f4bc3-e15f-4171-92c6-6169ede9c63c">5,619</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icc0d47b55d5c4d7a86368dd7a7fe9210_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjowN2JhNDY0MzU2YzU0MjJhODYyMjUwNmI5NDQ3Y2ZhMF81NDk3NTU4MTM5NDQ_426cd2c8-f87a-406f-abc7-37f457e25f6e">&#8212;</ix:nonFraction> at December 31, 2022 and 2021, respectively)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctNS0xLTEtNjQ2MTQ_1a5b0dc0-4fb8-4d35-9db5-011601ef4d65">100,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctNy0xLTEtNjQ2MTQ_608f8b95-8dee-4c33-b996-309aae6af0ff">56,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzgtNS0xLTEtNjQ2MTQ_d4ed5385-908a-400b-bae7-1befb0d32ba6">35,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzgtNy0xLTEtNjQ2MTQ_8f3c9020-ba7b-4f50-8cce-829d1132cfb1">25,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEwLTUtMS0xLTY0NjE0_2ba64372-ddd8-4dd2-83d1-a430703efb9b">136,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEwLTctMS0xLTY0NjE0_65433d4f-a072-4204-8a0a-066662be6b48">82,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzExLTUtMS0xLTY0NjE0_3c619f1f-a6a7-4670-99f9-5eca6c2e567b">134,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzExLTctMS0xLTY0NjE0_67a20273-2d32-4841-bec1-844b2a07d7c7">79,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTUtMS0xLTY0NjE0_8b3fee6b-e3e2-4eea-be7f-47689c43573b">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTctMS0xLTY0NjE0_8c1caf58-3bcc-4d4d-b33c-4ec2f4353402">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:InterestAndDebtExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE0LTUtMS0xLTY0NjE0_fce98638-d2f9-4977-b858-1ad4080cccfb">486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:InterestAndDebtExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE0LTctMS0xLTY0NjE0_f91e2354-d00e-4ce7-bfa2-c1c3b5c8044a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTUtMS0xLTcxMDg1_721f862d-0327-4f51-987c-f173aff72861">4,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTctMS0xLTcxMDg1_1505451c-73fc-419e-af9c-7bab89c53791">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE1LTUtMS0xLTY0NjE0_b6c35349-65cf-4527-acea-2f616d755c5a">129,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE1LTctMS0xLTY0NjE0_e09975ac-b103-475a-9ba0-51392ee5cb2d">79,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY5NjI3_1465f3a6-0b38-47b2-9d25-b7f8fc552a72"><ix:nonFraction unitRef="usdPerShare" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY5NjI3_5dd3f438-3a39-4ca7-a445-d6b32248f2e5">4.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY5NjI3_dc8de787-0b80-40ea-bcc8-ba596b0a34de"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY5NjI3_ec711815-de6d-4341-8945-c33448563533">6.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY5NjI3_5098489c-4839-4a30-96aa-1a4099a6fd4a"><ix:nonFraction unitRef="shares" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY5NjI3_b6e8e76f-b734-42f7-a471-97e8803f85d8">32,087,293</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY5NjI3_6838444c-0c3e-47e5-8a0a-d6d230246164"><ix:nonFraction unitRef="shares" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY5NjI3_9d97ec8c-baf1-4940-ab46-cf3338b289fd">11,918,712</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIxLTUtMS0xLTY5NjY5_b6c35349-65cf-4527-acea-2f616d755c5a">129,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIxLTctMS0xLTY5NjY5_e09975ac-b103-475a-9ba0-51392ee5cb2d">79,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY0NjE0_0f9ed125-42a0-4930-85b5-591ecca5ac76">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY0NjE0_50bd21d1-0880-4d35-998e-478cab282594">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIzLTUtMS0xLTcwMDc0_b91eda94-f9ed-47d5-b0be-01c6648f2621">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIzLTctMS0xLTcwMDc0_864dd8f5-6413-4107-b3f8-48da1ca7a1bf">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY0NjE0_aebcdf19-c567-440f-9869-f056ecc5f827">130,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY0NjE0_793a9752-f4e2-4c25-a222-da547a632fda">79,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:31.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.843%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTEtMS0xLTY0NjE0_9d47bb1d-05e4-42df-903d-a7f1befc2b1c">398,487</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTMtMS0xLTY0NjE0_5cda5817-da27-42aa-9352-39da8b281900">180,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82f4e2c253814d9993e96053bae40a2c_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTUtMS0xLTY0NjE0_b12baa45-6e5d-45b9-889a-2642f889b385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f4e2c253814d9993e96053bae40a2c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTctMS0xLTY0NjE0_764200de-1ab5-40ab-8013-f029cc2f1b2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if33717d39c2943d388f869ebe747c1e3_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTktMS0xLTY0NjE0_b97219c6-98e6-4bb5-9f4a-1bec8016b3a5">4,231,135</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33717d39c2943d388f869ebe747c1e3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTExLTEtMS02NDYxNA_699eb1f9-f3e8-4f94-9695-cde8051d33f3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1bba44fa4d4b6e9380aceefcb77a8a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTEzLTEtMS02NDYxNA_0d895435-8c85-452d-8f58-394532e8ce6e">218,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i895af20035af46daa806cd54af1820ae_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE1LTEtMS02NDYxNA_39f28aad-4576-41ad-bb4c-1d6606fa0a45">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa992c0e8b04d0ba561866e5ddc5c70_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE3LTEtMS02NDYxNA_5aa865ec-6228-4fa3-844c-98dffc821f9e">278,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE5LTEtMS02NDYxNA_a5d103cd-f57d-4b80-a2ae-4213dafae239">120,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTEtMS0xLTY0NjE0_e4bb38dc-7247-4c52-94ec-a160bee6de3b">138,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTMtMS0xLTY0NjE0_85ffc8ac-5c38-4b4a-a33a-ed64d5f4ef20">62,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTktMS0xLTY0NjE0_da95acab-9056-4c5b-95c6-da128094357f">9,203,732</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTExLTEtMS02NDYxNA_53750f71-5e98-40b9-8c68-91200b5ba803">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTEzLTEtMS02NDYxNA_08f6c8dd-a916-4d84-8fd1-8012f68dba78">62,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTE5LTEtMS02NDYxNA_fb57fe8f-5ef7-40e5-8078-8596f38f8fea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series B preferred stock and common stock in the 2021 Public Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ieae0b71a3dbf4614b433002bcd8498cd_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTAtMS0xLTY0NjE0L3RleHRyZWdpb246YTE2MzhhNWU0ZjhmNDdhMWJkNTkxOGY5YjkyMzg4M2RfOTM0NTg0ODgzNjIzMg_829bb904-88bf-4eb8-866d-a358ec2d8b06">1,291</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie244e1d6bb534436961dc38a043ef711_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTAtMS0xLTY0NjE0L3RleHRyZWdpb246YTE2MzhhNWU0ZjhmNDdhMWJkNTkxOGY5YjkyMzg4M2RfOTM0NTg0ODgzNjIzNw_51c7b351-523a-4ddf-a301-7e6bb649e296">5,983</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTUtMS0xLTY0NjE0_74cbcf7b-b40c-4c64-b71a-79ccb4907cf5">23,126</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTctMS0xLTY0NjE0_5a4e1991-9b46-42a3-ac54-85dca62869b6">15,669</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTktMS0xLTY0NjE0_b99704bd-0280-4d4a-8595-1f681d99c990">7,344,543</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTExLTEtMS02NDYxNA_34f62f7d-e029-41bb-8fd3-71b64fa254ca">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9fcc60a60e445c8f1795104a6c46f0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTEzLTEtMS02NDYxNA_d6bf0992-7dc8-438e-9558-6ed584304b66">74,734</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib443f38e5cd2438c9634efcd8b2278ea_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTE5LTEtMS02NDYxNA_8faf5fee-0a07-4d9d-b2c2-c8aa69754232">90,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercises of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTktMS0xLTY0NjE0_575f4713-b021-4410-832e-92d298e133b3">77,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTExLTEtMS02NDYxNA_a772d225-9eb2-40a7-b939-3849bd3b361b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTEzLTEtMS02NDYxNA_5bacb435-dea6-4919-8dea-a2d0e4f51b30">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTE5LTEtMS02NDYxNA_4cae90cd-446b-43e5-89b5-8cb3bc29802e">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTktMS0xLTY0NjE0_df7f33ef-b283-4ba6-a6f2-74fbf6d54129">106,831</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTExLTEtMS02NDYxNA_92dc1f4b-3d96-4ea7-9a13-a575f7b70b63">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTEzLTEtMS02NDYxNA_310663af-95b4-4725-980b-d6d12dc9372f">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTE5LTEtMS02NDYxNA_4bc24e0b-b367-4b82-803c-3927bb459b7e">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIzLTktMS0xLTY0NjE0_c5fadef1-25c8-40ab-a63b-5acbf3304d9e">10,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, 2021 ATM, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i4a6c2ed89fed4622a2d2aa7172d7f416_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTAtMS0xLTY0NjE0L3RleHRyZWdpb246Njc0M2FiMGRmYjUxNDM5YjlmN2Y2MmQ5NTk4NjMzZTNfOTM0NTg0ODgzNjE2NA_c0773aee-e879-487b-a50e-ad67c10b0a20">1,004</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTktMS0xLTY0NjE0_34c8f6d3-deaa-4bdc-815c-c4645011b475">2,551,269</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTExLTEtMS02NDYxNA_b4f5ac7e-ffe2-478e-a003-2cac5ce659d7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aed7cceb62b4b92bc8ed6ec984f2319_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTEzLTEtMS02NDYxNA_435e8f78-8bc1-4880-a14c-ab8ccb841178">32,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39fb3692ca914421afc3d247f7d8cca4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTE5LTEtMS02NDYxNA_f0ea5cff-9719-4f07-bdbf-11501619ad62">32,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTktMS0xLTY0NjE0_fa3c46a8-87ff-457d-a0aa-21d7670ed160">394,737</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTExLTEtMS02NDYxNA_e2c3b787-13ad-4280-aada-d5668350381a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTEzLTEtMS02NDYxNA_2aba1c53-696f-4695-9454-6a03b023451e">7,496</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTE5LTEtMS02NDYxNA_5aeeaae8-ed68-4e8a-8263-1a2b424e7aef">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTktMS0xLTY0NjE0_13963600-1760-408d-be67-de72ff395823">3,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTEzLTEtMS02NDYxNA_e5f1c968-0cb6-4cc4-beb9-51dafb2156c9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTE5LTEtMS02NDYxNA_b86f6fe8-e6c9-451d-b767-53d059bd2428">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI3LTEzLTEtMS02NDYxNA_fea3ff78-d1f8-4cd5-9838-011e0bd5a549">14,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI3LTE5LTEtMS02NDYxNA_a6ade767-486b-427e-8120-0144313c2391">14,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id35723f52a2d4347be6c1269abb323a8_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI5LTE1LTEtMS02NDYxNA_ef2e19e5-6bee-4648-839a-deb1e9b96754">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI5LTE5LTEtMS02NDYxNA_0def1049-9a39-4b23-830a-bfb7e34d1669">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb583c45106b4818a232ee9c4ad39c58_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMwLTE3LTEtMS02NDYxNA_50e5099d-3d4b-4487-a5e8-bbd50c7634bb">79,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMwLTE5LTEtMS02NDYxNA_1199b89b-910a-45b0-abcc-4074b22bdac8">79,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id86c28f6cc424ce98bea0a4a97eddb90_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTEtMS0xLTY0NjE0_c5b266f5-9bef-4827-9fba-f265afd06aea">260,437</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86c28f6cc424ce98bea0a4a97eddb90_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTMtMS0xLTY0NjE0_9187e56a-291b-4427-b0aa-07d74e71a55c">118,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9d6b724a9464b29ae68552713b5ed42_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTUtMS0xLTY0NjE0_658077a9-5f17-4f0b-9f44-31f0142ce7bf">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d6b724a9464b29ae68552713b5ed42_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTctMS0xLTY0NjE0_56c236ea-e05d-432e-b898-c0920d9c4eb5">15,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id337e30fdc0349c4816ac5a494a9223d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTktMS0xLTY0NjE0_e0e6da09-7d0f-4b3f-9c78-52ccb1c8ccfd">23,924,004</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id337e30fdc0349c4816ac5a494a9223d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTExLTEtMS02NDYxNA_ebfe5b3b-0b25-4ee5-a7e8-a77957485875">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2d086c62db415b86b0a9d226c455d4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTEzLTEtMS02NDYxNA_b2b0adce-ca5a-4af8-8704-be4234c87bc2">412,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab4425cde974494cabb81ce893b56b8b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE1LTEtMS02NDYxNA_207d0622-85cb-431e-a93e-4ac9ee6b2746">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e57058fb77d4e7fbf5cb93719753578_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE3LTEtMS02NDYxNA_2545d5d4-a95e-4640-a5c4-e71e1ef93ba2">358,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE5LTEtMS02NDYxNA_3417b05e-1fc5-43cc-be29-38b37e95e80e">187,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTEtMS0xLTY3OTMx_9ba23e63-9dda-4b6b-95f0-3473759162b1">72,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTMtMS0xLTY3OTM5_954b12ff-0525-4caa-ab2e-e56f5d44cc9d">32,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTktMS0xLTY3OTU1_55d14f8c-8422-4f84-9d25-4eccd2887963">4,803,965</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTExLTEtMS02Nzk1NQ_8593c895-d26d-447e-b39b-e0891fe9690f">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTEzLTEtMS02Nzk2Mw_079efc57-b031-484b-a9f3-939bc892176b">32,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTE5LTEtMS02Nzk3MQ_1609e6f3-dd77-41ef-94f9-c2ff5da67185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series B preferred stock and common stock, 2022 Public Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i508999d2a2594110b99007f534be4af5_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTAtMS0xLTY3OTExL3RleHRyZWdpb246OGYwZmZmOTA3ODY0NGY0NmFkNjg0OGNjNzRjMzBlOTVfNTQ5NzU1ODEzOTk0_76190795-c613-4003-b9f2-ab9f2869b804">2,992</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i25983ef470214368ab0eea4aa4373a8c_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTAtMS0xLTY3OTExL3RleHRyZWdpb246OGYwZmZmOTA3ODY0NGY0NmFkNjg0OGNjNzRjMzBlOTVfNTQ5NzU1ODE0MDAz_c91e68ab-1a7f-4cfe-a677-377460aba92b">18,146</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTUtMS0xLTY3OTQ3_33166cb6-e8a1-4ac5-a4bf-5135719fc9c7">28,084</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTctMS0xLTY3OTQ3_17b37277-bb2f-463d-8669-2c90a9447d29">41,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTktMS0xLTY3OTU1_33ce5a49-fdc1-420a-8153-de3115c48d5b">11,352,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTExLTEtMS02Nzk1NQ_346137d3-5238-49d8-8bdd-3ebdb69959fa">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789f9857a6f441e3aa1e17f4094afaf7_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTEzLTEtMS02Nzk2Mw_3c5bd350-44e3-4b37-8abc-79a9a565777d">248,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2335da7e52874d249a90521b0fd87ab1_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTE5LTEtMS02Nzk3MQ_9783e8fc-2f9e-4394-9ed5-22a0097d5473">289,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, September 2022 ATM, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="id0451fea21364299a740c764817cf380_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTAtMS0xLTY3OTExL3RleHRyZWdpb246NGY4MGE0OGE5YzI0NDk4ZjlhMTc1OWE4YTc0OTE3MDBfNTQ5NzU1ODEzOTYz_4c041bf1-09a9-44a9-ad2f-bc4fb9ae7045">926</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0397e407cad54193ab35946350fff184_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTktMS0xLTY3OTU1_e4571d1c-3b1a-4244-b21f-d4aa01db8fb2">964,357</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0397e407cad54193ab35946350fff184_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTExLTEtMS02Nzk1NQ_cf197da2-5067-4f60-bfb9-a1e51b4e43f8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ab3fa116a44b7da15ac250754235b3_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTEzLTEtMS02Nzk2Mw_91a407bb-1152-465b-a409-455bd93c818d">24,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id58d19c7f26d4ebd88665ae0a8aa7f16_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTE5LTEtMS02Nzk3MQ_55500077-b66e-495a-9fbe-62aa2ad1fe5a">24,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercises of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="INF" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTktMS0xLTY3OTU1_0da856d6-7bfb-4b77-a33e-90dffb6810a2">56,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTExLTEtMS02Nzk1NQ_c82f0599-c285-4f54-9074-406a953954d9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTEzLTEtMS02Nzk2Mw_53652da2-db83-49d7-8f8b-f4fca8037b0c">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTE5LTEtMS02Nzk3MQ_e9355468-124c-433e-8198-22b4cfaac494">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTktMS0xLTY3OTU1_bbaee154-6547-4c1b-a1e5-6592e3804f76">191,291</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTExLTEtMS02Nzk1NQ_4bd78650-9a46-4d55-87af-9d6de966bc40">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTEzLTEtMS02Nzk2Mw_053d3ebf-c6c2-4f77-88d2-495c4645ca7d">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTE5LTEtMS02Nzk3MQ_b3ddc3f6-c271-40ab-914e-8068fe9aa20d">2,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTktMS0xLTY3OTU1_e00ec069-77e4-426c-ad4c-899115b7e52f">13,024</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTEzLTEtMS02Nzk2Mw_b6aac3d6-83b1-4b5a-bea7-22f028149d6e">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTE5LTEtMS02Nzk3MQ_e590f13e-cd2e-4441-b736-9f06d3c7d6fd">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM4LTEzLTEtMS02Nzk2Mw_2cc57640-6d98-4f4b-8d55-2eca0d853b15">19,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM4LTE5LTEtMS02Nzk3MQ_7d6e6a77-b36d-45dd-b692-29b6c56c9463">19,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e66c30a3694f1299adfc4cecaa2744_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM5LTE1LTEtMS02Nzk2Mw_1d97879c-2c44-477d-b3b0-e2ee7e34a65b">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM5LTE5LTEtMS02Nzk3MQ_f0b914fa-57b4-49b4-be48-dd793568537f">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c84830c57044151be9237f1a7dd891b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQwLTE3LTEtMS02Nzk2Mw_1bf55463-a003-42fc-a877-1dc0ae5d87b2">129,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQwLTE5LTEtMS02Nzk3MQ_e487717e-ec59-4dc1-ba86-84235dba4be1">129,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ca19cad32d5468a88da45e616c993ef_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTEtMS0xLTY4MzY3_2ab38e4b-51c9-4074-bc1e-828fd57da3cf">188,381</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca19cad32d5468a88da45e616c993ef_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTMtMS0xLTY4MzY3_37acc53d-8bf6-4529-ac00-22158c31739b">85,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14703c6fcd204cf4bb4d52313293b090_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTUtMS0xLTY4MzY3_6ed802d7-3587-4f0d-bc5d-3b23cfc80bb7">51,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14703c6fcd204cf4bb4d52313293b090_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTctMS0xLTY4MzY3_20cc3a43-d559-4b38-996a-9b855dc4bc6a">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16c66a163e074d75953188a31b49a161_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTktMS0xLTY4MzY3_68aeffc4-056f-4e10-8520-fe9b231f9783">41,305,947</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c66a163e074d75953188a31b49a161_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTExLTEtMS02ODM2Nw_124e1a2c-bae1-418a-9ad0-43437486f00d">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d69f24ee32425883b5fb4906e7848c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTEzLTEtMS02ODM2Nw_898c2cd6-1de9-4a8e-9684-58bd84850eb7">741,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6153c8d6ca7244fcaaa83b242bba2e18_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE1LTEtMS02ODM2Nw_381e1b60-e9e4-49da-ac97-d3e6a43ee785">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic95cffa740f64b68af86df3f770a0b25_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE3LTEtMS02ODM2Nw_08d399d6-60db-45fa-ad8e-da82c0767685">488,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE5LTEtMS02ODM2Nw_6a79ebee-0d95-411e-97eb-a9ee29b9f57d">395,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMtMS0xLTEtNjQ2MTQ_13e51904-feeb-427e-b402-5746a8dbd813">129,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMtMy0xLTEtNjQ2MTQ_0a2e6a97-efc9-48ba-b431-1e4f231d4a71">79,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzYtMS0xLTEtNjQ2MTQ_022aefb9-e9ae-4206-953a-8d6a9df942d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzYtMy0xLTEtNjQ2MTQ_6ae7aeb9-3119-4c7a-b6db-208ecab45c9a">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzctMS0xLTEtNjQ2MTQ_9092af70-56bc-4dfd-a282-b692e2be560f">19,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzctMy0xLTEtNjQ2MTQ_9e9b2d22-6fd2-4256-8768-be82abfced33">14,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense and amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzgtMS0xLTEtNjQ2MTQ_2e261c14-f663-45d6-9846-a24f9021a45c">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzgtMy0xLTEtNjQ2MTQ_c70eb557-69eb-422c-a1d9-ec8eae59978d">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEwLTEtMS0xLTY0NjE0_e7f033be-7c86-4fb0-b1af-66a98c2ad700">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEwLTMtMS0xLTY0NjE0_09a174fa-fa92-410e-88d2-19ffca26a592">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion and amortization of premiums and discounts on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzExLTEtMS0xLTY0NjE0_4755ce6b-dc66-44e2-b369-5ed9874ce9b8">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzExLTMtMS0xLTY0NjE0_691e85b3-59e7-4a05-94bd-c893d5578890">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEyLTEtMS0xLTY0NjE0_35df93e6-856d-4fc7-81e3-02be8613d794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEyLTMtMS0xLTY0NjE0_cacee34a-c6ba-4707-bbee-6cf6418caa8f">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEzLTEtMS0xLTY0NjE0_f559682e-4bcd-4565-944a-953b3f9c6692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEzLTMtMS0xLTY0NjE0_11f18879-b023-4c43-b11d-19e34adf7316">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="vrdn:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE1LTEtMS0xLTY0NjE0_81da708b-e985-417d-918a-0c8358830e63">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="vrdn:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE1LTMtMS0xLTY0NjE0_ea7c0b90-2696-4a6c-a664-2d4934236cff">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE3LTEtMS0xLTY0NjE0_16c14879-4420-4089-999e-f883400a4fac">3,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE3LTMtMS0xLTY0NjE0_5c1417b8-8da5-4331-9d71-d1d9573efc82">1,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE4LTEtMS0xLTY0NjE0_4555049b-7e43-404f-afee-21812820962a">11,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE4LTMtMS0xLTY0NjE0_178b2176-fbcd-467f-8d80-dba53049d961">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE5LTEtMS0xLTY0NjE0_368172f1-000d-4fc7-b2f7-2d54f6013ba0">7,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE5LTMtMS0xLTY0NjE0_ef974539-1e7f-4c62-8d49-6e43fc0b80f9">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unbilled revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIwLTEtMS0xLTY0NjE0_55e97a24-94b0-4367-b507-a0f64302406d">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIwLTMtMS0xLTY0NjE0_f6ead69c-5c19-4f80-a4b8-04c858c3cbf2">451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIxLTEtMS0xLTY0NjE0_972fad43-9752-4797-8671-0750505d43e8">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIxLTMtMS0xLTY0NjE0_3e9c48b5-8fd5-43ef-b110-9ce070ba3c9b">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIyLTEtMS0xLTY0NjE0_27c4b68b-01f3-420e-be37-6208daac2d37">93,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIyLTMtMS0xLTY0NjE0_c128581f-0805-40ca-af4e-41a1ddc66096">54,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI0LTEtMS0xLTY0NjE0_abeda0ea-8b55-4b2a-ab8f-80e9cdc5eb45">223,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI0LTMtMS0xLTY0NjE0_2586b222-8334-4ded-b97d-9ca88b2856de">188,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI1LTEtMS0xLTY0NjE0_317da06c-f1fb-4a85-a240-3751be57db8b">108,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI1LTMtMS0xLTY0NjE0_00480f73-85cd-41e4-9ac4-0540ad711ca3">114,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI4LTEtMS0xLTY0NjE0_95d11ebe-dec7-4d0a-8140-50c0bb224003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI4LTMtMS0xLTY0NjE0_19e50250-453a-4ae6-a1c4-364a82a08ea0">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI5LTEtMS0xLTY0NjE0_1714dd9d-dcf4-45e7-92eb-aea6b4899687">797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI5LTMtMS0xLTY0NjE0_ac75923e-ea58-4d27-a3ac-a9330a701d4a">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMxLTEtMS0xLTY0NjE0_079fc507-d168-40af-b1ed-6a0281a05a1c">115,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMxLTMtMS0xLTY0NjE0_d3283777-c05d-4257-a3fb-fdddb888f468">74,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock, pursuant to 2022 Public Offering and September 2022 ATM Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMzLTEtMS0xLTY0NjE0_684f24be-9b98-4719-8fc4-ad110d510b3f">291,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock, pursuant to 2021 Public Offering and April 2021 ATM Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTMtMS0xLTY0NjE0_127ed81d-3110-4e52-9265-cacbf2893e6e">114,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of issuance costs associated with the sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM1LTEtMS0xLTY0NjE0_04daf698-f5fa-4d1b-a6ca-69acf3649ad1">19,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM1LTMtMS0xLTY0NjE0_b68028e3-618a-4c9e-8cf1-4d2d4ddf92e4">6,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of Series B preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM2LTEtMS0xLTY0NjE0_e5b15a40-002c-4b21-9bc3-bfdd87d43eff">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM2LTMtMS0xLTY0NjE0_975f2f29-2f6d-491c-bcff-7127b1bcf3bf">16,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of issuance costs associated with the sale of preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0697651628c4404996864ee40e782d4_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM3LTEtMS0xLTY0NjE0_ddea2a8b-f34a-4cce-a1bd-1b83b6cce4a8">2,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a876722929249349e7f7da5272ce756_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM3LTMtMS0xLTY0NjE0_9701c9ac-62cd-4097-a12e-ddb87bed5af9">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM4LTEtMS0xLTY0NjE0_83023646-34d8-4607-a376-c83e8c1b4774">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM4LTMtMS0xLTY0NjE0_bd4abd15-aedf-488c-8031-c6bd491609df">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM5LTEtMS0xLTY0NjE0_65b0bb58-0f51-48e1-ace3-43276402fcf5">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM5LTMtMS0xLTY0NjE0_2c94b836-4bb5-45d1-abe4-f99c4c62ba2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTEtMS0xLTcxODM4_accd5314-8003-4a76-b22b-7a9d57fc316b">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTMtMS0xLTcxODU2_ea029dcc-5dc6-4ff2-9da8-b5784523ccf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQwLTEtMS0xLTY0NjE0_03cf38f3-c326-4e4d-b615-c62d6b9787e1">2,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQwLTMtMS0xLTY0NjE0_2c2e71d0-d3f4-4a35-ad03-51c91b3f184a">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQxLTEtMS0xLTY0NjE0_8e3158f8-3850-4608-afc1-ce50ee1d25b8">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQxLTMtMS0xLTY0NjE0_24fa2db8-5a50-4144-814d-36f1d0c77c9c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ1LTEtMS0xLTY0NjE0_40b2fbaa-6dce-4845-8e7c-884ee4ad0a45">322,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ1LTMtMS0xLTY0NjE0_47827526-88ac-40f2-bdfd-525990c3af93">125,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ2LTEtMS0xLTY0NjE0_f223f6ae-dec1-4f9b-b341-d7e92e66135a">113,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ2LTMtMS0xLTY0NjE0_fba3aecd-c8cc-4796-8939-1d556baf31b7">3,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ3LTEtMS0xLTY0NjE0_39da7894-e9f5-48d7-bffd-b0f3e02b7fa7">42,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ3LTMtMS0xLTY0NjE0_5428266b-0cbd-414e-8d93-0066829c2fce">45,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ4LTEtMS0xLTY0NjE0_c7695870-9504-4a96-85ca-2daa41f91f32">155,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ4LTMtMS0xLTY0NjE0_2cd08fc1-0117-44db-aaa5-ec20540b4a55">42,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUwLTEtMS0xLTY0NjE0_efcbd7af-c5fb-485b-9267-1ad2bf00dc4c">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUwLTMtMS0xLTY0NjE0_0e60149f-bc9d-4bc1-9cfc-264b9de2111f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Purchase of property and equipment in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUyLTEtMS0xLTY0NjE0_76320516-09d9-40e9-ba7d-8623b4a101d0">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUyLTMtMS0xLTY0NjE0_2282c80d-6598-4531-9bd5-aebbc0f0a360">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of public offering costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="vrdn:AmortizationOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUzLTEtMS0xLTY0NjE0_fef27393-07cd-4b2b-a110-1ae130596545">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="vrdn:AmortizationOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUzLTMtMS0xLTY0NjE0_890deb18-58b8-4230-8285-3c2eb0359a62">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzcwNzY_125fc495-d946-43e1-a65a-000c44b55e73" continuedAt="ie8ab0439ab6f4cceb9f3b6862c1ce16e" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie8ab0439ab6f4cceb9f3b6862c1ce16e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Viridian&#8221;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#8217;s therapies. The Company&#8217;s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#8220;IGF-1R&#8221;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#8220;TED&#8221;). The Company&#8217;s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. In addition to developing therapies for TED, the Company is executing a similar strategic approach to identify opportunities in other rare and/or serious disease indications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#8217;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through December&#160;31, 2022, the Company has generated an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzU0OTc1NTgyNTg0Nw_8eb4542a-d26d-4679-915a-924ccc3e633a">488.2</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzU0OTc1NTgyNzQzOQ_b8de80e6-95a4-4384-9814-935d30cec672">424.6</ix:nonFraction> million in cash, cash equivalents, and short-term investments. As of the issuance date of these consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#8217;s clinical development efforts, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#8217;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#8217;s control, including success in developing its technology and drug product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTUw_913a090c-6456-467e-a3e3-cf63a16b06e2" continuedAt="i43ee3f34d7a74c39a6b7fa7c6a94a9c8" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i43ee3f34d7a74c39a6b7fa7c6a94a9c8" continuedAt="ib85406721ab841afafdf2b691d578c9e"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTYy_2ad0bcdf-4658-49f7-a877-4085d810ee86" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Viridian Therapeutics Europe Limited and Viridian Therapeutics S.&#224;.r.l., both of which were formed for the sole purpose of submitting regulatory filings in Europe, and Viridian Securities Corporation, which was formed in July 2021. The Company&#8217;s subsidiaries have no employees or operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="vrdn:GoingConcernPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NDk0_a7c64188-54dc-47bc-87ac-aed53c0c9d86" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents and short-term investments balance.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NjA1_8e51d9ca-ab0b-4720-8ca9-434788817884" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTU_f232b9d5-f47c-4a67-9a1d-b230c5dd9cb4" continuedAt="i26b47303219b49e2b39507771b780118" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib85406721ab841afafdf2b691d578c9e" continuedAt="i8e555a516d5e41f29f3d35d0d63e6650"><ix:continuation id="i26b47303219b49e2b39507771b780118" continuedAt="i414c9fc284794e0281f18f01c085e92a"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8e555a516d5e41f29f3d35d0d63e6650" continuedAt="if5a94bcf8ae04aa1ab3930c3703730f8"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i414c9fc284794e0281f18f01c085e92a">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTY_3c1e0f80-0d7f-4ef1-bd4d-ab287b3bd2c6" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Such expenses are included within operating activities in the consolidated statements of cash flows. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTc_b150cd43-fb7c-4c06-a45d-bfc16528130d" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTg_a9194798-74af-45b7-8014-36367d0dacb2" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation expense to employees and non-employees based on the fair value of each stock option or award on the date of the grant. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTk_478ed80b-be15-42e3-acd4-0a860b3ef7fa" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjA_66003189-dd5c-4952-9ea2-4927a86acc41" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if5a94bcf8ae04aa1ab3930c3703730f8" continuedAt="i3d1918354c824e86810833434e0e8e51"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjE_43f3553f-c198-4cc0-8ed0-afe486e0933e" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilizes observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjI_40676ad5-794a-46d3-b84e-4d42b61076f8" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjM_158568b2-1179-442a-a0d0-f6df660f014d" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921">three</span> to <ix:nonNumeric contextRef="ib14e5a6aafc64ee685e4abf45a236d64_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MzU_0dc8fe7a-fb73-46c6-a2cf-059ede08dd36">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3NTE_1229087d-e3a6-4daf-958b-735d2fad2abf" continuedAt="i6789bbea66554bf493fdf75473a274aa" escape="true">Operating Lease Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i6789bbea66554bf493fdf75473a274aa" continuedAt="iaf733427c5e5454db52fa44a154aaf2e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf733427c5e5454db52fa44a154aaf2e">and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</ix:continuation> Refer to Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies - Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information related to the Company&#8217;s operating leases.</span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3NTI_b28068fa-47ae-4f6a-b585-8e247c004b83" continuedAt="icecc61881017401b9e3267ebbd0fbab7" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Debt issuance costs represent </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3d1918354c824e86810833434e0e8e51" continuedAt="i6e8e3efdf3664630852bc85a3e18d956"><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="icecc61881017401b9e3267ebbd0fbab7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span></ix:continuation></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTc1_65668783-ab11-4262-933f-d50b0881d16f" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Preferred Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and at issuance classified the Series A Preferred Stock outside of stockholders&#8217; equity because, if convertibility of Series A Preferred Stock into common stock was not approved by the stockholders, the Series A Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. On December 31, 2020, the stockholders approved the convertibility of the Series A Preferred Stock into common stock and as such, the Company reclassified the Series A Preferred Stock to permanent equity. In September 2021, the Company issued Series B Preferred Stock with conversion rights which the Company has classified as permanent equity in its consolidated balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTM2_aa46b0c9-74c3-40ba-9980-df25d0d03495" continuedAt="i90b119288aca4afd84e6e38a75308e02" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90b119288aca4afd84e6e38a75308e02">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI1MzE3_250b3f82-0def-4a4c-9d0a-b316a874102e"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI1MzE3_61c7d4d1-763c-4f59-a919-901d5921814b">No</ix:nonFraction></ix:nonFraction> impairment charges were recorded during the years ended December 31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTIx_7304f811-6a4d-48ea-9c0e-0aeabf5089f2" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTcy_6d63754d-53ae-4d51-92e8-c5be0a645ecf" continuedAt="ie8c95ab484e549ac87c1cd6469c1d535" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8c95ab484e549ac87c1cd6469c1d535">Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the consolidated statements of changes in stockholders&#8217; equity.</ix:continuation> The Company had unrealized losses on investments of $<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI2MTY0_aa6fb112-ab94-486e-9ac6-da87d55e45c7">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI2MTcx_bfd12e76-606d-4088-a3c0-21f3233a462c">0.1</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTMx_06340887-0942-42eb-b03b-dc4ee8a761d4" continuedAt="i0f280f8e4bc548458aae80dd49b37384" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0f280f8e4bc548458aae80dd49b37384">The Company has <ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3NDY5_b9e065b0-0330-454f-9d5a-0075624dfa99">no</ix:nonFraction> unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3Njg5_64e336b0-f599-460c-8437-59e2ba3a5645"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3Njg5_c47e24f9-4457-4841-bc51-43e21863d4b3">No</ix:nonFraction></ix:nonFraction> such expenses have been recognized during the years ended December 31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="vrdn:WarrantsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTc2_35a14a72-b599-4fe9-a9b9-9ba7c22bcebd" continuedAt="ide19b712de1e41329c907200a8d17582" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6e8e3efdf3664630852bc85a3e18d956"><div style="text-align:justify"><ix:continuation id="ide19b712de1e41329c907200a8d17582"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NDk3_566dedfd-1c66-4fae-951c-c38c263a95c9" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;<ix:nonFraction unitRef="segment" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI4ODEw_406b16cd-9fd1-488a-a6ca-dc96ff7a1b8b">one</ix:nonFraction>&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTgw_a39e994c-a030-45c9-9965-b94cb76573f9" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2MQ_ff641800-b0b1-4a4b-9ef3-18a2129fe8bf" continuedAt="i3d98425f53b242699f21baa8d3689ffe" escape="true">INVESTMENTS AND FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3d98425f53b242699f21baa8d3689ffe" continuedAt="ia9e394c210c94a0b89c8229c691334f1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2Mg_287e723d-6a53-421d-bc64-4c10b7fa85fc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of December&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:34.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItMi0xLTEtNjYyNTk_0b34cc44-ea3f-4c6d-8a28-56034c85c0a0">137,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItNC0xLTEtNjYyNTk_e0beeba5-0b27-43e1-8f28-f8635ca35652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItNi0xLTEtNjYyNTk_de9b2c81-196a-491a-b0e8-cbd81d4a368c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItOC0xLTEtNjYyNTk_ed7879b1-14b0-46ec-b5c6-348aa62fe3f9">137,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtMi0xLTEtNjYyNTk_6b24c8f9-7985-4cc9-aa27-3bc38a6b5bb1">85,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtNC0xLTEtNjYyNTk_0f0ece46-1307-4274-9061-5315bd7c731f">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtNi0xLTEtNjYyNTk_2c5f9dd6-7037-4a89-8e9c-0cfc96899b1b">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtOC0xLTEtNjYyNTk_eb0094b3-a278-427a-a87a-b74fa6d8f4e8">85,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtMi0xLTEtNjYyNTk_155648f2-6d31-427b-abaa-64a0c7f5a124">199,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtNC0xLTEtNjYyNTk_cc34b5e7-efa5-4bee-9198-54c02c71732a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtNi0xLTEtNjYyNTk_5c0b77b2-02e8-42dc-9388-396688a851fb">385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtOC0xLTEtNjYyNTk_03ac41eb-68fe-4c1f-8405-09adcf1af86c">198,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtMi0xLTEtNjYyNTk_b7d81aa5-f569-40d5-bf57-a628145a1d4c">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtNC0xLTEtNjYyNTk_39ec7602-9610-4390-bfd3-d0cc0a9c0ee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtNi0xLTEtNjYyNTk_8410b3fc-21db-4999-b7bc-73c310ac23cc">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtOC0xLTEtNjYyNTk_e58e2de8-b739-46e5-bf80-81827dd7c97f">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtMi0xLTEtNjYyNTk_d6a6559b-4fcb-4c39-ab8e-b274d9d6e9f5">424,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtNC0xLTEtNjYyNTk_8a645d63-3717-4fc6-ae35-03de3527524e">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtNi0xLTEtNjYyNTk_f0df9b32-e65d-4a98-a3bf-550c43ea8e8b">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtOC0xLTEtNjYyNTk_0a381f90-d9e6-475d-99ce-948e8d436d26">424,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktMi0xLTEtNjYyNTk_539f9e27-621e-4923-9ba0-032ccf7021aa">42,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktNC0xLTEtNjYyNTk_2934dd9d-09b6-4d89-8e59-72956b0b0b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktNi0xLTEtNjYyNTk_de320bc9-947e-4eb6-b50b-f9ccb146eb78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktOC0xLTEtNjYyNTk_c5946199-efa5-494c-967b-0f9bfeffb8a8">42,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28384390d13f43e5b84481e6b9381841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTItMS0xLTY2MjU5_0fcb4304-4950-4fc9-bd48-4ebf1acdffe7">22,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28384390d13f43e5b84481e6b9381841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTQtMS0xLTY2MjU5_301ad98b-d1cf-44bd-a182-9f0ddd26aa12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28384390d13f43e5b84481e6b9381841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTYtMS0xLTY2MjU5_c3fbfa7f-7e44-4288-9be9-4aaeb08e4789">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28384390d13f43e5b84481e6b9381841_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTgtMS0xLTY2MjU5_343165c8-d3e8-4e20-8216-ef21e1815dfb">22,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTItMS0xLTY2MjU5_a2b7817a-49ad-4033-bffb-468f56aeca26">128,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTQtMS0xLTY2MjU5_466887c7-eec4-43ef-946a-e3ff14cf0edf">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTYtMS0xLTY2MjU5_6979d546-7a59-49a1-984a-38145aef0d37">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTgtMS0xLTY2MjU5_9ad7a1e5-63a5-46af-82bf-2ea5cdd82315">127,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTItMS0xLTY2MjU5_94872b6d-e7c7-4a52-9496-fe0e728223ce">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTQtMS0xLTY2MjU5_c5b3c2b8-c0f0-43fc-8f27-fed5084705f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTYtMS0xLTY2MjU5_0f1bf23d-2128-49aa-873b-2db3a7967f23">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTgtMS0xLTY2MjU5_f35a08bd-216b-4f75-b29c-9d8d83f1c2fc">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTItMS0xLTY2MjU5_a7e759df-558d-45d1-9ccc-a35b63443847">197,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTQtMS0xLTY2MjU5_9f1fd1ae-3410-40c8-afe6-eec97f64c105">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTYtMS0xLTY2MjU5_92bc1bd3-c793-4eb3-8302-23249c9ee54e">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTgtMS0xLTY2MjU5_17be7b18-9745-40a2-9dfc-e81f5eeab6e9">196,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company had realized gains of <ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDM0MzM_3060e53a-8e52-41be-bb73-a227b954b0c1">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDM0NDM_4c52fef8-b6ad-426e-a32d-ede037d66fcc">4</ix:nonFraction>&#160;thousand in its available for sale securities for the years ended December&#160;31, 2022 and 2021, respectively. The contractual maturity dates of all of the Company&#8217;s investments are all less than <ix:nonNumeric contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDMzNjc_911cce93-ea23-40e5-af2b-181203859df5">24</ix:nonNumeric> months.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2Mw_7ecec67b-5a71-4fe7-9eda-ab3f9f1d7599" continuedAt="id09f7c2eb0a741de8cee7b06861071e1" escape="true">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="ia9e394c210c94a0b89c8229c691334f1"><ix:continuation id="id09f7c2eb0a741de8cee7b06861071e1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdcc30d49604c4f8a177a5ad2200579_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtMi0xLTEtNjYzMTc_3fcbf25c-950b-434f-aa9c-b5bd8b7fa0f3">137,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9356ff5b031a4687b1c762d67b77aa89_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtNC0xLTEtNjYzMTc_fcc8bce2-9b1b-4a9a-8a81-07fe9eaee0d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138932474f284b93a8c0a3f2ea051590_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtNi0xLTEtNjYzMTc_9f2bc4e8-984b-4a24-9a46-c92a56fa2817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9db3f0dd54baab1199f7f903a42f9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtOC0xLTEtNjY2NDU_09612dbd-30f9-41e6-9fb8-a8ab6a331782">137,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtMi0xLTEtNjg0MjA_0dea94be-abe6-499a-adc0-67bcb81fef74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf415c64ea54fffaef87bbacbad114c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtNC0xLTEtNjgyMzY_b06c7833-1841-45c6-b298-a34de114d88b">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtNi0xLTEtNjg0MjA_e932cf4c-466c-46a0-9e1c-995c2cdc1825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtOC0xLTEtNjg0MjA_5e5bc641-875c-454f-b752-ae5d97f39a7d">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17544d63b7e4808a4b8208d12cb2e71_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctMi0xLTEtNjYzMTc_551d242e-494e-4eff-ab4f-93c85f8182d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d2676e80164d798e781f7504896a1f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctNC0xLTEtNjYzMTc_d78183cc-53e7-4965-bc4a-10b5727bcdec">85,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie994cb889acc4540af7bc488619bb148_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctNi0xLTEtNjYzMTc_9fb42eef-dd66-4746-b7a5-5cdaf689a6c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68f4338d1f44253b074041654004af8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctOC0xLTEtNjY2NDU_ed81e04d-607a-43de-9ccd-ded6a1142869">85,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtMi0xLTEtNjYzMTc_19a5d882-8aa6-4a2a-aed0-51e8e229e282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf415c64ea54fffaef87bbacbad114c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtNC0xLTEtNjYzMTc_00587d25-3888-4ad6-9c56-402fcf13c3e0">181,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtNi0xLTEtNjYzMTc_1af11ab8-abf0-44a1-9e24-09734a0ae512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtOC0xLTEtNjY2NDU_672ba107-9681-4a0d-bfb4-006f0c9790cd">181,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2795e5bc63324d8692234b45f12d6e89_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktMi0xLTEtNjYzMTc_93eb82a4-7e83-4d34-aac1-32558265f9c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495cfb882143496ab5fafbfd845fc230_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktNC0xLTEtNjYzMTc_56e97d28-8bac-47eb-826e-51bcf513e668">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7a54bdbf734a5f8559bb31501853dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktNi0xLTEtNjYzMTc_0142e9db-35ad-4da6-9909-88d17a833520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ec5d1cd14648b2a0cb3409d8481901_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktOC0xLTEtNjY2NDU_a2e20020-d04e-40af-ae49-e1405f7f0119">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb2d53f432d49a28a93868e1b8234d5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTItMS0xLTY2NjQ1_444f0913-7ef4-431a-8d27-790b2e7ad36a">137,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e890918a65f47ea962c20bc52a3a589_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTQtMS0xLTY2NjQ1_c666a7bc-f5a2-440f-b2c2-0844de3d31e8">286,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718d62966309427ab5d15be792791b49_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTYtMS0xLTY2NjQ1_1a5f5a8b-8890-437f-84f0-d47225fab078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f92b6bed324e2ba85a9852abf1b187_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTgtMS0xLTY2NjQ1_b8a79d5c-5b65-4f68-95f7-e5fc7f713b8a">424,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6d117211af41a28fb359bb1d81d933_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTItMS0xLTY2MzQy_35125dab-89b8-4179-bd63-ae408cd7b59d">42,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie418b540ddec4d8f9a908bc68dd410e2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTQtMS0xLTY2MzQy_c4e0cca2-9db0-4ca4-93a6-29f171548829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39731739ccb24de699b33ec24511466f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTYtMS0xLTY2MzQy_8e51fc84-ee87-45df-aa8e-c9f7439b1a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife91bebf75fa462f9dc8efd8e9e15192_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTgtMS0xLTY2MzQy_fe4220db-f719-4526-9942-359498beb1bb">42,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00032c150d7b4b26b67be5b777d07453_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTItMS0xLTY2MzQy_1f7b5086-4ad3-43fb-9940-ce16b48c9260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb7acaf82d94261b8bbef9198fb5b9d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTQtMS0xLTY2MzQy_5d997670-8e0a-43cc-82f8-601c2aa398ff">22,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397518dae3854f5aaf22291b12e28fbe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTYtMS0xLTY2MzQy_6e0ea7e6-5e22-4b3d-b9c3-522848092aec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0e75e0c7604e9682a93b1b039078c0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTgtMS0xLTY2MzQy_fe59e97f-4712-4cd9-a521-e6fad103876e">22,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b087108fec4701a4a2c61e0717f2a1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTItMS0xLTY2MzQy_9fa10d8b-b143-40ad-88c1-0d0bc6e44d91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e20b79c6ce409d9f6ade1210e3b210_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTQtMS0xLTY2MzQy_9e7126a3-d891-49de-a1bd-2d96b7d19638">127,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c21147b36794bedbd9fc27467dd2076_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTYtMS0xLTY2MzQy_29958194-1a58-4825-adf7-c85b8f2e90f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569d7eb69fb147f7a599cb9ed5033a75_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTgtMS0xLTY2MzQy_b43da260-1c13-4969-8df8-32cf36958274">127,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica72868174974c239b1ad5f7a2786253_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTItMS0xLTY2MzQy_55d7040b-0c21-4f90-8c09-9557166f0f8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa2353ccf1b493a906749cc46971b22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTQtMS0xLTY2MzQy_f849ec1d-975a-41f2-8ff1-aa1ae6faf1f9">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd00d8f83ece4bb8bf16db7bf032c030_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTYtMS0xLTY2MzQy_cfc7cba0-9777-4e2b-a827-28fb79f4dff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf96050c9b204ae3a4dc0d09a8f89a45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTgtMS0xLTY2MzQy_7e42820d-a8d7-4b52-8f44-724657abb60b">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2493b7d3e6f54fc4aca64c1b7e756944_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTItMS0xLTY2MzQy_ed32e210-6d24-4e98-aa3f-d13878ae2903">42,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7237ef7f504c42ac91f4cd23a2e8f7d5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTQtMS0xLTY2MzQy_bcc0b010-ea41-47e8-b0fd-2ff263fe9929">154,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic661c528426d40a4a7f6ff953d525bbf_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTYtMS0xLTY2MzQy_3a32d6fd-7de6-4044-b61f-adb48427a91b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962c21f5667a48bead2b497aa2cc2efb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTgtMS0xLTY2MzQy_e972cd5c-4318-49c5-aecc-73d24b9c01bc">196,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_142"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzg5Mw_4f0e588e-cd41-4f44-976a-7088c0998627" continuedAt="i8e314c8578a64a2f97b5e38c186ab2b0" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i8e314c8578a64a2f97b5e38c186ab2b0" continuedAt="i2bab1729a6214d4aac8d7758c9e8b1de"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzg5NQ_1d77749d-d16b-46f1-b1b8-bf236fe51027" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6583aa4bf42c9b1b52633f83d14a8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzctMS0xLTEtNjQ2MTQ_04567521-8e75-4df6-8b69-55c0314895a9">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25cc2ffa9f144a88bb763f938333daf_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzctMy0xLTEtNjQ2MTQ_50b47012-2057-4968-9927-db4a2143f312">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a117538c9041aebcee41fd26d43947_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzgtMS0xLTEtNjQ2MTQ_d92db2f0-c26f-4953-ae06-9bba69813401">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558bf4d01982457597bb849567a66261_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzgtMy0xLTEtNjQ2MTQ_daff88ac-d956-4572-8709-b78754de9aca">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia959ee789f0d49838e929580701a3357_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzktMS0xLTEtNjQ2MTQ_f190736d-d06c-4abd-8d8f-2e1a881f7293">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2828cb09ac024bbeb97dcdad08208d79_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzktMy0xLTEtNjQ2MTQ_ce1e7653-1cbc-4289-a9a0-26764377ccde">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad844ce133a4439b89b3b712bcebe2fd_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEwLTEtMS0xLTY0NjE0_704f07f0-ff9d-4ed3-9f10-09224ffd94f9">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb8a885c6c2471aac42e78a2b6716e1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEwLTMtMS0xLTY0NjE0_d91bf09a-d782-4122-811f-c96d688d5d7b">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzExLTEtMS0xLTY0NjE0_10af0583-dc4c-4024-a6aa-cdff4f5ec0cf">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzExLTMtMS0xLTY0NjE0_020b210b-411c-4b78-9f21-8387f262d5c3">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEyLTEtMS0xLTY0NjE0_dd9c6501-1c4d-4d1d-b3ed-1dc1cd1529b1">2,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEyLTMtMS0xLTY0NjE0_2f3d9165-9fa3-4c14-bb7b-ca5331fb8e9f">1,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEzLTEtMS0xLTY0NjE0_23bab53c-2817-4527-8480-a3674e01dd63">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEzLTMtMS0xLTY0NjE0_5cef05a1-baf1-4768-9078-b77bb7ec7662">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, certain lab equipment met the criteria to be classified and were reclassified as held for sale and included in prepaid expenses and other current assets. The assets held for sale totaled $<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzM4Nw_01aeaca5-48ab-4ea2-987d-853f0c8ca28a">0.1</ix:nonFraction> million, which was the net book value on the date of transfer. During the year ended December 31, 2021, the Company sold the equipment, received proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzU2MQ_9a076c77-82b6-4335-b6dc-286bec6378c1">0.1</ix:nonFraction> million and recorded a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzYwOQ_9d3fc5ac-23d7-495d-ae82-617117af6e68">0.1</ix:nonFraction> million. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bab1729a6214d4aac8d7758c9e8b1de">During the years ended December&#160;31, 2022 and 2021, depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzY5MA_bc033236-81c1-4639-ba4c-cb1cade971f7">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzcwNQ_9e68d044-40c3-4c84-9815-e147caefc875">0.1</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90ZXh0cmVnaW9uOjdlNmNjMzU3NWY2MjQzMzM4Mzg2MTdhNjQ5ODUyYmRjXzc5_02f95dfd-cd00-40c6-bbbe-f33cb33553f1" continuedAt="i793d37b78ced44f4afeb0ca5e3c05f29" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i793d37b78ced44f4afeb0ca5e3c05f29"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90ZXh0cmVnaW9uOjdlNmNjMzU3NWY2MjQzMzM4Mzg2MTdhNjQ5ODUyYmRjXzg3_8fde6528-3778-4686-8c94-49b8c6809cb5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:AccruedOutsourcingClinicalandPreclinicalStudies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzMtMS0xLTEtNjQ2MTQ_b91625e6-bc3d-480a-92dc-53efe80d9722">12,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:AccruedOutsourcingClinicalandPreclinicalStudies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzMtMy0xLTEtNjQ2MTQ_9a6d4247-7d1b-4cb9-910a-f18e0aa69659">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzQtMS0xLTEtNjQ2MTQ_c62c5d88-f4da-42b7-9fd7-848c0913b26c">4,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzQtMy0xLTEtNjQ2MTQ_9ab1515e-6b35-44ed-8ea2-4ff59d5acbc0">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMS0xLTEtNjQ2MTQ_3ee0237b-d398-4c40-8721-599256b0c194">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMy0xLTEtNjQ2MTQ_688eac3a-ae58-4513-941c-66c0e7b6b1bb">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:AccruedLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzYtMS0xLTEtNjQ2MTQ_1c1bdfd2-2c32-4b20-936b-a50443d19f9a">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:AccruedLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzYtMy0xLTEtNjQ2MTQ_f6b4d252-32e4-4add-9562-9aef3a0d2d64">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzctMS0xLTEtNjQ2MTQ_4cc71493-7e07-475a-b136-94b7e5619955">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzctMy0xLTEtNjQ2MTQ_20077e86-7040-418a-ace6-4893fc59ac0f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:AccruedLiabilityofWarrantsonTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzgtMS0xLTEtNjQ2MTQ_7c3a8b4b-00cc-4a22-b1b9-c02680d67c43">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:AccruedLiabilityofWarrantsonTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzgtMy0xLTEtNjQ2MTQ_1dda4328-0eee-4b50-a1c2-5bd8408f36d2">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzEwLTEtMS0xLTY0NjE0_3ffdfdb7-c1cb-45cd-b18e-66e9882be686">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzEwLTMtMS0xLTY0NjE0_3a1d4105-d061-4226-b23c-8ca3b75fd994">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzExLTEtMS0xLTY0NjE0_4363bc5d-f276-4287-a140-1a7a61e40528">18,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzExLTMtMS0xLTY0NjE0_7a89c7e7-6583-4f42-a690-95b3384422cd">11,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_148"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2MDM_e0de6bc9-e564-4088-a44d-113f8116865c" continuedAt="ia20ce9d8e72348d795d097ef053a739f" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="ia20ce9d8e72348d795d097ef053a739f" continuedAt="i70db1eb52f1a4a89920c88dc727e3897"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, the Company entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders named therein (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzNjY_f1631624-6368-4a28-b933-c5c631eb4e50">75.0</ix:nonFraction>&#160;million, in <ix:nonFraction unitRef="tranche" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzODA_b8e85f87-52d8-4e0c-8732-3e3e19c8a65d">four</ix:nonFraction> tranches (collectively the &#8220;Term Loan&#8221;), consisting of (1) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFirstTranche" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzOTA_7310695f-1cc5-4a1b-8f54-ddbcbbb611cd">25.0</ix:nonFraction>&#160;million, available to the Company through June 15, 2023; (2) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentFaceAmountSecondTranche" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MDU_0261db15-c2e6-42ea-b26e-4d6f53bda4e4">10.0</ix:nonFraction>&#160;million, subject to the achievement of certain regulatory milestones, available through June 15, 2023; (3) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentFaceAmountThirdTranche" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MjA_de125c4a-69e4-4b84-ae17-ba61f2460313">15.0</ix:nonFraction>&#160;million, subject to the achievement of certain regulatory milestones, available through March 15, 2024; and (4) a fourth tranche of $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFourthTranche" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MzU_29ea7e92-053f-4714-bdf8-6203fa04ef6c">25.0</ix:nonFraction>&#160;million, subject to approval by the Lenders&#8217; investment committee(s), available through December 15, 2024. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Loan Agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Term Loan has a maturity date of October 1, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Term Loan bears interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NTA_81299140-1532-499d-92ed-3d3492313996">7.45</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="iee91adf567604cd2aa42b110e5fac7af_D20220401-20220430" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NTc_129715d6-031a-42f8-bc99-0fef63195f77">4.2</ix:nonFraction>% above the Prime Rate, provided that the Term Loan interest rate shall not exceed a per annum rate of <ix:nonFraction unitRef="number" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:DebtInstrumentInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NjM_f0e1b31d-9ef0-444b-be12-ca16929a4c09">8.95</ix:nonFraction>%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of December 31, 2022 was <ix:nonFraction unitRef="number" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NzA_8060ae7b-5039-4cfb-8762-7461ef4a990f">8.95</ix:nonFraction>% based upon an increase in the prime rate in June 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per the terms of the Hercules Loan and Security Agreement, the Company was originally obligated to make interest-only payments through April 1, 2024. However, upon the achievement of a development milestone in August 2022 the interest-only period was extended to October 1, 2024. If additional development milestones are met, the interest-only period will be further extended to April 1, 2025. The Borrower is required to repay the Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to <ix:nonFraction unitRef="number" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="INF" name="vrdn:PrincipalAmountTermFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2NDkyNjc0NDkyNzA_42aba318-16c9-4978-8007-bda33d3d459e">6</ix:nonFraction>% of the principal amount of funded Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $<ix:nonFraction unitRef="usd" contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0OTE_e61cf916-f19c-4356-bd78-7cbc922fc4d0">5.0</ix:nonFraction>&#160;million. The Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MTk_986c207f-5b00-47f9-9f3f-a27c5d806240">0.2</ix:nonFraction>&#160;million in connection with the Term Loan. In addition, in connection with the initial draw, the Company paid to the Lenders a facility fee of $<ix:nonFraction unitRef="usd" contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430" decimals="-5" name="vrdn:DebtInstrumentFacilityFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0Nzc_ab06d53e-8cab-4009-b4ca-a23ce6c5f554">0.1</ix:nonFraction>&#160;million, as well as $<ix:nonFraction unitRef="usd" contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430" decimals="-5" name="vrdn:DebtInstrumentOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MDU_cb25a1fd-8062-4da2-931c-e4f36eccdae8">0.1</ix:nonFraction>&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#8220;Lender Expenses&#8221;). The debt issuance costs and the Lender Expenses are being amortized as additional interest expense over the term of the loan. Debt issuance costs and the Lender Expenses are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i70db1eb52f1a4a89920c88dc727e3897"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately <ix:nonFraction unitRef="number" contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2NDkyNjc0NDkyNzQ_50f83f89-19a2-4a4c-b16a-af8010a8418c">9.3</ix:nonFraction>%. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzU0OTc1NTgyMTUwNQ_1f0a42de-de70-4acc-9003-21b6c1bf73f3">0.5</ix:nonFraction>&#160;million during the year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MzI_8c7539ce-7943-47b2-b97b-0f78b20985b0" continuedAt="id1f161a908794370b62e5111a40deeaa" escape="true">The following table summarizes the impact of the Term Loan, on the Company&#8217;s consolidated balance sheet at December&#160;31, 2022:</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="id1f161a908794370b62e5111a40deeaa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzItMS0xLTEtNjUzOTA_dbfa972d-fe24-4438-a795-833b4bffa159">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzMtMS0xLTEtNjUzOTA_c29054e3-97bf-44a5-b6d0-881acf1a4c05">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzQtMS0xLTEtNjU4MDE_8ba4c74a-0496-4ad8-82e4-7441860a3a04">4,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MzM_e6abde02-edc9-4bfd-b233-a387acdc115d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan and Security Agreement as of December&#160;31, 2022 are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzEtMS0xLTEtNjUzOTA_1683a7a9-4ab2-45d2-8481-1c88a1c1b5ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzItMS0xLTEtNjUzOTA_0d2030a3-a17e-4d45-b405-73fef51e0c05">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzMtMS0xLTEtNjUzOTA_f3d96bc4-7c8f-45b5-9587-50c05ae86f0b">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzQtMS0xLTEtNjUzOTA_632c3da2-3a78-455d-8d59-dc86a66a9bf5">2,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzYtMS0xLTEtNjU4Mzk_930848c9-5e43-485a-b58b-d656300eb628">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_136"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU2NTE_92080d1b-0025-4d80-b4a3-12b9ccf681c7" continuedAt="ic65ac41f3d2044f9afa7d65896317a6f" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ic65ac41f3d2044f9afa7d65896317a6f" continuedAt="i6a3d022361284a9081f838e786886afd"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Zenas BioPharma</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma (the &#8220;Supply Agreement&#8221;) to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#8220;Zenas Agreements&#8221;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#8217;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 808&#8221;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#8217;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#8217;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6a3d022361284a9081f838e786886afd" continuedAt="i1e80163c29e047299090b55dab6d3dda"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#8217;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#8217;s estimated period to complete its activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the years ended December 31, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i87bf3ab4aa3946a18532afb870802102_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzM5NTg_b0565612-d9d7-408a-a0b1-f4e51740dcaf">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i84ae605e448441d3a3f0ac5f55eca328_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzM5NzM_f5ed44e6-1e9d-4203-8fb2-d312dc34f5dc">3.0</ix:nonFraction> million, respectively, of collaboration revenue related to the Zenas Agreements. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC beneficially owns more than <ix:nonFraction unitRef="number" contextRef="i0659d7dc0d044cddb185ec3b557387ce_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzQyMTM_12e87b2d-7c2c-44a2-b0c1-5c5f4a88998d">5</ix:nonFraction>% of the Company&#8217;s common stock and is also a <ix:nonFraction unitRef="number" contextRef="i0659d7dc0d044cddb185ec3b557387ce_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzQyNjA_06d7feb2-592d-4fc5-bfa2-e3c2a046953a">5</ix:nonFraction>% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#8217;s board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) entered into an antibody and discovery option agreement (the &#8220;Paragon Agreement&#8221;) under which the Company and Paragon will cooperate to develop one or more antibodies. Under the terms of the Paragon Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. The Paragon Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#8220;Final Deliverable&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#8217;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#8220;Option&#8221; and together, the &#8220;Options&#8221;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs at any time until the date that is 90 days after the Company&#8217;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#8220;Option Period&#8221;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Program will terminate. In consideration for Paragon&#8217;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $<ix:nonFraction unitRef="usd" contextRef="i8f5e9943af7844ce9cf70397131daf9b_D20220101-20220331" decimals="-5" name="vrdn:CollaborativeArrangementUpfrontFeePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTE0NA_d5d5259e-b992-48dd-8bf6-e6a9602e06bf">2.5</ix:nonFraction>&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of $<ix:nonFraction unitRef="usd" contextRef="ib0a42fb2ee584e7ca4c08ef5f57c78d4_D20221001-20221231" decimals="-5" name="vrdn:CollaborativeArrangementRightsAndLicensesFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzE2NDkyNjc0NjExNzk_bc3f5efd-94b6-424d-bda2-34b54663b43a">2.3</ix:nonFraction>&#160;million (the &#8220;First Amendment Payment&#8221;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program. During the year ended December 31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="id50bf97251614e40ab675969431f996b_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMzUwMw_ec43abc8-ab9e-4956-8eeb-96a3dadac2db">5.6</ix:nonFraction> million in research and development costs related to the Paragon Agreement.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1e80163c29e047299090b55dab6d3dda">As of December 31, 2022, the Paragon Agreement is considered a related party transaction because Fairmount beneficially owns more than <ix:nonFraction unitRef="number" contextRef="i021c11dfe09a4127921884ad1fc46e9d_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTY0Mw_07e38af8-464c-44d9-8ecd-bae598649827">5</ix:nonFraction>% of the Company&#8217;s capital stock and has two seats on the Company&#8217;s board of directors, and beneficially owns more than <ix:nonFraction unitRef="number" contextRef="i021c11dfe09a4127921884ad1fc46e9d_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTc2NQ_91562ced-c503-4be6-bcc1-849e207c1758">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers.</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3Xzg3NDA_e16b1b77-b3fb-457e-94e4-e96565dd2b40" continuedAt="i3a896ee1587942488763cbf4e82a406c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i3a896ee1587942488763cbf4e82a406c" continuedAt="i0e6c7381a5d744c38fc91365e76382f1"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ImmunoGen, Inc. </span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement (the &#8220;ImmunoGen License Agreement&#8221;) with Immunogen, Inc. (&#8220;ImmunoGen&#8221;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031" decimals="INF" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwMTM_df412ba6-b904-4963-93ea-69d00f4ac973">48.0</ix:nonFraction>&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="if84d62946a994027b63085a509c4d878_D20211201-20211231" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwMjg_8f81a317-dcd0-4793-a96b-9334d1ba3725">2.5</ix:nonFraction>&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#8220;IND&#8221;) application for VRDN-001 with the FDA. In May 2022, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="i7b67fa0e69554ec68418419f8b40c77e_D20220501-20220531" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNDI_e8c330ab-7ed3-4aae-b9a7-985b47d33659">3.0</ix:nonFraction>&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for VRDN-001. In December 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i124a3275b5a440f5acff5df5308106be_D20221201-20221231" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNTY_8d78c304-594c-42e1-bdeb-564f3a510615">10.0</ix:nonFraction>&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a Pivotal Clinical Trial for VRDN-001, amount which was paid in January 2023 and which was included in accounts payable in the consolidated balance sheet as of December 31, 2022. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031" decimals="INF" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNzE_a40825c6-da27-4179-b7b1-94edfab4cba4">95.0</ix:nonFraction>&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements with Xencor, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a subsequent technology license agreement (the &#8220;2021 Xencor License Agreement&#8221;) with Xencor for a non-exclusive license to certain antibody libraries developed by Xencor. Under the 2021 Xencor License Agreement, the Company received a <ix:nonNumeric contextRef="iacf8bb4484b14487a716974ff915120a_D20211201-20211231" name="vrdn:CollaborationArrangementResearchLicenseAndSelectionRightsTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3Xzg3NDE_c4b6c9c9-46de-48f3-8ec8-eef1d2fd7c32">one-year</ix:nonNumeric> research license to review the antibodies and the right to select up to three antibodies for further development. In consideration for rights granted by Xencor, the Company issued <ix:nonFraction unitRef="shares" contextRef="iab0808833c084902820bea4f3472d32b_I20211231" decimals="INF" name="vrdn:CollaborativeArrangementSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzIzMDI_6c656647-f3cf-4fdd-93b2-a8aed44f8fa0">394,737</ix:nonFraction> shares of our common stock to Xencor in December 2021. The shares were valued at $<ix:nonFraction unitRef="usd" contextRef="i6fa3a835940b42d39eb93c3ed98a799e_D20210101-20211231" decimals="-5" name="vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzIzODY_ee1b095e-86d9-4a39-8688-c1013317a1c0">7.5</ix:nonFraction>&#160;million and recorded as research and development expense during the year ended December 31, 2021. Under the terms of the 2021 Xencor License Agreement, if successful, for each licensed product, the Company would be obligated to make future milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iab0808833c084902820bea4f3472d32b_I20211231" decimals="-4" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI2NDk_c8d0cf70-c267-4370-9843-115e0a45d7b6">27.75</ix:nonFraction>&#160;million, which includes development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iab0808833c084902820bea4f3472d32b_I20211231" decimals="-4" name="vrdn:CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3MDg_928e4c3f-0f29-4813-84c1-2dffbce908a0">4.75</ix:nonFraction>&#160;million, special milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iab0808833c084902820bea4f3472d32b_I20211231" decimals="INF" name="vrdn:CollaborativeArrangementPotentialSpecialPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3NDg_0f680c86-3d16-4452-9e65-5379d28e3786">3.0</ix:nonFraction>&#160;million, and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iab0808833c084902820bea4f3472d32b_I20211231" decimals="INF" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3OTU_5d83f723-14a1-4140-b81c-0ff0c031fbb9">20.0</ix:nonFraction>&#160;million. Additionally, for each licensed product that the Company successfully commercializes, it would be responsible for royalty payments equal to a percentage in the mid-single digits of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2020, the Company entered into a license agreement (the &#8220;Xencor License Agreement&#8221;) with Xencor, under which Xencor granted the Company rights to an exclusive, worldwide, sublicensable, non-transferable, royalty-bearing license to use specified Xencor technology for the research, development, manufacturing, and commercialization of therapeutic antibodies targeting IGF-1R indications. In consideration for rights granted by Xencor, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic46a9b2c111841f28563bace994e0980_I20201231" decimals="INF" name="vrdn:CollaborativeArrangementSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM0NzQ_f75067c2-3977-4b53-843e-7a63f7b8e6a8">322,407</ix:nonFraction> shares of its common stock in December 2020. The shares were valued at $<ix:nonFraction unitRef="usd" contextRef="i5cf6615de6694ae69368169bef73730a_D20200101-20201231" decimals="-5" name="vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM1NDg_a79418fd-5f7d-4ac5-b3f6-2dfbe552aeed">6.0</ix:nonFraction>&#160;million and recorded as research and development expense in 2020. Under the terms of the Xencor License Agreement, the Company is obligated to make future development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic46a9b2c111841f28563bace994e0980_I20201231" decimals="-5" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM3Mzg_147c6487-92fe-4ade-9ab8-0c610d12fbe7">30.0</ix:nonFraction>&#160;million. Additionally, if the Company successfully commercializes any product candidate subject to the Xencor License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic46a9b2c111841f28563bace994e0980_I20201231" decimals="-5" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzQwMDQ_58446751-bb65-4d3c-addc-13b484166854">25.0</ix:nonFraction>&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of products containing the licensed technology in each country until the later of (i) the expiration of the last patent claim subject to the Xencor License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained, or (iii) the 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> anniversary of the date of the first commercial sale. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights Agreement </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the merger agreement with miRagen Therapeutics, Inc., on November 4, 2020, the Company and the Rights Agent (as defined therein) executed and delivered a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of the Company&#8217;s common stock as of November 6, 2020, other than former stockholders of Private Viridian, was entitled to one contractual contingent value right issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of its common stock held by such holder. No CVRs have been or may in the future be issued pursuant to the terms of the CVR Agreement as of December 31, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0e6c7381a5d744c38fc91365e76382f1" continuedAt="ia1eadd41a1394157aa152a4d2bea9214"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorado-based Office and Lab Space</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space. The lease agreement includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to <ix:nonFraction unitRef="renewal_term" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="vrdn:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwODY_0cbf0e9c-0ea8-4e84-a858-eca5ab2c2d9a">three</ix:nonFraction> terms of <ix:nonNumeric contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxMzI_27ce4fc7-291c-4b48-9ae2-2a561cc47301">three years</ix:nonNumeric> each. Minimum base lease payments under the lease agreement, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the lease agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxMzQ_5d943a95-f89c-42b2-8ea0-e9d7f08b312a">1.6</ix:nonFraction>&#160;million by calculating the present value of lease payments, discounted at <ix:nonFraction unitRef="number" contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNDg_cfe35ce9-72c7-4243-8e80-94d7d1d4f78c">6</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate, over the <ix:nonNumeric contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNTE_cc731ee6-c768-4057-9be4-03e853ec61d5">12</ix:nonNumeric> months expected remaining term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Massachusetts-based Office Space</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended, the &#8220;Original Lease&#8221;). The Original Lease included rent escalation clauses through the lease term. Minimum base lease payments under the lease agreement are recognized on a straight-line basis over the full term of the lease. Upon assumption of the Original Lease, the Company recognized a right-of-use asset and corresponding lease liability for the Original Lease of $<ix:nonFraction unitRef="usd" contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNjg_2aaa83c3-ed4d-4189-980b-d75026a7072a"><ix:nonFraction unitRef="usd" contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNjg_5be899aa-4851-4301-8034-bbdde1e19119">0.1</ix:nonFraction></ix:nonFraction>&#160;million by calculating the present value of lease payments, discounted at <ix:nonFraction unitRef="number" contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxODI_3302482e-052e-4749-99aa-3a41c287b142">6</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate, over the expected remaining term. In July 2021, the Company entered into an amendment to the Original Lease to increase its Massachusetts-based office space (the &#8220;First Amendment&#8221;). In April 2022, the Company entered into a second amendment to the Original Lease of its Massachusetts-based office space (the &#8220;Second Amendment&#8221;). The Second Amendment made certain modifications to both the Original Lease and First Amendment, including (i) the addition of <ix:nonFraction unitRef="sqft" contextRef="i8c0728b5d899440094213edef06f750b_I20220430" decimals="0" name="vrdn:AreaOfOfficeSpaceExpanded" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxODY_02811676-d243-4d04-bddb-5a80549996bd">2,432</ix:nonFraction> square feet of office space in the same building and (the &#8220;April 2022 Expansion Premises&#8221;), (ii) the termination of the <ix:nonFraction unitRef="sqft" contextRef="i8c0728b5d899440094213edef06f750b_I20220430" decimals="0" name="vrdn:AreaOfOfficeSpaceTerminated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxOTM_988fbb98-cfda-4f03-b18e-70448a1aaa4a">1,087</ix:nonFraction> square feet of leased space under the Original Lease seven days after the delivery of the April 2022 Expansion Premises, which occurred in the fourth quarter of 2022, and (iii) the extension of the expiration date of the <ix:nonFraction unitRef="sqft" contextRef="i8c0728b5d899440094213edef06f750b_I20220430" decimals="0" name="vrdn:AreaOfOfficeSpaceExtension" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMDA_36f85ea3-28ae-453d-978f-4b393b2c1a5a">3,284</ix:nonFraction> square feet of leased space under the First Amendment from October 2024 through November 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Second Amendment, the Company has the option to extend the lease term for an additional period of <ix:nonNumeric contextRef="i8c0728b5d899440094213edef06f750b_I20220430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMDY_a694e630-a749-4dc8-9430-279662b9bdb2">three years</ix:nonNumeric> upon notice to the landlord. The Second Amendment provides for annual base rent for the April 2022 Expansion Premises of approximately $<ix:nonFraction unitRef="usd" contextRef="i1aef7c7506834b01bc927bc477344c11_D20220401-20220430" decimals="-5" name="vrdn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMjU_3147a348-af4a-44ce-95ec-d96ffa023012">0.4</ix:nonFraction>&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a third amendment to the Original Lease of its Massachusetts-based office space (the &#8220;Third Amendment&#8221;). The Third Amendment makes certain modifications to the Original Lease, including (i) the addition of <ix:nonFraction unitRef="sqft" contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731" decimals="0" name="vrdn:AreaOfOfficeSpaceExpanded" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMzk_efb40b8c-70fa-4546-8443-4d91f39734c2">5,240</ix:nonFraction> square feet of office space in the same building (the &#8220;July 2022 Expansion Premises&#8221;), (ii) the termination of the <ix:nonFraction unitRef="sqft" contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731" decimals="0" name="vrdn:AreaOfOfficeSpaceTerminated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNDY_fd4bc7ea-b547-405f-bf69-72ff553989b7">1,087</ix:nonFraction> square feet of leased space under the Original Lease, and (iii) the extension of the expiration date of the <ix:nonFraction unitRef="sqft" contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731" decimals="0" name="vrdn:AreaOfOfficeSpaceExtension" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNTM_32d29739-678e-4e98-9af6-a08bf92606cd">3,284</ix:nonFraction> square feet of leased space under the First Amendment to <ix:nonNumeric contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNTk_185e1011-743d-44e6-8f46-cf3b1611f264">four years</ix:nonNumeric> from the delivery of the July 2022 Expansion Premises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Third Amendment, the Company has the option to extend the lease term for an additional period of <ix:nonNumeric contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNzY_60de7ecc-651c-4f96-8d9e-60c43aaa53e9">three years</ix:nonNumeric> upon notice to the landlord. The Third Amendment provides for annual base rent for the July 2022 Expansion Premises of approximately $<ix:nonFraction unitRef="usd" contextRef="id838e3d9eb3e439aae39d4378ce4ba61_D20220701-20220731" decimals="-5" name="vrdn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyOTU_c86b6c36-74ea-4808-bc4c-9c983c911a76">0.9</ix:nonFraction>&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMDg_00fded94-d8a4-4c11-a876-5374cbdfcc33" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of December&#160;31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:69.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzEtMi0xLTEtNjgzMDM_2da048f3-f8f0-43a4-a36c-fd6a5dd136c6">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzItMi0xLTEtNjgzMDM_edbe5ff0-2c53-467b-9762-1121f9d786cf">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzMtMi0xLTEtNjg3MjA_a89f9016-9ed9-4f8d-9c3d-9bfc8e7ba774">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzMtMi0xLTEtNjgzMDM_f7f9418e-06a7-44bb-8990-9847514bcc43">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzYtMi0xLTEtNjg3MTg_3e131336-0bab-4106-a7ff-d120144227e4">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzYtMi0xLTEtNjgzMDM_2e291904-2220-4fdf-bb6f-58e7865efb62">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzgtMi0xLTEtNjg3MTg_f6bc3c18-f731-456a-9ffd-19d2f1656b63">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia1eadd41a1394157aa152a4d2bea9214"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s operating lease obligations were reflected as short-term operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMTA_4be5d635-5ad9-44b1-a630-af5cb72e5a5b">0.6</ix:nonFraction>&#160;million within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjM_e8ea74a0-3f88-44a4-a851-a40562034c1a">accrued liabilities</span> and $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjU_3ee27506-06aa-4883-ba86-f9ff46e308e2">1.1</ix:nonFraction>&#160;million of long-term lease obligations as <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMzg_22c5afc1-2efb-427c-a693-1ae037736565">other liabilities</span> in the Company&#8217;s consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNDA_038b8f9a-78f7-4275-b1a2-dfc93915ee0e"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNDA_be30cdba-f665-4ed1-8cd2-037794722a45">0.5</ix:nonFraction></ix:nonFraction>&#160;million for both the years ended December&#160;31, 2022 and 2021, and which was included in operating expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay for operating expenses related to the leased space, which were $<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNTQ_53ed4b91-c302-4759-b1a0-7378813a522f"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNTQ_e43f27f6-e539-4fe6-a2bb-0a46110563c1">0.3</ix:nonFraction></ix:nonFraction>&#160;million for both the years ended December&#160;31, 2022 and 2021. The operating expenses are incurred separately and were not included in the present value of lease payments.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_154"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2MTAw_f6e47036-aa57-4979-9361-ed8f8daa90b3" continuedAt="i37bebc3a644e471783333ca19bd24d1c" escape="true">CAPITAL STOCK</ix:nonNumeric></span></div><ix:continuation id="i37bebc3a644e471783333ca19bd24d1c" continuedAt="ief69737746454786960acefc5bc35550"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="vrdn:CapitalStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyMzk_712cacef-71af-4866-9a5d-39eeae8936f1">205,000,000</ix:nonFraction> shares of its stock, of which <ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNTI_c7e5533e-b5ef-4b89-8ac4-91fc9a65beaf">200,000,000</ix:nonFraction> shares have been designated as common stock and <ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNjU_e8268619-bc2f-40e6-88a8-cf41b6596459">5,000,000</ix:nonFraction> shares have been designated as preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNzY_189c8fd2-5728-4f0b-816c-1c95d45be13e"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNzY_9a0733f0-cba6-45a9-b2e9-a6d092fbd08c">0.01</ix:nonFraction></ix:nonFraction> per share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="vrdn:CommonStockVoteperShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyODI_9c7d29d9-d601-4a80-a1da-4829ea23be6a">one</ix:nonFraction> vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an underwriting agreement (the &#8220;2022 Underwriting Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), SVB Securities LLC and Evercore Group L.L.C. (&#8220;Evercore&#8221;) relating to the offer and sale (the &#8220;2022 Offering&#8221;) of <ix:nonFraction unitRef="shares" contextRef="i3b72d2965ee0434c841cfb9e8258e086_D20220801-20220831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyOTE_ffab8e00-0967-4a9c-a121-2181f8744dce">11,352,640</ix:nonFraction> shares of the Company&#8217;s common stock, which includes <ix:nonFraction unitRef="shares" contextRef="i3a8b414d79224c589b4f8171dc32086e_D20220801-20220831" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMDM_cc58bf68-b5f2-49a8-8e0a-95e8d54d240d">1,725,000</ix:nonFraction> shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7803c980e7e94395b6662e71bdb21d08_I20220831" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMjE_0fa84154-a0b7-4ecc-83fd-569a0cc77ec6">23.50</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="ia279525ba3464bb3bd46c39083223a69_D20220801-20220831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMjk_3e785ff2-3700-49b6-a12f-40091db62788">28,084</ix:nonFraction> shares of Series B Non-Voting Convertible Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="if928b497323f4aa09bdc2a799e98f2d8_I20220831" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMTQ_0ceeeb3d-1300-4be6-9623-eed8e9eb2942">0.01</ix:nonFraction> per share, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if928b497323f4aa09bdc2a799e98f2d8_I20220831" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMzc_231268be-bead-4b72-9db5-8f346d37222d">1,566.745</ix:nonFraction> per share (collectively the &#8220;2022 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2022 Public Offering, including the exercise of the option were approximately $<ix:nonFraction unitRef="usd" contextRef="i0137f42d4153427eba19af3131416b54_D20220801-20220831" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNDk_83c81019-3f41-4326-83f4-41351f9a9489">311.0</ix:nonFraction>&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an underwriting agreement (the &#8220;2021 Underwriting Agreement&#8221;) with Jefferies, SVB Leerink LLC and Evercore for the sale and issuance of <ix:nonFraction unitRef="shares" contextRef="idfedb0c338d24c7fb89b19d4dc8f497d_D20210901-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNjU_79706f49-a0a1-490f-863b-3d7c655c5b7c">7,344,543</ix:nonFraction> shares of common stock, which includes <ix:nonFraction unitRef="shares" contextRef="i60581c1fe5a94b06a7f4dbec809547b3_D20210901-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNzY_c3e319b0-39d6-4a92-a3df-dbef893326b8">1,159,089</ix:nonFraction> shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iddf90d2e59564c068859bfb9affa9e2d_I20210930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzODc_8364c20c-9dfa-458f-8a8c-0313f32e5fd9">11.00</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="ib79b5053076944fa8214003d886b1ba3_D20210901-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzOTU_417c7f8d-fb54-44cf-844c-c53ea395ae52">23,126</ix:nonFraction> shares of Series B Non-Voting Convertible Preferred Stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fd1e3cfaeeb44ec8b6e9c11e444058e_I20210930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0MDM_80021e31-47da-415e-84fa-b6d8624b3214">733.37</ix:nonFraction> per share (collectively the &#8220;2021 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2021 Public Offering, including the exercise of the option, were approximately $<ix:nonFraction unitRef="usd" contextRef="i1af72201586744fbb2c99adcce15b017_D20210901-20210930" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0MTI_36277838-1257-4705-ac0c-7d506f875ad7">97.7</ix:nonFraction>&#160;million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0Mjc_50f8e719-b1cb-4e30-b900-9b9b403674de">175.0</ix:nonFraction>&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of <ix:nonFraction unitRef="number" contextRef="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930" decimals="INF" name="vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NDM_d0c02680-34db-4a85-be2b-d7e93530fc10">3.0</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. During the quarter ended December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg1Mzk3NQ_9773322f-cc22-43d2-8c9a-0f10c2e657cb">964,357</ix:nonFraction> shares have been sold under the September 2022 ATM Agreement with Jefferies at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231" decimals="2" name="vrdn:SaleOfStockWeightedAverageSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY4NDA_7f8b26e9-d4f1-46ff-9393-fcea6a69f644">26.01</ix:nonFraction> per share, for aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY4NDg_335f11b2-14ba-4e49-b37e-3b59f22683b5">24.2</ix:nonFraction>&#160;million, including commissions to Jefferies as a sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;November 2021 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="iffb9991b56694a0faf0dc09579f73d81_D20211101-20211130" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NDk_ddeae715-3c23-46ca-9744-5c3bac77c4da">75.0</ix:nonFraction>&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. The November 2021 ATM Agreement was terminated in connection with the September 2022 ATM Agreement. <ix:nonFraction unitRef="shares" contextRef="i9b4be6ccd9ad4885a999915b4b0caed6_D20211101-20220930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NjM_7512f5b9-ce78-463a-8ce6-3c162722836d">No</ix:nonFraction> shares were sold under the November 2021 ATM Agreement.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ief69737746454786960acefc5bc35550" continuedAt="i336fa4cedf364d74aaa09cda80eab0d3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;April 2021 ATM Agreement&#8221;) with Jefferies pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NzM_cbae6cc8-1f41-4d94-a8d6-41b90b002b9b">50.0</ix:nonFraction>&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies as its sales agent. Jefferies could receive a commission equal to <ix:nonFraction unitRef="number" contextRef="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430" decimals="INF" name="vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0ODg_06dd1983-e01a-48fe-8269-81359419019c">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through Jefferies under the April 2021 ATM Agreement. The April 2021 ATM Agreement was terminated in connection with the November 2021 ATM Agreement. An aggregate of <ix:nonFraction unitRef="shares" contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0OTQ_c74479a7-e6f6-412b-b247-33f35934b39e">2,551,269</ix:nonFraction> shares of common stock were sold pursuant to the April 2021 ATM Agreement prior to its termination, at a volume weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130" decimals="2" name="vrdn:SaleOfStockWeightedAverageSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1MDU_a6c78823-5230-4c83-bc0c-498d684e544c">13.13</ix:nonFraction> per share, for aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1MTM_efd9144b-8efa-4e6b-b6d0-4c665b39f4e1">32.4</ix:nonFraction>&#160;million, including commissions to Jefferies as sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Purchase Agreement - Aspire Capital Fund, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a common stock purchase agreement (the &#8220;Aspire Stock Purchase Agreement&#8221;), with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;), which provides that, subject to the terms, conditions, and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $<ix:nonFraction unitRef="shares" contextRef="icfe4499fee034827abde9a07a164e945_D20191201-20191231" decimals="INF" name="vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1Mjg_4a5d19aa-b619-4de5-99ed-203012f898b4">20.0</ix:nonFraction>&#160;million of shares of common stock over the <ix:nonNumeric contextRef="icfe4499fee034827abde9a07a164e945_D20191201-20191231" name="vrdn:SaleOfStockTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NDY_fc520324-17cc-44f9-abec-9040f5ff097a">30-month</ix:nonNumeric> term of the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NDg_3d41cc1f-66d5-4de1-8dae-783be86c179d">412,187</ix:nonFraction> shares of common stock to Aspire Capital at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231" decimals="2" name="vrdn:SaleOfStockWeightedAverageSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NTc_b65eb598-60ed-4409-8a68-31757c1dc2ec">21.35</ix:nonFraction> per share for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NjU_8eb0ddfe-b104-4578-9794-5d97ecdefeed">8.8</ix:nonFraction>&#160;million. The Company did <ix:nonFraction unitRef="shares" contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjU_6522b5e5-f192-4c23-86a5-a09c22f7510a"><ix:nonFraction unitRef="shares" contextRef="i0eac05f69eb14abb936aff1bddd334b7_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjU_84c32b46-dff8-41d0-a22d-e5775878212c">not</ix:nonFraction></ix:nonFraction> sell any shares to Aspire Capital during the years ended December 31, 2021 or 2022. As of December 31, 2022, the Company has the ability to sell an additional $<ix:nonFraction unitRef="shares" contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231" decimals="-5" name="vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1Nzk_aa3bcc3c-2bc7-4d10-8cf2-c2ae77f48acb">10.2</ix:nonFraction>&#160;million of shares of common stock to Aspire Capital. Under the Aspire Stock Purchase Agreement, the Company has the right, in its sole discretion, on any trading day selected by it, and within certain specified limitations, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to <ix:nonFraction unitRef="shares" contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231" decimals="INF" name="vrdn:SaleOfStockAmountOfSharesRequiredToBePurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1OTQ_df638b71-cad7-4896-813b-40fdedf7ca95">13,333</ix:nonFraction> shares of common stock per business day at a per share price equal to the lesser of (i) the lowest sale price of common stock on the purchase date or (ii) the average of the <ix:nonFraction unitRef="sale_price" contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231" decimals="INF" name="vrdn:SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MTA_3ea9b156-40a0-4965-9770-5b83b29423fa">three</ix:nonFraction> lowest closing sale prices for the common stock during the <ix:nonNumeric contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231" name="vrdn:SaleOfStockNumberOfConsecutiveDaysThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MDc_afe982be-e033-4458-81f7-0f26983ef77d">10</ix:nonNumeric> consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to require Aspire Capital to purchase up to an additional <ix:nonFraction unitRef="number" contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231" decimals="INF" name="vrdn:SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MDI_7870a3e0-e00a-4edc-bea9-5ee08d9d84c2">30</ix:nonFraction>% of the trading volume of the shares for the next business day at a purchase price (the &#8220;VWAP Purchase Price&#8221;), equal to the lesser of: (i) the closing sale price of the shares on the purchase date, or (ii) ninety-seven percent (<ix:nonFraction unitRef="number" contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231" decimals="INF" name="vrdn:SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjE_4ff0d556-0a8c-42ee-8f7e-bf0c3b86b67f">97</ix:nonFraction>%) of the next business day&#8217;s volume weighted average-price (each such purchase, a &#8220;VWAP Purchase&#8221;). The Company shall have the right, in its sole discretion, to determine a maximum number of shares and set a minimum market price threshold for each VWAP Purchase. The Company can only require a VWAP Purchase if the Company has also submitted a regular purchase on the notice date for the VWAP Purchase. There are no limits on the number of VWAP purchases that the Company may require.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Aspire Stock Purchase Agreement may be terminated by the Company at any time, at the Company&#8217;s discretion, without any cost to the Company. There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings, rights of first refusal, participation rights, penalties, or liquidated damages in the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to <ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2NzQ_2ec0c020-b60f-4dcd-b703-e55be663f98e">5,000,000</ix:nonFraction> shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least <ix:nonFraction unitRef="number" contextRef="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2ODU_d57daf71-4c76-45b5-ab65-89cd914478ef">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2OTA_2031fdbc-bde3-4c4d-8382-7509b452098e">66.67</ix:nonFraction> shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i336fa4cedf364d74aaa09cda80eab0d3" continuedAt="i350754556cd6411c8c0fa43201fee5ba"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="ifba8d787738a4d90b399133c72c646a5_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2OTc_3b7c9d93-fe9c-4cf2-940e-fb7676f2742e">4.99</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i37b9550134c5468b8fd0e59a39c182ae_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MDQ_ece122dc-d459-4016-aed7-8025d0bee76d">19.99</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="shares" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg2NDQxNw_01677419-b40b-469e-aa94-42a8335c019c"><ix:nonFraction unitRef="shares" contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg2NDQxNw_96193cb8-89b5-4611-8356-0128e958be88">188,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MTI_3ba870c2-1610-4428-ba37-958c3dd91dc7">260,437</ix:nonFraction> shares of Series A Preferred Stock outstanding, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="i16c66a163e074d75953188a31b49a161_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MjE_3c8608e0-bc66-4a4b-9a56-4ad0476bb941">66.67</ix:nonFraction> shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="i128e797bb49d4cd88ed84383f99ec141_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3Mjg_6e36cef3-b7ef-4c3f-8c04-fcd291186e60">4.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i606007a11a244c8c8b02f58f219ee3cb_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MzQ_f6452a32-08dc-49d0-8d84-a50e8e37fc2b">19.9</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in connection with the Offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="shares" contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3NDE_00632ba5-0957-4c5b-a29a-191422cf3906">51,210</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3NDk_9dde371b-5806-45ff-a7d9-d7c821dce828">23,126</ix:nonFraction> shares of Series B Preferred Stock outstanding, respectively. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_160"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:continuation id="i350754556cd6411c8c0fa43201fee5ba" continuedAt="i5d1fa86690cc4b749ccce21149a4e2fd">WARRANTS</ix:continuation></span></div><ix:continuation id="i5d1fa86690cc4b749ccce21149a4e2fd" continuedAt="ib40350bd2bdf423dac24d444c90d9f2b"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90ZXh0cmVnaW9uOjg4M2Y5M2FhNWMwOTQ4YTBiNzk2Y2I5MjllNTlkOTgwXzIzMTc_e282c86d-9c1f-4571-a70c-4a0dbc7fd24b" continuedAt="i502daa08e6fa4533bb54344c68dd2a27" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at December 31, 2022<br/>(No. Years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtMS0xLTEtNjQ2MTQ_564aec4e-fbfa-45f4-bbc4-03efe4dbf69d">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb45543c55a341d59828621ace35f8e4_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtMy0xLTEtNjQ2MTQ_c66d1f57-9b06-4fb7-8e7c-8e1979493c68">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtNS0xLTEtNjQ2MTQ_b05adef0-c4c9-430e-a81c-e5a22596b38c">127.95</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14d5a529d15d48ca9f86845a914722f5_D20220101-20221231" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtNy0xLTEtNjQ2MTQ_5ef5fd04-a425-49d5-852b-473e9fa6f88e">2.33</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0ef63c34dae44f0853d1416aa2f882e_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctMS0xLTEtNjQ2MTQ_7e85280a-7010-4126-bd0e-a13ead506f68">29,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife09cc8c10c94dc8996beb13848ad137_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctMy0xLTEtNjQ2MTQ_80df1bd0-3d88-4efc-bac8-b5e00c7a14d7">29,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if0ef63c34dae44f0853d1416aa2f882e_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctNS0xLTEtNjQ2MTQ_7420e2ea-c113-4ed5-b2a4-3c8e224cc1b3">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaaeea194517f4499b35939e81a5d9621_D20220101-20221231" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctNy0xLTEtNjQ2MTQ_abf88b4a-084b-402a-a957-13848f8400c0">7.73</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d62a34b1b4a4f5e9b01227f00998027_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtMS0xLTEtNjQ2MTQ_18a381d1-bba5-47b0-91f9-28e8d4c6ac33">332,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd6f20f151aa4c638e38a93431710146_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtMy0xLTEtNjQ2MTQ_d3d13bf1-1314-47d3-8bb1-ccc23ec85624">388,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9d62a34b1b4a4f5e9b01227f00998027_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtNS0xLTEtNjQ2MTQ_45f87d28-9f94-44e7-ad89-5f767ddc61f4">15.09</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89382e3a327947c289b5183a9f74f852_D20220101-20221231" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtNy0xLTEtNjQ2MTQ_0d94c2ff-e024-476e-a99d-5cbf4e26a121">2.12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktMS0xLTEtNjQ2MTQ_4b8053d3-4e37-4c97-9287-a5e2afd168cd">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied23b327864a44a984dcfb100731b721_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktMy0xLTEtNjQ2MTQ_132eac2e-26ad-4711-9072-46a75e60c61f">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktNS0xLTEtNjQ2MTQ_1a55adee-cfb1-4022-ae35-7d57ad24ebe9">0.47</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3974d6a34a904cfb85456eb0420ddb31_D20220101-20221231" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktNy0xLTEtNjQ2MTQ_d7c39e04-b2ee-42d1-ac18-9d4631468838">1.87</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTEtMS0xLTY0NjE0_2e209855-f4c7-42eb-a46e-c25379bfd9cd">363,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dc204ff96984e1783d7a194c6f1ac47_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTMtMS0xLTY0NjE0_793744e0-da0c-494d-8361-020ea8ebbdea">419,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTUtMS0xLTY0NjE0_9a1d7b31-ed19-4df3-8a91-cb6041135ef4">15.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTEtMS0xLTY0NjE0_a088a35b-4a12-42b3-b937-e700464b2cc2">363,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTMtMS0xLTY0NjE0_67ebbcd7-9d4e-4cae-973a-31cf9ac388c8">420,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTUtMS0xLTY0NjE0_642bc0cb-62e1-4df7-ac6e-963310f55ee8">15.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib40350bd2bdf423dac24d444c90d9f2b"><ix:continuation id="i502daa08e6fa4533bb54344c68dd2a27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzktMS0xLTEtNjQ2MTQ_775a7590-736a-4260-9911-e199d6b2a07a">420,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzktMy0xLTEtNjQ2MTQ_238c1826-fb25-403f-bca1-8f7471b9d53c">15.82</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="vrdn:ClassOfWarrantOrRightExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzEwLTEtMS0xLTY0NjE0_70113139-5b10-4d8b-a1ff-9fe5a2f44c1c">56,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="2" name="vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzEwLTMtMS0xLTY0NjE0_d7976ab1-f633-46be-9c12-9f1bc1664e44">16.50</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzExLTEtMS0xLTY0NjE0_d3d28315-2148-4a15-811c-bf634d0b86aa">363,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzExLTMtMS0xLTY1NzA0_f0b64815-2fd4-4d41-bd1e-fff250f80124">15.82</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_163"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTI_86a8259c-48fe-4c3f-a5cf-87787d3713dd" continuedAt="idbb114074b8b4f028ae2e445a434df8f" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idbb114074b8b4f028ae2e445a434df8f" continuedAt="iae5cd877e82a45d1b319b9335e0aa63e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;), its amended and restated 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), and the Viridian 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221; and collectively with the 2008 Plan and the 2016 Plan, the &#8220;Equity Incentive Plans&#8221;). Additionally, beginning in July 2021, the Company granted stock options outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#8220;Inducement Awards&#8221;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#8217;s Equity Incentive Plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2022 (the &#8220;Effective Date&#8221;), the Company&#8217;s stockholders approved the amendment and restatement of the 2016 Plan (the &#8220;Amended 2016 Plan&#8221;), which increased the number of shares reserved for issuance under the Amended 2016 Plan by <ix:nonFraction unitRef="shares" contextRef="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyMzg5Nw_079d26b7-ac46-473a-965d-b1a3009cee5a">3,050,000</ix:nonFraction> shares and transferred the number of shares that remain available for issuance under the 2020 Plan as of the Effective Date into the Amended 2016 Plan so that the Company operates from a single equity plan going forward. The term of the Amended 2016 Plan is <ix:nonNumeric contextRef="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608" name="vrdn:ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzE2NDkyNjc0NTUxNjI_8e2e4156-227d-4f3c-8c6d-c2934bfc72eb">10</ix:nonNumeric> years following the Effective Date. </span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTk_0cc351c0-42d7-4a2b-905c-b4e0b5dffc72" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following balances by plan:</span></div><div style="margin-bottom:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f880652d2a4b6798eccdac2488595d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzEtMS0xLTEtNjQ2MTQ_5ebd0369-fe51-4483-9f44-b96e01925d4c">1,513,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f880652d2a4b6798eccdac2488595d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzEtNS0xLTEtNjQ2MTQ_e9d78677-1234-4792-8ae8-36633df241a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzItMS0xLTEtNjQ2MTQ_1cad8a87-892f-4769-a563-8b5ce18c7dcc">930,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzItNS0xLTEtNjQ2MTQ_fa1ee6d7-00ac-465f-8721-8ea962552681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzMtMS0xLTEtNjQ2MTQ_b12fec0f-03ec-4bf4-9d81-36dfcf3276c4">3,278,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzMtNS0xLTEtNjQ2MTQ_2b0c3329-467e-4eaa-8e82-794be3f1915b">3,781,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzQtMS0xLTEtNjQ2MTQ_fea7c847-4ebc-4656-83ee-c1d28fa99611">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzQtNS0xLTEtNjQ2MTQ_7d755fbf-c02c-408d-88a8-7f71662b1386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzUtMS0xLTEtNjQ2MTQ_4592a1ec-c932-4fed-954c-6255797ed9e4">5,722,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzUtNS0xLTEtNjQ2MTQ_65a1e46d-c9af-4a10-ab1a-353f2651e817">3,781,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire <ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDM3Nw_bed3f999-775d-45ad-b87f-cfc97f577fd3">10</ix:nonNumeric> years from the date of grant. Generally, options vest <ix:nonFraction unitRef="number" contextRef="i5fdadfb509ff40919c0cab248bd849e5_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDQyOQ_74239243-06ab-454e-ab17-6488013b6178">25</ix:nonFraction>% on the first anniversary of the vesting commencement date and <ix:nonFraction unitRef="number" contextRef="i7b41fe046b334a039198964438e80c98_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDQ5NQ_940cf294-6642-47ca-a4cf-62f7f7c5bed6">75</ix:nonFraction>% ratably in equal monthly installments over the remaining <ix:nonNumeric contextRef="i7b41fe046b334a039198964438e80c98_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDU1Ng_bd2b8a2d-c96d-4f70-a0ac-7097f011a2b2">36</ix:nonNumeric> months. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to <ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDY2NQ_49d2c5e4-0d6a-49a7-8153-8026f81760fd">48</ix:nonNumeric> months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iae5cd877e82a45d1b319b9335e0aa63e" continuedAt="i2196fb165e114c76acb69deb920488c5"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzE_4cd33411-4dd9-4d53-a379-f04aab985689" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtMS0xLTEtNjQ2MTQ_3ca20d83-de1f-4dc6-b556-4b629331ad00">3,683,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtMy0xLTEtNjQ2MTQ_86db1177-0545-4a7b-8dea-3f0b2d674b46">16.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtNS0xLTEtNjQ2MTQ_56c930ef-e507-4103-b5eb-0844158a22a9">8.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtNy0xLTEtNjQ2MTQ_2e1946e3-ac5c-429f-bec1-61eb383920f0">15,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzItMS0xLTEtNjQ2MTQ_5b8868d0-431b-4646-9b32-0e23069d8486">2,545,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzItMy0xLTEtNjQ2MTQ_20fa5a38-4cfc-4771-aaa1-b6606e851a72">17.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzMtMS0xLTEtNjQ2MTQ_d03340ae-ed98-4904-b40d-c723e88fcd55">191,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzMtMy0xLTEtNjQ2MTQ_1af461bb-7825-4a04-9be4-94eb5c9a6963">14.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzQtMS0xLTEtNjQ2MTQ_09785197-8063-4c17-952c-2dc5c1fe2812">315,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzQtMy0xLTEtNjQ2MTQ_0ec39488-9c82-43f0-a11d-7c5742548e11">19.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtMS0xLTEtNjQ2MTQ_c7d607d0-8728-4702-be15-f98178c42bf4">5,722,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtMy0xLTEtNjQ2MTQ_39b74380-e8d6-4809-bab9-73ae4af71986">17.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtNS0xLTEtNjQ2MTQ_6cd6d835-f78a-447f-be7b-b0c719c94e0d">8.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtNy0xLTEtNjQ2MTQ_b714317b-e135-47aa-adca-86d824df9572">68,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtMS0xLTEtNjQ2MTQ_e3816387-4cd4-4adc-9dc2-483703823246">5,722,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtMy0xLTEtNjQ2MTQ_f7e2db15-27f8-454c-a62d-f5d922bf570a">17.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtNS0xLTEtNjQ2MTQ_b46f8d05-5233-4e6c-9000-5207c4e52cc8">8.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtNy0xLTEtNjQ2MTQ_ecdceded-5715-4b36-b3b3-2ba8e081fe1d">68,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctMS0xLTEtNjQ2MTQ_3df220af-33be-46d2-aa9c-4f8ff7e07d30">1,697,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctMy0xLTEtNjQ2MTQ_ff9aa5be-8c36-4bb3-b359-802e6d8ea351">16.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctNS0xLTEtNjQ2MTQ_4d741488-0acc-476c-a1cc-a60af1153c38">8.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctNy0xLTEtNjQ2MTQ_ce8ad6d4-9134-44aa-8f70-f5f98adcc3c9">21,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtMS0xLTEtNjQ2MTQ_1973c35f-236a-4652-82e6-4bb66c06f727">1,697,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtMy0xLTEtNjQ2MTQ_30268940-86e6-4f28-814a-ebaad2bae5fb">16.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtNS0xLTEtNjQ2MTQ_897d5da4-243e-4f64-8e43-3e71921cfed9">8.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtNy0xLTEtNjQ2MTQ_72e197d5-da16-4cf5-83d2-d59f641a3435">21,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#8217;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted to the Company&#8217;s employees and members of its board of directors during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzQ4NzI_aa7be309-9b9b-43d6-a4ad-3ebd37cb3981">12.95</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzQ4Nzk_4d760aac-6eaa-4257-a859-2ad513e0dffb">17.50</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTU_70ce2b8e-2a6a-48c8-96b1-4139864e0079" continuedAt="id11e389defcd4c88bb70b0a397c29ccb" escape="true">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-right:22.5pt"><ix:continuation id="id11e389defcd4c88bb70b0a397c29ccb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzItMS0xLTEtNjQ2MTQ_6b72eb76-6c4c-48ca-8e9a-859c42ebcf76">5.81</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzItMy0xLTEtNjQ2MTQ_ceb72f86-7bc1-4740-9a96-eced2bd8c2f1">5.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzMtMS0xLTEtNjQ2MTQ_db88e18a-e69b-467c-968b-517f0708e8ff">87.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzMtMy0xLTEtNjQ2MTQ_156dff88-186f-44d7-9bad-a983ae880a52">117.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzQtMS0xLTEtNjQ2MTQ_037633ae-8354-41ad-8405-4caabea77204">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzQtMy0xLTEtNjQ2MTQ_e2d6a512-31cf-406b-be0e-bf9059fe266e">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzUtMS0xLTEtNjQ2MTQ_44e0dddd-7e1f-4f6e-8a38-e21a4d43a191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzUtMy0xLTEtNjQ2MTQ_10122ce4-87d5-4f33-be40-1d37b6a62685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzYtMS0xLTEtNjQ2MTQ_ffeef7a5-82e9-4dbb-97f0-31a357d75c30">17.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzYtMy0xLTEtNjQ2MTQ_ebc17811-ecf7-4240-9b34-5e7879b40e9e">20.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of common stock at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzUxODE_c0b93f7f-164d-4777-826e-6354ea61d94a">85</ix:nonFraction>%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. New <ix:nonNumeric contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231" name="vrdn:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzY_e50b4df0-5239-4f4a-9c0f-e3887e0dddad">six-month</ix:nonNumeric> offering periods begin each August&#160;22 and February&#160;22. As of&#160;December&#160;31, 2022, the Company had&#160;<ix:nonFraction unitRef="shares" contextRef="i16c66a163e074d75953188a31b49a161_I20221231" decimals="0" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0MTg_2ef7076c-e5f6-4538-bc8a-9dd9bf49a654">309,541</ix:nonFraction>&#160;shares available for issuance, and <ix:nonFraction unitRef="shares" contextRef="id35aece8bbc142a1911840a29f94d84d_D20160101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0NTU_074bcb7a-cd26-4973-930d-4d1a32b4368e">27,074</ix:nonFraction> cumulative shares had been issued under the ESPP.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2196fb165e114c76acb69deb920488c5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzc_5bc1d04c-1f2a-4b2b-bf9f-88ccb1b2b856" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35dd0d5868d3450181c2d16f2687ac92_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzMtNS0xLTEtNjQ2MTQ_f4109fad-fcd8-47ba-9fe7-4959f1900d1b">7,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6738e86aeb641cfb7e9e094c2fc4c6f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzMtNy0xLTEtNjQ2MTQ_07ae8b64-d9de-4671-951c-9379e909350d">4,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b73a1e80a44f5590d1cc32f390331b_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzQtNS0xLTEtNjQ2MTQ_4aa188c9-d68b-483f-94f0-22078da8f364">12,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6eac4ba1e8146d09bc0d4159bb00c0c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzQtNy0xLTEtNjQ2MTQ_0e60d932-dc0c-4c8d-959c-3fcb7858906b">9,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzUtNS0xLTEtNjQ2MTQ_90043ac3-cf00-4c44-932b-a1c05778f008">19,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzUtNy0xLTEtNjQ2MTQ_444ef3eb-6d7c-4de0-991a-26fdef0dee18">14,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU4Njk_7c739ce1-3509-40f0-a4b2-654346722a9a">54.9</ix:nonFraction> million of total unrecognized employee and non-employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNDM_09d462be-8e7f-49e4-b695-a621a0397efb">2.77</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_166"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90ZXh0cmVnaW9uOmNlMjY5ZThlOGJkYzQ4NmU5YjJkMDNlZTY2YWVjY2ZiXzcyNA_0ad69bb0-286a-4662-b9eb-36e4953880cb" continuedAt="i58e76246a98449e49a4888f1c47fa6d4" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i58e76246a98449e49a4888f1c47fa6d4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90ZXh0cmVnaW9uOmNlMjY5ZThlOGJkYzQ4NmU5YjJkMDNlZTY2YWVjY2ZiXzcyNg_979a2e49-3703-4398-a1c5-0e7f6198da6c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65916045213f4b35b8eaac7d9d7c38f5_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzMtMS0xLTEtNjQ2MTQ_f131c55b-a29d-4685-8232-b5fcf683bffb">12,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49abc6a01de84a36bc043c40f8227f10_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzMtMy0xLTEtNjQ2MTQ_4e5db46b-85a3-41ea-88d4-11db7c3eb3a4">17,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29536a69b2634ac49eb9828516064751_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzQtMS0xLTEtNjQ2MTQ_375e206a-9698-45d9-ab15-c2eba3b5e87d">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2a030fb15c14da49fde0862e7c27a2a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzQtMy0xLTEtNjQ2MTQ_3b7f57a3-12b9-487f-9447-bf192859b8ea">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i697a762fdb594a17ba1c80bc48028a56_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzUtMS0xLTEtNjQ2MTQ_e7efed1b-69d8-4f01-a9e8-d39d4d9a9baa">5,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99e4eeddfa014778a51d0845f779bd05_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzUtMy0xLTEtNjQ2MTQ_37c0755a-515b-4e1e-bab2-9b373bbea30d">3,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd090a1fac43479584a8c5f526d77264_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzYtMS0xLTEtNjQ2MTQ_c55e82ba-67cb-48b7-b83e-2e8acba63500">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i087f0a8b9f354a148b61f301862025db_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzYtMy0xLTEtNjQ2MTQ_b4fa84d8-9c33-4a71-9883-2b74840ada8b">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzctMS0xLTEtNjQ2MTQ_df2c0694-5756-406b-905f-26168491eb54">22,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzctMy0xLTEtNjQ2MTQ_e381d566-ff1b-4dc7-955e-7a92bee31836">23,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_169"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NTk_4467c365-51f2-45be-af3a-1e74ae85704e" continuedAt="i8906ba6361414aa9bd59865caf2e0964" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i8906ba6361414aa9bd59865caf2e0964" continuedAt="i411b34837ffc41999ce2abfc73081c69"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded. This amount differs from the amount computed by applying the U.S.&#160;federal income tax rate of 21% to pretax loss due to the provision of a valuation allowance to the extent of the Company&#8217;s net deferred tax asset, as well as to state income taxes and nondeductible expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i411b34837ffc41999ce2abfc73081c69" continuedAt="i380075dfffab4e64afe4c418e62418d3"><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NzI_92abf643-1a41-4013-ab7c-5293c6be6cfa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzItMS0xLTEtNjQ2MTQ_7db84696-84e2-4d70-8df1-5d267749fb14">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzItMy0xLTEtNjQ2MTQ_9dfebe28-7383-413b-8d11-da0f29caacc2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzMtMS0xLTEtNjQ2MTQ_dc2f8023-918a-4cfe-a3c5-01c2a5c7eeb6">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzMtMy0xLTEtNjQ2MTQ_fcee938a-7754-4696-b5cc-116413e636e6">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzQtMS0xLTEtNjQ2MTQ_f096025d-a1ca-4acf-b694-84f6055482f6">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzQtMy0xLTEtNjQ2MTQ_ff475e1d-6bbb-4a42-9b45-2d3645b1cdd9">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzUtMS0xLTEtNjQ2MTQ_102fbefb-a9a4-415a-83d8-1faa4c2c8a75">24.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzUtMy0xLTEtNjQ2MTQ_0b7ac3a8-e549-4a95-b6a9-b2f271878c49">28.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzctMS0xLTEtNjQ2MTQ_764a0436-ebb8-4b87-a8b3-ed7378a756dd">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzctMy0xLTEtNjQ2MTQ_01e1e004-4611-4258-8b7a-292ba57c3cc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 limit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" name="vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEyLTEtMS0xLTY0NjE0_e7a90f7c-c167-4db4-8161-35255c754665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" name="vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEyLTMtMS0xLTY0NjE0_14bb82e9-b9d2-4bcc-896e-15d076b5e7b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEzLTEtMS0xLTY0NjE0_74a1df40-2e8c-403c-a0bc-959686765bb8">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEzLTMtMS0xLTY0NjE0_c4073fc3-298b-47e9-a96b-17509acadc49">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzE0LTEtMS0xLTY0NjE0_3affe2b6-2241-4cf8-8452-7c3d6a6d877f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzE0LTMtMS0xLTY0NjE0_a929c97d-4c70-4962-a96f-7642ece24541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NzM_a9699410-6b2d-4a5f-aaab-75223d28c5b6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzQtMS0xLTEtNjQ2MTQ_4e00d1ec-53d9-4c6b-8f0d-8c7ce2697120">46,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzQtMy0xLTEtNjQ2MTQ_231858c7-7959-4459-93be-bf9bd99fe79a">40,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMS0xLTEtNjk5ODc_8f451b7a-f902-4648-beae-4a3c103a12d9">3,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMy0xLTEtNjk5ODc_7a987c93-e323-4ec1-981e-7007c83fc2bd">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMS0xLTEtNjk5ODc_0439a84e-81d6-4683-96f1-b4c4b0aee466">4,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMy0xLTEtNjk5ODc_216544d3-59ec-4f74-aa9d-00338eacdb42">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMS0xLTEtNjQ2MTQ_b4cb0857-6970-42c4-acdb-ba082b695166">4,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMy0xLTEtNjQ2MTQ_edabbd20-a8a9-4e1d-912f-2fa8503b77df">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Start-up costs and amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMS0xLTEtNjQ2MTQ_d0260026-edf7-405a-9033-b7d7313feda8">9,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMy0xLTEtNjQ2MTQ_31b5e746-9ad6-48a1-bca9-d2cb9866e278">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRC &#167; 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzctMS0xLTEtNjQ2MTQ_59aba64a-2d2e-4221-b98c-e0047ff0070e">18,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzctMy0xLTEtNjQ2MTQ_cf732f2a-bc5e-4a8a-be9c-2efb4936b616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzgtMS0xLTEtNjQ2MTQ_1d704924-d600-49f1-bf9b-c156e5ea5b75">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzgtMy0xLTEtNjQ2MTQ_e9743fb1-1e02-447a-ad32-0eda9b08a992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEwLTEtMS0xLTY0NjE0_663aee35-ceba-4eca-b5f4-2b220672b421">86,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEwLTMtMS0xLTY0NjE0_70556077-0707-4227-bce0-38274ba01447">53,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzExLTEtMS0xLTY0NjE0_3e762d88-a31e-4ad1-b341-daa8a643baf3">86,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzExLTMtMS0xLTY0NjE0_dcf248e0-736a-46d2-9ebf-9176087ad1ce">53,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEyLTEtMS0xLTY0NjE0_9c5ee628-dbea-4329-88a5-8b5155bb4398">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEyLTMtMS0xLTY0NjE0_b575db53-593d-4540-9328-b514591aeb8c">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTEtMS0xLTcwMDA5_bb12be88-56c9-4fa0-aae0-a5e9f945e679">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTMtMS0xLTcwMDA5_10a2bc78-3a40-42b8-8dfa-bfa2a6e40fe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE1LTEtMS0xLTY0NjE0_96ae24ac-da26-4e3b-b279-7036781af5d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE1LTMtMS0xLTY0NjE0_dba65c87-50c8-4e70-888a-c97eac530a3f">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE2LTEtMS0xLTY0NjE0_04ea4e65-50c9-41f4-b2e6-702f0801efdf">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE2LTMtMS0xLTY0NjE0_5c5d2299-e04e-4574-8e94-5a9f6e3bc4f0">439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTEtMS0xLTY0NjE0_6a42df54-8ea8-407c-a933-a20574ef9437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTMtMS0xLTY0NjE0_e3714180-b018-441f-8ecf-93f5ffc6a1d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ie575904542f4433e911075dd3974f021_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2MzM_b2f14ec0-d711-46da-89c5-a3845d5fbcf3">175.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8bd65cfed6004a6e9be4b0f521ae67ef_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2NDk_75ea5487-98ac-4d60-992b-6a3bdab6fdd7">3.5</ix:nonFraction>&#160;million of federal net operating loss and research and experimentation tax carryforwards, respectively, which will begin to expire in 2029. At December 31, 2022 ,the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i041bd935d0394bcb91d5976137df8830_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2NjM_bc0c6a90-0526-462c-a1c3-f8c9a97b455d">196.7</ix:nonFraction>&#160;million of state net operating loss carryforwards which will begin to expire in 2030. In addition, the realization of net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions, which may result in the expiration of additional net operating losses before future utilization as a result of ownership changes. As a result of these ownership change provisions during 2020, the Company estimated an aggregate limitation on the utilization of net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231" decimals="-5" name="vrdn:TaxCreditCarryforwardLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2Nzk_dd3c9034-6186-4450-971a-306ceb83b6a2">59.0</ix:nonFraction>&#160;million. In addition to the limitation of net operating losses of $<ix:nonFraction unitRef="usd" contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231" decimals="-5" name="vrdn:TaxCreditCarryforwardLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2OTQ_b6b33000-09f3-41d3-b1c6-c7f80fda1649">59.0</ix:nonFraction>&#160;million, approximately $<ix:nonFraction unitRef="usd" contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231" decimals="-5" name="vrdn:TaxCreditCarryforwardWriteOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3MDk_f75b044f-96c6-4f26-9f83-98a5879c19e8">15.3</ix:nonFraction>&#160;million of research and development tax credits were derecognized with the inability of the Company to ever realize a benefit from those credits in the future. The Company determines on an annual basis whether net operating loss carryforwards will be limited. An IRC 382 analysis has been completed through December 31, 2022 and determined that there were no additional ownership changes. The Company will continue to evaluate changes in ownership and the related limitations on a go forward basis. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company&#8217;s net deferred tax assets before valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="-5" name="vrdn:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3MjQ_4fa3005b-feb9-4e99-9cdb-11c3b00028ec">86.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="-5" name="vrdn:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3Mzk_1e422d5c-89ef-4be7-9e5d-e37c7b7a1b47">53.4</ix:nonFraction>&#160;million, respectively. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i380075dfffab4e64afe4c418e62418d3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income or projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of its history of operating losses, the Company does not believe it is more likely than not that it will realize the benefits of its net deferred tax assets, and accordingly, has established a valuation allowance equal to <ix:nonFraction unitRef="number" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="INF" name="vrdn:DeferredTaxAssetValuationAllowancePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NTQ_51f9cc28-bf3e-4f59-891c-4ad40d6fcc79"><ix:nonFraction unitRef="number" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="INF" name="vrdn:DeferredTaxAssetValuationAllowancePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NTQ_ee8fe1f2-99ea-4298-8f9f-220ae8c5b6e6">100</ix:nonFraction></ix:nonFraction>% of its net deferred tax assets at December 31, 2022 and 2021. The change in valuation allowance was an increase of $<ix:nonFraction unitRef="usd" contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NjA_19549756-2597-4f9e-8451-05b29cee2877">33.2</ix:nonFraction>&#160;million in 2022 and an increase of $<ix:nonFraction unitRef="usd" contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NzU_5f5ecffe-18fa-4075-9d9a-8e9c702c6dea">24.4</ix:nonFraction>&#160;million in 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that there were no significant uncertain tax positions relevant to the jurisdictions where it is required to file income tax returns requiring recognition in the consolidated financial statements for the years ended 2022 and 2021. As of December 31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i369f8afef8e64303909112080068f0af_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3ODk_3556643a-5e9f-45c8-9d59-575392979735"><ix:nonFraction unitRef="usd" contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3ODk_8913457d-f8a5-4cc4-9c85-8e1c9a1fd2d3">no</ix:nonFraction></ix:nonFraction> accrued interest related to uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s federal and state returns for 2018 through 2022 remain open to examination by tax authorities.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_172"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNzIvZnJhZzpjNGMxOTBhZDExZTM0OTY5YWY0MjFhZDBhZGEzNzNmNC90ZXh0cmVnaW9uOmM0YzE5MGFkMTFlMzQ5NjlhZjQyMWFkMGFkYTM3M2Y0XzQw_0b4added-2bf7-424e-9ed4-fc5850db3e95" continuedAt="ic93fe1819fe049688f3d0a6539b7202c" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic93fe1819fe049688f3d0a6539b7202c">None.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="id5b8a3a67e4b4120aef8023d2c3721ae_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:26.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIRIDIAN THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 9, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Myers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Myers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer, and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristian Humer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristian Humer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer; Principal Accounting Officer)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Scott Myers and Kristian Humer, and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of l934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:27.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Myers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer, and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Myers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristian Humer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristian Humer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer; Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Tomas Kiselak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tomas Kiselak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Harwin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter Harwin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Arlene Morris</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlene Morris</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Moses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Moses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>exhibit45_descriptionofsec.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iab41776e610a49e1b9515d7b93d3c946_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.5</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">General</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a summary of the material terms of our capital stock, as well as other material terms of our second restated certificate of incorporation (&#8220;certificate of incorporation&#8221;) and second amended and restated bylaws (&#8220;bylaws&#8221;) and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our certificate of incorporation, authorizes us to issue up to 200,000,000 shares of common stock, $0.01 par value per share (&#8220;Common Stock&#8221;), and 5,000,000 shares of preferred stock (&#8220;Preferred Stock&#8221;), of which 435,000 shares are designated as Series A Non-Voting Convertible Preferred Stock, $0.01 par value per share, and 500,000 shares are designated as Series B Non-Voting Convertible Preferred Stock, $0.01 par value per share. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Common Stock</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Voting Rights</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each holder of our Common Stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, except on matters relating solely to terms of Preferred Stock. Under our certificate of incorporation and bylaws, our stockholders do not have cumulative voting rights. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Dividends</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to preferences that may be applicable to any then-outstanding Preferred Stock, holders of our Common Stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidation</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event of our liquidation, dissolution or winding up, holders of our Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of Preferred Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Rights and Preferences</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Holders of our Common Stock do not have any preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that we may designate in the future.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fully Paid and Nonassessable</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of our outstanding shares of Common Stock are fully paid and nonassessable.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Preferred Stock</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to 5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.5</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the Common Stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our board of directors, without stockholder approval, can issue Preferred Stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of Common Stock. Preferred Stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of Preferred Stock may have the effect of decreasing the market price of the Common Stock and may adversely affect the voting power of holders of Common Stock and reduce the likelihood that holders of our Common Stock will receive dividend payments and payments upon liquidation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will fix the designations, voting powers, preferences and rights of the Preferred Stock of each series we issue, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will describe the terms of the series of Preferred Stock being offered, including, to the extent applicable&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the title and stated value&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of shares we are offering&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the liquidation preference per share&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the purchase price&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the dividend rate, period and payment date and method of calculation for dividends&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the procedures for any auction and remarketing&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the provisions for a sinking fund&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the provisions for redemption or repurchase and any restrictions on our ability to exercise those redemption and repurchase rights&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any listing of the Preferred Stock on any securities exchange or market&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether the Preferred Stock will be convertible into our Common Stock, and the conversion rate or conversion price, or how they will be calculated, and the conversion period&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether the Preferred Stock will be exchangeable into debt securities, and the exchange rate or exchange price, or how they will be calculated, and the exchange period&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">voting rights of the Preferred Stock&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">preemptive rights&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">restrictions on transfer, sale or other assignment&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether interests in the Preferred Stock will be represented by depositary shares&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a discussion of material or special U.S. federal income tax considerations applicable to the Preferred Stock&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the relative ranking and preferences of the Preferred Stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.5</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any limitations on the issuance of any class or series of Preferred Stock ranking senior to or on a parity with the series of Preferred Stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the Preferred Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we issue shares of Preferred Stock, the shares will be fully paid and nonassessable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The issuance of Preferred Stock could adversely affect the voting power of holders of Common Stock and reduce the likelihood that the holders of our Common Stock will receive dividend payments and payments upon liquidation. The issuance could have the effect of decreasing the market price of the Common Stock. The issuance of Preferred Stock also could have the effect of delaying, deterring or preventing a change in control of us.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Registration Rights</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain of the holders of our Common Stock are entitled to rights with respect to the registration of such securities as set forth below under the Securities Act. These rights are provided under the terms of the Registration Rights Agreement between us and certain holders of our Common Stock. Under the terms of the Registration Rights Agreement, we have filed a registration statement on Form S-3 to sell registrable securities. We are required to use commercially reasonable efforts to effect a registration of such shares. The Registration Rights Agreement does not include demand registration rights or piggyback registration rights. All fees, costs and expenses of underwritten registrations under these agreements will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Indemnification</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Registration Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Expenses of Registration</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are generally required to bear all registration and selling expenses incurred in connection with the registration described above, other than underwriting discounts and selling commissions.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Anti-Takeover Provisions</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to Section 203 of the Delaware General Corporation Law, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">on or subsequent to the consummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8260;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.5</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 203 defines a &#8220;business combination&#8221; to include&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Certificate of Incorporation and Bylaws</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our certificate of incorporation and bylaws provide that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the authorized number of directors can be changed only by resolution of our board of directors&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our bylaws may be amended or repealed by our board of directors or stockholders&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our stockholders may not call special meetings of the stockholders or fill vacancies on our board of directors&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our stockholders may remove our directors only for cause&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">all vacancies, including newly created directorships, may, except as otherwise required by law or subject to the rights of holders of Preferred Stock as designated from time to time, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our board of directors will be authorized to issue, without stockholder approval, Preferred Stock, the rights of which will be determined at the discretion of our board of directors and that, if issued, could operate as a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that ours board of directors does not approve&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our stockholders do not have cumulative voting rights, and therefore our stockholders holding a majority of the shares of Common Stock outstanding will be able to elect all of our directors&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our stockholders must comply with advance notice provisions to bring business before or nominate directors for election at a stockholder meeting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employee to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws or (4) any action asserting a claim against us governed by the internal affairs doctrine. Notwithstanding the foregoing, these choice of forum provisions do not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.5</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Potential Effects of Authorized but Unissued Stock</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our shares of Common Stock and Preferred Stock are available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The existence of unissued and unreserved Common Stock and Preferred Stock may enable our board of directors to issue shares to persons friendly to current management or to issue Preferred Stock with terms that could render more difficult or discourage a third-party attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of Preferred Stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in our certificate of incorporation. The purpose of authorizing the board of directors to issue Preferred Stock and to determine the rights and preferences applicable to such Preferred Stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of Preferred Stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Amendments to Governing Documents</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Generally, the amendment of our certificate of incorporation requires approval by our board of directors and a majority vote of stockholders. Any amendment to our bylaws requires the approval of either a majority of our board of directors or approval of at least a majority of the votes entitled to be cast by the holders of our outstanding capital stock in elections of our board of directors.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Listing</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;VRDN.&#8221;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transfer Agent and Registrar</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The transfer agent and registrar for our Common Stock, our Series A Preferred Stock and our Series B Preferred Stock is VStock Transfer, LLC. The transfer agent and registrar&#8217;s address is 18 Lafayette Place, Woodmere, New York 11598.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>fy202210kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id63c3f2ddfc24d00bb51a5d35989d31f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(as of March&#160;9, 2023)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:253.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:253.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction of Incorporation</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viridian Therapeutics Europe Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viridian Therapeutics S.&#225;.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viridian Securities Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23_1xfinalconsentx2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id6ee986dc713454c80623c25cffdd794_1"></div><div style="min-height:156.24pt;width:100%"><div style="margin-top:63pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-237413, 333-251367, 333-260859 and 333-267351) on Form S-3 and (Nos. 333-216112, 333-223672, 333-230271, 333-237165, 333-250906, 333-254771, 333-263490 and 333-266895)  on Form S-8 of our report dated March 9, 2023 with respect to the consolidated financial statements of Viridian Therapeutics, Inc. </font></div><div><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KPMG LLP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boulder, Colorado</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">March 9, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>fy202210kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia03e16461c2f47a69444a34b7d00593a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Myers, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160; I have reviewed this Annual Report on Form 10-K, or this report, of Viridian Therapeutics, Inc., a Delaware corporation&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160; The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:27.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Myers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Myers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>fy202210kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id2dea33bc0414a4a8b6ae0c4b0a40cf5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kristian Humer, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160; I have reviewed this Annual Report on Form 10-K, or this report, of Viridian Therapeutics, Inc., a Delaware corporation&#59;</font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160; The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kristian Humer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristian Humer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer&#59; Principal Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>fy202210kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if827aa9bb3b7449eab20e5eeeaf4faba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned, Scott Myers, Chief Executive Officer of Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Kristian Humer, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the Annual Report on Form 10-K of the Company for the annual period ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Myers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Myers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kristian Humer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristian Humer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer&#59; Principal Accounting Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 9, 2023</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being &#8220;furnished&#8221; with this Report, shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vrdn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrdn="http://www.viridiantherapeutics.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.viridiantherapeutics.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.viridiantherapeutics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.viridiantherapeutics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000010 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTS" roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS">
        <link:definition>0000012 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTS" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS">
        <link:definition>0000013 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000014 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIES" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES">
        <link:definition>0000015 - Disclosure - ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.viridiantherapeutics.com/role/DEBT">
        <link:definition>0000016 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCK" roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCK">
        <link:definition>0000018 - Disclosure - CAPITAL STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTS" roleURI="http://www.viridiantherapeutics.com/role/WARRANTS">
        <link:definition>0000019 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>0000020 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE">
        <link:definition>0000021 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXES">
        <link:definition>0000022 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables">
        <link:definition>0000025 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>0000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIESTables" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables">
        <link:definition>0000027 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.viridiantherapeutics.com/role/DEBTTables">
        <link:definition>0000028 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSTables" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSTables">
        <link:definition>0000030 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>0000031 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables">
        <link:definition>0000032 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESTables">
        <link:definition>0000033 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>0000034 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>0000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTSDetails" roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails">
        <link:definition>0000036 - Disclosure - COLLABORATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails">
        <link:definition>0000037 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>0000038 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails">
        <link:definition>0000039 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails">
        <link:definition>0000040 - Disclosure - PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>0000041 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails">
        <link:definition>0000042 - Disclosure - ACCRUED LIABILITIES - Components of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails">
        <link:definition>0000043 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofLongTermDebtInstrumentsDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails">
        <link:definition>0000044 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofFuturePrincipalPaymentsDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails">
        <link:definition>0000045 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails">
        <link:definition>0000047 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1">
        <link:definition>0000047 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKDetails" roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails">
        <link:definition>0000048 - Disclosure - CAPITAL STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSStockWarrantsOutstandingDetails" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails">
        <link:definition>0000049 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSStockWarrantActivityDetails" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails">
        <link:definition>0000050 - Disclosure - WARRANTS - Stock Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000051 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONBalancebyPlansDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails">
        <link:definition>0000052 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>0000053 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails">
        <link:definition>0000054 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails">
        <link:definition>0000055 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails">
        <link:definition>0000056 - Disclosure - NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESEffectiveTaxRateReconciliationDetails" roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails">
        <link:definition>0000057 - Disclosure - INCOME TAXES - Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000058 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000059 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" abstract="false" name="ClassOfWarrantOrRightConversionPercentageOfOwnership" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_DebtInstrumentFacilityFee" abstract="false" name="DebtInstrumentFacilityFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" abstract="false" name="DeferredTaxLiabilitiesUnrealizedGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" abstract="false" name="CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_ImmunoGenIncMember" abstract="true" name="ImmunoGenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" abstract="false" name="CollaborationArrangementResearchLicenseAndSelectionRightsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_FairmountFundsManagementMember" abstract="true" name="FairmountFundsManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" abstract="false" name="TaxCreditCarryforwardLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" abstract="false" name="SaleOfStockAmountOfSharesRequiredToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" abstract="true" name="EquityclassifiedWarrantsIssuedNovember2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DeferredTaxAssetValuationAllowancePercent" abstract="false" name="DeferredTaxAssetValuationAllowancePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_ParagonTherapeuticsMember" abstract="true" name="ParagonTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" abstract="false" name="CollaborationArrangementPotentialMilestonePaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementUpfrontFeePayment" abstract="false" name="CollaborativeArrangementUpfrontFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_A2021PublicStockOfferingMember" abstract="true" name="A2021PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_AreaOfOfficeSpaceExtension" abstract="false" name="AreaOfOfficeSpaceExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementValueOfSharesIssuedForRightsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_AreaOfOfficeSpaceTerminated" abstract="false" name="AreaOfOfficeSpaceTerminated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="vrdn_AreaOfOfficeSpaceExpanded" abstract="false" name="AreaOfOfficeSpaceExpanded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="vrdn_OperatingLeaseAnnualBaseRent" abstract="false" name="OperatingLeaseAnnualBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" abstract="false" name="AccruedLiabilityofWarrantsonTemporaryEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_ZenasBioPharmaMember" abstract="true" name="ZenasBioPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_InducementGrantsMember" abstract="true" name="InducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" abstract="false" name="AccruedOutsourcingClinicalandPreclinicalStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" abstract="false" name="SaleOfStockAmountOfShareAuthorizedToBeSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_A2020PlanMember" abstract="true" name="A2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementRightsAndLicensesFee" abstract="false" name="CollaborativeArrangementRightsAndLicensesFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_PrincipalAmountTermFee" abstract="false" name="PrincipalAmountTermFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountFirstTranche" abstract="false" name="DebtInstrumentFaceAmountFirstTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" abstract="false" name="SaleOfStockNumberOfConsecutiveDaysThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" abstract="false" name="SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountThirdTranche" abstract="false" name="DebtInstrumentFaceAmountThirdTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" abstract="false" name="CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" abstract="true" name="LiabilityClassifiedWarrantsIssuedApril2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" abstract="false" name="CollaborativeArrangementPotentialSpecialPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CommitmentsandContingenciesLineItems" abstract="true" name="CommitmentsandContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsMember" abstract="true" name="EquityclassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ViridianMergerMember" abstract="true" name="ViridianMergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightRemainingTerm" abstract="false" name="ClassofWarrantorRightRemainingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_DebtInstrumentOtherExpenses" abstract="false" name="DebtInstrumentOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_Amended2016PlanMember" abstract="true" name="Amended2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_CapitalStockSharesAuthorized" abstract="false" name="CapitalStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_OperatingLeasesOperatingExpense" abstract="false" name="OperatingLeasesOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_TaxCreditCarryforwardWriteOff" abstract="false" name="TaxCreditCarryforwardWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountFourthTranche" abstract="false" name="DebtInstrumentFaceAmountFourthTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_A2008PlanMember" abstract="true" name="A2008PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" abstract="true" name="EquityClassifiedWarrantsAcquiredOctober2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_A2016PlanMember" abstract="true" name="A2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" abstract="false" name="ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" abstract="false" name="SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_AtthemarketOfferingMember" abstract="true" name="AtthemarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CommonStockVoteperShare" abstract="false" name="CommonStockVoteperShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_HerculesTermLoanMember" abstract="true" name="HerculesTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DebtInstrumentInterestRateMaximum" abstract="false" name="DebtInstrumentInterestRateMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_SaleOfStockTerm" abstract="false" name="SaleOfStockTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_CommitmentsandContingenciesTable" abstract="true" name="CommitmentsandContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_A2022PublicStockOfferingMember" abstract="true" name="A2022PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightActivityRollForward" abstract="true" name="ClassofWarrantorRightActivityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSection382LimitPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" abstract="true" name="EquityclassifiedWarrantsIssuedFebruary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementSharesIssuedForRightsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" abstract="false" name="SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_AmortizationOfStockIssuanceCosts" abstract="false" name="AmortizationOfStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountSecondTranche" abstract="false" name="DebtInstrumentFaceAmountSecondTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" abstract="false" name="DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" abstract="false" name="SaleofStockCommissionFeePercentageofGrossSaleProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_SaleOfStockWeightedAverageSharePrice" abstract="false" name="SaleOfStockWeightedAverageSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vrdn_XencorIncMember" abstract="true" name="XencorIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_AspireStockPurchaseAgreementMember" abstract="true" name="AspireStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_GoingConcernPolicyPolicyTextBlock" abstract="false" name="GoingConcernPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassofWarrantorRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>vrdn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0603815-130a-4f8b-a735-fb4355362e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0eda3f20-d41c-4250-9789-d63640c6212f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0603815-130a-4f8b-a735-fb4355362e99" xlink:to="loc_us-gaap_AssetsCurrent_0eda3f20-d41c-4250-9789-d63640c6212f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef84f164-5554-4c11-9191-6349a6b3eafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0603815-130a-4f8b-a735-fb4355362e99" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef84f164-5554-4c11-9191-6349a6b3eafb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fa8a341c-f838-45f4-8b78-a47ec4eaf950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0603815-130a-4f8b-a735-fb4355362e99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fa8a341c-f838-45f4-8b78-a47ec4eaf950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4bfcadc6-826e-4f78-b190-cb665aca8509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0603815-130a-4f8b-a735-fb4355362e99" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4bfcadc6-826e-4f78-b190-cb665aca8509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e7ca962c-4fc1-447a-a2de-891a6acd0613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9c2b4bf-5829-42d1-8089-3bdd21069217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7ca962c-4fc1-447a-a2de-891a6acd0613" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9c2b4bf-5829-42d1-8089-3bdd21069217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_caa5a088-63e7-4aff-8168-7aabb9d71ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7ca962c-4fc1-447a-a2de-891a6acd0613" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_caa5a088-63e7-4aff-8168-7aabb9d71ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0e4a332f-09e7-41f6-8373-3997ccf58af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7ca962c-4fc1-447a-a2de-891a6acd0613" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0e4a332f-09e7-41f6-8373-3997ccf58af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_520f7e23-85cd-494d-8d2f-77bcc6cb0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7ca962c-4fc1-447a-a2de-891a6acd0613" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_520f7e23-85cd-494d-8d2f-77bcc6cb0d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39a44858-e98b-43e9-ac1b-852b7f67a31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39a44858-e98b-43e9-ac1b-852b7f67a31a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_139dec8c-e52b-45e0-bbab-dde2b4804660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:to="loc_us-gaap_PreferredStockValue_139dec8c-e52b-45e0-bbab-dde2b4804660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_41fdc38b-f560-4122-82d3-251a1d637376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_41fdc38b-f560-4122-82d3-251a1d637376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7fc5439-5fb9-4364-8b22-04fb52a0bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7fc5439-5fb9-4364-8b22-04fb52a0bd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73b48601-32bf-40b9-aef4-2da2380dd1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb4d3411-2f4c-466c-9ae0-94cfceb520eb" xlink:to="loc_us-gaap_CommonStockValue_73b48601-32bf-40b9-aef4-2da2380dd1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d167015-1553-498e-a60e-f79eef7f2441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d39d8225-ce3b-4900-8682-5f91d9981228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d167015-1553-498e-a60e-f79eef7f2441" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d39d8225-ce3b-4900-8682-5f91d9981228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de679840-ce5e-4c9b-aa21-a12d79ee54dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d167015-1553-498e-a60e-f79eef7f2441" xlink:to="loc_us-gaap_StockholdersEquity_de679840-ce5e-4c9b-aa21-a12d79ee54dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6980dd86-273a-424d-9636-43f0d4d8d36a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d167015-1553-498e-a60e-f79eef7f2441" xlink:to="loc_us-gaap_Liabilities_6980dd86-273a-424d-9636-43f0d4d8d36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5f929be-48a0-4481-8de3-2ee997f38ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_750f171f-5331-4a95-997d-9dc4b0c44571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5f929be-48a0-4481-8de3-2ee997f38ddb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_750f171f-5331-4a95-997d-9dc4b0c44571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85ff955d-4d93-4ece-9c9f-598c694ee2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5f929be-48a0-4481-8de3-2ee997f38ddb" xlink:to="loc_us-gaap_LiabilitiesCurrent_85ff955d-4d93-4ece-9c9f-598c694ee2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_200b82d6-d204-4545-910c-c152481791e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5f929be-48a0-4481-8de3-2ee997f38ddb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_200b82d6-d204-4545-910c-c152481791e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4792cc9c-c30a-45d0-a3f0-526854a43e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5f929be-48a0-4481-8de3-2ee997f38ddb" xlink:to="loc_us-gaap_LongTermDebt_4792cc9c-c30a-45d0-a3f0-526854a43e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_390dc93e-c4d1-46a4-8118-6e7c68e62fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_858b1fe4-6e36-4992-a890-7b427d93b568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_390dc93e-c4d1-46a4-8118-6e7c68e62fb6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_858b1fe4-6e36-4992-a890-7b427d93b568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4b62cfba-56a9-4770-b424-8acba9e57166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_390dc93e-c4d1-46a4-8118-6e7c68e62fb6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4b62cfba-56a9-4770-b424-8acba9e57166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e975bc31-f7a2-4a33-83e3-16cfa4423216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_390dc93e-c4d1-46a4-8118-6e7c68e62fb6" xlink:to="loc_us-gaap_AccountsPayableCurrent_e975bc31-f7a2-4a33-83e3-16cfa4423216" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_97b8bd73-d546-4834-8306-b5969f63dfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25ca6528-f113-41ed-991a-ad382db7bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_97b8bd73-d546-4834-8306-b5969f63dfee" xlink:to="loc_us-gaap_NetIncomeLoss_25ca6528-f113-41ed-991a-ad382db7bd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_51599fd1-a323-466a-bab6-0ded499761d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_97b8bd73-d546-4834-8306-b5969f63dfee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_51599fd1-a323-466a-bab6-0ded499761d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f037e46-4654-4824-8841-726be7e85b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e39754a5-8432-4959-9de2-4be95a178643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3f037e46-4654-4824-8841-726be7e85b2a" xlink:to="loc_us-gaap_OperatingExpenses_e39754a5-8432-4959-9de2-4be95a178643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_41bf45e5-d8f0-4cd3-9769-46d6c9550f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3f037e46-4654-4824-8841-726be7e85b2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_41bf45e5-d8f0-4cd3-9769-46d6c9550f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6ecf0d19-c08a-4fd6-a15a-b37a0facccea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_73b0587e-27fd-4f12-bcdb-b044fbcdc242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6ecf0d19-c08a-4fd6-a15a-b37a0facccea" xlink:to="loc_us-gaap_InterestAndOtherIncome_73b0587e-27fd-4f12-bcdb-b044fbcdc242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_fdc98669-1a86-47bd-9b8c-b39d1cc59945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6ecf0d19-c08a-4fd6-a15a-b37a0facccea" xlink:to="loc_us-gaap_InterestAndDebtExpense_fdc98669-1a86-47bd-9b8c-b39d1cc59945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4295db72-93b0-4a3c-b253-692c42243cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_85ffc02b-57d8-4cd7-b87d-792a4de425b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4295db72-93b0-4a3c-b253-692c42243cff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_85ffc02b-57d8-4cd7-b87d-792a4de425b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a2c34f19-7bce-4b9a-a2a7-dcc4797a132d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0c242afa-2d70-4e8f-8cea-e69b747ab91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2c34f19-7bce-4b9a-a2a7-dcc4797a132d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0c242afa-2d70-4e8f-8cea-e69b747ab91c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c745d2d9-98ec-4e16-b8c2-f235732a378c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2c34f19-7bce-4b9a-a2a7-dcc4797a132d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c745d2d9-98ec-4e16-b8c2-f235732a378c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc09e744-8a9d-4a86-b5be-9a54c85821d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bcc198f8-df46-41a7-acef-64dde7db3123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bc09e744-8a9d-4a86-b5be-9a54c85821d7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bcc198f8-df46-41a7-acef-64dde7db3123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8615393e-b20d-4cf7-9838-71b6c7d7e4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bc09e744-8a9d-4a86-b5be-9a54c85821d7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8615393e-b20d-4cf7-9838-71b6c7d7e4d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b18f479c-5f8f-4f0e-9304-125d953e45d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f69da450-9691-4be8-8e8a-38f7ebf6cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b18f479c-5f8f-4f0e-9304-125d953e45d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f69da450-9691-4be8-8e8a-38f7ebf6cb3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846b90ba-be1a-4e3d-bdbe-0a80a9aae0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b18f479c-5f8f-4f0e-9304-125d953e45d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846b90ba-be1a-4e3d-bdbe-0a80a9aae0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b18efe4-5688-4b6d-8997-e8564fb89e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b18f479c-5f8f-4f0e-9304-125d953e45d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b18efe4-5688-4b6d-8997-e8564fb89e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9678af5c-62dc-40a6-ae5c-89865d40d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02f45297-d07b-4879-bc66-7b8aa4f67f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9678af5c-62dc-40a6-ae5c-89865d40d30d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02f45297-d07b-4879-bc66-7b8aa4f67f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e44a518a-4911-458e-a789-750069d63957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9678af5c-62dc-40a6-ae5c-89865d40d30d" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e44a518a-4911-458e-a789-750069d63957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_29c02263-2061-4877-82fa-e62b558e6b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9678af5c-62dc-40a6-ae5c-89865d40d30d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_29c02263-2061-4877-82fa-e62b558e6b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c8324b0-fd7d-4a2c-83fe-bccf5685c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9678af5c-62dc-40a6-ae5c-89865d40d30d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2c8324b0-fd7d-4a2c-83fe-bccf5685c8bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7a8f8341-984f-4c49-ba60-795d22d8bf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_7a8f8341-984f-4c49-ba60-795d22d8bf3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_858f9cb2-7450-4d2c-b801-998c569bdebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_858f9cb2-7450-4d2c-b801-998c569bdebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_51b884e4-7f87-43f5-97ae-d47e30a1c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_51b884e4-7f87-43f5-97ae-d47e30a1c64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6fe9bd70-7c3b-430a-a4ee-928327970f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6fe9bd70-7c3b-430a-a4ee-928327970f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_91828c00-3759-412b-9f62-3a352182cb0b" xlink:href="vrdn-20221231.xsd#vrdn_NonCashLeaseExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_vrdn_NonCashLeaseExpense_91828c00-3759-412b-9f62-3a352182cb0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7a9adb2-b4c8-47f9-8a53-51ede414bea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7a9adb2-b4c8-47f9-8a53-51ede414bea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_bbd73206-7e36-4487-a3df-48636292d2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_bbd73206-7e36-4487-a3df-48636292d2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a678d6e8-66eb-4eb9-9a92-0f9a132014b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a678d6e8-66eb-4eb9-9a92-0f9a132014b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1cd69ead-63f5-40c1-ba3d-095345f1a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1cd69ead-63f5-40c1-ba3d-095345f1a3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7bed4072-105c-463d-9705-a0325d155392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7bed4072-105c-463d-9705-a0325d155392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3a6f0537-2a95-485c-978d-c41f78163833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3a6f0537-2a95-485c-978d-c41f78163833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_99c2ac78-cb0a-4c59-a545-18fd47072219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_99c2ac78-cb0a-4c59-a545-18fd47072219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5b40bd86-f7a1-4299-9a04-150e22b6e167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_ShareBasedCompensation_5b40bd86-f7a1-4299-9a04-150e22b6e167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7af5b619-94b6-4c84-a021-c7eed9dd2a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5682fa4-3589-45eb-aff6-b953dd18fce8" xlink:to="loc_us-gaap_NetIncomeLoss_7af5b619-94b6-4c84-a021-c7eed9dd2a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b90c5940-8c36-4ae0-a4aa-a5e3f687d167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b90c5940-8c36-4ae0-a4aa-a5e3f687d167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9aa1ffb0-ae5d-4649-a015-f9d8d293beca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9aa1ffb0-ae5d-4649-a015-f9d8d293beca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_956c6a16-21b2-4c05-94be-da5e24a22bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_956c6a16-21b2-4c05-94be-da5e24a22bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_156d4112-809f-415f-8a14-e56e50c24c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_156d4112-809f-415f-8a14-e56e50c24c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_45db596d-bced-4098-af78-32e131e01dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_45db596d-bced-4098-af78-32e131e01dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_108e1b2c-c3e6-4292-944a-fadfd41023d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_108e1b2c-c3e6-4292-944a-fadfd41023d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b22c85cb-05ec-40a5-8b61-1a06800f396a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b22c85cb-05ec-40a5-8b61-1a06800f396a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_37245e34-23ca-40a0-9af7-d0e26a6bfe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcf1ffa3-575e-45f8-9b4c-08e2dfedd8b3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_37245e34-23ca-40a0-9af7-d0e26a6bfe41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_12dc3bdf-ef20-4ab4-9e83-d36fd88316a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b8d98536-df5d-4f6b-b0c7-beb3dd0f812c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_12dc3bdf-ef20-4ab4-9e83-d36fd88316a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b8d98536-df5d-4f6b-b0c7-beb3dd0f812c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45bed357-1368-4fa0-80b0-ff27c2dbff14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_12dc3bdf-ef20-4ab4-9e83-d36fd88316a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45bed357-1368-4fa0-80b0-ff27c2dbff14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a1a5018-4473-4205-9ce0-dd554ab9932d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_12dc3bdf-ef20-4ab4-9e83-d36fd88316a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a1a5018-4473-4205-9ce0-dd554ab9932d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9597459e-6d68-463b-8cba-e34211c271cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3511160b-9dee-419d-be5c-80a6f06a0eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9597459e-6d68-463b-8cba-e34211c271cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3511160b-9dee-419d-be5c-80a6f06a0eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a92fef8f-7e78-42da-a583-75b224135f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9597459e-6d68-463b-8cba-e34211c271cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a92fef8f-7e78-42da-a583-75b224135f97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5dee9b6c-2f88-4b44-807b-756b116c786d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f1a37951-a8a3-4100-86ff-088c495a2746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5dee9b6c-2f88-4b44-807b-756b116c786d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f1a37951-a8a3-4100-86ff-088c495a2746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa6357a5-b2ad-4b5d-8901-48f52e994c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5dee9b6c-2f88-4b44-807b-756b116c786d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa6357a5-b2ad-4b5d-8901-48f52e994c62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da613b6a-c0c4-4368-8f9c-be76a4752fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da613b6a-c0c4-4368-8f9c-be76a4752fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3653da63-268a-499c-8036-1b2e998cae08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3653da63-268a-499c-8036-1b2e998cae08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2358f39b-ed59-40e1-9a1e-2a8c4bd6b431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2358f39b-ed59-40e1-9a1e-2a8c4bd6b431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_41694950-7d2e-4d10-a23b-d7fe3a6a960d" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_41694950-7d2e-4d10-a23b-d7fe3a6a960d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d5e15c3f-0cdc-400e-9ab2-bc13693368e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d5e15c3f-0cdc-400e-9ab2-bc13693368e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent_5ce7aa96-3e85-4277-b1b6-05fd0595c16a" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_vrdn_AccruedLegalFeesCurrent_5ce7aa96-3e85-4277-b1b6-05fd0595c16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_37d58106-c6e3-49d8-a47a-f9eab72173e5" xlink:href="vrdn-20221231.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7902cca9-6a59-477e-b821-f7c44677f5aa" xlink:to="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_37d58106-c6e3-49d8-a47a-f9eab72173e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_972df735-5ccd-41dd-b412-b4b2019e319b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b53199fe-766c-49b7-848a-31262fdd4181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_972df735-5ccd-41dd-b412-b4b2019e319b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b53199fe-766c-49b7-848a-31262fdd4181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_604497de-227c-48d0-9459-ee1adebe839c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_972df735-5ccd-41dd-b412-b4b2019e319b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_604497de-227c-48d0-9459-ee1adebe839c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ad575bda-e657-4dbc-bd73-bf72bc2aa12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c820c9-6069-4c7a-aa1d-74b1e9de2660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ad575bda-e657-4dbc-bd73-bf72bc2aa12b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c820c9-6069-4c7a-aa1d-74b1e9de2660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_336a7592-428a-473b-af57-9d42bdd02503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ad575bda-e657-4dbc-bd73-bf72bc2aa12b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_336a7592-428a-473b-af57-9d42bdd02503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b59e787c-19eb-4568-aae4-59623e7054f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ad575bda-e657-4dbc-bd73-bf72bc2aa12b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b59e787c-19eb-4568-aae4-59623e7054f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_56ba5ab8-2860-48ef-83a7-6d3c19c009bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ad575bda-e657-4dbc-bd73-bf72bc2aa12b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_56ba5ab8-2860-48ef-83a7-6d3c19c009bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c38cea52-cb2a-4f0d-a748-5e0b776ab4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d0526cb-f6cd-4b8c-ba8c-d879019c0cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c38cea52-cb2a-4f0d-a748-5e0b776ab4c2" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d0526cb-f6cd-4b8c-ba8c-d879019c0cb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0d2824f3-e4df-4b30-89b5-b1da4d156302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c38cea52-cb2a-4f0d-a748-5e0b776ab4c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0d2824f3-e4df-4b30-89b5-b1da4d156302" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_516cc24c-d813-4cd7-958d-29103ae4dd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e914b5e6-52ff-4adf-a30b-bf18f168fced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_516cc24c-d813-4cd7-958d-29103ae4dd21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e914b5e6-52ff-4adf-a30b-bf18f168fced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_620a2e72-4960-48a2-8ef8-5ec3950a7864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_516cc24c-d813-4cd7-958d-29103ae4dd21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_620a2e72-4960-48a2-8ef8-5ec3950a7864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7a276eb1-69ec-41fd-9b22-31636f6523b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_516cc24c-d813-4cd7-958d-29103ae4dd21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7a276eb1-69ec-41fd-9b22-31636f6523b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_096f154b-2c8c-4715-a725-851bcda408df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_516cc24c-d813-4cd7-958d-29103ae4dd21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_096f154b-2c8c-4715-a725-851bcda408df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESEffectiveTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f2b5b4ce-1a9f-4b95-8bd7-423ccb71425e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f2b5b4ce-1a9f-4b95-8bd7-423ccb71425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9b4c3aed-7bd3-4109-b529-8dd6d9d98454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9b4c3aed-7bd3-4109-b529-8dd6d9d98454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_346c6d4e-d498-4728-bb11-79086774c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_346c6d4e-d498-4728-bb11-79086774c7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4a21851f-092a-4eac-afff-6d18e0d0394f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4a21851f-092a-4eac-afff-6d18e0d0394f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_67bd40a4-cd24-4552-b16f-53b3ee0ec933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_67bd40a4-cd24-4552-b16f-53b3ee0ec933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6164bae5-be79-4434-821e-980716b3d7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6164bae5-be79-4434-821e-980716b3d7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_c654d07c-09ba-45e1-8bfb-2824009a25ae" xlink:href="vrdn-20221231.xsd#vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f3405d1-0e34-418b-8cb7-3d2452ca18bc" xlink:to="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_c654d07c-09ba-45e1-8bfb-2824009a25ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2541f34e-8a03-4862-a4f9-ed066d79c767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fa939fc4-899f-4ef4-98a5-d63d790e0fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2541f34e-8a03-4862-a4f9-ed066d79c767" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fa939fc4-899f-4ef4-98a5-d63d790e0fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2039209e-420f-43fa-b32b-d7c10cbc8be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2541f34e-8a03-4862-a4f9-ed066d79c767" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2039209e-420f-43fa-b32b-d7c10cbc8be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_80099736-0906-4cf1-9ef1-a6ff44b402ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_00bdc0b4-aa3f-4dda-9fe5-7295982b7a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_80099736-0906-4cf1-9ef1-a6ff44b402ed" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_00bdc0b4-aa3f-4dda-9fe5-7295982b7a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bd435a14-56a4-45ad-b6d2-e5d78433ff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_80099736-0906-4cf1-9ef1-a6ff44b402ed" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bd435a14-56a4-45ad-b6d2-e5d78433ff19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c89e0b3a-1d2a-4c1e-9276-3dea410c4fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_18ee9c1f-6bd1-4469-96ec-7de85ae2be8e" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c89e0b3a-1d2a-4c1e-9276-3dea410c4fc4" xlink:to="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_18ee9c1f-6bd1-4469-96ec-7de85ae2be8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_6bf3d20f-bf55-4f31-92a0-42f0e5018435" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c89e0b3a-1d2a-4c1e-9276-3dea410c4fc4" xlink:to="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_6bf3d20f-bf55-4f31-92a0-42f0e5018435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58462881-4a37-4336-af3d-692bdeef203c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58462881-4a37-4336-af3d-692bdeef203c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a0a7f807-bdb4-4126-94e4-3a793abb152f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a0a7f807-bdb4-4126-94e4-3a793abb152f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_42e1047f-a267-4877-a680-6384913e3b55" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_42e1047f-a267-4877-a680-6384913e3b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_98fc81c4-e9c8-449c-b5ef-195073d281d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_98fc81c4-e9c8-449c-b5ef-195073d281d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_cbe685b7-a846-4025-a3e4-9c5a4440beaa" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_cbe685b7-a846-4025-a3e4-9c5a4440beaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9d5767d5-83a8-4d10-b3d0-67bd10761bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9d5767d5-83a8-4d10-b3d0-67bd10761bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9726a3ea-af53-4727-8b9c-4c7abf2452d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_12978838-11cf-4e57-a629-56e10ca8d5f0" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9726a3ea-af53-4727-8b9c-4c7abf2452d9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>vrdn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ia53498ccbe93480697aa62dc6b19140e_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:to="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf406e3-8033-46bd-af7f-cd98bf680eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf406e3-8033-46bd-af7f-cd98bf680eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6498fe2-0f97-46fa-b1fd-252e11438687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6498fe2-0f97-46fa-b1fd-252e11438687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_081d9abf-7a54-4c65-b37c-e382bc85da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_081d9abf-7a54-4c65-b37c-e382bc85da6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4b99044e-5c24-4ec9-94cf-eed6d9181d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_4b99044e-5c24-4ec9-94cf-eed6d9181d8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf7deda0-a745-4feb-9c21-92420030fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_AssetsCurrent_bf7deda0-a745-4feb-9c21-92420030fb97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f26024ac-8fd7-494d-bedf-94b219c3c782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f26024ac-8fd7-494d-bedf-94b219c3c782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_005469a2-3bed-412e-a7ba-9b5627ffa209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_005469a2-3bed-412e-a7ba-9b5627ffa209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_73884f09-940f-451f-b633-0a4507761d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_73884f09-940f-451f-b633-0a4507761d5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e1f7f77b-d914-4fa2-a0f9-308a1ae7c236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_Assets_e1f7f77b-d914-4fa2-a0f9-308a1ae7c236" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7239ac97-0cd7-4bfc-ab6d-0ae6b6f0b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_AccountsPayableCurrent_7239ac97-0cd7-4bfc-ab6d-0ae6b6f0b5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_59c984d6-5ba7-4100-b886-e2ca7ead7829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_59c984d6-5ba7-4100-b886-e2ca7ead7829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b4b7128-aef6-4abb-9714-11032fa3cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b4b7128-aef6-4abb-9714-11032fa3cb1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_15b08d29-7e7f-4bfe-9251-c3ac182bb5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_LiabilitiesCurrent_15b08d29-7e7f-4bfe-9251-c3ac182bb5a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8490ffb2-baaa-46d0-8984-70f64704ca53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LongTermDebt_8490ffb2-baaa-46d0-8984-70f64704ca53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2b76db2-91a2-4fcb-9740-0d28308af57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2b76db2-91a2-4fcb-9740-0d28308af57d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5c66376f-7f51-46cd-a585-cc1626287413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5c66376f-7f51-46cd-a585-cc1626287413" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe9b080e-cabe-4bae-88cd-15d7f2061485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_Liabilities_fe9b080e-cabe-4bae-88cd-15d7f2061485" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26666b3e-f281-436d-8ec2-cbe1c44a8344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26666b3e-f281-436d-8ec2-cbe1c44a8344" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5e8b81d9-c43a-47a8-ac16-181875aa725d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_PreferredStockValue_5e8b81d9-c43a-47a8-ac16-181875aa725d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fa36f1f1-74d4-4934-899c-8f18cc08f079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_CommonStockValue_fa36f1f1-74d4-4934-899c-8f18cc08f079" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_eeb0f75a-f7fc-4ba5-810e-f7c1887738d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_eeb0f75a-f7fc-4ba5-810e-f7c1887738d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7603d21-7995-4384-a06c-3a363aaf2df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7603d21-7995-4384-a06c-3a363aaf2df3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0c788e2e-b977-48f1-8e45-6469516a83ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0c788e2e-b977-48f1-8e45-6469516a83ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_561339c3-d742-4a86-ab0a-b86b33883303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_StockholdersEquity_561339c3-d742-4a86-ab0a-b86b33883303" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61ac2c58-36c7-4cd7-a417-8e2455cffabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61ac2c58-36c7-4cd7-a417-8e2455cffabf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:to="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_337022ab-a747-4953-8042-f399fa1e2696_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:to="loc_us-gaap_ClassOfStockDomain_337022ab-a747-4953-8042-f399fa1e2696_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:to="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_492e825e-220a-459a-82d9-02539a1582ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_492e825e-220a-459a-82d9-02539a1582ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0c141b2a-ceea-41ba-99e7-6173c03a42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0c141b2a-ceea-41ba-99e7-6173c03a42f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i64e74d9e2ac24601a0247d33f0d85859_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b15f4769-d8f2-4b46-bba9-a254f6b5a315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b15f4769-d8f2-4b46-bba9-a254f6b5a315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cf79c4fa-c2b8-42b0-bcf6-8481c556c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cf79c4fa-c2b8-42b0-bcf6-8481c556c66a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3f12e733-bcb6-4aee-8738-fac79cb4027b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3f12e733-bcb6-4aee-8738-fac79cb4027b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f0e38aed-21ef-4676-8b03-c9c662a7113d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f0e38aed-21ef-4676-8b03-c9c662a7113d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e8cefc7-e4a2-4ad8-9216-88e5a09fa366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e8cefc7-e4a2-4ad8-9216-88e5a09fa366" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_60ed4826-48cb-4c64-be89-67b030a25bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_60ed4826-48cb-4c64-be89-67b030a25bb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a30520bc-79b3-45c6-b5c7-31724802d489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesIssued_a30520bc-79b3-45c6-b5c7-31724802d489" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b4d941f1-d0e6-4458-a78e-40512f6dbbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b4d941f1-d0e6-4458-a78e-40512f6dbbdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_be1b836a-c15c-418f-837b-0c3dac84fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_be1b836a-c15c-418f-837b-0c3dac84fbcb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3dd787c-5d53-4360-822c-8c11e19ad40e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:to="loc_us-gaap_ClassOfStockDomain_a3dd787c-5d53-4360-822c-8c11e19ad40e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:to="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_94afa59b-a96d-4c86-8856-5139b439b279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_94afa59b-a96d-4c86-8856-5139b439b279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0b7fab67-4be0-42ea-b920-afa0e7f2e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0b7fab67-4be0-42ea-b920-afa0e7f2e96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_db357732-2a80-4e34-8106-805b2415dc22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:to="loc_us-gaap_RelatedPartyDomain_db357732-2a80-4e34-8106-805b2415dc22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:to="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_42bd1d39-3de9-4257-8390-5c5831390f9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:to="loc_srt_AffiliatedEntityMember_42bd1d39-3de9-4257-8390-5c5831390f9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended" id="i289cd482fde14bfb9305cd805f88d771_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94022989-fc36-442a-a248-c5f045fb0f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94022989-fc36-442a-a248-c5f045fb0f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:to="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:to="loc_us-gaap_RelatedPartyDomain_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:to="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_15026ed0-76e0-4c35-a95f-e40fa46440c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:to="loc_srt_AffiliatedEntityMember_15026ed0-76e0-4c35-a95f-e40fa46440c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i24e795c9b09d4cabad3617f3289c10bf_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9aebef7d-790e-4d1f-8f2f-a295279d0ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9aebef7d-790e-4d1f-8f2f-a295279d0ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_899d4e85-c293-46d2-9527-8e13bde20cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockholdersEquity_899d4e85-c293-46d2-9527-8e13bde20cca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f4143a98-b7fa-4ef1-8d1f-67a29d6c0b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f4143a98-b7fa-4ef1-8d1f-67a29d6c0b8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87a81079-e6b7-4e17-a751-2dadd25a95b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87a81079-e6b7-4e17-a751-2dadd25a95b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0ba84c7a-7042-4009-9da4-5461a3c25c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0ba84c7a-7042-4009-9da4-5461a3c25c9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca2eae2-18cc-43b0-b3e1-7fc2abb8a660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca2eae2-18cc-43b0-b3e1-7fc2abb8a660" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97c4f487-645b-46cb-a233-9d4127e310d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97c4f487-645b-46cb-a233-9d4127e310d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a72ad12e-4c20-4e3b-bb4e-85196ca02947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a72ad12e-4c20-4e3b-bb4e-85196ca02947" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7344faed-87b2-44db-97a8-f7ba16d27293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7344faed-87b2-44db-97a8-f7ba16d27293" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_fd8dabad-b17d-458b-9411-a9ae31b6be50" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_fd8dabad-b17d-458b-9411-a9ae31b6be50" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_3a453c1b-9e08-49b7-adbd-eafd4dc0eb58" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_3a453c1b-9e08-49b7-adbd-eafd4dc0eb58" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1dd93cbb-cc92-4295-98bc-3388a213d1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1dd93cbb-cc92-4295-98bc-3388a213d1d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e5603f14-7c4c-4851-bc4f-c81966b76021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e5603f14-7c4c-4851-bc4f-c81966b76021" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5042d6ad-fbcb-45ee-9041-b05525e82d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5042d6ad-fbcb-45ee-9041-b05525e82d02" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4a7b4796-156a-4382-a90b-dfc642ec115e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4a7b4796-156a-4382-a90b-dfc642ec115e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8206d482-38cb-4b54-81d6-ea5893a6000d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8206d482-38cb-4b54-81d6-ea5893a6000d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bd01b92f-52f8-453a-b3d9-32bb36156961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bd01b92f-52f8-453a-b3d9-32bb36156961" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a7b4a313-b196-4b5f-b868-c7db31cba637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a7b4a313-b196-4b5f-b868-c7db31cba637" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d432bf21-8264-48f5-9e6b-3624e8df5723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_NetIncomeLoss_d432bf21-8264-48f5-9e6b-3624e8df5723" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e3812400-085f-4cfc-b596-5f97fb77e910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_58565987-e0b2-4c6d-a674-2c9760b9f74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_453a0c83-381e-495b-b17c-edb01ec0edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:to="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:to="loc_us-gaap_EquityComponentDomain_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:to="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1c99991c-52c7-4527-9bbb-f339e8c72f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_PreferredStockMember_1c99991c-52c7-4527-9bbb-f339e8c72f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0e1a4e27-a688-42ad-841b-84e695b71f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_CommonStockMember_0e1a4e27-a688-42ad-841b-84e695b71f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ee94ceb-03d9-4f2b-b6db-f2de504632ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ee94ceb-03d9-4f2b-b6db-f2de504632ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d31cfd-6391-436f-bcb8-e4ecf39fe767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d31cfd-6391-436f-bcb8-e4ecf39fe767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f6e5628-5e73-414d-98ed-cb583d8d248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_RetainedEarningsMember_0f6e5628-5e73-414d-98ed-cb583d8d248a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_215e252b-9957-4df5-8614-2cef16128c7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:to="loc_us-gaap_ClassOfStockDomain_215e252b-9957-4df5-8614-2cef16128c7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:to="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1578e818-f3e3-4f26-ae7c-7657a39e2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1578e818-f3e3-4f26-ae7c-7657a39e2b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ec0ed5e5-d883-4f28-8d51-35cbc6797ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ec0ed5e5-d883-4f28-8d51-35cbc6797ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7fbc2ab-70c1-493d-b893-83f6c48b067d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7fbc2ab-70c1-493d-b893-83f6c48b067d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PublicOfferingMember_9cff8a90-a681-4aa0-bf2f-fdfdac869089" xlink:href="vrdn-20221231.xsd#vrdn_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:to="loc_vrdn_PublicOfferingMember_9cff8a90-a681-4aa0-bf2f-fdfdac869089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_6eb73835-290b-468d-9bc2-093d02da1595" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:to="loc_vrdn_AtthemarketOfferingMember_6eb73835-290b-468d-9bc2-093d02da1595" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="if74d1b475b254a84943179da4076cdd6_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_88873a00-8916-49f5-9668-22c1bd392c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_88873a00-8916-49f5-9668-22c1bd392c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:to="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:to="loc_us-gaap_ClassOfStockDomain_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:to="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d0353fba-8987-4081-9b31-f5c4cafcef3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d0353fba-8987-4081-9b31-f5c4cafcef3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4438c558-e335-41b8-a28a-8a9e3fb34dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:to="loc_us-gaap_EquityComponentDomain_4438c558-e335-41b8-a28a-8a9e3fb34dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:to="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_3d714a10-4ecb-46aa-a6ea-e643a6deb3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:to="loc_us-gaap_PreferredStockMember_3d714a10-4ecb-46aa-a6ea-e643a6deb3c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a2cee14-1996-42a0-a0be-7d598792373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:to="loc_us-gaap_CommonStockMember_7a2cee14-1996-42a0-a0be-7d598792373d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ae8289c-e508-49b2-9b1c-28f5f708daa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ae8289c-e508-49b2-9b1c-28f5f708daa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PublicOfferingMember_3abb21ca-6725-45a2-96f3-ce6ed0515231" xlink:href="vrdn-20221231.xsd#vrdn_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:to="loc_vrdn_PublicOfferingMember_3abb21ca-6725-45a2-96f3-ce6ed0515231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_0a097cbd-8685-42a0-8cb5-486afea67c28" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:to="loc_vrdn_AtthemarketOfferingMember_0a097cbd-8685-42a0-8cb5-486afea67c28" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="icfb16d741d24443ebd2a00b7273400ec_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2293cf4-d752-415b-9072-57ab16cb1abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_NetIncomeLoss_b2293cf4-d752-415b-9072-57ab16cb1abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4b24d314-42a5-415c-a9dc-191c5ca968c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4b24d314-42a5-415c-a9dc-191c5ca968c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be22680a-410f-4d75-b09e-4d6315fc936d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_ShareBasedCompensation_be22680a-410f-4d75-b09e-4d6315fc936d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b86949f8-09d5-4e7c-96f3-574062eabea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b86949f8-09d5-4e7c-96f3-574062eabea2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c29f1035-17e1-4840-9704-ec55e3265e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c29f1035-17e1-4840-9704-ec55e3265e0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a0346008-2249-4384-b3a7-6d7e084e9270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a0346008-2249-4384-b3a7-6d7e084e9270" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c7c5a61e-0665-4497-bc51-7267a447e0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c7c5a61e-0665-4497-bc51-7267a447e0a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_21017c3b-32b3-4718-a4cb-b486c609a566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_21017c3b-32b3-4718-a4cb-b486c609a566" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_14d4cf1f-6cc7-46bb-9fea-dd97aaab708e" xlink:href="vrdn-20221231.xsd#vrdn_NonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_vrdn_NonCashLeaseExpense_14d4cf1f-6cc7-46bb-9fea-dd97aaab708e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11a0148c-e9a6-406e-b09f-10b16980cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11a0148c-e9a6-406e-b09f-10b16980cdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07ef5eab-168e-414c-8c44-7243e2e963c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07ef5eab-168e-414c-8c44-7243e2e963c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d8d8a68c-b687-44ff-8633-c5f823b8a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d8d8a68c-b687-44ff-8633-c5f823b8a515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_f0ebe42d-f997-44c0-aa74-8c986ed2adca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_f0ebe42d-f997-44c0-aa74-8c986ed2adca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_160d1f06-d4cf-412e-a241-ee5c6d3091d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_160d1f06-d4cf-412e-a241-ee5c6d3091d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_014c191a-b603-4b9d-9875-e078863410b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_014c191a-b603-4b9d-9875-e078863410b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17466f1b-9785-402c-93dc-098705338840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17466f1b-9785-402c-93dc-098705338840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cf3ab900-96ea-458e-894e-ce41f639f2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cf3ab900-96ea-458e-894e-ce41f639f2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5011110b-da4b-49c7-9797-e213b81ec0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5011110b-da4b-49c7-9797-e213b81ec0b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7295096-5a57-4692-89f1-e0af10de1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7295096-5a57-4692-89f1-e0af10de1c2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_755a421f-c5de-44ed-af79-2cd1deab2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_755a421f-c5de-44ed-af79-2cd1deab2bb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_253d8c14-e099-4517-9629-fba8b374c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_253d8c14-e099-4517-9629-fba8b374c7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_21c6bc57-b096-46f8-8470-d4e97a864dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_21c6bc57-b096-46f8-8470-d4e97a864dba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_997f68a9-3106-4181-acf3-fa449ec0ce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_997f68a9-3106-4181-acf3-fa449ec0ce7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_54255e9a-141f-418a-a2f8-569a686a3841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_54255e9a-141f-418a-a2f8-569a686a3841" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_dcd01121-64d9-4152-a3ec-f008560c380b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_dcd01121-64d9-4152-a3ec-f008560c380b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ae6a1316-5c51-401a-a97f-d1a16792902c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ae6a1316-5c51-401a-a97f-d1a16792902c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3527cc42-0943-4df2-8c8b-780cc08cb0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3527cc42-0943-4df2-8c8b-780cc08cb0ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b7584a65-2c30-4087-93b0-b92760ce945f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b7584a65-2c30-4087-93b0-b92760ce945f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f9fbc2-dd38-40da-aeea-5154a22b3b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f9fbc2-dd38-40da-aeea-5154a22b3b99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_999ad650-9e02-451b-ad7b-9baa292b3d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_999ad650-9e02-451b-ad7b-9baa292b3d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb3eb7b6-adef-40de-954c-c99e3c200ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb3eb7b6-adef-40de-954c-c99e3c200ffb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3412ac7c-c52b-428d-893c-d4b2720bd0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cb69829f-563d-432b-a166-bd4762d6e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:to="loc_us-gaap_InterestPaidNet_cb69829f-563d-432b-a166-bd4762d6e7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3210bd78-bb9e-4723-a3e4-d71898cc3f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3210bd78-bb9e-4723-a3e4-d71898cc3f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AmortizationOfStockIssuanceCosts_ed34c5fe-b577-4fe1-8972-164ebb92a8c2" xlink:href="vrdn-20221231.xsd#vrdn_AmortizationOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:to="loc_vrdn_AmortizationOfStockIssuanceCosts_ed34c5fe-b577-4fe1-8972-164ebb92a8c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:to="loc_us-gaap_EquityComponentDomain_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:to="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8deebfb7-c6a7-4f04-92d9-e46fb54801e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:to="loc_us-gaap_CommonStockMember_8deebfb7-c6a7-4f04-92d9-e46fb54801e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_72c9e216-2824-4e7b-a5c6-5548e8bc4e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:to="loc_us-gaap_PreferredStockMember_72c9e216-2824-4e7b-a5c6-5548e8bc4e7c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i633bc1b5abef4f74849d13fed6ddfe3f_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0f042091-c72f-40d1-9427-aacadaa02a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0f042091-c72f-40d1-9427-aacadaa02a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77d2b37e-5dbb-41a6-8567-0b190803cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77d2b37e-5dbb-41a6-8567-0b190803cc89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e4fcd0fb-b9c3-4f77-9ad9-8723d9a0ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e4fcd0fb-b9c3-4f77-9ad9-8723d9a0ef85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8db02d8a-28ea-4156-b178-d3bd5430c099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8db02d8a-28ea-4156-b178-d3bd5430c099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_7d332d20-d478-4ca8-81d8-edb4c7da6b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_7d332d20-d478-4ca8-81d8-edb4c7da6b11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_14064f22-2f94-4d1a-ba9d-e6f805658108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_14064f22-2f94-4d1a-ba9d-e6f805658108" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:to="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b171b8bd-15fc-45ae-928b-481328f8a1d1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:to="loc_srt_RangeMember_b171b8bd-15fc-45ae-928b-481328f8a1d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:to="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76e21ce6-5923-4df3-a0c0-b40e4fcd3bdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:to="loc_srt_MinimumMember_76e21ce6-5923-4df3-a0c0-b40e4fcd3bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74b3d658-2725-4dd9-9792-40d5def6f931" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:to="loc_srt_MaximumMember_74b3d658-2725-4dd9-9792-40d5def6f931" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COLLABORATIONAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="extended" id="ie458a96b917f44579ec2d1ca0ca544e4_COLLABORATIONAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2227c89-39a9-4e1e-918d-105eaade70de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2227c89-39a9-4e1e-918d-105eaade70de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_04cf415e-2490-41f7-86a1-e56e5cc8c366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_04cf415e-2490-41f7-86a1-e56e5cc8c366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_154614bc-2781-49e7-9274-ebb49caf71ff" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_154614bc-2781-49e7-9274-ebb49caf71ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_2c52abf5-ebde-4f87-874e-4e41fa69e1e8" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_2c52abf5-ebde-4f87-874e-4e41fa69e1e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a97b36e-8d66-456f-b0b9-67bebbb9bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a97b36e-8d66-456f-b0b9-67bebbb9bfb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c51f0c8d-0bce-4a35-97dc-adb7882a3604_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c51f0c8d-0bce-4a35-97dc-adb7882a3604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember_91417037-073f-4b71-9fdc-0612f2848884" xlink:href="vrdn-20221231.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:to="loc_vrdn_ZenasBioPharmaMember_91417037-073f-4b71-9fdc-0612f2848884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember_45cab051-5467-41ee-ab87-5c97b307fc70" xlink:href="vrdn-20221231.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:to="loc_vrdn_ParagonTherapeuticsMember_45cab051-5467-41ee-ab87-5c97b307fc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abde4226-a1ef-46c5-b6ee-53208b14e6e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:to="loc_srt_ProductsAndServicesDomain_abde4226-a1ef-46c5-b6ee-53208b14e6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:to="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember_b2b12307-44e7-46e4-a540-13616e308184" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:to="loc_vrdn_CollaborationRevenueMember_b2b12307-44e7-46e4-a540-13616e308184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_047fdccf-ba18-457f-9354-13fb20c10797_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:to="loc_srt_OwnershipDomain_047fdccf-ba18-457f-9354-13fb20c10797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:to="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember_ca3498bf-dfbe-4f6e-96e0-bd76d86a0605" xlink:href="vrdn-20221231.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:to="loc_vrdn_FairmountFundsManagementMember_ca3498bf-dfbe-4f6e-96e0-bd76d86a0605" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="extended" id="i01d4b85483594a16bb42f08f28b0663b_INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27bbe38d-c561-454f-9a99-8231b0599e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27bbe38d-c561-454f-9a99-8231b0599e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6a6a223-6380-41ea-a5a2-15b8f5387cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6a6a223-6380-41ea-a5a2-15b8f5387cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf148d80-cafb-4cbe-a734-c71b6bd831b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf148d80-cafb-4cbe-a734-c71b6bd831b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34d6a0f9-ec3a-4014-9f32-e892d37cb9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34d6a0f9-ec3a-4014-9f32-e892d37cb9a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d16c4f43-bb4d-41be-b78f-5dc5a2be8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d16c4f43-bb4d-41be-b78f-5dc5a2be8d2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_62ba05aa-a565-430d-a091-5cf369a6f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_62ba05aa-a565-430d-a091-5cf369a6f3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c216014d-8de3-4e2a-9cd6-1bdf39db4fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c216014d-8de3-4e2a-9cd6-1bdf39db4fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_9c42a71b-bfce-4011-a4b4-f1ef0eac26e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_9c42a71b-bfce-4011-a4b4-f1ef0eac26e6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="extended" id="i2341025300ba49768236ff6289eea6cb_INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea41303c-7623-440f-9a7f-f16f782c9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea41303c-7623-440f-9a7f-f16f782c9ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c15e142c-d5c3-42ec-930e-e3546271de81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c15e142c-d5c3-42ec-930e-e3546271de81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_83cba4f6-f27c-40b6-bbda-4b85642ad5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_83cba4f6-f27c-40b6-bbda-4b85642ad5f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e659eb42-993a-4d8b-987e-bfc9043f4ac5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e659eb42-993a-4d8b-987e-bfc9043f4ac5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1e51ffe6-c10c-4764-8c51-8506a251ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1e51ffe6-c10c-4764-8c51-8506a251ea66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9cf9b2d-9665-4552-83d2-795527f7fd51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9cf9b2d-9665-4552-83d2-795527f7fd51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_61c97eac-8130-4b0d-9529-2cd9415ff40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_61c97eac-8130-4b0d-9529-2cd9415ff40f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dceebac1-b17f-45c3-a0c4-0f08b0ba8128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dceebac1-b17f-45c3-a0c4-0f08b0ba8128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad31f637-46e0-436e-b8a0-fd81c15730ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad31f637-46e0-436e-b8a0-fd81c15730ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9184cee8-0c95-45e2-bd4d-4e224f56f10a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9184cee8-0c95-45e2-bd4d-4e224f56f10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_492d6f12-aafa-4af3-b853-d1590e317f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_492d6f12-aafa-4af3-b853-d1590e317f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_77bcdbbb-45ea-4e1c-8ada-da8948ac5aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_77bcdbbb-45ea-4e1c-8ada-da8948ac5aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2c6d7e13-2b21-40e6-b33f-8df5271f4d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2c6d7e13-2b21-40e6-b33f-8df5271f4d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_0571fe84-4f5a-4dd5-a336-25d059debc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_0571fe84-4f5a-4dd5-a336-25d059debc05" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="extended" id="ie83fb42bd3614b718a6203bb9410e601_PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d26171d9-e4f4-497b-81c1-0fc7b861b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d26171d9-e4f4-497b-81c1-0fc7b861b36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f620b89-67e6-4904-8c25-e32d055f9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f620b89-67e6-4904-8c25-e32d055f9dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6de7e030-e3a0-4ccb-9f0d-fc56c4d33dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6de7e030-e3a0-4ccb-9f0d-fc56c4d33dfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7a827f-f1b7-4025-94fe-45505676c313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f7a827f-f1b7-4025-94fe-45505676c313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d178c158-5b83-4be1-a63f-f22298c07f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_EquipmentMember_d178c158-5b83-4be1-a63f-f22298c07f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f08f6844-146c-4b98-8211-64889361f53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f08f6844-146c-4b98-8211-64889361f53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_01168537-5154-4cc5-9b5d-236f9debfa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_01168537-5154-4cc5-9b5d-236f9debfa0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d240d1f0-2286-401b-aaa5-c74e03e8f175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d240d1f0-2286-401b-aaa5-c74e03e8f175" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended" id="id88942701ffc47888c2a822e87f4dfa8_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a9ba3802-b16c-4feb-adb0-5084f1070feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a9ba3802-b16c-4feb-adb0-5084f1070feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches_4689afdd-a2ee-46c0-a637-b0cda67c92b1" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentNumberOfTranches_4689afdd-a2ee-46c0-a637-b0cda67c92b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_87bd73e5-6a42-487e-80a5-505bc0311393" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_87bd73e5-6a42-487e-80a5-505bc0311393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_6f2624e0-9f0a-4ee9-b55b-f137f8d15913" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_6f2624e0-9f0a-4ee9-b55b-f137f8d15913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_83b8c897-6f85-4062-ae68-a7c4ffeb805c" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_83b8c897-6f85-4062-ae68-a7c4ffeb805c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_10d535f7-0f55-4bbd-8eee-7a69bce992a2" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_10d535f7-0f55-4bbd-8eee-7a69bce992a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_358cbd34-a0c2-4cf7-a94c-48eb209251d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_358cbd34-a0c2-4cf7-a94c-48eb209251d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9084fb4d-9ae2-45f3-b13a-d51f1d00f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9084fb4d-9ae2-45f3-b13a-d51f1d00f14d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum_d87965d3-3b48-4184-93a1-058c75059a97" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentInterestRateMaximum_d87965d3-3b48-4184-93a1-058c75059a97" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PrincipalAmountTermFee_e50b4042-4aaa-4180-a229-9edd1af95624" xlink:href="vrdn-20221231.xsd#vrdn_PrincipalAmountTermFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_PrincipalAmountTermFee_e50b4042-4aaa-4180-a229-9edd1af95624" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8b778f64-77c2-4102-b034-929821d4b913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8b778f64-77c2-4102-b034-929821d4b913" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_78afac89-ea67-4a59-8609-48bd04f3c9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_78afac89-ea67-4a59-8609-48bd04f3c9d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee_c83d6ea4-b370-4609-8150-ba2a4597e1d8" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFacilityFee_c83d6ea4-b370-4609-8150-ba2a4597e1d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses_ce575818-fece-48cc-8edb-634dec607775" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentOtherExpenses_ce575818-fece-48cc-8edb-634dec607775" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_cb4d6f5c-4708-4f30-a33d-d4dc934e1380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_cb4d6f5c-4708-4f30-a33d-d4dc934e1380" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_df569f62-c772-430f-8edb-019de392d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_InterestExpense_df569f62-c772-430f-8edb-019de392d9e3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08ee7554-683f-46db-8b62-2bc372e4c893_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08ee7554-683f-46db-8b62-2bc372e4c893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_a7efc1db-5fd3-445b-a6e4-e40cfe485700" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:to="loc_vrdn_HerculesTermLoanMember_a7efc1db-5fd3-445b-a6e4-e40cfe485700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_46e42d51-536a-4df7-b6ab-862a0e26fa17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_46e42d51-536a-4df7-b6ab-862a0e26fa17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1cf14aac-6c33-4a3e-9cb4-4dde2c4cec87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:to="loc_us-gaap_SecuredDebtMember_1cf14aac-6c33-4a3e-9cb4-4dde2c4cec87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_91e1d8dc-3959-4f2c-a05f-05d112b09a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:to="loc_us-gaap_VariableRateDomain_91e1d8dc-3959-4f2c-a05f-05d112b09a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:to="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_34ed8fbf-6116-4548-bd26-4b5775d05645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:to="loc_us-gaap_PrimeRateMember_34ed8fbf-6116-4548-bd26-4b5775d05645" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended" id="iec4aab240ab24449b6cc0b7a618975c2_DEBTScheduleofLongTermDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_06759611-db67-4e6d-b22a-fed21d95df18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_06759611-db67-4e6d-b22a-fed21d95df18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_89bfd445-7b37-4971-937e-aa2ff156199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_89bfd445-7b37-4971-937e-aa2ff156199c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_95141c29-4d0a-46eb-8d64-5f73891a1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_LongTermDebt_95141c29-4d0a-46eb-8d64-5f73891a1a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:to="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_9d03a8cd-3c1d-4471-b04f-85e62ab1de87" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:to="loc_vrdn_HerculesTermLoanMember_9d03a8cd-3c1d-4471-b04f-85e62ab1de87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_969f657b-d6ac-430c-8479-84e7bafc8d25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_969f657b-d6ac-430c-8479-84e7bafc8d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dc961c0f-9926-4149-88e1-0123ccba4804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:to="loc_us-gaap_SecuredDebtMember_dc961c0f-9926-4149-88e1-0123ccba4804" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended" id="i8077ac149677431389bce1368c0a6a0e_DEBTScheduleofFuturePrincipalPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7cb4ad96-439f-4571-beb4-820409db7aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7cb4ad96-439f-4571-beb4-820409db7aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a5421b3-8113-4f64-8c28-71b23dbac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a5421b3-8113-4f64-8c28-71b23dbac1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f7823a6-bac5-4970-8cac-9af116e0439a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f7823a6-bac5-4970-8cac-9af116e0439a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9e2a9aa5-19ed-49e8-ac2d-4a3babed7471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9e2a9aa5-19ed-49e8-ac2d-4a3babed7471" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30a5122d-1352-4375-9e51-71d5c4ebfc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30a5122d-1352-4375-9e51-71d5c4ebfc8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:to="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26cae46d-5759-46e3-b7ad-d5934619d19f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26cae46d-5759-46e3-b7ad-d5934619d19f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_19b6833d-1777-4c66-b473-a4ab7a26b15e" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:to="loc_vrdn_HerculesTermLoanMember_19b6833d-1777-4c66-b473-a4ab7a26b15e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1f84d17c-5108-417e-a385-605148d27e62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1f84d17c-5108-417e-a385-605148d27e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7eb9f5cf-f5e2-449d-ad46-b7fb2c2789fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:to="loc_us-gaap_SecuredDebtMember_7eb9f5cf-f5e2-449d-ad46-b7fb2c2789fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="icf3505e1e03a4cca8fd0c76e54eec603_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_9d38c5cf-df03-413f-b6a3-632cfa79c3d4" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_9d38c5cf-df03-413f-b6a3-632cfa79c3d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_bb144e81-de42-4f8b-9268-175113ebefd0" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_bb144e81-de42-4f8b-9268-175113ebefd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_4e412acc-fc30-4a0c-8033-d5208c4cef20" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_4e412acc-fc30-4a0c-8033-d5208c4cef20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_0eef9222-8e79-42e2-aa25-50fb8ac99db6" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_0eef9222-8e79-42e2-aa25-50fb8ac99db6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_92470adc-5efc-44ae-b47e-76c299e8ca1b" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_92470adc-5efc-44ae-b47e-76c299e8ca1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_4aa308e8-b4de-49cc-adce-f2af39fe2dbc" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_4aa308e8-b4de-49cc-adce-f2af39fe2dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_3aac244e-910e-4ff0-8da4-f5a4d89d0a49" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_3aac244e-910e-4ff0-8da4-f5a4d89d0a49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_b2a125dd-5ce4-4c2a-ae5d-b7f3cfa9bce3" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_b2a125dd-5ce4-4c2a-ae5d-b7f3cfa9bce3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_a3b383ac-d741-4b6c-a8a2-3dfcfc024f1d" xlink:href="vrdn-20221231.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_a3b383ac-d741-4b6c-a8a2-3dfcfc024f1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a581ba4a-c0c9-40f8-9cbb-6c9316e9395d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a581ba4a-c0c9-40f8-9cbb-6c9316e9395d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_36da01d9-1096-4598-9044-cdadfab8bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_36da01d9-1096-4598-9044-cdadfab8bfa9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_98a919cf-d50d-4276-bbe8-a570ddc4eb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_98a919cf-d50d-4276-bbe8-a570ddc4eb6b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8082de64-19e5-4584-b04f-4020593c8c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8082de64-19e5-4584-b04f-4020593c8c8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4059b91d-e28f-43b9-bb26-4ac50c96db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4059b91d-e28f-43b9-bb26-4ac50c96db0a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExpanded_b968ebc5-3b2e-4f08-8af1-39b454ab7d27" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExpanded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceExpanded_b968ebc5-3b2e-4f08-8af1-39b454ab7d27" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceTerminated_4d02aa70-82be-44ea-9404-f050204141a1" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceTerminated_4d02aa70-82be-44ea-9404-f050204141a1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExtension_d18ef015-68e9-407b-931b-9487e5ce482c" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceExtension_d18ef015-68e9-407b-931b-9487e5ce482c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent_9f9d0d5e-91e7-4511-9a57-47a651542ba7" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_OperatingLeaseAnnualBaseRent_9f9d0d5e-91e7-4511-9a57-47a651542ba7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f29d7fd-5a3e-4a48-ac1f-97b0f495f472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f29d7fd-5a3e-4a48-ac1f-97b0f495f472" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a8a2626-c69f-42ba-ae0f-feceb5cd64b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a8a2626-c69f-42ba-ae0f-feceb5cd64b7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c320871-2ab4-4f64-afc9-59fd63fd7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c320871-2ab4-4f64-afc9-59fd63fd7679" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6db31ed7-67fc-44c9-85c4-b8f5ba91638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6db31ed7-67fc-44c9-85c4-b8f5ba91638d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c7701a5-0d28-496b-95a3-25fe918fe890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c7701a5-0d28-496b-95a3-25fe918fe890" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense_60b6c36c-5cf4-4f6a-9369-a2a0b7bc6a25" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_OperatingLeasesOperatingExpense_60b6c36c-5cf4-4f6a-9369-a2a0b7bc6a25" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_667f9928-fbb3-4c73-9f14-3412ab3e7b52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_667f9928-fbb3-4c73-9f14-3412ab3e7b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember_29fc5bee-6616-4f10-a65b-97f2072881eb" xlink:href="vrdn-20221231.xsd#vrdn_ImmunoGenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:to="loc_vrdn_ImmunoGenIncMember_29fc5bee-6616-4f10-a65b-97f2072881eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_XencorIncMember_f53b92e8-98f6-40f2-bc4c-4ef58a459067" xlink:href="vrdn-20221231.xsd#vrdn_XencorIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:to="loc_vrdn_XencorIncMember_f53b92e8-98f6-40f2-bc4c-4ef58a459067" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CAPITALSTOCKDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="extended" id="i5aaad7c57ce04e4690b99c698a4be371_CAPITALSTOCKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized_6469a368-8d6c-4160-ae47-73ecf6e738be" xlink:href="vrdn-20221231.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_CapitalStockSharesAuthorized_6469a368-8d6c-4160-ae47-73ecf6e738be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13d55f13-f1e9-4598-8e8a-3506353e4ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13d55f13-f1e9-4598-8e8a-3506353e4ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9b7b01c4-5631-41f4-9101-b689713b591b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9b7b01c4-5631-41f4-9101-b689713b591b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb59aea-9ab0-420e-be20-a3f3f9b9c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb59aea-9ab0-420e-be20-a3f3f9b9c46f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd46eae2-93de-425b-b2c6-f4c432d3ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd46eae2-93de-425b-b2c6-f4c432d3ec51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVoteperShare_13e3125d-d089-4ba7-88b5-095f5e61526b" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockVoteperShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_CommonStockVoteperShare_13e3125d-d089-4ba7-88b5-095f5e61526b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_69776db6-cfc4-4b48-85f5-cae585631de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_69776db6-cfc4-4b48-85f5-cae585631de9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d4017095-6af2-4951-9063-a16c68dac020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d4017095-6af2-4951-9063-a16c68dac020" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf2d21e0-6ee3-4fdd-ad1d-05814e1b1c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf2d21e0-6ee3-4fdd-ad1d-05814e1b1c76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_253ff01f-77be-4d6f-a707-552470c3009a" xlink:href="vrdn-20221231.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_253ff01f-77be-4d6f-a707-552470c3009a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice_8ab84d30-0ce1-4f14-9261-e57dfe21e8f6" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockWeightedAverageSharePrice_8ab84d30-0ce1-4f14-9261-e57dfe21e8f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1619f521-b831-4685-b2f7-cccb35faa11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1619f521-b831-4685-b2f7-cccb35faa11a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_1c43f7d7-4358-455c-8451-aec6c815ebb3" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_1c43f7d7-4358-455c-8451-aec6c815ebb3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockTerm_d3714d1b-527c-4f97-b605-9bb788ecd38b" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockTerm_d3714d1b-527c-4f97-b605-9bb788ecd38b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_63830945-50cd-48a4-8f06-0a03d3829eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_63830945-50cd-48a4-8f06-0a03d3829eca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_11ad6a87-f8a2-4de0-803f-360c1a55527c" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_11ad6a87-f8a2-4de0-803f-360c1a55527c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_daaf4ab1-eb2f-4e96-97e9-2b4e44327073" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_daaf4ab1-eb2f-4e96-97e9-2b4e44327073" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_f91588e6-7ad3-4601-b37a-d756647bea67" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_f91588e6-7ad3-4601-b37a-d756647bea67" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_25e30ccb-2473-4bc9-8998-182d3d051084" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_25e30ccb-2473-4bc9-8998-182d3d051084" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_0f4b6091-3dcc-4f8b-83de-8959aeba335c" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_0f4b6091-3dcc-4f8b-83de-8959aeba335c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_6f6fce75-05ca-42f0-949d-60a8fb9fc097" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_6f6fce75-05ca-42f0-949d-60a8fb9fc097" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f41f1a7e-9343-49dc-bb7b-ca7b94623e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f41f1a7e-9343-49dc-bb7b-ca7b94623e95" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f79fc1d4-9d09-481d-ad3b-d549d1a04f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f79fc1d4-9d09-481d-ad3b-d549d1a04f1c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f093064-1d34-484d-8fa6-baced1e4c62e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:to="loc_us-gaap_EquityComponentDomain_4f093064-1d34-484d-8fa6-baced1e4c62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:to="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9d4c6d85-4620-4526-a90f-2a041b0d5ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:to="loc_us-gaap_CommonStockMember_9d4c6d85-4620-4526-a90f-2a041b0d5ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00b83303-7d97-4a68-993d-a4e06310df2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00b83303-7d97-4a68-993d-a4e06310df2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_50c78788-093a-4686-842e-40ba25537fc2" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_AtthemarketOfferingMember_50c78788-093a-4686-842e-40ba25537fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2022PublicStockOfferingMember_1e604436-8544-4aca-bb7c-5c804690f26e" xlink:href="vrdn-20221231.xsd#vrdn_A2022PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_A2022PublicStockOfferingMember_1e604436-8544-4aca-bb7c-5c804690f26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3ecbc982-f174-4ca0-9846-ca6ede13078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3ecbc982-f174-4ca0-9846-ca6ede13078e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2021PublicStockOfferingMember_f947e325-2d52-44cb-adff-d9d5df122004" xlink:href="vrdn-20221231.xsd#vrdn_A2021PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_A2021PublicStockOfferingMember_f947e325-2d52-44cb-adff-d9d5df122004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AspireStockPurchaseAgreementMember_e48ac5c0-7ffa-49f5-aa3c-5e46eed15210" xlink:href="vrdn-20221231.xsd#vrdn_AspireStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_AspireStockPurchaseAgreementMember_e48ac5c0-7ffa-49f5-aa3c-5e46eed15210" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d5c23896-5377-46e6-90d0-866aea1d6e2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:to="loc_us-gaap_ClassOfStockDomain_d5c23896-5377-46e6-90d0-866aea1d6e2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:to="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_126bdabc-d955-4381-be56-d33a1ba673fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_126bdabc-d955-4381-be56-d33a1ba673fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5219b015-53e9-45ad-bc40-7762bc67fb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5219b015-53e9-45ad-bc40-7762bc67fb0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d46fd411-80c3-47e4-b14e-776bb9e69973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d46fd411-80c3-47e4-b14e-776bb9e69973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember_a16cf920-8c47-4924-a3da-e1a2cffcf7d7" xlink:href="vrdn-20221231.xsd#vrdn_ViridianMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:to="loc_vrdn_ViridianMergerMember_a16cf920-8c47-4924-a3da-e1a2cffcf7d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af7768f4-7f8c-43a4-963e-f19a63a7f249_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:to="loc_srt_RangeMember_af7768f4-7f8c-43a4-963e-f19a63a7f249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:to="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6dd1bd57-c7df-476a-8bc3-523ac556df86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:to="loc_srt_MinimumMember_6dd1bd57-c7df-476a-8bc3-523ac556df86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33e82532-5ceb-4f0a-8aa1-54d0dbdf4bf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:to="loc_srt_MaximumMember_33e82532-5ceb-4f0a-8aa1-54d0dbdf4bf3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#WARRANTSStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="extended" id="i05c3d868590042acaac7c2bbac4e4f7b_WARRANTSStockWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_cdb8c3ec-a108-4fb2-8548-75d17a380020" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_cdb8c3ec-a108-4fb2-8548-75d17a380020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b8dea8-ebd6-492e-b9e2-5fa6ad3fcd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b8dea8-ebd6-492e-b9e2-5fa6ad3fcd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm_60da046c-6072-4ca8-b794-cf2f265a2e28" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_vrdn_ClassofWarrantorRightRemainingTerm_60da046c-6072-4ca8-b794-cf2f265a2e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d8add41b-ae1a-43e4-b139-48d172478298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d8add41b-ae1a-43e4-b139-48d172478298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_b36173cb-218a-4357-ad6b-e8149546b368" xlink:href="vrdn-20221231.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_b36173cb-218a-4357-ad6b-e8149546b368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_8a9141a8-1273-4af4-ac52-30e9994d0922" xlink:href="vrdn-20221231.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_8a9141a8-1273-4af4-ac52-30e9994d0922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_8f1e7c47-b32c-443b-9736-8fc3912f3a39" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_8f1e7c47-b32c-443b-9736-8fc3912f3a39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_f795e5ad-6cc5-4177-9821-7e963a2caab6" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_f795e5ad-6cc5-4177-9821-7e963a2caab6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember_cfa155df-5b19-4d17-8746-f59526ba5f3f" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsMember_cfa155df-5b19-4d17-8746-f59526ba5f3f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i4cca36c80de141d39abab4dd0810f657_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45dab6d4-797c-493d-9506-e16b68679427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45dab6d4-797c-493d-9506-e16b68679427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_fd48443c-3735-401e-802f-4b8fec7b5537" xlink:href="vrdn-20221231.xsd#vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_fd48443c-3735-401e-802f-4b8fec7b5537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3419dfed-780b-42f0-bd30-1318645c6171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3419dfed-780b-42f0-bd30-1318645c6171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07f8247e-7863-483b-8323-f413e07485f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07f8247e-7863-483b-8323-f413e07485f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_87b48bd1-eb45-4bfa-92c7-7c1fcaf8a3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_87b48bd1-eb45-4bfa-92c7-7c1fcaf8a3da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_333cf574-a698-4c78-96c9-a17eb3e4570d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_333cf574-a698-4c78-96c9-a17eb3e4570d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_963e9bbd-74b8-4707-9093-2de29a1294d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_963e9bbd-74b8-4707-9093-2de29a1294d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_f4ac3365-7308-4e32-9d17-9fc35e01c6e6" xlink:href="vrdn-20221231.xsd#vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_f4ac3365-7308-4e32-9d17-9fc35e01c6e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_ae29e281-bef5-406c-8d83-f95f8d7d02c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_ae29e281-bef5-406c-8d83-f95f8d7d02c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4c1923f5-9e40-4c2c-be8b-6874afc44c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4c1923f5-9e40-4c2c-be8b-6874afc44c11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4aa947b2-6d24-4387-b644-b3839967f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4aa947b2-6d24-4387-b644-b3839967f5e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6d33d34-743d-4f52-99c9-8a1cee460876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6d33d34-743d-4f52-99c9-8a1cee460876" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1c336018-dfdc-433b-b143-9a031c850d68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:to="loc_us-gaap_PlanNameDomain_1c336018-dfdc-433b-b143-9a031c850d68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:to="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_82055d39-bf9c-426d-9073-ef8511b868f4" xlink:href="vrdn-20221231.xsd#vrdn_Amended2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:to="loc_vrdn_Amended2016PlanMember_82055d39-bf9c-426d-9073-ef8511b868f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f5ae167-61e7-48f0-8640-bbf5b9e80156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f5ae167-61e7-48f0-8640-bbf5b9e80156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_edfbb245-a13b-48d5-8322-86a3a16af4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:to="loc_us-gaap_EmployeeStockOptionMember_edfbb245-a13b-48d5-8322-86a3a16af4eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:to="loc_us-gaap_VestingDomain_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:to="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9bcd5f7-8132-4d3b-bc25-3ec917e0ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9bcd5f7-8132-4d3b-bc25-3ec917e0ad35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_615a076f-fed1-4a80-a986-5bc158dbaf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_615a076f-fed1-4a80-a986-5bc158dbaf4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70a00b13-e6f0-4834-94f7-d30d9fea79c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:to="loc_us-gaap_EquityComponentDomain_70a00b13-e6f0-4834-94f7-d30d9fea79c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:to="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_27b0eac6-441f-4f43-b9ce-089f09a77fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:to="loc_us-gaap_CommonStockMember_27b0eac6-441f-4f43-b9ce-089f09a77fda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONBalancebyPlansDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails" xlink:type="extended" id="i22f274f386cd49809512cf9d73422a8d_SHAREBASEDCOMPENSATIONBalancebyPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f00685b0-0bab-4c9f-beb2-7f30d132652a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f00685b0-0bab-4c9f-beb2-7f30d132652a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36794cd8-2c43-4e9f-8bc8-699392bd0118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36794cd8-2c43-4e9f-8bc8-699392bd0118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:to="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27f5e90a-1274-40ab-910e-fd910004e099_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:to="loc_us-gaap_PlanNameDomain_27f5e90a-1274-40ab-910e-fd910004e099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:to="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember_56afc333-f478-4554-8127-ee50bf73d879" xlink:href="vrdn-20221231.xsd#vrdn_InducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_InducementGrantsMember_56afc333-f478-4554-8127-ee50bf73d879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember_cfeeb5f9-301e-4394-8c57-f83fed971703" xlink:href="vrdn-20221231.xsd#vrdn_A2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2020PlanMember_cfeeb5f9-301e-4394-8c57-f83fed971703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2016PlanMember_1dc9cdb5-9550-4d26-b97a-85cc36df0b09" xlink:href="vrdn-20221231.xsd#vrdn_A2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2016PlanMember_1dc9cdb5-9550-4d26-b97a-85cc36df0b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember_41070453-30f2-4319-9d3b-dc6f7f8e7161" xlink:href="vrdn-20221231.xsd#vrdn_A2008PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2008PlanMember_41070453-30f2-4319-9d3b-dc6f7f8e7161" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended" id="i4d82f474febc47509735783a650e4734_SHAREBASEDCOMPENSATIONStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15898c46-c8e1-4ee4-a014-8a741ad7b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15898c46-c8e1-4ee4-a014-8a741ad7b3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e060d1-d0da-4447-baa4-39b9e8fdd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e060d1-d0da-4447-baa4-39b9e8fdd9db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02f33b9b-4db3-46bf-96e0-b8882813ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02f33b9b-4db3-46bf-96e0-b8882813ed9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8779fdf5-dae2-412f-a2eb-492125e20fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8779fdf5-dae2-412f-a2eb-492125e20fbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fa8bc464-edf8-41c7-8d83-6d66f90a2dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa22d76a-ae7b-4275-828c-136ac5fd1ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa22d76a-ae7b-4275-828c-136ac5fd1ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c83436b9-234f-42a4-af7c-2cde355da542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c83436b9-234f-42a4-af7c-2cde355da542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fc33e7f0-3d27-431c-a45d-a90060127af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fc33e7f0-3d27-431c-a45d-a90060127af3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6543f9f0-13e5-449c-a880-1e789f941530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6543f9f0-13e5-449c-a880-1e789f941530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34a58e11-b765-4e68-9d44-43ff81b3cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34a58e11-b765-4e68-9d44-43ff81b3cd20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13259d0f-a939-43a7-a78d-69f7f75150dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13259d0f-a939-43a7-a78d-69f7f75150dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1a73104-6792-4f78-a24a-3613a12d93cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1a73104-6792-4f78-a24a-3613a12d93cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c58b90f-d272-4c0b-8d4c-bfe596d37753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4732ebb7-2956-4b7c-a735-83867980c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4732ebb7-2956-4b7c-a735-83867980c37b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6eee83e-a435-42f7-aa31-28ec0ec62645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6eee83e-a435-42f7-aa31-28ec0ec62645" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3de90e25-6682-4cdb-a1b5-9f11cc57cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3de90e25-6682-4cdb-a1b5-9f11cc57cf19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39a4f956-788f-4f03-b9d7-82b6a303c1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39a4f956-788f-4f03-b9d7-82b6a303c1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_29628b09-cf63-4f37-ae31-458e4b2d540e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_29628b09-cf63-4f37-ae31-458e4b2d540e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_baf6500a-3968-4bda-a880-2caa14a08b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_baf6500a-3968-4bda-a880-2caa14a08b7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6bcdfcc7-034e-4d19-87df-ab7bed1f968f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6bcdfcc7-034e-4d19-87df-ab7bed1f968f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c04bee5-7b28-4c5a-a41c-87389871ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c04bee5-7b28-4c5a-a41c-87389871ba75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6e7c0aef-8d97-48ef-a989-f0d62f32f401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6e7c0aef-8d97-48ef-a989-f0d62f32f401" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c557d67d-2e0c-4ad2-a796-c395ed4ac0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c557d67d-2e0c-4ad2-a796-c395ed4ac0eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4b0f2fea-81e3-4180-899a-a095cad2dd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4b0f2fea-81e3-4180-899a-a095cad2dd86" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:to="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cdd1701-498e-4e70-99aa-a385999968dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8cdd1701-498e-4e70-99aa-a385999968dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_07ab0d5d-a0be-4a89-a94a-10296c5da54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:to="loc_us-gaap_EmployeeStockOptionMember_07ab0d5d-a0be-4a89-a94a-10296c5da54e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="extended" id="i09a17d9bb25e424c9052255bccec85f2_SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fcdd58d2-4aa6-42c8-b951-988190dacf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fcdd58d2-4aa6-42c8-b951-988190dacf20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c9704d2-6104-45a3-9a5f-373c896dece5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c9704d2-6104-45a3-9a5f-373c896dece5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_43aafe90-60c7-45f3-b89d-aab56b8c6987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_43aafe90-60c7-45f3-b89d-aab56b8c6987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46d0e9ac-258c-4005-b894-7a68dd3c5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46d0e9ac-258c-4005-b894-7a68dd3c5e8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2ec6ad07-7fcc-40b3-9649-43fa314e7628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2ec6ad07-7fcc-40b3-9649-43fa314e7628" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:to="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8352e06f-4235-46a8-a923-e44815678a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8352e06f-4235-46a8-a923-e44815678a46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="extended" id="i2ef648a63b714789b4f17959b9eef8f2_SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca6c39d1-e488-4593-aeaa-09d67fda795b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca6c39d1-e488-4593-aeaa-09d67fda795b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74a388b5-b76d-4a6d-8826-8925d1b405a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74a388b5-b76d-4a6d-8826-8925d1b405a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d2553676-86c6-405c-ade9-fb04830ffee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d2553676-86c6-405c-ade9-fb04830ffee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d42dd802-0835-4f91-bee0-0261ae35216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d42dd802-0835-4f91-bee0-0261ae35216f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails" xlink:type="extended" id="ib74b529a9f8f4e4b92056800b52d4ee5_NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_97171ec8-2eac-476e-a677-9b918d9cb58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_97171ec8-2eac-476e-a677-9b918d9cb58e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65b889af-9770-4312-8b85-e279a6f5cb7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65b889af-9770-4312-8b85-e279a6f5cb7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f4db2938-c536-4e69-88bb-73da28307dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f4db2938-c536-4e69-88bb-73da28307dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_9d4f93a5-8e40-4009-aced-07ba058b146b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_9d4f93a5-8e40-4009-aced-07ba058b146b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_daaa453b-7d2b-4a99-afc7-0fc8550a6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_EmployeeStockOptionMember_daaa453b-7d2b-4a99-afc7-0fc8550a6ce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember_e5dce34c-e574-42af-ada5-4ac61c7d2c51" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_vrdn_CommonStockWarrantsMember_e5dce34c-e574-42af-ada5-4ac61c7d2c51" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i8fafd747f9f84c11b8232cb097f3fbf0_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2eb861e0-d218-4507-bdb9-51c366f735c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2eb861e0-d218-4507-bdb9-51c366f735c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_dbe3066f-0901-4df2-b399-7234e60fbecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_dbe3066f-0901-4df2-b399-7234e60fbecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_9a868771-60f8-4246-9d04-c7dfc6649d30" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardLimitationsOnUseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_9a868771-60f8-4246-9d04-c7dfc6649d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardWriteOff_198b7e70-6d38-42ce-bd9c-77e84ca22f27" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardWriteOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_TaxCreditCarryforwardWriteOff_198b7e70-6d38-42ce-bd9c-77e84ca22f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_097cdade-c444-4f4c-8846-af7d0fade081" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_097cdade-c444-4f4c-8846-af7d0fade081" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetValuationAllowancePercent_79f89a72-4d06-4df8-8f22-e5b294b571de" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetValuationAllowancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_DeferredTaxAssetValuationAllowancePercent_79f89a72-4d06-4df8-8f22-e5b294b571de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca933545-72db-4453-9fdd-530a6e421e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca933545-72db-4453-9fdd-530a6e421e47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2dc93f84-970a-4bf0-ac16-9aa28b1a408d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2dc93f84-970a-4bf0-ac16-9aa28b1a408d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bc156f2e-0553-47ad-b551-4a0e541e45d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bc156f2e-0553-47ad-b551-4a0e541e45d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_142df20a-d50c-4397-b924-2d449e6928fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:to="loc_us-gaap_DomesticCountryMember_142df20a-d50c-4397-b924-2d449e6928fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_02d36c7c-b3cd-48bd-89a2-1299f1a0bbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_02d36c7c-b3cd-48bd-89a2-1299f1a0bbc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42cb34a5-8b6c-496d-9d68-946aa1aa5995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_42cb34a5-8b6c-496d-9d68-946aa1aa5995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fb31f5b3-862a-4c82-aa27-bbc1d23fa9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:to="loc_us-gaap_ResearchMember_fb31f5b3-862a-4c82-aa27-bbc1d23fa9b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>vrdn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d93feca3-5285-43f7-ae36-6a14d39b790a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_912ee030-8798-472c-a4db-62d857fd4337_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_4bda9bb5-17c9-43de-be76-2470372c8a9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c966a588-9854-4eac-97ee-770fd6ad088c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7c39152f-440b-4529-8500-572052d83c1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_b437c059-2894-46bb-a9e3-31853d3abe75_terseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_label_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="lab_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_cff57ca1-32c4-48b2-a913-dd67a363246a_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount, fourth tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Fourth Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Fourth Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_b7b874f2-0555-40b5-a920-a76ee2eb37e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_692f3b1c-9e5c-44a9-a29e-1ba668dde9ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_bc3cedc2-1e5c-4c7a-927c-70baac12d944_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7c764b00-06df-4eaa-a40f-7db7669c5655_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_06d8557c-b5a8-43af-92b8-5bf845163ae0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2016PlanMember_7da26354-b97c-40d5-980c-d1468740e4a2_terseLabel_en-US" xlink:label="lab_vrdn_A2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_vrdn_A2016PlanMember_label_en-US" xlink:label="lab_vrdn_A2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan [Member]</link:label>
    <link:label id="lab_vrdn_A2016PlanMember_documentation_en-US" xlink:label="lab_vrdn_A2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2016PlanMember" xlink:href="vrdn-20221231.xsd#vrdn_A2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2016PlanMember" xlink:to="lab_vrdn_A2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_897c5cbc-ef91-4b6d-8cec-2b584c68eb7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of Series B preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_30196d3f-68cd-4b7b-97ea-a4cfe4e0db23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8a88f0bd-fcc3-4179-a5d7-462df855fb97_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1b25b9e9-7743-4d7d-aaee-fae16e1ebb0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_11722af3-003e-4056-8ad5-552abe5eb575_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average share price (in dollars per share)</link:label>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_label_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted Average Share Price</link:label>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted Average Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:to="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_f016b375-f877-4614-ad05-ae75bd2543bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_696afbf6-cb30-44b0-bc3e-6df1d86d0be0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2022PublicStockOfferingMember_8fb2c475-1865-42ef-951f-c8d6af50329d_terseLabel_en-US" xlink:label="lab_vrdn_A2022PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Public Stock Offering</link:label>
    <link:label id="lab_vrdn_A2022PublicStockOfferingMember_label_en-US" xlink:label="lab_vrdn_A2022PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Public Stock Offering [Member]</link:label>
    <link:label id="lab_vrdn_A2022PublicStockOfferingMember_documentation_en-US" xlink:label="lab_vrdn_A2022PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2022PublicStockOfferingMember" xlink:href="vrdn-20221231.xsd#vrdn_A2022PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2022PublicStockOfferingMember" xlink:to="lab_vrdn_A2022PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_b0b49e43-f976-4427-a701-19043e4ec84f_terseLabel_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fairmount Funds Management</link:label>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_label_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fairmount Funds Management [Member]</link:label>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_documentation_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fairmount Funds Management</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember" xlink:href="vrdn-20221231.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_FairmountFundsManagementMember" xlink:to="lab_vrdn_FairmountFundsManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1849522e-4485-46d8-b9fb-817562dfc40a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0640d5cc-bc48-4799-a74a-74d012506ccd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_90dd4866-34b6-4335-b151-aab887c8b4ce_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1534de9d-f43b-44eb-8f04-d3641360740f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6f41ae7-a954-4bc1-8d6f-60e3d62c2831_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a50865d5-55ec-4fe9-b940-c58d4ee699b1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationRevenueMember_0be304f6-b25c-4ac4-9e59-047678bfac1e_verboseLabel_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_vrdn_CollaborationRevenueMember_label_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_vrdn_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationRevenueMember" xlink:to="lab_vrdn_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d38c894a-9193-4f8f-8fa1-5ed4130517a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9132ab1f-b73d-4a35-8e79-be64da3bda16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f22cc1b-5d5c-4583-a7ad-dcd4389e0029_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f1bb5c7b-c69e-4e8b-83cb-dae522b11ada_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the conversion of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_cdfd03bc-947d-4f71-8538-c670595157fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_ae8f1cd8-f442-40aa-af5b-1981257e3405_terseLabel_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zenas BioPharma</link:label>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_label_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zenas BioPharma [Member]</link:label>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_documentation_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zenas BioPharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember" xlink:href="vrdn-20221231.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ZenasBioPharmaMember" xlink:to="lab_vrdn_ZenasBioPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_68904304-b8f8-410e-8bea-cd15bfb52b67_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7e5dc839-29b1-406a-8454-5ffafe64cf04_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0026f4a5-ee73-4d6b-9e69-c0884e60ef83_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_34aa10a5-5c3c-4e28-ade3-ea6f3f5904af_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9e7eed91-5f2b-4d95-8f6e-dd68f9837eae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de9adff6-d966-4ea0-8ed9-ee3df9740059_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3cfdf8c9-2eee-4408-8ad1-ecc5c7d75e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Payments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a0152884-f3c2-48e9-a981-8474fae92f38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_64cce12a-840f-4a4b-bb52-f1c317a11200_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cec66f19-c633-403f-bdfe-520e21afbb3b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_714bcf5d-9d83-4e3c-8692-2150a8f4822a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_5813559a-4f4e-4192-b3cc-1ecbb126d636_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_3088e2d6-c3b4-4bd9-8a5e-ba4d10843506_terseLabel_en-US" xlink:label="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan expiration period</link:label>
    <link:label id="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_label_en-US" xlink:label="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Plan Expiration Period</link:label>
    <link:label id="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_documentation_en-US" xlink:label="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Plan Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:href="vrdn-20221231.xsd#vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:to="lab_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExtension_e5de0a8e-7349-4ce9-a71a-ac89ea41f5bf_terseLabel_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space extension</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExtension_label_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Extension</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExtension_documentation_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExtension" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AreaOfOfficeSpaceExtension" xlink:to="lab_vrdn_AreaOfOfficeSpaceExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_daf47ed1-e4c1-4eaf-aef7-a88c3f473d84_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4cffa963-9534-4b38-8f85-39be5ad81da7_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_bd5cb3f9-c785-46e9-869e-cadff7c91f19_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_960c9452-317c-4eeb-9930-a1430a51e2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_94bc255c-56ed-471a-8fa9-61935c48f12f_terseLabel_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:href="vrdn-20221231.xsd#vrdn_GoingConcernPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:to="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c3e3a97e-e191-4766-bb45-17e9349cb6fc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_cfff9abd-2e7a-4250-8215-bd53c6aa7261_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_c7e1cbc9-c8cc-42e9-b504-5d459b868885_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6050b0b9-2d86-4763-b6f4-102aa70a972e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9bbbe5c-49d5-40ff-982f-931d98b0f6a2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AspireStockPurchaseAgreementMember_3db07540-83c6-4678-8472-236e92ed3a62_terseLabel_en-US" xlink:label="lab_vrdn_AspireStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Stock Purchase Agreement</link:label>
    <link:label id="lab_vrdn_AspireStockPurchaseAgreementMember_label_en-US" xlink:label="lab_vrdn_AspireStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_vrdn_AspireStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_vrdn_AspireStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AspireStockPurchaseAgreementMember" xlink:href="vrdn-20221231.xsd#vrdn_AspireStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AspireStockPurchaseAgreementMember" xlink:to="lab_vrdn_AspireStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_ce453169-103a-44ed-a02d-410f70044082_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_8ac410df-11d3-42f7-9723-a9db5c923b59_terseLabel_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued outsourced clinical trials and preclinical studies</link:label>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_label_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_documentation_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:href="vrdn-20221231.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:to="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b471ddde-b760-488c-9304-cfcae60befc2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, current, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fa943e62-8479-438c-a638-4a4c6ffd51b7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42fb4c0a-bf2e-40c2-93db-e931bd7d0062_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a9783eb6-e435-496b-bf78-f9b397bd178b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e6eed0e4-2512-4e70-ae95-47c7488026f0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_1b94af86-84fd-4180-840e-a32e7028a6a4_terseLabel_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_label_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Value</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_documentation_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:to="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_47ee8066-f8df-48a4-8a89-34d7008f15ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_79c86541-eafb-42da-85b1-b918b534dc47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_dd031972-0100-4878-9ec6-b6a1e7ebed7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_62d6fadb-684f-4aab-8e94-e0fbe14741e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2f18c34a-e1c8-46e2-8f10-b327157a55a0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b057c10-999d-4754-b735-ec1d44cc9cf3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_f2186d7e-b2df-4e2d-b910-9e9814403121_terseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_023ece5b-3679-47c4-905b-b285dee3d855_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, short-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_13581a71-c607-48fd-8426-596f56678924_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1728e847-ba84-49d3-88d8-b585a9153be0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1681d903-e25b-4322-8b12-edbeda1e1765_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_13f4b128-7f6d-4a15-ba09-de37c5f686ce_verboseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of underlying shares (in shares)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:to="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_442ef399-3cf0-454c-8e48-284f1df890ea_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f70631dd-a865-4bd0-85d8-773ac88964fe_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c65c7cfc-6b9c-4773-9a22-4320f2512a18_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_46e3410d-ebec-4caf-9d51-d20b4c2ea996_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease remaining term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8492f297-a3ad-4dda-b24e-5ac74a5f706e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_f6ba7882-8cf6-4afa-a484-bbdeb67823b9_terseLabel_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Therapeutics</link:label>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_label_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Therapeutics [Member]</link:label>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_documentation_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember" xlink:href="vrdn-20221231.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ParagonTherapeuticsMember" xlink:to="lab_vrdn_ParagonTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc10917b-d981-43c0-908d-5f76d147f7cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_0ed555f2-d45d-4199-a522-3d6291d803f0_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Activity [Roll Forward]</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Activity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightActivityRollForward" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightActivityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward" xlink:to="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_97023fff-e50b-4fc3-9004-d0b1e2f3744a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8d34ee91-47a5-4629-854b-f9b5a37a325b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in share)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_c702c831-5ccc-41af-8818-272637f225c8_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember" xlink:to="lab_vrdn_EquityclassifiedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30d01b6e-1627-410d-85ba-6ccf1cdd168e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e1855e48-c79b-4495-8798-6777d7da6338_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a6e2a42a-523b-49b9-a3c3-1f540762288a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0e71371e-bcef-431f-a1aa-24a016b6c3bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9e3239f0-4d22-4839-8725-39772acbd734_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b008d508-2758-46b1-b4ca-de538e922ce9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3fad5c79-1fd5-4947-81c3-5cfb55bf10ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_6b7770e8-07c3-4bbf-9a8d-feca7f8fbce0_terseLabel_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal fees and expenses</link:label>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedLegalFeesCurrent" xlink:to="lab_vrdn_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2c5ae15f-0798-4dff-9350-39ce8d2226e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains in available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7dedf67a-9ee1-45a5-994b-0276c56816f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_95faee17-b033-4a7b-8273-465e74c6039b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_adf2c922-aa9f-4040-9ee9-f6a74c60cd0b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_157e82db-b6f1-44dd-a8b0-8d1d65c922f7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ddefc077-d6f7-4186-b307-f5c8ef53b90c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_bf25eef2-b43c-4875-ab18-1eefad7e50a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_46fea5e9-6bfa-4426-b059-8a21713afb38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2223ad9d-9c3c-4e48-99cd-a9f1f73bd2a5_negatedTerseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-of-use Asset</link:label>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-of-use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_9764dcc0-e793-4293-86a8-9d1446f8e673_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum interest rate</link:label>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_label_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Maximum</link:label>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentInterestRateMaximum" xlink:to="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_4e8a3438-caa5-4f32-8be8-2b29c66113ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7476541a-188f-4ee4-b6c0-2435d9a3abef_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_14a887a2-6699-4f14-8245-d890a225eca2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_90c32834-ceee-4b4a-a9a8-26d2f2fc1476_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f591555a-2bd0-401d-a940-6f55c98df45d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, noncurrent, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_b3815777-eb5c-4884-a165-21e881196fd5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_37c71bf7-6a72-408f-9365-58dd0005ccf4_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6040aa47-dc3b-4be0-937e-b9c419fe5221_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_0daf538a-c582-4388-897f-db5006cb6116_terseLabel_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate limitation on utilization of certain net operating losses and credits</link:label>
    <link:label id="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_label_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Limitations On Use, Amount</link:label>
    <link:label id="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Limitations On Use, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:to="lab_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8a42b0e4-fe5b-4dcf-ae63-85ee240ff643_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Vesting Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_86bd8382-c3d0-40df-9d33-e192a6940b12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2ff168f3-6c6c-44a8-aca2-2dc6304bae8b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_d4b8c22d-98e1-45e2-8cf4-c167469aebee_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction value</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_01b7e93b-f6c5-41fe-bffa-a4a877193f42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_06d4516f-830c-46ad-9ecf-34e1b09ed876_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a6931a26-327b-4f15-8767-1ea32fcab36c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockTerm_b220350f-b34a-4bab-8faf-658c7e1a3d6f_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, term</link:label>
    <link:label id="lab_vrdn_SaleOfStockTerm_label_en-US" xlink:label="lab_vrdn_SaleOfStockTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Term</link:label>
    <link:label id="lab_vrdn_SaleOfStockTerm_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockTerm" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockTerm" xlink:to="lab_vrdn_SaleOfStockTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_5a1de4ab-7d06-454e-b5cd-e9f5096220c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_5e6b77d3-6cc7-4a5b-8432-8b28df59502d_netLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ea478d45-e773-44fd-8c4d-480789ff7d00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_58f129f4-d530-44bf-b7da-fa1e6c8b9868_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_27def604-dc53-432c-9eb9-c5fdae716345_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d5c65e5-377e-4b6d-974a-48396b18d3d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ddf6a209-9ef6-4441-b471-12e8c4a93e84_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_35228544-6658-4271-aa7d-9abd3581a189_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5146f108-3540-40eb-b919-213a0cd3fc8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b26d0dc5-a142-4fc2-a5b3-933937b015db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7c13b05b-0d87-48fb-ae94-0d1fd71f04d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7d0fb024-ef93-4426-93b5-e035bfc9362c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee compensation and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8da84f8f-a5e4-4a8e-9518-2b6e8a0f9137_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f63f25e7-a817-4905-80ce-a293a92cc7ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_8611fe03-d24d-4258-ae3f-1c1f4b676951_terseLabel_en-US" xlink:label="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase offering period</link:label>
    <link:label id="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:href="vrdn-20221231.xsd#vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4b927b3a-01c4-4744-956d-5aef15f7476b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense and amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f603cca7-fb89-4791-b46f-15cbbbcd204b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1a6f17d3-e871-4dc4-ac24-a3527634119e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ffb7ac61-49d1-4387-879e-de4ecd13d385_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Balances by Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_9f6dcf16-d804-4120-bcad-382f3b5200d9_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued February 2020</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Issued February 2020 [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Issued February 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:to="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_07b84d8f-44e0-4050-a2aa-0a15264be5cd_terseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Conversion, Percentage Of Ownership</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Conversion, Percentage Of Ownership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:to="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c89160cd-990a-4f9f-809f-b9622f32fe09_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ed2ada4-2251-4eec-8b68-2989de18a901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0f50de4a-7749-4596-94a6-3bb3ef1b856e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e7f9c8f-b839-482a-ab10-4184f6274a00_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining weighted-average period for RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_adaa0fa7-3062-4eb2-83da-421ca544b709_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_cd1d2b5c-1be4-4c9a-9116-2cb6bea3477a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock for cash under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_001dffc7-b05e-4d71-858e-0d4cf06adf16_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument other expenses</link:label>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_label_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Other Expenses</link:label>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentOtherExpenses" xlink:to="lab_vrdn_DebtInstrumentOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_9e41fa97-50b3-4f0b-a2d5-677fb93aff1b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_19b2755a-6c4c-4fd7-a38f-4a4eb519d1cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d065e5a5-20aa-4dd4-917e-d4e9a2e8a9f1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fb733795-2cfe-4e21-81cc-317e7c7fb17c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_deb72545-e2ae-47b7-9538-d8fff6b4a683_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International corporate bond holdings</link:label>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_e3e23439-942c-457c-b6f0-b5ef78d17c48_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International corporate bond holdings</link:label>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Corporate, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44b4f285-7b95-4bd5-baa7-6a1ac59daf0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock, net of issuance cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_0777c754-57de-4e7f-8fdf-a7e2f76cec5a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_e98a8f1e-3f43-4f1d-ba70-53086b0e2c87_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares authorized to be sold (in shares)</link:label>
    <link:label id="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_label_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Of Share Authorized To Be Sold</link:label>
    <link:label id="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Of Share Authorized To Be Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:to="lab_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4ba48da5-5cbb-461a-8720-079cc59c5358_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c6a0dd8-09d9-4f06-9ef5-8b1c28118f3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2021PublicStockOfferingMember_5121ba7a-5a1b-4bd3-b917-65010beb9d38_terseLabel_en-US" xlink:label="lab_vrdn_A2021PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Public Stock Offering</link:label>
    <link:label id="lab_vrdn_A2021PublicStockOfferingMember_label_en-US" xlink:label="lab_vrdn_A2021PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Public Stock Offering [Member]</link:label>
    <link:label id="lab_vrdn_A2021PublicStockOfferingMember_documentation_en-US" xlink:label="lab_vrdn_A2021PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2021PublicStockOfferingMember" xlink:href="vrdn-20221231.xsd#vrdn_A2021PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2021PublicStockOfferingMember" xlink:to="lab_vrdn_A2021PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ImmunoGenIncMember_e81cef78-6621-46b8-9bf8-2613a466f943_terseLabel_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen, Inc</link:label>
    <link:label id="lab_vrdn_ImmunoGenIncMember_label_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen, Inc [Member]</link:label>
    <link:label id="lab_vrdn_ImmunoGenIncMember_documentation_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember" xlink:href="vrdn-20221231.xsd#vrdn_ImmunoGenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ImmunoGenIncMember" xlink:to="lab_vrdn_ImmunoGenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_TaxCreditCarryforwardWriteOff_1b03bec1-5a1b-4540-9da6-c4cc83b095d4_terseLabel_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit write off</link:label>
    <link:label id="lab_vrdn_TaxCreditCarryforwardWriteOff_label_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Write Off</link:label>
    <link:label id="lab_vrdn_TaxCreditCarryforwardWriteOff_documentation_en-US" xlink:label="lab_vrdn_TaxCreditCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Write Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardWriteOff" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_TaxCreditCarryforwardWriteOff" xlink:to="lab_vrdn_TaxCreditCarryforwardWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6201662e-3751-43c3-a4c8-4130afa6b438_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_38629296-ec53-4b79-bef7-5cfed7271096_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8608126e-b7a4-44d6-9e15-1c7f9d1c9458_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_2e98bf79-4639-4126-8496-dd926484e944_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of additional share, percent of next business days' volume weighted average price</link:label>
    <link:label id="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_label_en-US" xlink:label="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Price Of Additional Share, Percent Of Next Business Days' Volume Weighted Average Price</link:label>
    <link:label id="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Price Of Additional Share, Percent Of Next Business Days' Volume Weighted Average Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:to="lab_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6bf041c6-cc8b-4e3d-990a-e4c349241b7b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceTerminated_efd5570c-aff5-47a9-bb06-bace867c6de1_terseLabel_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space terminated</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceTerminated_label_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Terminated</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceTerminated_documentation_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceTerminated" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AreaOfOfficeSpaceTerminated" xlink:to="lab_vrdn_AreaOfOfficeSpaceTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2c73d943-314f-4804-8765-c9bfc62c21a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f21f187a-0773-4a7d-9732-b0ef6e2dcbc6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1c6c0c8c-6233-439c-b73c-6a08eb5bdb2e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_0d3fc4a1-b7d8-488d-809a-9536a6c3e864_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_ee853a8d-88f9-4915-b278-ea199ee9ce9d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83f05959-cd5e-43ec-84ff-ad9237657136_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_c2cf3ac0-4c4a-491c-adca-b683144275c1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_bee67a7c-bf00-4a3c-aa43-10d605a774a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_2ae3be69-6656-4dc5-af79-77ab25f04149_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_71df6220-33f6-4b6a-a2fe-0edc8b076265_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_050ceb0c-338d-4a99-a2d4-0f4583a56975_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d95a6644-c914-491f-a1e7-df6ef7b353ce_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_caf4749b-76b0-48ca-8da8-6dbc18938ef1_negatedTerseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains/losses</link:label>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_label_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:to="lab_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b00021c-1ca4-4883-b0e6-47ebbcf3ec52_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9815eb2b-a821-47c9-b19b-707124af64a0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_PrincipalAmountTermFee_d3affc26-7231-4178-9371-dbd54245d086_terseLabel_en-US" xlink:label="lab_vrdn_PrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount fee term</link:label>
    <link:label id="lab_vrdn_PrincipalAmountTermFee_label_en-US" xlink:label="lab_vrdn_PrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount Term Fee</link:label>
    <link:label id="lab_vrdn_PrincipalAmountTermFee_documentation_en-US" xlink:label="lab_vrdn_PrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount Term Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PrincipalAmountTermFee" xlink:href="vrdn-20221231.xsd#vrdn_PrincipalAmountTermFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_PrincipalAmountTermFee" xlink:to="lab_vrdn_PrincipalAmountTermFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_163ebd1f-2f43-4314-ab04-c7fae3fc9e60_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_ffb4f82f-0dd0-4b7b-8c70-0c8ae7510c15_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and experimentation tax carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_be2b64de-ab8e-428e-a204-b5f8c82c59e9_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_582f1b2b-ddba-4e40-b80f-9a2e0bfdaece_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_18ea6bc4-d5f0-492b-9125-8562a04667ff_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_28ae11cd-6b33-4285-97b6-06d929173383_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_f251238f-ada9-4daf-b790-e25d11e8724c_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, research license and selection rights, term</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research License and Selection Rights, Term</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research License and Selection Rights, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:to="lab_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3bcad537-2b78-46ec-b93a-d4dc209e0af4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_ac96aae0-f3ff-48c2-9fb8-781a33d37f32_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d5bb33f4-e495-4883-adb8-68d77de09cee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_213b223e-6bde-4fb6-9fdb-7cfba230872e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized for plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ViridianMergerMember_245f2aff-96bb-4def-9e12-ab6b4fa26df6_terseLabel_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viridian Merger</link:label>
    <link:label id="lab_vrdn_ViridianMergerMember_label_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viridian Merger [Member]</link:label>
    <link:label id="lab_vrdn_ViridianMergerMember_documentation_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viridian Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember" xlink:href="vrdn-20221231.xsd#vrdn_ViridianMergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ViridianMergerMember" xlink:to="lab_vrdn_ViridianMergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e708664a-79d4-4e59-9981-8fef45d4e97b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31804d87-ace7-4671-97a4-9a31d1f56a62_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8c2b265e-31c3-4912-8258-69e577dea71d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eb0a8a1c-7c63-4ae5-b043-7c8851a22e6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_78ef236a-c7fb-4ff6-8df9-72ef19a9cf61_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5bf7ba93-eb0b-4407-b391-bcfd318832b6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_bb5f56ca-0732-457f-b6e3-b7c138176443_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held-for-sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_69ba4c63-46c5-4ddb-bec7-a944989294fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_22d6ae13-7770-4db3-9a82-1e9099865159_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential royalty payments</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Royalty Payments, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Royalty Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:to="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b1e04c8a-cac4-4e82-b201-c91667aa2ddf_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_1533e2c5-e78d-4bf7-942f-bd03965988d6_terseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_label_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-of-Use Asset, Net</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-of-Use Asset, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:to="lab_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9aabb8a2-e5e2-4f3d-925b-1eddbcf635c2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_36bd7664-cc12-4a71-9881-b9a95d92cf1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2b6adab5-e970-4bfb-a1ec-aedb6c53b9b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_a525aa94-d633-4858-a979-eb9889b531d2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_a73e4296-f78e-4fe3-93a2-824eafb5ba49_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b7323238-7622-4550-b66d-395c317597df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_278658ce-524b-45f0-bab3-38a1e4319f84_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6d460df0-699f-4f05-9e63-eeb79f09f9cf_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3cca15d9-19ba-4ce7-9657-63eda9cd28b3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_451ca300-b526-4911-ab25-5f863e478c72_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount, third tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Third Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Third Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_7a62695a-bc55-4f7f-8c5f-522addf69229_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_632eb52a-b636-4efa-bbdb-3c7ed138e6b2_terseLabel_en-US" xlink:label="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 382 limit</link:label>
    <link:label id="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_label_en-US" xlink:label="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 382 Limit, Percent</link:label>
    <link:label id="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_documentation_en-US" xlink:label="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 382 Limit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:href="vrdn-20221231.xsd#vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:to="lab_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7531b9be-c7c9-48ce-9ce0-a71ede2dd45e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e870ae9a-8b24-47a1-b496-2f2e19abf563_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_95e7d21a-f9cc-40ee-8b41-562ea5e2cab1_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a7be44f5-ab78-4d62-8d34-63faf3f4a36b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_258320b5-8ece-47db-8cd6-df9557cd948a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommitmentsandContingenciesTable_027e24aa-bb8a-4ff3-a0d6-3cee1a2099a8_terseLabel_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vrdn_CommitmentsandContingenciesTable_label_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vrdn_CommitmentsandContingenciesTable_documentation_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesTable" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommitmentsandContingenciesTable" xlink:to="lab_vrdn_CommitmentsandContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6cabbd41-a0cd-4b74-9b28-8b504f9a5ccb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_19a1072d-422f-4763-97f8-e714b9f1db62_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a4a613c5-fe49-4667-bc26-b6946b1e7ee2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8fd8b9cc-645f-42d6-85f4-6dc376629755_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_f6bb2f31-8ce9-4d5c-a9ac-8699932ba738_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional trading volume available for purchase, percent</link:label>
    <link:label id="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_label_en-US" xlink:label="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Trading Volume Available For Purchase, Percent</link:label>
    <link:label id="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Trading Volume Available For Purchase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:to="lab_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8d38466-4d27-4f36-a7e0-a6b22948133a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6d5a9708-09e4-4f0a-aef3-d7f6d3594bac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AmortizationOfStockIssuanceCosts_b8f4b5ff-7df0-467f-b532-98a083bca0c4_terseLabel_en-US" xlink:label="lab_vrdn_AmortizationOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of public offering costs</link:label>
    <link:label id="lab_vrdn_AmortizationOfStockIssuanceCosts_label_en-US" xlink:label="lab_vrdn_AmortizationOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Stock Issuance Costs</link:label>
    <link:label id="lab_vrdn_AmortizationOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_vrdn_AmortizationOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AmortizationOfStockIssuanceCosts" xlink:href="vrdn-20221231.xsd#vrdn_AmortizationOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AmortizationOfStockIssuanceCosts" xlink:to="lab_vrdn_AmortizationOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_13bdd4e6-012e-4b1c-85fc-5c1fdcc28fe7_verboseLabel_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market offering</link:label>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_9ae724c3-e366-4087-be6a-949576c8b5a1_terseLabel_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_label_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_documentation_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AtthemarketOfferingMember" xlink:to="lab_vrdn_AtthemarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1714e24b-146b-4433-ab8f-56493889a428_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a866af91-35e0-400d-b8d2-35d0fcc127f3_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_82b12802-c56f-4b39-b196-5e14e265cdf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f150e895-d135-4918-ab53-85459b921d09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_32b83336-0c7e-4793-aae2-a18ba49702b5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b06d3ddf-823c-4dab-b577-745d74cee4a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0df31c48-76b2-4bf0-8e4c-eb2446677b3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_237a6e4c-b4c6-4503-8c0d-aef90d6464c6_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3b60ffad-ac75-4d08-afe6-ffd9fbbdfbce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_58a7f153-e7bd-4391-b604-8b53b28b9569_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_acbc5dd3-5f8c-4174-b4dc-52ba0ec31607_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_852a5ba0-ceae-4160-afb4-58f1da8ae72e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ea870ae5-ade0-4f40-8902-4c8e1df40eeb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_ff09ce80-1b2f-45ed-b155-ab055d9e672b_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, milestone payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementMilestonePayment" xlink:to="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1005cf80-0df7-4f55-b05f-0f903f09e7a9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_99bb3a72-c90c-4cef-a300-d52d9ecc28ca_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0bb6320f-cb34-40ab-ac16-7ded9908c775_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_49e6d61f-53f2-433c-9ccd-92a2e854a5fa_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0d2bb5d8-91b9-42c0-a8c4-c7514387da55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7efed865-aa81-4239-b633-ce79283057ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c4d8958a-4313-4383-9ea0-c39f8eb13f78_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_86e5cc0b-e5d3-44d1-8e3f-f64881020fc8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_38799da5-8162-4a26-b2a5-ff610296d23b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_3823d377-9c2c-4c40-b9be-01c10489c04b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7982991-caf9-4215-8542-bd070bd75dcf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dae0efbd-4e5e-42a4-88ad-5c25239f2688_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aa34f695-54b9-41fd-bcd9-9c651aae69ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRC &#167; 174 capitalized costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_3e5ce360-6d46-4cbf-87c1-30b31da927f6_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares required to be purchased (in shares)</link:label>
    <link:label id="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_label_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Of Shares Required To Be Purchased</link:label>
    <link:label id="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Of Shares Required To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:to="lab_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_67b723fe-ba7c-4f0d-99ef-0a265865acc1_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f3549960-53b8-428a-89b9-2fb671941adf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9054e795-9e1b-4444-b698-03a929a1ba9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_9913bc4b-1523-4ff1-944c-a5764ac6a893_terseLabel_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued April 2017</link:label>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_label_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability-Classified Warrants, Issued April 2017 [Member]</link:label>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_documentation_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability-Classified Warrants, Issued April 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:href="vrdn-20221231.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:to="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61f3bb02-9da0-4bf6-bee4-ab8c7355ea1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_77c4d09b-2011-40bc-a954-2b77a6b75a38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_fe4ed28d-06fc-4eed-805f-3c9e786c5e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of machinery and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5fc369f-62b3-4f59-bbb3-aa5fc1acf509_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_86284fad-43e4-415a-b184-7329be03b27c_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_ecc912f3-bfdb-418f-a9f1-f35772c75ca9_netLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_5aebc60c-1572-4d4d-91b4-e9f6c32cd098_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock, as converted to shares of common stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxAssetValuationAllowancePercent_9da6b0ba-a860-41f2-a4d0-cf6e638407e6_terseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance percent</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetValuationAllowancePercent_label_en-US" xlink:label="lab_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Percent</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetValuationAllowancePercent_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetValuationAllowancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:to="lab_vrdn_DeferredTaxAssetValuationAllowancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_094ea5df-5217-41a8-900b-3746b9c5dd8a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_77a37bac-7ed7-4576-8413-da7935f7f4cf_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_e349c669-ffa3-4324-9160-7bbd1b2d61c9_negatedTerseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:to="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ad432d70-9a28-469e-a812-e638e3cd7aa9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by each warrant or right (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_96f408d8-e571-462e-91af-4d40d8d8b43f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2ed079fb-ddab-4541-8c1e-68f6074dd1c6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_089acedf-f035-40bd-b86f-f52c2f0f1ee2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_faa0aa68-79e2-4888-ad2f-c53b90ddd2d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a5f9f823-9764-408f-ae15-6041106fd439_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_344eecac-621c-4e4c-bcef-ad15076af9fb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements &#8211; To Be Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_fca80e0e-c0a7-43dd-9cad-c723a4aceef0_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:to="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e6445346-1524-444f-9945-e6c4a1090a32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a75f6d06-27d4-40f6-a2aa-90a8d01f8990_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_7faa6cff-a1a5-4c3c-8c05-150012dad7ec_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e6465793-8257-4d56-a212-bfca306b8739_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_37f1ca70-cd24-43eb-9d7b-fa7910fc3c1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0377bc10-ba0a-41f3-b089-3c68416d5180_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2e25673-e3ff-4613-9836-f1471b8b478f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b5b86368-4ce6-460a-a5b3-2d2b3ba5e4c4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_516c1e06-e675-4eae-9a73-b032a6c295be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_199ece96-5b53-430b-8a44-b5084dddfde4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3c3d3535-44e2-41ac-b2b6-b1d7adf5136b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ce76e61c-7a03-42f9-89a1-f8b3f4c5339d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_33860c09-f5ed-45f5-936f-9a5a07ef5071_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_32993bc8-7556-4cda-9cf6-56d3f823ddea_netLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_0b5cfe0d-f6ef-4870-a935-b76740937c1d_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock, as converted to shares of common stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74fda988-ee54-469e-80e9-d2ed4cc56b0b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_661f7726-f6a9-4347-bc8e-ef18b51da57b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_458f366c-3bcb-47a2-90bf-1494002bbc55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c9dac8c6-f963-4d4e-8e75-6425572acd47_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_792df817-45dd-48fe-bdec-3f592474aed3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4eb2582a-8b18-425b-8039-d53f97e3dcc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10901083-1dbb-4fe0-973f-a3f93afb3f9c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa438727-3f7f-4f46-b3cf-0bf37f9b228d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2752e0fd-96f3-446a-9e60-47be8b657562_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2008PlanMember_d4889518-5f46-400b-b765-ca850a25e4ea_terseLabel_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan</link:label>
    <link:label id="lab_vrdn_A2008PlanMember_label_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan [Member]</link:label>
    <link:label id="lab_vrdn_A2008PlanMember_documentation_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember" xlink:href="vrdn-20221231.xsd#vrdn_A2008PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2008PlanMember" xlink:to="lab_vrdn_A2008PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3ea8b9a1-822f-42c7-a1ee-a95b337d3857_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b3ac5a1-d8c2-4ee6-b99b-d8087cddceaa_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2585f638-3af0-4c26-8c4b-9e2afe8b236c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_aeb21eea-b00a-431e-9585-94eae112069d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommitmentsandContingenciesLineItems_2a2e49c5-22a9-49c4-899f-48d923dc503a_terseLabel_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vrdn_CommitmentsandContingenciesLineItems_label_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vrdn_CommitmentsandContingenciesLineItems_documentation_en-US" xlink:label="lab_vrdn_CommitmentsandContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesLineItems" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems" xlink:to="lab_vrdn_CommitmentsandContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bd6bb865-3450-44b4-b518-8b486f709d9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 200,000,000 shares authorized; 41,305,947 and 23,924,004 shares issued and outstanding as of December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1e5069cb-bc1b-4705-b562-a32251589623_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_098d23e2-529c-42ff-9033-e6f5cabc7c99_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders facility fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Facility Fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFacilityFee" xlink:to="lab_vrdn_DebtInstrumentFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_7e0a2062-4a73-48b0-9472-0386832920f9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExpanded_8322e749-4753-4b2f-bb71-5e3567251059_terseLabel_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExpanded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space expanded</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExpanded_label_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExpanded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Expanded</link:label>
    <link:label id="lab_vrdn_AreaOfOfficeSpaceExpanded_documentation_en-US" xlink:label="lab_vrdn_AreaOfOfficeSpaceExpanded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office Space Expanded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExpanded" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExpanded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AreaOfOfficeSpaceExpanded" xlink:to="lab_vrdn_AreaOfOfficeSpaceExpanded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7e404ddf-3e3f-40bd-ba45-2fe5d161dbec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ae179705-661c-4e5a-a2ae-6f5d41e2e958_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_18e47dcd-6899-40f0-89b6-969f11c224be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_80bed97f-1491-4ae9-878b-d2c9266f0903_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_2299ee04-cdda-4755-bb92-2c752cbefe08_terseLabel_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_WarrantsPolicyPolicyTextBlock" xlink:href="vrdn-20221231.xsd#vrdn_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_WarrantsPolicyPolicyTextBlock" xlink:to="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dff098f6-27b1-4bf9-a069-db375edb4d1a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bea6eca7-6b22-4e8c-a1a1-539d12527def_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89deac92-c1e2-4866-b9ab-b1f77abbc998_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b4cf46b3-229b-4f2b-94f5-5e2884d3564a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3b27370c-160b-4d4b-9cc9-e77c35ccd059_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_441df4bd-c618-4d0a-89f2-09ccd159c684_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2971b918-7435-4f25-a1c7-689664fc68da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1dc93f6d-1e55-431d-97de-103614e58473_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_fadfba9e-4f64-4db2-94a4-92ba2fcc46b7_terseLabel_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal terms (up to)</link:label>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="vrdn-20221231.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b16cb30f-7ccb-4897-ba29-cf86deb52838_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b7227359-1e29-4103-a3b3-94b81790ac3e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4d49969c-20b6-442e-9d56-48c62bf8367d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_06ecfc28-45a9-4a4b-9af1-072c59bf81fb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62c04bd4-1bd5-47d7-a027-3dcc7665c20f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3fa3d536-a449-4df6-86e1-ddf60e55ba92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_0ea375a2-d6ba-40b6-938b-86ca779e62cf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bfa59c80-e410-4c3a-9782-e4b166eacc5e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_8483a190-7ad3-454e-8881-64c1578ca05d_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, annual base rent</link:label>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_label_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Base Rent</link:label>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_documentation_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeaseAnnualBaseRent" xlink:to="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9d7977d0-bbd3-42ef-88c9-f151f39cdded_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_7ac98248-bfb0-4498-912d-e3b3e8c15e5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Allocated Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_82951434-e907-4511-979e-352862214e6e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a1d91d01-28e8-460d-839a-20659423f940_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9dbf02f7-1b69-4821-8462-b8c960818f37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f324f2e5-1f74-4b2b-852a-ad23d1861335_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term and Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_336d0229-b698-4fce-8026-a05997fe417f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bed8f3a4-d573-4d43-95ad-82bfc4462b93_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_e18df7ba-b6ea-4f21-aaab-161f89d41355_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_deefef36-db83-4689-a32b-cbd253da1b39_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ffe2daa9-11b6-49a9-986e-7ecd1a97adae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0d05e50b-5058-43ee-8be0-e7d560afca0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a9f28ec6-d5ea-4ab8-b6a7-88da00350729_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fae78ed3-501a-4939-ae54-a866f73e53b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26931467-e748-4ded-95e9-f050c1729c4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4692be5-0fd7-477e-a265-9dcea851b21f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c08b9cd3-0b30-4b2a-89ab-7c7cf210eff2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_cdda34b8-c65b-446b-840f-22e579c74d79_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_171109c2-f612-49a4-bd62-3e43d674f81a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba093a9b-0e52-406e-a992-28d09436069b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7d7d0549-90bb-498f-899b-6ffb1e5c1904_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6f30fc8b-f645-439d-9a0b-eef648022466_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41e954d6-7977-45f6-a9b6-ca07c33accc2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_00301667-90e0-48d0-8086-4f4e66b20d07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_790d3f83-9d97-4155-9ac2-75635802b1e4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_b848b897-5325-403a-bade-354022e1bd50_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2020PlanMember_4de9338f-19fc-4a1f-8a7b-6a460d3d6091_terseLabel_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_vrdn_A2020PlanMember_label_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan [Member]</link:label>
    <link:label id="lab_vrdn_A2020PlanMember_documentation_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember" xlink:href="vrdn-20221231.xsd#vrdn_A2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2020PlanMember" xlink:to="lab_vrdn_A2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e01d4fb7-bb1b-4877-86e8-987aa9d07ea7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6d8dc518-1685-43b8-8259-a7f162de01fe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6cd34cbc-98fb-4c3e-8af0-914947edefac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_22cf31a2-5a8a-4e97-96f4-d86c257fa767_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9f3ad071-0410-4903-b6a7-1dfc947837e7_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_55f01306-668f-4ccb-becf-f5800a1ce745_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e7d92ac-e6da-4607-800a-88ac88a043e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_71d54eb0-7a8d-4cfb-8ccf-447a8c7dee26_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cc64e2f9-467a-45ba-9bd0-8d3a77acb1a9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_79fa835a-c7c7-4f7c-8f47-b4ce89c4485e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c66f94a1-2b29-4ec9-a2ec-e98f323660d3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_Amended2016PlanMember_0a100a48-29c9-40f5-b172-e0392882919b_terseLabel_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2016 Plan</link:label>
    <link:label id="lab_vrdn_Amended2016PlanMember_label_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2016 Plan [Member]</link:label>
    <link:label id="lab_vrdn_Amended2016PlanMember_documentation_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2016 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember" xlink:href="vrdn-20221231.xsd#vrdn_Amended2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_Amended2016PlanMember" xlink:to="lab_vrdn_Amended2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_eb4b4fd0-0a85-4b91-925c-bc50937d8805_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommonStockVoteperShare_bb87bc4d-4772-4c3b-849c-6f64b7bc86b5_terseLabel_en-US" xlink:label="lab_vrdn_CommonStockVoteperShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, vote per share</link:label>
    <link:label id="lab_vrdn_CommonStockVoteperShare_label_en-US" xlink:label="lab_vrdn_CommonStockVoteperShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote per Share</link:label>
    <link:label id="lab_vrdn_CommonStockVoteperShare_documentation_en-US" xlink:label="lab_vrdn_CommonStockVoteperShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVoteperShare" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockVoteperShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommonStockVoteperShare" xlink:to="lab_vrdn_CommonStockVoteperShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6de51ae1-457c-4846-ada8-748ec1c6924b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5258b080-fa6f-41c9-9927-735d2095b632_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_cee5b716-6cd4-4ed2-b448-367a50ceabac_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive days threshold</link:label>
    <link:label id="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_label_en-US" xlink:label="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Consecutive Days Threshold</link:label>
    <link:label id="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Consecutive Days Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:to="lab_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_7df6e7b8-a91f-4eac-85b1-f3173ccd32ca_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and licenses fee</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Licenses Fee</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Licenses Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:to="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fbdc47a2-9e8c-4db6-8e12-5b07c4bfc3f9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_dc5c08bd-0921-47bd-99c9-5e09b730b86a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b440ee6e-1c83-41db-a556-29333ba446fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization (reversal of amortization) expense relating to operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ead5a9d3-28e6-42f8-aa82-c7c38e179b23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_acf9e856-9344-4b89-9817-cd250b1dcb6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL STOCK</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f88bc5a6-d5d1-4816-a396-fbf4a09d5b35_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WARRANTS</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a503275f-6258-4420-b2b1-5e43bd6b7b4b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_a9171b1b-7918-4cf7-a675-6484bb718c4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_2f877f78-037c-48a7-ad05-474d5d79d324_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c49ce800-d1a2-4ac9-a844-9fa43cfd8e12_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under license agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fe669eaa-a5ac-48fc-abfe-7d1b44c554e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_259f4359-7dea-4e6e-9224-a8347c4c6f4b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_56e51e65-4567-4f3d-b2b5-0e03a11dceb7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized employee stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_f403818c-0690-4a99-a3b2-2d768c03d88c_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. corporate paper and bonds</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_2d297974-a8ba-4de2-a3d5-1a8f6dbcf5bf_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. corporate paper and bonds</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Corporate, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7f5d0eab-9db7-4057-b3a6-f1194a46beec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fa884887-61c9-4bfa-b668-0323c82cd602_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_951855e2-58fd-4ef1-9035-2b051e8281e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1846990b-b84c-4e13-93b1-e0e8bca57a2d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5d5af269-9748-4e33-a69e-dc00dd4c16eb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_31d23a5f-ae82-4fde-8c17-6115875f316c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3a0b3d84-e64e-4e85-9c35-5b41233e0709_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AuditInformationAbstract_label_en-US" xlink:label="lab_vrdn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_vrdn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_vrdn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AuditInformationAbstract" xlink:href="vrdn-20221231.xsd#vrdn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AuditInformationAbstract" xlink:to="lab_vrdn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0d7037e8-af0d-438a-8231-415fcf0dfe77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_63e9b380-bfd5-4329-9c52-de794c825838_terseLabel_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired October 2020</link:label>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_label_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Acquired October 2020 [Member]</link:label>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_documentation_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Acquired October 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:href="vrdn-20221231.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:to="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_8dcc0284-d906-46ca-8a67-d3cd2664aee9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_05fc3346-0a4d-4706-9531-19927391dee8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2b0519a2-f606-4163-902b-3c8104ab3167_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0425757f-b4af-437e-8ebf-73080b94491c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_586ff6d6-59bd-4d07-a370-8efcb6311221_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4477c416-a6ba-4069-aa25-52d0ac1a3ab8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fda4cb19-2fee-4d5c-8ea0-f514f2771667_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion and amortization of premiums and discounts on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_af5e98e5-520f-48f0-a81e-e0b413060f46_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, potential development milestone payment, maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Potential Development Milestone Payment, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Potential Development Milestone Payment, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:to="lab_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a843b073-ca9d-4b8e-9f41-547f6a635deb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_bbde6abb-d18f-49f7-b78e-34dd8dabc43d_terseLabel_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up costs and amortized costs</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_label_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Start-up Costs and Amortized Costs</link:label>
    <link:label id="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_documentation_en-US" xlink:label="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Start-up Costs and Amortized Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:to="lab_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_655baea2-c138-4c33-a0ca-8e91c457aa4b_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_3d7507b9-1a8a-4c95-946e-6400a2afe58b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df408a62-de0f-4451-a091-a7cf2c14a76f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c4e9d4be-5d52-49c5-9554-9d97c8ca8f80_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_c0516e7a-9e1d-49e9-8612-5411a3759a34_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_0de3d297-6493-4c58-8e45-4bc795327a06_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from disposition of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fa7bf2e4-8117-481b-9f70-621c3999f533_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_2bb73e2a-3334-4656-93cb-8c5d520a491a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_59becc79-811c-4054-aa81-bfdae349a7b2_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, number of tranches</link:label>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentNumberOfTranches" xlink:to="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_00eccf14-f833-4cb9-8a3a-2e5f8737bc85_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1d91717f-9813-4007-9ab6-2f4c4f3ab155_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_db096fdc-d7f1-4d43-b74d-b20d8020c4ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_54298353-df2e-45b3-a73d-45d912b58b35_terseLabel_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_label_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommonStockWarrantsMember" xlink:to="lab_vrdn_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87475ec6-ff93-473c-9744-bc3d861fb96b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_a8e3927a-25f6-42cc-84b8-87a940db66da_terseLabel_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee percent</link:label>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_label_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_documentation_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:href="vrdn-20221231.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:to="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9533de96-ae84-4ff9-a246-dabcfb2dd95b_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c39c07a7-7c53-4d8d-bbf3-b1e4d197794b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bc62130b-6944-409e-95d2-a48005fd97d5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock, pursuant to 2022 and 2021 Public Offering and September 2022 and April 2021 ATM Agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7bc5a288-742b-4c13-99ca-392c4aabaec7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of Series B preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c0c0040-85af-4e1d-bd3d-0c9ea0006d74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0381fc68-7a17-41e5-988f-89fd0b321455_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_97b882c8-905f-4f5d-a6f4-9996f4ec7a77_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount, first tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, First Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0f8bf4cd-3d8c-463a-ab00-76043d899a30_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_637676ac-40fb-4f24-9cf0-d05c9cf81462_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_112d7222-f3a7-4a5e-93c9-e8cb8cb97e8b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cdf803f-a7ae-4b00-826d-96e3c48f1eb4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86812eaf-6ef3-4d7b-b0d6-ffe16ceaf21f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_adbac172-a757-46c3-b2f2-142aec5ab5b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_e696f860-7146-45ba-b5fe-d0a1408bf4ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ab09262e-8d1d-41a6-861c-0f156cc8b0b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_340b6ff9-2f0d-45d7-be64-a74489d3b4fa_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d782e45-4a5d-414e-a1e4-928967f7dabc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under license agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b6f5e1a7-749c-4f44-9158-91f0d440ddf8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_cfb6cef2-a9e7-4b92-9c4b-f5c3a2272142_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f1594e5e-61a9-432c-a9ef-afd3d1cef4be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a1554356-093a-4784-bb19-6046f0ca643e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_55616034-1e09-4df3-b9dc-42faaa74dcf1_terseLabel_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trials and Preclinical Study Accruals</link:label>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trials And Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:href="vrdn-20221231.xsd#vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:to="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0bcaa28a-7fee-4a8f-8ccd-4e2a2fe2fd5a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a43d362c-3399-4211-be19-2e99c63c9d48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5af6b9f0-3845-4f05-8379-cea6815a65f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4d8ab72d-6ce6-4f7b-bf83-39fae94de587_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c9fe46d0-b612-4da4-b49f-a940e27f546c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_PublicOfferingMember_baf3d8a3-59bd-4b59-ae27-b752bced86c3_terseLabel_en-US" xlink:label="lab_vrdn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_vrdn_PublicOfferingMember_label_en-US" xlink:label="lab_vrdn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_vrdn_PublicOfferingMember_documentation_en-US" xlink:label="lab_vrdn_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PublicOfferingMember" xlink:href="vrdn-20221231.xsd#vrdn_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_PublicOfferingMember" xlink:to="lab_vrdn_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d509aac5-80f5-413f-a2db-c675893219f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_611be478-7b0a-4e7a-b05d-c9dc7edea6e1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_b7748d39-5356-49f2-841d-f803a371e90f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_53c3346c-69ea-4b2f-bcb5-5671eae13c21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b03ada0e-b3fb-4545-93ea-5c306f9e1d10_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_8faa336f-6a16-47be-b912-768fcf0cdc60_terseLabel_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of liability-classified stock purchase warrants</link:label>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_label_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_documentation_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:to="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2fdfbb8a-ede2-4635-94d7-97e918d608bf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_829da5a4-08a1-4ee4-96b2-416e353b2c45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3ae3926b-75f4-4d72-afda-da65aac6f813_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7cf9a422-265e-4359-8448-6c4c408c6b8a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d4d9269-e4b7-48dc-a6ff-38f72a9ec79b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_229cd0a5-613e-42eb-aab7-d062f2b02f2f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c6b70f6c-6d48-4bc3-a5f2-93a76968ca06_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_abc1182e-be7d-4936-bbb4-c89602a8ef05_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9f953d81-e24d-40e0-a0da-6a0204181661_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_a00d249f-7e47-43a3-b6f9-07aa1b5415a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_57faef01-e615-4571-9ece-7f6c2a9ca69d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_1963ef7e-c7e4-4911-b2bd-9d0994027988_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0ccd95ba-d1c4-4a85-920e-cebdca4d39de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_9eefd5d1-90ef-4d4f-8b65-b3e479021758_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e5b2d1d5-fb95-4c59-ba87-fef6c46a3f30_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_556c6fd5-e73e-4c62-845b-71a2e8a0bc6c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3738b3a9-65e4-41f2-99e2-be0beb64fa70_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_60eb95ca-956e-4b20-b162-ce8548bfb8a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Vesting Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7eb7b4ee-2ecd-4a19-9925-c29dc7b51573_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b42b589-a9af-497a-978f-4f0cce0a19f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (up to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_133d640e-fdaf-447a-848f-316925556c2f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_92cb0612-27b2-477d-8ffd-c7d90c7dd453_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_109cb817-733b-460e-a250-ba88b031810e_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses of leases</link:label>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_label_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_documentation_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeasesOperatingExpense" xlink:to="lab_vrdn_OperatingLeasesOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a6618ba8-08be-4f45-b758-5b17342c77a1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5d082805-e3e3-40af-bc5a-4fe1b3206425_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_bbde7b48-787e-4fab-bfc3-a87ca35618b9_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contractual life</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Remaining Term</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Remaining Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightRemainingTerm" xlink:to="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2730fe9b-ce9b-4800-a1b3-0198944a71b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_c9be2b14-3fe4-45a4-8122-50c757cdb2ed_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average over number of lowest sale prices</link:label>
    <link:label id="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_label_en-US" xlink:label="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Sale Price Calculations, Average Over Number Of Sale Prices</link:label>
    <link:label id="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Sale Price Calculations, Average Over Number Of Sale Prices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:to="lab_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_6b1cfb24-de78-46bf-a0d4-ef0e3a57f1d1_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount, second tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Second Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Second Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_75bdd50a-f6a1-43a2-b96b-43a94cae691a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_03f14076-9d80-4ac4-afe1-08c878bd0c59_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_63329ec6-1e54-42a3-8125-4da405a8c0ee_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in exchange for rights granted (in shares)</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d42a5c99-fca7-4faf-a9a7-1c8928a809fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under license agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_69f9a7da-1085-483f-a258-5cc5402fd36f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_09e4f28b-e2bb-409e-bd48-405047f49f4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_cd7170cd-d2d2-4b7b-afc3-0ba0a7232480_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba53dfd9-34bd-43ba-a816-b59115c7e986_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Lease Payments under Noncancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2d8bbafd-09e8-45b8-82a9-b88d1bc7a500_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5a2fe1a4-934b-4fea-840e-46c7e31d4e09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_39d4789d-f840-4336-8b85-77b54e02aa51_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Potential Milestone Payment, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Potential Milestone Payment, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:to="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_8f25682b-2db3-480e-a18f-0f1546d6f14f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_NonCashLeaseExpense_05f80872-66ca-4cd8-b829-dd52f615bd4c_terseLabel_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_vrdn_NonCashLeaseExpense_label_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_vrdn_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense" xlink:href="vrdn-20221231.xsd#vrdn_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_NonCashLeaseExpense" xlink:to="lab_vrdn_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1127c705-8454-4f60-9f71-0d67a3addea0_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_155b968a-9dad-4d07-a66c-a9c7d7fc78c5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_63650c83-f73a-4a48-8055-524491c9e4cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5df8547f-26dd-4c4a-b606-9c88d77b20f3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9e58e335-f61b-4745-bb1b-5a200986860d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e06f6766-3495-47f4-9146-6792a56780b6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9ac2a133-3e4a-4e8a-8584-e2ac64aa508a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e18fda4c-2761-4d2d-be9c-c131f950c810_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e1cbfc50-0f99-4dbb-9041-32c223e88532_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_25f9522f-b54c-4f35-ac8c-6482db21d6bb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a07c3aac-8175-4f76-8d69-7f4ad8aea2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1d110405-d094-47fb-a682-347e7f6d4a63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_05a6f5c3-4668-47f9-ab86-9ff3e5cc9a4c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_773164cb-2585-470d-81cd-b750361f3085_terseLabel_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_label_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_documentation_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized" xlink:href="vrdn-20221231.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CapitalStockSharesAuthorized" xlink:to="lab_vrdn_CapitalStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5417d49d-e373-4387-8324-570b70cf5705_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3b79f015-ddcd-416e-a3af-549dcd1a6098_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6a94ae22-5b4a-4928-8141-31f7de345f61_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development - related party</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_283c1997-513f-41a1-9ee1-fb66ea8bb177_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5876fedf-2829-4665-88e9-e65c35d29a09_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_92b8c6fa-c401-4b7d-81c1-81dacc3d7c7b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_18e61c56-d1f7-417e-af1f-d0a99efb35e3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_InducementGrantsMember_54df07e0-0e62-4e09-bc1f-be725d39bc13_terseLabel_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_vrdn_InducementGrantsMember_label_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grants [Member]</link:label>
    <link:label id="lab_vrdn_InducementGrantsMember_documentation_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember" xlink:href="vrdn-20221231.xsd#vrdn_InducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_InducementGrantsMember" xlink:to="lab_vrdn_InducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ec81f20a-0729-4b63-b374-bc305c7dac92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ba3f6c08-11fe-4dbe-b325-f052d423d78c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f6edf37-375e-487c-a069-47f1193dda8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_76c98dfe-d280-4f13-b7ec-c66b5f4a7c1a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_f161c89d-02fb-49e2-baa9-4accd40aa5d1_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued in exchange for rights granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Value Of Shares Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Value Of Shares Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_37197d9f-fe5d-43c7-b686-4960191d70f6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ed4135c-d5f5-4721-a4ce-49b23b21bbbe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_df0f4272-3d46-49fe-b6f7-5173adf8f5ad_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued November 2017</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Issued November 2017 [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-classified Warrants, Issued November 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:to="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_84109c8e-cf27-4b10-ab81-ea38d74d1e93_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_6c9681b5-0195-4714-9f52-56d21d6d64be_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other professional service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bf5025be-dbd1-41ae-b807-998719bb6092_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_24c6947e-1c6d-4b40-92b3-a6c323d49e56_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_96d4f0c6-6743-445c-b3a9-d65e59e7a496_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_313d20f0-8c4f-4c23-8606-b6072ec69b50_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront fee payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fee Payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:to="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6fd049cc-77a3-466b-adfc-1379a40e560b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_11bf1d67-5e0f-4835-9a04-de75631b5e59_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_dfe97df1-db2b-4f14-a3d5-9feab7d74b47_terseLabel_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_label_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Shares</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_documentation_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:to="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d91cf5f6-d92a-453e-a627-708ad65b6181_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c17e7efc-939d-48e5-8f0f-5a53f83ccbb1_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_XencorIncMember_f60dd3c3-01d7-4089-b808-462f223e2ab7_terseLabel_en-US" xlink:label="lab_vrdn_XencorIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xencor, Inc</link:label>
    <link:label id="lab_vrdn_XencorIncMember_label_en-US" xlink:label="lab_vrdn_XencorIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xencor, Inc [Member]</link:label>
    <link:label id="lab_vrdn_XencorIncMember_documentation_en-US" xlink:label="lab_vrdn_XencorIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xencor, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_XencorIncMember" xlink:href="vrdn-20221231.xsd#vrdn_XencorIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_XencorIncMember" xlink:to="lab_vrdn_XencorIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23d8506a-e573-407e-9446-42a39e95064f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_3400b6a6-edf7-4c9f-bf39-7cea9deed729_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, potential special payments, maximum</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Special Payments, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Special Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:to="lab_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d019125e-82b8-4293-b6ab-6b1ff8c1e03a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_621d6cfb-6e5b-48bf-afc2-d0a5e8920dfe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab409412-efd2-4ec4-9cb6-3958ea0d5ffb_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_00191bd4-0e27-46bf-b415-1062d740452a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_47a07689-a832-4978-ba9f-deaf1e11aa64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value per option (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_65445ef3-a507-4815-a1c2-6f8de9beaf74_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8b285610-8f0f-409c-810f-b5da8c5ad22a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_14076c11-f731-4184-9d32-73754bc20825_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5b1b772a-6c9d-41be-9404-bafa8de6dd0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_HerculesTermLoanMember_f0cdd5e2-ef4e-4660-9048-c05c730e4140_terseLabel_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Capital, Inc</link:label>
    <link:label id="lab_vrdn_HerculesTermLoanMember_label_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Term Loan [Member]</link:label>
    <link:label id="lab_vrdn_HerculesTermLoanMember_documentation_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_HerculesTermLoanMember" xlink:to="lab_vrdn_HerculesTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2275d096-0012-46fa-9c63-95f62ba8892a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a87f3f93-c82b-43a7-bdc6-fecdec402368_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_504b3707-75db-45f4-ae74-ff38773bbd6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>vrdn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6289c3e2-0f0b-4349-9931-9aa639076063,g:617baa04-04f9-4960-ac50-2d30acd97e7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ebd1e94a-4d5e-4e89-afc4-4b7a2c25627f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentType_ebd1e94a-4d5e-4e89-afc4-4b7a2c25627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_93b25fec-8315-4b4b-8402-6100b584b59c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentAnnualReport_93b25fec-8315-4b4b-8402-6100b584b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_84eaeb1b-2d48-4411-a4e3-ab78c39ed8c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentPeriodEndDate_84eaeb1b-2d48-4411-a4e3-ab78c39ed8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_971e0cfb-d25f-4f5b-8907-09398b5598fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_CurrentFiscalYearEndDate_971e0cfb-d25f-4f5b-8907-09398b5598fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_63ed4d9c-41a6-4138-ab39-5813d54ba2a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentTransitionReport_63ed4d9c-41a6-4138-ab39-5813d54ba2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_49686059-23ab-4115-9bbe-495d6ed18754" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityFileNumber_49686059-23ab-4115-9bbe-495d6ed18754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d9ef0c3d-2230-4fd2-a2c3-8ba7f9bf2444" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityRegistrantName_d9ef0c3d-2230-4fd2-a2c3-8ba7f9bf2444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6ad76bab-92ec-4f10-8a1f-ed7ed8e66eb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6ad76bab-92ec-4f10-8a1f-ed7ed8e66eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_573dcdb5-ea80-4825-ba5c-1534b0d4295e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityTaxIdentificationNumber_573dcdb5-ea80-4825-ba5c-1534b0d4295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_33325b77-a7d0-4bd8-ae7e-2f142a8468ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityAddressAddressLine1_33325b77-a7d0-4bd8-ae7e-2f142a8468ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_67b5cc2c-a8b9-4641-a5f7-a7808bc2ebc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityAddressCityOrTown_67b5cc2c-a8b9-4641-a5f7-a7808bc2ebc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_04e42c01-ae14-44fe-a90e-6a52528afab9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityAddressStateOrProvince_04e42c01-ae14-44fe-a90e-6a52528afab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf23c46b-76a5-47ac-8de6-83d058101ded" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityAddressPostalZipCode_bf23c46b-76a5-47ac-8de6-83d058101ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ebfaa674-cd09-4d0a-a054-febb1cf3432d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_CityAreaCode_ebfaa674-cd09-4d0a-a054-febb1cf3432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_03a5f3c6-99ea-43ff-b47d-928b03dca7ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_LocalPhoneNumber_03a5f3c6-99ea-43ff-b47d-928b03dca7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a7a284a0-9385-4303-8590-e23aad54436d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_Security12bTitle_a7a284a0-9385-4303-8590-e23aad54436d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_20262b1d-9eb7-42c7-99a0-419d9cbd60b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_TradingSymbol_20262b1d-9eb7-42c7-99a0-419d9cbd60b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_52c837f3-c614-47be-a40d-bd0f8e310742" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_SecurityExchangeName_52c837f3-c614-47be-a40d-bd0f8e310742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_194b513c-2d03-434b-a359-19ed28700a9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_194b513c-2d03-434b-a359-19ed28700a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_57445cc3-bf2c-450e-b10d-72e5a2aaa24a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityVoluntaryFilers_57445cc3-bf2c-450e-b10d-72e5a2aaa24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_508d39d4-ff10-4558-8cf0-baf5f231c87f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityCurrentReportingStatus_508d39d4-ff10-4558-8cf0-baf5f231c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f5c419c5-6ad9-415a-9842-b76c3834b944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityInteractiveDataCurrent_f5c419c5-6ad9-415a-9842-b76c3834b944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_607293bf-647a-48d6-8965-e9c72c096470" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityFilerCategory_607293bf-647a-48d6-8965-e9c72c096470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2d869696-7889-4e7b-a322-83d39fa40513" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntitySmallBusiness_2d869696-7889-4e7b-a322-83d39fa40513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7f875c3b-01d8-44e4-9559-1921c43f122d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityEmergingGrowthCompany_7f875c3b-01d8-44e4-9559-1921c43f122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_22b84ccf-3e1a-41c6-9c7e-727c2a4e33a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_IcfrAuditorAttestationFlag_22b84ccf-3e1a-41c6-9c7e-727c2a4e33a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2cf88413-8f7b-4cc6-aebc-4169bfe6851e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityShellCompany_2cf88413-8f7b-4cc6-aebc-4169bfe6851e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b7c27922-cd6e-4466-9ee6-2e10328a82b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityPublicFloat_b7c27922-cd6e-4466-9ee6-2e10328a82b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_37f44a52-32c0-4801-bbde-d3c85f1c9b5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_37f44a52-32c0-4801-bbde-d3c85f1c9b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2844e22f-95e9-4609-8386-3b14dc45479d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2844e22f-95e9-4609-8386-3b14dc45479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0dfb255d-7c24-4180-8907-7a63a0b203e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_EntityCentralIndexKey_0dfb255d-7c24-4180-8907-7a63a0b203e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1869f866-1771-4f07-b63d-7a02a69948ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_AmendmentFlag_1869f866-1771-4f07-b63d-7a02a69948ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2d625a8e-c9c4-48fc-8d82-567f69fe3a69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentFiscalYearFocus_2d625a8e-c9c4-48fc-8d82-567f69fe3a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c5279d80-ac24-4e3c-b3d7-ccd179445834" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_80b52c25-75a5-4bd1-b1f6-6dab352728fc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c5279d80-ac24-4e3c-b3d7-ccd179445834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/AuditInformation" xlink:type="simple" xlink:href="vrdn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AuditInformationAbstract_2c07add8-e043-4d06-8dbf-a8b581755c6e" xlink:href="vrdn-20221231.xsd#vrdn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_faf0d4c1-6ad1-4633-9200-4b7abbef4ab9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_AuditInformationAbstract_2c07add8-e043-4d06-8dbf-a8b581755c6e" xlink:to="loc_dei_AuditorFirmId_faf0d4c1-6ad1-4633-9200-4b7abbef4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_49de75ab-7c35-4c19-800e-f1550608f05f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_AuditInformationAbstract_2c07add8-e043-4d06-8dbf-a8b581755c6e" xlink:to="loc_dei_AuditorName_49de75ab-7c35-4c19-800e-f1550608f05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f0961f01-10ef-4898-9bfd-cc4d0595b439" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_AuditInformationAbstract_2c07add8-e043-4d06-8dbf-a8b581755c6e" xlink:to="loc_dei_AuditorLocation_f0961f01-10ef-4898-9bfd-cc4d0595b439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8ead7c7d-9ab6-45b8-9beb-be160578a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ead7c7d-9ab6-45b8-9beb-be160578a4b6" xlink:to="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_337022ab-a747-4953-8042-f399fa1e2696" xlink:to="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_492e825e-220a-459a-82d9-02539a1582ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_492e825e-220a-459a-82d9-02539a1582ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0c141b2a-ceea-41ba-99e7-6173c03a42f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6c304da8-92e3-4fd6-bbf7-374ee92fbb29" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0c141b2a-ceea-41ba-99e7-6173c03a42f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9596d1bf-ae51-4b2a-9891-f1692c49489e" xlink:to="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:to="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf406e3-8033-46bd-af7f-cd98bf680eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf406e3-8033-46bd-af7f-cd98bf680eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6498fe2-0f97-46fa-b1fd-252e11438687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b6498fe2-0f97-46fa-b1fd-252e11438687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_081d9abf-7a54-4c65-b37c-e382bc85da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_081d9abf-7a54-4c65-b37c-e382bc85da6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4b99044e-5c24-4ec9-94cf-eed6d9181d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_4b99044e-5c24-4ec9-94cf-eed6d9181d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf7deda0-a745-4feb-9c21-92420030fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_70c71711-8e9a-448f-82ca-16ad090d684b" xlink:to="loc_us-gaap_AssetsCurrent_bf7deda0-a745-4feb-9c21-92420030fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f26024ac-8fd7-494d-bedf-94b219c3c782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f26024ac-8fd7-494d-bedf-94b219c3c782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_005469a2-3bed-412e-a7ba-9b5627ffa209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_005469a2-3bed-412e-a7ba-9b5627ffa209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_73884f09-940f-451f-b633-0a4507761d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_73884f09-940f-451f-b633-0a4507761d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e1f7f77b-d914-4fa2-a0f9-308a1ae7c236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19e5631f-57b5-4110-a95d-02763eaf898a" xlink:to="loc_us-gaap_Assets_e1f7f77b-d914-4fa2-a0f9-308a1ae7c236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8a573e26-bc6e-4e7f-953e-66c7be373051" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7239ac97-0cd7-4bfc-ab6d-0ae6b6f0b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_AccountsPayableCurrent_7239ac97-0cd7-4bfc-ab6d-0ae6b6f0b5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_59c984d6-5ba7-4100-b886-e2ca7ead7829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_59c984d6-5ba7-4100-b886-e2ca7ead7829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b4b7128-aef6-4abb-9714-11032fa3cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b4b7128-aef6-4abb-9714-11032fa3cb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_15b08d29-7e7f-4bfe-9251-c3ac182bb5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75956076-4bff-4383-8442-a2d712f10944" xlink:to="loc_us-gaap_LiabilitiesCurrent_15b08d29-7e7f-4bfe-9251-c3ac182bb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8490ffb2-baaa-46d0-8984-70f64704ca53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LongTermDebt_8490ffb2-baaa-46d0-8984-70f64704ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2b76db2-91a2-4fcb-9740-0d28308af57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2b76db2-91a2-4fcb-9740-0d28308af57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5c66376f-7f51-46cd-a585-cc1626287413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5c66376f-7f51-46cd-a585-cc1626287413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe9b080e-cabe-4bae-88cd-15d7f2061485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_Liabilities_fe9b080e-cabe-4bae-88cd-15d7f2061485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26666b3e-f281-436d-8ec2-cbe1c44a8344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26666b3e-f281-436d-8ec2-cbe1c44a8344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5e8b81d9-c43a-47a8-ac16-181875aa725d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_PreferredStockValue_5e8b81d9-c43a-47a8-ac16-181875aa725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fa36f1f1-74d4-4934-899c-8f18cc08f079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_CommonStockValue_fa36f1f1-74d4-4934-899c-8f18cc08f079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_eeb0f75a-f7fc-4ba5-810e-f7c1887738d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_eeb0f75a-f7fc-4ba5-810e-f7c1887738d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7603d21-7995-4384-a06c-3a363aaf2df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7603d21-7995-4384-a06c-3a363aaf2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0c788e2e-b977-48f1-8e45-6469516a83ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0c788e2e-b977-48f1-8e45-6469516a83ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_561339c3-d742-4a86-ab0a-b86b33883303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e14a85-2692-490d-bf1f-6338af8093a9" xlink:to="loc_us-gaap_StockholdersEquity_561339c3-d742-4a86-ab0a-b86b33883303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61ac2c58-36c7-4cd7-a417-8e2455cffabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d41e0915-61fc-4ee8-bea8-e564414de88c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61ac2c58-36c7-4cd7-a417-8e2455cffabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7c99c347-dd08-414d-b898-443af3fc5c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7c99c347-dd08-414d-b898-443af3fc5c79" xlink:to="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3dd787c-5d53-4360-822c-8c11e19ad40e" xlink:to="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_94afa59b-a96d-4c86-8856-5139b439b279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_94afa59b-a96d-4c86-8856-5139b439b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0b7fab67-4be0-42ea-b920-afa0e7f2e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_50d00a46-cc3e-4763-9323-9336645838bc" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0b7fab67-4be0-42ea-b920-afa0e7f2e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_db357732-2a80-4e34-8106-805b2415dc22" xlink:to="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_42bd1d39-3de9-4257-8390-5c5831390f9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6402aa65-e76b-48af-a109-5a90bd6d11d9" xlink:to="loc_srt_AffiliatedEntityMember_42bd1d39-3de9-4257-8390-5c5831390f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eb7d477d-160f-4e05-949a-0db22a370f22" xlink:to="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b15f4769-d8f2-4b46-bba9-a254f6b5a315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b15f4769-d8f2-4b46-bba9-a254f6b5a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cf79c4fa-c2b8-42b0-bcf6-8481c556c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cf79c4fa-c2b8-42b0-bcf6-8481c556c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3f12e733-bcb6-4aee-8738-fac79cb4027b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3f12e733-bcb6-4aee-8738-fac79cb4027b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f0e38aed-21ef-4676-8b03-c9c662a7113d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f0e38aed-21ef-4676-8b03-c9c662a7113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e8cefc7-e4a2-4ad8-9216-88e5a09fa366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e8cefc7-e4a2-4ad8-9216-88e5a09fa366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_60ed4826-48cb-4c64-be89-67b030a25bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_60ed4826-48cb-4c64-be89-67b030a25bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a30520bc-79b3-45c6-b5c7-31724802d489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesIssued_a30520bc-79b3-45c6-b5c7-31724802d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b4d941f1-d0e6-4458-a78e-40512f6dbbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b4d941f1-d0e6-4458-a78e-40512f6dbbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_be1b836a-c15c-418f-837b-0c3dac84fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ec22f21-10d8-4121-bd46-38953051c50b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_be1b836a-c15c-418f-837b-0c3dac84fbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9b4bc80f-3f38-4c89-ba5a-4e1844b525ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_RevenuesAbstract_9b4bc80f-3f38-4c89-ba5a-4e1844b525ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2d50769-8f1c-4f02-97c9-1badda2038c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9b4bc80f-3f38-4c89-ba5a-4e1844b525ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2d50769-8f1c-4f02-97c9-1badda2038c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_24f3c06f-3f2b-496d-a03b-d6d3e6b38eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_24f3c06f-3f2b-496d-a03b-d6d3e6b38eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_da46592b-e07e-4762-acd3-6f04c13f1a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_24f3c06f-3f2b-496d-a03b-d6d3e6b38eeb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_da46592b-e07e-4762-acd3-6f04c13f1a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08e04c54-b775-441e-a3a2-ca43454990e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_24f3c06f-3f2b-496d-a03b-d6d3e6b38eeb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08e04c54-b775-441e-a3a2-ca43454990e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ead08e69-afdf-4fe8-9ba1-5072e53b47f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_24f3c06f-3f2b-496d-a03b-d6d3e6b38eeb" xlink:to="loc_us-gaap_OperatingExpenses_ead08e69-afdf-4fe8-9ba1-5072e53b47f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bea45e5a-bc40-4ef2-9740-82253fd6e98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_bea45e5a-bc40-4ef2-9740-82253fd6e98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_813f74d5-ed2a-402b-86f8-33251898274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_813f74d5-ed2a-402b-86f8-33251898274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_2f322cb5-6cbf-4afd-b6d5-8726db3c0486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_813f74d5-ed2a-402b-86f8-33251898274f" xlink:to="loc_us-gaap_InterestAndOtherIncome_2f322cb5-6cbf-4afd-b6d5-8726db3c0486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_2f791261-1a00-419e-a07f-e3ac0e24f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_813f74d5-ed2a-402b-86f8-33251898274f" xlink:to="loc_us-gaap_InterestAndDebtExpense_2f791261-1a00-419e-a07f-e3ac0e24f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2ac77af2-840d-4bcd-8a67-809c8065c6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_813f74d5-ed2a-402b-86f8-33251898274f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2ac77af2-840d-4bcd-8a67-809c8065c6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2362574f-e97e-485e-b63c-dcd2949704af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_NetIncomeLoss_2362574f-e97e-485e-b63c-dcd2949704af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bbc2e867-b289-4b4d-af14-f8a6307bd7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_EarningsPerShareBasic_bbc2e867-b289-4b4d-af14-f8a6307bd7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4f828f4b-9eba-4f52-8bb6-4c5eed4fa7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4f828f4b-9eba-4f52-8bb6-4c5eed4fa7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7c7abd58-9aac-4c6e-9ab1-ea2c0dfe9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7c7abd58-9aac-4c6e-9ab1-ea2c0dfe9e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07ac6a8c-14a3-4447-b74c-66668a103074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07ac6a8c-14a3-4447-b74c-66668a103074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f37160d6-9f09-4d45-bfa6-7d58f65d2f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f37160d6-9f09-4d45-bfa6-7d58f65d2f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e68f5305-9b6d-439f-9515-7772acdd776f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e68f5305-9b6d-439f-9515-7772acdd776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dcfa55fd-8358-4325-892a-60a3b804cc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_919c6ae5-b4de-4807-bda1-cfa8a35c37cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dcfa55fd-8358-4325-892a-60a3b804cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4e793f02-7103-4df6-b866-bcfd2c38b0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e793f02-7103-4df6-b866-bcfd2c38b0d5" xlink:to="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9695cce9-56e8-4b36-a3d0-7dc5ec6555f4" xlink:to="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_15026ed0-76e0-4c35-a95f-e40fa46440c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f71abe3e-8050-401d-9569-bf268e12aed2" xlink:to="loc_srt_AffiliatedEntityMember_15026ed0-76e0-4c35-a95f-e40fa46440c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_281a08b3-01ca-44f5-8f2b-3ed63798ff8e" xlink:to="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94022989-fc36-442a-a248-c5f045fb0f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ecf23168-3988-4e8b-92f1-95e3137b22ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94022989-fc36-442a-a248-c5f045fb0f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_55eb1b1e-c6bf-44bd-9a43-0a350a255449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_55eb1b1e-c6bf-44bd-9a43-0a350a255449" xlink:to="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cc85dfe-0af8-4be1-9c8c-9762bf7a1111" xlink:to="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1c99991c-52c7-4527-9bbb-f339e8c72f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_PreferredStockMember_1c99991c-52c7-4527-9bbb-f339e8c72f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0e1a4e27-a688-42ad-841b-84e695b71f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_CommonStockMember_0e1a4e27-a688-42ad-841b-84e695b71f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ee94ceb-03d9-4f2b-b6db-f2de504632ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ee94ceb-03d9-4f2b-b6db-f2de504632ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d31cfd-6391-436f-bcb8-e4ecf39fe767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d31cfd-6391-436f-bcb8-e4ecf39fe767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f6e5628-5e73-414d-98ed-cb583d8d248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948d6669-2463-44cb-8174-ab66aba36bd8" xlink:to="loc_us-gaap_RetainedEarningsMember_0f6e5628-5e73-414d-98ed-cb583d8d248a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_215e252b-9957-4df5-8614-2cef16128c7a" xlink:to="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1578e818-f3e3-4f26-ae7c-7657a39e2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1578e818-f3e3-4f26-ae7c-7657a39e2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ec0ed5e5-d883-4f28-8d51-35cbc6797ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc654b79-fe5d-4288-bb5c-19680f795bcd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ec0ed5e5-d883-4f28-8d51-35cbc6797ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c7fbc2ab-70c1-493d-b893-83f6c48b067d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PublicOfferingMember_9cff8a90-a681-4aa0-bf2f-fdfdac869089" xlink:href="vrdn-20221231.xsd#vrdn_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:to="loc_vrdn_PublicOfferingMember_9cff8a90-a681-4aa0-bf2f-fdfdac869089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_6eb73835-290b-468d-9bc2-093d02da1595" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b60a00b-062a-4e73-b5b0-da8f1b56955a" xlink:to="loc_vrdn_AtthemarketOfferingMember_6eb73835-290b-468d-9bc2-093d02da1595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3502c71b-fb75-4fc8-8277-367452676afa" xlink:to="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5575a87-f9ec-4ec4-a1c8-0b01159894d7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9aebef7d-790e-4d1f-8f2f-a295279d0ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9aebef7d-790e-4d1f-8f2f-a295279d0ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_899d4e85-c293-46d2-9527-8e13bde20cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockholdersEquity_899d4e85-c293-46d2-9527-8e13bde20cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f4143a98-b7fa-4ef1-8d1f-67a29d6c0b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f4143a98-b7fa-4ef1-8d1f-67a29d6c0b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87a81079-e6b7-4e17-a751-2dadd25a95b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87a81079-e6b7-4e17-a751-2dadd25a95b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0ba84c7a-7042-4009-9da4-5461a3c25c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0ba84c7a-7042-4009-9da4-5461a3c25c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca2eae2-18cc-43b0-b3e1-7fc2abb8a660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca2eae2-18cc-43b0-b3e1-7fc2abb8a660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97c4f487-645b-46cb-a233-9d4127e310d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97c4f487-645b-46cb-a233-9d4127e310d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a72ad12e-4c20-4e3b-bb4e-85196ca02947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a72ad12e-4c20-4e3b-bb4e-85196ca02947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7344faed-87b2-44db-97a8-f7ba16d27293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7344faed-87b2-44db-97a8-f7ba16d27293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_fd8dabad-b17d-458b-9411-a9ae31b6be50" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_fd8dabad-b17d-458b-9411-a9ae31b6be50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_3a453c1b-9e08-49b7-adbd-eafd4dc0eb58" xlink:href="vrdn-20221231.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_3a453c1b-9e08-49b7-adbd-eafd4dc0eb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1dd93cbb-cc92-4295-98bc-3388a213d1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1dd93cbb-cc92-4295-98bc-3388a213d1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e5603f14-7c4c-4851-bc4f-c81966b76021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e5603f14-7c4c-4851-bc4f-c81966b76021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5042d6ad-fbcb-45ee-9041-b05525e82d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5042d6ad-fbcb-45ee-9041-b05525e82d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4a7b4796-156a-4382-a90b-dfc642ec115e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4a7b4796-156a-4382-a90b-dfc642ec115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8206d482-38cb-4b54-81d6-ea5893a6000d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8206d482-38cb-4b54-81d6-ea5893a6000d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bd01b92f-52f8-453a-b3d9-32bb36156961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bd01b92f-52f8-453a-b3d9-32bb36156961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a7b4a313-b196-4b5f-b868-c7db31cba637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a7b4a313-b196-4b5f-b868-c7db31cba637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d432bf21-8264-48f5-9e6b-3624e8df5723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_NetIncomeLoss_d432bf21-8264-48f5-9e6b-3624e8df5723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e3812400-085f-4cfc-b596-5f97fb77e910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e3812400-085f-4cfc-b596-5f97fb77e910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_58565987-e0b2-4c6d-a674-2c9760b9f74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_StockholdersEquity_58565987-e0b2-4c6d-a674-2c9760b9f74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_453a0c83-381e-495b-b17c-edb01ec0edc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a4e5f7bf-709b-4e10-998a-1af64a449419" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_453a0c83-381e-495b-b17c-edb01ec0edc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8e9116b-ffdf-4b31-85f6-6e4281583cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8e9116b-ffdf-4b31-85f6-6e4281583cd8" xlink:to="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e603bbfd-aa14-4d80-8e76-0ca2a3c5d434" xlink:to="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d0353fba-8987-4081-9b31-f5c4cafcef3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c470c2e9-6209-4acb-8a97-463aa8b3d467" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d0353fba-8987-4081-9b31-f5c4cafcef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4438c558-e335-41b8-a28a-8a9e3fb34dc4" xlink:to="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_3d714a10-4ecb-46aa-a6ea-e643a6deb3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:to="loc_us-gaap_PreferredStockMember_3d714a10-4ecb-46aa-a6ea-e643a6deb3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7a2cee14-1996-42a0-a0be-7d598792373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a636e091-45c4-45a7-8246-26b6dafd6c30" xlink:to="loc_us-gaap_CommonStockMember_7a2cee14-1996-42a0-a0be-7d598792373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ae8289c-e508-49b2-9b1c-28f5f708daa4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PublicOfferingMember_3abb21ca-6725-45a2-96f3-ce6ed0515231" xlink:href="vrdn-20221231.xsd#vrdn_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:to="loc_vrdn_PublicOfferingMember_3abb21ca-6725-45a2-96f3-ce6ed0515231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_0a097cbd-8685-42a0-8cb5-486afea67c28" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1d34e60-2ecb-4cba-89aa-a6536cfb8dac" xlink:to="loc_vrdn_AtthemarketOfferingMember_0a097cbd-8685-42a0-8cb5-486afea67c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8939f73-8632-4aad-b96e-6c730f763c77" xlink:to="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_88873a00-8916-49f5-9668-22c1bd392c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5d57b9d7-b47c-4102-8daf-bdf65aca70e6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_88873a00-8916-49f5-9668-22c1bd392c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9e70fcc7-b7b1-47ea-ac91-cf2e930980d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e70fcc7-b7b1-47ea-ac91-cf2e930980d4" xlink:to="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ad6814cc-40ca-4bf9-9a79-aa28c94afbb3" xlink:to="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8deebfb7-c6a7-4f04-92d9-e46fb54801e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:to="loc_us-gaap_CommonStockMember_8deebfb7-c6a7-4f04-92d9-e46fb54801e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_72c9e216-2824-4e7b-a5c6-5548e8bc4e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3c3849b8-b9e8-40d6-a9e8-9c493941ae20" xlink:to="loc_us-gaap_PreferredStockMember_72c9e216-2824-4e7b-a5c6-5548e8bc4e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3a69d571-e481-4b6d-a8b3-3b32a1341001" xlink:to="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2293cf4-d752-415b-9072-57ab16cb1abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_NetIncomeLoss_b2293cf4-d752-415b-9072-57ab16cb1abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4b24d314-42a5-415c-a9dc-191c5ca968c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4b24d314-42a5-415c-a9dc-191c5ca968c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be22680a-410f-4d75-b09e-4d6315fc936d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_ShareBasedCompensation_be22680a-410f-4d75-b09e-4d6315fc936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b86949f8-09d5-4e7c-96f3-574062eabea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b86949f8-09d5-4e7c-96f3-574062eabea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c29f1035-17e1-4840-9704-ec55e3265e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c29f1035-17e1-4840-9704-ec55e3265e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a0346008-2249-4384-b3a7-6d7e084e9270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a0346008-2249-4384-b3a7-6d7e084e9270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c7c5a61e-0665-4497-bc51-7267a447e0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c7c5a61e-0665-4497-bc51-7267a447e0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_21017c3b-32b3-4718-a4cb-b486c609a566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_21017c3b-32b3-4718-a4cb-b486c609a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_14d4cf1f-6cc7-46bb-9fea-dd97aaab708e" xlink:href="vrdn-20221231.xsd#vrdn_NonCashLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_vrdn_NonCashLeaseExpense_14d4cf1f-6cc7-46bb-9fea-dd97aaab708e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a018ddf-3878-4501-bd58-9b0a29cf9680" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11a0148c-e9a6-406e-b09f-10b16980cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11a0148c-e9a6-406e-b09f-10b16980cdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07ef5eab-168e-414c-8c44-7243e2e963c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07ef5eab-168e-414c-8c44-7243e2e963c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d8d8a68c-b687-44ff-8633-c5f823b8a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d8d8a68c-b687-44ff-8633-c5f823b8a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_f0ebe42d-f997-44c0-aa74-8c986ed2adca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_f0ebe42d-f997-44c0-aa74-8c986ed2adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_160d1f06-d4cf-412e-a241-ee5c6d3091d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78562b24-0d1d-47bf-b73f-747326cc9abe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_160d1f06-d4cf-412e-a241-ee5c6d3091d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_014c191a-b603-4b9d-9875-e078863410b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_688b6d22-98bf-416d-86fe-694896323570" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_014c191a-b603-4b9d-9875-e078863410b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17466f1b-9785-402c-93dc-098705338840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_17466f1b-9785-402c-93dc-098705338840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cf3ab900-96ea-458e-894e-ce41f639f2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cf3ab900-96ea-458e-894e-ce41f639f2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5011110b-da4b-49c7-9797-e213b81ec0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5011110b-da4b-49c7-9797-e213b81ec0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7295096-5a57-4692-89f1-e0af10de1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7295096-5a57-4692-89f1-e0af10de1c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_755a421f-c5de-44ed-af79-2cd1deab2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a9e90ede-7d26-43d7-9fb9-44c640a4e6c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_755a421f-c5de-44ed-af79-2cd1deab2bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_253d8c14-e099-4517-9629-fba8b374c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_253d8c14-e099-4517-9629-fba8b374c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_21c6bc57-b096-46f8-8470-d4e97a864dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_21c6bc57-b096-46f8-8470-d4e97a864dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_997f68a9-3106-4181-acf3-fa449ec0ce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_997f68a9-3106-4181-acf3-fa449ec0ce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_54255e9a-141f-418a-a2f8-569a686a3841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_54255e9a-141f-418a-a2f8-569a686a3841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_dcd01121-64d9-4152-a3ec-f008560c380b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_dcd01121-64d9-4152-a3ec-f008560c380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ae6a1316-5c51-401a-a97f-d1a16792902c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ae6a1316-5c51-401a-a97f-d1a16792902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3527cc42-0943-4df2-8c8b-780cc08cb0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3527cc42-0943-4df2-8c8b-780cc08cb0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b7584a65-2c30-4087-93b0-b92760ce945f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b7584a65-2c30-4087-93b0-b92760ce945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f9fbc2-dd38-40da-aeea-5154a22b3b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e119c7f9-3bc5-41ac-89c4-20e7e0298811" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19f9fbc2-dd38-40da-aeea-5154a22b3b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_999ad650-9e02-451b-ad7b-9baa292b3d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_999ad650-9e02-451b-ad7b-9baa292b3d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb3eb7b6-adef-40de-954c-c99e3c200ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb3eb7b6-adef-40de-954c-c99e3c200ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3412ac7c-c52b-428d-893c-d4b2720bd0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3412ac7c-c52b-428d-893c-d4b2720bd0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cb69829f-563d-432b-a166-bd4762d6e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f8ae928-6d09-47b0-a640-7015762b5ad8" xlink:to="loc_us-gaap_InterestPaidNet_cb69829f-563d-432b-a166-bd4762d6e7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c61bef-4132-49ed-945f-6681119412c2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3210bd78-bb9e-4723-a3e4-d71898cc3f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3210bd78-bb9e-4723-a3e4-d71898cc3f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AmortizationOfStockIssuanceCosts_ed34c5fe-b577-4fe1-8972-164ebb92a8c2" xlink:href="vrdn-20221231.xsd#vrdn_AmortizationOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a02116a0-6e9c-466c-94b4-7f2cdc365e53" xlink:to="loc_vrdn_AmortizationOfStockIssuanceCosts_ed34c5fe-b577-4fe1-8972-164ebb92a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_036e87ec-0316-47cf-a94d-9502c5edbd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_eb8e2477-688d-4d97-afa6-eb8f9cca1ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_036e87ec-0316-47cf-a94d-9502c5edbd17" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_eb8e2477-688d-4d97-afa6-eb8f9cca1ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9f29f2b-0ebf-4f9c-ae01-0d54adbe89db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fe200a9b-a165-4162-a3a1-3edb2bc8bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9f29f2b-0ebf-4f9c-ae01-0d54adbe89db" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fe200a9b-a165-4162-a3a1-3edb2bc8bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COLLABORATIONAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2be65d0a-90e0-4442-91da-16998d85033a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_49503de7-f0d4-4c8e-864d-859cc7618f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2be65d0a-90e0-4442-91da-16998d85033a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_49503de7-f0d4-4c8e-864d-859cc7618f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e8656400-f1d5-463f-b4a4-c7e43c88a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_a1dfa6f8-bb80-4c76-b3ef-0968d37d150d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e8656400-f1d5-463f-b4a4-c7e43c88a0d5" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_a1dfa6f8-bb80-4c76-b3ef-0968d37d150d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f681d775-39d8-4ad3-8fde-23e81361575d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_69936de2-be61-4399-858e-13ba45dae5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f681d775-39d8-4ad3-8fde-23e81361575d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_69936de2-be61-4399-858e-13ba45dae5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES" xlink:type="simple" xlink:href="vrdn-20221231.xsd#ACCRUEDLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dd4c533a-4ef0-4cd5-af44-75ebfa547fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0fa24ec7-b68f-4652-a8a2-4e90882ca1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dd4c533a-4ef0-4cd5-af44-75ebfa547fcb" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0fa24ec7-b68f-4652-a8a2-4e90882ca1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBT" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aed4cf29-c428-4a1c-8940-1a3b940ced05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1014c698-cad4-4c9d-8bd5-bb4d81c3dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aed4cf29-c428-4a1c-8940-1a3b940ced05" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1014c698-cad4-4c9d-8bd5-bb4d81c3dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6320c12e-0af5-439c-8215-76ca322a49fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a02187f1-95e4-4876-bc6a-2110aceb1240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6320c12e-0af5-439c-8215-76ca322a49fc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a02187f1-95e4-4876-bc6a-2110aceb1240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCK" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CAPITALSTOCK"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCK" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ab855fa-8057-4400-8e82-491efa12767e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_48a6eb2b-357c-44d7-8fe8-677784c8316e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ab855fa-8057-4400-8e82-491efa12767e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_48a6eb2b-357c-44d7-8fe8-677784c8316e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#WARRANTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_00e68b24-0e17-4707-b383-3fefd99c790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9888ad81-6ac0-42e7-a5bf-7f7c5f1316dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_00e68b24-0e17-4707-b383-3fefd99c790c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9888ad81-6ac0-42e7-a5bf-7f7c5f1316dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb36ddf8-2fab-44f9-81af-4dc27cb3a547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638633fe-9f7f-4fd6-98e6-3089ccd614d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb36ddf8-2fab-44f9-81af-4dc27cb3a547" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638633fe-9f7f-4fd6-98e6-3089ccd614d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="vrdn-20221231.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6c197ecc-4ced-4c08-84de-3260d5e8cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7131c0a7-9b17-42eb-8d03-1d589532be69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6c197ecc-4ced-4c08-84de-3260d5e8cb3c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7131c0a7-9b17-42eb-8d03-1d589532be69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXES" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_36c429f3-f062-415b-bf19-b9f0db1186df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_dda95921-587f-4982-9394-397c79233903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_36c429f3-f062-415b-bf19-b9f0db1186df" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_dda95921-587f-4982-9394-397c79233903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a85134d2-0680-40ac-9b4c-b5c3170fe688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f42fc7d9-461a-400e-8d7d-e9f94f3b2c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a85134d2-0680-40ac-9b4c-b5c3170fe688" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f42fc7d9-461a-400e-8d7d-e9f94f3b2c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ff5c1b9f-ffff-4764-a067-60954ba544ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ff5c1b9f-ffff-4764-a067-60954ba544ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_GoingConcernPolicyPolicyTextBlock_47d050dd-f084-46dd-9c27-359d11f729a7" xlink:href="vrdn-20221231.xsd#vrdn_GoingConcernPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_vrdn_GoingConcernPolicyPolicyTextBlock_47d050dd-f084-46dd-9c27-359d11f729a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b47a4c17-bbea-4dbc-bbb9-3145eb1f03dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_UseOfEstimates_b47a4c17-bbea-4dbc-bbb9-3145eb1f03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_182c122b-1e7c-4b37-bd6e-9a314cfd77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_182c122b-1e7c-4b37-bd6e-9a314cfd77dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1a20c213-d863-431b-a15a-df9b5fdd5978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1a20c213-d863-431b-a15a-df9b5fdd5978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_b393952f-c4e6-4162-ab94-d920ab5b742e" xlink:href="vrdn-20221231.xsd#vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_b393952f-c4e6-4162-ab94-d920ab5b742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d6a3a3c1-40c0-4ac5-a8c6-96f58d9bd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d6a3a3c1-40c0-4ac5-a8c6-96f58d9bd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f786bf79-8dfc-4108-9a4e-20d80e15df96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f786bf79-8dfc-4108-9a4e-20d80e15df96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7d5f0aae-0f89-4edd-a916-a76dcacf2ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7d5f0aae-0f89-4edd-a916-a76dcacf2ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f31238c2-8c37-47a1-b87f-312e0f8d2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f31238c2-8c37-47a1-b87f-312e0f8d2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4c91c15b-1523-4fb5-b8fb-f2749710bd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4c91c15b-1523-4fb5-b8fb-f2749710bd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_953fad4d-5c1e-418f-b79f-06b797d0013f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_953fad4d-5c1e-418f-b79f-06b797d0013f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a6466433-89ea-4fe6-bd24-927abf90f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a6466433-89ea-4fe6-bd24-927abf90f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_395931ea-61ac-458c-b046-27443900da49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_DebtPolicyTextBlock_395931ea-61ac-458c-b046-27443900da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_961430fb-14e7-49f5-931f-70a1752ad0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_961430fb-14e7-49f5-931f-70a1752ad0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0b4f7f4b-df2d-482a-8ed6-d0ccb056c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0b4f7f4b-df2d-482a-8ed6-d0ccb056c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c7290ffc-2abb-4661-a25e-b98ab8c3a581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c7290ffc-2abb-4661-a25e-b98ab8c3a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_11b05c9f-3343-4b7e-8490-649eea38a211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_11b05c9f-3343-4b7e-8490-649eea38a211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d93fc8b2-d9cf-40c0-b437-43ec4070d59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d93fc8b2-d9cf-40c0-b437-43ec4070d59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_WarrantsPolicyPolicyTextBlock_2c06202c-899c-456d-a53c-80182b99f086" xlink:href="vrdn-20221231.xsd#vrdn_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_vrdn_WarrantsPolicyPolicyTextBlock_2c06202c-899c-456d-a53c-80182b99f086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_65f732be-6dce-436d-9a38-efc718d10aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_65f732be-6dce-436d-9a38-efc718d10aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb5ed287-f534-43da-81a4-0cbe3ad56928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74295fce-b6a7-419b-816c-af4f4d717f9d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb5ed287-f534-43da-81a4-0cbe3ad56928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_158b6b40-d601-489d-b9bb-46de49cc39c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_17e2835c-7cff-43c4-9339-04b863db55ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_158b6b40-d601-489d-b9bb-46de49cc39c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_17e2835c-7cff-43c4-9339-04b863db55ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e05667b7-99b2-40ad-a7f6-ffd0ec22fbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_158b6b40-d601-489d-b9bb-46de49cc39c4" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e05667b7-99b2-40ad-a7f6-ffd0ec22fbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_73c76441-cc06-432e-b68e-9c66f828176a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4ff80aad-0dee-4215-b294-c5f3d740877e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_73c76441-cc06-432e-b68e-9c66f828176a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4ff80aad-0dee-4215-b294-c5f3d740877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#ACCRUEDLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4d084e40-e8c7-454d-be30-b3b019bad4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4fca6054-cf7a-4d75-a528-2cd61ea1ac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4d084e40-e8c7-454d-be30-b3b019bad4b2" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4fca6054-cf7a-4d75-a528-2cd61ea1ac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f68c1100-3444-48fb-a32e-aa1c65c3cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d6c6333f-28df-4e94-a90d-d6b5f8600c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f68c1100-3444-48fb-a32e-aa1c65c3cb1d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d6c6333f-28df-4e94-a90d-d6b5f8600c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_018d32a7-fcf1-40e0-9764-b8001db31b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f68c1100-3444-48fb-a32e-aa1c65c3cb1d" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_018d32a7-fcf1-40e0-9764-b8001db31b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_663621ad-40de-4666-bd8b-3c831c185855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe31cc9d-5711-4dab-9488-178553c6935f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_663621ad-40de-4666-bd8b-3c831c185855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe31cc9d-5711-4dab-9488-178553c6935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#WARRANTSTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a70450a3-3741-48dd-b902-a9d01993d811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b03b490c-59fa-4c80-a66c-e7c7f1374741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a70450a3-3741-48dd-b902-a9d01993d811" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b03b490c-59fa-4c80-a66c-e7c7f1374741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_107f6fb6-ae0f-43db-a29b-df437b01807d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5d405062-48b5-4946-94f0-f290d8193ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_107f6fb6-ae0f-43db-a29b-df437b01807d" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5d405062-48b5-4946-94f0-f290d8193ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_20bbd196-4b9c-4272-93ae-88b242456c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_107f6fb6-ae0f-43db-a29b-df437b01807d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_20bbd196-4b9c-4272-93ae-88b242456c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5be9f8ed-9d8c-4232-8c35-d5812c38ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_107f6fb6-ae0f-43db-a29b-df437b01807d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5be9f8ed-9d8c-4232-8c35-d5812c38ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6a513c33-ebb9-4579-8fd8-cb0de0abda9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_107f6fb6-ae0f-43db-a29b-df437b01807d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6a513c33-ebb9-4579-8fd8-cb0de0abda9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_05c33768-8ed9-4254-a2ee-38c71cbd99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_551b55e7-0c81-407d-83e7-4c706837a8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05c33768-8ed9-4254-a2ee-38c71cbd99d2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_551b55e7-0c81-407d-83e7-4c706837a8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a4b2cd25-d49d-4712-b86b-0e0bd081afcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_37f72c34-58a2-459b-9c53-1fb7523b10ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a4b2cd25-d49d-4712-b86b-0e0bd081afcb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_37f72c34-58a2-459b-9c53-1fb7523b10ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0107fc72-7b7e-416a-acc1-7277e9b8c204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a4b2cd25-d49d-4712-b86b-0e0bd081afcb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0107fc72-7b7e-416a-acc1-7277e9b8c204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e36db930-3013-4599-833b-75451929cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e56266da-6ec8-41b0-9436-6bee6bc65019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e36db930-3013-4599-833b-75451929cd36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e56266da-6ec8-41b0-9436-6bee6bc65019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ff708433-cb17-4c0d-a56c-bf074b31e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e36db930-3013-4599-833b-75451929cd36" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ff708433-cb17-4c0d-a56c-bf074b31e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a4555762-c32d-4644-9d0c-a50952ece8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4555762-c32d-4644-9d0c-a50952ece8a1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:to="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b171b8bd-15fc-45ae-928b-481328f8a1d1" xlink:to="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76e21ce6-5923-4df3-a0c0-b40e4fcd3bdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:to="loc_srt_MinimumMember_76e21ce6-5923-4df3-a0c0-b40e4fcd3bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74b3d658-2725-4dd9-9792-40d5def6f931" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99f3e564-b384-4777-a1ff-60111fe7c341" xlink:to="loc_srt_MaximumMember_74b3d658-2725-4dd9-9792-40d5def6f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7c1e7b3d-5413-43ed-a6dc-60edba203266" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0f042091-c72f-40d1-9427-aacadaa02a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0f042091-c72f-40d1-9427-aacadaa02a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77d2b37e-5dbb-41a6-8567-0b190803cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77d2b37e-5dbb-41a6-8567-0b190803cc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e4fcd0fb-b9c3-4f77-9ad9-8723d9a0ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e4fcd0fb-b9c3-4f77-9ad9-8723d9a0ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8db02d8a-28ea-4156-b178-d3bd5430c099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8db02d8a-28ea-4156-b178-d3bd5430c099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_7d332d20-d478-4ca8-81d8-edb4c7da6b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_7d332d20-d478-4ca8-81d8-edb4c7da6b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_14064f22-2f94-4d1a-ba9d-e6f805658108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7d9d358-120c-4b13-abcb-a229add0670d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_14064f22-2f94-4d1a-ba9d-e6f805658108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COLLABORATIONAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b98d97bc-164b-40bc-aff7-830c1c79b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b98d97bc-164b-40bc-aff7-830c1c79b3ab" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c51f0c8d-0bce-4a35-97dc-adb7882a3604" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember_91417037-073f-4b71-9fdc-0612f2848884" xlink:href="vrdn-20221231.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:to="loc_vrdn_ZenasBioPharmaMember_91417037-073f-4b71-9fdc-0612f2848884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember_45cab051-5467-41ee-ab87-5c97b307fc70" xlink:href="vrdn-20221231.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_387dbf86-8082-419a-9738-b22b08720e2a" xlink:to="loc_vrdn_ParagonTherapeuticsMember_45cab051-5467-41ee-ab87-5c97b307fc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_abde4226-a1ef-46c5-b6ee-53208b14e6e5" xlink:to="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember_b2b12307-44e7-46e4-a540-13616e308184" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfe1bad5-52c9-49ec-bb20-816e643c94a0" xlink:to="loc_vrdn_CollaborationRevenueMember_b2b12307-44e7-46e4-a540-13616e308184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_047fdccf-ba18-457f-9354-13fb20c10797" xlink:to="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember_ca3498bf-dfbe-4f6e-96e0-bd76d86a0605" xlink:href="vrdn-20221231.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1b1b4a05-ccb7-4dcb-9b12-631e25b95b8b" xlink:to="loc_vrdn_FairmountFundsManagementMember_ca3498bf-dfbe-4f6e-96e0-bd76d86a0605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0106295-d18b-4530-bc2d-99d6c01d79a1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2227c89-39a9-4e1e-918d-105eaade70de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c2227c89-39a9-4e1e-918d-105eaade70de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_04cf415e-2490-41f7-86a1-e56e5cc8c366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_04cf415e-2490-41f7-86a1-e56e5cc8c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_154614bc-2781-49e7-9274-ebb49caf71ff" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_154614bc-2781-49e7-9274-ebb49caf71ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_2c52abf5-ebde-4f87-874e-4e41fa69e1e8" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_2c52abf5-ebde-4f87-874e-4e41fa69e1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a97b36e-8d66-456f-b0b9-67bebbb9bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b584c718-0b66-47cd-a9f7-5f9377608498" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a97b36e-8d66-456f-b0b9-67bebbb9bfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e9913c8-00f3-4a95-bf8d-4c99818f3e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e9913c8-00f3-4a95-bf8d-4c99818f3e54" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d9a5edf-08f7-4b07-b4e5-6d8d5510ae88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d16c4f43-bb4d-41be-b78f-5dc5a2be8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d16c4f43-bb4d-41be-b78f-5dc5a2be8d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_62ba05aa-a565-430d-a091-5cf369a6f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_62ba05aa-a565-430d-a091-5cf369a6f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c216014d-8de3-4e2a-9cd6-1bdf39db4fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c216014d-8de3-4e2a-9cd6-1bdf39db4fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_9c42a71b-bfce-4011-a4b4-f1ef0eac26e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85c66968-0dc0-4a58-b188-5a06e5c398ea" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_9c42a71b-bfce-4011-a4b4-f1ef0eac26e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_04421de3-a5bd-4025-a367-c0f25479171a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27bbe38d-c561-454f-9a99-8231b0599e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27bbe38d-c561-454f-9a99-8231b0599e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6a6a223-6380-41ea-a5a2-15b8f5387cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6a6a223-6380-41ea-a5a2-15b8f5387cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf148d80-cafb-4cbe-a734-c71b6bd831b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf148d80-cafb-4cbe-a734-c71b6bd831b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34d6a0f9-ec3a-4014-9f32-e892d37cb9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e8faa00-e074-4b75-a85e-d7a3ffafd6b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34d6a0f9-ec3a-4014-9f32-e892d37cb9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc600d02-9880-4169-9863-2c8a87ee589e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_32003758-3910-4193-8cbd-171f6b83bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc600d02-9880-4169-9863-2c8a87ee589e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_32003758-3910-4193-8cbd-171f6b83bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_879d1a96-a968-4382-ba41-1c92fca5c389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc600d02-9880-4169-9863-2c8a87ee589e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_879d1a96-a968-4382-ba41-1c92fca5c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ed0d1ced-809b-4990-80a6-54aa19cc4211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ed0d1ced-809b-4990-80a6-54aa19cc4211" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e659eb42-993a-4d8b-987e-bfc9043f4ac5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1e51ffe6-c10c-4764-8c51-8506a251ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_200f7f8a-b2f0-4963-9053-22b56bf2766a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1e51ffe6-c10c-4764-8c51-8506a251ea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e9cf9b2d-9665-4552-83d2-795527f7fd51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_61c97eac-8130-4b0d-9529-2cd9415ff40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_61c97eac-8130-4b0d-9529-2cd9415ff40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dceebac1-b17f-45c3-a0c4-0f08b0ba8128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dceebac1-b17f-45c3-a0c4-0f08b0ba8128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad31f637-46e0-436e-b8a0-fd81c15730ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59fd7a78-a99f-4ead-a3e9-0aa7581b4bf4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad31f637-46e0-436e-b8a0-fd81c15730ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9184cee8-0c95-45e2-bd4d-4e224f56f10a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_492d6f12-aafa-4af3-b853-d1590e317f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_492d6f12-aafa-4af3-b853-d1590e317f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_77bcdbbb-45ea-4e1c-8ada-da8948ac5aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_77bcdbbb-45ea-4e1c-8ada-da8948ac5aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2c6d7e13-2b21-40e6-b33f-8df5271f4d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2c6d7e13-2b21-40e6-b33f-8df5271f4d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_0571fe84-4f5a-4dd5-a336-25d059debc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_edea3c46-a1c1-40b5-b192-5c9e69d517b5" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_0571fe84-4f5a-4dd5-a336-25d059debc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_454cab7d-8453-43fb-943f-e755eaa12831" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_06d1d942-9ffd-4e03-9942-0920523860fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea41303c-7623-440f-9a7f-f16f782c9ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6ea3064a-bb9c-4d6a-9cf8-9a2d3fb95276" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea41303c-7623-440f-9a7f-f16f782c9ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c15e142c-d5c3-42ec-930e-e3546271de81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_d5c3dc1b-73d1-48f7-830b-3068547893af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c15e142c-d5c3-42ec-930e-e3546271de81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_83cba4f6-f27c-40b6-bbda-4b85642ad5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f9f2f09a-5118-419f-8ae1-513e21e87ad6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_83cba4f6-f27c-40b6-bbda-4b85642ad5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_af0dd695-a594-45c8-980f-1307fb3bbd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_af0dd695-a594-45c8-980f-1307fb3bbd9f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f7a827f-f1b7-4025-94fe-45505676c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d178c158-5b83-4be1-a63f-f22298c07f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_EquipmentMember_d178c158-5b83-4be1-a63f-f22298c07f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f08f6844-146c-4b98-8211-64889361f53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f08f6844-146c-4b98-8211-64889361f53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_01168537-5154-4cc5-9b5d-236f9debfa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_01168537-5154-4cc5-9b5d-236f9debfa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d240d1f0-2286-401b-aaa5-c74e03e8f175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1450b63b-bb97-4490-b9c3-f0342d8482d8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d240d1f0-2286-401b-aaa5-c74e03e8f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c73e2639-7073-4012-a4d5-1c03ca3c62b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d26171d9-e4f4-497b-81c1-0fc7b861b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d26171d9-e4f4-497b-81c1-0fc7b861b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f620b89-67e6-4904-8c25-e32d055f9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f620b89-67e6-4904-8c25-e32d055f9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6de7e030-e3a0-4ccb-9f0d-fc56c4d33dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f8f04c67-8474-4c7c-aedf-8e60557080a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6de7e030-e3a0-4ccb-9f0d-fc56c4d33dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63d602bd-e60f-4edb-b9c9-e601972bad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_9c650261-3321-46d7-89d2-84b5338a10db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63d602bd-e60f-4edb-b9c9-e601972bad3c" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_9c650261-3321-46d7-89d2-84b5338a10db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_0a27805f-e37f-4a1a-b29f-50dba7bf2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63d602bd-e60f-4edb-b9c9-e601972bad3c" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_0a27805f-e37f-4a1a-b29f-50dba7bf2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_2f9a1dad-c124-458d-8e1e-38afe35c6339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63d602bd-e60f-4edb-b9c9-e601972bad3c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_2f9a1dad-c124-458d-8e1e-38afe35c6339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e36a3c26-5e2e-4d85-8c08-7f3fc1dce7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63d602bd-e60f-4edb-b9c9-e601972bad3c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e36a3c26-5e2e-4d85-8c08-7f3fc1dce7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_504375fa-e99d-40b8-8faa-1ce46783e309" xlink:href="vrdn-20221231.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_504375fa-e99d-40b8-8faa-1ce46783e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8efa6334-0e41-4c55-b8d0-436d7ce33e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8efa6334-0e41-4c55-b8d0-436d7ce33e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f35b0f00-f074-4b10-bef3-01cfd5382753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f35b0f00-f074-4b10-bef3-01cfd5382753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent_71be4c1a-f7ee-4041-8585-bdfb2d5d02ba" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_vrdn_AccruedLegalFeesCurrent_71be4c1a-f7ee-4041-8585-bdfb2d5d02ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_084d2eeb-1940-4a40-b1b5-35d463a5bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_084d2eeb-1940-4a40-b1b5-35d463a5bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_805d0cf4-359b-47df-96db-215a87cef75e" xlink:href="vrdn-20221231.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_805d0cf4-359b-47df-96db-215a87cef75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a85ba838-e6f5-4153-b947-b22c71f53483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a85ba838-e6f5-4153-b947-b22c71f53483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e988b0ac-e354-45b8-bbe2-698a43a7d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e988b0ac-e354-45b8-bbe2-698a43a7d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_375f1135-0cbc-480f-a42b-4b7880d976d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13927a40-7ef7-446f-ae41-63a7a1654d87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_375f1135-0cbc-480f-a42b-4b7880d976d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6248b598-02dd-4159-b89e-da666dfedce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6248b598-02dd-4159-b89e-da666dfedce3" xlink:to="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_08ee7554-683f-46db-8b62-2bc372e4c893" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_a7efc1db-5fd3-445b-a6e4-e40cfe485700" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e0eb774-9b33-4dbb-9279-095ebcf4be45" xlink:to="loc_vrdn_HerculesTermLoanMember_a7efc1db-5fd3-445b-a6e4-e40cfe485700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e42d51-536a-4df7-b6ab-862a0e26fa17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1cf14aac-6c33-4a3e-9cb4-4dde2c4cec87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1274748a-59c1-445c-857f-b96f2a037116" xlink:to="loc_us-gaap_SecuredDebtMember_1cf14aac-6c33-4a3e-9cb4-4dde2c4cec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_91e1d8dc-3959-4f2c-a05f-05d112b09a4c" xlink:to="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_34ed8fbf-6116-4548-bd26-4b5775d05645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_854539fb-0525-4204-bcc5-c21ffa537a63" xlink:to="loc_us-gaap_PrimeRateMember_34ed8fbf-6116-4548-bd26-4b5775d05645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0eff7cd2-2f9e-4e9c-a0a1-e238efaf88be" xlink:to="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a9ba3802-b16c-4feb-adb0-5084f1070feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a9ba3802-b16c-4feb-adb0-5084f1070feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches_4689afdd-a2ee-46c0-a637-b0cda67c92b1" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentNumberOfTranches_4689afdd-a2ee-46c0-a637-b0cda67c92b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_87bd73e5-6a42-487e-80a5-505bc0311393" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_87bd73e5-6a42-487e-80a5-505bc0311393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_6f2624e0-9f0a-4ee9-b55b-f137f8d15913" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_6f2624e0-9f0a-4ee9-b55b-f137f8d15913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_83b8c897-6f85-4062-ae68-a7c4ffeb805c" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_83b8c897-6f85-4062-ae68-a7c4ffeb805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_10d535f7-0f55-4bbd-8eee-7a69bce992a2" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_10d535f7-0f55-4bbd-8eee-7a69bce992a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_358cbd34-a0c2-4cf7-a94c-48eb209251d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_358cbd34-a0c2-4cf7-a94c-48eb209251d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9084fb4d-9ae2-45f3-b13a-d51f1d00f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9084fb4d-9ae2-45f3-b13a-d51f1d00f14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum_d87965d3-3b48-4184-93a1-058c75059a97" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentInterestRateMaximum_d87965d3-3b48-4184-93a1-058c75059a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_PrincipalAmountTermFee_e50b4042-4aaa-4180-a229-9edd1af95624" xlink:href="vrdn-20221231.xsd#vrdn_PrincipalAmountTermFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_PrincipalAmountTermFee_e50b4042-4aaa-4180-a229-9edd1af95624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8b778f64-77c2-4102-b034-929821d4b913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8b778f64-77c2-4102-b034-929821d4b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_78afac89-ea67-4a59-8609-48bd04f3c9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_78afac89-ea67-4a59-8609-48bd04f3c9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee_c83d6ea4-b370-4609-8150-ba2a4597e1d8" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentFacilityFee_c83d6ea4-b370-4609-8150-ba2a4597e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses_ce575818-fece-48cc-8edb-634dec607775" xlink:href="vrdn-20221231.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_vrdn_DebtInstrumentOtherExpenses_ce575818-fece-48cc-8edb-634dec607775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_cb4d6f5c-4708-4f30-a33d-d4dc934e1380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_cb4d6f5c-4708-4f30-a33d-d4dc934e1380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_df569f62-c772-430f-8edb-019de392d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72447309-dcfd-4aa1-a902-8596cfd41763" xlink:to="loc_us-gaap_InterestExpense_df569f62-c772-430f-8edb-019de392d9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19dc1659-226e-45bb-b8a7-83daea060757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19dc1659-226e-45bb-b8a7-83daea060757" xlink:to="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:to="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4b137ecd-6d5a-4346-a29e-ae916eb6cd0e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_9d03a8cd-3c1d-4471-b04f-85e62ab1de87" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376d9bb8-b1e0-428a-a9ba-0650615dbb15" xlink:to="loc_vrdn_HerculesTermLoanMember_9d03a8cd-3c1d-4471-b04f-85e62ab1de87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969f657b-d6ac-430c-8479-84e7bafc8d25" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dc961c0f-9926-4149-88e1-0123ccba4804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d009b018-6336-48ab-8dda-ec3c826d4dd2" xlink:to="loc_us-gaap_SecuredDebtMember_dc961c0f-9926-4149-88e1-0123ccba4804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0fafc083-6329-45bd-b209-ce3bd7e8c992" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_06759611-db67-4e6d-b22a-fed21d95df18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_06759611-db67-4e6d-b22a-fed21d95df18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_89bfd445-7b37-4971-937e-aa2ff156199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_89bfd445-7b37-4971-937e-aa2ff156199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_95141c29-4d0a-46eb-8d64-5f73891a1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5f90dee-59cc-4435-81ef-7e8c0386151c" xlink:to="loc_us-gaap_LongTermDebt_95141c29-4d0a-46eb-8d64-5f73891a1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_380d9281-2ef0-4f82-b3fe-5378f7688a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_380d9281-2ef0-4f82-b3fe-5378f7688a22" xlink:to="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:to="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_26cae46d-5759-46e3-b7ad-d5934619d19f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_19b6833d-1777-4c66-b473-a4ab7a26b15e" xlink:href="vrdn-20221231.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42825a75-eea5-40fc-a78e-587f92bf506f" xlink:to="loc_vrdn_HerculesTermLoanMember_19b6833d-1777-4c66-b473-a4ab7a26b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f84d17c-5108-417e-a385-605148d27e62" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7eb9f5cf-f5e2-449d-ad46-b7fb2c2789fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1d894940-3e2f-4c26-b06d-1296bff854e7" xlink:to="loc_us-gaap_SecuredDebtMember_7eb9f5cf-f5e2-449d-ad46-b7fb2c2789fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e39b35d2-0f95-4acd-9ae4-f7a138d52adb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7cb4ad96-439f-4571-beb4-820409db7aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7cb4ad96-439f-4571-beb4-820409db7aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a5421b3-8113-4f64-8c28-71b23dbac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a5421b3-8113-4f64-8c28-71b23dbac1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f7823a6-bac5-4970-8cac-9af116e0439a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f7823a6-bac5-4970-8cac-9af116e0439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9e2a9aa5-19ed-49e8-ac2d-4a3babed7471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9e2a9aa5-19ed-49e8-ac2d-4a3babed7471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30a5122d-1352-4375-9e51-71d5c4ebfc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11364c17-4a09-4f7d-b072-dcf3916317ec" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30a5122d-1352-4375-9e51-71d5c4ebfc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a58807f-200c-448a-9927-140d458eca6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a58807f-200c-448a-9927-140d458eca6a" xlink:to="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_667f9928-fbb3-4c73-9f14-3412ab3e7b52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember_29fc5bee-6616-4f10-a65b-97f2072881eb" xlink:href="vrdn-20221231.xsd#vrdn_ImmunoGenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:to="loc_vrdn_ImmunoGenIncMember_29fc5bee-6616-4f10-a65b-97f2072881eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_XencorIncMember_f53b92e8-98f6-40f2-bc4c-4ef58a459067" xlink:href="vrdn-20221231.xsd#vrdn_XencorIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51aa3f74-2844-4928-8121-a383f2426b17" xlink:to="loc_vrdn_XencorIncMember_f53b92e8-98f6-40f2-bc4c-4ef58a459067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:href="vrdn-20221231.xsd#vrdn_CommitmentsandContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesTable_524f373e-26bd-4d65-912a-eff67c489acc" xlink:to="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_9d38c5cf-df03-413f-b6a3-632cfa79c3d4" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_9d38c5cf-df03-413f-b6a3-632cfa79c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_bb144e81-de42-4f8b-9268-175113ebefd0" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_bb144e81-de42-4f8b-9268-175113ebefd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_4e412acc-fc30-4a0c-8033-d5208c4cef20" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_4e412acc-fc30-4a0c-8033-d5208c4cef20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_0eef9222-8e79-42e2-aa25-50fb8ac99db6" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm_0eef9222-8e79-42e2-aa25-50fb8ac99db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_92470adc-5efc-44ae-b47e-76c299e8ca1b" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_92470adc-5efc-44ae-b47e-76c299e8ca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_4aa308e8-b4de-49cc-adce-f2af39fe2dbc" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_4aa308e8-b4de-49cc-adce-f2af39fe2dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_3aac244e-910e-4ff0-8da4-f5a4d89d0a49" xlink:href="vrdn-20221231.xsd#vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum_3aac244e-910e-4ff0-8da4-f5a4d89d0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_b2a125dd-5ce4-4c2a-ae5d-b7f3cfa9bce3" xlink:href="vrdn-20221231.xsd#vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum_b2a125dd-5ce4-4c2a-ae5d-b7f3cfa9bce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_a3b383ac-d741-4b6c-a8a2-3dfcfc024f1d" xlink:href="vrdn-20221231.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_a3b383ac-d741-4b6c-a8a2-3dfcfc024f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a581ba4a-c0c9-40f8-9cbb-6c9316e9395d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a581ba4a-c0c9-40f8-9cbb-6c9316e9395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_36da01d9-1096-4598-9044-cdadfab8bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_36da01d9-1096-4598-9044-cdadfab8bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_98a919cf-d50d-4276-bbe8-a570ddc4eb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_98a919cf-d50d-4276-bbe8-a570ddc4eb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8082de64-19e5-4584-b04f-4020593c8c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8082de64-19e5-4584-b04f-4020593c8c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4059b91d-e28f-43b9-bb26-4ac50c96db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4059b91d-e28f-43b9-bb26-4ac50c96db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExpanded_b968ebc5-3b2e-4f08-8af1-39b454ab7d27" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExpanded"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceExpanded_b968ebc5-3b2e-4f08-8af1-39b454ab7d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceTerminated_4d02aa70-82be-44ea-9404-f050204141a1" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceTerminated"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceTerminated_4d02aa70-82be-44ea-9404-f050204141a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AreaOfOfficeSpaceExtension_d18ef015-68e9-407b-931b-9487e5ce482c" xlink:href="vrdn-20221231.xsd#vrdn_AreaOfOfficeSpaceExtension"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_AreaOfOfficeSpaceExtension_d18ef015-68e9-407b-931b-9487e5ce482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent_9f9d0d5e-91e7-4511-9a57-47a651542ba7" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_OperatingLeaseAnnualBaseRent_9f9d0d5e-91e7-4511-9a57-47a651542ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f29d7fd-5a3e-4a48-ac1f-97b0f495f472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f29d7fd-5a3e-4a48-ac1f-97b0f495f472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a8a2626-c69f-42ba-ae0f-feceb5cd64b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a8a2626-c69f-42ba-ae0f-feceb5cd64b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c320871-2ab4-4f64-afc9-59fd63fd7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c320871-2ab4-4f64-afc9-59fd63fd7679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6db31ed7-67fc-44c9-85c4-b8f5ba91638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6db31ed7-67fc-44c9-85c4-b8f5ba91638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c7701a5-0d28-496b-95a3-25fe918fe890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c7701a5-0d28-496b-95a3-25fe918fe890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense_60b6c36c-5cf4-4f6a-9369-a2a0b7bc6a25" xlink:href="vrdn-20221231.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_CommitmentsandContingenciesLineItems_992ba79f-57d4-444c-b9dc-64c7677bdc65" xlink:to="loc_vrdn_OperatingLeasesOperatingExpense_60b6c36c-5cf4-4f6a-9369-a2a0b7bc6a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6734338d-a183-405b-b01c-212524b0d53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6734338d-a183-405b-b01c-212524b0d53a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2279d042-bbba-4778-bfb9-8ea2f5d30a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2279d042-bbba-4778-bfb9-8ea2f5d30a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b141657b-a466-40ab-ad76-6e9d3443665e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b141657b-a466-40ab-ad76-6e9d3443665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fea22a9f-e793-4c03-9b62-21d42a09af22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fea22a9f-e793-4c03-9b62-21d42a09af22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_11e4887f-10f2-454d-8938-802c7559a543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_11e4887f-10f2-454d-8938-802c7559a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_824eac67-73a2-4a91-860f-e0d5ef98598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_824eac67-73a2-4a91-860f-e0d5ef98598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cbea7c40-4b5b-4084-bcbf-93c7e14719ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cbea7c40-4b5b-4084-bcbf-93c7e14719ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ee9b48d9-9287-46d0-a24d-4101d862e093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5621cde3-2df2-44f8-836e-b71e1f332e20" xlink:to="loc_us-gaap_OperatingLeaseLiability_ee9b48d9-9287-46d0-a24d-4101d862e093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="vrdn-20221231.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#CAPITALSTOCKDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6a9fcb99-5835-4841-96e8-be9ab1b4b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6a9fcb99-5835-4841-96e8-be9ab1b4b9b1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f093064-1d34-484d-8fa6-baced1e4c62e" xlink:to="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9d4c6d85-4620-4526-a90f-2a041b0d5ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_90dea118-3b58-4ff2-a3f0-448919956719" xlink:to="loc_us-gaap_CommonStockMember_9d4c6d85-4620-4526-a90f-2a041b0d5ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00b83303-7d97-4a68-993d-a4e06310df2a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_50c78788-093a-4686-842e-40ba25537fc2" xlink:href="vrdn-20221231.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_AtthemarketOfferingMember_50c78788-093a-4686-842e-40ba25537fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2022PublicStockOfferingMember_1e604436-8544-4aca-bb7c-5c804690f26e" xlink:href="vrdn-20221231.xsd#vrdn_A2022PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_A2022PublicStockOfferingMember_1e604436-8544-4aca-bb7c-5c804690f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3ecbc982-f174-4ca0-9846-ca6ede13078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3ecbc982-f174-4ca0-9846-ca6ede13078e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2021PublicStockOfferingMember_f947e325-2d52-44cb-adff-d9d5df122004" xlink:href="vrdn-20221231.xsd#vrdn_A2021PublicStockOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_A2021PublicStockOfferingMember_f947e325-2d52-44cb-adff-d9d5df122004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AspireStockPurchaseAgreementMember_e48ac5c0-7ffa-49f5-aa3c-5e46eed15210" xlink:href="vrdn-20221231.xsd#vrdn_AspireStockPurchaseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81eb8ca5-6fbf-402a-9152-dd42be11cd2a" xlink:to="loc_vrdn_AspireStockPurchaseAgreementMember_e48ac5c0-7ffa-49f5-aa3c-5e46eed15210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d5c23896-5377-46e6-90d0-866aea1d6e2c" xlink:to="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_126bdabc-d955-4381-be56-d33a1ba673fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_126bdabc-d955-4381-be56-d33a1ba673fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5219b015-53e9-45ad-bc40-7762bc67fb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f16e1b4a-f74e-49a1-9af7-054c2e821ca9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5219b015-53e9-45ad-bc40-7762bc67fb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d46fd411-80c3-47e4-b14e-776bb9e69973" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember_a16cf920-8c47-4924-a3da-e1a2cffcf7d7" xlink:href="vrdn-20221231.xsd#vrdn_ViridianMergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_f0775dce-17f3-4c84-9733-c00b37a737e5" xlink:to="loc_vrdn_ViridianMergerMember_a16cf920-8c47-4924-a3da-e1a2cffcf7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_af7768f4-7f8c-43a4-963e-f19a63a7f249" xlink:to="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6dd1bd57-c7df-476a-8bc3-523ac556df86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:to="loc_srt_MinimumMember_6dd1bd57-c7df-476a-8bc3-523ac556df86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33e82532-5ceb-4f0a-8aa1-54d0dbdf4bf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_25b83cb9-d5d8-4d8c-b5f3-d834a78fa180" xlink:to="loc_srt_MaximumMember_33e82532-5ceb-4f0a-8aa1-54d0dbdf4bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7757040-91b5-4a92-8876-b3cc97ce91b0" xlink:to="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized_6469a368-8d6c-4160-ae47-73ecf6e738be" xlink:href="vrdn-20221231.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_CapitalStockSharesAuthorized_6469a368-8d6c-4160-ae47-73ecf6e738be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13d55f13-f1e9-4598-8e8a-3506353e4ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13d55f13-f1e9-4598-8e8a-3506353e4ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9b7b01c4-5631-41f4-9101-b689713b591b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9b7b01c4-5631-41f4-9101-b689713b591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb59aea-9ab0-420e-be20-a3f3f9b9c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb59aea-9ab0-420e-be20-a3f3f9b9c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd46eae2-93de-425b-b2c6-f4c432d3ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd46eae2-93de-425b-b2c6-f4c432d3ec51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVoteperShare_13e3125d-d089-4ba7-88b5-095f5e61526b" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockVoteperShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_CommonStockVoteperShare_13e3125d-d089-4ba7-88b5-095f5e61526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_69776db6-cfc4-4b48-85f5-cae585631de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_69776db6-cfc4-4b48-85f5-cae585631de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d4017095-6af2-4951-9063-a16c68dac020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d4017095-6af2-4951-9063-a16c68dac020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf2d21e0-6ee3-4fdd-ad1d-05814e1b1c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bf2d21e0-6ee3-4fdd-ad1d-05814e1b1c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_253ff01f-77be-4d6f-a707-552470c3009a" xlink:href="vrdn-20221231.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_253ff01f-77be-4d6f-a707-552470c3009a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice_8ab84d30-0ce1-4f14-9261-e57dfe21e8f6" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockWeightedAverageSharePrice_8ab84d30-0ce1-4f14-9261-e57dfe21e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1619f521-b831-4685-b2f7-cccb35faa11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1619f521-b831-4685-b2f7-cccb35faa11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_1c43f7d7-4358-455c-8451-aec6c815ebb3" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold_1c43f7d7-4358-455c-8451-aec6c815ebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockTerm_d3714d1b-527c-4f97-b605-9bb788ecd38b" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockTerm_d3714d1b-527c-4f97-b605-9bb788ecd38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_63830945-50cd-48a4-8f06-0a03d3829eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_63830945-50cd-48a4-8f06-0a03d3829eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_11ad6a87-f8a2-4de0-803f-360c1a55527c" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased_11ad6a87-f8a2-4de0-803f-360c1a55527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_daaf4ab1-eb2f-4e96-97e9-2b4e44327073" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices_daaf4ab1-eb2f-4e96-97e9-2b4e44327073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_f91588e6-7ad3-4601-b37a-d756647bea67" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold_f91588e6-7ad3-4601-b37a-d756647bea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_25e30ccb-2473-4bc9-8998-182d3d051084" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent_25e30ccb-2473-4bc9-8998-182d3d051084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_0f4b6091-3dcc-4f8b-83de-8959aeba335c" xlink:href="vrdn-20221231.xsd#vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice_0f4b6091-3dcc-4f8b-83de-8959aeba335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_6f6fce75-05ca-42f0-949d-60a8fb9fc097" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_6f6fce75-05ca-42f0-949d-60a8fb9fc097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f41f1a7e-9343-49dc-bb7b-ca7b94623e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f41f1a7e-9343-49dc-bb7b-ca7b94623e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f79fc1d4-9d09-481d-ad3b-d549d1a04f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_204342f5-9777-4b84-8789-e24cdf5ebe46" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f79fc1d4-9d09-481d-ad3b-d549d1a04f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#WARRANTSStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_48f57206-d9ba-4cfd-8582-cbc5d4eecc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_48f57206-d9ba-4cfd-8582-cbc5d4eecc9e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d8add41b-ae1a-43e4-b139-48d172478298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_b36173cb-218a-4357-ad6b-e8149546b368" xlink:href="vrdn-20221231.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_b36173cb-218a-4357-ad6b-e8149546b368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_8a9141a8-1273-4af4-ac52-30e9994d0922" xlink:href="vrdn-20221231.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_8a9141a8-1273-4af4-ac52-30e9994d0922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_8f1e7c47-b32c-443b-9736-8fc3912f3a39" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_8f1e7c47-b32c-443b-9736-8fc3912f3a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_f795e5ad-6cc5-4177-9821-7e963a2caab6" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_f795e5ad-6cc5-4177-9821-7e963a2caab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember_cfa155df-5b19-4d17-8746-f59526ba5f3f" xlink:href="vrdn-20221231.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_dafa422c-3455-4ab4-a038-5ed071c38866" xlink:to="loc_vrdn_EquityclassifiedWarrantsMember_cfa155df-5b19-4d17-8746-f59526ba5f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9b185c6f-9957-430a-931c-5f53bd55444f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_cdb8c3ec-a108-4fb2-8548-75d17a380020" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_cdb8c3ec-a108-4fb2-8548-75d17a380020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b8dea8-ebd6-492e-b9e2-5fa6ad3fcd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67b8dea8-ebd6-492e-b9e2-5fa6ad3fcd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm_60da046c-6072-4ca8-b794-cf2f265a2e28" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6a49bf3e-7b01-42b8-bf6e-09609e9249c9" xlink:to="loc_vrdn_ClassofWarrantorRightRemainingTerm_60da046c-6072-4ca8-b794-cf2f265a2e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#WARRANTSStockWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_886d1fd9-139e-48e5-bc1e-272849147b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightActivityRollForward_39217a0c-8e45-4792-9b57-2edf0ad2b75b" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightActivityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_886d1fd9-139e-48e5-bc1e-272849147b65" xlink:to="loc_vrdn_ClassofWarrantorRightActivityRollForward_39217a0c-8e45-4792-9b57-2edf0ad2b75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_52f3a016-0259-4efd-b56e-8266ad46f1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_39217a0c-8e45-4792-9b57-2edf0ad2b75b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_52f3a016-0259-4efd-b56e-8266ad46f1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod_e3a7b85e-a228-47c0-ba1a-cc1b6cf12b06" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_39217a0c-8e45-4792-9b57-2edf0ad2b75b" xlink:to="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod_e3a7b85e-a228-47c0-ba1a-cc1b6cf12b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_da0d3551-be11-4e3b-b726-d2ba1d574890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_39217a0c-8e45-4792-9b57-2edf0ad2b75b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_da0d3551-be11-4e3b-b726-d2ba1d574890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_71040668-deb1-4ecc-9e35-b18deb5a6ba9" xlink:href="vrdn-20221231.xsd#vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_886d1fd9-139e-48e5-bc1e-272849147b65" xlink:to="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_71040668-deb1-4ecc-9e35-b18deb5a6ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2d1e7a5f-d8c0-4779-8552-5f10e4ea1618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_71040668-deb1-4ecc-9e35-b18deb5a6ba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2d1e7a5f-d8c0-4779-8552-5f10e4ea1618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_40ceb9da-8f77-49ad-8ac7-360e81102cea" xlink:href="vrdn-20221231.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_71040668-deb1-4ecc-9e35-b18deb5a6ba9" xlink:to="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_40ceb9da-8f77-49ad-8ac7-360e81102cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7e97caa2-e99a-416f-b7f2-1537b24373fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_71040668-deb1-4ecc-9e35-b18deb5a6ba9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7e97caa2-e99a-416f-b7f2-1537b24373fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b659145-6b4b-4dbe-8ded-ba04e6230540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b659145-6b4b-4dbe-8ded-ba04e6230540" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1c336018-dfdc-433b-b143-9a031c850d68" xlink:to="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_82055d39-bf9c-426d-9073-ef8511b868f4" xlink:href="vrdn-20221231.xsd#vrdn_Amended2016PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3515722-00d9-476f-9538-81f8b673cc8f" xlink:to="loc_vrdn_Amended2016PlanMember_82055d39-bf9c-426d-9073-ef8511b868f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f5ae167-61e7-48f0-8640-bbf5b9e80156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_edfbb245-a13b-48d5-8322-86a3a16af4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddc82151-bf11-4376-b588-c92ce0a3e813" xlink:to="loc_us-gaap_EmployeeStockOptionMember_edfbb245-a13b-48d5-8322-86a3a16af4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_608e6d7c-c77b-4ad7-ba9f-7ccf21f5dfe2" xlink:to="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9bcd5f7-8132-4d3b-bc25-3ec917e0ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9bcd5f7-8132-4d3b-bc25-3ec917e0ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_615a076f-fed1-4a80-a986-5bc158dbaf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cbba96a1-2ae0-4795-bdca-7781e030607a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_615a076f-fed1-4a80-a986-5bc158dbaf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70a00b13-e6f0-4834-94f7-d30d9fea79c4" xlink:to="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_27b0eac6-441f-4f43-b9ce-089f09a77fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7a42e7c2-399b-49ac-b182-1a3010df1de5" xlink:to="loc_us-gaap_CommonStockMember_27b0eac6-441f-4f43-b9ce-089f09a77fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_27499ae8-b3e2-485a-ab4a-2d8903a44ba3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45dab6d4-797c-493d-9506-e16b68679427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_45dab6d4-797c-493d-9506-e16b68679427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_fd48443c-3735-401e-802f-4b8fec7b5537" xlink:href="vrdn-20221231.xsd#vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod_fd48443c-3735-401e-802f-4b8fec7b5537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3419dfed-780b-42f0-bd30-1318645c6171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3419dfed-780b-42f0-bd30-1318645c6171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07f8247e-7863-483b-8323-f413e07485f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07f8247e-7863-483b-8323-f413e07485f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_87b48bd1-eb45-4bfa-92c7-7c1fcaf8a3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_87b48bd1-eb45-4bfa-92c7-7c1fcaf8a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_333cf574-a698-4c78-96c9-a17eb3e4570d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_333cf574-a698-4c78-96c9-a17eb3e4570d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_963e9bbd-74b8-4707-9093-2de29a1294d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_963e9bbd-74b8-4707-9093-2de29a1294d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_f4ac3365-7308-4e32-9d17-9fc35e01c6e6" xlink:href="vrdn-20221231.xsd#vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_f4ac3365-7308-4e32-9d17-9fc35e01c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_ae29e281-bef5-406c-8d83-f95f8d7d02c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_ae29e281-bef5-406c-8d83-f95f8d7d02c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4c1923f5-9e40-4c2c-be8b-6874afc44c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4c1923f5-9e40-4c2c-be8b-6874afc44c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4aa947b2-6d24-4387-b644-b3839967f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4aa947b2-6d24-4387-b644-b3839967f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6d33d34-743d-4f52-99c9-8a1cee460876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_328c0166-81fc-443b-8c8b-c2e9fb65c4b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6d33d34-743d-4f52-99c9-8a1cee460876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONBalancebyPlansDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11d10846-e8ea-41f4-9859-7a4f5ed33d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11d10846-e8ea-41f4-9859-7a4f5ed33d6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:to="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27f5e90a-1274-40ab-910e-fd910004e099" xlink:to="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember_56afc333-f478-4554-8127-ee50bf73d879" xlink:href="vrdn-20221231.xsd#vrdn_InducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_InducementGrantsMember_56afc333-f478-4554-8127-ee50bf73d879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember_cfeeb5f9-301e-4394-8c57-f83fed971703" xlink:href="vrdn-20221231.xsd#vrdn_A2020PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2020PlanMember_cfeeb5f9-301e-4394-8c57-f83fed971703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2016PlanMember_1dc9cdb5-9550-4d26-b97a-85cc36df0b09" xlink:href="vrdn-20221231.xsd#vrdn_A2016PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2016PlanMember_1dc9cdb5-9550-4d26-b97a-85cc36df0b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember_41070453-30f2-4319-9d3b-dc6f7f8e7161" xlink:href="vrdn-20221231.xsd#vrdn_A2008PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ff268524-bdbc-4aa6-bf89-9c955722c93f" xlink:to="loc_vrdn_A2008PlanMember_41070453-30f2-4319-9d3b-dc6f7f8e7161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1afcdce9-42ca-4d88-a8cd-ff3818ab3ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f00685b0-0bab-4c9f-beb2-7f30d132652a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f00685b0-0bab-4c9f-beb2-7f30d132652a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36794cd8-2c43-4e9f-8bc8-699392bd0118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b2a96d7-93dc-4c6b-9123-0161a70a66cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36794cd8-2c43-4e9f-8bc8-699392bd0118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a1ccfc3-2bca-4b31-8a65-4ab4de8e60b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a1ccfc3-2bca-4b31-8a65-4ab4de8e60b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:to="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8cdd1701-498e-4e70-99aa-a385999968dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_07ab0d5d-a0be-4a89-a94a-10296c5da54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fcfb339-2199-40d7-89ed-395bdef69041" xlink:to="loc_us-gaap_EmployeeStockOptionMember_07ab0d5d-a0be-4a89-a94a-10296c5da54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d93e0fd7-50bf-42b7-9459-4357f95b25cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15898c46-c8e1-4ee4-a014-8a741ad7b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15898c46-c8e1-4ee4-a014-8a741ad7b3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e060d1-d0da-4447-baa4-39b9e8fdd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e060d1-d0da-4447-baa4-39b9e8fdd9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02f33b9b-4db3-46bf-96e0-b8882813ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02f33b9b-4db3-46bf-96e0-b8882813ed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8779fdf5-dae2-412f-a2eb-492125e20fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8779fdf5-dae2-412f-a2eb-492125e20fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fa8bc464-edf8-41c7-8d83-6d66f90a2dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655a9e97-3af6-44df-8c7c-43da618cc7d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fa8bc464-edf8-41c7-8d83-6d66f90a2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa22d76a-ae7b-4275-828c-136ac5fd1ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa22d76a-ae7b-4275-828c-136ac5fd1ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c83436b9-234f-42a4-af7c-2cde355da542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c83436b9-234f-42a4-af7c-2cde355da542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fc33e7f0-3d27-431c-a45d-a90060127af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_fc33e7f0-3d27-431c-a45d-a90060127af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6543f9f0-13e5-449c-a880-1e789f941530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6543f9f0-13e5-449c-a880-1e789f941530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34a58e11-b765-4e68-9d44-43ff81b3cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34a58e11-b765-4e68-9d44-43ff81b3cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13259d0f-a939-43a7-a78d-69f7f75150dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13259d0f-a939-43a7-a78d-69f7f75150dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1a73104-6792-4f78-a24a-3613a12d93cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1a73104-6792-4f78-a24a-3613a12d93cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c58b90f-d272-4c0b-8d4c-bfe596d37753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_55e520da-e550-4ce1-ad64-61d626cf432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c58b90f-d272-4c0b-8d4c-bfe596d37753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4732ebb7-2956-4b7c-a735-83867980c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4732ebb7-2956-4b7c-a735-83867980c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6eee83e-a435-42f7-aa31-28ec0ec62645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6eee83e-a435-42f7-aa31-28ec0ec62645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3de90e25-6682-4cdb-a1b5-9f11cc57cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3de90e25-6682-4cdb-a1b5-9f11cc57cf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c2cb43e-ecbc-406a-8d55-745d3d85c51f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39a4f956-788f-4f03-b9d7-82b6a303c1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39a4f956-788f-4f03-b9d7-82b6a303c1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_29628b09-cf63-4f37-ae31-458e4b2d540e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_29628b09-cf63-4f37-ae31-458e4b2d540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_baf6500a-3968-4bda-a880-2caa14a08b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_baf6500a-3968-4bda-a880-2caa14a08b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6bcdfcc7-034e-4d19-87df-ab7bed1f968f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6bcdfcc7-034e-4d19-87df-ab7bed1f968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c04bee5-7b28-4c5a-a41c-87389871ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c04bee5-7b28-4c5a-a41c-87389871ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6e7c0aef-8d97-48ef-a989-f0d62f32f401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6e7c0aef-8d97-48ef-a989-f0d62f32f401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c557d67d-2e0c-4ad2-a796-c395ed4ac0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c557d67d-2e0c-4ad2-a796-c395ed4ac0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4b0f2fea-81e3-4180-899a-a095cad2dd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbaa9b7b-caaf-4e02-91db-31409764cfed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4b0f2fea-81e3-4180-899a-a095cad2dd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33b69136-f7b0-416e-8a2e-ced84520dbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33b69136-f7b0-416e-8a2e-ced84520dbf1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:to="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9dd8f4b6-0317-4bd4-8f0f-79beef46d0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8352e06f-4235-46a8-a923-e44815678a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4997f29f-9e15-43f0-83ac-4d94d6b0e12e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8352e06f-4235-46a8-a923-e44815678a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0a29c9a-a674-4ab1-8f92-bb9e52f73283" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fcdd58d2-4aa6-42c8-b951-988190dacf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fcdd58d2-4aa6-42c8-b951-988190dacf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c9704d2-6104-45a3-9a5f-373c896dece5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c9704d2-6104-45a3-9a5f-373c896dece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_43aafe90-60c7-45f3-b89d-aab56b8c6987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_43aafe90-60c7-45f3-b89d-aab56b8c6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46d0e9ac-258c-4005-b894-7a68dd3c5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46d0e9ac-258c-4005-b894-7a68dd3c5e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2ec6ad07-7fcc-40b3-9649-43fa314e7628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d650e32-86d7-4a23-be27-6a5e0a6856f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2ec6ad07-7fcc-40b3-9649-43fa314e7628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc1cbde5-2932-4a7f-b916-45ab8dd2df19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc1cbde5-2932-4a7f-b916-45ab8dd2df19" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74a388b5-b76d-4a6d-8826-8925d1b405a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d2553676-86c6-405c-ade9-fb04830ffee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d2553676-86c6-405c-ade9-fb04830ffee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d42dd802-0835-4f91-bee0-0261ae35216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2431715-7fd9-42b3-942a-6959c92437dd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d42dd802-0835-4f91-bee0-0261ae35216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1aabbdb7-23a2-44b9-944a-051de3590551" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca6c39d1-e488-4593-aeaa-09d67fda795b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0b03314-8a84-4d39-80e1-914cfe07a094" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca6c39d1-e488-4593-aeaa-09d67fda795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_966210a3-78db-44ed-9852-566c991ffc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_966210a3-78db-44ed-9852-566c991ffc75" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65b889af-9770-4312-8b85-e279a6f5cb7d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f4db2938-c536-4e69-88bb-73da28307dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f4db2938-c536-4e69-88bb-73da28307dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_9d4f93a5-8e40-4009-aced-07ba058b146b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_9d4f93a5-8e40-4009-aced-07ba058b146b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_daaa453b-7d2b-4a99-afc7-0fc8550a6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_us-gaap_EmployeeStockOptionMember_daaa453b-7d2b-4a99-afc7-0fc8550a6ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember_e5dce34c-e574-42af-ada5-4ac61c7d2c51" xlink:href="vrdn-20221231.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5497f1d1-6b0a-44f1-a2f8-8e202559d689" xlink:to="loc_vrdn_CommonStockWarrantsMember_e5dce34c-e574-42af-ada5-4ac61c7d2c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e25cf2e1-94a2-450b-b1ca-71c33f72f57c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_97171ec8-2eac-476e-a677-9b918d9cb58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d611e0e-900a-4ea9-a7e6-1bbf0b00a786" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_97171ec8-2eac-476e-a677-9b918d9cb58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESEffectiveTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a11c197-1202-4ba4-a742-c96836676793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a11c197-1202-4ba4-a742-c96836676793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6c3e7dd7-7ee1-489c-a558-771e48137e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6c3e7dd7-7ee1-489c-a558-771e48137e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_92dbb701-d9d4-4fba-ad1f-88ef92c8f141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_92dbb701-d9d4-4fba-ad1f-88ef92c8f141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3219f5d6-a70d-4726-b1e7-64475b3fba17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3219f5d6-a70d-4726-b1e7-64475b3fba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_bc7fbc95-ccac-4842-90d3-c4922e07afdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_bc7fbc95-ccac-4842-90d3-c4922e07afdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_b1f91d24-4328-4029-8677-8139c7ad06a4" xlink:href="vrdn-20221231.xsd#vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent_b1f91d24-4328-4029-8677-8139c7ad06a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1a91d179-33d3-4ae4-8abe-946737354f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1a91d179-33d3-4ae4-8abe-946737354f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0a19123-da4c-44df-934c-7dbdd9e8de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87eae4c4-f740-4924-8e72-659421f62f8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0a19123-da4c-44df-934c-7dbdd9e8de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0da5c0c4-cf78-4020-b7df-4dfa4a873beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da5c0c4-cf78-4020-b7df-4dfa4a873beb" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_dd6e2bec-4f81-40c5-a664-0fe82bfa00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_dd6e2bec-4f81-40c5-a664-0fe82bfa00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_91564667-d718-44a1-9c6f-67cb2e8b2dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_91564667-d718-44a1-9c6f-67cb2e8b2dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_67146211-33fb-4164-be38-399a69d35709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_67146211-33fb-4164-be38-399a69d35709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a3bcf1e6-8af4-40b1-9c06-fefdbf1852a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a3bcf1e6-8af4-40b1-9c06-fefdbf1852a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_50900719-84f0-4180-ac6a-6501797e7092" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts_50900719-84f0-4180-ac6a-6501797e7092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ee1720a5-1443-48b2-8f6a-a49fc8fa1c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ee1720a5-1443-48b2-8f6a-a49fc8fa1c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_707ac477-99ca-4afe-b1f2-802d98ec067c" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet_707ac477-99ca-4afe-b1f2-802d98ec067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_73a3af98-4529-482a-950a-c0369a7d036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_73a3af98-4529-482a-950a-c0369a7d036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a1cee23-d143-430b-9519-311d58d9359f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a1cee23-d143-430b-9519-311d58d9359f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ff5b5220-5f29-409b-b4c9-9510a5614dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_168f628b-d19d-4b7b-97bd-70d7c55b1e43" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ff5b5220-5f29-409b-b4c9-9510a5614dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_33883760-e1fa-4689-9c02-2ed09fe5ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da5c0c4-cf78-4020-b7df-4dfa4a873beb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_33883760-e1fa-4689-9c02-2ed09fe5ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_659ff74d-9169-465b-8245-97d0fcda5e83" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_33883760-e1fa-4689-9c02-2ed09fe5ee5e" xlink:to="loc_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss_659ff74d-9169-465b-8245-97d0fcda5e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8bbb3333-70b8-4bd2-9bdf-b33c7b01c2ad" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_33883760-e1fa-4689-9c02-2ed09fe5ee5e" xlink:to="loc_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8bbb3333-70b8-4bd2-9bdf-b33c7b01c2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_31cc69c4-2921-458e-9485-dcdabcfaad81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_33883760-e1fa-4689-9c02-2ed09fe5ee5e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_31cc69c4-2921-458e-9485-dcdabcfaad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9a4abd7e-a897-4b72-a1ee-4078aa0a8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da5c0c4-cf78-4020-b7df-4dfa4a873beb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9a4abd7e-a897-4b72-a1ee-4078aa0a8aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9112ef20-b895-4a60-b742-9d1841425cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9112ef20-b895-4a60-b742-9d1841425cda" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bc156f2e-0553-47ad-b551-4a0e541e45d5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_142df20a-d50c-4397-b924-2d449e6928fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:to="loc_us-gaap_DomesticCountryMember_142df20a-d50c-4397-b924-2d449e6928fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_02d36c7c-b3cd-48bd-89a2-1299f1a0bbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d85c371e-3b56-431e-905b-273ad88f5c1a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_02d36c7c-b3cd-48bd-89a2-1299f1a0bbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_42cb34a5-8b6c-496d-9d68-946aa1aa5995" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fb31f5b3-862a-4c82-aa27-bbc1d23fa9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6deb6c6b-d93a-45e1-989b-201074d9d187" xlink:to="loc_us-gaap_ResearchMember_fb31f5b3-862a-4c82-aa27-bbc1d23fa9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e9ddeadc-62f9-4b91-98c5-94fe1e7b8e89" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2eb861e0-d218-4507-bdb9-51c366f735c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2eb861e0-d218-4507-bdb9-51c366f735c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_dbe3066f-0901-4df2-b399-7234e60fbecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_dbe3066f-0901-4df2-b399-7234e60fbecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_9a868771-60f8-4246-9d04-c7dfc6649d30" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardLimitationsOnUseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount_9a868771-60f8-4246-9d04-c7dfc6649d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_TaxCreditCarryforwardWriteOff_198b7e70-6d38-42ce-bd9c-77e84ca22f27" xlink:href="vrdn-20221231.xsd#vrdn_TaxCreditCarryforwardWriteOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_TaxCreditCarryforwardWriteOff_198b7e70-6d38-42ce-bd9c-77e84ca22f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_097cdade-c444-4f4c-8846-af7d0fade081" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance_097cdade-c444-4f4c-8846-af7d0fade081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DeferredTaxAssetValuationAllowancePercent_79f89a72-4d06-4df8-8f22-e5b294b571de" xlink:href="vrdn-20221231.xsd#vrdn_DeferredTaxAssetValuationAllowancePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_vrdn_DeferredTaxAssetValuationAllowancePercent_79f89a72-4d06-4df8-8f22-e5b294b571de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca933545-72db-4453-9fdd-530a6e421e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca933545-72db-4453-9fdd-530a6e421e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2dc93f84-970a-4bf0-ac16-9aa28b1a408d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_74b37125-76df-4180-a2d8-6b77e5f40e77" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_2dc93f84-970a-4bf0-ac16-9aa28b1a408d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vrdn-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrdn-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  U 0,# 2(  A$! Q$!_\0
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M0PO$OCZUTMI+/3@MU=KE6;_EG&??U/L*YG0_#^H^-+YM2U2[<VP;#/N&YO\
M94?PBNDU#X=:3J+O=6=U-;-,3)\I#H<\\ _XUA2_#_Q%I<OGZ7>I(PZ&*0Q/
M_A^M<S3OJ*I&JY7FKKR/1[*QMM.M$M;.%884&%51_G)J'6K#^T]'NK($AI8R
M%.>_4?J*YGPQJ7BT:JFGZS8R/;E3NN'CP5P./F'!YX]:[2K3N=E.2E'16,+P
MAJ+:AH4:S$_:+4F&4'KD=,_ABMBYN([2UEN)3B.)"['V KFH1_8?CB2+[MKJ
MR;U]!(.O]?SJ7QE/)/!:Z+;MB;4)0IQV0<D_Y]Z9H'@R&:6UNM7N"?,U&8N
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MZ4C*KJ4=0RL,$$9!% %+0N-!T_\ Z]H__015^FQQI#&L<:A$0!551@ >E.H
M**** "BBB@ IBQ1H[.L:JS?>8#!/UHHH ?1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0
(           !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vrdn-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrdn-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (+ HH# 2(  A$! Q$!_\0
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M44 %%%% !1110 4444 >@_ /_DK6A?\ ;?\ ]$25Y]7H/P#_ .2M:%_VW_\
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M\,#_ !W_ .A%_P#*O8?_ !^OK<HK4Z=!J<DG?J_)'AXZ$IU$XJ^G^9\_45]
M_P## _QW_P"A%_\ *O8?_'Z/^&!_CO\ ]"+_ .5>P_\ C]>W]:H?\_%]Z//]
MC4_E?W'S]17T#_PP/\=_^A%_\J]A_P#'Z/\ A@?X[_\ 0B_^5>P_^/T?6J'_
M #\7WH/8U/Y7]Q\_45] _P## _QW_P"A%_\ *O8?_'Z/^&!_CO\ ]"+_ .5>
MP_\ C]'UJA_S\7WH/8U/Y7]Q\_45] _\,#_'?_H1?_*O8?\ Q^C_ (8'^.__
M $(O_E7L/_C]'UJA_P _%]Z#V-3^5_<?/U%?0/\ PP/\=_\ H1?_ "KV'_Q^
MC_A@?X[_ /0B_P#E7L/_ (_1]:H?\_%]Z#V-3^5_<?/U%?0/_# _QW_Z$7_R
MKV'_ ,?H_P"&!_CO_P!"+_Y5[#_X_1]:H?\ /Q?>@]C4_E?W'S]17T#_ ,,#
M_'?_ *$7_P J]A_\?H_X8'^._P#T(O\ Y5[#_P"/T?6J'_/Q?>@]C4_E?W'G
M_P  _P#DK6A?]M__ $1)7GU?67PB_8E^-/A?XAZ3J>I^#/LUC!YWF2_VI9/M
MW0NHX68D\D=N]<=_PP/\=_\ H1?_ "KV'_Q^LUB:'.WSK9=5YE>RJ<J]U_<?
M/U%?0/\ PP/\=_\ H1?_ "KV'_Q^C_A@?X[_ /0B_P#E7L/_ (_6GUJA_P _
M%]Z)]C4_E?W'S]17T#_PP/\ '?\ Z$7_ ,J]A_\ 'Z/^&!_CO_T(O_E7L/\
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ML2_&GPO\0])U/4_!GV:Q@\[S)?[4LGV[H74<+,2>2.W>N._X8'^._P#T(O\
MY5[#_P"/UFL30YV^=;+JO,KV53E7NO[CY^HKZ!_X8'^._P#T(O\ Y5[#_P"/
MT?\ # _QW_Z$7_RKV'_Q^M/K5#_GXOO1/L:G\K^X^?J*^@?^&!_CO_T(O_E7
ML/\ X_1_PP/\=_\ H1?_ "KV'_Q^CZU0_P"?B^]![&I_*_N/GZBOH'_A@?X[
M_P#0B_\ E7L/_C]'_# _QW_Z$7_RKV'_ ,?H^M4/^?B^]![&I_*_N/GZBOH'
M_A@?X[_]"+_Y5[#_ ./T?\,#_'?_ *$7_P J]A_\?H^M4/\ GXOO0>QJ?RO[
MCY^HKZ!_X8'^._\ T(O_ )5[#_X_1_PP/\=_^A%_\J]A_P#'Z/K5#_GXOO0>
MQJ?RO[CY^HKZ!_X8'^.__0B_^5>P_P#C]'_# _QW_P"A%_\ *O8?_'Z/K5#_
M )^+[T'L:G\K^X^?J*^@?^&!_CO_ -"+_P"5>P_^/T?\,#_'?_H1?_*O8?\
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M%% !116Q#HKR0HV0-R@_I2O8=KDNN:<7_P!(C&3_ !J/YUA5VU4+K1;>Y8L
M8G]4_P *A2[ERCV.8HK;_P"$;]+C_P <_P#KT?\ "-_]//\ XY_]>JYD3RLQ
M**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^
MO1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]
M>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG
M_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^
M.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_
M (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\
M"-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ
M**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^
MO1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]
M>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG
M_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^
M.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_
M (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\
M"-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ
M**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^
MO1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]
M>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG
M_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_ (1O_IY_\<_^O1_PC?\ T\_^
M.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\ "-_]//\ XY_]>CF0<K,2BMO_
M (1O_IY_\<_^O1_PC?\ T\_^.?\ UZ.9!RLQ**V_^$;_ .GG_P <_P#KT?\
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M_P"+K\R:*[_J$?YCYS_6&K_S[1^FW_"W/ O_ $.GA[_P:P?_ !='_"W/ O\
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M%'U"/\P?ZPU?^?:/TV_X6YX%_P"AT\/?^#6#_P"+H_X6YX%_Z'3P]_X-8/\
MXNOS)HH^H1_F#_6&K_S[1^FW_"W/ O\ T.GA[_P:P?\ Q='_  MSP+_T.GA[
M_P &L'_Q=?F311]0C_,'^L-7_GVC]-O^%N>!?^AT\/?^#6#_ .+H_P"%N>!?
M^AT\/?\ @U@_^+K\R:*/J$?Y@_UAJ_\ /M'Z;?\ "W/ O_0Z>'O_  :P?_%T
M?\+<\"_]#IX>_P#!K!_\77YDT4?4(_S!_K#5_P"?:/TV_P"%N>!?^AT\/?\
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MWJD3*I"#2D[-G?45PWA?XU>$?&5Y;6VCWUY=-<(TD4K:7=Q0LH4L6\UX@F,
M\YY[4WPO\</!/C+4+2QTO6Q)<WBEK5+FUFMA< #)\HRHH?CGY2>*?)+L0JU)
MVM):^9W=%%%0;!1110 4444 <O\ $_P!I_Q3^'OB'PEJ8_T+5[.2U9\9,;$?
M)(/]I&VL/=17S]\"_"OCWQM<>)O&?Q%T6YT[Q%I/A\>#M+MKA3NN&C0M>7B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)UK3]?L4O-,OK;4;-SA;BTF66,_1E)%7:DM-/5!1110,**** "BBB@ HHHH
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MD<D\Y'%?3%%7[7NC!X1W=I=%T[?,\:^$[:;K'Q5\5:YX0MA;^#;C3[6&2:&
MPVUY?J\A:2($ -B,HK,!@G'7%>RT45E*7,[G92I^SC8****@U"BBB@ HHHH
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MO_!5!_\ $4?\*C\"_P#0E^'O_!5!_P#$5^>O_"W/'7_0Z>(?_!K/_P#%T?\
M"W/'7_0Z>(?_  :S_P#Q='U.I_.']M87_GS^1^A7_"H_ O\ T)?A[_P50?\
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M.I_.']M87_GS^1^A7_"H_ O_ $)?A[_P50?_ !%'_"H_ O\ T)?A[_P50?\
MQ%?GK_PMSQU_T.GB'_P:S_\ Q='_  MSQU_T.GB'_P &L_\ \71]3J?SA_;6
M%_Y\_D?H5_PJ/P+_ -"7X>_\%4'_ ,11_P *C\"_]"7X>_\ !5!_\17YZ_\
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M8=&72X 1_P".5TUK:PV5ND%O#'!!&-J1Q*%51Z #I7YF_P#"W/'7_0Z>(?\
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M?_$TGV.?_G_F_P"^(_\ XF@"Y15/['/_ ,_\W_?$?_Q-'V.?_G_F_P"^(_\
MXF@"Y15/['/_ ,_\W_?$?_Q-'V.?_G_F_P"^(_\ XF@"Y15/['/_ ,_\W_?$
M?_Q-'V.?_G_F_P"^(_\ XF@"Y15/['/_ ,_\W_?$?_Q-'V.?_G_F_P"^(_\
MXF@"Y15/['/_ ,_\W_?$?_Q-'V.?_G_F_P"^(_\ XF@"Y15/['/_ ,_\W_?$
M?_Q-'V.?_G_F_P"^(_\ XF@"Y15/['/_ ,_\W_?$?_Q-'V.?_G_F_P"^(_\
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M?L<__/\ S?\ ?$?_ ,31]CG_ .?^;_OB/_XFCVU3^9_>P^I87_GU'[D>9?\
M#*OPM_Z%?_RH77_QVC_AE7X6_P#0K_\ E0NO_CM>F_8Y_P#G_F_[XC_^)H^Q
MS_\ /_-_WQ'_ /$T>VJ?S/[V'U+"_P#/J/W(\R_X95^%O_0K_P#E0NO_ ([1
M_P ,J_"W_H5__*A=?_':]-^QS_\ /_-_WQ'_ /$T?8Y_^?\ F_[XC_\ B:/;
M5/YG][#ZEA?^?4?N1YE_PRK\+?\ H5__ "H77_QVC_AE7X6_]"O_ .5"Z_\
MCM>F_8Y_^?\ F_[XC_\ B:/L<_\ S_S?]\1__$T>VJ?S/[V'U+"_\^H_<CS+
M_AE7X6_]"O\ ^5"Z_P#CM'_#*OPM_P"A7_\ *A=?_':]-^QS_P#/_-_WQ'_\
M31]CG_Y_YO\ OB/_ .)H]M4_F?WL/J6%_P"?4?N1YE_PRK\+?^A7_P#*A=?_
M !VC_AE7X6_]"O\ ^5"Z_P#CM>F_8Y_^?^;_ +XC_P#B:/L<_P#S_P W_?$?
M_P 31[:I_,_O8?4L+_SZC]R/,O\ AE7X6_\ 0K_^5"Z_^.T?\,J_"W_H5_\
MRH77_P =KTW['/\ \_\ -_WQ'_\ $T?8Y_\ G_F_[XC_ /B:/;5/YG][#ZEA
M?^?4?N1YE_PRK\+?^A7_ /*A=?\ QVC_ (95^%O_ $*__E0NO_CM>F_8Y_\
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M_?$?_P 31]CG_P"?^;_OB/\ ^)H]M4_F?WL/J6%_Y]1^Y'F7_#*OPM_Z%?\
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M_P#XFC['/_S_ ,W_ 'Q'_P#$T 7**I_8Y_\ G_F_[XC_ /B:/L<__/\ S?\
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M%.1\CKZ$G"GUR/05]VUY->BZ,^4^PP&,6.H^T2LUHPHHHKG/2"BBB@ HHHH
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MKD[(PQY)B8#Y03_">!DX(&!7IX.O&G>$CY7.LOJXEQK45=I6:/G3X.^)M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K_VA:C@W,/\
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MYDQ("!BHW$<GY5()..:I1HRO:*T\B)5L;#E<ZDDI;>\_T.^_X:J^*7_0T?\
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M.-RF0?+W'/'07/$G[.^KZ#H4ERMQ/<:C;&V6ZM7L)8H5,[*JB*=OEE*LZ*V
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MAU2WN;BPN_LN?)>6"9HF>//.UMN1Z9QVKLZR:Y79G3"2G%26S"BBBD6%%%%
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MHGPV^'\OPYT>336\4:YXGB+J8I-<>W9K= H41Q^3#$ G'0@UUU%$JTY+ED]
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M(0;45!@$G'"C\:^Q?^&(? O_ $%O$/\ X$P?_&:/^&(? O\ T%O$/_@3!_\
M&:KZW1(>38Z5T[:^9\S6WQPUFW6VN6TS1[C7[6!;>#Q!-:EKV-57:ISNV,ZK
M@!V4L,#FLKP[\3+W1-'DTF]TS3?$6F-.;J.VU>)Y!#,1AG1D=6&[ R,X..E?
M5W_#$/@7_H+>(?\ P)@_^,T?\,0^!?\ H+>(?_ F#_XS4?6<.:_V7F+=VU]_
M]7/DSP_XV6S^)FD^*;ZTBCBMM2@O9;73H$B0(CJ2L:# '"X'ZGO6[J7QPU.:
M^M9M/TK2M+2#5X]9D%M;LIO+B-BT;3?.>!D_*FT98G%?2W_#$/@7_H+>(?\
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MH^N4@_L/&=E]Y\0T5]O?\,0^!?\ H+>(?_ F#_XS1_PQ#X%_Z"WB'_P)@_\
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MDDUJT45.^K-DE%66P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M ^X_[ZC_ /BZN44 4_MT_P#T#[C_ +ZC_P#BZ/MTW_0/N/\ OJ/_ .+JY12
MI_;IO^@?<?\ ?4?_ ,71]NF_Z!]Q_P!]1_\ Q=7** *?VZ;_ *!]Q_WU'_\
M%T?;IO\ H'W'_?4?_P 75RB@"G]NF_Z!]Q_WU'_\71]NF_Z!]Q_WU'_\75RB
M@"G]NF_Z!]Q_WU'_ /%T?;IO^@?<?]]1_P#Q=7** *?VZ;_H'W'_ 'U'_P#%
MT?;IO^@?<?\ ?4?_ ,75RB@"G]NF_P"@?<?]]1__ !='VZ;_ *!]Q_WU'_\
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M%9RPCC'F4D_^'_K4N-=-V:/K229(5#2.L:DA06.!DG %+)(L,;.[*B*,LS'
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M10 4444 %%%% !1110 5G:7X<TG0[:ZM].TNSL+>[FDN;B*VMTC6:60YDD<
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M_ \C%G\&^'W8]6;2X"3_ ..4W_A4?@7_ *$OP]_X*H/_ (BN_P"OQ_E/G/\
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MV  /H    .  !5"OTV_X5'X%_P"A+\/?^"J#_P"(H_X5'X%_Z$OP]_X*H/\
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M]SZ5D5I&/<SE+L:K>(KCM'&![@_XTG_"17/]R+\C_C6715\J)YF:G_"17/\
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M1RH.9FI_PD5S_<B_(_XT?\)%<_W(OR/^-9=%'*@YF:G_  D5S_<B_(_XT?\
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M;K):KNN2\DB8R@R_+$ ?-SUIDW@+5)OV=;O2I/#MX]]<>/#>2V363F62 ^(
MYE*;<E/)&[=C&P9SBG[&C?=[VW7GKL+VD[?B>P:1^T!X!US2=8U&TU]?LND&
M'[;Y]I/"\(F;;$WEN@8HYX# %3ZUTFN>.]"\-:@;'4]06UNAI]QJIC9')^RP
M%!-)D C"^8G'4YX!KP7]H'P3K^O^+/B'/I.B7NH++X-TH0&"!BMS-!J=Q,\*
M-C#2^6 =N<_,OJ*B\=:MJ/Q2\<7NI:-X5\21Z3'X UVP2ZU#1[BU,MW*;8K
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M8K<]8(O^^!1]AMO^?>+_ +X%3T4P(/L-M_S[Q?\ ? H^PVW_ #[Q?]\"IZ*
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M[X%?'7_#Q;_JGW_E:_\ N>C_ (>+?]4^_P#*U_\ <]'U:MV_(/[4P7\_X/\
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M/$"Q,-/T.VE=YB/E\V5&C5,^I#.WT6OOKQ)H5OXH\.ZIHUVTB6FHVLMG,T1
M<)(A1BI((!P3C@UXN*Y56_,^ZRGVDL&T_.W]>IX7\)OBIJOB#QCH5E:>,V\=
M6-QITESK*/IL=N-*<(K1GS8T13N?<FTY/!/:M2T_:>M6M?%1N=)LS=Z+I3ZL
MD.FZU#?+/&CA&1GC&(W#%>"#PV1FN]N/A+H5QJ-A>_Z3%-;:6^C2^7*%%W:,
MFT1S<?-M/S*1@@D]CBN=3]G71'L+BTO-;US4(I-#?P]'Y\L \BS9D8*@2)1N
M7RUPS D\YSQC/FI-W:.E4\5!6B^_Y>=W^/X&5XD_:0;PW#ID=SX=BM-4O+&3
M56L=2UB"T,=H'*QG<PPTT@!(B'3!!88KH?B=\0KBW^!=[XO\-71MI;BQM[NR
MN'C5RBRM'@E6!7.U^AR,UJ>,/A38>+-6L]4BU/4M"U2WMFLOMFF/$'DMR0WE
ML)(W7 (R" &!)P:TO%G@2Q\9>![KPM?7%VEC<0) T\,@\\!2I#!F!&[*@Y(-
M1>%XM+U-N2O::<NFGW?U^AQ/]O>*/A[XXT?0M;U__A*--URUO'@N7LXK>ZM9
MK>,2'_5@(Z,I(Y4$$#DYJCX7^.KW4G@;1TT][RZUK2+2_>ZU+4(;>9Q*2K>6
M-BK/(NTLRIMX(P.<#K_#_P (].T?5IM5OM6UCQ)JSVSV<=[K-RLCV\3_ 'UB
M5$1$W8&2%R<#FL[_ (41H_V'P[IYU?67TK1%M!#I\DT312-;E6C=LQ[E;*C)
MC*;NAXXI\T.I')76L7IVO?MU?S[F1:_M(:7=?$%?#ZV=N+%M6?1%O/[2B^T_
M:ERN3:_?$1=2@DSR<<8.:ETO]H&VNO'%[X<N=.M?,C@NI[9M,U:&^EE, RT;
MQ1\Q.RY*@DYP1U!KH=-^$=AHOBR?6K#5M5M+>>\DU"728Y8_LCW#@[W/R>9@
MDEBH?;NYQ69HOP#TC0[C3'@UO7#;Z5%=0:;:_:(D2S2X4K($*1JY(SE69BPP
M.:/W0[8K37KY;:?\'S,6W_:1MF^'J^*+C2[2-;F\AL;&&+6(7CDEE!(6:4@>
M04 )<./EP<;J[;X6_$BV^)V@W5]##%;7%E>26-U#;W:742R*%;*2IPZE74@X
M'7&.*Q/^%!:'-8:G'=:GJUYJ%]=V]\=6DDB6YBF@!$3ILC5"5!8$LK%MQW9K
ML_"?AK_A%=)-F=3OM7D:1I7NM09#(S-VPBJJ@8X"J *F7L[>ZM2Z2Q',O:/2
MWE_7Z&U1116)W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 454_M
M2U''F_\ CI_PH_M6U_YZ_P#CI_PH MT54_M6U_YZ_P#CI_PH_M6U_P">O_CI
M_P * +=%5/[5M?\ GK_XZ?\ "C^U;7_GK_XZ?\* +=%5/[5M?^>O_CI_PH_M
M6U_YZ_\ CI_PH MT54_M6U_YZ_\ CI_PH_M6U_YZ_P#CI_PH MT54_M6U_YZ
M_P#CI_PH_M6U_P">O_CI_P * +=%5/[5M?\ GK_XZ?\ "C^U;7_GK_XZ?\*
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M\* +=%5/[5M?^>O_ (Z?\*/[5M?^>O\ XZ?\* +=%%% !1110 4444 %%%%
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MU(50!S4RG%QLEJ:4Z-2%3F<VU_P?ZUW+]%%%8G:%%%% !1110 4444 %%%%
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M%=/NO_[EO_WVW^%&Z_\ [EO_ -]M_A1S2[A[&G_*ON.8_P"%*_#S_H0_#/\
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MPH N453W7_\ <M_^^V_PHW7_ /<M_P#OMO\ "@"Y15/=?_W+?_OMO\*-U_\
MW+?_ +[;_"@"Y15/=?\ ]RW_ .^V_P *-U__ '+?_OMO\* +E%4]U_\ W+?_
M +[;_"C=?_W+?_OMO\* +E%4]U__ '+?_OMO\*-U_P#W+?\ [[;_  H N453
MW7_]RW_[[;_"C=?_ -RW_P"^V_PH N453W7_ /<M_P#OMO\ "C=?_P!RW_[[
M;_"@"Y15/=?_ -RW_P"^V_PHW7_]RW_[[;_"@"Y15/=?_P!RW_[[;_"C=?\
M]RW_ .^V_P * +E%4]U__<M_^^V_PHW7_P#<M_\ OMO\* +E%4]U_P#W+?\
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M3A+0^6SG!U*SC6IJ]E9GRO17:R?!'XB1N5/@3Q*2/[NDW##\PE-_X4K\0_\
MH0_$W_@GN/\ XBO3YX]SY/V-7^5_<<9179_\*5^(?_0A^)O_  3W'_Q%'_"E
M?B'_ -"'XF_\$]Q_\13YX]P]C4_E?W'&45V?_"E?B'_T(?B;_P $]Q_\11_P
MI7XA_P#0A^)O_!/<?_$4<\>X>QJ?RO[CC**[/_A2OQ#_ .A#\3?^">X_^(H_
MX4K\0_\ H0_$W_@GN/\ XBCGCW#V-3^5_<<9179_\*5^(?\ T(?B;_P3W'_Q
M%'_"E?B'_P!"'XF_\$]Q_P#$4<\>X>QJ?RO[CC**[/\ X4K\0_\ H0_$W_@G
MN/\ XBMOPM^S1\3/%FH1VT'A'4M/#'#7&J0-:1H.[$R $@>@!/H#2<XK5LJ.
M'K2=E!_<=1^Q/I5SJ'Q_TBX@5C#8VUU/.1T"&)HQG_@4BU^A?BZXU:U\+ZK+
MH5JMYK2VTGV*!W5%:;:=F2Q  SC.>PKSW]GGX V'P+\-S0^>FHZ]?$->WZIM
M! ^[&@/(1<GW)))QP!ZS7B8BHJE3F6R/O<NPL\-AN2>C>OH>"^"_@KXO^&WB
M/P=J,.O6_B&VL8Y-,OK:.R6U?[-,3(\ID,A\TK,%?!&3N?'7%4_A[\/?&-AJ
MGP[TK5O#D=MI/A5=1MKC4&O(9$NUFC98V2,,6VD$9# ')Z8YKZ&HK/VLGO\
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M<Z"BN?W/_P ]IO\ OZW^-&Y_^>TW_?UO\: N=!16!N?G]]-_W];_ !I-S_\
M/:;_ +^M_C0%SH**Y_<__/:;_OZW^-&Y_P#GM-_W];_&@+G045S^Y_\ GM-_
MW];_ !HW/_SVF_[^M_C0%SH**Y_<_P#SVF_[^M_C1N?_ )[3?]_6_P : N=!
M17/[G_Y[3?\ ?UO\:-S_ //:;_OZW^- 7.@HKG]S_P#/:;_OZW^-&Y_^>TW_
M '];_&@+G045S^Y_^>TW_?UO\:-S_P#/:;_OZW^- 7.@HKG]S_\ /:;_ +^M
M_C1N?_GM-_W];_&@+G045S^Y_P#GM-_W];_&C<__ #VF_P"_K?XT!<Z"BN?W
M/_SVF_[^M_C1N?\ Y[3?]_6_QH"YT%%<_N?_ )[3?]_6_P :-S_\]IO^_K?X
MT!<Z"BN?W/\ \]IO^_K?XT;G_P">TW_?UO\ &@+G045S^Y_^>TW_ '];_&C<
M_P#SVF_[^M_C0%SH**Y_<_\ SVF_[^M_C1N?_GM-_P!_6_QH"YT%%<_N?_GM
M-_W];_&C<_\ SVF_[^M_C0%SH**Y_<__ #VF_P"_K?XT;G_Y[3?]_6_QH"YT
M%%<_N?\ Y[3?]_6_QHW/_P ]IO\ OZW^- 7.@HKG]S_\]IO^_K?XT;G_ .>T
MW_?UO\: N=!17/[G_P">TW_?UO\ &C<__/:;_OZW^- 7.@HKG]S_ //:;_OZ
LW^-&Y_\ GM-_W];_ !H"YT%%<_N?_GM-_P!_6_QHW/\ \]IO^_K?XT!<_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611682256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viridian Therapeutics, Inc./DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1187261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street, Suite 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">272-4600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRDN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,897,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for the 2023 annual meeting of shareholders (the &#8220;2023 Proxy Statement&#8221;) are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744707627392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boulder, Colorado<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611456016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 155,579<span></span>
</td>
<td class="nump">$ 42,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">268,971<span></span>
</td>
<td class="nump">154,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,521<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Unbilled revenue - related party</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">431,173<span></span>
</td>
<td class="nump">200,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">435,091<span></span>
</td>
<td class="nump">203,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,234<span></span>
</td>
<td class="nump">2,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">18,827<span></span>
</td>
<td class="nump">11,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue - related party</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,349<span></span>
</td>
<td class="nump">13,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">4,645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue - related party</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,027<span></span>
</td>
<td class="nump">15,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 200,000,000 shares authorized; 41,305,947 and 23,924,004 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">741,067<span></span>
</td>
<td class="nump">412,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(390)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(488,174)<span></span>
</td>
<td class="num">(358,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">395,064<span></span>
</td>
<td class="nump">187,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">435,091<span></span>
</td>
<td class="nump">203,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">85,470<span></span>
</td>
<td class="nump">118,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 15,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611521904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">41,305,947<span></span>
</td>
<td class="nump">23,924,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">41,305,947<span></span>
</td>
<td class="nump">23,924,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="nump">$ 100,894<span></span>
</td>
<td class="nump">$ 56,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="nump">$ 5,619<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">435,000<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">260,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">260,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744612832624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 1,772<span></span>
</td>
<td class="nump">$ 2,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="nump">100,894<span></span>
</td>
<td class="nump">56,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">35,182<span></span>
</td>
<td class="nump">25,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">136,076<span></span>
</td>
<td class="nump">82,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(134,304)<span></span>
</td>
<td class="num">(79,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">4,916<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other expense</a></td>
<td class="num">(486)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (129,874)<span></span>
</td>
<td class="num">$ (79,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (4.05)<span></span>
</td>
<td class="num">$ (6.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (4.05)<span></span>
</td>
<td class="num">$ (6.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net loss per share (in shares)</a></td>
<td class="nump">32,087,293<span></span>
</td>
<td class="nump">11,918,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">32,087,293<span></span>
</td>
<td class="nump">11,918,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in unrealized loss on investments</a></td>
<td class="num">$ (233)<span></span>
</td>
<td class="num">$ (149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (130,107)<span></span>
</td>
<td class="num">$ (79,562)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611280672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="nump">$ 100,894<span></span>
</td>
<td class="nump">$ 56,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="nump">$ 5,619<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744608456320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public offering</div></th>
<th class="th"><div>At-the-market offering</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Convertible Preferred Stock </div>
<div>Public offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 120,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,801<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (278,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,231,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,203,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,344,543<span></span>
</td>
<td class="nump">2,551,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,476<span></span>
</td>
<td class="nump">$ 32,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,734<span></span>
</td>
<td class="nump">$ 32,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock under license agreement</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon the vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">14,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in unrealized loss on investments</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(79,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,413)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,437<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="nump">260,437<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 187,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,164<span></span>
</td>
<td class="nump">$ 15,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="num">(358,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">23,924,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,924,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,803,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,352,640<span></span>
</td>
<td class="nump">964,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,650<span></span>
</td>
<td class="nump">$ 24,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248,528<span></span>
</td>
<td class="nump">$ 24,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for cash upon the exercise of stock options under equity incentive plans</a></td>
<td class="nump">2,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">19,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in unrealized loss on investments</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,874)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 395,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,470<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 741,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="num">$ (488,174)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">41,305,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,305,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611514288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 18,146<span></span>
</td>
<td class="nump">$ 5,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Preferred Stock | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,992<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614453008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (129,874)<span></span>
</td>
<td class="num">$ (79,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock under license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">19,765<span></span>
</td>
<td class="nump">14,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense and amortization of debt issuance costs</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization of premiums and discounts on available-for-sale securities</a></td>
<td class="num">(210)<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_NonCashLeaseExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,339)<span></span>
</td>
<td class="num">(1,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">11,524<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Unbilled revenue</a></td>
<td class="nump">349<span></span>
</td>
<td class="num">(451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(288)<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(93,838)<span></span>
</td>
<td class="num">(54,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(223,264)<span></span>
</td>
<td class="num">(188,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">108,935<span></span>
</td>
<td class="nump">114,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(797)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(115,126)<span></span>
</td>
<td class="num">(74,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, pursuant to 2022 and 2021 Public Offering and September 2022 and April 2021 ATM Agreement</a></td>
<td class="nump">291,874<span></span>
</td>
<td class="nump">114,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Series B preferred stock</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">16,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(446)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">322,244<span></span>
</td>
<td class="nump">125,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">113,280<span></span>
</td>
<td class="num">(3,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">42,299<span></span>
</td>
<td class="nump">45,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">155,579<span></span>
</td>
<td class="nump">42,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AmortizationOfStockIssuanceCosts', window );">Amortization of public offering costs</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="num">(19,072)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="num">$ (2,992)<span></span>
</td>
<td class="num">$ (1,291)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AmortizationOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AmortizationOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744697994944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Viridian&#8221;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#8217;s therapies. The Company&#8217;s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#8220;IGF-1R&#8221;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#8220;TED&#8221;). The Company&#8217;s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. In addition to developing therapies for TED, the Company is executing a similar strategic approach to identify opportunities in other rare and/or serious disease indications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#8217;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through December&#160;31, 2022, the Company has generated an accumulated deficit of $488.2 million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $424.6 million in cash, cash equivalents, and short-term investments. As of the issuance date of these consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#8217;s clinical development efforts, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#8217;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#8217;s control, including success in developing its technology and drug product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744617788560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Viridian Therapeutics Europe Limited and Viridian Therapeutics S.&#224;.r.l., both of which were formed for the sole purpose of submitting regulatory filings in Europe, and Viridian Securities Corporation, which was formed in July 2021. The Company&#8217;s subsidiaries have no employees or operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents and short-term investments balance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Such expenses are included within operating activities in the consolidated statements of cash flows. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation expense to employees and non-employees based on the fair value of each stock option or award on the date of the grant. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilizes observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921">three</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Right-of-Use Assets and Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies - Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information related to the Company&#8217;s operating leases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Debt issuance costs represent </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Preferred Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and at issuance classified the Series A Preferred Stock outside of stockholders&#8217; equity because, if convertibility of Series A Preferred Stock into common stock was not approved by the stockholders, the Series A Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. On December 31, 2020, the stockholders approved the convertibility of the Series A Preferred Stock into common stock and as such, the Company reclassified the Series A Preferred Stock to permanent equity. In September 2021, the Company issued Series B Preferred Stock with conversion rights which the Company has classified as permanent equity in its consolidated balance sheets.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the consolidated statements of changes in stockholders&#8217; equity. The Company had unrealized losses on investments of $0.2 million and $0.1 million during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses. No such expenses have been recognized during the years ended December 31, 2022 and 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615190928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Zenas BioPharma</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma (the &#8220;Supply Agreement&#8221;) to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#8220;Zenas Agreements&#8221;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#8217;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 808&#8221;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#8217;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#8217;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#8217;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#8217;s estimated period to complete its activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the years ended December 31, 2022 and 2021, the Company recognized $1.8 million and $3.0 million, respectively, of collaboration revenue related to the Zenas Agreements. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC beneficially owns more than 5% of the Company&#8217;s common stock and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#8217;s board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) entered into an antibody and discovery option agreement (the &#8220;Paragon Agreement&#8221;) under which the Company and Paragon will cooperate to develop one or more antibodies. Under the terms of the Paragon Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. The Paragon Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#8220;Final Deliverable&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#8217;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#8220;Option&#8221; and together, the &#8220;Options&#8221;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs at any time until the date that is 90 days after the Company&#8217;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#8220;Option Period&#8221;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Program will terminate. In consideration for Paragon&#8217;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $2.5&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of $2.3&#160;million (the &#8220;First Amendment Payment&#8221;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program. During the year ended December 31, 2022, the Company recorded $5.6 million in research and development costs related to the Paragon Agreement.</span></div>As of December 31, 2022, the Paragon Agreement is considered a related party transaction because Fairmount beneficially owns more than 5% of the Company&#8217;s capital stock and has two seats on the Company&#8217;s board of directors, and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744707618544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">INVESTMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text">INVESTMENTS AND FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of December&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:34.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company had realized gains of zero and $4&#160;thousand in its available for sale securities for the years ended December&#160;31, 2022 and 2021, respectively. The contractual maturity dates of all of the Company&#8217;s investments are all less than 24 months.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:43.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.753%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615216656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, certain lab equipment met the criteria to be classified and were reclassified as held for sale and included in prepaid expenses and other current assets. The assets held for sale totaled $0.1 million, which was the net book value on the date of transfer. During the year ended December 31, 2021, the Company sold the equipment, received proceeds of approximately $0.1 million and recorded a loss of approximately $0.1 million. </span></div>During the years ended December&#160;31, 2022 and 2021, depreciation and amortization expense was $0.3 million and $0.1 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615304096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text">ACCRUED LIABILITIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615134528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022, the Company entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders named therein (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $75.0&#160;million, in four tranches (collectively the &#8220;Term Loan&#8221;), consisting of (1) an initial tranche of $25.0&#160;million, available to the Company through June 15, 2023; (2) a second tranche of $10.0&#160;million, subject to the achievement of certain regulatory milestones, available through June 15, 2023; (3) a third tranche of $15.0&#160;million, subject to the achievement of certain regulatory milestones, available through March 15, 2024; and (4) a fourth tranche of $25.0&#160;million, subject to approval by the Lenders&#8217; investment committee(s), available through December 15, 2024. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Loan Agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Term Loan has a maturity date of October 1, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 7.45% and (ii) 4.2% above the Prime Rate, provided that the Term Loan interest rate shall not exceed a per annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of December 31, 2022 was 8.95% based upon an increase in the prime rate in June 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per the terms of the Hercules Loan and Security Agreement, the Company was originally obligated to make interest-only payments through April 1, 2024. However, upon the achievement of a development milestone in August 2022 the interest-only period was extended to October 1, 2024. If additional development milestones are met, the interest-only period will be further extended to April 1, 2025. The Borrower is required to repay the Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $5.0&#160;million. The Company incurred debt issuance costs of $0.2&#160;million in connection with the Term Loan. In addition, in connection with the initial draw, the Company paid to the Lenders a facility fee of $0.1&#160;million, as well as $0.1&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#8220;Lender Expenses&#8221;). The debt issuance costs and the Lender Expenses are being amortized as additional interest expense over the term of the loan. Debt issuance costs and the Lender Expenses are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately 9.3%. The Company recorded interest expense of $0.5&#160;million during the year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the impact of the Term Loan, on the Company&#8217;s consolidated balance sheet at December&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan and Security Agreement as of December&#160;31, 2022 are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615164064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ImmunoGen, Inc. </span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement (the &#8220;ImmunoGen License Agreement&#8221;) with Immunogen, Inc. (&#8220;ImmunoGen&#8221;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $48.0&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $2.5&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#8220;IND&#8221;) application for VRDN-001 with the FDA. In May 2022, the Company paid a $3.0&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for VRDN-001. In December 2022, the Company recorded $10.0&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a Pivotal Clinical Trial for VRDN-001, amount which was paid in January 2023 and which was included in accounts payable in the consolidated balance sheet as of December 31, 2022. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $95.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements with Xencor, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a subsequent technology license agreement (the &#8220;2021 Xencor License Agreement&#8221;) with Xencor for a non-exclusive license to certain antibody libraries developed by Xencor. Under the 2021 Xencor License Agreement, the Company received a one-year research license to review the antibodies and the right to select up to three antibodies for further development. In consideration for rights granted by Xencor, the Company issued 394,737 shares of our common stock to Xencor in December 2021. The shares were valued at $7.5&#160;million and recorded as research and development expense during the year ended December 31, 2021. Under the terms of the 2021 Xencor License Agreement, if successful, for each licensed product, the Company would be obligated to make future milestone payments of up to $27.75&#160;million, which includes development milestone payments of up to $4.75&#160;million, special milestone payments of up to $3.0&#160;million, and commercial milestone payments of up to $20.0&#160;million. Additionally, for each licensed product that the Company successfully commercializes, it would be responsible for royalty payments equal to a percentage in the mid-single digits of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2020, the Company entered into a license agreement (the &#8220;Xencor License Agreement&#8221;) with Xencor, under which Xencor granted the Company rights to an exclusive, worldwide, sublicensable, non-transferable, royalty-bearing license to use specified Xencor technology for the research, development, manufacturing, and commercialization of therapeutic antibodies targeting IGF-1R indications. In consideration for rights granted by Xencor, the Company issued 322,407 shares of its common stock in December 2020. The shares were valued at $6.0&#160;million and recorded as research and development expense in 2020. Under the terms of the Xencor License Agreement, the Company is obligated to make future development milestone payments of up to $30.0&#160;million. Additionally, if the Company successfully commercializes any product candidate subject to the Xencor License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $25.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of products containing the licensed technology in each country until the later of (i) the expiration of the last patent claim subject to the Xencor License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained, or (iii) the 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> anniversary of the date of the first commercial sale. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights Agreement </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the merger agreement with miRagen Therapeutics, Inc., on November 4, 2020, the Company and the Rights Agent (as defined therein) executed and delivered a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of the Company&#8217;s common stock as of November 6, 2020, other than former stockholders of Private Viridian, was entitled to one contractual contingent value right issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of its common stock held by such holder. No CVRs have been or may in the future be issued pursuant to the terms of the CVR Agreement as of December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorado-based Office and Lab Space</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space. The lease agreement includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to three terms of three years each. Minimum base lease payments under the lease agreement, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the lease agreement of approximately $1.6&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#8217;s estimated incremental borrowing rate, over the 12 months expected remaining term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Massachusetts-based Office Space</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended, the &#8220;Original Lease&#8221;). The Original Lease included rent escalation clauses through the lease term. Minimum base lease payments under the lease agreement are recognized on a straight-line basis over the full term of the lease. Upon assumption of the Original Lease, the Company recognized a right-of-use asset and corresponding lease liability for the Original Lease of $0.1&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#8217;s estimated incremental borrowing rate, over the expected remaining term. In July 2021, the Company entered into an amendment to the Original Lease to increase its Massachusetts-based office space (the &#8220;First Amendment&#8221;). In April 2022, the Company entered into a second amendment to the Original Lease of its Massachusetts-based office space (the &#8220;Second Amendment&#8221;). The Second Amendment made certain modifications to both the Original Lease and First Amendment, including (i) the addition of 2,432 square feet of office space in the same building and (the &#8220;April 2022 Expansion Premises&#8221;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease seven days after the delivery of the April 2022 Expansion Premises, which occurred in the fourth quarter of 2022, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment from October 2024 through November 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Second Amendment, the Company has the option to extend the lease term for an additional period of three years upon notice to the landlord. The Second Amendment provides for annual base rent for the April 2022 Expansion Premises of approximately $0.4&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a third amendment to the Original Lease of its Massachusetts-based office space (the &#8220;Third Amendment&#8221;). The Third Amendment makes certain modifications to the Original Lease, including (i) the addition of 5,240 square feet of office space in the same building (the &#8220;July 2022 Expansion Premises&#8221;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment to four years from the delivery of the July 2022 Expansion Premises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Third Amendment, the Company has the option to extend the lease term for an additional period of three years upon notice to the landlord. The Third Amendment provides for annual base rent for the July 2022 Expansion Premises of approximately $0.9&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of December&#160;31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:69.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s operating lease obligations were reflected as short-term operating lease liabilities of $0.6&#160;million within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjM_e8ea74a0-3f88-44a4-a851-a40562034c1a">accrued liabilities</span> and $1.1&#160;million of long-term lease obligations as <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMzg_22c5afc1-2efb-427c-a693-1ae037736565">other liabilities</span> in the Company&#8217;s consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.5&#160;million for both the years ended December&#160;31, 2022 and 2021, and which was included in operating expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay for operating expenses related to the leased space, which were $0.3&#160;million for both the years ended December&#160;31, 2022 and 2021. The operating expenses are incurred separately and were not included in the present value of lease payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615130736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">CAPITAL STOCK</a></td>
<td class="text">CAPITAL STOCK<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an underwriting agreement (the &#8220;2022 Underwriting Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), SVB Securities LLC and Evercore Group L.L.C. (&#8220;Evercore&#8221;) relating to the offer and sale (the &#8220;2022 Offering&#8221;) of 11,352,640 shares of the Company&#8217;s common stock, which includes 1,725,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $23.50 per share, and 28,084 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.01 per share, at a public offering price of $1,566.745 per share (collectively the &#8220;2022 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2022 Public Offering, including the exercise of the option were approximately $311.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an underwriting agreement (the &#8220;2021 Underwriting Agreement&#8221;) with Jefferies, SVB Leerink LLC and Evercore for the sale and issuance of 7,344,543 shares of common stock, which includes 1,159,089 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $11.00 per share and 23,126 shares of Series B Non-Voting Convertible Preferred Stock at a public offering price of $733.37 per share (collectively the &#8220;2021 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2021 Public Offering, including the exercise of the option, were approximately $97.7&#160;million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. During the quarter ended December 31, 2022, 964,357 shares have been sold under the September 2022 ATM Agreement with Jefferies at a weighted average price of $26.01 per share, for aggregate net proceeds of approximately $24.2&#160;million, including commissions to Jefferies as a sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;November 2021 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $75.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. The November 2021 ATM Agreement was terminated in connection with the September 2022 ATM Agreement. No shares were sold under the November 2021 ATM Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;April 2021 ATM Agreement&#8221;) with Jefferies pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $50.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies as its sales agent. Jefferies could receive a commission equal to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the April 2021 ATM Agreement. The April 2021 ATM Agreement was terminated in connection with the November 2021 ATM Agreement. An aggregate of 2,551,269 shares of common stock were sold pursuant to the April 2021 ATM Agreement prior to its termination, at a volume weighted average price of $13.13 per share, for aggregate net proceeds of approximately $32.4&#160;million, including commissions to Jefferies as sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Purchase Agreement - Aspire Capital Fund, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a common stock purchase agreement (the &#8220;Aspire Stock Purchase Agreement&#8221;), with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;), which provides that, subject to the terms, conditions, and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20.0&#160;million of shares of common stock over the 30-month term of the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2020, the Company sold 412,187 shares of common stock to Aspire Capital at a weighted-average price of $21.35 per share for aggregate net proceeds of $8.8&#160;million. The Company did not sell any shares to Aspire Capital during the years ended December 31, 2021 or 2022. As of December 31, 2022, the Company has the ability to sell an additional $10.2&#160;million of shares of common stock to Aspire Capital. Under the Aspire Stock Purchase Agreement, the Company has the right, in its sole discretion, on any trading day selected by it, and within certain specified limitations, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to 13,333 shares of common stock per business day at a per share price equal to the lesser of (i) the lowest sale price of common stock on the purchase date or (ii) the average of the three lowest closing sale prices for the common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to require Aspire Capital to purchase up to an additional 30% of the trading volume of the shares for the next business day at a purchase price (the &#8220;VWAP Purchase Price&#8221;), equal to the lesser of: (i) the closing sale price of the shares on the purchase date, or (ii) ninety-seven percent (97%) of the next business day&#8217;s volume weighted average-price (each such purchase, a &#8220;VWAP Purchase&#8221;). The Company shall have the right, in its sole discretion, to determine a maximum number of shares and set a minimum market price threshold for each VWAP Purchase. The Company can only require a VWAP Purchase if the Company has also submitted a regular purchase on the notice date for the VWAP Purchase. There are no limits on the number of VWAP purchases that the Company may require.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Aspire Stock Purchase Agreement may be terminated by the Company at any time, at the Company&#8217;s discretion, without any cost to the Company. There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings, rights of first refusal, participation rights, penalties, or liquidated damages in the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, there were 188,381 and 260,437 shares of Series A Preferred Stock outstanding, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in connection with the Offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. As of December 31, 2022 and 2021, there were 51,210 and 23,126 shares of Series B Preferred Stock outstanding, respectively. </span></div>WARRANTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at December 31, 2022<br/>(No. Years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615228672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text">CAPITAL STOCK<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an underwriting agreement (the &#8220;2022 Underwriting Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), SVB Securities LLC and Evercore Group L.L.C. (&#8220;Evercore&#8221;) relating to the offer and sale (the &#8220;2022 Offering&#8221;) of 11,352,640 shares of the Company&#8217;s common stock, which includes 1,725,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $23.50 per share, and 28,084 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.01 per share, at a public offering price of $1,566.745 per share (collectively the &#8220;2022 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2022 Public Offering, including the exercise of the option were approximately $311.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an underwriting agreement (the &#8220;2021 Underwriting Agreement&#8221;) with Jefferies, SVB Leerink LLC and Evercore for the sale and issuance of 7,344,543 shares of common stock, which includes 1,159,089 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $11.00 per share and 23,126 shares of Series B Non-Voting Convertible Preferred Stock at a public offering price of $733.37 per share (collectively the &#8220;2021 Public Offering&#8221;). The aggregate gross proceeds to the Company from the 2021 Public Offering, including the exercise of the option, were approximately $97.7&#160;million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. During the quarter ended December 31, 2022, 964,357 shares have been sold under the September 2022 ATM Agreement with Jefferies at a weighted average price of $26.01 per share, for aggregate net proceeds of approximately $24.2&#160;million, including commissions to Jefferies as a sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;November 2021 ATM Agreement&#8221;) with Jefferies, pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $75.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. The November 2021 ATM Agreement was terminated in connection with the September 2022 ATM Agreement. No shares were sold under the November 2021 ATM Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;April 2021 ATM Agreement&#8221;) with Jefferies pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $50.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies as its sales agent. Jefferies could receive a commission equal to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the April 2021 ATM Agreement. The April 2021 ATM Agreement was terminated in connection with the November 2021 ATM Agreement. An aggregate of 2,551,269 shares of common stock were sold pursuant to the April 2021 ATM Agreement prior to its termination, at a volume weighted average price of $13.13 per share, for aggregate net proceeds of approximately $32.4&#160;million, including commissions to Jefferies as sales agent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Purchase Agreement - Aspire Capital Fund, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a common stock purchase agreement (the &#8220;Aspire Stock Purchase Agreement&#8221;), with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;), which provides that, subject to the terms, conditions, and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20.0&#160;million of shares of common stock over the 30-month term of the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2020, the Company sold 412,187 shares of common stock to Aspire Capital at a weighted-average price of $21.35 per share for aggregate net proceeds of $8.8&#160;million. The Company did not sell any shares to Aspire Capital during the years ended December 31, 2021 or 2022. As of December 31, 2022, the Company has the ability to sell an additional $10.2&#160;million of shares of common stock to Aspire Capital. Under the Aspire Stock Purchase Agreement, the Company has the right, in its sole discretion, on any trading day selected by it, and within certain specified limitations, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to 13,333 shares of common stock per business day at a per share price equal to the lesser of (i) the lowest sale price of common stock on the purchase date or (ii) the average of the three lowest closing sale prices for the common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to require Aspire Capital to purchase up to an additional 30% of the trading volume of the shares for the next business day at a purchase price (the &#8220;VWAP Purchase Price&#8221;), equal to the lesser of: (i) the closing sale price of the shares on the purchase date, or (ii) ninety-seven percent (97%) of the next business day&#8217;s volume weighted average-price (each such purchase, a &#8220;VWAP Purchase&#8221;). The Company shall have the right, in its sole discretion, to determine a maximum number of shares and set a minimum market price threshold for each VWAP Purchase. The Company can only require a VWAP Purchase if the Company has also submitted a regular purchase on the notice date for the VWAP Purchase. There are no limits on the number of VWAP purchases that the Company may require.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Aspire Stock Purchase Agreement may be terminated by the Company at any time, at the Company&#8217;s discretion, without any cost to the Company. There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings, rights of first refusal, participation rights, penalties, or liquidated damages in the Aspire Stock Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, there were 188,381 and 260,437 shares of Series A Preferred Stock outstanding, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in connection with the Offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. As of December 31, 2022 and 2021, there were 51,210 and 23,126 shares of Series B Preferred Stock outstanding, respectively. </span></div>WARRANTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at December 31, 2022<br/>(No. Years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615216656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;), its amended and restated 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), and the Viridian 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221; and collectively with the 2008 Plan and the 2016 Plan, the &#8220;Equity Incentive Plans&#8221;). Additionally, beginning in July 2021, the Company granted stock options outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#8220;Inducement Awards&#8221;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#8217;s Equity Incentive Plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2022 (the &#8220;Effective Date&#8221;), the Company&#8217;s stockholders approved the amendment and restatement of the 2016 Plan (the &#8220;Amended 2016 Plan&#8221;), which increased the number of shares reserved for issuance under the Amended 2016 Plan by 3,050,000 shares and transferred the number of shares that remain available for issuance under the 2020 Plan as of the Effective Date into the Amended 2016 Plan so that the Company operates from a single equity plan going forward. The term of the Amended 2016 Plan is 10 years following the Effective Date. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following balances by plan:</span></div><div style="margin-bottom:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire 10 years from the date of grant. Generally, options vest 25% on the first anniversary of the vesting commencement date and 75% ratably in equal monthly installments over the remaining 36 months. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to 48 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,977&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,616&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.95&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,258&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.95&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#8217;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted to the Company&#8217;s employees and members of its board of directors during the years ended December&#160;31, 2022 and 2021 was $12.95 and $17.50, respectively. The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-top:5pt;padding-right:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of common stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. New six-month offering periods begin each August&#160;22 and February&#160;22. As of&#160;December&#160;31, 2022, the Company had&#160;309,541&#160;shares available for issuance, and 27,074 cumulative shares had been issued under the ESPP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $54.9 million of total unrecognized employee and non-employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of 2.77 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615130736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615199104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded. This amount differs from the amount computed by applying the U.S.&#160;federal income tax rate of 21% to pretax loss due to the provision of a valuation allowance to the extent of the Company&#8217;s net deferred tax asset, as well as to state income taxes and nondeductible expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 limit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Start-up costs and amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRC &#167; 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had approximately $175.6&#160;million and $3.5&#160;million of federal net operating loss and research and experimentation tax carryforwards, respectively, which will begin to expire in 2029. At December 31, 2022 ,the Company had approximately $196.7&#160;million of state net operating loss carryforwards which will begin to expire in 2030. In addition, the realization of net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions, which may result in the expiration of additional net operating losses before future utilization as a result of ownership changes. As a result of these ownership change provisions during 2020, the Company estimated an aggregate limitation on the utilization of net operating loss carryforwards of $59.0&#160;million. In addition to the limitation of net operating losses of $59.0&#160;million, approximately $15.3&#160;million of research and development tax credits were derecognized with the inability of the Company to ever realize a benefit from those credits in the future. The Company determines on an annual basis whether net operating loss carryforwards will be limited. An IRC 382 analysis has been completed through December 31, 2022 and determined that there were no additional ownership changes. The Company will continue to evaluate changes in ownership and the related limitations on a go forward basis. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company&#8217;s net deferred tax assets before valuation allowance was $86.6&#160;million and $53.4&#160;million, respectively. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income or projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of its history of operating losses, the Company does not believe it is more likely than not that it will realize the benefits of its net deferred tax assets, and accordingly, has established a valuation allowance equal to 100% of its net deferred tax assets at December 31, 2022 and 2021. The change in valuation allowance was an increase of $33.2&#160;million in 2022 and an increase of $24.4&#160;million in 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that there were no significant uncertain tax positions relevant to the jurisdictions where it is required to file income tax returns requiring recognition in the consolidated financial statements for the years ended 2022 and 2021. As of December 31, 2022 and 2021, the Company had no accrued interest related to uncertain tax positions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s federal and state returns for 2018 through 2022 remain open to examination by tax authorities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615216656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSNone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611315024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Viridian Therapeutics Europe Limited and Viridian Therapeutics S.&#224;.r.l., both of which were formed for the sole purpose of submitting regulatory filings in Europe, and Viridian Securities Corporation, which was formed in July 2021. The Company&#8217;s subsidiaries have no employees or operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_GoingConcernPolicyPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents and short-term investments balance.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div>The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Such expenses are included within operating activities in the consolidated statements of cash flows. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock', window );">Clinical Trials and Preclinical Study Accruals</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation expense to employees and non-employees based on the fair value of each stock option or award on the date of the grant. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilizes observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921">three</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Lease Right-of-Use Assets and Liabilities</a></td>
<td class="text">Operating Lease Right-of-Use Assets and Liabilities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span>and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt and Debt Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Debt issuance costs represent </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Convertible Preferred Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and at issuance classified the Series A Preferred Stock outside of stockholders&#8217; equity because, if convertibility of Series A Preferred Stock into common stock was not approved by the stockholders, the Series A Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. On December 31, 2020, the stockholders approved the convertibility of the Series A Preferred Stock into common stock and as such, the Company reclassified the Series A Preferred Stock to permanent equity. In September 2021, the Company issued Series B Preferred Stock with conversion rights which the Company has classified as permanent equity in its consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the consolidated statements of changes in stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div>The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements &#8211; To Be Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615242000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities, Available-for-sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of December&#160;31, 2022 and December&#160;31, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:34.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:43.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.753%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615255200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615164064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615211520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text">The following table summarizes the impact of the Term Loan, on the Company&#8217;s consolidated balance sheet at December&#160;31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments of Debt</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan and Security Agreement as of December&#160;31, 2022 are as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615274416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Lease Payments under Noncancelable Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of December&#160;31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:69.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615209296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at December 31, 2022<br/>(No. Years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611287264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Summary of Balances by Plan</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had the following balances by plan:</span></div><div style="margin-bottom:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,449&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.23&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,977&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,616&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.95&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,258&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.95&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions for Stock Options</a></td>
<td class="text">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocation of Share-based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744615274416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock, as converted to shares of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744606363312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 limit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Start-up costs and amortized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRC &#167; 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744616756624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 488,174<span></span>
</td>
<td class="nump">$ 358,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 424,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744612851168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized losses on investments</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744612055024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,772<span></span>
</td>
<td class="nump">$ 2,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,894<span></span>
</td>
<td class="nump">56,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember', window );">Zenas BioPharma | Fairmount Funds Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember', window );">Zenas BioPharma | Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember', window );">Paragon Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementUpfrontFeePayment', window );">Collaborative arrangement, upfront fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementRightsAndLicensesFee', window );">Collaborative arrangement, rights and licenses fee</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember', window );">Paragon Therapeutics | Fairmount Funds Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementRightsAndLicensesFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Licenses Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementRightsAndLicensesFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementUpfrontFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Fee Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementUpfrontFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=vrdn_FairmountFundsManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=vrdn_FairmountFundsManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vrdn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vrdn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744609664176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 424,840<span></span>
</td>
<td class="nump">$ 197,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(514)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">424,450<span></span>
</td>
<td class="nump">196,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">85,578<span></span>
</td>
<td class="nump">22,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">85,605<span></span>
</td>
<td class="nump">22,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">199,350<span></span>
</td>
<td class="nump">128,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(385)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">198,966<span></span>
</td>
<td class="nump">127,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="nump">4,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="nump">$ 4,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614460496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains in available for sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Available-for-sale securities, term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744610070976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 424,450<span></span>
</td>
<td class="nump">$ 196,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">198,966<span></span>
</td>
<td class="nump">127,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">85,605<span></span>
</td>
<td class="nump">22,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">424,450<span></span>
</td>
<td class="nump">196,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">181,390<span></span>
</td>
<td class="nump">127,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">85,605<span></span>
</td>
<td class="nump">22,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">137,903<span></span>
</td>
<td class="nump">42,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">286,547<span></span>
</td>
<td class="nump">154,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">181,390<span></span>
</td>
<td class="nump">127,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">85,605<span></span>
</td>
<td class="nump">22,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614488576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,330<span></span>
</td>
<td class="nump">$ 2,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,004)<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614452880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss from disposition of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744610042464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES - Components of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies', window );">Accrued outsourced clinical trials and preclinical studies</a></td>
<td class="nump">$ 12,576<span></span>
</td>
<td class="nump">$ 6,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and related taxes</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedLegalFeesCurrent', window );">Accrued legal fees and expenses</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued other professional service fees</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity', window );">Value of liability-classified stock purchase warrants</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 18,827<span></span>
</td>
<td class="nump">$ 11,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Total accrued liabilities<span></span>
</td>
<td class="text">Total accrued liabilities<span></span>
</td>
<td class="text">Total accrued liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liability of Warrants on Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedLiabilityofWarrantsonTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Outsourcing Clinical and Pre-clinical Studies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedOutsourcingClinicalandPreclinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744612960752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Capital, Inc | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentNumberOfTranches', window );">Debt instrument, number of tranches | tranche</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFirstTranche', window );">Debt instrument, face amount, first tranche</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountSecondTranche', window );">Debt instrument, face amount, second tranche</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountThirdTranche', window );">Debt instrument, face amount, third tranche</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFourthTranche', window );">Debt instrument, face amount, fourth tranche</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.45%<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentInterestRateMaximum', window );">Maximum interest rate</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_PrincipalAmountTermFee', window );">Principal amount fee term</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFacilityFee', window );">Lenders facility fee</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentOtherExpenses', window );">Debt instrument other expenses</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Capital, Inc | Secured Debt | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, First Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountFourthTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Fourth Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountFourthTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountSecondTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Second Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountSecondTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountThirdTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Third Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountThirdTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Facility Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_PrincipalAmountTermFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal Amount Term Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_PrincipalAmountTermFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611477840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Long-Term Debt Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 4,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Capital, Inc | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross proceeds</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(355)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 4,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614455936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Principal Payments (Details) - Hercules Capital, Inc - Secured Debt<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744610256064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>renewal_term</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms (up to) | renewal_term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,680,000<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="nump">$ 1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">$ 613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 613,000<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AreaOfOfficeSpaceExpanded', window );">Area of office space expanded | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AreaOfOfficeSpaceTerminated', window );">Area of office space terminated | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AreaOfOfficeSpaceExtension', window );">Area of office space extension | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeaseAnnualBaseRent', window );">Operating lease, annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability noncurrent</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, noncurrent, statement of financial position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization (reversal of amortization) expense relating to operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeasesOperatingExpense', window );">Operating expenses of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember', window );">ImmunoGen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementMilestonePayment', window );">Collaborative arrangement, milestone payment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum', window );">Potential royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vrdn_XencorIncMember', window );">Xencor, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,750,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum', window );">Potential royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm', window );">Collaboration arrangement, research license and selection rights, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted', window );">Shares issued in exchange for rights granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,737<span></span>
</td>
<td class="nump">322,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted', window );">Value of shares issued in exchange for rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum', window );">Collaboration arrangement, potential development milestone payment, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum', window );">Collaborative arrangement, potential special payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AreaOfOfficeSpaceExpanded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area Of Office Space Expanded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AreaOfOfficeSpaceExpanded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AreaOfOfficeSpaceExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area Of Office Space Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AreaOfOfficeSpaceExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AreaOfOfficeSpaceTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area Of Office Space Terminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AreaOfOfficeSpaceTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Potential Development Milestone Payment, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Potential Milestone Payment, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research License and Selection Rights, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Royalty Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Special Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Shares Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementSharesIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Value Of Shares Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CommitmentsandContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Commitments and Contingencies [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CommitmentsandContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeasesOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeasesOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vrdn_XencorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vrdn_XencorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744614453296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744603081296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>sale_price </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CapitalStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CommonStockVoteperShare', window );">Common stock, vote per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of Series B preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291,874,000<span></span>
</td>
<td class="nump">$ 114,242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">260,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds', window );">Commission fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2022PublicStockOfferingMember', window );">2022 Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2022PublicStockOfferingMember', window );">2022 Public Stock Offering | Series B Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,566.745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2021PublicStockOfferingMember', window );">2021 Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2021PublicStockOfferingMember', window );">2021 Public Stock Offering | Series B Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AspireStockPurchaseAgreementMember', window );">Aspire Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">412,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockWeightedAverageSharePrice', window );">Weighted-average share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold', window );">Amount of shares authorized to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockTerm', window );">Sale of stock, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Transaction value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices', window );">Average over number of lowest sale prices | sale_price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold', window );">Number of consecutive days threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock, as converted to shares of common stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock, as converted to shares of common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964,357<span></span>
</td>
<td class="nump">2,551,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds', window );">Commission fee percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockWeightedAverageSharePrice', window );">Weighted-average share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.01<span></span>
</td>
<td class="nump">$ 13.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of Series B preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="nump">$ 32,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2022 Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,352,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2021 Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,344,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Aspire Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased', window );">Amount of shares required to be purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent', window );">Additional trading volume available for purchase, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice', window );">Price of additional share, percent of next business days' volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Conversion, Percentage Of Ownership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CommonStockVoteperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CommonStockVoteperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Trading Volume Available For Purchase, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Of Share Authorized To Be Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Of Shares Required To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Consecutive Days Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Price Of Additional Share, Percent Of Next Business Days' Volume Weighted Average Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Sale Price Calculations, Average Over Number Of Sale Prices</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockWeightedAverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted Average Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockWeightedAverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2022PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2022PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2021PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2021PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AspireStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_AspireStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=vrdn_ViridianMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=vrdn_ViridianMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744606233264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">363,963<span></span>
</td>
<td class="nump">420,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.82<span></span>
</td>
<td class="nump">$ 15.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member', window );">Issued April 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 127.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member', window );">Acquired October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">29,446<span></span>
</td>
<td class="nump">29,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member', window );">Issued February 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">332,130<span></span>
</td>
<td class="nump">388,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member', window );">Issued November 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">1 year 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">363,182<span></span>
</td>
<td class="nump">419,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Remaining Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744616439584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Stock Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightActivityRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">420,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightExercisedInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="num">(56,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">363,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">16.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightActivityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Activity [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightActivityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744612983040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized employee stock-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period for RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod', window );">Stock purchase offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares', window );">Number of shares available for issuance under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,024<span></span>
</td>
<td class="nump">3,312<span></span>
</td>
<td class="nump">27,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per option (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.95<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock | Initial Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock | Subsequent Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember', window );">Amended 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized for plan (in shares)</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod', window );">Plan expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Plan Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744609659536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Balance by Plans (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">5,722,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">3,781,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_InducementGrantsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">1,513,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2020PlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">930,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2016PlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">3,278,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">3,781,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2008PlanMember', window );">2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_InducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_InducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_A2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_A2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_A2008PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_A2008PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744609903856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,722,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,683,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,545,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(191,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(315,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,722,449<span></span>
</td>
<td class="nump">3,683,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (in shares)</a></td>
<td class="nump">5,722,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,697,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested (in shares)</a></td>
<td class="nump">1,697,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 16.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">17.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">14.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">19.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">17.23<span></span>
</td>
<td class="nump">$ 16.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest (in dollars per share)</a></td>
<td class="nump">17.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">16.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested (in dollars per share)</a></td>
<td class="nump">$ 16.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term and Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding (Aggregate Intrinsic Value)</a></td>
<td class="nump">$ 68,977<span></span>
</td>
<td class="nump">$ 15,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest (Aggregate Intrinsic Value)</a></td>
<td class="nump">68,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable (Aggregate Intrinsic Value)</a></td>
<td class="nump">21,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested (Aggregate Intrinsic Value)</a></td>
<td class="nump">$ 21,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744610020000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term, in years</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.80%<span></span>
</td>
<td class="nump">117.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.72<span></span>
</td>
<td class="nump">$ 20.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744609657984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 19,765<span></span>
</td>
<td class="nump">$ 14,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">7,298<span></span>
</td>
<td class="nump">4,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 12,467<span></span>
</td>
<td class="nump">$ 9,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611421856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">22,059<span></span>
</td>
<td class="nump">23,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">12,559<span></span>
</td>
<td class="nump">17,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock, as converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">3,414<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">5,722<span></span>
</td>
<td class="nump">3,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744610248160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Effective Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal and state tax credits</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.50%)<span></span>
</td>
<td class="num">(28.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other permanent items</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent', window );">Section 382 limit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Section 382 Limit, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744611462864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 40,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">3,803<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based expense</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts', window );">Start-up costs and amortized costs</a></td>
<td class="nump">9,460<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">IRC &#167; 174 capitalized costs</a></td>
<td class="nump">18,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">86,684<span></span>
</td>
<td class="nump">53,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(86,602)<span></span>
</td>
<td class="num">(53,430)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss', window );">Unrealized gains/losses</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Right-of-Use Asset, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Start-up Costs and Amortized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right-of-use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139744609915728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount', window );">Aggregate limitation on utilization of certain net operating losses and credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_TaxCreditCarryforwardWriteOff', window );">Tax credit write off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">$ 86,600,000<span></span>
</td>
<td class="nump">$ 53,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DeferredTaxAssetValuationAllowancePercent', window );">Valuation allowance percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 33,200,000<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and experimentation tax carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">175,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 196,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxAssetValuationAllowancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Valuation Allowance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxAssetValuationAllowancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_TaxCreditCarryforwardLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Limitations On Use, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_TaxCreditCarryforwardLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_TaxCreditCarryforwardWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Write Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_TaxCreditCarryforwardWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>vrdn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vrdn="http://www.viridiantherapeutics.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrdn-20221231.xsd" xlink:type="simple"/>
    <context id="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i33b03f6820f64be1a5cf5d792fdee0ec_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4bddb80bbec7433dba39aa163dc3a5dd_I20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i369f8afef8e64303909112080068f0af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4388ce6ee5d4297a40f002234ac2faf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if05bfdb09f134543bd371b54e8ca91a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9442e34fd9c44319d656358b37cacf1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d116b0d685d4c0892407cdf68ea7473_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i778249cf6ce9418b9ad4f911c7d378a8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc0d47b55d5c4d7a86368dd7a7fe9210_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82f4e2c253814d9993e96053bae40a2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if33717d39c2943d388f869ebe747c1e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff1bba44fa4d4b6e9380aceefcb77a8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i895af20035af46daa806cd54af1820ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaa992c0e8b04d0ba561866e5ddc5c70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieae0b71a3dbf4614b433002bcd8498cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie244e1d6bb534436961dc38a043ef711_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c9fcc60a60e445c8f1795104a6c46f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib443f38e5cd2438c9634efcd8b2278ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a6c2ed89fed4622a2d2aa7172d7f416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7aed7cceb62b4b92bc8ed6ec984f2319_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39fb3692ca914421afc3d247f7d8cca4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id35723f52a2d4347be6c1269abb323a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb583c45106b4818a232ee9c4ad39c58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id86c28f6cc424ce98bea0a4a97eddb90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9d6b724a9464b29ae68552713b5ed42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id337e30fdc0349c4816ac5a494a9223d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea2d086c62db415b86b0a9d226c455d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab4425cde974494cabb81ce893b56b8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e57058fb77d4e7fbf5cb93719753578_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2267406c415407baff04941844c5d1b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i508999d2a2594110b99007f534be4af5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25983ef470214368ab0eea4aa4373a8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i789f9857a6f441e3aa1e17f4094afaf7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2335da7e52874d249a90521b0fd87ab1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0451fea21364299a740c764817cf380_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0397e407cad54193ab35946350fff184_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74ab3fa116a44b7da15ac250754235b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id58d19c7f26d4ebd88665ae0a8aa7f16_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0e66c30a3694f1299adfc4cecaa2744_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c84830c57044151be9237f1a7dd891b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ca19cad32d5468a88da45e616c993ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14703c6fcd204cf4bb4d52313293b090_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16c66a163e074d75953188a31b49a161_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16d69f24ee32425883b5fb4906e7848c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6153c8d6ca7244fcaaa83b242bba2e18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic95cffa740f64b68af86df3f770a0b25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0697651628c4404996864ee40e782d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a876722929249349e7f7da5272ce756_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iecdf32196c3b49e9a21b4456f68dc18a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib14e5a6aafc64ee685e4abf45a236d64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6eb1090043441ef956275d1fb66e81c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cdd597646b44d52894aecdbad5728ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28384390d13f43e5b84481e6b9381841_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i319fa86bec5d4b28816c65ae30472b0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib504c0d9b1b1464ca139986003bd5108_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cdcc30d49604c4f8a177a5ad2200579_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9356ff5b031a4687b1c762d67b77aa89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i138932474f284b93a8c0a3f2ea051590_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73f9db3f0dd54baab1199f7f903a42f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcf415c64ea54fffaef87bbacbad114c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia17544d63b7e4808a4b8208d12cb2e71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25d2676e80164d798e781f7504896a1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie994cb889acc4540af7bc488619bb148_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id68f4338d1f44253b074041654004af8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2795e5bc63324d8692234b45f12d6e89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i495cfb882143496ab5fafbfd845fc230_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd7a54bdbf734a5f8559bb31501853dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1ec5d1cd14648b2a0cb3409d8481901_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cb2d53f432d49a28a93868e1b8234d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e890918a65f47ea962c20bc52a3a589_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i718d62966309427ab5d15be792791b49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03f92b6bed324e2ba85a9852abf1b187_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a6d117211af41a28fb359bb1d81d933_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie418b540ddec4d8f9a908bc68dd410e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39731739ccb24de699b33ec24511466f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife91bebf75fa462f9dc8efd8e9e15192_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00032c150d7b4b26b67be5b777d07453_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bb7acaf82d94261b8bbef9198fb5b9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i397518dae3854f5aaf22291b12e28fbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b0e75e0c7604e9682a93b1b039078c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20b087108fec4701a4a2c61e0717f2a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91e20b79c6ce409d9f6ade1210e3b210_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c21147b36794bedbd9fc27467dd2076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i569d7eb69fb147f7a599cb9ed5033a75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica72868174974c239b1ad5f7a2786253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aa2353ccf1b493a906749cc46971b22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd00d8f83ece4bb8bf16db7bf032c030_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf96050c9b204ae3a4dc0d09a8f89a45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2493b7d3e6f54fc4aca64c1b7e756944_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7237ef7f504c42ac91f4cd23a2e8f7d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic661c528426d40a4a7f6ff953d525bbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i962c21f5667a48bead2b497aa2cc2efb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18f6583aa4bf42c9b1b52633f83d14a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia25cc2ffa9f144a88bb763f938333daf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01a117538c9041aebcee41fd26d43947_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i558bf4d01982457597bb849567a66261_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia959ee789f0d49838e929580701a3357_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2828cb09ac024bbeb97dcdad08208d79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad844ce133a4439b89b3b712bcebe2fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2cb8a885c6c2471aac42e78a2b6716e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39e7dc6d42804fb38aabcd93c116f6af_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="iee91adf567604cd2aa42b110e5fac7af_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i5068b8f88948444a8959f2c27cf864e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5106586991db467b98afa08d33f637c0_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i87bf3ab4aa3946a18532afb870802102_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84ae605e448441d3a3f0ac5f55eca328_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0659d7dc0d044cddb185ec3b557387ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f5e9943af7844ce9cf70397131daf9b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib0a42fb2ee584e7ca4c08ef5f57c78d4_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id50bf97251614e40ab675969431f996b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i021c11dfe09a4127921884ad1fc46e9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="if84d62946a994027b63085a509c4d878_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b67fa0e69554ec68418419f8b40c77e_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i124a3275b5a440f5acff5df5308106be_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iacf8bb4484b14487a716974ff915120a_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab0808833c084902820bea4f3472d32b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa3a835940b42d39eb93c3ed98a799e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic46a9b2c111841f28563bace994e0980_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cf6615de6694ae69368169bef73730a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:XencorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic802c0b9ae6945e4a39732c93b32f251_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87f669c23fa44047a98623dceb3ec78b_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i8c0728b5d899440094213edef06f750b_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i1aef7c7506834b01bc927bc477344c11_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="if8403d7b138f480f8845cd9631fed10a_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="id838e3d9eb3e439aae39d4378ce4ba61_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i3b72d2965ee0434c841cfb9e8258e086_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i3a8b414d79224c589b4f8171dc32086e_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i7803c980e7e94395b6662e71bdb21d08_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="ia279525ba3464bb3bd46c39083223a69_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="if928b497323f4aa09bdc2a799e98f2d8_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i0137f42d4153427eba19af3131416b54_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2022PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="idfedb0c338d24c7fb89b19d4dc8f497d_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60581c1fe5a94b06a7f4dbec809547b3_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iddf90d2e59564c068859bfb9affa9e2d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib79b5053076944fa8214003d886b1ba3_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9fd1e3cfaeeb44ec8b6e9c11e444058e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1af72201586744fbb2c99adcce15b017_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2021PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iffb9991b56694a0faf0dc09579f73d81_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i9b4be6ccd9ad4885a999915b4b0caed6_D20211101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="icfe4499fee034827abde9a07a164e945_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i86483928bea44016893e50c31509dba0_D20191201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0eac05f69eb14abb936aff1bddd334b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idad687f93f544b899dde34ad1e484822_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AspireStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifba8d787738a4d90b399133c72c646a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37b9550134c5468b8fd0e59a39c182ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i128e797bb49d4cd88ed84383f99ec141_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i606007a11a244c8c8b02f58f219ee3cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb45543c55a341d59828621ace35f8e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14d5a529d15d48ca9f86845a914722f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0ef63c34dae44f0853d1416aa2f882e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife09cc8c10c94dc8996beb13848ad137_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaeea194517f4499b35939e81a5d9621_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d62a34b1b4a4f5e9b01227f00998027_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd6f20f151aa4c638e38a93431710146_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89382e3a327947c289b5183a9f74f852_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied23b327864a44a984dcfb100731b721_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3974d6a34a904cfb85456eb0420ddb31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1dc204ff96984e1783d7a194c6f1ac47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i17f880652d2a4b6798eccdac2488595d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fdadfb509ff40919c0cab248bd849e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b41fe046b334a039198964438e80c98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d7ad7937f2e4f1a815947ffda355a35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0930912c457940afaf6c32b75e459522_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id35aece8bbc142a1911840a29f94d84d_D20160101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i35dd0d5868d3450181c2d16f2687ac92_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6738e86aeb641cfb7e9e094c2fc4c6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4b73a1e80a44f5590d1cc32f390331b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6eac4ba1e8146d09bc0d4159bb00c0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65916045213f4b35b8eaac7d9d7c38f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i49abc6a01de84a36bc043c40f8227f10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29536a69b2634ac49eb9828516064751_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2a030fb15c14da49fde0862e7c27a2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i697a762fdb594a17ba1c80bc48028a56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99e4eeddfa014778a51d0845f779bd05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd090a1fac43479584a8c5f526d77264_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i087f0a8b9f354a148b61f301862025db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie575904542f4433e911075dd3974f021_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8bd65cfed6004a6e9be4b0f521ae67ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i041bd935d0394bcb91d5976137df8830_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vrdn:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>vrdn:tranche</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewal_term">
        <measure>vrdn:renewal_term</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>vrdn:vote</measure>
    </unit>
    <unit id="sale_price">
        <measure>vrdn:sale_price</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF80LTEtMS0xLTY0NjE0_44d08031-211a-433a-95ad-2c9d58ece6b1">0001590750</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF82LTEtMS0xLTY0NjE0_ada5add7-149e-4f15-93b2-a51b69f27e65">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF83LTEtMS0xLTY0NjE0_271b5101-b436-4710-b389-a85b58b8cfe5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF84LTEtMS0xLTY0NjE0_674f5e5d-74d5-4be9-b1e5-c0b6a433770a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV80L2ZyYWc6NWRiMzg4OWViNGExNDcwMmEwMzEwZTE2MTM1OGU1M2IvdGFibGU6NjRmNmRmOGJlNGI5NDcxM2E5ZTEyZjBkZTJjYTJlZTAvdGFibGVyYW5nZTo2NGY2ZGY4YmU0Yjk0NzEzYTllMTJmMGRlMmNhMmVlMF85LTEtMS0xLTY0NjE0_7ad0a5c4-0e08-4834-a219-cb6a5b64b49f">Viridian Therapeutics, Inc./DE</dei:EntityRegistrantName>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iecdf32196c3b49e9a21b4456f68dc18a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjM_e8ea74a0-3f88-44a4-a851-a40562034c1a">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMzg_22c5afc1-2efb-427c-a693-1ae037736565">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA4_6bf13a90-0ac6-4200-a3ce-6bf511ce2a83">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk0_8ab359c8-b38b-4978-9526-4ac82f56855a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yMTM_83c6db10-cd71-4fc3-9bad-60e5447de495">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yMTM_d63f5aba-e3bd-4984-8395-b6050a8f2261">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzkw_9842e365-9405-47d8-bb69-a16f290bd7ab">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzkx_7155c7be-f41b-448d-8fda-bbe858b6c162">001-36483</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OWQxOThkZGY1NGY0NGNkMGJiMjdmNzI3OTI3YjNmNDAvdGFibGVyYW5nZTo5ZDE5OGRkZjU0ZjQ0Y2QwYmIyN2Y3Mjc5MjdiM2Y0MF8wLTAtMS0xLTY0NjE0_60a1241d-5990-410e-821f-6a7e526c0cee">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OWQxOThkZGY1NGY0NGNkMGJiMjdmNzI3OTI3YjNmNDAvdGFibGVyYW5nZTo5ZDE5OGRkZjU0ZjQ0Y2QwYmIyN2Y3Mjc5MjdiM2Y0MF8wLTItMS0xLTY0NjE0_f99c18ff-ba51-4608-867f-70efadad26e4">47-1187261</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA5_76e03e4c-b407-4554-b081-884e00aad615">221 Crescent Street, Suite 401</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODEw_f44cca91-25be-4f12-98a0-1a24decbfbe3">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODEz_67023e9e-c51d-44e1-8dae-224878299f99">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk1_b9ec36ff-b1ee-4c23-b7f3-c32cd2a0a2a2">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODE0_ade761dd-66ab-4aca-8ca9-97a32f37501b">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODE1_d58cb2ab-4d56-4797-acab-e5ce3278d074">272-4600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTAtMS0xLTY0NjE0_699535da-3d4e-4ab1-b0e3-81261a0208ea">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTEtMS0xLTY0NjE0_0d28555d-b32e-4326-a152-2330c795ad28">VRDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6YmZiYzBjYjUxNWQ4NDU1YjhmOWU1NmY5NzYwMzZkOTQvdGFibGVyYW5nZTpiZmJjMGNiNTE1ZDg0NTViOGY5ZTU2Zjk3NjAzNmQ5NF8xLTItMS0xLTY0NjE0_8556dfc1-5754-4cc0-8961-bc2c7adf84b3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk2_e62c1729-9fbd-419b-9677-c9ea62718cf1">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODAx_5b77d173-e73e-4571-b352-880013107450">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA2_d9d8cd4f-e08a-4f13-a22b-288dd5505e3b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk3_6edaca73-93c3-4092-82a3-07591f73f49f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18xLTAtMS0xLTY0NjE0_a118754a-0928-4a50-9785-58dfcaf66944">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18xLTMtMS0xLTY0NjE0_80641ea0-3af3-4c79-a57d-082d44bf30cd">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGFibGU6OTljOWRmNTkyNjljNGVlMjhhOWMyMmFmMDNkNjczNzcvdGFibGVyYW5nZTo5OWM5ZGY1OTI2OWM0ZWUyOGE5YzIyYWYwM2Q2NzM3N18yLTMtMS0xLTY0NjE0_e021b5d7-db43-4eb3-99cf-4ab9b393c225">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODAy_7f86306c-3738-42f6-84fc-e2564aeabc5e">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zNzk5_4206095d-8c35-4731-9df0-227c7723783b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i33b03f6820f64be1a5cf5d792fdee0ec_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8yOTg5_4d785ad6-5513-4ce5-844c-597dd64a5ddd"
      unitRef="usd">329300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4bddb80bbec7433dba39aa163dc3a5dd_I20230303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zMzMw_41368f4c-6d14-46c8-85f0-7128c931e156"
      unitRef="shares">42897951</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xL2ZyYWc6MWVmNWQyOThjZWEwNDk0NDkxMWFlZTIxZTdiNzliZmQvdGV4dHJlZ2lvbjoxZWY1ZDI5OGNlYTA0OTQ0OTExYWVlMjFlN2I3OWJmZF8zODA3_94e42c29-7bf2-4c3a-a1b0-bb7561cb77bc">Portions of the registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of shareholders (the &#x201c;2023 Proxy Statement&#x201d;) are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDMvZnJhZzplMmE0Zjg5YmRhNzE0YmQ1OGQ4NmY5NmJiMDllOTAyZi90YWJsZTo5NDIyMGJmZmZhY2M0NjJmOGU2YzhhOTE0ZTkxYjcyYi90YWJsZXJhbmdlOjk0MjIwYmZmZmFjYzQ2MmY4ZTZjOGE5MTRlOTFiNzJiXzEtMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjpjYWVhOTkwZDc1Mjk0OTIxYTMyZDdiMTJiYmQ1Y2FjMV8xMDE_1beb501d-2a47-4d3d-b304-390323e4f468">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDYvZnJhZzo4ZjU4NzA1YzVmYjQ0NGUyOWRmMTZmMWMwZmE4MzdkMC90ZXh0cmVnaW9uOjhmNTg3MDVjNWZiNDQ0ZTI5ZGYxNmYxYzBmYTgzN2QwXzU3MjA_ef3dad55-2611-4654-9f81-1a5c7308d32c">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMDYvZnJhZzo4ZjU4NzA1YzVmYjQ0NGUyOWRmMTZmMWMwZmE4MzdkMC90ZXh0cmVnaW9uOjhmNTg3MDVjNWZiNDQ0ZTI5ZGYxNmYxYzBmYTgzN2QwXzU3MjE_ec6a1a52-4866-4b47-a06d-7ed82ce990a7">Boulder, Colorado</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzYtMS0xLTEtNjQ2MTQ_74691384-28ca-4b60-8770-fa950d59e026"
      unitRef="usd">155579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzYtMy0xLTEtNjQ2MTQ_fdbdd8e6-eeb8-4603-bb41-6e9948be6d33"
      unitRef="usd">42299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzctMS0xLTEtNjQ2MTQ_936450a0-7601-4b29-b270-cf2bc4cfb477"
      unitRef="usd">268971000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzctMy0xLTEtNjQ2MTQ_9ce888f0-a386-489f-95ef-ef52562daa8d"
      unitRef="usd">154666000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzgtMS0xLTEtNjQ2MTQ_d307ea6a-3e4e-4bad-91e2-c4c2389de5c9"
      unitRef="usd">6521000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzgtMy0xLTEtNjQ2MTQ_c4d36887-8458-4ee3-82d2-411403d4e51c"
      unitRef="usd">2747000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzktMS0xLTEtNjQ2MTQ_fe23be44-9230-4674-9f90-c1f76c64e6a6"
      unitRef="usd">102000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzktMy0xLTEtNjQ2MTQ_b6dc5abc-9285-435a-a434-af1f7f18378e"
      unitRef="usd">451000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:AssetsCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEwLTEtMS0xLTY0NjE0_b3868102-7018-4ad7-9288-04b0f931e82d"
      unitRef="usd">431173000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEwLTMtMS0xLTY0NjE0_0b3fcdc5-b36a-499a-a003-4d75727ab5cd"
      unitRef="usd">200163000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzExLTEtMS0xLTY0NjE0_01642c03-90b3-4eea-b38e-f1104007bf8a"
      unitRef="usd">1326000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzExLTMtMS0xLTY0NjE0_87d95dc0-6626-434a-bb4c-28c4a23f689f"
      unitRef="usd">375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEyLTEtMS0xLTY0NjE0_5f3abf38-85a4-4d08-aff9-6a88451d007c"
      unitRef="usd">1610000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzEyLTMtMS0xLTY0NjE0_f313d895-92ee-40b9-9bba-b2fa31a055bf"
      unitRef="usd">1680000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE0LTEtMS0xLTY0NjE0_02a95f28-9d98-496c-abab-030a2686eb46"
      unitRef="usd">982000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE0LTMtMS0xLTY0NjE0_9df4b492-d5fd-4d84-846a-966108ebd42c"
      unitRef="usd">1491000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE1LTEtMS0xLTY0NjE0_7387a12f-4b36-4831-97d1-a7e2b7c3cfb6"
      unitRef="usd">435091000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE1LTMtMS0xLTY0NjE0_81dd6b3d-5625-4563-ae1c-ba6719c3d28a"
      unitRef="usd">203709000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE5LTEtMS0xLTY0NjE0_8841f891-7cc6-45df-86b4-ceb4e3aa7b47"
      unitRef="usd">14234000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzE5LTMtMS0xLTY0NjE0_a1180b4c-88bb-4913-93b6-c747c21ef541"
      unitRef="usd">2329000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIwLTEtMS0xLTY0NjE0_f1ba25ed-dbbb-4663-b283-f5e242de003f"
      unitRef="usd">18827000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIwLTMtMS0xLTY0NjE0_ca608e91-987f-4fac-963b-7f040548ec21"
      unitRef="usd">11018000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIxLTEtMS0xLTY0NjE0_cb531315-ee6a-44ab-8f09-8811850f8467"
      unitRef="usd">288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIxLTMtMS0xLTY0NjE0_68fe7d53-803a-4c3d-b771-b693c254f3a3"
      unitRef="usd">289000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIyLTEtMS0xLTY0NjE0_2e7d84fe-9c34-4994-92cf-c3e236a843ec"
      unitRef="usd">33349000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzIyLTMtMS0xLTY0NjE0_d42c51a7-b64c-4766-98e5-652b136f0b41"
      unitRef="usd">13636000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI1LTEtMS0xLTY0NjE0_98c4c3a2-412b-4b9c-874d-07db62b4b099"
      unitRef="usd">4645000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI1LTMtMS0xLTY0NjE0_af774922-2882-407c-80b7-c1b1a50cd759"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI2LTEtMS0xLTY0NjE0_d4403f77-5849-40cc-b465-098004c5d47c"
      unitRef="usd">861000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI2LTMtMS0xLTY0NjE0_a86afa25-3404-4ce0-a33b-7a8170966673"
      unitRef="usd">1149000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI3LTEtMS0xLTY0NjE0_5ef1294b-9f55-44c5-a871-ff185bad88e2"
      unitRef="usd">1172000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI3LTMtMS0xLTY0NjE0_b4168c5e-97e5-45fa-a862-45c0c3d6ccaa"
      unitRef="usd">1208000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI4LTEtMS0xLTY1MDY5_4362a842-ef54-4fa5-811a-2d8cb0b28624"
      unitRef="usd">40027000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI4LTMtMS0xLTY1MTI2_df6ac238-7db8-498b-80e5-1fe8c0c43c31"
      unitRef="usd">15993000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI5LTEtMS0xLTY0NjE0_b820f1cc-5ecc-4399-a54a-832e13ba55cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzI5LTMtMS0xLTY0NjE0_b4b25095-0e2c-4ab2-95bd-29acb0dd9dc1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTAz_6e794f9d-0f2a-4742-8ccc-ab8aea75077c"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTAz_87d36551-c588-4976-aced-ccc185db5e5f"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfOTM0NTg0ODgzNjM0MQ_5767909d-db36-4382-99e8-bb4f45e5dbd6"
      unitRef="shares">435000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfOTM0NTg0ODgzNjM0MQ_9cb87110-1193-451e-ab05-01a0decc2240"
      unitRef="shares">435000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTEz_01677419-b40b-469e-aa94-42a8335c019c"
      unitRef="shares">188381</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTEz_96193cb8-89b5-4611-8356-0128e958be88"
      unitRef="shares">188381</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTIz_1b6672fe-6cb5-4746-80a3-f8cbc541f52e"
      unitRef="shares">260437</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MWUxYmE5YjA0MmY5NDM1MzhkOWJkMTE2YjdhNDlkN2FfNTQ5NzU1ODE0MTIz_435e5a36-7aff-4df5-a6d0-87333996aa42"
      unitRef="shares">260437</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTEtMS0xLTY0NjE0_abc73415-5980-4667-920c-20e1052aaac9"
      unitRef="usd">85470000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMxLTMtMS0xLTY0NjE0_039109ef-5f51-4869-8b52-394e967808e5"
      unitRef="usd">118164000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTAx_ea4d14e3-a8cf-447c-8638-2504b240d806"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTAx_ee367e0e-a888-452c-a0b9-f0511bd0ab15"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfOTM0NTg0ODgzNjMzNw_380d3918-f691-473a-96a6-0ffa4b36b449"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfOTM0NTg0ODgzNjMzNw_d8b2401b-0949-4cb1-8ee2-784d78536653"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTEw_9733476f-3ecd-49b5-b7e4-36c172109d2a"
      unitRef="shares">51210</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTEw_cc8f2657-6c4f-403c-b158-344fa0470d96"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTE5_0c49d8f5-6246-4562-8778-7372b8a5186d"
      unitRef="shares">23126</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTAtMS0xLTY0NjE0L3RleHRyZWdpb246ZmU4ZmMwZjVmMDZmNDY4MGIyY2Y3NDM3NGVjNGM3NjFfNTQ5NzU1ODE0MTE5_a9f049b6-585c-4c5b-b8fc-bd20c3d545dd"
      unitRef="shares">23126</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTEtMS0xLTY0NjE0_1e4db0e0-4829-4ac0-9dd6-b96bb25d9d97"
      unitRef="usd">56677000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMyLTMtMS0xLTY0NjE0_04c8daba-3342-407e-82de-9f7dbba40ef8"
      unitRef="usd">15669000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTAw_357e2dd4-1b3e-4fb8-a98f-9e5e1a70af0c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTAw_eb19e01b-8408-410b-9637-e806f3b66f57"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfOTM0NTg0ODgzNjMzNQ_35af0906-4e5d-4008-99dc-07987ed07774"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfOTM0NTg0ODgzNjMzNQ_f5fec42b-5a3d-42f0-bbcf-24b0092b29af"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MDU5_698dcf45-fbec-4daa-a7d4-8ac7702b186b"
      unitRef="shares">41305947</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MDU5_b9c21dfa-4835-4f7e-b81a-3ed3236f50e2"
      unitRef="shares">41305947</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTEz_5ab62ba7-6930-4e3f-9b9d-95914c77ff15"
      unitRef="shares">23924004</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTAtMS0xLTY0NjE0L3RleHRyZWdpb246MjhiOTQ5ZGRmYThiNGEyMmI2NDczZGIxZDExNTUwM2RfNTQ5NzU1ODE0MTEz_b106d214-fc21-4252-9ec2-0e3651a7024f"
      unitRef="shares">23924004</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTEtMS0xLTY0NjE0_79917fcc-4478-461c-98dd-5b4945fccc80"
      unitRef="usd">414000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzMzLTMtMS0xLTY0NjE0_26756916-aaa3-4885-83a3-64c9e7fe2b49"
      unitRef="usd">239000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM0LTEtMS0xLTY0NjE0_c653c63d-e72e-4ce4-a17f-9da47bda190b"
      unitRef="usd">741067000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM0LTMtMS0xLTY0NjE0_5e6c9589-f362-43dd-833d-904b02b31f4d"
      unitRef="usd">412101000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM1LTEtMS0xLTY0NjE0_4e6cdbb4-cd8e-406a-8f40-8599e619d2fb"
      unitRef="usd">-390000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM1LTMtMS0xLTY0NjE0_f3919149-c0c7-45ff-a043-550464de0216"
      unitRef="usd">-157000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM2LTEtMS0xLTY0NjE0_955e9249-3f20-4d2d-bfb4-5be4f8d051d7"
      unitRef="usd">-488174000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM2LTMtMS0xLTY0NjE0_570124e4-a4bc-450e-80f5-17c252205754"
      unitRef="usd">-358300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM3LTEtMS0xLTY1MDY5_04b4c5c7-ee1d-4022-88a6-897321a1bdb1"
      unitRef="usd">395064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM3LTMtMS0xLTY1MTI2_fa09458f-ae73-4773-90ba-921f22ae714b"
      unitRef="usd">187716000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM4LTEtMS0xLTY1MDY5_ea3cce98-60b3-4f81-b040-059a446a0b4a"
      unitRef="usd">435091000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTIvZnJhZzo4YzE0OWE0NWUxYjg0ZjI4YTFkZTI1YTMzODUyY2ZmNS90YWJsZTpkMjYyYzkyZjMwODM0MTZiODA4YTg4OTBjMmIzYjk2ZC90YWJsZXJhbmdlOmQyNjJjOTJmMzA4MzQxNmI4MDhhODg5MGMyYjNiOTZkXzM4LTMtMS0xLTY1MTI2_ee6ccb8c-8d14-4ed9-82a3-9353f53fcc07"
      unitRef="usd">203709000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzMtNS0xLTEtNjQ2MTQ_c8177af4-f5c0-4e38-8a6d-392481696d9d"
      unitRef="usd">1772000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzMtNy0xLTEtNjQ2MTQ_886aea6a-a79c-4aa9-bc12-8ac9277e0ec2"
      unitRef="usd">2963000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i778249cf6ce9418b9ad4f911c7d378a8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjowN2JhNDY0MzU2YzU0MjJhODYyMjUwNmI5NDQ3Y2ZhMF81NDk3NTU4MTM5MzQ_6f7f4bc3-e15f-4171-92c6-6169ede9c63c"
      unitRef="usd">5619000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icc0d47b55d5c4d7a86368dd7a7fe9210_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctMC0xLTEtNjQ2MTQvdGV4dHJlZ2lvbjowN2JhNDY0MzU2YzU0MjJhODYyMjUwNmI5NDQ3Y2ZhMF81NDk3NTU4MTM5NDQ_426cd2c8-f87a-406f-abc7-37f457e25f6e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctNS0xLTEtNjQ2MTQ_1a5b0dc0-4fb8-4d35-9db5-011601ef4d65"
      unitRef="usd">100894000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzctNy0xLTEtNjQ2MTQ_608f8b95-8dee-4c33-b996-309aae6af0ff"
      unitRef="usd">56886000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzgtNS0xLTEtNjQ2MTQ_d4ed5385-908a-400b-bae7-1befb0d32ba6"
      unitRef="usd">35182000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzgtNy0xLTEtNjQ2MTQ_8f3c9020-ba7b-4f50-8cce-829d1132cfb1"
      unitRef="usd">25805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEwLTUtMS0xLTY0NjE0_2ba64372-ddd8-4dd2-83d1-a430703efb9b"
      unitRef="usd">136076000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEwLTctMS0xLTY0NjE0_65433d4f-a072-4204-8a0a-066662be6b48"
      unitRef="usd">82691000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzExLTUtMS0xLTY0NjE0_3c619f1f-a6a7-4670-99f9-5eca6c2e567b"
      unitRef="usd">-134304000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzExLTctMS0xLTY0NjE0_67a20273-2d32-4841-bec1-844b2a07d7c7"
      unitRef="usd">-79728000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTUtMS0xLTY0NjE0_8b3fee6b-e3e2-4eea-be7f-47689c43573b"
      unitRef="usd">4916000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTctMS0xLTY0NjE0_8c1caf58-3bcc-4d4d-b33c-4ec2f4353402"
      unitRef="usd">318000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndDebtExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE0LTUtMS0xLTY0NjE0_fce98638-d2f9-4977-b858-1ad4080cccfb"
      unitRef="usd">486000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE0LTctMS0xLTY0NjE0_f91e2354-d00e-4ce7-bfa2-c1c3b5c8044a"
      unitRef="usd">3000</us-gaap:InterestAndDebtExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTUtMS0xLTcxMDg1_721f862d-0327-4f51-987c-f173aff72861"
      unitRef="usd">4430000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzEzLTctMS0xLTcxMDg1_1505451c-73fc-419e-af9c-7bab89c53791"
      unitRef="usd">315000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE1LTUtMS0xLTY0NjE0_b6c35349-65cf-4527-acea-2f616d755c5a"
      unitRef="usd">-129874000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE1LTctMS0xLTY0NjE0_e09975ac-b103-475a-9ba0-51392ee5cb2d"
      unitRef="usd">-79413000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY5NjI3_1465f3a6-0b38-47b2-9d25-b7f8fc552a72"
      unitRef="usdPerShare">-4.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY5NjI3_5dd3f438-3a39-4ca7-a445-d6b32248f2e5"
      unitRef="usdPerShare">-4.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY5NjI3_dc8de787-0b80-40ea-bcc8-ba596b0a34de"
      unitRef="usdPerShare">-6.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY5NjI3_ec711815-de6d-4341-8945-c33448563533"
      unitRef="usdPerShare">-6.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY5NjI3_5098489c-4839-4a30-96aa-1a4099a6fd4a"
      unitRef="shares">32087293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY5NjI3_b6e8e76f-b734-42f7-a471-97e8803f85d8"
      unitRef="shares">32087293</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY5NjI3_6838444c-0c3e-47e5-8a0a-d6d230246164"
      unitRef="shares">11918712</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY5NjI3_9d97ec8c-baf1-4940-ab46-cf3338b289fd"
      unitRef="shares">11918712</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIxLTUtMS0xLTY5NjY5_b6c35349-65cf-4527-acea-2f616d755c5a"
      unitRef="usd">-129874000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIxLTctMS0xLTY5NjY5_e09975ac-b103-475a-9ba0-51392ee5cb2d"
      unitRef="usd">-79413000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTUtMS0xLTY0NjE0_0f9ed125-42a0-4930-85b5-591ecca5ac76"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE2LTctMS0xLTY0NjE0_50bd21d1-0880-4d35-998e-478cab282594"
      unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIzLTUtMS0xLTcwMDc0_b91eda94-f9ed-47d5-b0be-01c6648f2621"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzIzLTctMS0xLTcwMDc0_864dd8f5-6413-4107-b3f8-48da1ca7a1bf"
      unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTUtMS0xLTY0NjE0_aebcdf19-c567-440f-9869-f056ecc5f827"
      unitRef="usd">-130107000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTUvZnJhZzozYzhjY2RiNGJjM2M0NzkxYWY4MjQ3MmQ3MzhiMmI3NS90YWJsZTplMGYwM2Q0Y2MzN2U0MThjODVkYzNkZTExYTM3ODRlYi90YWJsZXJhbmdlOmUwZjAzZDRjYzM3ZTQxOGM4NWRjM2RlMTFhMzc4NGViXzE3LTctMS0xLTY0NjE0_793a9752-f4e2-4c25-a222-da547a632fda"
      unitRef="usd">-79562000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTEtMS0xLTY0NjE0_9d47bb1d-05e4-42df-903d-a7f1befc2b1c"
      unitRef="shares">398487</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTMtMS0xLTY0NjE0_5cda5817-da27-42aa-9352-39da8b281900"
      unitRef="usd">180801000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i82f4e2c253814d9993e96053bae40a2c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTUtMS0xLTY0NjE0_b12baa45-6e5d-45b9-889a-2642f889b385"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i82f4e2c253814d9993e96053bae40a2c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTctMS0xLTY0NjE0_764200de-1ab5-40ab-8013-f029cc2f1b2a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if33717d39c2943d388f869ebe747c1e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTktMS0xLTY0NjE0_b97219c6-98e6-4bb5-9f4a-1bec8016b3a5"
      unitRef="shares">4231135</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if33717d39c2943d388f869ebe747c1e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTExLTEtMS02NDYxNA_699eb1f9-f3e8-4f94-9695-cde8051d33f3"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff1bba44fa4d4b6e9380aceefcb77a8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTEzLTEtMS02NDYxNA_0d895435-8c85-452d-8f58-394532e8ce6e"
      unitRef="usd">218089000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i895af20035af46daa806cd54af1820ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE1LTEtMS02NDYxNA_39f28aad-4576-41ad-bb4c-1d6606fa0a45"
      unitRef="usd">-8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibaa992c0e8b04d0ba561866e5ddc5c70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE3LTEtMS02NDYxNA_5aa865ec-6228-4fa3-844c-98dffc821f9e"
      unitRef="usd">-278887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE4LTE5LTEtMS02NDYxNA_a5d103cd-f57d-4b80-a2ae-4213dafae239"
      unitRef="usd">120037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTEtMS0xLTY0NjE0_e4bb38dc-7247-4c52-94ec-a160bee6de3b"
      unitRef="shares">-138050</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9d933a148f5c478b8c448ed688cd3cae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTMtMS0xLTY0NjE0_85ffc8ac-5c38-4b4a-a33a-ed64d5f4ef20"
      unitRef="usd">-62637000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTktMS0xLTY0NjE0_da95acab-9056-4c5b-95c6-da128094357f"
      unitRef="shares">9203732</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTExLTEtMS02NDYxNA_53750f71-5e98-40b9-8c68-91200b5ba803"
      unitRef="usd">92000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTEzLTEtMS02NDYxNA_08f6c8dd-a916-4d84-8fd1-8012f68dba78"
      unitRef="usd">62545000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzE5LTE5LTEtMS02NDYxNA_fb57fe8f-5ef7-40e5-8078-8596f38f8fea"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ieae0b71a3dbf4614b433002bcd8498cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTAtMS0xLTY0NjE0L3RleHRyZWdpb246YTE2MzhhNWU0ZjhmNDdhMWJkNTkxOGY5YjkyMzg4M2RfOTM0NTg0ODgzNjIzMg_829bb904-88bf-4eb8-866d-a358ec2d8b06"
      unitRef="usd">1291000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie244e1d6bb534436961dc38a043ef711_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTAtMS0xLTY0NjE0L3RleHRyZWdpb246YTE2MzhhNWU0ZjhmNDdhMWJkNTkxOGY5YjkyMzg4M2RfOTM0NTg0ODgzNjIzNw_51c7b351-523a-4ddf-a301-7e6bb649e296"
      unitRef="usd">5983000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTUtMS0xLTY0NjE0_74cbcf7b-b40c-4c64-b71a-79ccb4907cf5"
      unitRef="shares">23126</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iedde74fc03094c1897ca5acb388d823c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTctMS0xLTY0NjE0_5a4e1991-9b46-42a3-ac54-85dca62869b6"
      unitRef="usd">15669000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTktMS0xLTY0NjE0_b99704bd-0280-4d4a-8595-1f681d99c990"
      unitRef="shares">7344543</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia5d7620f1d4a4908b418431112efe9df_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTExLTEtMS02NDYxNA_34f62f7d-e029-41bb-8fd3-71b64fa254ca"
      unitRef="usd">73000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7c9fcc60a60e445c8f1795104a6c46f0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTEzLTEtMS02NDYxNA_d6bf0992-7dc8-438e-9558-6ed584304b66"
      unitRef="usd">74734000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib443f38e5cd2438c9634efcd8b2278ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIwLTE5LTEtMS02NDYxNA_8faf5fee-0a07-4d9d-b2c2-c8aa69754232"
      unitRef="usd">90476000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTktMS0xLTY0NjE0_575f4713-b021-4410-832e-92d298e133b3"
      unitRef="shares">77871</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTExLTEtMS02NDYxNA_a772d225-9eb2-40a7-b939-3849bd3b361b"
      unitRef="usd">1000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTEzLTEtMS02NDYxNA_5bacb435-dea6-4919-8dea-a2d0e4f51b30"
      unitRef="usd">1284000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIxLTE5LTEtMS02NDYxNA_4cae90cd-446b-43e5-89b5-8cb3bc29802e"
      unitRef="usd">1285000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTktMS0xLTY0NjE0_df7f33ef-b283-4ba6-a6f2-74fbf6d54129"
      unitRef="shares">106831</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTExLTEtMS02NDYxNA_92dc1f4b-3d96-4ea7-9a13-a575f7b70b63"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTEzLTEtMS02NDYxNA_310663af-95b4-4725-980b-d6d12dc9372f"
      unitRef="usd">1026000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIyLTE5LTEtMS02NDYxNA_4bc24e0b-b367-4b82-803c-3927bb459b7e"
      unitRef="usd">1027000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzIzLTktMS0xLTY0NjE0_c5fadef1-25c8-40ab-a63b-5acbf3304d9e"
      unitRef="shares">10574</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4a6c2ed89fed4622a2d2aa7172d7f416_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTAtMS0xLTY0NjE0L3RleHRyZWdpb246Njc0M2FiMGRmYjUxNDM5YjlmN2Y2MmQ5NTk4NjMzZTNfOTM0NTg0ODgzNjE2NA_c0773aee-e879-487b-a50e-ad67c10b0a20"
      unitRef="usd">1004000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTktMS0xLTY0NjE0_34c8f6d3-deaa-4bdc-815c-c4645011b475"
      unitRef="shares">2551269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i374936d4401542b89b6d8a8114d1b386_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTExLTEtMS02NDYxNA_b4f5ac7e-ffe2-478e-a003-2cac5ce659d7"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7aed7cceb62b4b92bc8ed6ec984f2319_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTEzLTEtMS02NDYxNA_435e8f78-8bc1-4880-a14c-ab8ccb841178"
      unitRef="usd">32423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i39fb3692ca914421afc3d247f7d8cca4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI0LTE5LTEtMS02NDYxNA_f0ea5cff-9719-4f07-bdbf-11501619ad62"
      unitRef="usd">32449000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTktMS0xLTY0NjE0_fa3c46a8-87ff-457d-a0aa-21d7670ed160"
      unitRef="shares">394737</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTExLTEtMS02NDYxNA_e2c3b787-13ad-4280-aada-d5668350381a"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTEzLTEtMS02NDYxNA_2aba1c53-696f-4695-9454-6a03b023451e"
      unitRef="usd">7496000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI1LTE5LTEtMS02NDYxNA_5aeeaae8-ed68-4e8a-8263-1a2b424e7aef"
      unitRef="usd">7500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTktMS0xLTY0NjE0_13963600-1760-408d-be67-de72ff395823"
      unitRef="shares">3312</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTEzLTEtMS02NDYxNA_e5f1c968-0cb6-4cc4-beb9-51dafb2156c9"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI2LTE5LTEtMS02NDYxNA_b86f6fe8-e6c9-451d-b767-53d059bd2428"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaf385323cf4e44319b6da7dcd44dbfb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI3LTEzLTEtMS02NDYxNA_fea3ff78-d1f8-4cd5-9838-011e0bd5a549"
      unitRef="usd">14465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI3LTE5LTEtMS02NDYxNA_a6ade767-486b-427e-8120-0144313c2391"
      unitRef="usd">14465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="id35723f52a2d4347be6c1269abb323a8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI5LTE1LTEtMS02NDYxNA_ef2e19e5-6bee-4648-839a-deb1e9b96754"
      unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzI5LTE5LTEtMS02NDYxNA_0def1049-9a39-4b23-830a-bfb7e34d1669"
      unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="icb583c45106b4818a232ee9c4ad39c58_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMwLTE3LTEtMS02NDYxNA_50e5099d-3d4b-4487-a5e8-bbd50c7634bb"
      unitRef="usd">-79413000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMwLTE5LTEtMS02NDYxNA_1199b89b-910a-45b0-abcc-4074b22bdac8"
      unitRef="usd">-79413000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id86c28f6cc424ce98bea0a4a97eddb90_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTEtMS0xLTY0NjE0_c5b266f5-9bef-4827-9fba-f265afd06aea"
      unitRef="shares">260437</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id86c28f6cc424ce98bea0a4a97eddb90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTMtMS0xLTY0NjE0_9187e56a-291b-4427-b0aa-07d74e71a55c"
      unitRef="usd">118164000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie9d6b724a9464b29ae68552713b5ed42_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTUtMS0xLTY0NjE0_658077a9-5f17-4f0b-9f44-31f0142ce7bf"
      unitRef="shares">23126</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9d6b724a9464b29ae68552713b5ed42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTctMS0xLTY0NjE0_56c236ea-e05d-432e-b898-c0920d9c4eb5"
      unitRef="usd">15669000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id337e30fdc0349c4816ac5a494a9223d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTktMS0xLTY0NjE0_e0e6da09-7d0f-4b3f-9c78-52ccb1c8ccfd"
      unitRef="shares">23924004</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id337e30fdc0349c4816ac5a494a9223d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTExLTEtMS02NDYxNA_ebfe5b3b-0b25-4ee5-a7e8-a77957485875"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea2d086c62db415b86b0a9d226c455d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTEzLTEtMS02NDYxNA_b2b0adce-ca5a-4af8-8704-be4234c87bc2"
      unitRef="usd">412101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab4425cde974494cabb81ce893b56b8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE1LTEtMS02NDYxNA_207d0622-85cb-431e-a93e-4ac9ee6b2746"
      unitRef="usd">-157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e57058fb77d4e7fbf5cb93719753578_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE3LTEtMS02NDYxNA_2545d5d4-a95e-4640-a5c4-e71e1ef93ba2"
      unitRef="usd">-358300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMxLTE5LTEtMS02NDYxNA_3417b05e-1fc5-43cc-be29-38b37e95e80e"
      unitRef="usd">187716000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTEtMS0xLTY3OTMx_9ba23e63-9dda-4b6b-95f0-3473759162b1"
      unitRef="shares">-72056</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6bfbeb347b07459bba990d4cca5db07d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTMtMS0xLTY3OTM5_954b12ff-0525-4caa-ab2e-e56f5d44cc9d"
      unitRef="usd">-32694000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTktMS0xLTY3OTU1_55d14f8c-8422-4f84-9d25-4eccd2887963"
      unitRef="shares">4803965</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTExLTEtMS02Nzk1NQ_8593c895-d26d-447e-b39b-e0891fe9690f"
      unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTEzLTEtMS02Nzk2Mw_079efc57-b031-484b-a9f3-939bc892176b"
      unitRef="usd">32646000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMyLTE5LTEtMS02Nzk3MQ_1609e6f3-dd77-41ef-94f9-c2ff5da67185"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i508999d2a2594110b99007f534be4af5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTAtMS0xLTY3OTExL3RleHRyZWdpb246OGYwZmZmOTA3ODY0NGY0NmFkNjg0OGNjNzRjMzBlOTVfNTQ5NzU1ODEzOTk0_76190795-c613-4003-b9f2-ab9f2869b804"
      unitRef="usd">2992000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i25983ef470214368ab0eea4aa4373a8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTAtMS0xLTY3OTExL3RleHRyZWdpb246OGYwZmZmOTA3ODY0NGY0NmFkNjg0OGNjNzRjMzBlOTVfNTQ5NzU1ODE0MDAz_c91e68ab-1a7f-4cfe-a677-377460aba92b"
      unitRef="usd">18146000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTUtMS0xLTY3OTQ3_33166cb6-e8a1-4ac5-a4bf-5135719fc9c7"
      unitRef="shares">28084</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ef1924b759a44b5a58ce4d5e6017148_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTctMS0xLTY3OTQ3_17b37277-bb2f-463d-8669-2c90a9447d29"
      unitRef="usd">41008000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTktMS0xLTY3OTU1_33ce5a49-fdc1-420a-8153-de3115c48d5b"
      unitRef="shares">11352640</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4cde7ae755dc49a99407d59f7839285d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTExLTEtMS02Nzk1NQ_346137d3-5238-49d8-8bdd-3ebdb69959fa"
      unitRef="usd">114000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i789f9857a6f441e3aa1e17f4094afaf7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTEzLTEtMS02Nzk2Mw_3c5bd350-44e3-4b37-8abc-79a9a565777d"
      unitRef="usd">248528000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2335da7e52874d249a90521b0fd87ab1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzMzLTE5LTEtMS02Nzk3MQ_9783e8fc-2f9e-4394-9ed5-22a0097d5473"
      unitRef="usd">289650000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id0451fea21364299a740c764817cf380_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTAtMS0xLTY3OTExL3RleHRyZWdpb246NGY4MGE0OGE5YzI0NDk4ZjlhMTc1OWE4YTc0OTE3MDBfNTQ5NzU1ODEzOTYz_4c041bf1-09a9-44a9-ad2f-bc4fb9ae7045"
      unitRef="usd">926000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0397e407cad54193ab35946350fff184_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTktMS0xLTY3OTU1_e4571d1c-3b1a-4244-b21f-d4aa01db8fb2"
      unitRef="shares">964357</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0397e407cad54193ab35946350fff184_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTExLTEtMS02Nzk1NQ_cf197da2-5067-4f60-bfb9-a1e51b4e43f8"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i74ab3fa116a44b7da15ac250754235b3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTEzLTEtMS02Nzk2Mw_91a407bb-1152-465b-a409-455bd93c818d"
      unitRef="usd">24150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id58d19c7f26d4ebd88665ae0a8aa7f16_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM0LTE5LTEtMS02Nzk3MQ_55500077-b66e-495a-9fbe-62aa2ad1fe5a"
      unitRef="usd">24160000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTktMS0xLTY3OTU1_0da856d6-7bfb-4b77-a33e-90dffb6810a2"
      unitRef="shares">56666</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTExLTEtMS02Nzk1NQ_c82f0599-c285-4f54-9074-406a953954d9"
      unitRef="usd">1000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTEzLTEtMS02Nzk2Mw_53652da2-db83-49d7-8f8b-f4fca8037b0c"
      unitRef="usd">934000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM1LTE5LTEtMS02Nzk3MQ_e9355468-124c-433e-8198-22b4cfaac494"
      unitRef="usd">935000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTktMS0xLTY3OTU1_bbaee154-6547-4c1b-a1e5-6592e3804f76"
      unitRef="shares">191291</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTExLTEtMS02Nzk1NQ_4bd78650-9a46-4d55-87af-9d6de966bc40"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTEzLTEtMS02Nzk2Mw_053d3ebf-c6c2-4f77-88d2-495c4645ca7d"
      unitRef="usd">2760000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM2LTE5LTEtMS02Nzk3MQ_b3ddc3f6-c271-40ab-914e-8068fe9aa20d"
      unitRef="usd">2762000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTktMS0xLTY3OTU1_e00ec069-77e4-426c-ad4c-899115b7e52f"
      unitRef="shares">13024</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTEzLTEtMS02Nzk2Mw_b6aac3d6-83b1-4b5a-bea7-22f028149d6e"
      unitRef="usd">183000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM3LTE5LTEtMS02Nzk3MQ_e590f13e-cd2e-4441-b736-9f06d3c7d6fd"
      unitRef="usd">183000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e4af372a4884d38bf0e2d61787774ed_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM4LTEzLTEtMS02Nzk2Mw_2cc57640-6d98-4f4b-8d55-2eca0d853b15"
      unitRef="usd">19765000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM4LTE5LTEtMS02Nzk3MQ_7d6e6a77-b36d-45dd-b692-29b6c56c9463"
      unitRef="usd">19765000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="id0e66c30a3694f1299adfc4cecaa2744_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM5LTE1LTEtMS02Nzk2Mw_1d97879c-2c44-477d-b3b0-e2ee7e34a65b"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzM5LTE5LTEtMS02Nzk3MQ_f0b914fa-57b4-49b4-be48-dd793568537f"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1c84830c57044151be9237f1a7dd891b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQwLTE3LTEtMS02Nzk2Mw_1bf55463-a003-42fc-a877-1dc0ae5d87b2"
      unitRef="usd">-129874000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQwLTE5LTEtMS02Nzk3MQ_e487717e-ec59-4dc1-ba86-84235dba4be1"
      unitRef="usd">-129874000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4ca19cad32d5468a88da45e616c993ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTEtMS0xLTY4MzY3_2ab38e4b-51c9-4074-bc1e-828fd57da3cf"
      unitRef="shares">188381</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4ca19cad32d5468a88da45e616c993ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTMtMS0xLTY4MzY3_37acc53d-8bf6-4529-ac00-22158c31739b"
      unitRef="usd">85470000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i14703c6fcd204cf4bb4d52313293b090_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTUtMS0xLTY4MzY3_6ed802d7-3587-4f0d-bc5d-3b23cfc80bb7"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i14703c6fcd204cf4bb4d52313293b090_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTctMS0xLTY4MzY3_20cc3a43-d559-4b38-996a-9b855dc4bc6a"
      unitRef="usd">56677000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i16c66a163e074d75953188a31b49a161_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTktMS0xLTY4MzY3_68aeffc4-056f-4e10-8520-fe9b231f9783"
      unitRef="shares">41305947</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i16c66a163e074d75953188a31b49a161_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTExLTEtMS02ODM2Nw_124e1a2c-bae1-418a-9ad0-43437486f00d"
      unitRef="usd">414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16d69f24ee32425883b5fb4906e7848c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTEzLTEtMS02ODM2Nw_898c2cd6-1de9-4a8e-9684-58bd84850eb7"
      unitRef="usd">741067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6153c8d6ca7244fcaaa83b242bba2e18_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE1LTEtMS02ODM2Nw_381e1b60-e9e4-49da-ac97-d3e6a43ee785"
      unitRef="usd">-390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic95cffa740f64b68af86df3f770a0b25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE3LTEtMS02ODM2Nw_08d399d6-60db-45fa-ad8e-da82c0767685"
      unitRef="usd">-488174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMTgvZnJhZzpkYWQ0YjBjZGYxNzI0MzNhYThjNjA0YzA2NzI4MjRkYi90YWJsZTo5N2JiMDJiYzg5ZjU0NzJjOTI2OTQ4MzYzNWYxYzBmMi90YWJsZXJhbmdlOjk3YmIwMmJjODlmNTQ3MmM5MjY5NDgzNjM1ZjFjMGYyXzQxLTE5LTEtMS02ODM2Nw_6a79ebee-0d95-411e-97eb-a9ee29b9f57d"
      unitRef="usd">395064000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMtMS0xLTEtNjQ2MTQ_13e51904-feeb-427e-b402-5746a8dbd813"
      unitRef="usd">-129874000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMtMy0xLTEtNjQ2MTQ_0a2e6a97-efc9-48ba-b431-1e4f231d4a71"
      unitRef="usd">-79413000</us-gaap:NetIncomeLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzYtMS0xLTEtNjQ2MTQ_022aefb9-e9ae-4206-953a-8d6a9df942d3"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzYtMy0xLTEtNjQ2MTQ_6ae7aeb9-3119-4c7a-b6db-208ecab45c9a"
      unitRef="usd">7500000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzctMS0xLTEtNjQ2MTQ_9092af70-56bc-4dfd-a282-b692e2be560f"
      unitRef="usd">19765000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzctMy0xLTEtNjQ2MTQ_9e9b2d22-6fd2-4256-8768-be82abfced33"
      unitRef="usd">14465000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzgtMS0xLTEtNjQ2MTQ_2e261c14-f663-45d6-9846-a24f9021a45c"
      unitRef="usd">228000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzgtMy0xLTEtNjQ2MTQ_c70eb557-69eb-422c-a1d9-ec8eae59978d"
      unitRef="usd">87000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEwLTEtMS0xLTY0NjE0_e7f033be-7c86-4fb0-b1af-66a98c2ad700"
      unitRef="usd">255000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEwLTMtMS0xLTY0NjE0_09a174fa-fa92-410e-88d2-19ffca26a592"
      unitRef="usd">120000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzExLTEtMS0xLTY0NjE0_4755ce6b-dc66-44e2-b369-5ed9874ce9b8"
      unitRef="usd">210000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzExLTMtMS0xLTY0NjE0_691e85b3-59e7-4a05-94bd-c893d5578890"
      unitRef="usd">-965000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEyLTEtMS0xLTY0NjE0_35df93e6-856d-4fc7-81e3-02be8613d794"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEyLTMtMS0xLTY0NjE0_cacee34a-c6ba-4707-bbee-6cf6418caa8f"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEzLTEtMS0xLTY0NjE0_f559682e-4bcd-4565-944a-953b3f9c6692"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzEzLTMtMS0xLTY0NjE0_11f18879-b023-4c43-b11d-19e34adf7316"
      unitRef="usd">-77000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <vrdn:NonCashLeaseExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE1LTEtMS0xLTY0NjE0_81da708b-e985-417d-918a-0c8358830e63"
      unitRef="usd">36000</vrdn:NonCashLeaseExpense>
    <vrdn:NonCashLeaseExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE1LTMtMS0xLTY0NjE0_ea7c0b90-2696-4a6c-a664-2d4934236cff"
      unitRef="usd">-102000</vrdn:NonCashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE3LTEtMS0xLTY0NjE0_16c14879-4420-4089-999e-f883400a4fac"
      unitRef="usd">3339000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE3LTMtMS0xLTY0NjE0_5c1417b8-8da5-4331-9d71-d1d9573efc82"
      unitRef="usd">1496000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE4LTEtMS0xLTY0NjE0_4555049b-7e43-404f-afee-21812820962a"
      unitRef="usd">11524000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE4LTMtMS0xLTY0NjE0_178b2176-fbcd-467f-8d80-dba53049d961"
      unitRef="usd">1655000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE5LTEtMS0xLTY0NjE0_368172f1-000d-4fc7-b2f7-2d54f6013ba0"
      unitRef="usd">7716000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzE5LTMtMS0xLTY0NjE0_ef974539-1e7f-4c62-8d49-6e43fc0b80f9"
      unitRef="usd">1380000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIwLTEtMS0xLTY0NjE0_55e97a24-94b0-4367-b507-a0f64302406d"
      unitRef="usd">-349000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIwLTMtMS0xLTY0NjE0_f6ead69c-5c19-4f80-a4b8-04c858c3cbf2"
      unitRef="usd">451000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIxLTEtMS0xLTY0NjE0_972fad43-9752-4797-8671-0750505d43e8"
      unitRef="usd">-288000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIxLTMtMS0xLTY0NjE0_3e9c48b5-8fd5-43ef-b110-9ce070ba3c9b"
      unitRef="usd">636000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIyLTEtMS0xLTY0NjE0_27c4b68b-01f3-420e-be37-6208daac2d37"
      unitRef="usd">-93838000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzIyLTMtMS0xLTY0NjE0_c128581f-0805-40ca-af4e-41a1ddc66096"
      unitRef="usd">-54581000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI0LTEtMS0xLTY0NjE0_abeda0ea-8b55-4b2a-ab8f-80e9cdc5eb45"
      unitRef="usd">223264000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI0LTMtMS0xLTY0NjE0_2586b222-8334-4ded-b97d-9ca88b2856de"
      unitRef="usd">188431000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI1LTEtMS0xLTY0NjE0_317da06c-f1fb-4a85-a240-3751be57db8b"
      unitRef="usd">108935000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI1LTMtMS0xLTY0NjE0_00480f73-85cd-41e4-9ac4-0540ad711ca3"
      unitRef="usd">114398000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI4LTEtMS0xLTY0NjE0_95d11ebe-dec7-4d0a-8140-50c0bb224003"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI4LTMtMS0xLTY0NjE0_19e50250-453a-4ae6-a1c4-364a82a08ea0"
      unitRef="usd">79000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI5LTEtMS0xLTY0NjE0_1714dd9d-dcf4-45e7-92eb-aea6b4899687"
      unitRef="usd">797000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzI5LTMtMS0xLTY0NjE0_ac75923e-ea58-4d27-a3ac-a9330a701d4a"
      unitRef="usd">338000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMxLTEtMS0xLTY0NjE0_079fc507-d168-40af-b1ed-6a0281a05a1c"
      unitRef="usd">-115126000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMxLTMtMS0xLTY0NjE0_d3283777-c05d-4257-a3fb-fdddb888f468"
      unitRef="usd">-74292000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzMzLTEtMS0xLTY0NjE0_684f24be-9b98-4719-8fc4-ad110d510b3f"
      unitRef="usd">291874000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTMtMS0xLTY0NjE0_127ed81d-3110-4e52-9265-cacbf2893e6e"
      unitRef="usd">114242000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM1LTEtMS0xLTY0NjE0_04daf698-f5fa-4d1b-a6ca-69acf3649ad1"
      unitRef="usd">19072000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic703530b5dda4ed0a68d4a8b5b9ce7fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM1LTMtMS0xLTY0NjE0_b68028e3-618a-4c9e-8cf1-4d2d4ddf92e4"
      unitRef="usd">6987000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM2LTEtMS0xLTY0NjE0_e5b15a40-002c-4b21-9bc3-bfdd87d43eff"
      unitRef="usd">44000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM2LTMtMS0xLTY0NjE0_975f2f29-2f6d-491c-bcff-7127b1bcf3bf"
      unitRef="usd">16960000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic0697651628c4404996864ee40e782d4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM3LTEtMS0xLTY0NjE0_ddea2a8b-f34a-4cce-a1bd-1b83b6cce4a8"
      unitRef="usd">2992000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4a876722929249349e7f7da5272ce756_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM3LTMtMS0xLTY0NjE0_9701c9ac-62cd-4097-a12e-ddb87bed5af9"
      unitRef="usd">1291000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM4LTEtMS0xLTY0NjE0_83023646-34d8-4607-a376-c83e8c1b4774"
      unitRef="usd">935000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM4LTMtMS0xLTY0NjE0_bd4abd15-aedf-488c-8031-c6bd491609df"
      unitRef="usd">1285000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM5LTEtMS0xLTY0NjE0_65b0bb58-0f51-48e1-ace3-43276402fcf5"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM5LTMtMS0xLTY0NjE0_2c94b836-4bb5-45d1-abe4-f99c4c62ba2c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTEtMS0xLTcxODM4_accd5314-8003-4a76-b22b-7a9d57fc316b"
      unitRef="usd">446000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzM0LTMtMS0xLTcxODU2_ea029dcc-5dc6-4ff2-9da8-b5784523ccf3"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQwLTEtMS0xLTY0NjE0_03cf38f3-c326-4e4d-b615-c62d6b9787e1"
      unitRef="usd">2762000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQwLTMtMS0xLTY0NjE0_2c2e71d0-d3f4-4a35-ad03-51c91b3f184a"
      unitRef="usd">1027000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQxLTEtMS0xLTY0NjE0_8e3158f8-3850-4608-afc1-ce50ee1d25b8"
      unitRef="usd">183000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQxLTMtMS0xLTY0NjE0_24fa2db8-5a50-4144-814d-36f1d0c77c9c"
      unitRef="usd">39000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ1LTEtMS0xLTY0NjE0_40b2fbaa-6dce-4845-8e7c-884ee4ad0a45"
      unitRef="usd">322244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ1LTMtMS0xLTY0NjE0_47827526-88ac-40f2-bdfd-525990c3af93"
      unitRef="usd">125275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ2LTEtMS0xLTY0NjE0_f223f6ae-dec1-4f9b-b341-d7e92e66135a"
      unitRef="usd">113280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ2LTMtMS0xLTY0NjE0_fba3aecd-c8cc-4796-8939-1d556baf31b7"
      unitRef="usd">-3598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ3LTEtMS0xLTY0NjE0_39da7894-e9f5-48d7-bffd-b0f3e02b7fa7"
      unitRef="usd">42299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c0a45b1ccfa47cfae0cd5a2329c90dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ3LTMtMS0xLTY0NjE0_5428266b-0cbd-414e-8d93-0066829c2fce"
      unitRef="usd">45897000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ4LTEtMS0xLTY0NjE0_c7695870-9504-4a96-85ca-2daa41f91f32"
      unitRef="usd">155579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzQ4LTMtMS0xLTY0NjE0_2cd08fc1-0117-44db-aaa5-ec20540b4a55"
      unitRef="usd">42299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUwLTEtMS0xLTY0NjE0_efcbd7af-c5fb-485b-9267-1ad2bf00dc4c"
      unitRef="usd">293000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUwLTMtMS0xLTY0NjE0_0e60149f-bc9d-4bc1-9cfc-264b9de2111f"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUyLTEtMS0xLTY0NjE0_76320516-09d9-40e9-ba7d-8623b4a101d0"
      unitRef="usd">380000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUyLTMtMS0xLTY0NjE0_2282c80d-6598-4531-9bd5-aebbc0f0a360"
      unitRef="usd">4000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <vrdn:AmortizationOfStockIssuanceCosts
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUzLTEtMS0xLTY0NjE0_fef27393-07cd-4b2b-a110-1ae130596545"
      unitRef="usd">75000</vrdn:AmortizationOfStockIssuanceCosts>
    <vrdn:AmortizationOfStockIssuanceCosts
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjEvZnJhZzo2MjRkY2VmMGU1MDg0N2UzOGExNTkxMGE3MmM2ZTJjOS90YWJsZTpiNGI1NzIxNTkyZGM0OWU3YjkyZWE5NzZiNWI3ZTk0ZS90YWJsZXJhbmdlOmI0YjU3MjE1OTJkYzQ5ZTdiOTJlYTk3NmI1YjdlOTRlXzUzLTMtMS0xLTY0NjE0_890deb18-58b8-4230-8285-3c2eb0359a62"
      unitRef="usd">87000</vrdn:AmortizationOfStockIssuanceCosts>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzcwNzY_125fc495-d946-43e1-a65a-000c44b55e73">DESCRIPTION OF BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Viridian Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;Viridian&#x201d;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#x2019;s therapies. The Company&#x2019;s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#x201c;IGF-1R&#x201d;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#x201c;TED&#x201d;). The Company&#x2019;s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. In addition to developing therapies for TED, the Company is executing a similar strategic approach to identify opportunities in other rare and/or serious disease indications.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#x2019;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through December&#160;31, 2022, the Company has generated an accumulated deficit of $488.2 million. The Company expects to continue to generate operating losses for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#x2019;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had approximately $424.6 million in cash, cash equivalents, and short-term investments. As of the issuance date of these consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will continue to require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#x2019;s clinical development efforts, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#x2019;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#x2019;s control, including success in developing its technology and drug product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#x2019;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzU0OTc1NTgyNTg0Nw_8eb4542a-d26d-4679-915a-924ccc3e633a"
      unitRef="usd">-488200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMjcvZnJhZzoyZjJlNGJlNGYxNGE0ZjcyOGJjNGJhMjNmNTVkNzg5Mi90ZXh0cmVnaW9uOjJmMmU0YmU0ZjE0YTRmNzI4YmM0YmEyM2Y1NWQ3ODkyXzU0OTc1NTgyNzQzOQ_b8de80e6-95a4-4384-9814-935d30cec672"
      unitRef="usd">424600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTUw_913a090c-6456-467e-a3e3-cf63a16b06e2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Viridian Therapeutics Europe Limited and Viridian Therapeutics S.&#xe0;.r.l., both of which were formed for the sole purpose of submitting regulatory filings in Europe, and Viridian Securities Corporation, which was formed in July 2021. The Company&#x2019;s subsidiaries have no employees or operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company&#x2019;s management performed an evaluation of its activities through the date of filing of these consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Economic Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s evaluation entails, among other things, analyzing the results of the Company&#x2019;s clinical development efforts, license and collaboration agreements as well as the entity&#x2019;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#x2019;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents and short-term investments balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses and the valuation of share-based awards. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#x2019;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s agreements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to manufacture or have manufactured clinical trial materials, laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Such expenses are included within operating activities in the consolidated statements of cash flows. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or when other significant risk factors are abated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its consolidated financial statements based on certain facts and circumstances at that time. The Company&#x2019;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#x2019;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#x2019;s research and development expenses may be necessary in future periods as its estimates change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for share-based compensation expense to employees and non-employees based on the fair value of each stock option or award on the date of the grant. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are reported as a component of stockholders&#x2019; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs utilizes observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Right-of-Use Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Leases (Topic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;842), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#x201c;ASC 842&#x201d;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#x2019;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#x2019;s operating lease assets in the Company&#x2019;s consolidated balance sheets. The Company&#x2019;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#x2019;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 8. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies - Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information related to the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Debt issuance costs represent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;legal and other direct costs incurred in connection with the Company&#x2019;s Term Loan (as defined in Note 6. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and at issuance classified the Series A Preferred Stock outside of stockholders&#x2019; equity because, if convertibility of Series A Preferred Stock into common stock was not approved by the stockholders, the Series A Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#x2019;s redemption request. On December 31, 2020, the stockholders approved the convertibility of the Series A Preferred Stock into common stock and as such, the Company reclassified the Series A Preferred Stock to permanent equity. In September 2021, the Company issued Series B Preferred Stock with conversion rights which the Company has classified as permanent equity in its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the consolidated statements of changes in stockholders&#x2019; equity. The Company had unrealized losses on investments of $0.2 million and $0.1 million during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses. No such expenses have been recognized during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 718, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#x2019;s partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements &#x2013; To Be Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTYy_2ad0bcdf-4658-49f7-a877-4085d810ee86">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Viridian Therapeutics Europe Limited and Viridian Therapeutics S.&#xe0;.r.l., both of which were formed for the sole purpose of submitting regulatory filings in Europe, and Viridian Securities Corporation, which was formed in July 2021. The Company&#x2019;s subsidiaries have no employees or operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. All significant intercompany balances have been eliminated in consolidation. The Company&#x2019;s management performed an evaluation of its activities through the date of filing of these consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <vrdn:GoingConcernPolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NDk0_a7c64188-54dc-47bc-87ac-aed53c0c9d86">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s evaluation entails, among other things, analyzing the results of the Company&#x2019;s clinical development efforts, license and collaboration agreements as well as the entity&#x2019;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#x2019;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents and short-term investments balance.&lt;/span&gt;&lt;/div&gt;</vrdn:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NjA1_8e51d9ca-ab0b-4720-8ca9-434788817884">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses and the valuation of share-based awards. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTU_f232b9d5-f47c-4a67-9a1d-b230c5dd9cb4">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#x2019;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s agreements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTY_3c1e0f80-0d7f-4ef1-bd4d-ab287b3bd2c6">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to manufacture or have manufactured clinical trial materials, laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Such expenses are included within operating activities in the consolidated statements of cash flows. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or when other significant risk factors are abated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTc_b150cd43-fb7c-4c06-a45d-bfc16528130d">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its consolidated financial statements based on certain facts and circumstances at that time. The Company&#x2019;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#x2019;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#x2019;s research and development expenses may be necessary in future periods as its estimates change.&lt;/span&gt;&lt;/div&gt;</vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTg_a9194798-74af-45b7-8014-36367d0dacb2">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for share-based compensation expense to employees and non-employees based on the fair value of each stock option or award on the date of the grant. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MTk_478ed80b-be15-42e3-acd4-0a860b3ef7fa">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjA_66003189-dd5c-4952-9ea2-4927a86acc41">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are reported as a component of stockholders&#x2019; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjE_43f3553f-c198-4cc0-8ed0-afe486e0933e">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs utilizes observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjI_40676ad5-794a-46d3-b84e-4d42b61076f8">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjM_158568b2-1179-442a-a0d0-f6df660f014d">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MjQ_2951a045-9f58-4238-b844-5a26e297c921"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib14e5a6aafc64ee685e4abf45a236d64_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3MzU_0dc8fe7a-fb73-46c6-a2cf-059ede08dd36">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3NTE_1229087d-e3a6-4daf-958b-735d2fad2abf">Operating Lease Right-of-Use Assets and Liabilities&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Leases (Topic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;842), &lt;/span&gt;and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#x201c;ASC 842&#x201d;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#x2019;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#x2019;s operating lease assets in the Company&#x2019;s consolidated balance sheets. The Company&#x2019;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#x2019;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzE2NDkyNjc1MTE3NTI_b28068fa-47ae-4f6a-b585-8e247c004b83">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. Debt issuance costs represent &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;legal and other direct costs incurred in connection with the Company&#x2019;s Term Loan (as defined in Note 6. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.&lt;/span&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTc1_65668783-ab11-4262-933f-d50b0881d16f">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, and at issuance classified the Series A Preferred Stock outside of stockholders&#x2019; equity because, if convertibility of Series A Preferred Stock into common stock was not approved by the stockholders, the Series A Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#x2019;s redemption request. On December 31, 2020, the stockholders approved the convertibility of the Series A Preferred Stock into common stock and as such, the Company reclassified the Series A Preferred Stock to permanent equity. In September 2021, the Company issued Series B Preferred Stock with conversion rights which the Company has classified as permanent equity in its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTM2_aa46b0c9-74c3-40ba-9980-df25d0d03495">Impairment of Long-Lived AssetsThe Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI1MzE3_250b3f82-0def-4a4c-9d0a-b316a874102e"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI1MzE3_61c7d4d1-763c-4f59-a919-901d5921814b"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTIx_7304f811-6a4d-48ea-9c0e-0aeabf5089f2">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTcy_6d63754d-53ae-4d51-92e8-c5be0a645ecf">Comprehensive LossComprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the consolidated statements of changes in stockholders&#x2019; equity.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI2MTY0_aa6fb112-ab94-486e-9ac6-da87d55e45c7"
      unitRef="usd">-200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI2MTcx_bfd12e76-606d-4088-a3c0-21f3233a462c"
      unitRef="usd">-100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTMx_06340887-0942-42eb-b03b-dc4ee8a761d4">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations and comprehensive loss as general and administrative expenses.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3NDY5_b9e065b0-0330-454f-9d5a-0075624dfa99"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3Njg5_64e336b0-f599-460c-8437-59e2ba3a5645"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI3Njg5_c47e24f9-4457-4841-bc51-43e21863d4b3"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <vrdn:WarrantsPolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTc2_35a14a72-b599-4fe9-a9b9-9ba7c22bcebd">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 718, &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.&lt;/span&gt;</vrdn:WarrantsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NDk3_566dedfd-1c66-4fae-951c-c38c263a95c9">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#x2019;s partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI4ODEw_406b16cd-9fd1-488a-a6ca-dc96ff7a1b8b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzAvZnJhZzo3ZWU2ODZkZDVhM2Q0NDg4YWQ4YmMwMWEwNDM2ZTFhZC90ZXh0cmVnaW9uOjdlZTY4NmRkNWEzZDQ0ODhhZDhiYzAxYTA0MzZlMWFkXzI5NTgw_a39e994c-a030-45c9-9965-b94cb76573f9">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements &#x2013; To Be Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2MQ_ff641800-b0b1-4a4b-9ef3-18a2129fe8bf">INVESTMENTS AND FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following as of December&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company had realized gains of zero and $4&#160;thousand in its available for sale securities for the years ended December&#160;31, 2022 and 2021, respectively. The contractual maturity dates of all of the Company&#x2019;s investments are all less than 24 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2Mg_287e723d-6a53-421d-bc64-4c10b7fa85fc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following as of December&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItMi0xLTEtNjYyNTk_0b34cc44-ea3f-4c6d-8a28-56034c85c0a0"
      unitRef="usd">137903000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItNC0xLTEtNjYyNTk_e0beeba5-0b27-43e1-8f28-f8635ca35652"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItNi0xLTEtNjYyNTk_de9b2c81-196a-491a-b0e8-cbd81d4a368c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6eb1090043441ef956275d1fb66e81c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzItOC0xLTEtNjYyNTk_ed7879b1-14b0-46ec-b5c6-348aa62fe3f9"
      unitRef="usd">137903000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtMi0xLTEtNjYyNTk_6b24c8f9-7985-4cc9-aa27-3bc38a6b5bb1"
      unitRef="usd">85578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtNC0xLTEtNjYyNTk_0f0ece46-1307-4274-9061-5315bd7c731f"
      unitRef="usd">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtNi0xLTEtNjYyNTk_2c5f9dd6-7037-4a89-8e9c-0cfc96899b1b"
      unitRef="usd">96000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cdd597646b44d52894aecdbad5728ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzMtOC0xLTEtNjYyNTk_eb0094b3-a278-427a-a87a-b74fa6d8f4e8"
      unitRef="usd">85605000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtMi0xLTEtNjYyNTk_155648f2-6d31-427b-abaa-64a0c7f5a124"
      unitRef="usd">199350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtNC0xLTEtNjYyNTk_cc34b5e7-efa5-4bee-9198-54c02c71732a"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtNi0xLTEtNjYyNTk_5c0b77b2-02e8-42dc-9388-396688a851fb"
      unitRef="usd">385000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i753c65f59ed345b59b31d0fc3b9c23a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzQtOC0xLTEtNjYyNTk_03ac41eb-68fe-4c1f-8405-09adcf1af86c"
      unitRef="usd">198966000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtMi0xLTEtNjYyNTk_b7d81aa5-f569-40d5-bf57-a628145a1d4c"
      unitRef="usd">2009000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtNC0xLTEtNjYyNTk_39ec7602-9610-4390-bfd3-d0cc0a9c0ee5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtNi0xLTEtNjYyNTk_8410b3fc-21db-4999-b7bc-73c310ac23cc"
      unitRef="usd">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50518ce5332d4b1d98453d1c3dc19c3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzUtOC0xLTEtNjYyNTk_e58e2de8-b739-46e5-bf80-81827dd7c97f"
      unitRef="usd">1976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtMi0xLTEtNjYyNTk_d6a6559b-4fcb-4c39-ab8e-b274d9d6e9f5"
      unitRef="usd">424840000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtNC0xLTEtNjYyNTk_8a645d63-3717-4fc6-ae35-03de3527524e"
      unitRef="usd">124000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtNi0xLTEtNjYyNTk_f0df9b32-e65d-4a98-a3bf-550c43ea8e8b"
      unitRef="usd">514000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzYtOC0xLTEtNjYyNTk_0a381f90-d9e6-475d-99ce-948e8d436d26"
      unitRef="usd">424450000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktMi0xLTEtNjYyNTk_539f9e27-621e-4923-9ba0-032ccf7021aa"
      unitRef="usd">42199000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktNC0xLTEtNjYyNTk_2934dd9d-09b6-4d89-8e59-72956b0b0b11"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktNi0xLTEtNjYyNTk_de320bc9-947e-4eb6-b50b-f9ccb146eb78"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bfbba8ed9bb4bc0ab51db58bb5922d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzktOC0xLTEtNjYyNTk_c5946199-efa5-494c-967b-0f9bfeffb8a8"
      unitRef="usd">42199000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i28384390d13f43e5b84481e6b9381841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTItMS0xLTY2MjU5_0fcb4304-4950-4fc9-bd48-4ebf1acdffe7"
      unitRef="usd">22215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i28384390d13f43e5b84481e6b9381841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTQtMS0xLTY2MjU5_301ad98b-d1cf-44bd-a182-9f0ddd26aa12"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i28384390d13f43e5b84481e6b9381841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTYtMS0xLTY2MjU5_c3fbfa7f-7e44-4288-9be9-4aaeb08e4789"
      unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28384390d13f43e5b84481e6b9381841_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEwLTgtMS0xLTY2MjU5_343165c8-d3e8-4e20-8216-ef21e1815dfb"
      unitRef="usd">22161000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTItMS0xLTY2MjU5_a2b7817a-49ad-4033-bffb-468f56aeca26"
      unitRef="usd">128005000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTQtMS0xLTY2MjU5_466887c7-eec4-43ef-946a-e3ff14cf0edf"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTYtMS0xLTY2MjU5_6979d546-7a59-49a1-984a-38145aef0d37"
      unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i319fa86bec5d4b28816c65ae30472b0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzExLTgtMS0xLTY2MjU5_9ad7a1e5-63a5-46af-82bf-2ea5cdd82315"
      unitRef="usd">127917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTItMS0xLTY2MjU5_94872b6d-e7c7-4a52-9496-fe0e728223ce"
      unitRef="usd">4603000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTQtMS0xLTY2MjU5_c5b3c2b8-c0f0-43fc-8f27-fed5084705f8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTYtMS0xLTY2MjU5_0f1bf23d-2128-49aa-873b-2db3a7967f23"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib504c0d9b1b1464ca139986003bd5108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEyLTgtMS0xLTY2MjU5_f35a08bd-216b-4f75-b29c-9d8d83f1c2fc"
      unitRef="usd">4588000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTItMS0xLTY2MjU5_a7e759df-558d-45d1-9ccc-a35b63443847"
      unitRef="usd">197022000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTQtMS0xLTY2MjU5_9f1fd1ae-3410-40c8-afe6-eec97f64c105"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTYtMS0xLTY2MjU5_92bc1bd3-c793-4eb3-8302-23249c9ee54e"
      unitRef="usd">163000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTpmOGYxNTIwYTgxODg0MDlmYTc5OTNmOGUwNGFiMDZhZS90YWJsZXJhbmdlOmY4ZjE1MjBhODE4ODQwOWZhNzk5M2Y4ZTA0YWIwNmFlXzEzLTgtMS0xLTY2MjU5_17be7b18-9745-40a2-9dfc-e81f5eeab6e9"
      unitRef="usd">196865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDM0MzM_3060e53a-8e52-41be-bb73-a227b954b0c1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDM0NDM_4c52fef8-b6ad-426e-a32d-ede037d66fcc"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzE2NDkyNjc0NDMzNjc_911cce93-ea23-40e5-af2b-181203859df5">P24M</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90ZXh0cmVnaW9uOmFiZjE0ZTMwMDljNjQ2MTBhNjkwY2VkY2E2OTYwYzMxXzc2Mw_7ecec67b-5a71-4fe7-9eda-ab3f9f1d7599">The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2cdcc30d49604c4f8a177a5ad2200579_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtMi0xLTEtNjYzMTc_3fcbf25c-950b-434f-aa9c-b5bd8b7fa0f3"
      unitRef="usd">137903000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9356ff5b031a4687b1c762d67b77aa89_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtNC0xLTEtNjYzMTc_fcc8bce2-9b1b-4a9a-8a81-07fe9eaee0d5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i138932474f284b93a8c0a3f2ea051590_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtNi0xLTEtNjYzMTc_9f2bc4e8-984b-4a24-9a46-c92a56fa2817"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i73f9db3f0dd54baab1199f7f903a42f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzUtOC0xLTEtNjY2NDU_09612dbd-30f9-41e6-9fb8-a8ab6a331782"
      unitRef="usd">137903000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtMi0xLTEtNjg0MjA_0dea94be-abe6-499a-adc0-67bcb81fef74"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idcf415c64ea54fffaef87bbacbad114c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtNC0xLTEtNjgyMzY_b06c7833-1841-45c6-b298-a34de114d88b"
      unitRef="usd">17576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtNi0xLTEtNjg0MjA_e932cf4c-466c-46a0-9e1c-995c2cdc1825"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzYtOC0xLTEtNjg0MjA_5e5bc641-875c-454f-b752-ae5d97f39a7d"
      unitRef="usd">17576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia17544d63b7e4808a4b8208d12cb2e71_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctMi0xLTEtNjYzMTc_551d242e-494e-4eff-ab4f-93c85f8182d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25d2676e80164d798e781f7504896a1f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctNC0xLTEtNjYzMTc_d78183cc-53e7-4965-bc4a-10b5727bcdec"
      unitRef="usd">85605000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie994cb889acc4540af7bc488619bb148_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctNi0xLTEtNjYzMTc_9fb42eef-dd66-4746-b7a5-5cdaf689a6c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id68f4338d1f44253b074041654004af8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzctOC0xLTEtNjY2NDU_ed81e04d-607a-43de-9ccd-ded6a1142869"
      unitRef="usd">85605000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacd52b437d724cb9a0cd9f62fabb06d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtMi0xLTEtNjYzMTc_19a5d882-8aa6-4a2a-aed0-51e8e229e282"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcf415c64ea54fffaef87bbacbad114c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtNC0xLTEtNjYzMTc_00587d25-3888-4ad6-9c56-402fcf13c3e0"
      unitRef="usd">181390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c7b56386f9e465e8ec5f3472e3ed799_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtNi0xLTEtNjYzMTc_1af11ab8-abf0-44a1-9e24-09734a0ae512"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f591e0a1a7543d992a40b4c7d3830a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzgtOC0xLTEtNjY2NDU_672ba107-9681-4a0d-bfb4-006f0c9790cd"
      unitRef="usd">181390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2795e5bc63324d8692234b45f12d6e89_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktMi0xLTEtNjYzMTc_93eb82a4-7e83-4d34-aac1-32558265f9c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i495cfb882143496ab5fafbfd845fc230_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktNC0xLTEtNjYzMTc_56e97d28-8bac-47eb-826e-51bcf513e668"
      unitRef="usd">1976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd7a54bdbf734a5f8559bb31501853dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktNi0xLTEtNjYzMTc_0142e9db-35ad-4da6-9909-88d17a833520"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic1ec5d1cd14648b2a0cb3409d8481901_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzktOC0xLTEtNjY2NDU_a2e20020-d04e-40af-ae49-e1405f7f0119"
      unitRef="usd">1976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1cb2d53f432d49a28a93868e1b8234d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTItMS0xLTY2NjQ1_444f0913-7ef4-431a-8d27-790b2e7ad36a"
      unitRef="usd">137903000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e890918a65f47ea962c20bc52a3a589_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTQtMS0xLTY2NjQ1_c666a7bc-f5a2-440f-b2c2-0844de3d31e8"
      unitRef="usd">286547000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i718d62966309427ab5d15be792791b49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTYtMS0xLTY2NjQ1_1a5f5a8b-8890-437f-84f0-d47225fab078"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03f92b6bed324e2ba85a9852abf1b187_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzEwLTgtMS0xLTY2NjQ1_b8a79d5c-5b65-4f68-95f7-e5fc7f713b8a"
      unitRef="usd">424450000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a6d117211af41a28fb359bb1d81d933_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTItMS0xLTY2MzQy_35125dab-89b8-4179-bd63-ae408cd7b59d"
      unitRef="usd">42199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie418b540ddec4d8f9a908bc68dd410e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTQtMS0xLTY2MzQy_c4e0cca2-9db0-4ca4-93a6-29f171548829"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i39731739ccb24de699b33ec24511466f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTYtMS0xLTY2MzQy_8e51fc84-ee87-45df-aa8e-c9f7439b1a87"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife91bebf75fa462f9dc8efd8e9e15192_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE1LTgtMS0xLTY2MzQy_fe4220db-f719-4526-9942-359498beb1bb"
      unitRef="usd">42199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00032c150d7b4b26b67be5b777d07453_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTItMS0xLTY2MzQy_1f7b5086-4ad3-43fb-9940-ce16b48c9260"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bb7acaf82d94261b8bbef9198fb5b9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTQtMS0xLTY2MzQy_5d997670-8e0a-43cc-82f8-601c2aa398ff"
      unitRef="usd">22161000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i397518dae3854f5aaf22291b12e28fbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTYtMS0xLTY2MzQy_6e0ea7e6-5e22-4b3d-b9c3-522848092aec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b0e75e0c7604e9682a93b1b039078c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE3LTgtMS0xLTY2MzQy_fe59e97f-4712-4cd9-a521-e6fad103876e"
      unitRef="usd">22161000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20b087108fec4701a4a2c61e0717f2a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTItMS0xLTY2MzQy_9fa10d8b-b143-40ad-88c1-0d0bc6e44d91"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91e20b79c6ce409d9f6ade1210e3b210_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTQtMS0xLTY2MzQy_9e7126a3-d891-49de-a1bd-2d96b7d19638"
      unitRef="usd">127917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c21147b36794bedbd9fc27467dd2076_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTYtMS0xLTY2MzQy_29958194-1a58-4825-adf7-c85b8f2e90f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i569d7eb69fb147f7a599cb9ed5033a75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE4LTgtMS0xLTY2MzQy_b43da260-1c13-4969-8df8-32cf36958274"
      unitRef="usd">127917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica72868174974c239b1ad5f7a2786253_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTItMS0xLTY2MzQy_55d7040b-0c21-4f90-8c09-9557166f0f8f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1aa2353ccf1b493a906749cc46971b22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTQtMS0xLTY2MzQy_f849ec1d-975a-41f2-8ff1-aa1ae6faf1f9"
      unitRef="usd">4588000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd00d8f83ece4bb8bf16db7bf032c030_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTYtMS0xLTY2MzQy_cfc7cba0-9777-4e2b-a827-28fb79f4dff5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf96050c9b204ae3a4dc0d09a8f89a45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzE5LTgtMS0xLTY2MzQy_7e42820d-a8d7-4b52-8f44-724657abb60b"
      unitRef="usd">4588000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2493b7d3e6f54fc4aca64c1b7e756944_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTItMS0xLTY2MzQy_ed32e210-6d24-4e98-aa3f-d13878ae2903"
      unitRef="usd">42199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7237ef7f504c42ac91f4cd23a2e8f7d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTQtMS0xLTY2MzQy_bcc0b010-ea41-47e8-b0fd-2ff263fe9929"
      unitRef="usd">154666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic661c528426d40a4a7f6ff953d525bbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTYtMS0xLTY2MzQy_3a32d6fd-7de6-4044-b61f-adb48427a91b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i962c21f5667a48bead2b497aa2cc2efb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzkvZnJhZzphYmYxNGUzMDA5YzY0NjEwYTY5MGNlZGNhNjk2MGMzMS90YWJsZTo3YmNmMjU4YWY1YTk0NTU5ODQ4YzUzN2I2ODhlYTg3Yi90YWJsZXJhbmdlOjdiY2YyNThhZjVhOTQ1NTk4NDhjNTM3YjY4OGVhODdiXzIwLTgtMS0xLTY2MzQy_e972cd5c-4318-49c5-aecc-73d24b9c01bc"
      unitRef="usd">196865000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzg5Mw_4f0e588e-cd41-4f44-976a-7088c0998627">PROPERTY AND EQUIPMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, certain lab equipment met the criteria to be classified and were reclassified as held for sale and included in prepaid expenses and other current assets. The assets held for sale totaled $0.1 million, which was the net book value on the date of transfer. During the year ended December 31, 2021, the Company sold the equipment, received proceeds of approximately $0.1 million and recorded a loss of approximately $0.1 million. &lt;/span&gt;&lt;/div&gt;During the years ended December&#160;31, 2022 and 2021, depreciation and amortization expense was $0.3 million and $0.1 million, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzg5NQ_1d77749d-d16b-46f1-b1b8-bf236fe51027">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i18f6583aa4bf42c9b1b52633f83d14a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzctMS0xLTEtNjQ2MTQ_04567521-8e75-4df6-8b69-55c0314895a9"
      unitRef="usd">1160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia25cc2ffa9f144a88bb763f938333daf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzctMy0xLTEtNjQ2MTQ_50b47012-2057-4968-9927-db4a2143f312"
      unitRef="usd">775000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i01a117538c9041aebcee41fd26d43947_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzgtMS0xLTEtNjQ2MTQ_d92db2f0-c26f-4953-ae06-9bba69813401"
      unitRef="usd">1113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i558bf4d01982457597bb849567a66261_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzgtMy0xLTEtNjQ2MTQ_daff88ac-d956-4572-8709-b78754de9aca"
      unitRef="usd">749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia959ee789f0d49838e929580701a3357_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzktMS0xLTEtNjQ2MTQ_f190736d-d06c-4abd-8d8f-2e1a881f7293"
      unitRef="usd">725000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2828cb09ac024bbeb97dcdad08208d79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzktMy0xLTEtNjQ2MTQ_ce1e7653-1cbc-4289-a9a0-26764377ccde"
      unitRef="usd">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad844ce133a4439b89b3b712bcebe2fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEwLTEtMS0xLTY0NjE0_704f07f0-ff9d-4ed3-9f10-09224ffd94f9"
      unitRef="usd">332000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2cb8a885c6c2471aac42e78a2b6716e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEwLTMtMS0xLTY0NjE0_d91bf09a-d782-4122-811f-c96d688d5d7b"
      unitRef="usd">197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzExLTEtMS0xLTY0NjE0_10af0583-dc4c-4024-a6aa-cdff4f5ec0cf"
      unitRef="usd">3330000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzExLTMtMS0xLTY0NjE0_020b210b-411c-4b78-9f21-8387f262d5c3"
      unitRef="usd">2151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEyLTEtMS0xLTY0NjE0_dd9c6501-1c4d-4d1d-b3ed-1dc1cd1529b1"
      unitRef="usd">2004000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEyLTMtMS0xLTY0NjE0_2f3d9165-9fa3-4c14-bb7b-ca5331fb8e9f"
      unitRef="usd">1776000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEzLTEtMS0xLTY0NjE0_23bab53c-2817-4527-8480-a3674e01dd63"
      unitRef="usd">1326000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90YWJsZTphMzMwMmVkNTUwY2Y0MGQzOGZhZDBhZDczYTNkN2FlYi90YWJsZXJhbmdlOmEzMzAyZWQ1NTBjZjQwZDM4ZmFkMGFkNzNhM2Q3YWViXzEzLTMtMS0xLTY0NjE0_5cef05a1-baf1-4768-9078-b77bb7ec7662"
      unitRef="usd">375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzM4Nw_01aeaca5-48ab-4ea2-987d-853f0c8ca28a"
      unitRef="usd">100000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzU2MQ_9a076c77-82b6-4335-b6dc-286bec6378c1"
      unitRef="usd">100000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzYwOQ_9d3fc5ac-23d7-495d-ae82-617117af6e68"
      unitRef="usd">-100000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzY5MA_bc033236-81c1-4639-ba4c-cb1cade971f7"
      unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDIvZnJhZzpmMTlmOWQ2NmExOGE0ZGQxOTIxMWQ5ZGJlZTkxMDA1YS90ZXh0cmVnaW9uOmYxOWY5ZDY2YTE4YTRkZDE5MjExZDlkYmVlOTEwMDVhXzcwNQ_9e68d044-40c3-4c84-9815-e147caefc875"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90ZXh0cmVnaW9uOjdlNmNjMzU3NWY2MjQzMzM4Mzg2MTdhNjQ5ODUyYmRjXzc5_02f95dfd-cd00-40c6-bbbe-f33cb33553f1">ACCRUED LIABILITIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued outsourced clinical trials and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b"&gt;Operating lease liability, short-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal fees and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other professional service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of liability-classified stock purchase warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90ZXh0cmVnaW9uOjdlNmNjMzU3NWY2MjQzMzM4Mzg2MTdhNjQ5ODUyYmRjXzg3_8fde6528-3778-4686-8c94-49b8c6809cb5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued outsourced clinical trials and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_20e7ab3e-ba4f-4970-936c-67ac53121397"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMC0xLTEtNjQ2MTQ_781e0b3a-9e09-40e7-ba8b-9a6fcf503a1b"&gt;Operating lease liability, short-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal fees and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other professional service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of liability-classified stock purchase warrants &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vrdn:AccruedOutsourcingClinicalandPreclinicalStudies
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzMtMS0xLTEtNjQ2MTQ_b91625e6-bc3d-480a-92dc-53efe80d9722"
      unitRef="usd">12576000</vrdn:AccruedOutsourcingClinicalandPreclinicalStudies>
    <vrdn:AccruedOutsourcingClinicalandPreclinicalStudies
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzMtMy0xLTEtNjQ2MTQ_9a6d4247-7d1b-4cb9-910a-f18e0aa69659"
      unitRef="usd">6316000</vrdn:AccruedOutsourcingClinicalandPreclinicalStudies>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzQtMS0xLTEtNjQ2MTQ_c62c5d88-f4da-42b7-9fd7-848c0913b26c"
      unitRef="usd">4772000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzQtMy0xLTEtNjQ2MTQ_9ab1515e-6b35-44ed-8ea2-4ff59d5acbc0"
      unitRef="usd">3652000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMS0xLTEtNjQ2MTQ_3ee0237b-d398-4c40-8721-599256b0c194"
      unitRef="usd">613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzUtMy0xLTEtNjQ2MTQ_688eac3a-ae58-4513-941c-66c0e7b6b1bb"
      unitRef="usd">520000</us-gaap:OperatingLeaseLiabilityCurrent>
    <vrdn:AccruedLegalFeesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzYtMS0xLTEtNjQ2MTQ_1c1bdfd2-2c32-4b20-936b-a50443d19f9a"
      unitRef="usd">177000</vrdn:AccruedLegalFeesCurrent>
    <vrdn:AccruedLegalFeesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzYtMy0xLTEtNjQ2MTQ_f6b4d252-32e4-4add-9562-9aef3a0d2d64"
      unitRef="usd">80000</vrdn:AccruedLegalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzctMS0xLTEtNjQ2MTQ_4cc71493-7e07-475a-b136-94b7e5619955"
      unitRef="usd">392000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzctMy0xLTEtNjQ2MTQ_20077e86-7040-418a-ace6-4893fc59ac0f"
      unitRef="usd">140000</us-gaap:AccruedProfessionalFeesCurrent>
    <vrdn:AccruedLiabilityofWarrantsonTemporaryEquity
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzgtMS0xLTEtNjQ2MTQ_7c3a8b4b-00cc-4a22-b1b9-c02680d67c43"
      unitRef="usd">100000</vrdn:AccruedLiabilityofWarrantsonTemporaryEquity>
    <vrdn:AccruedLiabilityofWarrantsonTemporaryEquity
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzgtMy0xLTEtNjQ2MTQ_1dda4328-0eee-4b50-a1c2-5bd8408f36d2"
      unitRef="usd">100000</vrdn:AccruedLiabilityofWarrantsonTemporaryEquity>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzEwLTEtMS0xLTY0NjE0_3ffdfdb7-c1cb-45cd-b18e-66e9882be686"
      unitRef="usd">197000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzEwLTMtMS0xLTY0NjE0_3a1d4105-d061-4226-b23c-8ca3b75fd994"
      unitRef="usd">210000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzExLTEtMS0xLTY0NjE0_4363bc5d-f276-4287-a140-1a7a61e40528"
      unitRef="usd">18827000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDUvZnJhZzo3ZTZjYzM1NzVmNjI0MzMzODM4NjE3YTY0OTg1MmJkYy90YWJsZTo2YWZkMTAxZGVkMmQ0MjRkYWE5ZjZmODMxOTkwNzljYi90YWJsZXJhbmdlOjZhZmQxMDFkZWQyZDQyNGRhYTlmNmY4MzE5OTA3OWNiXzExLTMtMS0xLTY0NjE0_7a89c7e7-6583-4f42-a690-95b3384422cd"
      unitRef="usd">11018000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2MDM_e0de6bc9-e564-4088-a44d-113f8116865c">DEBT&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loan and Security Agreement with Hercules Capital, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022, the Company entered into a loan and security agreement (the &#x201c;Hercules Loan and Security Agreement&#x201d;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#x201c;Borrower&#x201d;), Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and certain other lenders named therein (the &#x201c;Lenders&#x201d;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $75.0&#160;million, in four tranches (collectively the &#x201c;Term Loan&#x201d;), consisting of (1) an initial tranche of $25.0&#160;million, available to the Company through June 15, 2023; (2) a second tranche of $10.0&#160;million, subject to the achievement of certain regulatory milestones, available through June 15, 2023; (3) a third tranche of $15.0&#160;million, subject to the achievement of certain regulatory milestones, available through March 15, 2024; and (4) a fourth tranche of $25.0&#160;million, subject to approval by the Lenders&#x2019; investment committee(s), available through December 15, 2024. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Loan Agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#x2019;s intellectual property. The Term Loan has a maturity date of October 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Term Loan bears interest at a floating per annum rate equal to the greater of (i) 7.45% and (ii) 4.2% above the Prime Rate, provided that the Term Loan interest rate shall not exceed a per annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of December 31, 2022 was 8.95% based upon an increase in the prime rate in June 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Per the terms of the Hercules Loan and Security Agreement, the Company was originally obligated to make interest-only payments through April 1, 2024. However, upon the achievement of a development milestone in August 2022 the interest-only period was extended to October 1, 2024. If additional development milestones are met, the interest-only period will be further extended to April 1, 2025. The Borrower is required to repay the Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $5.0&#160;million. The Company incurred debt issuance costs of $0.2&#160;million in connection with the Term Loan. In addition, in connection with the initial draw, the Company paid to the Lenders a facility fee of $0.1&#160;million, as well as $0.1&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#x201c;Lender Expenses&#x201d;). The debt issuance costs and the Lender Expenses are being amortized as additional interest expense over the term of the loan. Debt issuance costs and the Lender Expenses are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;asset in accordance with ASU No. 2015-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately 9.3%. The Company recorded interest expense of $0.5&#160;million during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the impact of the Term Loan, on the Company&#x2019;s consolidated balance sheet at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan and Security Agreement as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzNjY_f1631624-6368-4a28-b933-c5c631eb4e50"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <vrdn:DebtInstrumentNumberOfTranches
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzODA_b8e85f87-52d8-4e0c-8732-3e3e19c8a65d"
      unitRef="tranche">4</vrdn:DebtInstrumentNumberOfTranches>
    <vrdn:DebtInstrumentFaceAmountFirstTranche
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzIzOTA_7310695f-1cc5-4a1b-8f54-ddbcbbb611cd"
      unitRef="usd">25000000</vrdn:DebtInstrumentFaceAmountFirstTranche>
    <vrdn:DebtInstrumentFaceAmountSecondTranche
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MDU_0261db15-c2e6-42ea-b26e-4d6f53bda4e4"
      unitRef="usd">10000000</vrdn:DebtInstrumentFaceAmountSecondTranche>
    <vrdn:DebtInstrumentFaceAmountThirdTranche
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MjA_de125c4a-69e4-4b84-ae17-ba61f2460313"
      unitRef="usd">15000000</vrdn:DebtInstrumentFaceAmountThirdTranche>
    <vrdn:DebtInstrumentFaceAmountFourthTranche
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0MzU_29ea7e92-053f-4714-bdf8-6203fa04ef6c"
      unitRef="usd">25000000</vrdn:DebtInstrumentFaceAmountFourthTranche>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NTA_81299140-1532-499d-92ed-3d3492313996"
      unitRef="number">0.0745</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iee91adf567604cd2aa42b110e5fac7af_D20220401-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NTc_129715d6-031a-42f8-bc99-0fef63195f77"
      unitRef="number">0.042</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vrdn:DebtInstrumentInterestRateMaximum
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NjM_f0e1b31d-9ef0-444b-be12-ca16929a4c09"
      unitRef="number">0.0895</vrdn:DebtInstrumentInterestRateMaximum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0NzA_8060ae7b-5039-4cfb-8762-7461ef4a990f"
      unitRef="number">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vrdn:PrincipalAmountTermFee
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2NDkyNjc0NDkyNzA_42aba318-16c9-4978-8007-bda33d3d459e"
      unitRef="number">0.06</vrdn:PrincipalAmountTermFee>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0OTE_e61cf916-f19c-4356-bd78-7cbc922fc4d0"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MTk_986c207f-5b00-47f9-9f3f-a27c5d806240"
      unitRef="usd">200000</us-gaap:DeferredFinanceCostsNet>
    <vrdn:DebtInstrumentFacilityFee
      contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI0Nzc_ab06d53e-8cab-4009-b4ca-a23ce6c5f554"
      unitRef="usd">100000</vrdn:DebtInstrumentFacilityFee>
    <vrdn:DebtInstrumentOtherExpenses
      contextRef="i5106586991db467b98afa08d33f637c0_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MDU_cb25a1fd-8062-4da2-931c-e4f36eccdae8"
      unitRef="usd">100000</vrdn:DebtInstrumentOtherExpenses>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i39e7dc6d42804fb38aabcd93c116f6af_I20220430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzE2NDkyNjc0NDkyNzQ_50f83f89-19a2-4a4c-b16a-af8010a8418c"
      unitRef="number">0.093</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzU0OTc1NTgyMTUwNQ_1f0a42de-de70-4acc-9003-21b6c1bf73f3"
      unitRef="usd">500000</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MzI_8c7539ce-7943-47b2-b97b-0f78b20985b0">The following table summarizes the impact of the Term Loan, on the Company&#x2019;s consolidated balance sheet at December&#160;31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzItMS0xLTEtNjUzOTA_dbfa972d-fe24-4438-a795-833b4bffa159"
      unitRef="usd">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzMtMS0xLTEtNjUzOTA_c29054e3-97bf-44a5-b6d0-881acf1a4c05"
      unitRef="usd">355000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTpmYThiZGE1MTU4Zjk0YjQ1YmJhNDMxMTA1OWVjMjgwYy90YWJsZXJhbmdlOmZhOGJkYTUxNThmOTRiNDViYmE0MzExMDU5ZWMyODBjXzQtMS0xLTEtNjU4MDE_8ba4c74a-0496-4ad8-82e4-7441860a3a04"
      unitRef="usd">4645000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90ZXh0cmVnaW9uOjA0ZTFmYjNhMGE5NTRjODBhOWQ3YTZjNTI2MzUzODNiXzQ5NDc4MDIzMzI1MzM_e6abde02-edc9-4bfd-b233-a387acdc115d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan and Security Agreement as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzEtMS0xLTEtNjUzOTA_1683a7a9-4ab2-45d2-8481-1c88a1c1b5ef"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzItMS0xLTEtNjUzOTA_0d2030a3-a17e-4d45-b405-73fef51e0c05"
      unitRef="usd">551000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzMtMS0xLTEtNjUzOTA_f3d96bc4-7c8f-45b5-9587-50c05ae86f0b"
      unitRef="usd">2331000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzQtMS0xLTEtNjUzOTA_632c3da2-3a78-455d-8d59-dc86a66a9bf5"
      unitRef="usd">2118000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5068b8f88948444a8959f2c27cf864e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNDgvZnJhZzowNGUxZmIzYTBhOTU0YzgwYTlkN2E2YzUyNjM1MzgzYi90YWJsZTo4NTZjNTc0YzdhZDk0NmExYTZmM2EzNmM1NzcyNGQ5NC90YWJsZXJhbmdlOjg1NmM1NzRjN2FkOTQ2YTFhNmYzYTM2YzU3NzI0ZDk0XzYtMS0xLTEtNjU4Mzk_930848c9-5e43-485a-b58b-d656300eb628"
      unitRef="usd">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU2NTE_92080d1b-0025-4d80-b4a3-12b9ccf681c7">COLLABORATION AGREEMENTS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Zenas BioPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#x201c;Zenas BioPharma&#x201d;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma (the &#x201c;Supply Agreement&#x201d;) to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#x201c;Zenas Agreements&#x201d;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#x2019;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 808&#x201d;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#x2019;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#x2019;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#x2019;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#x2019;s estimated period to complete its activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the years ended December 31, 2022 and 2021, the Company recognized $1.8 million and $3.0 million, respectively, of collaboration revenue related to the Zenas Agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC beneficially owns more than 5% of the Company&#x2019;s common stock and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company and Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) entered into an antibody and discovery option agreement (the &#x201c;Paragon Agreement&#x201d;) under which the Company and Paragon will cooperate to develop one or more antibodies. Under the terms of the Paragon Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#x2019;s commitment of the necessary personnel and resources to perform these activities. The Paragon Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#x201c;Final Deliverable&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#x2019;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#x201c;Option&#x201d; and together, the &#x201c;Options&#x201d;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs at any time until the date that is 90 days after the Company&#x2019;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#x201c;Option Period&#x201d;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Program will terminate. In consideration for Paragon&#x2019;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $2.5&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of $2.3&#160;million (the &#x201c;First Amendment Payment&#x201d;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program. During the year ended December 31, 2022, the Company recorded $5.6 million in research and development costs related to the Paragon Agreement.&lt;/span&gt;&lt;/div&gt;As of December 31, 2022, the Paragon Agreement is considered a related party transaction because Fairmount beneficially owns more than 5% of the Company&#x2019;s capital stock and has two seats on the Company&#x2019;s board of directors, and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i87bf3ab4aa3946a18532afb870802102_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzM5NTg_b0565612-d9d7-408a-a0b1-f4e51740dcaf"
      unitRef="usd">1800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i84ae605e448441d3a3f0ac5f55eca328_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzM5NzM_f5ed44e6-1e9d-4203-8fb2-d312dc34f5dc"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i0659d7dc0d044cddb185ec3b557387ce_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzQyMTM_12e87b2d-7c2c-44a2-b0c1-5c5f4a88998d"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i0659d7dc0d044cddb185ec3b557387ce_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzQyNjA_06d7feb2-592d-4fc5-bfa2-e3c2a046953a"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <vrdn:CollaborativeArrangementUpfrontFeePayment
      contextRef="i8f5e9943af7844ce9cf70397131daf9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTE0NA_d5d5259e-b992-48dd-8bf6-e6a9602e06bf"
      unitRef="usd">2500000</vrdn:CollaborativeArrangementUpfrontFeePayment>
    <vrdn:CollaborativeArrangementRightsAndLicensesFee
      contextRef="ib0a42fb2ee584e7ca4c08ef5f57c78d4_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzE2NDkyNjc0NjExNzk_bc3f5efd-94b6-424d-bda2-34b54663b43a"
      unitRef="usd">2300000</vrdn:CollaborativeArrangementRightsAndLicensesFee>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id50bf97251614e40ab675969431f996b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMzUwMw_ec43abc8-ab9e-4956-8eeb-96a3dadac2db"
      unitRef="usd">5600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i021c11dfe09a4127921884ad1fc46e9d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTY0Mw_07e38af8-464c-44d9-8ecd-bae598649827"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i021c11dfe09a4127921884ad1fc46e9d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xMzYvZnJhZzo3ZDA1Y2E0YWFlNmQ0NDcwYTEwNWE1MzNmNjBiMjkwOS90ZXh0cmVnaW9uOjdkMDVjYTRhYWU2ZDQ0NzBhMTA1YTUzM2Y2MGIyOTA5XzU0OTc1NTgzMTc2NQ_91562ced-c503-4be6-bcc1-849e207c1758"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3Xzg3NDA_e16b1b77-b3fb-457e-94e4-e96565dd2b40">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with ImmunoGen, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company became party to a license agreement (the &#x201c;ImmunoGen License Agreement&#x201d;) with Immunogen, Inc. (&#x201c;ImmunoGen&#x201d;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $48.0&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $2.5&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#x201c;IND&#x201d;) application for VRDN-001 with the FDA. In May 2022, the Company paid a $3.0&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for VRDN-001. In December 2022, the Company recorded $10.0&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a Pivotal Clinical Trial for VRDN-001, amount which was paid in January 2023 and which was included in accounts payable in the consolidated balance sheet as of December 31, 2022. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $95.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements with Xencor, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a subsequent technology license agreement (the &#x201c;2021 Xencor License Agreement&#x201d;) with Xencor for a non-exclusive license to certain antibody libraries developed by Xencor. Under the 2021 Xencor License Agreement, the Company received a one-year research license to review the antibodies and the right to select up to three antibodies for further development. In consideration for rights granted by Xencor, the Company issued 394,737 shares of our common stock to Xencor in December 2021. The shares were valued at $7.5&#160;million and recorded as research and development expense during the year ended December 31, 2021. Under the terms of the 2021 Xencor License Agreement, if successful, for each licensed product, the Company would be obligated to make future milestone payments of up to $27.75&#160;million, which includes development milestone payments of up to $4.75&#160;million, special milestone payments of up to $3.0&#160;million, and commercial milestone payments of up to $20.0&#160;million. Additionally, for each licensed product that the Company successfully commercializes, it would be responsible for royalty payments equal to a percentage in the mid-single digits of net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2020, the Company entered into a license agreement (the &#x201c;Xencor License Agreement&#x201d;) with Xencor, under which Xencor granted the Company rights to an exclusive, worldwide, sublicensable, non-transferable, royalty-bearing license to use specified Xencor technology for the research, development, manufacturing, and commercialization of therapeutic antibodies targeting IGF-1R indications. In consideration for rights granted by Xencor, the Company issued 322,407 shares of its common stock in December 2020. The shares were valued at $6.0&#160;million and recorded as research and development expense in 2020. Under the terms of the Xencor License Agreement, the Company is obligated to make future development milestone payments of up to $30.0&#160;million. Additionally, if the Company successfully commercializes any product candidate subject to the Xencor License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $25.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of products containing the licensed technology in each country until the later of (i) the expiration of the last patent claim subject to the Xencor License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained, or (iii) the 12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; anniversary of the date of the first commercial sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Rights Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the merger agreement with miRagen Therapeutics, Inc., on November 4, 2020, the Company and the Rights Agent (as defined therein) executed and delivered a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;), pursuant to which each holder of the Company&#x2019;s common stock as of November 6, 2020, other than former stockholders of Private Viridian, was entitled to one contractual contingent value right issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of its common stock held by such holder. No CVRs have been or may in the future be issued pursuant to the terms of the CVR Agreement as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Colorado-based Office and Lab Space&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space. The lease agreement includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to three terms of three years each. Minimum base lease payments under the lease agreement, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the lease agreement of approximately $1.6&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#x2019;s estimated incremental borrowing rate, over the 12 months expected remaining term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Massachusetts-based Office Space&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended, the &#x201c;Original Lease&#x201d;). The Original Lease included rent escalation clauses through the lease term. Minimum base lease payments under the lease agreement are recognized on a straight-line basis over the full term of the lease. Upon assumption of the Original Lease, the Company recognized a right-of-use asset and corresponding lease liability for the Original Lease of $0.1&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#x2019;s estimated incremental borrowing rate, over the expected remaining term. In July 2021, the Company entered into an amendment to the Original Lease to increase its Massachusetts-based office space (the &#x201c;First Amendment&#x201d;). In April 2022, the Company entered into a second amendment to the Original Lease of its Massachusetts-based office space (the &#x201c;Second Amendment&#x201d;). The Second Amendment made certain modifications to both the Original Lease and First Amendment, including (i) the addition of 2,432 square feet of office space in the same building and (the &#x201c;April 2022 Expansion Premises&#x201d;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease seven days after the delivery of the April 2022 Expansion Premises, which occurred in the fourth quarter of 2022, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment from October 2024 through November 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Second Amendment, the Company has the option to extend the lease term for an additional period of three years upon notice to the landlord. The Second Amendment provides for annual base rent for the April 2022 Expansion Premises of approximately $0.4&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into a third amendment to the Original Lease of its Massachusetts-based office space (the &#x201c;Third Amendment&#x201d;). The Third Amendment makes certain modifications to the Original Lease, including (i) the addition of 5,240 square feet of office space in the same building (the &#x201c;July 2022 Expansion Premises&#x201d;), (ii) the termination of the 1,087 square feet of leased space under the Original Lease, and (iii) the extension of the expiration date of the 3,284 square feet of leased space under the First Amendment to four years from the delivery of the July 2022 Expansion Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Third Amendment, the Company has the option to extend the lease term for an additional period of three years upon notice to the landlord. The Third Amendment provides for annual base rent for the July 2022 Expansion Premises of approximately $0.9&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under noncancellable leases as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company&#x2019;s operating lease obligations were reflected as short-term operating lease liabilities of $0.6&#160;million within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjM_e8ea74a0-3f88-44a4-a851-a40562034c1a"&gt;accrued liabilities&lt;/span&gt; and $1.1&#160;million of long-term lease obligations as &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMzg_22c5afc1-2efb-427c-a693-1ae037736565"&gt;other liabilities&lt;/span&gt; in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.5&#160;million for both the years ended December&#160;31, 2022 and 2021, and which was included in operating expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also required to pay for operating expenses related to the leased space, which were $0.3&#160;million for both the years ended December&#160;31, 2022 and 2021. The operating expenses are incurred separately and were not included in the present value of lease payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum
      contextRef="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwMTM_df412ba6-b904-4963-93ea-69d00f4ac973"
      unitRef="usd">48000000</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementMilestonePayment
      contextRef="if84d62946a994027b63085a509c4d878_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwMjg_8f81a317-dcd0-4793-a96b-9334d1ba3725"
      unitRef="usd">2500000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementMilestonePayment
      contextRef="i7b67fa0e69554ec68418419f8b40c77e_D20220501-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNDI_e8c330ab-7ed3-4aae-b9a7-985b47d33659"
      unitRef="usd">3000000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementMilestonePayment
      contextRef="i124a3275b5a440f5acff5df5308106be_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNTY_8d78c304-594c-42e1-bdeb-564f3a510615"
      unitRef="usd">10000000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum
      contextRef="i26c6bd25daa1435bbaae0eae494d9dc3_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwNzE_a40825c6-da27-4179-b7b1-94edfab4cba4"
      unitRef="usd">95000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:CollaborationArrangementResearchLicenseAndSelectionRightsTerm
      contextRef="iacf8bb4484b14487a716974ff915120a_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3Xzg3NDE_c4b6c9c9-46de-48f3-8ec8-eef1d2fd7c32">P1Y</vrdn:CollaborationArrangementResearchLicenseAndSelectionRightsTerm>
    <vrdn:CollaborativeArrangementSharesIssuedForRightsGranted
      contextRef="iab0808833c084902820bea4f3472d32b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzIzMDI_6c656647-f3cf-4fdd-93b2-a8aed44f8fa0"
      unitRef="shares">394737</vrdn:CollaborativeArrangementSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted
      contextRef="i6fa3a835940b42d39eb93c3ed98a799e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzIzODY_ee1b095e-86d9-4a39-8688-c1013317a1c0"
      unitRef="usd">7500000</vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum
      contextRef="iab0808833c084902820bea4f3472d32b_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI2NDk_c8d0cf70-c267-4370-9843-115e0a45d7b6"
      unitRef="usd">27750000</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum
      contextRef="iab0808833c084902820bea4f3472d32b_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3MDg_928e4c3f-0f29-4813-84c1-2dffbce908a0"
      unitRef="usd">4750000</vrdn:CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementPotentialSpecialPaymentsMaximum
      contextRef="iab0808833c084902820bea4f3472d32b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3NDg_0f680c86-3d16-4452-9e65-5379d28e3786"
      unitRef="usd">3000000</vrdn:CollaborativeArrangementPotentialSpecialPaymentsMaximum>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum
      contextRef="iab0808833c084902820bea4f3472d32b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzI3OTU_5d83f723-14a1-4140-b81c-0ff0c031fbb9"
      unitRef="usd">20000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:CollaborativeArrangementSharesIssuedForRightsGranted
      contextRef="ic46a9b2c111841f28563bace994e0980_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM0NzQ_f75067c2-3977-4b53-843e-7a63f7b8e6a8"
      unitRef="shares">322407</vrdn:CollaborativeArrangementSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted
      contextRef="i5cf6615de6694ae69368169bef73730a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM1NDg_a79418fd-5f7d-4ac5-b3f6-2dfbe552aeed"
      unitRef="usd">6000000</vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum
      contextRef="ic46a9b2c111841f28563bace994e0980_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzM3Mzg_147c6487-92fe-4ade-9ab8-0c610d12fbe7"
      unitRef="usd">30000000</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum
      contextRef="ic46a9b2c111841f28563bace994e0980_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzQwMDQ_58446751-bb65-4d3c-addc-13b484166854"
      unitRef="usd">25000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcwODY_0cbf0e9c-0ea8-4e84-a858-eca5ab2c2d9a"
      unitRef="renewal_term">3</vrdn:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxMzI_27ce4fc7-291c-4b48-9ae2-2a561cc47301">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxMzQ_5d943a95-f89c-42b2-8ea0-e9d7f08b312a"
      unitRef="usd">1600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNDg_cfe35ce9-72c7-4243-8e80-94d7d1d4f78c"
      unitRef="number">0.06</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic802c0b9ae6945e4a39732c93b32f251_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNTE_cc731ee6-c768-4057-9be4-03e853ec61d5">P12M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNjg_2aaa83c3-ed4d-4189-980b-d75026a7072a"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxNjg_5be899aa-4851-4301-8034-bbdde1e19119"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i87f669c23fa44047a98623dceb3ec78b_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxODI_3302482e-052e-4749-99aa-3a41c287b142"
      unitRef="number">0.06</us-gaap:LesseeOperatingLeaseDiscountRate>
    <vrdn:AreaOfOfficeSpaceExpanded
      contextRef="i8c0728b5d899440094213edef06f750b_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxODY_02811676-d243-4d04-bddb-5a80549996bd"
      unitRef="sqft">2432</vrdn:AreaOfOfficeSpaceExpanded>
    <vrdn:AreaOfOfficeSpaceTerminated
      contextRef="i8c0728b5d899440094213edef06f750b_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcxOTM_988fbb98-cfda-4f03-b18e-70448a1aaa4a"
      unitRef="sqft">1087</vrdn:AreaOfOfficeSpaceTerminated>
    <vrdn:AreaOfOfficeSpaceExtension
      contextRef="i8c0728b5d899440094213edef06f750b_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMDA_36f85ea3-28ae-453d-978f-4b393b2c1a5a"
      unitRef="sqft">3284</vrdn:AreaOfOfficeSpaceExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8c0728b5d899440094213edef06f750b_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMDY_a694e630-a749-4dc8-9430-279662b9bdb2">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vrdn:OperatingLeaseAnnualBaseRent
      contextRef="i1aef7c7506834b01bc927bc477344c11_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMjU_3147a348-af4a-44ce-95ec-d96ffa023012"
      unitRef="usd">400000</vrdn:OperatingLeaseAnnualBaseRent>
    <vrdn:AreaOfOfficeSpaceExpanded
      contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyMzk_efb40b8c-70fa-4546-8443-4d91f39734c2"
      unitRef="sqft">5240</vrdn:AreaOfOfficeSpaceExpanded>
    <vrdn:AreaOfOfficeSpaceTerminated
      contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNDY_fd4bc7ea-b547-405f-bf69-72ff553989b7"
      unitRef="sqft">1087</vrdn:AreaOfOfficeSpaceTerminated>
    <vrdn:AreaOfOfficeSpaceExtension
      contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNTM_32d29739-678e-4e98-9af6-a08bf92606cd"
      unitRef="sqft">3284</vrdn:AreaOfOfficeSpaceExtension>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNTk_185e1011-743d-44e6-8f46-cf3b1611f264">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if8403d7b138f480f8845cd9631fed10a_I20220731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyNzY_60de7ecc-651c-4f96-8d9e-60c43aaa53e9">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vrdn:OperatingLeaseAnnualBaseRent
      contextRef="id838e3d9eb3e439aae39d4378ce4ba61_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzcyOTU_c86b6c36-74ea-4808-bc4c-9c983c911a76"
      unitRef="usd">900000</vrdn:OperatingLeaseAnnualBaseRent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMDg_00fded94-d8a4-4c11-a876-5374cbdfcc33">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under noncancellable leases as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzEtMi0xLTEtNjgzMDM_2da048f3-f8f0-43a4-a36c-fd6a5dd136c6"
      unitRef="usd">717000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzItMi0xLTEtNjgzMDM_edbe5ff0-2c53-467b-9762-1121f9d786cf"
      unitRef="usd">748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzMtMi0xLTEtNjg3MjA_a89f9016-9ed9-4f8d-9c3d-9bfc8e7ba774"
      unitRef="usd">245000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzMtMi0xLTEtNjgzMDM_f7f9418e-06a7-44bb-8990-9847514bcc43"
      unitRef="usd">230000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzYtMi0xLTEtNjg3MTg_3e131336-0bab-4106-a7ff-d120144227e4"
      unitRef="usd">1940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzYtMi0xLTEtNjgzMDM_2e291904-2220-4fdf-bb6f-58e7865efb62"
      unitRef="usd">217000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90YWJsZTpiOTZiYTBkYTdiOTk0YjIyYjQ5YmY0YjU1NGMxY2JhNC90YWJsZXJhbmdlOmI5NmJhMGRhN2I5OTRiMjJiNDliZjRiNTU0YzFjYmE0XzgtMi0xLTEtNjg3MTg_f6bc3c18-f731-456a-9ffd-19d2f1656b63"
      unitRef="usd">1723000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMTA_4be5d635-5ad9-44b1-a630-af5cb72e5a5b"
      unitRef="usd">600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczMjU_3ee27506-06aa-4883-ba86-f9ff46e308e2"
      unitRef="usd">1100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNDA_038b8f9a-78f7-4275-b1a2-dfc93915ee0e"
      unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNDA_be30cdba-f665-4ed1-8cd2-037794722a45"
      unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <vrdn:OperatingLeasesOperatingExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNTQ_53ed4b91-c302-4759-b1a0-7378813a522f"
      unitRef="usd">300000</vrdn:OperatingLeasesOperatingExpense>
    <vrdn:OperatingLeasesOperatingExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTEvZnJhZzpiNzM5NDdlMDA1OWI0MDE4YmEzNzY3ZGUxYWYwMmViNy90ZXh0cmVnaW9uOmI3Mzk0N2UwMDU5YjQwMThiYTM3NjdkZTFhZjAyZWI3XzE2NDkyNjc0NzczNTQ_e43f27f6-e539-4fe6-a2bb-0a46110563c1"
      unitRef="usd">300000</vrdn:OperatingLeasesOperatingExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2MTAw_f6e47036-aa57-4979-9361-ed8f8daa90b3">CAPITAL STOCK&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#x2019;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into an underwriting agreement (the &#x201c;2022 Underwriting Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), SVB Securities LLC and Evercore Group L.L.C. (&#x201c;Evercore&#x201d;) relating to the offer and sale (the &#x201c;2022 Offering&#x201d;) of 11,352,640 shares of the Company&#x2019;s common stock, which includes 1,725,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $23.50 per share, and 28,084 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.01 per share, at a public offering price of $1,566.745 per share (collectively the &#x201c;2022 Public Offering&#x201d;). The aggregate gross proceeds to the Company from the 2022 Public Offering, including the exercise of the option were approximately $311.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into an underwriting agreement (the &#x201c;2021 Underwriting Agreement&#x201d;) with Jefferies, SVB Leerink LLC and Evercore for the sale and issuance of 7,344,543 shares of common stock, which includes 1,159,089 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $11.00 per share and 23,126 shares of Series B Non-Voting Convertible Preferred Stock at a public offering price of $733.37 per share (collectively the &#x201c;2021 Public Offering&#x201d;). The aggregate gross proceeds to the Company from the 2021 Public Offering, including the exercise of the option, were approximately $97.7&#160;million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Sales Agreements - Jefferies LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;September 2022 ATM Agreement&#x201d;) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. During the quarter ended December 31, 2022, 964,357 shares have been sold under the September 2022 ATM Agreement with Jefferies at a weighted average price of $26.01 per share, for aggregate net proceeds of approximately $24.2&#160;million, including commissions to Jefferies as a sales agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;November 2021 ATM Agreement&#x201d;) with Jefferies, pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $75.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. The November 2021 ATM Agreement was terminated in connection with the September 2022 ATM Agreement. No shares were sold under the November 2021 ATM Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;April 2021 ATM Agreement&#x201d;) with Jefferies pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $50.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies as its sales agent. Jefferies could receive a commission equal to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the April 2021 ATM Agreement. The April 2021 ATM Agreement was terminated in connection with the November 2021 ATM Agreement. An aggregate of 2,551,269 shares of common stock were sold pursuant to the April 2021 ATM Agreement prior to its termination, at a volume weighted average price of $13.13 per share, for aggregate net proceeds of approximately $32.4&#160;million, including commissions to Jefferies as sales agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Purchase Agreement - Aspire Capital Fund, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into a common stock purchase agreement (the &#x201c;Aspire Stock Purchase Agreement&#x201d;), with Aspire Capital Fund, LLC (&#x201c;Aspire Capital&#x201d;), which provides that, subject to the terms, conditions, and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20.0&#160;million of shares of common stock over the 30-month term of the Aspire Stock Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2020, the Company sold 412,187 shares of common stock to Aspire Capital at a weighted-average price of $21.35 per share for aggregate net proceeds of $8.8&#160;million. The Company did not sell any shares to Aspire Capital during the years ended December 31, 2021 or 2022. As of December 31, 2022, the Company has the ability to sell an additional $10.2&#160;million of shares of common stock to Aspire Capital. Under the Aspire Stock Purchase Agreement, the Company has the right, in its sole discretion, on any trading day selected by it, and within certain specified limitations, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to 13,333 shares of common stock per business day at a per share price equal to the lesser of (i) the lowest sale price of common stock on the purchase date or (ii) the average of the three lowest closing sale prices for the common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to require Aspire Capital to purchase up to an additional 30% of the trading volume of the shares for the next business day at a purchase price (the &#x201c;VWAP Purchase Price&#x201d;), equal to the lesser of: (i) the closing sale price of the shares on the purchase date, or (ii) ninety-seven percent (97%) of the next business day&#x2019;s volume weighted average-price (each such purchase, a &#x201c;VWAP Purchase&#x201d;). The Company shall have the right, in its sole discretion, to determine a maximum number of shares and set a minimum market price threshold for each VWAP Purchase. The Company can only require a VWAP Purchase if the Company has also submitted a regular purchase on the notice date for the VWAP Purchase. There are no limits on the number of VWAP purchases that the Company may require.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Aspire Stock Purchase Agreement may be terminated by the Company at any time, at the Company&#x2019;s discretion, without any cost to the Company. There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings, rights of first refusal, participation rights, penalties, or liquidated damages in the Aspire Stock Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s second restated certificate of incorporation, the Company&#x2019;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#x2019;s stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, there were 188,381 and 260,437 shares of Series A Preferred Stock outstanding, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in connection with the Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. As of December 31, 2022 and 2021, there were 51,210 and 23,126 shares of Series B Preferred Stock outstanding, respectively. &lt;/span&gt;&lt;/div&gt;WARRANTS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s outstanding warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Underlying Shares (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life at December 31, 2022&lt;br/&gt;(No. Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued April 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued February 2020 (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued November 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vrdn:CapitalStockSharesAuthorized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyMzk_712cacef-71af-4866-9a5d-39eeae8936f1"
      unitRef="shares">205000000</vrdn:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNTI_c7e5533e-b5ef-4b89-8ac4-91fc9a65beaf"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNjU_e8268619-bc2f-40e6-88a8-cf41b6596459"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNzY_189c8fd2-5728-4f0b-816c-1c95d45be13e"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyNzY_9a0733f0-cba6-45a9-b2e9-a6d092fbd08c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <vrdn:CommonStockVoteperShare
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyODI_9c7d29d9-d601-4a80-a1da-4829ea23be6a"
      unitRef="vote">1</vrdn:CommonStockVoteperShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3b72d2965ee0434c841cfb9e8258e086_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYyOTE_ffab8e00-0967-4a9c-a121-2181f8744dce"
      unitRef="shares">11352640</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3a8b414d79224c589b4f8171dc32086e_D20220801-20220831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMDM_cc58bf68-b5f2-49a8-8e0a-95e8d54d240d"
      unitRef="shares">1725000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7803c980e7e94395b6662e71bdb21d08_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMjE_0fa84154-a0b7-4ecc-83fd-569a0cc77ec6"
      unitRef="usdPerShare">23.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia279525ba3464bb3bd46c39083223a69_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMjk_3e785ff2-3700-49b6-a12f-40091db62788"
      unitRef="shares">28084</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if928b497323f4aa09bdc2a799e98f2d8_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMTQ_0ceeeb3d-1300-4be6-9623-eed8e9eb2942"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if928b497323f4aa09bdc2a799e98f2d8_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzMzc_231268be-bead-4b72-9db5-8f346d37222d"
      unitRef="usdPerShare">1566.745</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0137f42d4153427eba19af3131416b54_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNDk_83c81019-3f41-4326-83f4-41351f9a9489"
      unitRef="usd">311000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idfedb0c338d24c7fb89b19d4dc8f497d_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNjU_79706f49-a0a1-490f-863b-3d7c655c5b7c"
      unitRef="shares">7344543</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i60581c1fe5a94b06a7f4dbec809547b3_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzNzY_c3e319b0-39d6-4a92-a3df-dbef893326b8"
      unitRef="shares">1159089</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iddf90d2e59564c068859bfb9affa9e2d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzODc_8364c20c-9dfa-458f-8a8c-0313f32e5fd9"
      unitRef="usdPerShare">11.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib79b5053076944fa8214003d886b1ba3_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODYzOTU_417c7f8d-fb54-44cf-844c-c53ea395ae52"
      unitRef="shares">23126</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9fd1e3cfaeeb44ec8b6e9c11e444058e_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0MDM_80021e31-47da-415e-84fa-b6d8624b3214"
      unitRef="usdPerShare">733.37</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1af72201586744fbb2c99adcce15b017_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0MTI_36277838-1257-4705-ac0c-7d506f875ad7"
      unitRef="usd">97700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0Mjc_50f8e719-b1cb-4e30-b900-9b9b403674de"
      unitRef="usd">175000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds
      contextRef="i1b93004d003541ad85ff40e6af472e9b_D20220901-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NDM_d0c02680-34db-4a85-be2b-d7e93530fc10"
      unitRef="number">0.030</vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg1Mzk3NQ_9773322f-cc22-43d2-8c9a-0f10c2e657cb"
      unitRef="shares">964357</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vrdn:SaleOfStockWeightedAverageSharePrice
      contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY4NDA_7f8b26e9-d4f1-46ff-9393-fcea6a69f644"
      unitRef="usdPerShare">26.01</vrdn:SaleOfStockWeightedAverageSharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icf7e3b429ae643e8a123d73461b6dbfc_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY4NDg_335f11b2-14ba-4e49-b37e-3b59f22683b5"
      unitRef="usd">24200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iffb9991b56694a0faf0dc09579f73d81_D20211101-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NDk_ddeae715-3c23-46ca-9744-5c3bac77c4da"
      unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9b4be6ccd9ad4885a999915b4b0caed6_D20211101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NjM_7512f5b9-ce78-463a-8ce6-3c162722836d"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0NzM_cbae6cc8-1f41-4d94-a8d6-41b90b002b9b"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds
      contextRef="i0d18cce1e920439c8f1124d94d2b83a7_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0ODg_06dd1983-e01a-48fe-8269-81359419019c"
      unitRef="number">0.030</vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY0OTQ_c74479a7-e6f6-412b-b247-33f35934b39e"
      unitRef="shares">2551269</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vrdn:SaleOfStockWeightedAverageSharePrice
      contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1MDU_a6c78823-5230-4c83-bc0c-498d684e544c"
      unitRef="usdPerShare">13.13</vrdn:SaleOfStockWeightedAverageSharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib9e7d1fdc3e44f21b61bc6cfcae7a347_D20210401-20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1MTM_efd9144b-8efa-4e6b-b6d0-4c665b39f4e1"
      unitRef="usd">32400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold
      contextRef="icfe4499fee034827abde9a07a164e945_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1Mjg_4a5d19aa-b619-4de5-99ed-203012f898b4"
      unitRef="shares">20000000</vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold>
    <vrdn:SaleOfStockTerm
      contextRef="icfe4499fee034827abde9a07a164e945_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NDY_fc520324-17cc-44f9-abec-9040f5ff097a">P30M</vrdn:SaleOfStockTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NDg_3d41cc1f-66d5-4de1-8dae-783be86c179d"
      unitRef="shares">412187</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vrdn:SaleOfStockWeightedAverageSharePrice
      contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NTc_b65eb598-60ed-4409-8a68-31757c1dc2ec"
      unitRef="usdPerShare">21.35</vrdn:SaleOfStockWeightedAverageSharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i86483928bea44016893e50c31509dba0_D20191201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1NjU_8eb0ddfe-b104-4578-9794-5d97ecdefeed"
      unitRef="usd">8800000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjU_6522b5e5-f192-4c23-86a5-a09c22f7510a"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0eac05f69eb14abb936aff1bddd334b7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjU_84c32b46-dff8-41d0-a22d-e5775878212c"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold
      contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1Nzk_aa3bcc3c-2bc7-4d10-8cf2-c2ae77f48acb"
      unitRef="shares">10200000</vrdn:SaleOfStockAmountOfShareAuthorizedToBeSold>
    <vrdn:SaleOfStockAmountOfSharesRequiredToBePurchased
      contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY1OTQ_df638b71-cad7-4896-813b-40fdedf7ca95"
      unitRef="shares">13333</vrdn:SaleOfStockAmountOfSharesRequiredToBePurchased>
    <vrdn:SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices
      contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MTA_3ea9b156-40a0-4965-9770-5b83b29423fa"
      unitRef="sale_price">3</vrdn:SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices>
    <vrdn:SaleOfStockNumberOfConsecutiveDaysThreshold
      contextRef="ia1b1dc76b4b24187a49e51344cc6ecab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MDc_afe982be-e033-4458-81f7-0f26983ef77d">P10D</vrdn:SaleOfStockNumberOfConsecutiveDaysThreshold>
    <vrdn:SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent
      contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MDI_7870a3e0-e00a-4edc-bea9-5ee08d9d84c2"
      unitRef="number">0.30</vrdn:SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent>
    <vrdn:SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice
      contextRef="idad687f93f544b899dde34ad1e484822_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0ODY2MjE_4ff0d556-0a8c-42ee-8f7e-bf0c3b86b67f"
      unitRef="number">0.97</vrdn:SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2NzQ_2ec0c020-b60f-4dcd-b703-e55be663f98e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2ODU_d57daf71-4c76-45b5-ab65-89cd914478ef"
      unitRef="number">0.30</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i0438c59c2c6c44c9ac21a3bbe8ca4dfb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2OTA_2031fdbc-bde3-4c4d-8382-7509b452098e"
      unitRef="shares">66.67</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="ifba8d787738a4d90b399133c72c646a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ2OTc_3b7c9d93-fe9c-4cf2-940e-fb7676f2742e"
      unitRef="number">0.0499</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="i37b9550134c5468b8fd0e59a39c182ae_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MDQ_ece122dc-d459-4016-aed7-8025d0bee76d"
      unitRef="number">0.1999</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg2NDQxNw_01677419-b40b-469e-aa94-42a8335c019c"
      unitRef="shares">188381</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic4388ce6ee5d4297a40f002234ac2faf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzU0OTc1NTg2NDQxNw_96193cb8-89b5-4611-8356-0128e958be88"
      unitRef="shares">188381</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if05bfdb09f134543bd371b54e8ca91a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MTI_3ba870c2-1610-4428-ba37-958c3dd91dc7"
      unitRef="shares">260437</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i16c66a163e074d75953188a31b49a161_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MjE_3c8608e0-bc66-4a4b-9a56-4ad0476bb941"
      unitRef="shares">66.67</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="i128e797bb49d4cd88ed84383f99ec141_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3Mjg_6e36cef3-b7ef-4c3f-8c04-fcd291186e60"
      unitRef="number">0.049</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="i606007a11a244c8c8b02f58f219ee3cb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3MzQ_f6452a32-08dc-49d0-8d84-a50e8e37fc2b"
      unitRef="number">0.199</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic9442e34fd9c44319d656358b37cacf1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3NDE_00632ba5-0957-4c5b-a29a-191422cf3906"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7d116b0d685d4c0892407cdf68ea7473_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNTQvZnJhZzo0M2JiYTEwZDk4NDY0NDQ2ODNkZDc0NDJiMTJjMTViZC90ZXh0cmVnaW9uOjQzYmJhMTBkOTg0NjQ0NDY4M2RkNzQ0MmIxMmMxNWJkXzE2NDkyNjc0OTQ3NDk_9dde371b-5806-45ff-a7d9-d7c821dce828"
      unitRef="shares">23126</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90ZXh0cmVnaW9uOjg4M2Y5M2FhNWMwOTQ4YTBiNzk2Y2I5MjllNTlkOTgwXzIzMTc_e282c86d-9c1f-4571-a70c-4a0dbc7fd24b">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s outstanding warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Underlying Shares (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life at December 31, 2022&lt;br/&gt;(No. Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued April 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued February 2020 (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued November 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtMS0xLTEtNjQ2MTQ_564aec4e-fbfa-45f4-bbc4-03efe4dbf69d"
      unitRef="shares">781</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="ifb45543c55a341d59828621ace35f8e4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtMy0xLTEtNjQ2MTQ_c66d1f57-9b06-4fb7-8e7c-8e1979493c68"
      unitRef="shares">781</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if06716a4afa14d1c9d9ad1afc606ecc3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtNS0xLTEtNjQ2MTQ_b05adef0-c4c9-430e-a81c-e5a22596b38c"
      unitRef="usdPerShare">127.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm
      contextRef="i14d5a529d15d48ca9f86845a914722f5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzQtNy0xLTEtNjQ2MTQ_5ef5fd04-a425-49d5-852b-473e9fa6f88e">P2Y3M29D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="if0ef63c34dae44f0853d1416aa2f882e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctMS0xLTEtNjQ2MTQ_7e85280a-7010-4126-bd0e-a13ead506f68"
      unitRef="shares">29446</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="ife09cc8c10c94dc8996beb13848ad137_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctMy0xLTEtNjQ2MTQ_80df1bd0-3d88-4efc-bac8-b5e00c7a14d7"
      unitRef="shares">29446</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if0ef63c34dae44f0853d1416aa2f882e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctNS0xLTEtNjQ2MTQ_7420e2ea-c113-4ed5-b2a4-3c8e224cc1b3"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm
      contextRef="iaaeea194517f4499b35939e81a5d9621_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzctNy0xLTEtNjQ2MTQ_abf88b4a-084b-402a-a957-13848f8400c0">P7Y8M23D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i9d62a34b1b4a4f5e9b01227f00998027_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtMS0xLTEtNjQ2MTQ_18a381d1-bba5-47b0-91f9-28e8d4c6ac33"
      unitRef="shares">332130</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="ibd6f20f151aa4c638e38a93431710146_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtMy0xLTEtNjQ2MTQ_d3d13bf1-1314-47d3-8bb1-ccc23ec85624"
      unitRef="shares">388796</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9d62a34b1b4a4f5e9b01227f00998027_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtNS0xLTEtNjQ2MTQ_45f87d28-9f94-44e7-ad89-5f767ddc61f4"
      unitRef="usdPerShare">15.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm
      contextRef="i89382e3a327947c289b5183a9f74f852_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzgtNy0xLTEtNjQ2MTQ_0d94c2ff-e024-476e-a99d-5cbf4e26a121">P2Y1M13D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktMS0xLTEtNjQ2MTQ_4b8053d3-4e37-4c97-9287-a5e2afd168cd"
      unitRef="shares">1606</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="ied23b327864a44a984dcfb100731b721_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktMy0xLTEtNjQ2MTQ_132eac2e-26ad-4711-9072-46a75e60c61f"
      unitRef="shares">1606</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i97c6c121d74a4d978b3dcc2829a5fe22_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktNS0xLTEtNjQ2MTQ_1a55adee-cfb1-4022-ae35-7d57ad24ebe9"
      unitRef="usdPerShare">0.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm
      contextRef="i3974d6a34a904cfb85456eb0420ddb31_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzktNy0xLTEtNjQ2MTQ_d7c39e04-b2ee-42d1-ac18-9d4631468838">P1Y10M13D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTEtMS0xLTY0NjE0_2e209855-f4c7-42eb-a46e-c25379bfd9cd"
      unitRef="shares">363182</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i1dc204ff96984e1783d7a194c6f1ac47_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTMtMS0xLTY0NjE0_793744e0-da0c-494d-8361-020ea8ebbdea"
      unitRef="shares">419848</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9c0497fb62354b8eb6cfd2e1237213d9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzEwLTUtMS0xLTY0NjE0_9a1d7b31-ed19-4df3-8a91-cb6041135ef4"
      unitRef="usdPerShare">15.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTEtMS0xLTY0NjE0_a088a35b-4a12-42b3-b937-e700464b2cc2"
      unitRef="shares">363963</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTMtMS0xLTY0NjE0_67ebbcd7-9d4e-4cae-973a-31cf9ac388c8"
      unitRef="shares">420629</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpmY2FkMzQ1ZTQ3YzI0MTQxYTk2NTBiZWQ1YmE3MDkzNi90YWJsZXJhbmdlOmZjYWQzNDVlNDdjMjQxNDFhOTY1MGJlZDViYTcwOTM2XzExLTUtMS0xLTY0NjE0_642bc0cb-62e1-4df7-ac6e-963310f55ee8"
      unitRef="usdPerShare">15.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzktMS0xLTEtNjQ2MTQ_775a7590-736a-4260-9911-e199d6b2a07a"
      unitRef="shares">420629</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzktMy0xLTEtNjQ2MTQ_238c1826-fb25-403f-bca1-8f7471b9d53c"
      unitRef="usdPerShare">15.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassOfWarrantOrRightExercisedInPeriod
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzEwLTEtMS0xLTY0NjE0_70113139-5b10-4d8b-a1ff-9fe5a2f44c1c"
      unitRef="shares">56666</vrdn:ClassOfWarrantOrRightExercisedInPeriod>
    <vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzEwLTMtMS0xLTY0NjE0_d7976ab1-f633-46be-9c12-9f1bc1664e44"
      unitRef="usdPerShare">16.50</vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzExLTEtMS0xLTY0NjE0_d3d28315-2148-4a15-811c-bf634d0b86aa"
      unitRef="shares">363963</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjAvZnJhZzo4ODNmOTNhYTVjMDk0OGEwYjc5NmNiOTI5ZTU5ZDk4MC90YWJsZTpkNmU2ZDU2ODUwNjQ0ZDdmYmMyMzgxY2ZmNTFmMGI2My90YWJsZXJhbmdlOmQ2ZTZkNTY4NTA2NDRkN2ZiYzIzODFjZmY1MWYwYjYzXzExLTMtMS0xLTY1NzA0_f0b64815-2fd4-4d41-bd1e-fff250f80124"
      unitRef="usdPerShare">15.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTI_86a8259c-48fe-4c3f-a5cf-87787d3713dd">SHARE-BASED COMPENSATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#x201c;2008 Plan&#x201d;), its amended and restated 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;), and the Viridian 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d; and collectively with the 2008 Plan and the 2016 Plan, the &#x201c;Equity Incentive Plans&#x201d;). Additionally, beginning in July 2021, the Company granted stock options outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#x201c;Inducement Awards&#x201d;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#x2019;s Equity Incentive Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2022 (the &#x201c;Effective Date&#x201d;), the Company&#x2019;s stockholders approved the amendment and restatement of the 2016 Plan (the &#x201c;Amended 2016 Plan&#x201d;), which increased the number of shares reserved for issuance under the Amended 2016 Plan by 3,050,000 shares and transferred the number of shares that remain available for issuance under the 2020 Plan as of the Effective Date into the Amended 2016 Plan so that the Company operates from a single equity plan going forward. The term of the Amended 2016 Plan is 10 years following the Effective Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had the following balances by plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Available for Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire 10 years from the date of grant. Generally, options vest 25% on the first anniversary of the vesting commencement date and 75% ratably in equal monthly installments over the remaining 36 months. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to 48 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#x2019;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted to the Company&#x2019;s employees and members of its board of directors during the years ended December&#160;31, 2022 and 2021 was $12.95 and $17.50, respectively. The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) allows qualified employees to purchase shares of common stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. New six-month offering periods begin each August&#160;22 and February&#160;22. As of&#160;December&#160;31, 2022, the Company had&#160;309,541&#160;shares available for issuance, and 27,074 cumulative shares had been issued under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $54.9 million of total unrecognized employee and non-employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of 2.77 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyMzg5Nw_079d26b7-ac46-473a-965d-b1a3009cee5a"
      unitRef="shares">3050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <vrdn:ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod
      contextRef="i2c3f2c46bf4a46feaa0418136bd85452_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzE2NDkyNjc0NTUxNjI_8e2e4156-227d-4f3c-8c6d-c2934bfc72eb">P10Y</vrdn:ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTk_0cc351c0-42d7-4a2b-905c-b4e0b5dffc72">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had the following balances by plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Available for Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i17f880652d2a4b6798eccdac2488595d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzEtMS0xLTEtNjQ2MTQ_5ebd0369-fe51-4483-9f44-b96e01925d4c"
      unitRef="shares">1513174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i17f880652d2a4b6798eccdac2488595d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzEtNS0xLTEtNjQ2MTQ_e9d78677-1234-4792-8ae8-36633df241a2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzItMS0xLTEtNjQ2MTQ_1cad8a87-892f-4769-a563-8b5ce18c7dcc"
      unitRef="shares">930332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia85570c2d14f4006b495e5c9d36f3ed6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzItNS0xLTEtNjQ2MTQ_fa1ee6d7-00ac-465f-8721-8ea962552681"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzMtMS0xLTEtNjQ2MTQ_b12fec0f-03ec-4bf4-9d81-36dfcf3276c4"
      unitRef="shares">3278757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i04a2d81625c748c5bec8cc8cd1e39e19_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzMtNS0xLTEtNjQ2MTQ_2b0c3329-467e-4eaa-8e82-794be3f1915b"
      unitRef="shares">3781888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzQtMS0xLTEtNjQ2MTQ_fea7c847-4ebc-4656-83ee-c1d28fa99611"
      unitRef="shares">186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0f91ebdabaaa4ccaadf8cc9567f791c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzQtNS0xLTEtNjQ2MTQ_7d755fbf-c02c-408d-88a8-7f71662b1386"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzUtMS0xLTEtNjQ2MTQ_4592a1ec-c932-4fed-954c-6255797ed9e4"
      unitRef="shares">5722449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmNjVlYWFmN2FhOGQ0MjkwOGU0NGNiMjgyMzljYjc3ZS90YWJsZXJhbmdlOmY2NWVhYWY3YWE4ZDQyOTA4ZTQ0Y2IyODIzOWNiNzdlXzUtNS0xLTEtNjQ2MTQ_65a1e46d-c9af-4a10-ab1a-353f2651e817"
      unitRef="shares">3781888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDM3Nw_bed3f999-775d-45ad-b87f-cfc97f577fd3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5fdadfb509ff40919c0cab248bd849e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDQyOQ_74239243-06ab-454e-ab17-6488013b6178"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7b41fe046b334a039198964438e80c98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDQ5NQ_940cf294-6642-47ca-a4cf-62f7f7c5bed6"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7b41fe046b334a039198964438e80c98_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDU1Ng_bd2b8a2d-c96d-4f70-a0ac-7097f011a2b2">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0OTc1NTgyNDY2NQ_49d2c5e4-0d6a-49a7-8153-8026f81760fd">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzE_4cd33411-4dd9-4d53-a379-f04aab985689">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtMS0xLTEtNjQ2MTQ_3ca20d83-de1f-4dc6-b556-4b629331ad00"
      unitRef="shares">3683839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtMy0xLTEtNjQ2MTQ_86db1177-0545-4a7b-8dea-3f0b2d674b46"
      unitRef="usdPerShare">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtNS0xLTEtNjQ2MTQ_56c930ef-e507-4103-b5eb-0844158a22a9">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzEtNy0xLTEtNjQ2MTQ_2e1946e3-ac5c-429f-bec1-61eb383920f0"
      unitRef="usd">15969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzItMS0xLTEtNjQ2MTQ_5b8868d0-431b-4646-9b32-0e23069d8486"
      unitRef="shares">2545500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzItMy0xLTEtNjQ2MTQ_20fa5a38-4cfc-4771-aaa1-b6606e851a72"
      unitRef="usdPerShare">17.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzMtMS0xLTEtNjQ2MTQ_d03340ae-ed98-4904-b40d-c723e88fcd55"
      unitRef="shares">191291</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzMtMy0xLTEtNjQ2MTQ_1af461bb-7825-4a04-9be4-94eb5c9a6963"
      unitRef="usdPerShare">14.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzQtMS0xLTEtNjQ2MTQ_09785197-8063-4c17-952c-2dc5c1fe2812"
      unitRef="shares">315599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzQtMy0xLTEtNjQ2MTQ_0ec39488-9c82-43f0-a11d-7c5742548e11"
      unitRef="usdPerShare">19.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtMS0xLTEtNjQ2MTQ_c7d607d0-8728-4702-be15-f98178c42bf4"
      unitRef="shares">5722449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtMy0xLTEtNjQ2MTQ_39b74380-e8d6-4809-bab9-73ae4af71986"
      unitRef="usdPerShare">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtNS0xLTEtNjQ2MTQ_6cd6d835-f78a-447f-be7b-b0c719c94e0d">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzUtNy0xLTEtNjQ2MTQ_b714317b-e135-47aa-adca-86d824df9572"
      unitRef="usd">68977000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtMS0xLTEtNjQ2MTQ_e3816387-4cd4-4adc-9dc2-483703823246"
      unitRef="shares">5722449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtMy0xLTEtNjQ2MTQ_f7e2db15-27f8-454c-a62d-f5d922bf570a"
      unitRef="usdPerShare">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtNS0xLTEtNjQ2MTQ_b46f8d05-5233-4e6c-9000-5207c4e52cc8">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzYtNy0xLTEtNjQ2MTQ_ecdceded-5715-4b36-b3b3-2ba8e081fe1d"
      unitRef="usd">68977000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctMS0xLTEtNjQ2MTQ_3df220af-33be-46d2-aa9c-4f8ff7e07d30"
      unitRef="shares">1697616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctMy0xLTEtNjQ2MTQ_ff9aa5be-8c36-4bb3-b359-802e6d8ea351"
      unitRef="usdPerShare">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctNS0xLTEtNjQ2MTQ_4d741488-0acc-476c-a1cc-a60af1153c38">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzctNy0xLTEtNjQ2MTQ_ce8ad6d4-9134-44aa-8f70-f5f98adcc3c9"
      unitRef="usd">21258000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtMS0xLTEtNjQ2MTQ_1973c35f-236a-4652-82e6-4bb66c06f727"
      unitRef="shares">1697616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtMy0xLTEtNjQ2MTQ_30268940-86e6-4f28-814a-ebaad2bae5fb"
      unitRef="usdPerShare">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtNS0xLTEtNjQ2MTQ_897d5da4-243e-4f64-8e43-3e71921cfed9">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZToyMGY3YjE0MDk5ODQ0NzM4OWE2YjA3ODY5ZGEzOTY3Yi90YWJsZXJhbmdlOjIwZjdiMTQwOTk4NDQ3Mzg5YTZiMDc4NjlkYTM5NjdiXzgtNy0xLTEtNjQ2MTQ_72e197d5-da16-4cf5-83d2-d59f641a3435"
      unitRef="usd">21258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzQ4NzI_aa7be309-9b9b-43d6-a4ad-3ebd37cb3981"
      unitRef="usdPerShare">12.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzQ4Nzk_4d760aac-6eaa-4257-a859-2ad513e0dffb"
      unitRef="usdPerShare">17.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNTU_70ce2b8e-2a6a-48c8-96b1-4139864e0079">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzItMS0xLTEtNjQ2MTQ_6b72eb76-6c4c-48ca-8e9a-859c42ebcf76">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzItMy0xLTEtNjQ2MTQ_ceb72f86-7bc1-4740-9a96-eced2bd8c2f1">P5Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzMtMS0xLTEtNjQ2MTQ_db88e18a-e69b-467c-968b-517f0708e8ff"
      unitRef="number">0.878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzMtMy0xLTEtNjQ2MTQ_156dff88-186f-44d7-9bad-a983ae880a52"
      unitRef="number">1.177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzQtMS0xLTEtNjQ2MTQ_037633ae-8354-41ad-8405-4caabea77204"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzQtMy0xLTEtNjQ2MTQ_e2d6a512-31cf-406b-be0e-bf9059fe266e"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzUtMS0xLTEtNjQ2MTQ_44e0dddd-7e1f-4f6e-8a38-e21a4d43a191"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0930912c457940afaf6c32b75e459522_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzUtMy0xLTEtNjQ2MTQ_10122ce4-87d5-4f33-be40-1d37b6a62685"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ie863ce82974d4c11b56bbc4c8e1198b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzYtMS0xLTEtNjQ2MTQ_ffeef7a5-82e9-4dbb-97f0-31a357d75c30"
      unitRef="usdPerShare">17.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i9d7ad7937f2e4f1a815947ffda355a35_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTpmMmIyYjNjNzg4MDU0MGU3YmVkZmI1MzdkZWQxNzc5Ni90YWJsZXJhbmdlOmYyYjJiM2M3ODgwNTQwZTdiZWRmYjUzN2RlZDE3Nzk2XzYtMy0xLTEtNjQ2MTQ_ebc17811-ecf7-4240-9b34-5e7879b40e9e"
      unitRef="usdPerShare">20.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzUxODE_c0b93f7f-164d-4777-826e-6354ea61d94a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vrdn:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod
      contextRef="ie2267406c415407baff04941844c5d1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzY_e50b4df0-5239-4f4a-9c0f-e3887e0dddad">P6M</vrdn:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares
      contextRef="i16c66a163e074d75953188a31b49a161_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0MTg_2ef7076c-e5f6-4538-bc8a-9dd9bf49a654"
      unitRef="shares">309541</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id35aece8bbc142a1911840a29f94d84d_D20160101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU0NTU_074bcb7a-cd26-4973-930d-4d1a32b4368e"
      unitRef="shares">27074</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNzc_5bc1d04c-1f2a-4b2b-bf9f-88ccb1b2b856">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i35dd0d5868d3450181c2d16f2687ac92_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzMtNS0xLTEtNjQ2MTQ_f4109fad-fcd8-47ba-9fe7-4959f1900d1b"
      unitRef="usd">7298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6738e86aeb641cfb7e9e094c2fc4c6f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzMtNy0xLTEtNjQ2MTQ_07ae8b64-d9de-4671-951c-9379e909350d"
      unitRef="usd">4701000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic4b73a1e80a44f5590d1cc32f390331b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzQtNS0xLTEtNjQ2MTQ_4aa188c9-d68b-483f-94f0-22078da8f364"
      unitRef="usd">12467000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6eac4ba1e8146d09bc0d4159bb00c0c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzQtNy0xLTEtNjQ2MTQ_0e60d932-dc0c-4c8d-959c-3fcb7858906b"
      unitRef="usd">9764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzUtNS0xLTEtNjQ2MTQ_90043ac3-cf00-4c44-932b-a1c05778f008"
      unitRef="usd">19765000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90YWJsZTo1NzMzNDA0MGYwMTQ0ODI1YjJlODJmYjJjMzA2ZWM0MC90YWJsZXJhbmdlOjU3MzM0MDQwZjAxNDQ4MjViMmU4MmZiMmMzMDZlYzQwXzUtNy0xLTEtNjQ2MTQ_444ef3eb-6d7c-4de0-991a-26fdef0dee18"
      unitRef="usd">14465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzU4Njk_7c739ce1-3509-40f0-a4b2-654346722a9a"
      unitRef="usd">54900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjMvZnJhZzo4N2Y4YTNmMDE3Mjk0ZDVhYjQ1YWZkODVjY2E3Y2ZhNi90ZXh0cmVnaW9uOjg3ZjhhM2YwMTcyOTRkNWFiNDVhZmQ4NWNjYTdjZmE2XzYwNDM_09d462be-8e7f-49e4-b695-a621a0397efb">P2Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90ZXh0cmVnaW9uOmNlMjY5ZThlOGJkYzQ4NmU5YjJkMDNlZTY2YWVjY2ZiXzcyNA_0ad69bb0-286a-4662-b9eb-36e4953880cb">NET LOSS PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock, as converted to shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock, as converted to shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90ZXh0cmVnaW9uOmNlMjY5ZThlOGJkYzQ4NmU5YjJkMDNlZTY2YWVjY2ZiXzcyNg_979a2e49-3703-4398-a1c5-0e7f6198da6c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock, as converted to shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock, as converted to shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i65916045213f4b35b8eaac7d9d7c38f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzMtMS0xLTEtNjQ2MTQ_f131c55b-a29d-4685-8232-b5fcf683bffb"
      unitRef="shares">12559000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49abc6a01de84a36bc043c40f8227f10_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzMtMy0xLTEtNjQ2MTQ_4e5db46b-85a3-41ea-88d4-11db7c3eb3a4"
      unitRef="shares">17363000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29536a69b2634ac49eb9828516064751_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzQtMS0xLTEtNjQ2MTQ_375e206a-9698-45d9-ab15-c2eba3b5e87d"
      unitRef="shares">3414000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia2a030fb15c14da49fde0862e7c27a2a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzQtMy0xLTEtNjQ2MTQ_3b7f57a3-12b9-487f-9447-bf192859b8ea"
      unitRef="shares">1542000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i697a762fdb594a17ba1c80bc48028a56_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzUtMS0xLTEtNjQ2MTQ_e7efed1b-69d8-4f01-a9e8-d39d4d9a9baa"
      unitRef="shares">5722000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i99e4eeddfa014778a51d0845f779bd05_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzUtMy0xLTEtNjQ2MTQ_37c0755a-515b-4e1e-bab2-9b373bbea30d"
      unitRef="shares">3684000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icd090a1fac43479584a8c5f526d77264_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzYtMS0xLTEtNjQ2MTQ_c55e82ba-67cb-48b7-b83e-2e8acba63500"
      unitRef="shares">364000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i087f0a8b9f354a148b61f301862025db_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzYtMy0xLTEtNjQ2MTQ_b4fa84d8-9c33-4a71-9883-2b74840ada8b"
      unitRef="shares">421000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzctMS0xLTEtNjQ2MTQ_df2c0694-5756-406b-905f-26168491eb54"
      unitRef="shares">22059000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjYvZnJhZzpjZTI2OWU4ZThiZGM0ODZlOWIyZDAzZWU2NmFlY2NmYi90YWJsZTo0ZjYzYWQ5NDk3MTU0ZDg1ODcyZjQ0OWViNGRhOTExZS90YWJsZXJhbmdlOjRmNjNhZDk0OTcxNTRkODU4NzJmNDQ5ZWI0ZGE5MTFlXzctMy0xLTEtNjQ2MTQ_e381d566-ff1b-4dc7-955e-7a92bee31836"
      unitRef="shares">23010000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NTk_4467c365-51f2-45be-af3a-1e74ae85704e">INCOME TAXES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded. This amount differs from the amount computed by applying the U.S.&#160;federal income tax rate of 21% to pretax loss due to the provision of a valuation allowance to the extent of the Company&#x2019;s net deferred tax asset, as well as to state income taxes and nondeductible expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 382 limit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Start-up costs and amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IRC &#xa7; 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the Company had approximately $175.6&#160;million and $3.5&#160;million of federal net operating loss and research and experimentation tax carryforwards, respectively, which will begin to expire in 2029. At December 31, 2022 ,the Company had approximately $196.7&#160;million of state net operating loss carryforwards which will begin to expire in 2030. In addition, the realization of net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions, which may result in the expiration of additional net operating losses before future utilization as a result of ownership changes. As a result of these ownership change provisions during 2020, the Company estimated an aggregate limitation on the utilization of net operating loss carryforwards of $59.0&#160;million. In addition to the limitation of net operating losses of $59.0&#160;million, approximately $15.3&#160;million of research and development tax credits were derecognized with the inability of the Company to ever realize a benefit from those credits in the future. The Company determines on an annual basis whether net operating loss carryforwards will be limited. An IRC 382 analysis has been completed through December 31, 2022 and determined that there were no additional ownership changes. The Company will continue to evaluate changes in ownership and the related limitations on a go forward basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company&#x2019;s net deferred tax assets before valuation allowance was $86.6&#160;million and $53.4&#160;million, respectively. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income or projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of its history of operating losses, the Company does not believe it is more likely than not that it will realize the benefits of its net deferred tax assets, and accordingly, has established a valuation allowance equal to 100% of its net deferred tax assets at December 31, 2022 and 2021. The change in valuation allowance was an increase of $33.2&#160;million in 2022 and an increase of $24.4&#160;million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that there were no significant uncertain tax positions relevant to the jurisdictions where it is required to file income tax returns requiring recognition in the consolidated financial statements for the years ended 2022 and 2021. As of December 31, 2022 and 2021, the Company had no accrued interest related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s federal and state returns for 2018 through 2022 remain open to examination by tax authorities.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NzI_92abf643-1a41-4013-ab7c-5293c6be6cfa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 382 limit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzItMS0xLTEtNjQ2MTQ_7db84696-84e2-4d70-8df1-5d267749fb14"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzItMy0xLTEtNjQ2MTQ_9dfebe28-7383-413b-8d11-da0f29caacc2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzMtMS0xLTEtNjQ2MTQ_dc2f8023-918a-4cfe-a3c5-01c2a5c7eeb6"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzMtMy0xLTEtNjQ2MTQ_fcee938a-7754-4696-b5cc-116413e636e6"
      unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzQtMS0xLTEtNjQ2MTQ_f096025d-a1ca-4acf-b694-84f6055482f6"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzQtMy0xLTEtNjQ2MTQ_ff475e1d-6bbb-4a42-9b45-2d3645b1cdd9"
      unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzUtMS0xLTEtNjQ2MTQ_102fbefb-a9a4-415a-83d8-1faa4c2c8a75"
      unitRef="number">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzUtMy0xLTEtNjQ2MTQ_0b7ac3a8-e549-4a95-b6a9-b2f271878c49"
      unitRef="number">-0.285</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzctMS0xLTEtNjQ2MTQ_764a0436-ebb8-4b87-a8b3-ed7378a756dd"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzctMy0xLTEtNjQ2MTQ_01e1e004-4611-4258-8b7a-292ba57c3cc4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEyLTEtMS0xLTY0NjE0_e7a90f7c-c167-4db4-8161-35255c754665"
      unitRef="number">0</vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent>
    <vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEyLTMtMS0xLTY0NjE0_14bb82e9-b9d2-4bcc-896e-15d076b5e7b3"
      unitRef="number">0</vrdn:EffectiveIncomeTaxRateReconciliationSection382LimitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEzLTEtMS0xLTY0NjE0_74a1df40-2e8c-403c-a0bc-959686765bb8"
      unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzEzLTMtMS0xLTY0NjE0_c4073fc3-298b-47e9-a96b-17509acadc49"
      unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzE0LTEtMS0xLTY0NjE0_3affe2b6-2241-4cf8-8452-7c3d6a6d877f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTo5OWI1OTJmOWFiZWU0ZThiYTY5Y2U2NWI1N2ExNGUwMS90YWJsZXJhbmdlOjk5YjU5MmY5YWJlZTRlOGJhNjljZTY1YjU3YTE0ZTAxXzE0LTMtMS0xLTY0NjE0_a929c97d-4c70-4962-a96f-7642ece24541"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzM5NzM_a9699410-6b2d-4a5f-aaab-75223d28c5b6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Start-up costs and amortized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IRC &#xa7; 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzQtMS0xLTEtNjQ2MTQ_4e00d1ec-53d9-4c6b-8f0d-8c7ce2697120"
      unitRef="usd">46000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzQtMy0xLTEtNjQ2MTQ_231858c7-7959-4459-93be-bf9bd99fe79a"
      unitRef="usd">40992000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMS0xLTEtNjk5ODc_8f451b7a-f902-4648-beae-4a3c103a12d9"
      unitRef="usd">3803000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMy0xLTEtNjk5ODc_7a987c93-e323-4ec1-981e-7007c83fc2bd"
      unitRef="usd">1686000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMS0xLTEtNjk5ODc_0439a84e-81d6-4683-96f1-b4c4b0aee466"
      unitRef="usd">4986000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMy0xLTEtNjk5ODc_216544d3-59ec-4f74-aa9d-00338eacdb42"
      unitRef="usd">3055000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMS0xLTEtNjQ2MTQ_b4cb0857-6970-42c4-acdb-ba082b695166"
      unitRef="usd">4161000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzUtMy0xLTEtNjQ2MTQ_edabbd20-a8a9-4e1d-912f-2fa8503b77df"
      unitRef="usd">3123000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMS0xLTEtNjQ2MTQ_d0260026-edf7-405a-9033-b7d7313feda8"
      unitRef="usd">9460000</vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts>
    <vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzYtMy0xLTEtNjQ2MTQ_31b5e746-9ad6-48a1-bca9-d2cb9866e278"
      unitRef="usd">5013000</vrdn:DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzctMS0xLTEtNjQ2MTQ_59aba64a-2d2e-4221-b98c-e0047ff0070e"
      unitRef="usd">18252000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzctMy0xLTEtNjQ2MTQ_cf732f2a-bc5e-4a8a-be9c-2efb4936b616"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzgtMS0xLTEtNjQ2MTQ_1d704924-d600-49f1-bf9b-c156e5ea5b75"
      unitRef="usd">22000</vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet>
    <vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzgtMy0xLTEtNjQ2MTQ_e9743fb1-1e02-447a-ad32-0eda9b08a992"
      unitRef="usd">0</vrdn:DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEwLTEtMS0xLTY0NjE0_663aee35-ceba-4eca-b5f4-2b220672b421"
      unitRef="usd">86684000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEwLTMtMS0xLTY0NjE0_70556077-0707-4227-bce0-38274ba01447"
      unitRef="usd">53869000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzExLTEtMS0xLTY0NjE0_3e762d88-a31e-4ad1-b341-daa8a643baf3"
      unitRef="usd">86602000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzExLTMtMS0xLTY0NjE0_dcf248e0-736a-46d2-9ebf-9176087ad1ce"
      unitRef="usd">53430000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEyLTEtMS0xLTY0NjE0_9c5ee628-dbea-4329-88a5-8b5155bb4398"
      unitRef="usd">82000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzEyLTMtMS0xLTY0NjE0_b575db53-593d-4540-9328-b514591aeb8c"
      unitRef="usd">439000</us-gaap:DeferredTaxAssetsNet>
    <vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTEtMS0xLTcwMDA5_bb12be88-56c9-4fa0-aae0-a5e9f945e679"
      unitRef="usd">82000</vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss>
    <vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTMtMS0xLTcwMDA5_10a2bc78-3a40-42b8-8dfa-bfa2a6e40fe2"
      unitRef="usd">0</vrdn:DeferredTaxLiabilitiesUnrealizedGainLoss>
    <vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE1LTEtMS0xLTY0NjE0_96ae24ac-da26-4e3b-b279-7036781af5d8"
      unitRef="usd">0</vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE1LTMtMS0xLTY0NjE0_dba65c87-50c8-4e70-888a-c97eac530a3f"
      unitRef="usd">439000</vrdn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE2LTEtMS0xLTY0NjE0_04ea4e65-50c9-41f4-b2e6-702f0801efdf"
      unitRef="usd">82000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE2LTMtMS0xLTY0NjE0_5c5d2299-e04e-4574-8e94-5a9f6e3bc4f0"
      unitRef="usd">439000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTEtMS0xLTY0NjE0_6a42df54-8ea8-407c-a933-a20574ef9437"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90YWJsZTpmZjAyZDAzNWZlMDI0ZWY5YTMwMTllM2NkMDgxMDZmMy90YWJsZXJhbmdlOmZmMDJkMDM1ZmUwMjRlZjlhMzAxOWUzY2QwODEwNmYzXzE3LTMtMS0xLTY0NjE0_e3714180-b018-441f-8ecf-93f5ffc6a1d9"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie575904542f4433e911075dd3974f021_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2MzM_b2f14ec0-d711-46da-89c5-a3845d5fbcf3"
      unitRef="usd">175600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8bd65cfed6004a6e9be4b0f521ae67ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2NDk_75ea5487-98ac-4d60-992b-6a3bdab6fdd7"
      unitRef="usd">3500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i041bd935d0394bcb91d5976137df8830_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2NjM_bc0c6a90-0526-462c-a1c3-f8c9a97b455d"
      unitRef="usd">196700000</us-gaap:OperatingLossCarryforwards>
    <vrdn:TaxCreditCarryforwardLimitationsOnUseAmount
      contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2Nzk_dd3c9034-6186-4450-971a-306ceb83b6a2"
      unitRef="usd">59000000</vrdn:TaxCreditCarryforwardLimitationsOnUseAmount>
    <vrdn:TaxCreditCarryforwardLimitationsOnUseAmount
      contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ2OTQ_b6b33000-09f3-41d3-b1c6-c7f80fda1649"
      unitRef="usd">59000000</vrdn:TaxCreditCarryforwardLimitationsOnUseAmount>
    <vrdn:TaxCreditCarryforwardWriteOff
      contextRef="ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3MDk_f75b044f-96c6-4f26-9f83-98a5879c19e8"
      unitRef="usd">15300000</vrdn:TaxCreditCarryforwardWriteOff>
    <vrdn:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3MjQ_4fa3005b-feb9-4e99-9cdb-11c3b00028ec"
      unitRef="usd">86600000</vrdn:DeferredTaxAssetsNetBeforeValuationAllowance>
    <vrdn:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3Mzk_1e422d5c-89ef-4be7-9e5d-e37c7b7a1b47"
      unitRef="usd">53400000</vrdn:DeferredTaxAssetsNetBeforeValuationAllowance>
    <vrdn:DeferredTaxAssetValuationAllowancePercent
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NTQ_51f9cc28-bf3e-4f59-891c-4ad40d6fcc79"
      unitRef="number">1</vrdn:DeferredTaxAssetValuationAllowancePercent>
    <vrdn:DeferredTaxAssetValuationAllowancePercent
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NTQ_ee8fe1f2-99ea-4298-8f9f-220ae8c5b6e6"
      unitRef="number">1</vrdn:DeferredTaxAssetValuationAllowancePercent>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NjA_19549756-2597-4f9e-8451-05b29cee2877"
      unitRef="usd">33200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9d73e8820e564a6993a0e1b79835eedd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3NzU_5f5ecffe-18fa-4075-9d9a-8e9c702c6dea"
      unitRef="usd">24400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i369f8afef8e64303909112080068f0af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3ODk_3556643a-5e9f-45c8-9d59-575392979735"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i8f2764507e7e4eb3bc12c916d9987aa9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNjkvZnJhZzoyYTUyOWMxMGVkYjM0ZDZhOWZlYWU1ODQxOGE0ZTkzMS90ZXh0cmVnaW9uOjJhNTI5YzEwZWRiMzRkNmE5ZmVhZTU4NDE4YTRlOTMxXzE2NDkyNjc0NjQ3ODk_8913457d-f8a5-4cc4-9c85-8e1c9a1fd2d3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ1YjhhM2E2N2U0YjQxMjBhZWY4MDIzZDJjMzcyMWFlL3NlYzpkNWI4YTNhNjdlNGI0MTIwYWVmODAyM2QyYzM3MjFhZV8xNzIvZnJhZzpjNGMxOTBhZDExZTM0OTY5YWY0MjFhZDBhZGEzNzNmNC90ZXh0cmVnaW9uOmM0YzE5MGFkMTFlMzQ5NjlhZjQyMWFkMGFkYTM3M2Y0XzQw_0b4added-2bf7-424e-9ed4-fc5850db3e95">SUBSEQUENT EVENTSNone.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#X-!Y!7H^8'DZZPF>\ZEY%'V<44)O##5!7!^P;G<':@;[/\?P.#_4$L#!!0
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M>Z%->;MA:?HI2!M@]@]"Z-/$'M!UZ.PO4$L#!!0    ( /TZ:59 *C,>2 8
M %,<   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULM9EM;]LV$,>_"N$6
MQ08XL4CJ,0\&$J=#"W1M4*?;:\5F8J&2Z)*4T^S3[RC9EBU2C+.Y+]I(\O'T
M/Y&\WYUT\<3%=[E@3*&?15[*R\%"J>79:"1G"U:D\I0O60F_/'!1I I.Q>-(
M+@5+Y_6@(A\1SPM'19J5@_%%?>U6C"]XI?*L9+<"R:HH4O%\S7+^=#G @\V%
MK]GC0ND+H_'%,GUD4Z:^+6\%G(VV7N99P4J9\1()]G YN,)G$^KK ;7%7QE[
MDCO'2(=RS_EW??)Q?CGPM"*6LYG2+E+XLV(3EN?:$^CXL78ZV-Y3#]P]WGC_
MHPX>@KE/)9OP_.]LKA:7@WB YNPAK7+UE3]]8.N  NUOQG-9_X^>UK;> ,TJ
MJ7BQ'@P*BJQL_J8_UP]B9P#V>P:0]0!RZ "Z'D#K0!ME=5@WJ4K'%X(_(:&M
MP9L^J)]-/1JBR4H]C5,EX-<,QJGQY,OGZ9=/'V^N[M[?H.NK3U>?)^_1],/[
M]W=3=(*^36_0;V]_1V]15J*[!:]D6L[EQ4C!G?7XT6Q]E^OF+J3G+C=L=HHH
M'B+B$6(9/CE\.-X?/H)XMT&3;="D]D?[@JZ$8*5"J91,R3-;/(T#W^Y [ZTS
MN4QG['( FT<RL6*#\;LW./3.;=$=R=E>K'0;*W5Y'T]2N4 P:VBF#]B/*ENE
M.01OG<7&552[T@E@-<9!$$3)Q6BU&X]IYA.2M%9[0OVM4-\I=+K@0ITH)@I8
M;"LF5=&GLO$3[MR>A'$2X8Y*TPP'?AB&=IG!5F;@E'DKV#+-YHC]A$PJF:R?
M+5<+)F"[[BXKF_+ D!0&I*O;-"*1']E5AUO5H5/UM_(^RW,VA\R[8F7%8&\+
MEJ<*KBQ3H9YM8D/S^7FDH]6T\0-LEQIMI49.J7=<I?D!SS(R;TTQCFA'H6D&
MA,,AM8N,MR+C%U8!@!2>6SW[>E,M]6H=HI(IF];8?)24A!VEIA&- KO,9"LS
M<<K\ B)3E96/*&? .B0TU$[XPTD%)_6CM:E-3+4A]CIJ;4:Q9Y>+O99&GEMP
MO9'Z)WT]?/>V2=Q=E!8C["<]RQ+OD!(?L# =VK!E109>TMW?%COBT<CKR9^X
MI1H^#&MYEL)NSU3&[&S#1X7;L;SM!]WB#;OY=C6;\0I  7GL.;W/F35@:ED0
MA/K=B3'-""5]T])R#;O!!@I%!8EV9UJL(BV\BF,2=45:S+"'XQZ5+=:PFVN;
MQ;,$"NOZFC_H:IC!Q5=! UOH%<?=&&Q&?<^Y11QV,VX?'"\];9-<E%*_6^E8
MS# -:4\-@5O&83?D/O'RL:EUYNR^GQO8 KG0#[HB3:N^1-SR#;L!=_-?YMXD
M6!P:V<_"0NSW37X+.OP"Z6IPO#3I%FCAR,"'Q8IX/1N,M&@C;K0UR_,%A<1$
ME^]Y1A*PF.$@27J*&M(BCK@1-^%%D36%=],S\%)7#ZR<]>EU^K,G?V1MD?Z_
MH_V8=WI!-S6GBL^^+W@^9T*^>Q,3')W7%9UZMC>&Q^T,?P4\20M/\D)S"/,-
MN5[J1S!$;[U3#^OMC:!%K-@YM-O>T&O^(;E(A>YV*@5]6O8/FY\C'P^I%PP3
M/ZH7"Z'#A/A@[&^,,RDU^.H.J5)2P8&N15.IZ0)-/2ON8=-NW@LT3J##'T*J
MD4M6O^#)K9F&F*3V<1?G%B-">Q(-:6E.7J#Y?)YI0,)>UGW@259"9[W,8&];
MA9JTCGSLA<:&-NU\3(#K/7);K!,WUJ'XJ(JJ2=SK+I47L)86^DW<BJ&<2_O&
M-A%]0I-N$V"SPD%/KTI:DA,WR7=%0Q&2S3(K'8D)YQ,_CG%DK 2+(0UBZO5@
MDK0<)X<TJ[(WA5AEF[BF2>"%AFK3#L=1A'N*#]*RG;C9;I"HWGFO#,+$N+79
ML=BYFAW2 I^X@3]E0BN_0K=B4ZK4F=PJUNGJU3G[2-[V7^>U=03UCLDKZJQ*
M7AO[L;SMQ][6)]1=G[1S+?OFFIK==1SX43=S6<PPCO'.)MR7V)83U(GLS;J\
M/F1=NEV]>FY^R6OFG??,]*CKTEF9O#KV(WG;C[TM"JB[*#AD7?K&2_,@#*-N
M(6 QPV#739>CG2\^^G/;GZEXS$J)<O8 X[S3", LFB]8S8GBR_HCT#U7BA?U
MX8*E,%?: 'Y_X%QM3O1WI>UWQ/&_4$L#!!0    ( /TZ:5:8HIJ'+@0  "L3
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULO5AK<^(V%/TK&G>GD\QL
M8TLVQJ3 #! ZNS/[8$*V_:S8 FMB6ZXD8+>_OO(C-L9&0,,V'X(MWWMTCB[7
M1VBX8_Q%A(1(\#V.$C$R0BG3>],4?DAB+.Y82A+U9,5XC*6ZY6M3I)S@($^*
M(Q-9EFO&F";&>)B/+?AXR#8RH@E9<" V<8SYCRF)V&YD0.-UX)&N0YD-F.-A
MBM=D2>2W=,'5G5FA!#0FB: L 9RL1L8$WL]0GI!'_$G)3NQ=@TS*,V,OV<W'
M8&18&2,2$5]F$%A];,F,1%&&I'C\78(:U9Q9XO[U*_H?N7@EYAD+,F/17S20
MX<CP#!"0%=Y$\I'M/I!24"_#\UDD\O]@5\2Z P/X&R%97"8K!C%-BD_\O5R(
MO03H'DE 90(Z3'".)-AE@IT++9CELAZPQ.,A9SO LVB%EEWD:Y-G*S4TR<JX
ME%P]I2I/CF=?ORR_?OKX,'F:/X#IY-/DRVP.EA_F\Z<EN%E@3A(9$DE]'-V"
MW\"WY0.X>7<+W@&:@*>0;01. C$TI6*2X9E^.>NTF!4=F14B\)DI9 'F24""
M)H"I)%0ZT*N.*=(B/A#_#MCP/4 60AV$9N>G0PT=NUI6.\=SCN MU)>1<$X"
MH"KHO[P'*>9@BZ,- 3=JZ0(619@+D!+54:%:Y=NN-2RF\/(ILG;<CJT[2[';
M[NO2\LA> O<BQ3X9&:K+!>%;8HQ__06ZUN\:E4ZETKE,9:Y% +R1(>/T'_4@
M4UN,=DHL\-T]B3TK_SM0J>7Q'U7V*I4]K<H9BV/UPGE#(7OG%/)$4(.Z6U%W
M+Z!^<77<5G609776YYS(AH)^I:!_N0(JQ.8T^WZ+DP-MJS=P^@?DVX'('B#'
MLIQN[E[%W;N<N[)2(=5;DR;K4P*\<P6T _4"!I6 @5; H^HES/T0*+[*&[?*
M]%-EX5(Y 2<1EJH&JAWDCR[R!7)_CQ.T+&_@'%!OA_5<SW.[>4.K=C5+RWRR
M6M&(Y@SGB:3=%/48Y[]5"B770FLJWO-Q^--J54(WJP '!Z7JB#K2W!#5K)&6
M]9)PJIIB FHK66;MTLE2"W5QN:Z$UA1>[P_@_[!!@&?M$$Y%-174W@]_MOG#
MMOL[=J]M+J?CFA)J8X=Z9S\FX3Q_*<'W:4'/L[W6^K?CD&LY=O\(_=K<H=[=
M#^A?8BVP;=C=W#N,7<>]MG6H]_6R\:=G-;X6ZN+&OQ):4WB])X#Z3<%U&M\[
MJ_%/1#45U)L"J-\57*'Q!T>V_8<"3L8U?RO6VP.DWQZ\K?%+\ 8MB. A^XXP
M9$-T9&^#:J='>J=_0]N7R">9M\.ZF)M[QPXQX>O\-$8 GVT26?QRKT:K$Y])
M?LYQ,#Z%][/BW*:&*8Z1/F.^IHD $5DI2.NNK]ZEO#B9*6XD2_/#C6<F)8OS
MRY#@@/ L0#U?,29?;[()JO.Q\;]02P,$%     @ _3II5O%D&+/4!   41(
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MZ4VVJ2>H?GZ;Y^73%Q>5_S7??-ZV<?E?4$L#!!0    ( /TZ:58&Z?+RS@(
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MK,.O.59ZI!D85&)GY2S^72-RN+OA;2"+K$[D0S$6%R+.6$?"MHXT<J7$4@%
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M-HHV"0W ^\KA5)YO:('Q6_W%?P!02P,$%     @ _3II5GJ:#[B9(0  C6D
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M*4'DA@XL5_'1; T2@.-,/WBS^.M?+BZ>OUYTBWHQ*Y:VWR 1NXTI-\5.=[I
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M-M;%0"MET+Y%!:KW(;YMU9XFP0 4 ! L=FN[:&!@&^P.[,$K4,YF#FH.S$-
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M;^#\?O36#\SF95KLLOU(C7/(EZ"#@RC$:0Y=1[O#J"!]<9I!.#T MQJ_J#3
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M]#=ACIPI+$"*$>(^8V_YK4Y*=I\L0[N00HDM7LG:_P74]G<J5?28[9;X-42
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M.<"VDX+"N5(4V[5R#%EV\>](F5E+W HHVG0%A"6=7"#K2WPP#&>LM"P*VYI
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M%#W6PU,'TJD3TMN:(04 D#V1Q: Q<J% IP?)[E6?CL>X3)"L&4*Z]ZALKWL
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M8&O^N%82@4L'\/W2VI ?B$'W>Y^7_P%02P,$%     @ _3II5CP3E51&!0
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M M#]0]1/K&I\\5\I2T^)'U;T=J-V!O2]5,KN)R[ X6]@_C=02P,$%     @
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ME78TWAJQH/\)&J] Y[G6[G7A'71_J-E?4$L#!!0    ( /TZ:5:YQHV@6@@
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M 7'LO4R0@H*=+;00Y#8$J%VRBSPO"_6S* ;LHL )713L0V+53&@ZJ-& V:6
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M+%@H5!8MHQ NF%RR* FEVDK%$41.E0*+4L;S;"U5] ?,RR3<2',!VALY@\$
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M$1#(I$I==IG/XRAD'Y>@I"A9I>Q=PF;Y"CP?N8&ZQ0$+ NE&"?# $Y:C5>]
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M>"IK'V0&O?P=ULF9 979Y"- G%@T C&M>>:P-)__!D9F]4Y =2IPU,?[.-H
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M&)U.!_[HU]Q85;KOW@MEK<K=Y5IP>$P">+]4F/[K&]J@_4/(]?\!4$L#!!0
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M!>^M<2@62#AO7ODV)UPH-BYCV0 _!RGSP8>V]12=@WULY0BF>$+RZ:V\4O3
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MOKJ)]*JU\R?_9L7GT<E"!'D\&?MS\ +6C1Z*5G[$RC*SWC[M?M@+R?J7*7]
M&-<O_REVKA0MC..!.[3U14&M;K!$F3[E#%5:AN8X#D)&<O%C5WQFQ+E;)#G,
M@@?LQ5*YCFN9&&5B(C@4^6C[4V2[*00O*)9V/ZIGXNGI\]'CSJ_?X>+^I,5]
MB*V5PSKGAR 5E_X(VXGC)2@:I;6:A3Q!%@<>X> +A-;Q.ZJ"KK@_0PY@^>9#
M:=)$\\*T.6P>*F4M!940=7W0<N<7MR\>XHG/6RUJXU'(@/%Q6NZ-HBZ'LKX&
MOZ]<*XP.1-7X4D*8*L+E#F;4:Q9K0TG];ZFZ&U2C7EUA8A&GHMQ(FV:TB071
M*,X(YY+WQYP&F%I,A3HY12@)\ 2O5"'<EF#J0!0)IGB19HF^".DEW>YZ(18F
M, [?[-NC=X$\(<8^0>IA,B,#,)>GJBH>.N*$-97/#MKJX1,ZA11T!7\O@;S1
MH /!70#K$DZ3TRO: @:Z&W.HEY--A;)[Z:@U)7DKW?S+@O(XSU\5[RGT._>8
MDX*.MS]L>(J'?<O5"54_XN,A9,B8W!S+L-ZJ(A83UB&KF4\X/YC0#5 Q.0KL
M5\GKB8%WMDSN4W= ]0;-R= R)H.&%;?D]Y*UW_ ^N?]6-#FM++R4+-KXUE3T
M0*RA?#=G.9*79%H0@)(7&T^C-IR,6_789Y*$*KY.<2^T/@D28%7.[30E%<+<
MF(RGQ^G!^O6A0H@IVI"HA5<[[,G4Y.]/_+8D,[$?F6 6].J=!^\3WS001-3"
MH2Q2?L:B>:0\$1LC?\XM]<5BY1<_1,]9C/Z(^\S'.;-Z)KP;W9G(DY6/+ X=
M^TF,_EFQ2V.K?[@K]T&&#Q-SHU8SWN)Q/G[_!AU>;R6K2ZKG$IL6N^(SA*J#
MMO,_@)<HUI24A/K0$8I-,-Z/R8/[Z@AVQ; IO>R]?Q!@8#YL%?8Y^ SAK#P#
M0P^?RST5TC5<Q2Y;4=A;NE'FT OG>AZE"M%?)&6R4K6XL? -\6O.UB!8H7,B
M%GJ.1]'QS(,9?4L0]4MKU5;2$R0.*4!D1A2N.CBK3]N6A!I/3$B+:(3Q82=D
M1L&"[8-S +Z-*S:JJ:65OE7#.QMEUWA?P_GXC0N??/LX+@1#]).5Z!\"E-=I
MR,@S9G;IZRJ\'@)O#O KZ>G#'$Y2R63QW6*Y_]_2#O(V_9J,\A:4-)KD>V9=
M8B</.#)@(8J&RY6KJ&6!V6/P1/PZ1H)XSOQ\_)CX'Z$:]EYA^H*NT9J:U13/
MCU]$?^E]M$F#]!F=9?CRHA^8.J-H"*L=VRDP!A8];:(E-EZBQ38LO1-TH&D6
M(K)T,L7N>/+KN BQA3#+AV>.S].TZJ;D]/DMG<]8,RR0O;@'@<[+MDINA1G.
MFN-&407V=)E#>DB##:HWKPR3]!D5#PXF2WW8\1GS'AQ*JS*(4!D&Y>!"?V&8
M^U@SQ:[7X9T?^M:[WKJ^;$.V=MUK/IP)>BBY(FM!/828QORZHY1:/%O\-50D
M/YI9,3\[?SX]FQ<39AIP7?G8\HNG<PB[QT0BGLL^'S]3_58M.^EI@3^N'*Z_
M0BRX$_'GCX/C9]H_BT?P0_V$ L'\,A0ZU0;O-7CXQ88K&O@2(A^.957&O!A)
M68Q:6[3)0,F^BI6DU!^M<6G1<01B!V^]*G>ZDXQ)Z6+@.GBP_*NGV[/IV9-)
M<>53Y=/B"K5D.-08OGBXZ)<=$_7)L^F3LT<OBX7>[AJ]VGMMFETO!F.'4#L;
M1&Z4DT:MI0+,KK]@Y*"T.7 Z>TC OJ",OC> B8=E3 ' X(_@"!7/92U\--X%
M0G.#"!H2GUS"^@\9["S+%,H+/NT?[8JBAG(^+2PO'1J7--AH8(FCMCNVD9V/
M=W^!:WB-Y[G0H05R2*/B I-O@T+RP] &&UVH,$(&$C%V;3IIH0U =@$(%W?N
MR-.F13,"Z]DFU#UR/CI6C'S$M3Y6<HO+XNF+L^GYV73Q\\_3)Q>38O';)2J\
MU:JX:%N#_1VH@U\6EY)GJ**?\2$_5OQ988\]!1'))7&<CRU37H\9"US/0I'K
M<W&$6KSC0]?JCK3I4E5E[S@<##@.=;23P.7*AZ3"=B.N;>A4$<66SCT97W&2
M.@NHD%*,"0?=\). XX8'B1O*)IQ/!6\Z=I /50/A#\JQ@*= 38-UN<>WZ;1I
M,D%2"J\5ERFIA@:""-Y!"W(/U,6V KE:\FQRM..(#E'<!P@>Q<<QDOFJ$@H2
MCGK)[LD6 !*L^[8D_<-,0,T*"[S"CW:#-P[FT/F>)@_SS3'A4'7RYO@&5FY]
M.F[60V'*BP.':QGLI,ELW'@X'9N1SL>[A:YB5AWH\-ZTZ^E[2M>R=SJHY_XC
MB%DG 1]=D]LCP+?=QR9X?\O?B4 &\_UX',U?CX,B0$EHOFTDZR'2;8T*1YV:
M1K(>Y-QA20KE5VZ/P$-3(']CN)['1HWY>'?%1U"S[R'$16H7U&HQA-[O!E+@
ME:05*?'&?T'&@^*TLJDDPEONN5#O[6H8("KJAJ[CI1H9['JMDFZA:(MR!0*Z
M%;U:4A[Q3BCI4T5QP&OI#@[T'L#(JL8+#%<R4;DIY6P&;TW*65Q,:)KC&RHG
ML,>& M-A?)!F*K=T"=[R%-X.H$]\H8.2,$YV02^$4\%^3X*H!#&:KY"C98$<
MC+)2;".8WU'Z!_18M<&KGL'*(S\,LM+W LF?$%8DUK=TQ!N=$8\N4L))_Y2/
MZ*061,V<IRN<=!E?R%]EU= T*U%E"V(HF(M-RZ3^(C'R+OUU!HEW>8_&UZ@Y
M3OL(HX2+S07SN]H#J([ZI;P=SC)\Q_#335E2K.WHK>5>?.D0PZ0![#XY*)+<
M6[NBNP?$NJ7@T,V7Q_!YK+*8' $*5]=R5QP.1&K07:K<Y-E9O81 2>KR?$T9
M?^?K<EP].FHE/=3G+LMAC-RK=^0JXZJ6G/*X2"YYP^;!&_9TD]1 ?M:<CU#3
M^3(Y=4TQ)-H1.4Y='R$MGAXG4\.\?W_LABH"TU:U)3>(P2ANT$J/[:/CSN?C
MRUNI3A%%13*P=<&EQPH,I62DV)U1PQ]LR2\$0#.IY&(1K*I(L9\#-Q3UX^T?
M[XJNBXG*(^XD/TX6V]LE^9Q8G/RZ!R(0XB4IV YUY*1]WX,+%8M 45),"1G'
M9=4]?$?M:1-F;,KP<Z&$6ZSY& )E!,-5RS&Y )QL.SQ*?2+H"KW&Y2!3DKAW
M?!^099L^M >G.58+R4 \N\+E(1R] 7DQW,N;[_"P09<\U_R*Y+N8'^$/+6F0
M_\=T;&RLF(^W0_R#LJ3#SNL]AQ9?=Q(NAX 3Z]C^6XP>?#?<L&\T=JM(=JA4
M8')P<=R&FEUS%O4SWQ>0Q=*#\-+<Y+N+Q9OD%D2(V"?%6U:4O78;RE(G\DC9
MLM\X&ID<#GYV]FPR\.6+<WC\%H3QFNX)8-[_FZK7U#Z.'_"MG\Y?3/+VXJE$
M4-G#2;9+; WSZ*> -PL(7:Y*; CI D&/FQ;3$>$<5-J:MDRN]L%N,=)M((<>
MQ>H6K_?C\UFQ8IK-(='<$7B&Y4X BRS%,6#21CLF(+&&.A^O>2X4'W2]BFWV
M@[+RW5#R:]%(D[!;13TD0;,X&4DG2,NT%1%O69<OT\NVL_OX)0N,A7S=<@M@
MB LGG*JGID*]I9R#'#V,65"^9BA1[KO-WLEI<7]0(+FTY&M+U\LNNGA+*C8=
M'AS &,J88@]1Z]/7M6I-<A,^]5;5>),!YH.PCKGKI$6A-7><-)K'ZN-\O&B8
M_D*'-3$1YZCGXOS\%5[9\$85%[7!7RX89(+_TQF*=Y2#QS/,Z([0R>56W>0_
MF9"!B1=D^SB5M$UH9W%25B&1HLX)4_,]? =7ZI6X G^ *>E7Q Z%D&$^\A*
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MYP6--Z#WA=;NH/@ W0=K_@]02P,$%     @ _3II5D523TU) P  60<  !D
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MAJ[V=KBF?RE4+$#K2RG-?L(&VK^ST;]02P,$%     @ _3II5AK3]J#. @
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M:=#)M":!0HIG;KN0+H&6$"J(.2E+!8D4F95-,$;)4E":Z5(+^5HA,1(1*=T
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ML)#'F(K0'R@2*:K=;PX(90KU=@IPHQ](+)-6?S96;"L*?*]ROE=6OH,DGJ
M/@-SIG5.9/-=PI'PPY)[.E=/0^&(K'7G5[Z'][FN]U9=?<IHG,1EQ*V&+TU
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MJ=+<?9UW[^7FMD*,7MD7>AFO]UQ?(%&$[PC%<NRB!:4XV8*8%#@2X6Z\7_(
M*.(!3E#3Z*\SP42G'&+V=UO_R"O0;Z^ G!2/68I]F!EBUF- [\&8__J+/;1^
M:XN-3IBK$^9I@C6BV"^CV%?1Y]=P#\D.VM17&G957R?,S6&C#";7MONY/1J)
M(7%?5_5I(6<R[)6%&FH-2K4&/U&+ :9^D'7QM9 N(FG6Q3^)93#"'-8HQ90_
MM,FI)'>54R?,'3R5T[+&D_Z!H'FQ8:W88#@>#]L5'9:*#I6*_@D)9F@9DJL
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MNFC-:%4YN3U^\PV SIQ\I97F:J5YNFC-6%:' ;;Z-."U!RP%_B<G+.I*= [
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M? .LR!/>1N*>[G^0O" WQ5O2B&=_P3Z/M0RPW')!XSQ9,HC#Y/ ?_\H;<90
MG98$E">@]R;8>8*=%7I@EI5U@04>#QG= Y9&2[3T(.M-EBVK"9-T&F>"R;NA
MS!/CZ>WCY>SAYO+V808FMQ?@:C*]!X^3Z_DEN+F<S.;WEX=[)V":[ @7<@8%
M!Y\OB,!AQ+_(Z_/9!?C\Z0OX!,($/*SIEN-DQ8>FD.S2,<QESN3;@0EJ87)!
MEJ? AE\!LA!2I)^_/QU6TTW9DZ(QJ&@,RO#L5KR% #.RW+)0A(1_!9.=K!@O
M(G(B%\\)QQ$!?UW+)# 5).9_JPH^C."H1T@7Z!G?X"49&7(%<L)VQ!C__AOT
MK#]4Y?<$5FF&733#UJ&/)S%E(OR7K, YY4)5ZB%_D.6GTK$;.\CQ'6MH[HZ+
M:(;!8)#-]TY!SRGH.5IZWQGE',P3J6-1QO*[U"_E(WC \8['1TZ-8S/&4]-S
M"WIN-WK7\IPH^;F-L4]<6">H"(*>K>;H%1P]+<<K'#+PB*,M4='R&B/*V77<
M^NPVPV#@^9ZKIC8HJ VTU&YH0EZDYK&?TM6>MBWBHL7HNM9Z JN4ZQ?E^A\N
M/'Z?S>@)K-*,H&A&\#^%)V@^<_8@L.S:H]D,<Q , O63":W2/:V>E"<'.F90
M7S[:D"K!(WN'?6E/CJ1EJ NI,BQ]%FJ=ZPWER9/?G%]%G&Z"2^.#>N>;G\Y.
M@9#=XUOV GBQ+)5<M5!=EUU?:-7"2TN%SH?+$-3:=N>&](16;4AIXE#OXF]+
M$6P:L^^Z [_^J#;#$$*PQ25AZ>!0;^$=M$AAU*BQHII!;6N]='*HM_(N:C1H
MON4$7IVC(LAU6EB6!@RUEO:6(OF*6?8LMTZM&28GV8,MY$I#A'I'S 1I2=F&
M,BP(V. -84#NN,""MFV[M("=5V%/:-5-66FXR/KX;9G6TSOORWI"JS:D-'BD
M-_BW90DU35L:H]UX>U?%(=^R6H0)'>VD]0[_?F%""K>OLVR&M&S/4&GR2&_R
M'60I1ZHHCNW7%[\J*FC1)51:,M)O<_6ZA!1[V\ /O+IFJN+0(("#%GJE02*]
M04X305B"TZ]S.#J2J%28P)I&JS!Y5O=4B]MY/?:$5NU"Z<+(^WB!TAI]YX;T
MA%9M2.GY2._Y[Q"HIHLCRPKJSVTSRO&LEL\>J#1[I#?[#N+4=/2&A.I"J@1+
MPT=ZP^\B3LU=[HE=?Z]3!;6]?-JE+]OZC;!>F_+DVG>_NC(IHAS7]VO4S*./
MW>DO#3>8/<L9 Q%YDFG6Z4"N?W;X>'\X$723??]>4"%HG!VN"5X1E@;(^T^4
MBM>3])-Z\1/*^#]02P,$%     @ _3II5KC0  VG @  O@8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&ULK55=;]HP%/TK5]DTM5+;A$#;J0N1PD<U
MI($J*.QAVH-)+L2J$S/;@6Z_?K834MH%M$E[2>SK>\\]QXY/@AT73S)%5/"<
ML5QVG52IS9WKRCC%C,@KOL%<KZRXR(C24[%VY48@26Q1QES?\V[<C-#<"0,;
M>Q!AP O%:(X/ F21943\["'CNZ[3<O:!*5VGR@3<,-B0-<Y0S3</0L_<&B6A
M&>:2\AP$KKI.U+KK7YM\F["@N),'8S!*EIP_F<DHZ3J>(80,8V40B'YML8^,
M&2!-XT>%Z=0M3>'A>(]^;[5K+4LBL<_95YJHM.M\="#!%2F8FO+=9ZST6((Q
M9](^85?FWOH.Q(54/*N*-8.,YN6;/%?[<%#0NCE2X%<%_MN"SI&"=E70MD)+
M9E;6@"@2!H+O0)ALC68&=F]LM59#<W.*,R7T*M5U*AQ-%L/9XW@X>9Q!-!G
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M*=)5_=RQN[0HTF7]<J'"N<JJ@/+[^S0M?KZI'F6V>W3=Y']02P,$%     @
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MVL.O0A8MJYAHD=M;?RXT]A [3+#+@S0.^'XAA-Y.S +5_X;P+U!+ P04
M" #].FE6F>)TU/D#  "@#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6RM5VUOXC@0_BM6;G7:E=KF!0C0 Z26='5(/6W5E]T/J_U@P@!6G3AG.X7^
M^QLG(84DS;&H7R!.YAG/\W@\]HPV0CZK-8 FVXC':FRMM4XN;5N%:XBHNA )
MQ/AE*61$-0[ERE:)!+K(0!&W/<?Q[8BRV)J,LG=W<C(2J>8LACM)5!I%5+Y>
M Q>;L>5:NQ?W;+76YH4]&25T!0^@GY([B2.[]+)@$<2*B9A(6(ZM*_<R<#-
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MP%0!>7]-J7@Y40^H]HYG_P-02P,$%     @ _3II5KZ@A W[ @  Q0L  !D
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M5'-1S4,U']4"5!.H%J):A&H2U6)44Y2F=P--^LQ!TV<.FCY#-1?5/%3S42U
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MP+_>Y/.'I$C-\_>9Q=Y5CL[?AVH>JOFH%J":0+40U2)4DZ@6HYJB-+TO:$*
M(W3^OA$:!$0U%]4\5/-1+4 U@6HAJD6H)E$M1C5%:7H_T.0%1]C\?6:I=Q^
MSM^':AZJ^:@6H)I M1#5(E23HZ.S <;'-U$MFXQLQYXUUX)Z'3:QO9$Q#W3Q
MCW1Q_U"FMW].GM(\N4]?"O%W7J*3@:8K5'-1S4,U']4"5!.H%J):A&H2U6)4
M4[6V?TO(L4^'XP]Z@2:U-S+/W'>YRC;K<G>'[MTR4F5F?4N[O5"C83Y4<U'-
M0S4?U8)1RZ*GK5. "K3=$-4B5),MOQ-[X+2MPHZVJRA-+^LFA#<ZLK+L_FWW
M'ZPRS5>M=8LF\%#-134/U7Q4"XX\E\.!M<K6Y4/;B$N@1Q*B6H1J$M5B5%.4
MIE=[D\D;F3-Y/^7)NDCFY7;^W9=/UG^0N#4[O>L=S=*AFH=J/JH%J"90+42U
M"-4DJL6HIFIM/^$]F^G##+VXFYC<Z,B,>_7E>59]M=:;U;?J2_7*OLR>TZ*T
MBNT+_>Z:O:B*?OO=/W??M58_FJ!#-1?5/%3S42U -8%J(:I%J"9'[U=]'1X.
MX=%8'*7I==_$XD;F6-Q?WDI]GJV+=+XI%T^I=9O\6ECE0]7@0W5=WEKE:$8.
MU5Q4\U#-1[4 U02JA:@6H9H\4A3V8%<!K:_G:&R.TK3B'S>QN;$Y-G?U\J&8
MFX\^%&/>O6^1HYJ+:AZJ^:@6H)I M1#5(E23J!:CFJ(TO?";Q-S8)E,R8S0M
MAVHNJGFHYJ-:@&H"U4)4BU!-HEJ,:HK2]'Z@2<N-S5/F-:/_[= _7Y3;S]7.
MD^4RO;6^_6JER?S!>D[R/-F^>9=;^?:]_&/OTIF;[-U9H)$Z5/-0S4>U -5$
MK=GVWF7Q9'(Z.?BH0(BV&J&:['@.,=JJHC2]P)L8W-@<@]L?X5O_MOZ^R!>W
MBV1MJ32_3_/6\D73<*CFHIJ':CZJ!:@F4"U$M0C5)*K%J*8H3>\*FB3>>(2.
M^<E@T16JN:CFH9J/:@&J"50+42U"-8EJ,:HI2M/[@2:+-S9G\;ZFZ_1N,5\D
M2RM[7J=Y\;!X;.T T+0=JKFHYJ&:CVH!JHEQV_J^P\-!/!JT0S79Y01BM$E%
M:7JY-AF[L3F7]5TNT=% 'JJYJ.:AFH]J :J)6CM^B8Z&[U!-=CR'&&U549I>
MX$VL;FR.U9DOT:M'U&*]6&U:D[5FNG<AHTD[5/-0S4>U -4$JH6H%J&:1+48
MU12EZ9U"$\<;H[/6C=',':JYJ.:AFH]J :H)5 M1+4(UB6HQJBE*T_N!)IXW
M-B>1.E^LHW$\5'-1S4,U']4"5!.U9@^TB]W!Z/S\<$B/)NU0378]B1AM5E&:
M5K:3)E@WZ1ZL:Q_3)[]\-*8WTWU+&=5<5/-0S4>U -4$JH6H%J&:1+48U12E
MZ9U"$[J;H*&["1JZ0S47U3Q4\U$M0#6!:B&J1:@F42U&-45I>C_0A.XFYM!=
MUS&]F>G= :!!.E3S4,U'M0#51*T=#(?M\W=C>K39"-5DUY.(T685I>EEVT3I
M)KVB=#>_<Q$:\XU]\['TKGTTA8=J'JKYJ!:@FD"U$-4B5).H%J.:HC2]%VE2
M>),1>A% )H^N4,U%-0_5?%0+4$V@6HAJ$:I)5(M135&:W@\T*;P)D\(S,[T[
M #2%AVH>JOFH%J":J+7W]\0/KP'0(!ZJR8[G$*.M*DK3B[;)XDW,6;SO< E@
M>!\ #>FAFHMJ'JKYJ!:@FD"U$-4B5).H%J.:HC2]%VD"?Y,I>@F 9OQ0S44U
M#]5\5 M03:!:B&H1JDE4BU%-49K>#S09OXEYRKW.EP!HN _57%3S4,U'M0#5
M1*V]OX5^> F QO90378\AQAM55&:7K1-(&]B#N0=7 )<_J3,"\V9N=[%BP;S
M4,U#-1_5 E03J!:B6H1J$M5B5%.4IG4$TR;B-QV0H_@IFNI#-1?5/%3S42U
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MS$>JLJ/[Q4-M0(W830-J=A2C5TJX0!<HRM/E$/GDM<XK!](K%PBL0LY@1\[
M.&>5L-1DT4(_Z'7A-UHW#3\DF ,)Y@*!52@8[B@8OG/]&$*2" GF0(*Y0& 5
M$D<[$D?&=31/N;=6U*"$!QY%;*GKA5Y960GYI#.=IPC324]]MR0!5^^K_$EI
MGF<2IK2.->. 35G+P2[V$KO5'O4/2@GDB"X06(6-BQT;%T8VLG2&DBTG;+E4
MA485H+S>U 7;B-<TV&;G!D5YJ5L/D&ZX0& 5!FRKE%"6<9IW:?1(N7[:"T%$
MGI5:(H\AS>I]($1*8K544J5).'(7\SDZ4SHI[_RQCB/S@$U)*M &>TNB:UWT
M>_;!H@ =U3T]:C7<>XK5-H;[9AO/@]23!=LC8ET$NOIN6ZZ1)"3Q20*,+C0F
MP/XA%';7PKW#^/_8K=NU<;676],+#ZUA[TA8<1E6; SKET278H$D0[L4?^J=
MR0S9.$R0: XHF@N%5B6G%-[V>RMO&U1Z@Z(YH&@N%%J5RE)^VV;][;XD <_)
M.UZDS1B-V3![9%NY'*P-/:CHAD*KAKZ4Y[99]GZE0I8O1^@L352VJ\__H&+\
MA%N]D>$]"=03%PJM2D IP6VS!O]6;(N@[;9()@\R7:!)02RK05EQ3H6?-65%
MNIXC4,5>H(WV:S1N7QP*A[INPW;_L$;_'RK;+F6V;12 )TLY^@?=Q($,2(BV
M2V)^/!6!:FI0- <4S85"J[)6ZFI[]-XU'E1H@Z(YH&@N%%J5RE*4VV;ANU=H
M]%Y(+1>@.KQ J^YZX!^2%ZCHAD*K_BY7JFYL5MUO2'*+]%'0[ZE>(*?SG'FX
MIH2 HCF@:"X46I6X4K]C^YWS' 95[Z!H#BB:"X56I;+<,\#F/8,WY#DS0F,N
M<$V>&Q[F.= Q72BT:HQ+Z8^->K2!:#$#-0ZUV:VN:7,7U!,7"JU*0"G8L5D>
M3U7F\54.PI8]0/.0Q+6Q!Q7LH&@.*)H+A59EH]3PN/_>U0-4^X.B.:!H+A1:
ME<IR-P";=P.FOA]HZI0,W?YPDLHUX]G)%+V9_Y:=^F*,ZL\,?4O]58O"S.Q,
M8R) ?Y2'0JL24>X78/-^@4YJB+YE7_($D&$G<68V;1Q_4.4/A9;'O[-W'#.B
M?)6=@Q7(8VDL\Y.'N];=6=MI=L+TH'UF7SKYB=D2)C_ >TOX*E#B)Z1+!:E?
M@5J(YV=B\QO)DNS0YR.3DD79Y9H2GW+=07V_9$QN;_0 NY/)DW\!4$L#!!0
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M"S#:[HZ$@0U5DQM:'"E0)L2+<D,9()]SC^TG2TWFT$QH679QR.G[/I9M0V_
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M1O "YPKT.L^9VDU0R.W("[V#X9ZO,F,-?CPLV0H7:+Z5<T4[OT9)>8Z%YK(
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M<&6 ]W/&Y&:C'JB&>_\W4$L#!!0    ( /TZ:59,I7<DPP,  -L1   9
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M^6!QPIS,7N%,LRQ)TA3;T?$XJ&",[5N:PD_8&Z8-&%@<B/1G>XU7&^^0Y_L
MJ^ES'8)EBG<BEBF^UX"$]PT861:N-A8'&%@5L-Z!^.$XT%-A3I) 53%MV!.,
M(UF&(="+X1Y-4V1W4OB$ZX,])4F296$$L+""),$0>!IQ!%, &C D29KWX-[[
M*%Z_I^+-__=&OP%02P,$%     @ _3II5I>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #].FE6?8(]XN<$  #^)@
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MQ?+"( D7_HRF;$:F=$$#CY'DEK$T,0!M - ^&R"YB#(#T@$@G3>$3%*]6;)
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MLNCO>6OJ[CV?#7^R7+T"4$L! A0#%     @ _3II5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #]
M.FE6RZ(G[NX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #].FE6F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /TZ:5:Z6>1)
M$ @  !,P   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #].FE6D&3U33$"  "M!0  &
M@(%3$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ _3II
M5D J,QY(!@  4QP  !@              ("!NA(  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( /TZ:5:8HIJ'+@0  "L3   8
M      " @3@9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #].FE6\608L]0$  !1$@  &               @(&<'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ _3II5M*PY-:> @  CP8  !@
M             ("!IB(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( /TZ:5;G..[#) \  %W0   8              " @7HE  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #].FE6!NGR\LX"  ",
M"   &               @('4-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ _3II5G848$&T"   M2D  !@              ("!V#<
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /TZ:59-<0:,
MT D  +<7   9              " @<)   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ _3II5GJ:#[B9(0  C6D  !D
M ("!R4H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #]
M.FE6P#35C)$,  #[(P  &0              @(&9;   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /TZ:58\$Y541@4  $\.   9
M          " @6%Y  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ _3II5A1L,H^I P  &0@  !D              ("!WGX  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #].FE6DSW[-Q4#  "M
M!@  &0              @(&^@@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( /TZ:5:YQHV@6@@  -L5   9              " @0J&
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ _3II5M']
MCQ<[#0  SRX  !D              ("!FXX  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " #].FE6Z2*"*1X0  !".P  &0
M    @($-G   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M /TZ:5;/[,4Q,A   $X[   9              " @6*L  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ _3II5@9MGOC7"@  DQP  !D
M             ("!R[P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #].FE65!XY*H0#  "5"   &0              @('9QP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /TZ:5:2C"QC: D
M !09   9              " @93+  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ _3II5M,"!,D' @  HP0  !D              ("!
M,]4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #].FE6
M0F:>37T?  !3:0  &0              @(%QUP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( /TZ:5:N_ T]N@0   0-   9
M      " @27W  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ _3II5G<B-T[T @  408  !D              ("!%OP  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #].FE6)Q,?5"P#  "\!@
M&0              @(%!_P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( /TZ:59%4D]-20,  %D'   9              " @:0" 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ _3II5EAOMB.Y
M @  T04  !D              ("!) 8! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #].FE6 %?&2X0$  #I"@  &0
M@($4"0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /TZ
M:59Y 8-2L04  *D-   9              " @<\- 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ _3II5AK3]J#. @  *P8  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( /TZ:5:BS1]9X@0  $X9   9
M  " @2XG 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M_3II5KC0  VG @  O@8  !D              ("!1RP! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #].FE6"=K=JG (  #&3@  &0
M            @($E+P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( /TZ:59\G/LJM0,  $T1   9              " @<PW 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ _3II5@O&,Z3G @
M0P@  !D              ("!N#L! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #].FE6F>)TU/D#  "@#@  &0              @('6
M/@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /TZ:59V
M)+.C P4  $<>   9              " @09# 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ _3II5KZ@A W[ @  Q0L  !D
M     ("!0$@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M" #].FE6)R6Y,FP"  #V!0  &0              @(%R2P$ >&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /TZ:5;B716'/PH  "UL   9
M              " @15. 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!
M A0#%     @ _3II5N>[@AS( @  &0<  !D              ("!BU@! 'AL
M+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #].FE6/:&7Z*H5
M  !H: $ &0              @(&*6P$ >&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;%!+ 0(4 Q0    ( /TZ:5:53B^>RP0  ',<   9              "
M@6MQ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ _3II
M5C/:(1[( @  1 @  !D              ("!;78! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #].FE6(".NEFP&  "E+   &0
M        @(%L>0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( /TZ:5:A9MT.6@,  'H/   9              " @0^  0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ _3II5J=&J%24!0  &A\
M !D              ("!H(,! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #].FE6/FE\:%H#   5"0  &0              @(%KB0$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /TZ:59R14\Y
M2@,  .@+   9              " @?R, 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ _3II5DRE=R3# P  VQ$  !D
M ("!?9 ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #]
M.FE67_,#[5<#  "U"@  &0              @(%WE $ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /TZ:5:N LH# @0  +<.   9
M          " @068 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#
M%     @ _3II5NHGKSAZ!   >1<  !D              ("!/IP! 'AL+W=O
M<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #].FE6B:06:#P#  #L
M$P  #0              @ 'OH $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M /TZ:5:7BKL<P    !,"   +              "  5:D 0!?<F5L<R\N<F5L
M<U!+ 0(4 Q0    ( /TZ:59]@CWBYP0  /XF   /              "  3^E
M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #].FE6678!^/4!   X(P
M&@              @ %3J@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #].FE6%\C,&]L!  #1(@  $P              @ & K $
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0P!# $P2  ",K@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>355</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CAPITALSTOCK</Role>
      <ShortName>CAPITAL STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTS</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/DEBT</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/WARRANTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/INCOMETAXES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - COLLABORATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails</Role>
      <ShortName>COLLABORATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - ACCRUED LIABILITIES - Components of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails</Role>
      <ShortName>ACCRUED LIABILITIES - Components of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails</Role>
      <ShortName>DEBT - Schedule of Long-Term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails</Role>
      <ShortName>DEBT - Schedule of Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - CAPITAL STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails</Role>
      <ShortName>CAPITAL STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/CAPITALSTOCK</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails</Role>
      <ShortName>WARRANTS - Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - WARRANTS - Stock Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails</Role>
      <ShortName>WARRANTS - Stock Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Balance by Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - INCOME TAXES - Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vrdn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:PropertyPlantAndEquipmentUsefulLife -  vrdn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="vrdn-20221231.htm">vrdn-20221231.htm</File>
    <File>ex23_1xfinalconsentx2022.htm</File>
    <File>exhibit45_descriptionofsec.htm</File>
    <File>fy202210kex211.htm</File>
    <File>fy202210kex311.htm</File>
    <File>fy202210kex312.htm</File>
    <File>fy202210kex321.htm</File>
    <File>vrdn-20221231.xsd</File>
    <File>vrdn-20221231_cal.xml</File>
    <File>vrdn-20221231_def.xml</File>
    <File>vrdn-20221231_lab.xml</File>
    <File>vrdn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vrdn-20221231_g1.jpg</File>
    <File>vrdn-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="665">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrdn-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 665,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 217,
   "dts": {
    "calculationLink": {
     "local": [
      "vrdn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrdn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vrdn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrdn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrdn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrdn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 533,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 10
   },
   "keyCustom": 62,
   "keyStandard": 293,
   "memberCustom": 24,
   "memberStandard": 33,
   "nsprefix": "vrdn",
   "nsuri": "http://www.viridiantherapeutics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.viridiantherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - COLLABORATION AGREEMENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS",
     "shortName": "COLLABORATION AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - ACCRUED LIABILITIES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.viridiantherapeutics.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - CAPITAL STOCK",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.viridiantherapeutics.com/role/CAPITALSTOCK",
     "shortName": "CAPITAL STOCK",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - WARRANTS",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.viridiantherapeutics.com/role/WARRANTS",
     "shortName": "WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.viridiantherapeutics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.viridiantherapeutics.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.viridiantherapeutics.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - WARRANTS (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSTables",
     "shortName": "WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.viridiantherapeutics.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - COLLABORATION AGREEMENTS (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
     "shortName": "COLLABORATION AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i87bf3ab4aa3946a18532afb870802102_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i03f92b6bed324e2ba85a9852abf1b187_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Components of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i369f8afef8e64303909112080068f0af_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i369f8afef8e64303909112080068f0af_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:AccruedOutsourcingClinicalandPreclinicalStudies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - ACCRUED LIABILITIES - Components of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails",
     "shortName": "ACCRUED LIABILITIES - Components of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:AccruedOutsourcingClinicalandPreclinicalStudies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - DEBT - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
     "shortName": "DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i5068b8f88948444a8959f2c27cf864e8_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i5068b8f88948444a8959f2c27cf864e8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
     "shortName": "DEBT - Schedule of Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i5068b8f88948444a8959f2c27cf864e8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:LesseeOperatingLeaseNumberOfRenewalTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewal_term",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:LesseeOperatingLeaseNumberOfRenewalTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewal_term",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:CapitalStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - CAPITAL STOCK (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
     "shortName": "CAPITAL STOCK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i9b4be6ccd9ad4885a999915b4b0caed6_D20211101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails",
     "shortName": "WARRANTS - Stock Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i369f8afef8e64303909112080068f0af_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - WARRANTS - Stock Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails",
     "shortName": "WARRANTS - Stock Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i369f8afef8e64303909112080068f0af_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plans (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
     "shortName": "SHARE-BASED COMPENSATION - Balance by Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i7b182c39f9074a4ab632a61c8c11e82f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE - Summary of Potential Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - INCOME TAXES - Effective Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails",
     "shortName": "INCOME TAXES - Effective Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i8f2764507e7e4eb3bc12c916d9987aa9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:TaxCreditCarryforwardLimitationsOnUseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ib148f603c63a4a409f28c278e3fd2772_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vrdn:TaxCreditCarryforwardLimitationsOnUseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i9cd71d9ebfdd4bfba2b7e378ef51bf10_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i25983ef470214368ab0eea4aa4373a8c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "i25983ef470214368ab0eea4aa4373a8c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrdn-20221231.htm",
      "contextRef": "ia72a543ca15a4f4a8d35701cc16ad4b6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in share)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r520",
      "r599",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r283",
      "r312",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r351",
      "r487",
      "r509",
      "r521",
      "r522",
      "r538",
      "r543",
      "r550",
      "r594",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r351",
      "r487",
      "r509",
      "r521",
      "r522",
      "r538",
      "r543",
      "r550",
      "r594",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r241",
      "r489",
      "r539",
      "r549",
      "r589",
      "r590",
      "r597",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r241",
      "r489",
      "r539",
      "r549",
      "r589",
      "r590",
      "r597",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r343",
      "r351",
      "r381",
      "r382",
      "r383",
      "r463",
      "r487",
      "r509",
      "r521",
      "r522",
      "r538",
      "r543",
      "r550",
      "r588",
      "r594",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r343",
      "r351",
      "r381",
      "r382",
      "r383",
      "r463",
      "r487",
      "r509",
      "r521",
      "r522",
      "r538",
      "r543",
      "r550",
      "r588",
      "r594",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r283",
      "r312",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion and amortization of premiums and discounts on available-for-sale securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued other professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68",
      "r152"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r158",
      "r506",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r26",
      "r116",
      "r452",
      "r510",
      "r511",
      "r565",
      "r566",
      "r567",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r575",
      "r576",
      "r577",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r103",
      "r104",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r302",
      "r444",
      "r536",
      "r537",
      "r570"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Non-cash interest expense and amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r140",
      "r154",
      "r183",
      "r226",
      "r235",
      "r239",
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r421",
      "r423",
      "r436",
      "r548",
      "r592",
      "r593",
      "r641"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r149",
      "r159",
      "r183",
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r421",
      "r423",
      "r436",
      "r548",
      "r592",
      "r593",
      "r641"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r65",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held-for-sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r245",
      "r259"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r61",
      "r244",
      "r259",
      "r502"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r59",
      "r259"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r50",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r44",
      "r49"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r122"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r203",
      "r204",
      "r206",
      "r208",
      "r215",
      "r216",
      "r252",
      "r271",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r310",
      "r311",
      "r314",
      "r318",
      "r325",
      "r436",
      "r523",
      "r561",
      "r571",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "verboseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "verboseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails",
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of securities called by each warrant or right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r133",
      "r145"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r265",
      "r266",
      "r516",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r575",
      "r576",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 200,000,000 shares authorized; 41,305,947 and 23,924,004 shares issued and outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r164",
      "r166",
      "r172",
      "r503",
      "r507"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r137",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r328",
      "r330",
      "r341"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Unbilled revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r328",
      "r329",
      "r341"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r328",
      "r329",
      "r341"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r181",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r303",
      "r304",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r129",
      "r131",
      "r139",
      "r187",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r445",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r131",
      "r139",
      "r307"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Gross proceeds",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r125",
      "r127",
      "r280",
      "r445",
      "r534",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r125",
      "r309",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r187",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r445",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r82",
      "r85",
      "r86",
      "r87",
      "r124",
      "r125",
      "r127",
      "r136",
      "r187",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r445",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt and Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "negatedTerseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains in available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Available-for-sale securities, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r126",
      "r595"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r4",
      "r5",
      "r130",
      "r138",
      "r403"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "IRC \u00a7 174 capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r628"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r628"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r110",
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r112",
      "r629"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r42",
      "r225"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r355",
      "r386",
      "r387",
      "r389",
      "r394",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Summary of Balances by Plan"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r60",
      "r542",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by corporation domiciled in United States of America (US).",
        "label": "Debt Security, Corporate, US [Member]",
        "terseLabel": "U.S. corporate paper and bonds",
        "verboseLabel": "U.S. corporate paper and bonds"
       }
      }
     },
     "localname": "DomesticCorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r173",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r203",
      "r206",
      "r207",
      "r208",
      "r212",
      "r428",
      "r429",
      "r504",
      "r508",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r173",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r206",
      "r207",
      "r208",
      "r212",
      "r428",
      "r429",
      "r504",
      "r508",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r184",
      "r398",
      "r413"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r626",
      "r630"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r626",
      "r630"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r626",
      "r630"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r626",
      "r630"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r626",
      "r630"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Federal and state tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized employee stock-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining weighted-average period for RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.",
        "label": "Employee Stock Ownership Plan (ESOP), Number of Allocated Shares",
        "terseLabel": "Number of shares available for issuance under ESPP (in shares)"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r147",
      "r168",
      "r169",
      "r170",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r214",
      "r253",
      "r327",
      "r390",
      "r391",
      "r392",
      "r410",
      "r411",
      "r427",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "verboseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r117",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r294",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r431",
      "r460",
      "r461",
      "r462",
      "r534",
      "r535",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r294",
      "r344",
      "r349",
      "r431",
      "r460",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r294",
      "r344",
      "r349",
      "r431",
      "r461",
      "r534",
      "r535",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r294",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r431",
      "r462",
      "r534",
      "r535",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r294",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r460",
      "r461",
      "r462",
      "r534",
      "r535",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r305",
      "r323",
      "r425",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r532",
      "r582",
      "r583",
      "r584",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r60",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by corporation not domiciled in United States of America (US).",
        "label": "Debt Security, Corporate, Non-US [Member]",
        "terseLabel": "International corporate bond holdings",
        "verboseLabel": "International corporate bond holdings"
       }
      }
     },
     "localname": "ForeignCorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r570",
      "r586",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss from disposition of equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r42",
      "r66",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r399",
      "r401",
      "r408",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r396",
      "r397",
      "r401",
      "r402",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Unbilled revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r488",
      "r569"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders\u2019 deficit"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedTerseLabel": "Interest and other expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r126",
      "r135",
      "r171",
      "r224",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r176",
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r251",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock under license agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Operating Lease Right-of-Use Assets and Liabilities"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Lease Payments under Noncancelable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r183",
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r422",
      "r423",
      "r424",
      "r436",
      "r530",
      "r592",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r132",
      "r143",
      "r548",
      "r573",
      "r585",
      "r635"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r150",
      "r183",
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r422",
      "r423",
      "r424",
      "r436",
      "r548",
      "r592",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r131",
      "r141",
      "r293",
      "r308",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r74",
      "r187",
      "r298"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r74",
      "r187",
      "r298"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r74",
      "r187",
      "r298"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r74",
      "r187",
      "r298"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r18",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r43",
      "r134",
      "r146",
      "r148",
      "r162",
      "r165",
      "r170",
      "r183",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r205",
      "r226",
      "r234",
      "r238",
      "r240",
      "r252",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r429",
      "r436",
      "r531",
      "r592"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements \u2013 To Be Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r226",
      "r234",
      "r238",
      "r240",
      "r531"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, short-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, liability, noncurrent, statement of financial position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization (reversal of amortization) expense relating to operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r450",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Lease remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r249"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "netLabel": "Change in unrealized loss on investments",
        "terseLabel": "Change in unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r33",
      "r58",
      "r174"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of Series B preferred stock",
        "verboseLabel": "Proceeds from the issuance of common stock, pursuant to 2022 and 2021 Public Offering and September 2022 and April 2021 ATM Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of Series B preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r58",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of machinery and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r101"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the issuance of common stock for cash under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r67",
      "r151"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r69",
      "r144",
      "r505",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r350",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r350",
      "r453",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development - related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and experimentation tax carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r88",
      "r142",
      "r513",
      "r515",
      "r548"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r147",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r253",
      "r390",
      "r391",
      "r392",
      "r410",
      "r411",
      "r427",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r222",
      "r223",
      "r233",
      "r236",
      "r237",
      "r241",
      "r242",
      "r243",
      "r339",
      "r340",
      "r489"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaboration revenue - related party",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r342",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Transaction value"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "verboseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r18",
      "r82",
      "r85",
      "r86",
      "r87",
      "r124",
      "r125",
      "r127",
      "r136",
      "r534",
      "r536",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Payments of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/PROPERTYANDEQUIPMENTComponentsofPropertyandEquipmentDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r352",
      "r354",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r155",
      "r156",
      "r157",
      "r215",
      "r310",
      "r311",
      "r312",
      "r314",
      "r318",
      "r323",
      "r325",
      "r538",
      "r561",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r562",
      "r563",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "netLabel": "Series A Convertible Preferred Stock",
        "terseLabel": "Series A Preferred Stock, as converted to shares of common stock",
        "verboseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r562",
      "r563",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "netLabel": "Series B Convertible Preferred Stock",
        "terseLabel": "Series B Preferred Stock, as converted to shares of common stock",
        "verboseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (up to)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized for plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term and Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value per option (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding (Aggregate Intrinsic Value)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "verboseLabel": "Vested (Aggregate Intrinsic Value)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "verboseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested or expected to vest (Aggregate Intrinsic Value)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Initial Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Subsequent Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r359",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term, in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable (Aggregate Intrinsic Value)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (Weighted Average Remaining Contractual Term)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (Weighted Average Remaining Contractual Term)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested (Weighted Average Remaining Contractual Term)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested or expected to vest (Weighted Average Remaining Contractual Term)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r50",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r183",
      "r203",
      "r204",
      "r206",
      "r208",
      "r215",
      "r216",
      "r252",
      "r271",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r310",
      "r311",
      "r314",
      "r318",
      "r325",
      "r436",
      "r523",
      "r561",
      "r571",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "verboseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r81",
      "r147",
      "r168",
      "r169",
      "r170",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r200",
      "r214",
      "r253",
      "r327",
      "r390",
      "r391",
      "r392",
      "r410",
      "r411",
      "r427",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r452",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r214",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r81",
      "r82",
      "r88",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon the conversion of convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock for cash under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock under license agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock for cash upon the exercise of stock options under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r22",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon the conversion of convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock for cash under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock under license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r88",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock for cash upon the exercise of stock options under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r57",
      "r548",
      "r573",
      "r585",
      "r635"
     ],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r182",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "CAPITAL STOCK",
        "verboseLabel": "WARRANTS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCK",
      "http://www.viridiantherapeutics.com/role/WARRANTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "verboseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r305",
      "r323",
      "r425",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r582",
      "r583",
      "r584",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r528",
      "r540",
      "r542",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities",
        "verboseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueMeasurementsDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized losses on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r395",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r217",
      "r218",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r202",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used to compute diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r201",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used to compute basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_A2008PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2008 Plan",
        "label": "2008 Plan [Member]",
        "terseLabel": "2008 Plan"
       }
      }
     },
     "localname": "A2008PlanMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_A2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Plan",
        "label": "2016 Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "A2016PlanMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_A2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Plan",
        "label": "2020 Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "A2020PlanMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_A2021PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Public Stock Offering",
        "label": "2021 Public Stock Offering [Member]",
        "terseLabel": "2021 Public Stock Offering"
       }
      }
     },
     "localname": "A2021PublicStockOfferingMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_A2022PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Public Stock Offering",
        "label": "2022 Public Stock Offering [Member]",
        "terseLabel": "2022 Public Stock Offering"
       }
      }
     },
     "localname": "A2022PublicStockOfferingMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_AccruedLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal Fees, Current",
        "label": "Accrued Legal Fees, Current",
        "terseLabel": "Accrued legal fees and expenses"
       }
      }
     },
     "localname": "AccruedLegalFeesCurrent",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_AccruedLiabilityofWarrantsonTemporaryEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liability of Warrants on Temporary Equity",
        "label": "Accrued Liability of Warrants on Temporary Equity",
        "terseLabel": "Value of liability-classified stock purchase warrants"
       }
      }
     },
     "localname": "AccruedLiabilityofWarrantsonTemporaryEquity",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_AccruedOutsourcingClinicalandPreclinicalStudies": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Outsourcing Clinical and Pre-clinical Studies",
        "label": "Accrued Outsourcing Clinical and Pre-clinical Studies",
        "terseLabel": "Accrued outsourced clinical trials and preclinical studies"
       }
      }
     },
     "localname": "AccruedOutsourcingClinicalandPreclinicalStudies",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_Amended2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2016 Plan",
        "label": "Amended 2016 Plan [Member]",
        "terseLabel": "Amended 2016 Plan"
       }
      }
     },
     "localname": "Amended2016PlanMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_AmortizationOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Stock Issuance Costs",
        "label": "Amortization Of Stock Issuance Costs",
        "terseLabel": "Amortization of public offering costs"
       }
      }
     },
     "localname": "AmortizationOfStockIssuanceCosts",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_AreaOfOfficeSpaceExpanded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Office Space Expanded",
        "label": "Area Of Office Space Expanded",
        "terseLabel": "Area of office space expanded"
       }
      }
     },
     "localname": "AreaOfOfficeSpaceExpanded",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vrdn_AreaOfOfficeSpaceExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Office Space Extension",
        "label": "Area Of Office Space Extension",
        "terseLabel": "Area of office space extension"
       }
      }
     },
     "localname": "AreaOfOfficeSpaceExtension",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vrdn_AreaOfOfficeSpaceTerminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Office Space Terminated",
        "label": "Area Of Office Space Terminated",
        "terseLabel": "Area of office space terminated"
       }
      }
     },
     "localname": "AreaOfOfficeSpaceTerminated",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vrdn_AspireStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aspire Stock Purchase Agreement [Member]",
        "label": "Aspire Stock Purchase Agreement [Member]",
        "terseLabel": "Aspire Stock Purchase Agreement"
       }
      }
     },
     "localname": "AspireStockPurchaseAgreementMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_AtthemarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market Offering [Member]",
        "label": "At-the-market Offering [Member]",
        "terseLabel": "ATM Agreement",
        "verboseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtthemarketOfferingMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "vrdn_CapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Stock, Shares Authorized",
        "label": "Capital Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CapitalStockSharesAuthorized",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Conversion, Percentage Of Ownership",
        "label": "Class of Warrant or Right, Conversion, Percentage Of Ownership",
        "terseLabel": "Beneficial ownership"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightConversionPercentageOfOwnership",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_ClassOfWarrantOrRightExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised in Period",
        "label": "Class of Warrant or Right, Exercised in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedInPeriod",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value",
        "label": "Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net",
        "verboseLabel": "Number of underlying shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_ClassofWarrantorRightActivityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Activity [Roll Forward]",
        "label": "Class of Warrant or Right, Activity [Roll Forward]",
        "terseLabel": "Number"
       }
      }
     },
     "localname": "ClassofWarrantorRightActivityRollForward",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrdn_ClassofWarrantorRightRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Remaining Term",
        "label": "Class of Warrant or Right, Remaining Term",
        "terseLabel": "Remaining contractual life"
       }
      }
     },
     "localname": "ClassofWarrantorRightRemainingTerm",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]",
        "label": "Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ClassofWarrantorRightWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]",
        "label": "Clinical Trials And Pre-clinical Study Accruals [Policy Text Block]",
        "terseLabel": "Clinical Trials and Preclinical Study Accruals"
       }
      }
     },
     "localname": "ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrdn_CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Potential Development Milestone Payment, Maximum",
        "label": "Collaboration Arrangement, Potential Development Milestone Payment, Maximum",
        "terseLabel": "Collaboration arrangement, potential development milestone payment, maximum"
       }
      }
     },
     "localname": "CollaborationArrangementPotentialDevelopmentMilestonePaymentMaximum",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Potential Milestone Payment, Maximum",
        "label": "Collaboration Arrangement, Potential Milestone Payment, Maximum",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementPotentialMilestonePaymentMaximum",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborationArrangementResearchLicenseAndSelectionRightsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Research License and Selection Rights, Term",
        "label": "Collaboration Arrangement, Research License and Selection Rights, Term",
        "terseLabel": "Collaboration arrangement, research license and selection rights, term"
       }
      }
     },
     "localname": "CollaborationArrangementResearchLicenseAndSelectionRightsTerm",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue [Member]",
        "label": "Collaboration Revenue [Member]",
        "verboseLabel": "Collaboration revenue - related party"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "Collaborative arrangement, milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Royalty Payments, Maximum",
        "label": "Collaborative Arrangement, Potential Royalty Payments, Maximum",
        "terseLabel": "Potential royalty payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialRoyaltyPaymentsMaximum",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborativeArrangementPotentialSpecialPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Special Payments, Maximum",
        "label": "Collaborative Arrangement, Potential Special Payments, Maximum",
        "terseLabel": "Collaborative arrangement, potential special payments, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialSpecialPaymentsMaximum",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborativeArrangementRightsAndLicensesFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Licenses Fee",
        "label": "Collaborative Arrangement, Rights And Licenses Fee",
        "terseLabel": "Collaborative arrangement, rights and licenses fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndLicensesFee",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborativeArrangementSharesIssuedForRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Shares Issued For Rights Granted",
        "label": "Collaborative Arrangement, Shares Issued For Rights Granted",
        "terseLabel": "Shares issued in exchange for rights granted (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementSharesIssuedForRightsGranted",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_CollaborativeArrangementUpfrontFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Fee Payment",
        "label": "Collaborative Arrangement, Upfront Fee Payment",
        "terseLabel": "Collaborative arrangement, upfront fee payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontFeePayment",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Value Of Shares Issued For Rights Granted",
        "label": "Collaborative Arrangement, Value Of Shares Issued For Rights Granted",
        "terseLabel": "Value of shares issued in exchange for rights granted"
       }
      }
     },
     "localname": "CollaborativeArrangementValueOfSharesIssuedForRightsGranted",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_CommitmentsandContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesLineItems",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrdn_CommitmentsandContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesTable",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrdn_CommonStockVoteperShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Vote per Share",
        "label": "Common Stock, Vote per Share",
        "terseLabel": "Common stock, vote per share"
       }
      }
     },
     "localname": "CommonStockVoteperShare",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrdn_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARESummaryofPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_DebtInstrumentFaceAmountFirstTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Face Amount, First Tranche",
        "label": "Debt Instrument, Face Amount, First Tranche",
        "terseLabel": "Debt instrument, face amount, first tranche"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmountFirstTranche",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DebtInstrumentFaceAmountFourthTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Face Amount, Fourth Tranche",
        "label": "Debt Instrument, Face Amount, Fourth Tranche",
        "terseLabel": "Debt instrument, face amount, fourth tranche"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmountFourthTranche",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DebtInstrumentFaceAmountSecondTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Face Amount, Second Tranche",
        "label": "Debt Instrument, Face Amount, Second Tranche",
        "terseLabel": "Debt instrument, face amount, second tranche"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmountSecondTranche",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DebtInstrumentFaceAmountThirdTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Face Amount, Third Tranche",
        "label": "Debt Instrument, Face Amount, Third Tranche",
        "terseLabel": "Debt instrument, face amount, third tranche"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmountThirdTranche",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DebtInstrumentFacilityFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Facility Fee",
        "label": "Debt Instrument, Facility Fee",
        "terseLabel": "Lenders facility fee"
       }
      }
     },
     "localname": "DebtInstrumentFacilityFee",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DebtInstrumentInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Maximum",
        "label": "Debt Instrument, Interest Rate, Maximum",
        "terseLabel": "Maximum interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateMaximum",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_DebtInstrumentNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Tranches",
        "label": "Debt Instrument, Number Of Tranches",
        "terseLabel": "Debt instrument, number of tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTranches",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrdn_DebtInstrumentOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Other Expenses",
        "label": "Debt Instrument, Other Expenses",
        "terseLabel": "Debt instrument other expenses"
       }
      }
     },
     "localname": "DebtInstrumentOtherExpenses",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DeferredTaxAssetValuationAllowancePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Valuation Allowance, Percent",
        "label": "Deferred Tax Asset, Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance percent"
       }
      }
     },
     "localname": "DeferredTaxAssetValuationAllowancePercent",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "terseLabel": "Net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Right-of-Use Asset, Net",
        "label": "Deferred Tax Assets, Operating Lease, Right-of-Use Asset, Net",
        "terseLabel": "Operating lease right-of-use asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAssetNet",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Start-up Costs and Amortized Costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Start-up Costs and Amortized Costs",
        "terseLabel": "Start-up costs and amortized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseStartUpCostsAndAmortizedCosts",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right-of-use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease Right-of-use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_DeferredTaxLiabilitiesUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Unrealized Gain (Loss)",
        "label": "Deferred Tax Liabilities, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized gains/losses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainLoss",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_EffectiveIncomeTaxRateReconciliationSection382LimitPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Section 382 Limit, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Section 382 Limit, Percent",
        "terseLabel": "Section 382 limit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSection382LimitPercent",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity-classified Warrants, Acquired October 2020",
        "label": "Equity-classified Warrants, Acquired October 2020 [Member]",
        "terseLabel": "Acquired October 2020"
       }
      }
     },
     "localname": "EquityClassifiedWarrantsAcquiredOctober2020Member",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity-classified Warrants, Issued February 2020 [Member]",
        "label": "Equity-classified Warrants, Issued February 2020 [Member]",
        "terseLabel": "Issued February 2020"
       }
      }
     },
     "localname": "EquityclassifiedWarrantsIssuedFebruary2020Member",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_EquityclassifiedWarrantsIssuedNovember2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity-classified Warrants, Issued November 2017 [Member]",
        "label": "Equity-classified Warrants, Issued November 2017 [Member]",
        "terseLabel": "Issued November 2017"
       }
      }
     },
     "localname": "EquityclassifiedWarrantsIssuedNovember2017Member",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_EquityclassifiedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity-classified Warrants [Member]",
        "label": "Equity-classified Warrants [Member]",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "EquityclassifiedWarrantsMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_FairmountFundsManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fairmount Funds Management",
        "label": "Fairmount Funds Management [Member]",
        "terseLabel": "Fairmount Funds Management"
       }
      }
     },
     "localname": "FairmountFundsManagementMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_GoingConcernPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going Concern [Policy Text Block]",
        "label": "Going Concern Policy [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrdn_HerculesTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Term Loan",
        "label": "Hercules Term Loan [Member]",
        "terseLabel": "Hercules Capital, Inc"
       }
      }
     },
     "localname": "HerculesTermLoanMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_ImmunoGenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImmunoGen, Inc",
        "label": "ImmunoGen, Inc [Member]",
        "terseLabel": "ImmunoGen, Inc"
       }
      }
     },
     "localname": "ImmunoGenIncMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_InducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grants",
        "label": "Inducement Grants [Member]",
        "terseLabel": "Inducement Awards"
       }
      }
     },
     "localname": "InducementGrantsMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "terseLabel": "Number of renewal terms (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability-Classified Warrants, Issued April 2017 [Member]",
        "label": "Liability-Classified Warrants, Issued April 2017 [Member]",
        "terseLabel": "Issued April 2017"
       }
      }
     },
     "localname": "LiabilityClassifiedWarrantsIssuedApril2017Member",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_OperatingLeaseAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Base Rent",
        "label": "Operating Lease, Annual Base Rent",
        "terseLabel": "Operating lease, annual base rent"
       }
      }
     },
     "localname": "OperatingLeaseAnnualBaseRent",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_OperatingLeasesOperatingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Operating Expense",
        "label": "Operating Leases, Operating Expense",
        "terseLabel": "Operating expenses of leases"
       }
      }
     },
     "localname": "OperatingLeasesOperatingExpense",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_ParagonTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paragon Therapeutics",
        "label": "Paragon Therapeutics [Member]",
        "terseLabel": "Paragon Therapeutics"
       }
      }
     },
     "localname": "ParagonTherapeuticsMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_PrincipalAmountTermFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Amount Term Fee",
        "label": "Principal Amount Term Fee",
        "terseLabel": "Principal amount fee term"
       }
      }
     },
     "localname": "PrincipalAmountTermFee",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vrdn_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Additional Trading Volume Available For Purchase, Percent",
        "label": "Sale Of Stock, Additional Trading Volume Available For Purchase, Percent",
        "terseLabel": "Additional trading volume available for purchase, percent"
       }
      }
     },
     "localname": "SaleOfStockAdditionalTradingVolumeAvailableForPurchasePercent",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_SaleOfStockAmountOfShareAuthorizedToBeSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Of Share Authorized To Be Sold",
        "label": "Sale Of Stock, Amount Of Share Authorized To Be Sold",
        "terseLabel": "Amount of shares authorized to be sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountOfShareAuthorizedToBeSold",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_SaleOfStockAmountOfSharesRequiredToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Of Shares Required To Be Purchased",
        "label": "Sale Of Stock, Amount Of Shares Required To Be Purchased",
        "terseLabel": "Amount of shares required to be purchased (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountOfSharesRequiredToBePurchased",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_SaleOfStockNumberOfConsecutiveDaysThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Consecutive Days Threshold",
        "label": "Sale Of Stock, Number Of Consecutive Days Threshold",
        "terseLabel": "Number of consecutive days threshold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfConsecutiveDaysThreshold",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Price Of Additional Share, Percent Of Next Business Days' Volume Weighted Average Price",
        "label": "Sale Of Stock, Price Of Additional Share, Percent Of Next Business Days' Volume Weighted Average Price",
        "terseLabel": "Price of additional share, percent of next business days' volume weighted average price"
       }
      }
     },
     "localname": "SaleOfStockPriceOfAdditionalSharePercentOfNextBusinessDaysVolumeWeightedAveragePrice",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Sale Price Calculations, Average Over Number Of Sale Prices",
        "label": "Sale Of Stock, Sale Price Calculations, Average Over Number Of Sale Prices",
        "terseLabel": "Average over number of lowest sale prices"
       }
      }
     },
     "localname": "SaleOfStockSalePriceCalculationsAverageOverNumberOfSalePrices",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrdn_SaleOfStockTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Term",
        "label": "Sale Of Stock, Term",
        "terseLabel": "Sale of stock, term"
       }
      }
     },
     "localname": "SaleOfStockTerm",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_SaleOfStockWeightedAverageSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted Average Share Price",
        "label": "Sale Of Stock, Weighted Average Share Price",
        "terseLabel": "Weighted-average share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAverageSharePrice",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds",
        "label": "Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds",
        "terseLabel": "Commission fee percent"
       }
      }
     },
     "localname": "SaleofStockCommissionFeePercentageofGrossSaleProceeds",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrdn_ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Plan Expiration Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Plan Expiration Period",
        "terseLabel": "Plan expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentPlanExpirationPeriod",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Stock purchase offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Shares",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Shares",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedShares",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Value",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Value",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedValue",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_TaxCreditCarryforwardLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Limitations On Use, Amount",
        "label": "Tax Credit Carryforward, Limitations On Use, Amount",
        "terseLabel": "Aggregate limitation on utilization of certain net operating losses and credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUseAmount",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_TaxCreditCarryforwardWriteOff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Write Off",
        "label": "Tax Credit Carryforward, Write Off",
        "terseLabel": "Tax credit write off"
       }
      }
     },
     "localname": "TaxCreditCarryforwardWriteOff",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrdn_ViridianMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viridian Merger",
        "label": "Viridian Merger [Member]",
        "terseLabel": "Viridian Merger"
       }
      }
     },
     "localname": "ViridianMergerMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_WarrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Policy",
        "label": "Warrants Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrdn_XencorIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor, Inc",
        "label": "Xencor, Inc [Member]",
        "terseLabel": "Xencor, Inc"
       }
      }
     },
     "localname": "XencorIncMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrdn_ZenasBioPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zenas BioPharma",
        "label": "Zenas BioPharma [Member]",
        "terseLabel": "Zenas BioPharma"
       }
      }
     },
     "localname": "ZenasBioPharmaMember",
     "nsuri": "http://www.viridiantherapeutics.com/20221231",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r555": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r556": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r557": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r558": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r559": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001590750-23-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001590750-23-000002-xbrl.zip
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M@DB5286+68;Y!A2+#3%!"E5IH4JRM4&NS8@64Y;#VWN9MP A9'DH\EW4K.3
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MTL==#JOCM-P_O]_U67UFR@_>X"=02P,$%     @ _3II5C04:BZ &   /*$
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M;$"_8W[^')_W2#@BR#X=&+VL5*:J"J!*$X11/H3O>P,%?'AR\#0>"Y< 6@!
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M,&ILB36 ]<W_'J1[KS+%= X&$2F>8Y6;^<K7HE?(/(DE[P-1HJX-,2R+E%:
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MR]] Y;:ATB81;C2A.P)!7Y.ML6H<J&(DK,Q5&Q"6%N-(Z.O9P.BNI)K&,FZ
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MV/G88-*D<4%I67PF W^ "N@1Z%Y;%_)2P<XK4-4]1_EZD*GM%8)*($%\?_?
M2]/0WM-U= 4=K>V+]E;.R140O;?=&:1%5.#%KMFF%&4#W"QIAXY;K5$>KBHF
M<D+M5M$[Y3N28I=F[!D "#761=S=E!$7T-$]ZB-+OB$DLW3_,&<INJQOVB9(
M%K$ ZHD[$Z6R[3E'443?F: (C4 I_\%BAP.5R!FFTXGAF5'\8+N#3:G8[8?D
MG:MS#4C9=S/4)RUSB5!1)T"J1@;H*ATR<X80$ZFBCSF,-H =35XSZ^VUQ4 \
M H%-P985F+0)AMTV!I%;R+4L=L9;'[#DBOHRN+IR[,'?A)ECB3C,D8.168OG
M3[_UJW!N-.O+<?OH&G?L<1LIJ#OSBJU00TUGFR&;I,;-3I4B=Q/LPCNZEAL7
M1),]UM^%KVGU8*LQLP1C<6JX[VT@-#85K<&*09TH]\UC/3"( D"8A7+G*\I<
MLG+-Q!5^#9U04!N)FWV%+@]<<L];HF3'#)V#-5OS/D7!S3Y5>1K+26+],'.P
M1VOL_NST*>D^=1+LJ!228QVFVM#O+=)OV\4-5&55!/A=2PDK6;NVK1AP+@@6
M'H3&OC<V$:Q$_9N:BD>)$3.E?*9VMYDM!PEJ'-1[7W"5Y-9R$TD@D&H6.LQR
M^,\SAF?/Q#Y"X=GNRX/ (F*J[+ +IAC-?J5 7ZO9T&KE?1.$O\]!^/MK@,26
M0JHRI+2;J?O<A@<=H1N-^BY"QS-535C (7\RN2\SU\65R:^\@M#OH+V:M6RT
MVKN (F;$CJ(,6=!PTTF4(YMJZUES#[*K]-1,[.U^&WKF.0'DV@0O:Z<;J-\V
MU",5EAOGLV^<NB /VS/!<=T&K*N ,EY?Z%@<KNG9*HO$:5\;/G _,*(/^M4<
MG!MMN8Y.;3J":X?GWP"U&"_/P29CM?)W.T07-ZQ)5^M/.%8%Z 0NO'H#_723
M2787",31@D3ILEX/'@]B!FL=6K8;22PHO9*<<S9I)+5KISZG))%L*Y) 1X3'
MT(ARP]@V+V&\8*=;99K)M(]-#R32=5W3?^=/'XE!U?F&_F])CU)2"?<;9"?V
M?&JPR=F$/1\A%,2_NMOM+!F@N0;B=EX;:TU"'T=+!&M'G/-93TF&M$[VCE.6
M^N9&[J4@1E:@$<8W&PO*28ISC,3>TR6-8Z7)N\QE'@A>?&8$]+C;-.]TZ3*;
M'^@RFX>Q]R^ZK"RZNL=S"I)D&[OQ+@1%Y!QKO<>M&Q@;O&+%,;E,@;R+G*X
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M#,@7M"^DL!/'&]8-ZU:=AZ1'6U@P"Z)S_-C7F?O"H2S']LQ@UAW/B;!98]X
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M<-+LB<N1TAJPKB$<9!0C"P8 R<@ILXGL? $V0%E6D<V%JSR]/5^ %14-D4F
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M,^UF'Y>-*$1!'67>I*PK4CP=8PX*UI"H%%D ]^1[]!V;]AO$K3P:,*M;KE]
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ME>++:5,.'? "8(+;B?!0*NQAB! U#M8;:U(,RAGC(Q!!<R&CU-@M0 7/[41
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MT^2A[= +IG2'JS!EX22TB^.*!<X29GF26-<*F6"M,,&*ZGPN&71 FCD27<I
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MCUZ8B<8PQ""*HL4<?'1OF(X^G<9+@G1$PLVEQI@]8\P&8VAII"#16ZZ9P1(
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M6LW#YI%O-]]NHD9K\W3OT\?.UOKJL$$^#/>^-FCC:.-P_Z,Z>T?VAWN?G&C
M_>:G#\.MUN'1_J?Z:7/]"X+_GZ5V]UN;9_LMGS>_MO/]SH<3__8C\W_^U=XG
M[1-[5)Q!7_#^^B;?>@O?;ZVBK=8'^'_]#+[9AN^TFV23;GWZJ[._H;Y"']AG
M82.F1H/J-$[4&&CXFJ$NU. ZQ]@%8A1]\0:CVG\J;7=!A3<WV&G:7(*N<0F[
ME4O&'#+NS,/VX'8^_:5ARB_95C?\^CT)LT6_7W2N"]G1 #!V'-Y?RCZ!;/OD
MD_U<OQ]!JE:[W8%I;X?CHNR_R #(=DP?6C_KOX[Y6?"U?CEX;E+7_/H%?58F
M[9GE5,U296M,2U73G(#\&:=(Y$)Q;A)K@R<I?KM+\&;!ZR-I \/8W%U]EVW7
MWV]MM[+WN]L[NZO-5M;:RL!ZML!$9IAF6]L9YK_X7[.MC:SU9SV[9%C/C>KJ
M6BO=QIJR&5K5^VF:C:+,^H<ABWD/('XV!/\KJQ889X\@2>\K1%H?X=2KHN3A
M2JT#WSQ,K]6\&=92WVJA^[Q$:]AH-3XK<&"\!7OEO,0U%AVM:6M\3:# &9,^
M,,T?5/6M#<H2Z+51,<D>T.&^-'N6Y/*"1FZLJ05J/2A"Q6J*:EZS G%D5"1$
M@*.T'ESE+8^T3W+;KFK$EUFBQ/6KV=QKE**\#R:7/PD7IFH '@.*E]"_ZG2&
MNX%#-.W>,T0.IY]!0DB@@M<T0[P&"@TPA!6Z9E+IND;62V/'R('=0 [98X+E
MVUD^FR5Z:6VO-G<V*WQR-W09S=$E_#*Z\,1 3/]<R+)1L"N+9=$9#;5?W*TZ
MO^G)S'1D*>N4]U+0%A!:.V3=P87)>$"M5:^BDQOPQ6;UP>>GE,X^2\RYDS;4
M(L/@SC#E:RIZ4TMGD7%E!4PE2<%>7*/IP-/O1A*^)31YYR#KE>[?+U*J\9PB
MGP_PRM'QP8O,M/MWW1HW.HFOXN.SWZYR<PJWGH2RGP-R&W^VZL'H]C@22Q Z
M/GOQ:B8BKNZEY3YN;F^N;ZXVD[[:7GU?WVUMKNV\S#:;:RMSKYY^J9\9UZ_$
M*RMB5H:#J@:^V\],+^L=!U?MLI7EW2SO]S)W:$KHZ]UQE]N&U3<6M,/X 5N4
M/I0U&%[;'/?"Z\D?O_F\=]PVP]=YM^ID]=(_81>,T H:!>_[)?S?3[X\OKU2
MW7K5]S?O,;4"+'SG;;2"_]$]O,(Y^X=O?J>S]VOV5341H\F ^4ZD^_<+>BZ?
MQ\:GX-9K<GR6X:OVI1WBC2D?S?:+&7/SHX/ED=E)2<D2,')5JU%E(,>I^K7"
M7_4X80@N9<3ZX;@L3E(["^IO;N3V[:[8^O3A#)[_LO]V#S??[J'FV^:7QMN_
M\L:1[S2_@GEJ;=*]HV:GN;XZ?N<C?(MW]UL%WU^O@VG;_K)_M(OVCSZ@/?+A
M=*^S.6P2&/V1X]!&WB![J+&A3M^U5ON-'73VK@7?.*JCSP(93!CV-:XUJC&,
M0DT1'&O"R,")<,B%D!S6MCDU9?BVI9M(RA2%X)%U-KH9@7^ 03U'R6Z9L\UQ
M*GRT4&R!T>5CB^SF59&-.AU/&6/-&HYK+&UFJ82,-8E"--YX(@)[\8;)&L9*
M$G$CNG2+T$[7A/6+XUES^1UHK#(I&;B,!?B,979TJ:PEP;/\LOFI'BL/3#?_
M6OW^]8>5'4J3]6*:*F1^9W9S97ME9R4;EU27V55ASYK%RFWS5_'=JPJ,_@"(
MOZU8Y#GJU%7OR]#KC?_U#CJ %U*?_E3*GW^6(B :F*M9AF0M'6=7LTCAFE(L
M(&2,%YB_> .3F*W!/"66R';Z90C]E]G.( =]P- M$?C'HMX:_+E5MHK3Q82O
M/T.[^NGGR-)^FAKFB=M08Q&3FE8&U=*QI3XX&VV@J?ZGW3\TG=D1J;(;6^5[
M<#7 1CRW0#U0ZNMG(1&A08>:X^ M,!9 P+P)-4*8DHIH#;#DQ9O&ZLVLU2/1
MZ'T![F![/S\>^8K/BD+-KU_P9ZN#HR+A0AQ EARA-2LCK3E*G"<&&6)2U)(P
M_G,1RYG@BS&1$TH[+D$&\V/3SL)9<-6R#;@,4"/TOENQ=$O^<:;CVCX/"/Z?
M?X'?+7_K9?W0#L>'17<2\7^98&E[D&!B!BZX 0GRX?5,\TX/66Z0!!I&^0R%
M&-0L^FQ\D )[7Q/"V%0_96KIB->:EB;M!"0YPA;$06#YZW4A?O#44+44X'UB
MS05VWG^*/OBSY\I9DDCCN:@QJ64-:&1K@;N0CE7R2(+S321)CCFZMYZ=4_5T
ML1QNG+H(9?#9\:#L#5(.HU]D\$1R\,9)9O*+_36IZ)21777]U_<9+[]CO N3
MUZ!R!7$Y]0P$(2M<33^Q4?563R.Q,:9)BE.\QL?]K%>T<Y\EIOQM?"N1]]J=
M;P0\1I2?EU#PJ, B[[>KQ%TP[C"KCL6Y1USX.4Q,:2I LC/LV*+]RR7@]3/3
M4HZ^\#2GK#G. 5>L%,[<H>D>P(5N=GJ8PY4+_7IE*N\G@V--=_O,/64^?$"T
M,[9]0TQLI086$NV,4A5[G?U\[^L?1WM'NV?P+FNN[Z:^=K8^[>)F9X\WO^Z=
M-K[N?P'T<RU5<0SM0+_?-O-FJPY(Z0 U6Q_SK;=[?+^U2_:/OM#FT>K79N<#
M;VY 'V]D%[7FE'M3HYZ!2VHLKED4:$UA(K!!!*E@1I5.( ?5 ON7V?\"0XRS
M8U-F)Z8]"*F<*^L=?BOY^%V5LQ2/Z8O'V *,#,!2-NXA&_6KLH$\49QS7[.4
M@&Q0(FI "E(CE"(G-3=P_\6;C]OKS<=G_"=MB!_!9M3'YCW9_)ME*\GX+WS%
MRN/)S;7T-PB-\-'A&I><U9ASJ*:T ,/BB)/I9"YF*0!4\$";IN?-?T=V)4N+
M&D,_>_=N[9OB].V,Y,UJX4N.+%DHQ[UWS7$_N.*X9\VB&^X9K9C1$#>[/F67
M0V:'F3L,0.).6K>:CP9QJ=(R[V4F.PWM=NU+MSB%?@;3@]%YN-$;I/BJZ64^
MQ+P[*L3<'K132I!/IN/25,+,K&1[\,=X/<+#YS8^0;?_DWJ],^YT=1+R<XN\
M-;]^(9^#( Y+HFLZIJ556-N:%E+6G Y&$(F5BQB\K.+.95,/M1KY=O8\F^.E
M4#\O4-VB#U?^.\B36@%M4JU0**OE3;W;XH-I_6Q17ORJUM%>Z)M'EJJ/17O0
M[9NR6N90]IZ9-$$?SCYS*Z7'DM:"I( ^N00#2@%]*H40IAA)QM%2FJ8O3:>'
MH2H]NR92O^!?LT.P0TF.?&;:[7-ANBQE-HP?@#:O"M85@;IDL29 - E9NIW6
M=&4>[G8/JD>/R^!"%<G#)*O6[_:R7Z ]@*Q9;^ .P?,NTI*$R:*J_J'I7^_[
MJ>G=U 75R^,Q_ HFMNNS7\AXZ5D:J 7T"P_9(QA&!4?2\_!FZLJXL;1VLE?U
MI.JIZ?4SC3)OAKV51UH%-5[[/%JVF9S=OND/GJ&Z()^]]LIY%FL!*9/J=&C-
M$&)K1"GO.4<\4/OB#2CQVY.2L]8:"[.1RY0&_DC5 7<$NHL+2_ZTM7929*##
M.GF_#ZHOM$&7E44WQ3G:PRR<A'*8;28GT+BJ2&7=]$VV,4)*5Y3Z11N7H5-R
M1$9,-/9&ML/!H&TNO+:=6BO[)?TI?R.4K)S[+'FUDNPXK22[2]>/&IB2PA]U
M_UR%A]ZO*P^/X2Y-;)K7L:I^9KH9'"/Z601OG $HIZFC-88TH#AB: U)KG&4
M-#(=;]7-,])-,]7*V?/13E7<HPU#"9EQ#K13:9**21*:@A[=6Z^"9]>MW7JC
MUP&U!E\I)V@(A+H#DS!\F0 H- > +4W;0790%J?]P\GM%<"CH>I;%62IUNA7
M=7RIXHW ,._H874;_S9Y[+L/W-V_R8,)A(X?OJ.ODR<G82"<(,X$5E_&TG>O
M/+Z[LN6"=Q:FM(7(%8S%]$M;Y KH^^F7MJ 50?C4F\7P(E<S6 K<R;UOAZL+
M?L9-C)(W%,TB^EJQTKO;I?:A%H2>3\5L%H2.=Y^9]HK0RP2>S=!6GRT!GX^H
M/LIF,>4:\-!!40YO27=6#U7<Y<8/+73F<ZO5/MKZM-UIMKX,FT?MH^;;!,P/
M#[<^-8:-SD:GL=[\TCQR ,[=C86_\ Q/"X:W6IL$_D;[GW:'6V_K?._K)CRS
M=PK])$WH9Q/?4DUCTH)>SDP-(+ZJ,<-134O%:USYZ$P40C.6W.]; -QC+=R?
MO9B+)ZFG=^X"MT^2D ^NL:KI_&/0@R_W>D]J(]_'5E&-:\492# <#*I1$VF-
M.:EKADM?0XIXQFRDR/GO;@3\(_;Y!];83W\Y_DR%I'Z["_N VN])JH+)-+ZM
M9G%M-(E/:XO.1]4)PQLZ(2""+?>RYBT#G1 LK6GM8BH'UI9JZ@CA=V[Q^>/%
M6;>48LTX:A>_$1U+JSOO67:1L@U5C@% 7:J_Z!?9H#>*K,%01SMWW[(-9E%6
MWVH/T\=/<_@T?#;KPMB*A"=.\EX%$KNFZW+33BY]VG(K/9S.WO&F]+TL[;&5
M^]N7?F68_F)^O35(]OU(Z[7#88Z+4>=?EZ%='11_X[B8BZA9%0!#%Z\8VRO:
M@_[-5[YWPLSHGX?EA7H\"#5;!O.E9F(_E*]-^]0,>VF/Q <[VN8?1IQ!HT4R
M/Q'G2Q4,8Z2:UK>DL*OI]T-O= 1?8IVTV2'T#28Z)?G/ESZ;7@_P6+HT8:<0
M8ZAR/-WQXN_T9IY2/UW@U60-RJ*=%6"Q+K'P!4@>@%!<5!TQQ"ZM3]PQI370
M;&WKK!V&58'$+YAGNRL[Z809241:S/AK&OC%*,=5E+8-INB2H,2\[(PR9<?P
M;9,> MFJR@M]U6,S\'E_W*^5F29G']">;KI8KJ:!%N7J!;DWVN;@:9G3GRJE
M&'Z640F*A*M12<&+)U'4%(NN%@@7S 1C'0_?-X=/.&75.PSM]L0^9K_<K,Z=
MU"Q?RLV ]/ZZDE55A _O/*;^/4F@^%.):/Z9$220YKZF'$U[N5-<TSZB&B'2
M24FH5/0;>[FG6L/9YJ,71JC2X@9S< ""DR2K,UK9,%HM-Y:'DZ(R3,GTIH3N
M^*<;+;3K50LB@(NK0L(JX1M3Z1TTUILT<"&4+S-K$D0<'"?;#;=<&R!7@H>F
MG8I*<A=NOG1NTJ]\$O[X:] =RR]%HV,NJOK[D6E,=K.;75JZL6:.\SY8]-'B
MC9=5Y<G_&@OX1E7] <\/NOE(O <]_^*JO%-J$8U"$10%LP$;[B)X(II$'P(*
M;G1,)P)]_ *4C,L[(+K_?E'C-X7^?67T-]J%N79^0W?0J?FB7QN_#DXV>,[P
MJGA>&@#:/P -X*7BQHL:YSB%?P('V\9<C6OI/5@W[KU_\882O7*^!=&$C.-Z
M.9"6-OQ:R:K#F2MVO)5KQZNHK^[_4U8,[_,2 %\Q^C%Y%+RA7K76NLB*TVXO
MP^A_)XS6*<IS[BT&_<KCN2DI!KY0%:R&\:G2R1)5>*^J>1JUG1#M,%5S 6MU
MSDN[+B1K!1@[3[8,4"0X#V:RZ>3Y$\G?Z@]ZD_+Z;G" >4T)ZB-+F_ZD38!Z
M::Q76XCGNUF";P;.$'QHX?39:D7G1CK_=ZP;*M4 _TP#"]EI^L>=8E\M#NY=
MDWQFO;<*61N<9)1Z:Z@V!@OJ'4UL6$D^1?#?RY*_V=RXI0KXXOCO$5-N73#*
M_70!>EZZX&OC:^/T,\-4J C"+SQF-2:<JBD.:$!BHIRF.& N7KQAY*72\J7F
M^(9"&*WZOL4BW6%<+JCR70FX?0$?GJ<5?.M;:[N->K.UDPXZV-I^O[6]F@Z=
M_6,OVZYOU+?KS;7Z?79MFZU@/\+I2KV+/>.#_V,(;8.RZ+K0@@_]T0;&>&:R
M!WV@GS4+C#BB:])& G:8FIK!%M6LE5Q@9Z6T[D460#T=)W9)R:XW[U/,9%R:
M=X>\30KX3A+N*\Z&E<6J0CCGRS225@7#FX[)S#HA5+ 3&JQ$^;!H>S"5V2_I
MP7$A7O7\^ZJQG4ECXRJ\7]-V=Y?V9 :;FJP!F%XPZN6$SLD4OS=E/]O<W#PO
M?QZ=TYEMG\>@-D!+9^G4U^1Y5JV.W%*_4L'-VWJ1G0(4N5AR4T5.4\=3@.CR
M$IN$,LZCGI<.[4DO0-] $*HU*]^8UIL',%X_(&Z$E%?N'0UXC+#JO&T12>Z.
M[=[_%'/Y8C[BP?.RA_5BG+US>]\WF^OUOV\YU?EQJV^U7E&<_I/B6[U"]/2K
M625?$>3NV_^X2!:O@.LWS2+91\OLW[Y%R4RSWN]!Y:0]\W]H*S#COAR4Q:#K
M:^-N.A="C-_:G66&Z?X;,CL:^.IV*]N\SP8WWQOM/7CBSC;NW.D&7=KLYLH'
M?I@VL?K//Z;-MPK18GPPSASU#]S;\1D9KZL$6WH*^F3FIB_989E<C']]W]YC
M<$$W6_5&AD'6S/W+(A^"H+?6#:<S\NZ6Q26I?XS4?^SN;#;K.SMS0^L?P$I+
M6O\8K?D=1'YL,[I4U5.BJ9ZHZM6?U=4_3]&EKGYP6F]O[OPGVUA=:VUM_ZR^
MGAZ]E_KZP>A-U+04]A);SP51"9DH[#^6X/H9T'JWN5W?V7KWL;Z>[;16-S:R
MM:U&E<&:&^(OM?>#$9]/37LOX?9\$)6/M3=9HNUG0.KWVUOOZ]NMS?H2:S\#
M:D]/6R^Q]GP058VU-5U"[6= ZG?UMZOO,M#9:_7Z^F;S[1)B/P.B<[V$V$^*
MJ!2/E39;0NQG0.K&9K.>[:QNU%M[V?KFSMJ[K9W=[27>?@ZD_Y[JOE:WB7DE
M=__0>O^CRI>';N/Y%"]-I7II/-RL^K>>FW'?M>_6Y9W.IZR]YK Z[Y;Q+OWF
M!57.<@S!^-)O?@:D;JQN_Z?>RC:VMK/M^MO-G=;V:K,U7H>Q4^6KMII9_</N
M9FOO)3SQKEIRM=/:6OO/GUOOUNO;66.UU:IO[V2KS?5L<V=G%RZ]W]U>^W-U
MI[Z3;6V,W\UVZFN[VYM3B*8N'?,%X"J!EH[YDR(J0V.K():.^3,@-3CA]>V/
M]?6YH?525S\8K:>GJY<(?CZ(2L>Z6BX1_#,@=6.UN?JVGLK*SF%[BJ7N[NQL
M G1/L!P>>+>WLUG!\8W-YFIS;7/U'6#[YCH \O$SH/%WW[6J1U+9PVJZL83J
MSX!]EE#]B1&53\K4Y')5R'.@]8?=U69KLP4:^V.]4N5PX=WD]Z6L6K;ZQ]9N
M*QL'?-):DKGACJ5Z?S#N$'*)[I\642=U;6J)[I\!J2_P^@ZH]/IH_[.DY7=V
MW[]_5_U>W=[+UE=;JW/##DMU_F#L,#UUOD3K<T%4,:EXTTNP_@Q(O?;G:O-M
M/>U@62EQ@.>K;[?K8[7^:;/U9[:ZMK:U"TH]74BQF='/S>;;ZH4+<W"![.>&
M;Y9Z_\'X9@GCGQI1V43O_W249HGC%X#6:UO-UO;6NQ%VKY:IK$^AU'F)V1>
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MX]'9T,[#27@Y'MCD<L<,KU\ZS=OMZ]<"$+ #/;A^/<U.WAW<N)[&[_+C6]Z
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MSC[<+. /,\KN<F-@&?X>O5"B<Q\@LM/N_,'%L@=?.3U&_E<OO^^[^>IOOID
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M<M1O8HER@M&)'-$A2\3O+FO=CXS7-U(K.G0,M%?[6C-9($UOJ(8SR[THH5#
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M[W\KY!91@-V#YW\!&??%?5[UXTS+/?D7)[)[V^M_ &F9XR#/G"'O3JK%+"H
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MT$S9-V?/NU3074L#T@8D7I&EH$YA:&A<SP\.1HA]3%%J*-1GY;Q<SS@-^P6
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MD@1O-.#M)R?)(#\Z4CY3GC>;K#,(;]^JC!2XC1<U62\,*X!1V(XV&4*I -.
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M02_CB(00$#)B/L29^3RS*"##L=N 9H;O?S,'7I/VO0/^$0Q*!;PQHV,0Z!$
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MZ%HR\<H@F"V)8U-&8U:F ]L& +H&'20D;/?)C$:Q))<$SL)-*D>GY.TCZI1
M%])TR>3HA]44OIO&_0N-1X9NG8CU(V()IVDJLM(Z2X+ZG6SFFHP'&@Y[!MV6
MM7VJ-Q]L$U(C17:$K8NF:>.UQ$&3!,OR')+748ND.>(S0]^5^_*IVRA>^<1[
MEHOWF-?F9Y(/<SQYVM16"R- BWS<T]ZL+6@2I]JKPPF5S_%3X_,*V(O#*;8
MY_3(#NB$0&?J]6+HC)LEX.(S0 /M"7PZS/5F+R43(TXRGUE$4OYP>ZT%\N;%
MI; N+(4KH..P^<JX5OD;5I<[*S:D+P_/<CRTB7?9 AO:!;'6TGOIJO)ET4-&
M9EF?;RY223#RFP)CT;<++Y,G,QMAP7'\Y?0&+&Z?DPX'C;0O3\.KB'V-'"8#
M"4-CUG^RW!+XD)]E6]6HZ%/ (P" ALNW:,H.@2 $CL^;/-:"H$S56-3DJA2
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M^H=RD2A9J_%:&3)#8(Q6O.&'JI]]"89&O]@GQ2.4&]#2-1T=?0$:D9G7WM%
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M5FVOOF."NMIA[P49+KM-CA?/>SXK4B*/F"/3:' ONB3AT$DA0K\E7RAT3B?
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M-G4 :W[(B(\GSP3V /+KD],C?JK5P2 YZJX:K[M'<Q&KXO'*U5215>!/ JQ
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MY;P[CIA@DQ W%((/5N\AQ39H ]\;9Q8]7;.-S(1;8G9\_^SPC)62+I_W;;<
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M6LT!6.]1GNQ"P8U2QINHOF^MJC^<#,;=34;GW>RBD_/-QI9/O<J4%",)"*?
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MD]_Y^O2??WK[P_,_._BW>44B@(L.9HUWN=CIN"TD]24S5=A*%"GES)Q[DRO
M;7+?9?KU8+BJ68=$/H9N)5_3?W&YJ4HRA>$0PQE/$7S#Q21NYM($;N(NIBB!
M2$NH28^J@VBJ/IG45D=%K#WW*<O"P7\OI4DYJ19K5UWL9!:Z=07!\M%!G+<K
MIJ5&N)'9#0R>7H"L[;+<K,U/&+_LZ>('S5O'-/$!GX-S%YF:F&=\2[V"(N<6
MK+DA%,E.36R&?_V!7)CH[\7#%_O(#F:_+NIU0A.+A",'R*7G0[4ZH30D="JS
MS=E^!D@AVOKSG]_@C:IAV$R.=W[_]) /NS <O9<D'5$E@QF+ -PV) :D[70I
M5/>;55T?O+%+>9AD2F\XW1Z.IJ92\+@TBOOV*2%REF[UN4DUO\[FZ*%[#?ES
M]@<JGJ,]AM_4,GOB!7-'BF.M^?'M\T+7/5,WX-SH)6"WPZ:CF["N3_"\] )4
MX41Z/GR-CIU^J'9P&=]5U2YSL=S! -M8*265J@_MFS7I9R(1U?H:,E*$CEC"
M$D+C_?M&3JHO/RM-3?='.2C?=A3\ ^C(-9=@^Q_GA"<L&,[[<,?ZSCF1OXY+
MA"A2#X)1O=C5VV$W;@PK*B6S0EG\K<!>B *)8B&1!-P:UH0,^MCFJ@6=[EMQ
M5#AW'GQ!L9XC_P&YJ>>OSK1^>BUYD59"V6EBXXF<9!7SY\)YTY'U1IJ;_=E.
M.;2@1[[3[T?[BO)9,1\2A@(&\L$;H7SH(O[4:R+3V#[P-SB0=_7N/F^>EH6:
M,L!+H6@&&[I :Y A":MRR=6+"$3J,"Y"PD()1M8"5>RQ2P4PA: "FE*Y]BBQ
M 0XA5 3('.)",).3"_41M@U+L0I6 B7]M>]@3HKAR$)2_-Z2WV8*[=A*.T&3
M<Q@V%R;! J6%=X(ED;I[A+XER)MUN]QK2;FWM!%[N0:K3W3K/1]-)AJK+J@T
MP"Z[->&,X!9,!T^79>?J6%[VY>4OC^7E^X\:TH=Z C.-)@X&L&5R'%YOSRFO
M;XU/4X#*>=W."&\D3-9<AYG+*RY&B45IP9#>D"1]JGK#4BG21W_H!]$!#/3S
M>,@'ZZ$&N78->T\*WUQ&_=DPHIQK#$LXX2SMI>N6K4UX[<MT +W[48/XM9LC
MNV2$>M:0';":@AQ^?J9&NT].%YCJ7H,X9U:995S]_OQ2&V*Z1&XWSHWGVL'8
M>O(HD#6MFK""-MH0>!"PQ1JH3%'&]PV#RK/55><X>=MK'NJTDAG!DY80!_G;
M:_Q*JXI\+I<;&@%MPN)BM*4 ZN:RW! J+?BWA,8JF)9VPY]M*5B6@G;=_!V3
M(U$^<UFMJ\KA+'<SW2(: /67P#,'A[;<5!EDUV($[7I30]%VD'7+"70&1D=X
MVM_WU'0FD_B\;2XZK5W20@XO H? M1&7R& 9:NM,<8;7E4@2RBT4:.K2%.Z"
M& 1*OG&I5=85K4LER]P/Z+M\E*;CI6'.U750SRK!!3*-'F=]VATME+YN1$>1
MAL*9G(2_>1_>N"1:EO+B@M0-!\< AXFQFH_5LF,;'%>QG_T[ ,7KNJ>E!F:#
M<#/:\,91(&OK?+^ZJ(9%S]SZ@L&/&^A[_O-SL?S261/LXE.8FCYYM$F@%";[
M+-B[#?W@\P4Z#E;2>FKL[,DXQC53:!/<%OQ:C5Y2P:O/GGS^)+JL#GN]1M\@
MV3.*S_I]6,]-K*Z1-K+$;'8IDB.$A?S<HCFA;'>+6_)C) %9OJN@VZW;:40W
MB6&K85S#(M,1C"/W31[:H[GJ:+8ZAFU\EB:R9?7\7CI(<$Y+_T48^I-V?4+V
M ZDUJO/UV@[@#23XODP'#MTY$Z,9[OZ*ULL+<TSLFM9HBR']\LF_TU6^#O]#
M7:!-==$.+%E#_@$#0!U@'K@?-;1M),)CM%NP5:A,KHSPJN[B UR4.V&9*,9R
M%)$9,;ZH 4O:_2 @ ;DQ2V-H*)X"5>2U'ZEM^CF$H*WH]_)1T".W+C((%85^
M]/6J&7MWUL]A%'"2/K7&P701]2#(P Q'T3%NJN:RK'BB41:5LSCL8*DN<WHF
MU0VEL%U2)-I0=<ZF,9S)*;D8+;_'G) MA:_L$J'_A8V'8N*P]IB2UC?\L97E
M=@WUVIUVG&]ECKU8_$7!1\3Q4]3*R/.6^-_AW'6OI0%!](H4B"4>N;*R)!DM
M.+0D"O_TVP+8*#V02CBLS(9".7XDZIWY,6Y,XAP2,D93A]OWG-052@FNHF'S
M?*\C*?GUY*)B579\1>UE4_\C+,&-=N)+O,%8GS#(T#_H319$>TCJ]UI\I+3:
MI@R&6V[/(XHE)7T3/[RG^UH>^'LE1;!'?S$R1 3/U2J%!3V565Y>J-P[@24U
M.%JUDB"/C684[II,?/I(+<]?VX'.8R,2H.'^Z?59H?)D87*2HW[4\VPI*R8C
MSH9%?.!+E949+!#D$DS9!:2Q(A"\9 $-,FU/]&*M08N]7WG$Q6[?7ZK2WWCO
M^UN(+8G\RG/69(*"9(-AHG*_FLV@'WR@V7BDJ>3GZA;0(+SV[_G 7V=.("/F
M;_>-V,/A1O=#:6'4TK]W.K^1'YD0<*.(,\SV%/SL0+QA<PBOHR<%59Z)Q1N$
MI7II99JLUT933L!AXH<NA'1K*+2!&*1TV+!\)]3@C4==(LF$37;:UJ" -T,'
M"5K(@X3<^L]F%*0>R"Q!"C*6759>I%"[MKL(X?E_*11&X66@/>%,O1MX'H?F
MACNLDM?+O@X11"\E$Q,%[*\O*W976N'A%6@CL"X3?I[1V+MQ1L[>K9'@"NWY
MXW2U:/,= L?5@CM!5A4WA=(Y22VC0 2@9=05^)MP^C<UERJHY?\FEK;R"_.
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M6 FY>UJ'G[AO@!L"VW%"322I*,>(FA[GQ<&01"/B(8>^..Q$@4SAC7Z0:2E
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M2)?'N WNR*OT(.9L23*WE?C*\PQ&=":*'%\Y6+-0N:T$F )336$L_8O D>Y
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M_KMXF+]4H\15$=RV8'_H@$3*0O\%WTR2)X6NSL(M3[<*UUVY9\M4GE,%.YR
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MBI@W&(3@[9NS. +XQN"_<#7KB)L6"I7>:%/@/8'9.U?.'CT_[[IWX)W":C"
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M>W1\(-@/'5>6HYN K7)8P'&6TT.I,$>2LXS)3J:J/GA1S03[7LNYA%62G50
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M)*7'WB'PR &%L^-">5#1BZ3;.^YA=CU0V@]MFA[""7*<OT^ST:D>U-6$_EJ
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M>TO)3[*:BY>T9BJ[\M_>O'K[TJXM!GIEO&E(SK *F&KWZ@D/0H+> Y+LQ7A
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M)I=0DYQ<EZA*+B7SE>U7IKU,68&M00YB[XVL[9XAGFKJI' <_J @LJG'$FR
MG@^^A@-UX'6[J5N%P_]_]MZTN6TD:Q?\*XR>Z@E7!*06M7BIBCL1*B]5>J^W
ML5S=T_-E B1 "6428 .@9/:OGSQKGL3"1=Y(6Q-WWG:)))#+R9-G?9Y*'N=D
M0CSV>CEGG<N93+^>)@0O.)8U*#:JYL9T.50^< &Q>R"6H=(#$5!-AMXYIA#<
M@P*P3BI&BUK=FQ0\_QQ=<%(4;MD6!''GFPDE.^O3MGMJC;U@9\U:WW:;?;,M
M.7J\OK ,]93"_IC5Q]HN=.->85'*\&$$1LN) >.*!U=X0Y5$\8E)%G-5,6HB
MG(^6.0/J"5Y9H,<Z<M<&B4+S2PPI6@5 718.RC (-_P-@2<55%+?M,&.M>?Q
M@Y;B+AM>W#4M)4H4]@5+?O@1_-/[E+U-V9_=I^RW7S7?ZVRU/]SM3@1GB^D5
MVH--4A*^.(0&G(BTW($@:\Q=5>AQUS[NW'$<(^%L4]!=9T: +8U7N3EEQJ%O
MXECV/A8M8$$A9@LS*XF0$^OU;%-<DB4"OY92,Q=WP2W<6*8-;73H7C(N2KAH
ML)VAI@(F(C8=3],8\K!Q[<-.'%_J4DAXVJEY@"P@#=PT^P8/!W\X/^4FY;DT
M'X13!FM?O*Q=CCE$:/ TR-,_2S\B!M2^FW;$\]Q4KZH_4Q/C6"*^5.O^HLL&
M&[W<(G1<I8T  #;$9WPQ NRF>/AX8 [JX@ .#/OW@VI9U="LA9L\SA*?SZ86
MMNI:TI6(#@;WEPC.[37D(&X+C[O9)5"E5&:X^0'P;TIX95SFAK:#R&@5XWF]
MH6N="WJYA-Y"I"%YK[O _PL+2413;ORWX#^SYL'L/)7WR>-84S"I<-PQV$:-
M4K<+&>2S?=6%K;G0\D NFP= 4:[D0,P<7@3P:T9I?9NRN]J(<]&AE>+(&-AJ
MFU^CI3#EP,Q397X(K5I@%V]5ICW#<N5&Z7R,02O?B"!9JK B@NP]6N?(Y"=@
MR[AZ5HN;$23:*O(T@W?^,GB0_2Q%V%U6U08-+VYH#S+W%-I]@S[MY8%ESV.H
MF\! EV^SGRIG5CAY1UHUGC]OJ\;8UZD?W':YNV'G"/WP%BUX.44IER#CGFE&
MVG2@(A4$P8Q#",;;&.3CXJ&<@VI<Y(0V3U&^!I.&KX=M542I,(.Y ^XU6NP)
M_[E*F^]%WT-Z!3[D4%+M].L%%@*]=6],H8<-<>XDX7CQ]IW$1,4!T@IDGWF'
MMFA8RIFV NL$JDSROABB%8J'KD4GV'RI8=:8]6\I(1NA_G+Z $(S-WP>RZ4R
MRV'F!,T^ Z9%@7+FQ"3H@9Y?@@\41.],058XL#@(#D1AOS#; ;;H6XLO\=48
M0W*_:0[5IM<DV$O?<6^_+J9P ^$+M>P-JTFY $#O$7V)UMM *Z@^.9P)IA[H
MF1/61Q12J$F&8B8!1?I!#$^/N?# VH[A_-''J]WE.J^I$BXU4PG-;#,28YC9
M6GW.<DH&$J7.E-?Z8?LR6CG1=DS(,X#&7!+G]>J9!=P'8?B[I*/!(;.4+P-W
M0DQH&$Y8CF$H8C2XI8EH*L''JG96M6Z9N.QJH>PN?6O@]*U*CW.U96_GYAV:
M*V$ 2-ZQUUV6C=Q*HW*'RG;H$*B;8EF:NOLMMVBWM-L(%\@!5$F(B&-)AK'+
M2K5Z4BA=Q,_5$V;FE5B;UU+;,:3)B-(09P2I"[S1TZF'>N@4)66-60J.OFT0
M\V^F*7!^LVN2$)E%P :/)&E,4K, PE'CM\!ZO68#*NS:&37FQPN-A3%5FGY8
MU;38S!%[Y!(.'$0PBC2@(UBQS5IC[I3WM%BF::5X+X1V4>$E A%$<&PSJD)G
MV4&$'_<''#@&^?SH4\"U\-!V5Z7TOS8'P[M(E%W@#03+A0:&9_R87R\KC(HC
MG(KY.61:LDJZ*N5;Z*^ &)9%[B;0_)'97;NNY"C"K*[!S!,$%QDXW>:U !9E
M[O9=8-ET45[%.==J\R+QHR*[Y(@PPP.9I7&%5R-76Q'7)I3.-9HV*<C #2#$
M+"3&(QTI_FDCWX)N5+"@\$!/0C-*,7)$9B$@4*:-?@1#P 30EER#5VS)[[@S
MJE2K)T$_(?R\1'2",R""*L< @PL5A-*Y5<+X5FCP<%*MXU&-XQ2>H;;I?'M=
M\%Y3=4='Y_9FVJD($9[Z%$"T:67==,J"Y@79VV?) A"E/E+8/])+H"U]OMD]
M<+#M].RA5,ZJ$2EU9.+RSS?B:.BM5+BO,(H1K&,X&FS<"J2=[@D?SB6HK/\L
M,F=_LJ>G@T-EI?1TAX-76>6)";D*WYE'"R=Q)1 JR0P,35?C:FCV35EX<>U2
MD:3*EPT[-HQBQI!QRFSNUA+K#JS)U['1B->34M!!])9:<#CVP$DI4P8MBV'7
M($@2' O0<[-@?3F09M^ZLRII2^OZO<'5\MGC[FZ0(/2 3#W2PU<:@M(&M5!'
M:Q'WG>SL$J[4ZF\6%M6Q"\PC@/'PD4Y>E\B2N@DW#5_@ #BVHG,.@Q3])AJ8
M5] EQ]ND*8K8@.:TT'T/!Z\7;BY8*F!$ <,5&%@J\@/\CT:G')H^7+L4A#^Q
MW$?B1N*G]A5GO\!2-:8TA/_54XL6WLQ94G4A@(UK6E?1,"0\.5,^)+BFOC3-
M1F\DO"6SE>Y[*43#OHE&D(P+NZ@H01M2UPXN-)4 4<[ITCR63B>>-MS?&530
M:VC;V[EY>E74&46(!*+ M_?! GI9,':4I? JN'4^0--;.W+J!+S/HMLL^L/[
M+/KVJ[8Z%[ :.:,H&\PZ88!F4J8<&3+\I()XM8)593X%P!CP@8!,MQ8'A\^7
M[0V72)#M45E@&LI?!UCII/@TV+Y AQV-VOV\\%8AZ5"'>)QQ?9)BZ2@.29>B
M@?4(% Q41D&5XQRZR *)X!0GU7:_=N*!E4;'3R!->W0D*"^!>4_%"%K7Z[%#
M.AY,:36<#,>KXSKP ^AK[E(%I=R1UH, "X6>$")FH]'LIQ2\<CM08(B)2CE\
M3&E"G@U5\%,U238G!]37&H+7:@4$7+RV;.A=!OO 40HO2BMQ^ *TJQ%G=/BI
MA-Z$$2JL_4A+]%JX#,XFCK.<X=0YZ(5Y/@UTNNDPRRI&D$:Q0NM* AI7!"T0
M +BL%-AKEL8YI\B#+(3:+"TT*H_DLUIGHHY;&A2K7J"=*F140^H:X*\?H<DX
M+DKG%M683L(R<&[G_)!.LVM E<4]L?UN+=@0(I"V>$B8T\!YC-,6+-FR81/=
M6K[76V: L\9+PP(U"1R,))%OHOF9P,JN8L9.T3R?,+RYO_4E 0@L0FQ*OT#N
M@%/A(@4KNN0XJR2-%'4 N(!R"<:+G@*D$S*&C0C\X55;BD/PL9$YP#=7U]!S
M$>>1):WTG128:9:XX2A%L#+W^AGU"6+NBD#4!@9.V5_-#7J[?H 7+*/RQ4W?
M"^0?H7'Y)<>4-/1<++(@YA2Z&<*JLR$.(^O!SFZICFXM5K]9R&3>53"@ X6*
M\XY>$M0*H@XC UB"3ZX9>1\!UB!7B72(57U %(?Z-^H^H<8%Q6+6U>#KW&=M
M*4I00O-,0:+>[8<97[7IL1VL<$]7U%JCEKGMPFZ)0D?6G9QI$M(24-1).P.Z
MW-OS:MO]@T Q!6L36_Q%,2Z:HV2-JP]:LECY$&C']<A:U2@#&^@QPB$8Z*L#
M!GMY:M\J_ML'(G,G_'2._RTX52'M1W\M<DHJ*Z0[A&4IZ0A$HNDD9,:RV>#1
MM!A_:,9^&JPJK;A8VO32^P(FSWS%*,4=:"81-[I-(12E:._0F@@-Y5S>2KE'
M$VZV#$Y",H^I($7/#KZ-C%^5=,-QSL$0@"G$C*_&#?@X\-ZUF$-8&=(40K\G
M8007\[K+<$#QS#G8@<ZKRQ0VB3\AN]^)8YFG2T70G:22"7:6/E&J^_='^):R
M6,934@/.&D)4,DGB26C-]S6#D#"DL]E$Y7M=C3A&?&[B5V&(G&HR[42I!A!5
M0DYA/]PN9R3L<H/<W9%N1DW&^UF*_-T-Z'_AH0BZ#"4R9G)'0:%5D$=HI_-U
MV[2XI-DB/)$MHA+',J$H7>,XK\8^0B,WG&*AG=,&&!P! 77T(4=Q)S(78\N,
M@>DX\[7G'M1T3_4WP,-IDS3J Q/V[$/HCG1!5AQ&@UK2;$IE< IG($0F@-^E
MO'NTM586TN= 3UT%W-3&1NZH7[I.IUV&"?SHJBQN">$N +BP2">4D5B1D-"3
MH*(NL>S64 C)KL%4VG'2N-LD2#)W8X,W15?O'"%JYXCW"O@1@R:RKS+M'5X.
M*.+)I="E 2(&%P-"#]X6#^$3FZ1"!5?%>[]TI9O1<2CD"/B 31- L$_FWU^G
M!M4<+V"OC=2:W&186$QLT]*03>)8GFDZQ-LVK< Z8]=7\:;!:*; )22!L B6
MZ5%39K#D+$JI"[_QZ"P*HF9MG*V!S+G<-5GU#<SDU(,))A#R06(6<+<7E6G5
M!/8>)UP18'E<>ZN+UD/:/<=.RM"C6)^$'<=ST@59JW':CQ,GZ:8]3AE.4EJB
M?36$EV%0/MS4S?4K'K629] (\T$ W<-^L4\E1^&3-P<>MHG,2N,L5\NU4;9K
M@--5A""-_T,_?'Q3E#[6OY]ZJ*O -@#@[NK1\5NHUM#:W6D9]/'(/1.1+PRF
M_H2EKF6:801T:>DKXQGTT:@18$JR>Z C.^I2V(6#\I"TW-D-W+JJPT/UAU6X
M_J_:MXAU?=S+L@)I+P#\V3 D\$.FAA_=IX;O8 Q)^2O12CJM@V4/>+G%'(0C
M!CT,IW#?"_.(^*A52+RX6M\+I2Y. [LN-W^&].W593&=^B"^@F=KU02?*?U
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M:,:P)"PQ8.7# %=@H>3P)JY:G)?9#3:#8Y,"?-G7"$*M6!E?!?"IHGX]\$_
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MFQ U[[HH=&NP=\Y]6V2*_T*3Q:@XWDM^GJM(RIV7GU60'I,[QSOX7DE5>#]
MD2JY*5((9JFN48\ "@.FQPDLD[<,E1#P<UA0DAARM*6@PS-8:,?>"#X0PPPM
M)6CA'N93KJ)L&BHE@!FUS-SP:T9W]YZ7D[(<BS7H B3>6AA8$\Y?/122,[/Z
MY@U=$,!7 , <0@G!UV: CI4OW'U;+*HF7A"VP70CF^*<H#756>X+:,K'NTD@
M#JL/8')5:=V$^YGX@$0;0'(UT.N*P@D!<","IVMG-Z1$1DL9<9!4NU!=IQ#O
MJBPW)WFS'Q+/O5O01+/T5Z6IR_0066:2O;6?:#6BB8MV*^-<7\6,TV/(V\U
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MM4.Q#6 $)2Q$DY5^=*H<ZR!]&9/OL&K=LI0X(! -Y!T:"Y%46%+G06Q;Y75
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MV/B"S5"96$7%X:I?NPDC:D'7RQ_:EZL:B ):TF).W:@ J<2O\."S\ 6A3K1
MM!>SV2(O?D\):^1M7,97[AGO/>F.F]-%/CYL#^KAX5FPP-?I#/+?RZB#L@$!
M7)W93:OT*V.?A,\[/CP--TQPFW8?G6E#V-3-NG<1]#? 2[TMR@],4GI5(EB@
MA8AK IN*#._L:FUY1_S(N'!T3YR<6;/G3M?$\9G17]M=$T^"<^GUU=4&XV=[
MS-\5'=?#P^ 6,IJU6Z,.[J!1 ^RXYOM/#H?=>J<!54<0.)XOX7LY7RVLN%V=
MUY90<>@(G1KAW?#DA ?GZ/!D^W/3'LQF3EA&3EB9(;#'!(;O3:<VSIT0B[L/
MNX'@K-A7B]'!E$\&C:N83"HWM-$29AG<Y2TXNX9M]D=:CA< _'4/4V1ABD[N
M88JV7[6714RVYR6 , (Z\[GWO^]TD(;M@_0Y#TZ_WO]2@"A/]@T0Y67VGT66
MP%["QCYE3.5W@A[;6HBO+GG#8S+,$0P1\#13HB,P (L 3 W0/0QSB !T@F*$
MC -I4GE&=J6^  9F17$N9C,0L;H8?XCP+Y<I OJ> ^[6)$6 ILO6I[\U/[50
M16YA:X"EQK/"U#FC6L"I\JLJ"HP4YH).L]EH45:*M<BCI@A83_0+4/D0TZ8;
M" ;!D(#B_J?3X]/0/P5(U(A04F&\-VY)\GH-8FD'N00B6.6U1QTF[.Z4(1%Q
MBV#O D!R"Y&9<QRP GZ1Q$*!G[4/\4;A[)W1FB*[>>%IZY4,8$(@R(+TCB*)
M@/KTBUKIFY. Y!ME.& 2/QQ<9DC6M$ EG,X5E%1.PDK9N$F#-P&XUF*V($LB
M22?9.*O)RGG\V#LX[IV+$:"FU03ZZ/Z/G"?>6V>"0:4'AHS 5)?CU^8C[6 ^
M7^F#!\0C^,P53DY_1,G+X HDWKMF5'9)!/$\0FPGR\D!8Q17N#-E"[O0]=TW
M_:^NTR[:YZ[('T8ZE&C!LJZSZC)(;2BD1C\(S*O?&^M9]F/N.[72 MQ'OYC1
M[I@,AO,,C+(FA!6\'$(P.IT:@+L9'+T.:A4DUXH5K=UC__8-D>#DW#/X;K!7
M =T3$(3SFV!#AGVJG]8OJRK$PL,;1O$ ]?F#F_0Z&Z.:>!.2:^!K4]WN3(#]
M8+B8!>E$]S../I-B^/2';%*# JN+)N9%G$WA[4KOH)P.=*Z1J@D((-(D@HV8
MQ#=N 3!V[6XEY"<#]-KI-&)B>E1D;L0I<Q%GSCV$:%YNX/+;L,T-OA&>1R^Y
MS5/ WT-J'0L;Z2$/"9]/R2:JL1/DAO %$L+@D40R-(X7E=R81%KD5Z5! !-7
MP(4"H)'3XA;38^X .&W.ES'2'PG!R^'@8@*?051FD6OX7ZC-VN<>R0"50D#H
M81#JF)F^(&9=)$ZIA8H4PIKN)/($D,M&"3<TQDU6!.%;8XRHB=\,.]-$78;E
MP6N309=ORT*8 F#6* #IQVNW@&24Q#=.O'"J?N.]@5(5;ASK%NU?2K?D#NZ8
MB4A2)Q%IXY;S8*6@"II4)0@#CPL&L*7P2X@3HPCQ<H.0(^%"VX)%D&1#:P*W
MO<B0-RYAPQKFI?+EP(O0PO*4*($V61$?V]-B@M7QIX6'JB;3-U#^0I%9C*9(
M:<X42"NL:^.!>OFRYV2RF$[@^*RT:!H<R$C$@\#I+/ZH7H)!Y4GPHU+L<GHI
MGBXA-PB\/)SSQ"F-J@TWVFG>MZPY5 :3Z0*@P.NTJ9C &OO/(BYKHM:1?\*K
M,1;@_H;_*_G_0"VN6!*^/DES80Z^B_[M#L+\M260='&?FC#G'JYUX6"%TTW5
M"U8(3+@/!01U .G"$;A3>5;@@C,7HWL.4+4"@*]<0W*YJ/M*OP:KC[@N;X '
MMC9*&,(S93:N6Q;TY37^M.,Z 5<&2.M4)0.0NUZ1.4J%N]*1F:_U7;07P:7Q
M5S]>2:R:_7U6IF!AIH2)[QFP## ^8,M?.]V4\K'P,/DR%( *!@,!?'!8(Z'-
M$5(&]]((+$J06.*GF2)&,M@;513<WY-%B=](W!XM(VMI3Y=\C>"$85!B8]M[
MU(@_6P-I>9/RKJ':$E#^O79=MDR"K(A"DE^G(6^.9E%6?,^C"&_RP;FS#J8#
MZ[?C[8[.,W*L365E*ED97ZGU (2;N3]T@58LI3*FDJB;HJE(ZYW$"'%R[2X7
M(L"BZ!I0;I)F)[*T)='5NC\]J(NK%$\%[E7XW (Y<MU!FBY)T_& ?RO*$DQ<
M&534L\?*;B(?^UF 7I-AX^NG*?)(M(;GW_J2ON$)4O[4*K1-5I!F\%)>(WCN
M"V8HC,EOPHW#&!ON'GT$_IU[S%40U#2@[8LY)KP>G?E\;(17.?I=P+9U#50O
M=CWM<KZ'U\'(_7HR9Q+=P[\,'@Q_IN1KAOX[/Y)J/X*7&H7.U];_+/)T,#Q#
M*3WY=?#@V#U)PGKV.<,C^QPG0W\QQR"1@@0E=K)SYK;WKL0F@SB!0=376=D8
MP]D7',,KM/)X$*=42//@% 8"VP2RW[NJ9B3*)\O<C$8HAX]^-8%9#+)D=9VF
M#ZJ?N\:CN1<9$@5'B'NQ;RSJ]C5O[LZ5=D<$0@9H#CI)<AHJ*9WZ,Y+4)<T_
MF?=U1.'V2T_#DNKY&HP0I%U36A"L ,.;;.DYVL3Y8C8 KPQB0A1O0_YU9\K4
M%'2!L_CH\/3L[R1![CR='A[_G>);^-VW):C9=\@\JFI&^77\8'08^+KJ&L*U
M8&NE'Y'0.&X.R+W[\>&3L[\;BC4H)HR7* ;N6JB!]Q88J9SK#/,L+)MG$B^5
MM@._>SAXR]J3@S>3+50I!""@P*9P=JQS<,& 8BN8(Q% ):*L;$7N/O>E<RRJ
M]OYTPO^'NU%NTI)I5#M.?-Q=T$N&>?"J^]RZS:V?[FIN?6>4!/G:6/8"#"N8
MTW1"_&9<%ZB@142=GVA\J4YI)+]_EK*YT3@"_![6X?9=]C"<$94S$%^A.<*W
M-7Z]0J7\+XH<VI@&$,4M&QJ&=;I3":3,O(YPC@\QO.BY;]T$Q"#/BF:4UK=
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M=!\=-#RL:PI6V$-4,I9\<BZ#1L66Z#=DFK%$Y-&?$WYB,_+SL^._=;QL&R;
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M6V,%&ADX8UD!4,,]GX ,C)@/$C'O*=QW?W;;22>!6?0[+=Z3?6.U HITDKX
M%,VT=3Y)_$D!MN%5\=BVE42JY&R<P!-5L=I62]Y8!^J^MNRD6VD3SBL2-W*R
MV-XCS\A-V= Y&Y-P)3(1SR\3C5VX73)QN+^C[1;)F+2?C,F?8!2."D9JSRH8
M0Z #D;0&LC';2HMPNPX%E4N4;%]NIND[L@KY9PKO/&'5L+/FHN_A 3[C4+"P
M!S$EA#G.7D0<1IBK#,*B!L'QE6RI5,I?LF.=BL:0,;BT!!-WEWFS+,A5FB5Z
M)=JR(53KDNE+]+:37KU!=)?QJWN4%X"\7<T^O]3$EDD?I]7E)1H9OIU_7T8U
MTEKZ.S^LX'GH]>,:Z4>0MC!=6(5/GPZWT15SBA92,&DS)JOBM/FVQ6G/&9YF
M/#%/TT1-12PCT6:7:"#/X#=_+Z+, ^GVTIJHLR1]S7E9/?0EIK5,VC!:Z'KR
M[*@6>BJO.KD:6L1]SA Q,Z*';J53=%Y%=",G:_M[\-^6)4J8/(F5**+,A,D8
MR?9$R6;[CNNY(-D(LSTV'"CS*86MT!V7\XB9VVFG@46R7R[Q2D,>EV^Z%@P\
MI7XAV^)*=F'?LY+JQ+Q;ZI\(P@.23F9EW2!3%VM)&+?3IM6!)51)&?K?*]&&
M 121,R7]]$]2K<.C%^LI_"7;8;<!3RX"4WN#$.J($R9D8G%>^V1M5B3JF_0,
MXP%:Y"(3O+(@X%?A 'H=43BJ>0<AV/XE;PCN198.BS 0:Z/&WH)-NT60R[H\
M8S,8_68&+M]>^X/0E<F:5V%YO X8!/2C/_%-G+1$(TQ;&=#EC<YWUH!XF'^B
ML+ "=UXIA1W^S#$1E//(^MP-&DEH'80A;&<']LYZG[2;"];&%T%2Z_*,S0"#
ME4'E1@H2LKJT,:,QK@U4_BN)G( +*EQ/LH!A8@L9<YO0B(34(UC(G]AS=O8_
MI]>RK=TJG4[:;LE;ZX^D%3:Z49Y$E,%V"%5UPKH2Y]+*?1Q_&N5RPS'!*)</
MK0Z=U\8VRN4&(^:0C4U[-O:A6N48UEEGJ0!*?FX#.B97HF&5;V385:?XUG$,
M5P"(7G7;65?DI7U.N@V)J4"8_2'^U#YA]8F%G:CXJ##8A])#U47EF_!"M !H
M#\*.=A<+52](1D9%W7!(>1;@[G5$T)"]C8<?O3N*5S"RZZE(D?L!)M=)U+DH
MAC!\8Y""M&^^L0>WB"!+&]W.]%M&>#?K-INB?7M_T5>_O$0-U,-CS#'T\Z+=
M&XU285#0EN(7$C$,]HUH7(O;;&=O9*+-I(7&%G9\3?))[O\G:.^-<^7X%L$R
MG<,#53R/,XE*X8%Z=P<[TP9<4K3>$%>9?-/[Y6V/.I*6GKZ^Z6WQ]&([)T0+
MZ??E7P]FL6OG,RD$>?'FXNM=_56/3$>^\W<9<:=^:^_B.;]SZ/1W/G3G0V-U
MO%V.^>(?NXOY?$OPT%/YKL^]A3]5G<<X\SWVX5?Z_LQ+8"SQ4;UR59$IQA)?
M3[V2/*I7OD]: GZ%WS9 KUQ3(]P8\L:0UX!+=O'_&DM^FQ&7S&/)*\B<%9$Q
MM[[NGNX>[EJ8.G8.KE%ZI>+5AB\#0-9O]FVWC]&B'8B6S-#Q34/>*FA6WQ#;
M7G3]WG4QU8VY;_3@/% ,[U9JIYNJ"K_$DOWS[N2356EE'4 B:1VE83=/U%J/
M%5R79VP&^1N=[3%P.#W\:U.UMA<#A[JX25MI\Q;4F8YL94K7. TO9%,\#RW6
M5 TPJH11)7IH<7CP:5T$X2:CQ:%HA-U&;A]]2EJ_5**QT30VFCN,IO$8=AR5
MWZ^+6-QD[#B2<=)*%@@=:ZHR&+7#J!T]Z/AT\&Y=I.(F0\<G$<B&43A>!U\8
MA>,QU/A\4EX7@;C)J/&Y+56NSR*ME355%XS*852.'#S8NLC$30".PQ1&8WU6
M22L5M9<BU">\1Z(CK/=)0UI_Q&F[*3I%79&*CJJT--SH!@+P @&?1%;2 MC1
MY]L6X/>?Z[('Z_*,S6">Q89?OTR,\\\)_QN-$7BE8<=DE[/%1\?Z;-=WZ$R/
M?43 3"*<A4FO)V(N;/@+L=C"BH$]::9#)#]T_64WZR3Q[0NMA#IVBW3YIPL!
M(B=0E1C39J)%35X]ZB+)K#AIJ 3TX1BA2D<V+=?&?P1__D%T*.>)/.^YY$_1
MW[N#$E="U<;*U$UQM]U*L@LKZUY=-72Y+-%HW%H"UO[J5CU#M&[[K\^*H>G:
M52H$J7QH=:_@Z:HF5EO^MRNSSEOKJIW^3B(9E:R+]%K"NJL*6*(S>'M3W/:N
M5I(RSAO/B8;5:4O1T>W-QX-6+<("1'JA3\/QJ!8(8CW(_N"R_JQDM&L=]GKY
MI&VU$/U:)T7466FX[5V@ZW#!^-J_2M:__\4)L=_^O__[O__[_Y7T'_BM'OK]
M;0ED*+I@0&1=U5"O]Z)A)2#7%M1&Z*6 #01XN[#^2/ZT6FD''@N@JE9 *0]_
M)/#I==IM1%8C^25A-_*GAVGS2G82K8A<B';32F)8)U62 "X!; @;::9C<N\%
M?KT6D/@_,P#$ Y,I^'I]YE-I12JD$!X(CP)=4Y.^(ANE;UI UWK+6YGHI.U;
M"["_-;( KV5;9XFQW:1MK2N #D<B1A7#2P78?62:$@7:"_14T: :#>!.A1#%
MW6!Z1!KQX.XK8/>BD&]Q#Y\(D$-/@5<%$N H3.'NMJZ*&"@LCF5;JLBPI*5+
M$-[VQ,N]NE EZ_I"JEJ%0+&10D$8BU24JC/B],6JV*+.]$_C74.N&T"N%= '
M0J"(2 <'7B<@E[3(9;9;OZ=%U/-REA.-XFS,VK4$T$:DBG!&FOIRZE7$*]HZ
M6%D Z0VU\<LZ0#H: ]4U[32[ L+N9M/H/;,P5E=B,B%M11/^I-?/P3RI(OCK
M!$2P>J)Z5-8-+N$^Q4^-1 3 +)U;2P>2JR<H3: 8XC(Y8.U-XJ<SP8M.29%P
MM#< :(5ABALF[.'4E.II&<V3DGW5;4GT?W=F*+5BVSL/OVQ5)HLWT;=0J9>K
M%G9WK??')_"+C?ZV3K]6JP<G9U,]#%/'/FVEULA,TW.N@1&^.W68JTRM7YLL
M>C)F>HREM,]*Z[1/Z\_)O7]FXOWJ%W4R:WVKG%2.*@<UJ_Y7^>3@<_EKO7)X
M6K(JM</IQ+<N8Z_4CLK_6/5CZ_"X=GK\J7)T4"\?6>\KM8/:8>7@DW5:AP^J
MY5K]],E3F1TE-L]AR?U=A\WF6GQ:E0 R>SK_2_DI9SA3>&:=YY=RK6Y&8N:+
MC^4)]>=L5[4!5^ZV[,E%.V?H3[147=/ZX^_/U0_6IT^?2]8[Y>H#R^'PN&0=
M=*.D Q:*&J-5.7IC_2>Y4419ZS;A1:%V#L':G:@U2H1'!"!%*+ C6,P$CZCC
MV3@,L2LB%K@_CU0BJPV6&-(9K83B':LEFHK>9?*F>)=Z527:*<0S_78;'*6_
M/Y&3WV>TVHTNR[]_?/ OCYM?\-GEQ465E$F-?+7/+K_<5"_?7?SX?L:J1Y6[
M'T<?+ZMWX6WU^_O&)UIKG-U=_:I]K["S>NVB=ADU:A\J=K5>N3[[_JUY?'1P
M6R5?;L_NJK1Z^?[BQS=^4SVJ_O[1^GCQX^ZJ46V6[1^7Y\Y9\^2B=E>VS^#=
MQQ^^L%KSS*DU/R;5HT;CN'YP^R/Q[;/O'[,?]=2I'55NJQ\^-G\T?UR<D:I=
MN_S8//[PE9S=75P<U^%Y]5\W9Y?A[5GOGG\^7@3-J'%\^<NN7L*XU)W-]Y=G
M=U](M7G&?M1_7!Y_*#O5^@F\ZWU2N_N8_'-7[E0/[9M/]7*G=@G7U;_\CCY\
M8]%?'QL_2.-W<'EU"?.#]_VZ_G$4XBH\^[A>N3FK5V]_'$5)M?XQ47,Y(^\O
MJWK.Y9\XD(%CXP@1P3S$(AJA@-H,4=^FA$K859?O[&/N_&=OA!#VK3\G^'D7
M#E03Y&E;4?%TA<(@V!,1C#PI6=M(M-=,#YCD9:C31I*WK'DG&MHI=WHA92=[
M$J48KE_G76:&ZPT]].C!&>/ZTYX?7.NUQU<R?WI>B^DP;5ZUY84*9/TMK4]I
M9F#A]9"!8V#!T$./'OB#L'"HSZCTD=MI)PU_7:3*B,Q4H KVWEKE_W:3SJV!
MAE=#"JZ!!D,/!3T0_# TB.S">M](KXUJ\'KVVS/\;^BA1P],G3]W\@C>$2 8
M%!L<0((!@5>SZ?ZJ06!*\LHCQZ_#9_!;$?KP0/^ IT0^N.L0^3!ZV.U.2?^9
M<94/5%3[\Z((\B.^.4[XQHCS0<I=SH0F$TN]2)X8LMJT9^==*MJ1FN=1TI9A
M)VUG+SK,!_JAOWG:XDZEK$73D7[.&]4R/0EGF.'Q5=+2Y7Q;>D-F$*0ON!W?
M99YX(M2I+0Q0C5B%[39A!+>*Z,/AX0?%P4&F#PX443VPG9KZ1EK:_Y&OAW[V
MGRK!55&E#&4SD&V+XI*ESI/U;? +SD."-;[+:'0<V8AADHZZ,L,15V8CS6 \
MX<"MD4UP:TCMUBCEMRLS)U9FC@[J56.XE0*8"7YK6;I ?7[A\.A:6FWZ0\7[
M2!V^W+C-AS\R[+B_^X,)_+D+BV6EW39,0]/-C/=95WFQ 2L625N]#:8F&HU!
MS@]\K0*=L_QY@T?TQ& O+KG8CQFV8S#IK-O(EUYE:(TMO_IHIC6$ :LTK;3=
M5&'..D!<92M8Y[(%#]3I8F$H=<UJ,0#AJ[P"=D-FTR/5IB'"A@').Y$E^0(6
MD/*R\D5'H#].ERJ8O:"2*[@X*<+81ZFM8+SA#*5=ZQB88.RN1-LB\D81NR*O
M'I,4X#K3@%01#MTV4C&9QKELU_J>1]V+(M5MF,)B%233'B@"FC+5V N-H,<P
M0YK!,=@OF5JK0MK^\;65]!THV9_6'Y\/#X[?Y:TQU&M5FF*BGMW+G!EH(/IM
M!>_V$B)[;TSNIU2HKS77Q#)27*-2!'K)"@UQG?695EQ=P>!UL&);IX&J+]K]
M'(SLL1X=,(9FDNDR)[U'ZDG=Y\*UT8B^:^J(NJ':BL'F3UM&5<8Z@MWK+T4^
M/Y!L:3;\;;%Y><KEM=0)='I-  <5FN7+K5ZE]B\-=)XH:-I9VM+++[*LV]:O
M%D':[?13GV:#?44^<5M*-<@^UJN=Z5TRR*6*NCJE5K;; "'P7]R&4:GY#%%4
MGL U3(]*'2C!IVV8&[P+)BA;Y\"C^LMBBDH6%%,LA$"B%/@6#$7G&:8-2U>Z
M&,R@K=5MX)5=ZR#K9^H,-J6D7C3.&L7:P;NT::NWH,@?F_E]5@!+K/-T"D%4
M9.FHAQ2XHJZZ!RV6C.-<E+<4]$R!KZ=,6Y,<_*J$M5K5 M1::9[@6[Q^C?GI
M>)B%BFZ\!4'DDCD-9=1MY_XCH'(U.RT)DNQ7-I5>>TO[*.D_0MBE81X<'X]B
MU5RT1#FH*@K0X]JU3G5Z]>#B_MSD#:Q="QY54C0AK([*+ ^44"Y94N6B*QX&
M"!5Z6W.V;RJ1D$-GD3M=/'.V.>9"L%ADT<C2H='\%HVNZ/3?-$DELKI*U&F]
M&\QJG2<*"PS#3II%/K#*KKP=DKJZ-<BU!,41_AU[A:)EI5)>#9>UFG6WM(@-
M9".1OPNH'$+@(I=?9^KU<3'HJSM#VO"K5_(.E; -8>ETW*Q55<5_VB^MZ%EA
M;U0YR.N21#IOO-EMZ=QR59T ]'LE0$3O:S#R-)86Y23@*=UV6Y==@(&DT4!@
MS";I<ODJLM'7INUQ[6GDZT)CRE^EOE&E%&2ALHC.&^L/_&=AM>4PE;-1IIX[
MS+#ZY4H>]3&K>/(,$EH56R!_ N?^3AN_"]5#*W2)MFI H0(KL76N@:5(^4R4
MS"TR\QORQKKL1N<%&^GMZ$^Q8$$Q98>B5.827334GUIX@FTE;H=YJB?A9D#<
MCO@%!IOJ'@3@FS9D#K+7_935DD*3H=$5R#%Y<)IB2@7S:Z$+VBJH BJS>WQH
M$Q^@H*$UC'[WMRV%<2: YTFGM\M/%*CKBA.@/K2[FI@Z&>QEJ%PB<)5>I(YZ
M84YX@-7]C[,.+)Y\6?\2*'MJ?[I9EE<MR\^7<J^",S-/E=2&Z^F#UB1;*L=:
MR8D9%T 3:]\*'$A#X*,PS7)M1B%5GL4-$_V=A+(OI'0M@_XCE2@4;:6NM<]%
M*[G+C:>2DJC=6(0=L)V4@CKZ93_;N_?,=J:]/GI2&C'37H:W3G[7YE=IQ/3+
M5>%LI.:+QMG?@+II-[-RHLC78#!%]8@&2."&5G?C6+N\V[U55 ZCM(^;4B@]
M2$-UCCJ#QZ@-4L,&CFUUM7L('J>FF[:S7'L%B,C Y+5TP6T]/&!T^%?!?Q:"
MO9+K4;(%2G(C5SPB4 Y P]"N@5Q/'EDJ&+7&OY<EWX+L>NGXB>QI*$_EPMR:
M^A],=EU0?QL-;4A/=KFML0D .MU082-M)A4Z8R&7YD:I7,A,Q'U0T97P5-IL
M0QE/8VIJUE4-\(#2PKRRE+ZSKY_GC*.&]+NPL1\" %VJ*6E']ZEN:P\A'TB_
M?H'CQ%42N_)2:"#.;; >O?5P+Y( ;$F@#*X@5?I;7R\=*'4Y-0)@]!2ZGNVJ
M'M02("ZT(T+\%DE#&T$]NBW,TCX9]\W $54PZY=N Y(MACMLD0IE>.<Z92=W
MN?].M6P#_I/)[Z'2;X/[<PP>6(A]7P=\TKA5)EKN.<G%<)]SQ+F23V ?PT1E
MI[!">T6GNHJC<]-X*J"O ;HIH1>#?$JOM79:.++!O 9E\';81:"\?KFC(1>=
M(HK:N;=#E6B:C&'O53DCT"X:1668(;1\OG31'B5]:M>6_9,IP$E]/I23JW8-
MC-C^6N@78-C3JD>5++B@MX79$/7DUA30#%(T<YM7VRNTD@)5!_O>5"5\.FE+
M]@:?ZAHW2KGKYEZ"D7&/>]CZ ^R#=6^4N?14YTI(YFZ=L>4='N)]RL]+2_5N
M+VD_(6RUTL1R]DPR54@KE--\?U.]'KGKJYC/C-*I=Y"8FZ3SRM#@MGAYWQ#K
M-KNY:!H^M1M8R .:GNYH*6*WD K4>L-VM> K/FKGS*0^F[^"PNKX>R_;6T'F
M<PT^>/&\Y[,B[SEE/RZ_LMK= 3Z[^]:$]]BU#U]OC[^?-*OU'\WJ]^KUCV:9
M5>^B7]5#W_[QSX4=-K^UQ'>_>WQYT:S5SVGUZ-ME[?N/I';TQ?Y1KS@_/IS=
MU)IG-V=W[YIG]?.[&OER_<_=5WCWP4\9TTA$CH.(BS%BKL.0'W.,L'!"C]JP
MGB3<V>_EJ(\G'R_"4,=DB#RG4BQASBYQ%F_3SQ1JH0S,'+XFH4I/80 6!GP@
MMNT_@S-?9)[+Y[!/::[^;"67E7_*T!7 400Q[KJ(!<Q#PG8CY,F(DU#ZOBV\
MG?VB_D,)* QV6T3IH^PVG:Q62C]5Y5_Y][^P:[_UM4%,9^5]^X&HP@?52Q-X
M.KH%=+K-]Y3 4W\A@:=%L;.YC<5G%LE3>=7K6PQKDPMYC=3O>G?PZ:!V6+9.
M_RJ7YZC<M>JQ_Z%/=-,N/"-2Q\$W*E+-RBYT4%%^#EW\%8F.^'/MY].WRE=;
MS\SW=WG>[^"IY<P\LNOZ9.'ES##>=>E\?1T>_LZA2QJL__+=(EX@66SC!OQH
M?3E_EF2IR5UL<I9:-'+PQX!#B^+ATXMYJA+/TNXG1R'5-@8KD%5'A59O8ANU
M6,JFF:4;R2P3WK:%PT^AKO7N%N;/-.>#+)-#V2%SM,.:NO]KT[#KB2-<0D?.
ME]OU*2WBBI@IH7?_S5S;OZ8-'Y^WE9,9V-+_TC7?4Y4.T\\M4J>$OT5C)/5K
M5'V;:?*VM0'4_#_/FN';\9SO=9I:X>9\K_M5I"I$/<F=G-TLVAGU>O*8>"YS
M;$]ZDLF !B$FH8_=R/>Y)X3_LS)P=D8R3)JBD?W?'41[KL]NALZ%N'JCZ$C]
MOSR@H!.9==J)RG!07QRTHM$/AJ[<L?+((1C/3>=-J]M$4:K3Q]7K@.]@5:7F
MP)?UJ=8K?9_JV5W9/OY>MFO?O]Z<79[;/R[5<][_^E&OX+-Z]>[XZ.OM&?G1
MK)WV*K9>_:I>GL'S?MW^N*Q>'Q]5X5T_$G@/W'?.CNOO+JO-RMW9Y2_RXW"L
M8FOSRVWM\N/E<?UCLWIWP*IW7VYJS0K,Z>+B^.C<J7ZHWIY=UI+C^H]?_]R=
M=:JG(Q5;?WK,]3'E#!$>"L0"UT;<\VR@/-^Q(\>7-G%W]K'CE!S/[WEB>[2S
MGWL[G\,K/2A\ L\L4N8;X'J5P$5=/^8BEC&7+J,V]6T?8V)SVW9Y;(M8 Q<V
MP+5)P'4["EQQ%$01;"^2,N"(N39%0< P<J7O,QY(-Z)T9Y^1$O'7";<69 EL
MA/IX>I&V.P@L\J8*8P$V:4[2'?NK0)ZV"A/A>)-!:U':UD$O*.]]VCX%C!ED
MQA[)H#/XJ[#8#$PM#J;">_J53]66"AMYKHU!OR(^"@CH5V%,@I"%<< \;V>?
MN+SD>_BY./4 5BQ+OYK5W-YVYEZ41F*8^R69>TP'\4/).6P?$I2[B'$_1KXC
M8R1CAS@NB83@D3*>6,EUW35B[FWR87UNRRN1#,4&#S)UPA&7Y5QZR:QFXB9#
MUZ+TDF(GROE&@.5TK'8A/RTP<+5PN#J_IXM$%/90N )1V$?0142$?"P) CV$
M4.Y'T@G]G7VWY)!G:R+KY^DQ[+Q@3<2P\ZK9>4S["%E$7<X]Q)G#$9.2(DXB
M@AC&S*81DPX.P;0H><Q;(W;>)@?(UU:0-!HZ2^:W;'6EA?KY,CJ[Q[A"EGWP
M5.1S?4\Z%X?=K),V"X2JR8[!GR?ASZ][ZD0L"0TD8\@GU$;,]532C&^C$,>>
M&[I,ND(='=EDC2P?X]983V7",.HB&75,40C<*'1$$ *C<@<QZ@@D&&5(Q,"I
M,>;4XT!IS%DG_^,B71346V\UH9YV5"6^A7DC'@].>Y58M+#S$V/"+ >9RM<*
ME7(UXLRN79;MGP'E+@<5 7DV!AM&1)X"*8YL%MBQ3[$$BP:@B>(2]NB"K)C9
MV&.#W!5;RN\+.U(Q_+X\?J^.\KL=T#@$;00%U!6(^3ZH(K9-$8L\QR.>")PP
M4E'S=@F[F\'O6Q#:_;FM2N5W;O,:;?_M)E=Y(;26[!@/QM(/3?*U_]P0K<Y!
M*RKWEE\;1@:K%H95-_=T$QN[C(0 3CZ@EO*O"D M+E&,L0WTX04@?7;V<8F2
M=3K;-1Z.]=0R'F9DPZM/Y-4QO8)[D>]$H8U<E[B(4294-&BHHMJ9(#1VN1_O
M[%//62-.?56I@)/YK&C6WCJW&E+HRO7P'4ICU,WR<F/S*1#;<$R[* 6BOP6?
MU Z<J,$<QU\SJ:T>HT$L$)5N[VD03DQ%$%..N",8V#@V1R*.?>0*SIF#(U B
M0J5!N-A>HQ-:$W"QGAJ$X>05<O*8?A%33"/N.\@G4B)F!S[R@P"4#!(+BH7M
M.$&L.9FO$R=O@6]"!QT]Y\QD&VR8A>D2@PBO6MH*>QY3 RY/ 1?[OJ.!"-^)
M"4=^Y'/$?#=$(A !LJDMB,M=&3!W9]_G)I#B];+HPI2$R2QJE(-%\N^8<N!'
M,0N83U#DQ!&H^9PASER!?!<4>RZ#B!&MYC/_M498>&L>B)E'6$S6$N8^/IKI
M@'7=5N+)]0%FG_YK@>+%QI$8[%T@]N)[NI-'84\PB1$+J$K!HQCY7H21\"0)
MO)"&<>"J !*G9#\??9_*$FM>W,0@VY8AVV(C9@RR+1;9QH^T<!2Y 8V0XQ('
M,<>E2$@<HD"X'O9#&A%U_$QL6O+L154X63JR%4IG;R ]0LY+];] B;^A"8,*
M:T5I5U61GJ=DZ9J-\E4=+DZN,_IIJ/N4BDPZ[:3AKXM4-8_(BK8DECIE?R#/
M:D750I?VC&U*INL5&!UJ.F:JC,Y4H<%?[XT]Z/5$OA*WJK*)*2ZZ%37Z%F9F
M%^3S.:<>$\>]>.74N6=V<\YPS'V,O# $L]N)8L3=@*%0!DQ2(;R >3O[F)4(
M96MT(&JJAAI$6H%Y;!!I!8@T9BX+C+FM0CXY#P+$?$R13P,7A1[S0H)E[#"L
MJF%0\FK+@:Z_GC?>-=A$;"Q?.5)K/F0J&S1:.!I5[N>UQC@0Q)$1B@*%1JY+
M44 X1;$C"2.1M&VJXL5XB9-G%^<Q41UKR\8+U"@,&Z^"C<>4BE"X-I=@Y@#J
MQHC%(D2^2P/DQ3:S'<8E:!; QKAD8[Y&;+Q-WJ.>6_ J;6MN3&/@I%C"AXLM
MN[4-D>K+++O5PZ[;0Q,V.@\XW<]/#0.'8HH=)*7*I6<B0"!4?#" P!1R[)@S
M5Y46Y\]&IO5SP!B.74']+<.QS^;8,74"]D1ZD4,1MREP;$@C%'@>1H'KTY X
M+*:"*HY]K1Z*S2K$M2 _Q?.BK#89G!:E3ABS9ZDX=3]OE0!*<19+Y(>4J2H]
MJL9G&*.02D)=P1F5X<X^I27*G@U53^62#7)M;"_G+THM,9R_;,X?TU!4JHJ#
MA0<J"0L1\UP7^5PZR'5(@*D;VX$Z1<&TY-)%%;U95<SA- B(DNRJ(6[53!X!
MBU5=N4WM63ZEK?.\15PD@V?4%-L&8V]A^A2L>1V67'6,,GBZ0#R]GY[B\Q#,
M/*&:,I  L< /$?=8A&PO"EP2L,#V_9U]5H)M72.;SWAIUE0=FLJX<7(C(W0G
MVZGAV2?S['@D2>QYS"<$$<Z!<6T/>-8./!3B  O'#B// 9[5$>;D[1IQ[38%
M@Q^-'_&8UBKK=,9CJH/,"T?DG@H1,693@"3D<.8#'(4A"ICK(-L'^<%")V*J
MB!AWUZFV@(DC64\%8F:F-4;!(CEZ7,'@KH@%<1!E-D,LE*J!K(HJ$1Q[MN^Z
MKD=5O1"\,._JV@65K+EZD5<5>^X!T#:8-@LM+3;D[C5@M!0PHO=KE,H8$Y\%
MR(\=!S%0*)#@'D9QC+D3B(AS2308><\N/V8\%&O+Q@LM/V;8> 5L/*93! R[
M/'0D\CVIJD7$ MC8)?!;:(<T<L-0Z&8%L*=KQ,;;%UQB@DK61.$8 BD#30N$
M)C:D8>#JT9GSDU&7",X(4CEX*HC>01QC@4C$P\ .", 4V]EG=LE>6"Z,B29Y
M32R_A&@2P_*+9?GJ@.7K%?(SBET1$LJ1%P6JHC$/$+=!+\&QY*"/,!I2%4;B
ME'S_V5W>UB2,9+,J*DW)I4F;S:2CFA+E%944%\+092M\2%V980UFVIP>."Y'
M%[C)DC>MI/%_=SKMKKSO%^U/_* 5'0Y/VX#!T\#@?JV0@!,[QF&(' D_&/5]
M)!PF$*=$8AH(QPE#Q61C,/!BE;:61*Q/D6+/)E;;$.N,Q'K/C@Z(8_L.LB4!
M8A4!0;X31(CX I35*/*C$$\EUA7UVPC23B=MOHR(F%1D3^HB>Z88VS,E?W];
MH^1W[]G%(Y"Z_@TF>DPOL.N?V[UXBTSM?\E2CX&G'UC !.AWJEN\ =KI&:G:
ME%?C-_S/0TCY6;9/+T1;CB$FZ(F<A]*5THD8\3W![-@&@4X9*)=Q@9CW3/U*
M[?W]WHO%:#3U?A;MX_9I1\6*?!.-KAR\W8#G$\"S"J!Y, *>G^A)0_YU<OOC
M>W05$.96U9B;9>?L\L"N-L^<VE$55^\N?AU___BK6B^3L\OHHG;4^%4C[^-:
M_8M3N_N*CX_*,-Z#NY^N]'P6^Q&R8R(0\QA!/ Q59Q0NI/! Z5-A#W-056P[
M01P%MA]CRAQ&@XAZ.' 86";"Q\*=;$T:JGH55,6]B+J.@U'H<&68>BX2H03@
M#D/,G2API!/O[-N[]OUHFGL?J$ SZ[?:Z[?65#K,% UDJP$V36_90;=SD;8!
MVZ/9G!R&+E=/E\?UJEVKG]OPGKO:)8SYRT_'<STP"53%(-7(@')0/'W)51O;
MF %91D'D/H!W$^EL25!GZ&R#Z<P/ ^YA;".,?8J8@R6(5!OL'2QLV+*0$&87
M#3/L^[T,[X-@3GB6Z%/#6H'A<;>3=41+Z="&2M>52D>E=/GNIXU=SV/81P&S
M5?4T'VA4^ PQ(CBE3FAC_R'=;_5D5LFRKL'!#:(PWP7T R1$W \<H#",$:>.
M"RA(N/0='DC.57T^7J)\%E50><O72#8;V-LXHJS<_<2!ZWHDEL@-%5%ZS$7<
M%A3%/ Q"A^'8(7*M5$ #>QM&8:#624> ?>&).$8LBATDW,A&W*.4^KXK!",[
M^\2U2XS>C\68JOPEF@XT"*8#Y+%$IJKQ'<E0-@/9MB@N64K&ZNL4U94LN/E*
MPK-^R\8@8RM*?J\R0O,EO>E/.#Z:3W^Y'P0QRL?:566"(1;+P&/GGR((/<JP
M@QR?VZH6L(=\8H>(V!+;#A%"A/[./G=*S'O9YO%]3MBL$.L-8>#Y)+%AX!=@
MX+$S89OZV/9EC)S8P8AQUT<\< BB/I.^ZW&;2T=5 >8E[+YLMY-1#E[U<?34
M<TN\2YQU.[I\M]RC2Y\Q(BF+(S]DC&(_<AV7@EU)O5"$,39'ER_*X[>/:=D_
MFE_9CV;U^L?EMV;U",9X!.OSH0+C/:.@<=/:AV^7M0_P[^6]0Z:;GU*P"#-)
MD> A:-E,%9!P*4?$L1D\W(ZX_9 K?SI5>1'&;F!'+@<=,+2Y3U1UBBAVN10>
M\Z@YNGS-5"6IZTE; E6IHTN'A$C8@8] K\ XB&P18&?Y1Y=+(D%SI+0I=#EV
MI'17N_Y)N1V!BL11[/J@'WE4(-\5+K+C6*BV[ %C_I/=]<L1H(;.-IC.(JZD
M)PZ0[:M**&& $9>2((^SR.,.=5V'[NP[MKVRH\ME$JEQKJXW@8Z=*5W_]#U*
MF>?&B,HP0DP=+ 6>9(BZ(?8(6) 1$6L%@^:4:!/)+ QY3%S'0V[(P+JP:8A
M\^.(,A8+FWEVY(-UX> 2D-Q23BZ7J@(:U-LH<G1^VB'S(QX[R(4G@5GB$L0]
MCR./>B3@PL'<C9Z*>DNE,(-ZFTAFPH]M$*DN<K@3@N[G!"C@,4!?1%1]"X<Y
M$9 9H25,[A<F7]N#RV?5KMN0<X_Y5!AS[O$"_#MV<(DEBP);VHAQ O:6"&WD
M1Y&+ M\- N)$?N1[H&FX)==[V2:F\QU<OGCQR0UAX/FDL6'@%V#@\8-+%O)(
M! *!8:HK64O$2221'WM1$ AFRYCK,@RN^[*5)I]Y;KFL?,N7/+=46=YIZSEG
MD/.539F@1>=#,4=%"^35NT?#_"XOX-HOSH\/)\VS^D52^U"^A7>3VE%X]^-#
MY>;'4?FF5O]Z724GXT=%US^IXTD210SA@$K$XH CX?,8^=*16'BP]_9\N9/S
M%=\R)+7Y)"4#[$OE>^?,YHAA.U"=L#TDN>W&-'#=V/&6?_JX#$@S1T*;0I3W
MCH2^ -(!EOFVBYAT(M!P@#9]/PJ1[0$@R<CV/(\]U?NT#) S1+;!1!8[L0P9
M"9 C*! 9B6T4!&&," MLVR<!\46\LT_R<\=5G3TNCTJ-@W0#R'1$0!]]=7ZZ
M/H_"F#DH#F2(6"0$$AZH@%R$GF>3 ',W6!\D-,<\&T9>@1\2',4",4X=,"D\
MB0*.!:(RHH2"]F>K,O$,EZCME'PV2_+0TT\>EZ?^&<S;-*)46;R.4$T4A8=<
MG]J@ E(P<0,_0K[C8P:P%\<J)')=:,Q@WH:15X!M-R*8H1BP#_0^AR!?A@39
MDKJJ2;)-6*S/''W"0.V[G_JQMN>.VY!OM;A&=WT^+LXLS+'$$WET[%S1\WWL
MQ:H6+/.X*KX0(E!>(^0$S&<.?!%R58(&KU,NE<F&7,^:[H8[G\V=8X>&Q/4<
M%W 2"2$HJ/O<09S";RX+?>G%D@0JFI_09Y\8KE^FX\R]Z5Z2R0Y@R&JY1<.Z
M$DF$DI85BJND(QJK[WF[(6"S*%5@L/2?8>4KK<-\W4T4PP(!R;ZG+H2N0T.7
M1DAZ1*IVF0P)T!^0'PGF!9' OAWL['L,EVS7Q"&]7BY>E,I@N'@E7#RF5CC2
M#7V'^RBFJBT=!7V?4V!JWV:!30**8Q8II9^4\(0SY(T/1MH,U2(,N\UN0X5B
M6*EN@1NFS:NVO)"M+/DMK4::O4 GW)=<D3]6HF5D,$WX[1Y0#;9#]]4\'-Z,
M2@OV1GZ"':G)SG%<%S<&HYZ&4?B>IL$ HZ(@8"B,.&@:MBL0CYF-N./[TL5^
M1&+0-$#PW,.G/XU/XA5P\/P:AN'@%^+@,2TCIC[V,?-1:(>>:H,;(V$SBAS'
M9BZ+)&R?JR*>[]L)+\+!6^6W&%(N(ADG8=+9+H?%B^H2)[(C8$116;1;L&S9
MT&X<Y9MA[)\%(A.YIUOXCB-] LA$8V(C%I$(!3&H&DX@6<PCV\&1!_8/YR7L
MW3_XF!V=C -C?;EZX?J%X>I5<_6X5\.S,6'*(\F"$/0-6R)NQP["7D@<0FS'
M<QA8# XOT0EAH2_"U8MT:%!OO76.>MH1C3R':F+/PN<X,Y;0CWM#'+&+.DX9
M[B59UOMAT&J!:$6'=!!</3IS?MHL8*$#AI&46&5+$((X%R[BOD<)%CB( JS\
M&T[)7E@AVR7TY7YQ+\CVLOZBSF ,ZR^;]:L#UJ]7R,]8V#YS>(R$]"AB'OSP
M[4 @G^"8$/@0LT UO/%*'KY?0&5-67^1[A-WS1LOYZI,(Q%!TD@ZJH*UB@J=
M7;5Y;$V*S<JG^(;"JD1I5]7#[LWL>: W:3F;210UY,LLY_^\X/H\2N4ON3 O
MH =^&A#U02LRHF&IHH'=TPJEH #8/D>N'8!HB#E&@<UL9#N^8,P5=L!$T1'2
M7]3)_.*X:7;9T>>J13JW#*P:6%U3'=O ZFIA=4SCEM(-PX"'B$>8(28C'W$B
M0.VF#HWAOS"T/94U3DN>O:CJ2R\/JUHEW^L(>&DO,VFHO-+0LT())-\NF''_
M/T%[;W\TH6GM;EL88F"[!QGZB6]4]&$2/@PB1('(J926"%5,EFC=JH2Q5MJ!
M]W52JW,A,ZE@1.^H/F.-DY9HA8GV?\('39A*MCMUTL5[&-GU'!C=59KI&,DW
M;=D0*MWL[742=2YZ8#9T8T%K]N 6$< @NIWIMZQP@1]<3C:603?T4XTVASTG
MX((*%S3<@,%M F#9)C0B(?4(%O(GUBFF^5T7[4$=L7.)@K84OY"(889O1.-:
MW&8[>R,+T4Q::&SAQ]=L.L5N(+D7N^%-W(UOE9/*4>6@9M7_*I\<?"Y_K5<.
M3TM6I78XG6K79>R'Q[73XT^5HX-Z^<@ZK<,_U7*M?FH=O[>./\-LZA6XP#JH
M'5F'Q]7/)^6_RK73RK>R]>GX]'3M)_='T@)\2;OPC"@K6?(FE$ITJ$Q6[8.X
MDNWB+P >\>?:S\>:.L*F:)\#2RKIZ(SJV?T!:\DVP#XM36'@#7&5R3>]7]Y&
M27;5$+=ODI9^O;[I;?'T C#5"\8DJ7Y?_O4 !W;M' L*-U?QYN+K7?W5F':0
M?^?A7=_WIWYM[^+_YV%3J#<'T$H>,9J>?>5#(QO[SJ'3I_S0G0\M%<:[+IYY
MJ=9@L(3,]-A'W*./GH3,L\.//M2_=^D$LS9GM]6X7_ECH*'Y[TR*ME5N13+2
MTG0X1W]$27^)-5_&E4\8Z%-LBO7>9.6NG!H2\,0);]O"X:>PP<)+^*[8?-"3
M/I&_9:LKW\Q ,2_+R_.?A<_PC(4QPWH-<M61V<OQ3<Y(R8=*;X4U$MHUV<[I
MVD*6-OYEI.JU/A KM;YD_DS?_5S>]Q>%I">[WY_F0'_1N3W!@RX\(AQ&0X$=
MP6(F>$15H&888E=$+'!_'BE);V,;H]E.* NH?]].FX?P(C6$[TGGXK";P7K(
M=J45-KIJ'0^R3,)_D<[EV0SO^M>>=_WN[.[B\HR<)+4/\$Q2M6MWOV[.U'LN
MO]!J$_Y_=Y%4FQ4ZY%UO5#^<7<,S[3-2O5/CJ]8O+H^/OOTZNZO]^E$OWYS5
MJ_3XZ*1QEHQ[U[]>_[@\@/&?7*KQ_*A_N3G^4&6U[R?P[I-&M?[^ N;%:A^^
M)?_<53LU[5DO=VJ77TBU_N5GR+'GB9BAV EUY3>.N' C1'W".'9]-_*CG7U<
M\CRR1KG$!K<,;CV$6W[D4<DYL:7C,N'Z/A6VQ('G<^I(&44:MW /MV8X C2X
M]=*X=3N*6YR[0@I7U>;U0\2$\)&*FE%5>GWBJ?;>(0%SJN2[=(UPJU"&Q\Z*
M<-X;Y3GJ/,"32B%89T?(4NV2M7[&@DR@M18\QU=263VM<TO>7,D6H. FFO.S
M)N!M^C->>6.HF?U.F13M\$(?OD4@X1OIE3K=M_X8L=?!?G^P:]1XES>/$^:'
ML1M*GV$>^& IQ3[&H1=1CPL^A\V4#_.@%1T-!EG.V:Q\T],\PO]VD[:,*JW/
M[30$)>0PS38F:7$3=)"P4ST<T4%^1Q^^L>BOCXT?I/$[N$RO:^3C1>WHS*[>
M?25G=S".RX\7QT=GM]7+K]>U9L6I'7VA9^3'1?4]Q[6C7[16_\JJ]:I3O?OR
MTXV]F 4A11([,6+8P\@GH8M<L,%D)/W0I>'.OE-R\?T0)TV_3R'1,+0CY@6.
M$SDABSS!7>KR"'[Q8NF#7CR'>KP@$HV3&QFA.]E.#76N"77"YS\9<<.(A!S%
MW!.JGD^,1!!ZB +1JA9I3NR"K-5Y$^3M!/KLS%R+>RSJ88-TAU=:'&@CG(I&
M0*X%!(T[%[%P CM2?D75.9'!/B,_"AQD8S# L8Q9Y#H[^T! )>Z;&N6OF.67
MX(\S++\>+#_FEW-M'H/-XR >255CF%(4^+Z+J.T+(5T1VW&L6YUSOJCLV'5+
M@,5$&[5K[:[Y(%NR+1I:"1-1,VDE6:>MX]-?L==FP\HF;8#F59 1H/#!"!$5
M0&R@=G%0>WY/NXJ8C!S*0:>RN3+*[  %0GH(!S(&M8N20+BJ9%()\U=X=FNX
M>FG*E>'J57+U^,%F3$/?)C;PLA> X>38B(.B@SCQ(XPI"6-56H@X)6X[:\35
MKZ,8VHS,F9<02>\=>6V@[K2*8DZO''\7KE7USU(+P,T,XBX.<<O7G^I?QQIU
M@:+$J$=0%$7*3141Q&F$D6#4]FP*VI2O2CI1MV1[2R_IM*D.K&WE_H5K7X;[
ME\S]X2CWNX#=-&*JOCU  ".V:O5N"V2[\#\22#=@?&>?DY+[_*(]*V'^1?JR
MUEX54UT?K+B=-GOJ6-K:1#5L@<;NJP+BIQ0%7X >-J4Z>!^2!YU&#"@O$)1O
M[JED-'2Q'V, 95=XB+F>C7P_]I$C0^&&!&2MIU4R5J(3VH4_N1SX>FAC!@2>
M#P(+4,<,"+P4"(QK9IZ /?(H(A$%S8PSC (98L09"PAH:Y$7>CO[GE_R"%]W
M#-B&/&[=F<M*-'M8?Q1.L3\W,0Y\%1G3:Y.S\,01;MM1>475B)!91Y^5IT,D
MOH%T;<[47LJGVZ.B@U;>P#!7(HP"L4 %XNZ>%<$#&DOI!DA2"0J$E (4""]&
MS'.Y'S+84@I6!"OYSZ_4;P[(UY>9%^ZBG<;,AE^?R*]C"C\/<2ABAR,:A"%B
M$8M00"G\)D,2 [M29I.=?8KO:_NOX^![0]6A0M/?0'UHNP.X5^Q<G8JA1S+H
M]&.+#(8^!4/M>SI/K#I0N)2CB,0^8K[GH8 #I&+8)IO;81BJUNML0O2U:;W^
M*CAUF=J.X=3G<.J8MA/[6!+J,!39MDJ5D,"IL2 (E" :."&WF6H7<[]\R<8W
M6*<OUGME#D=FR6K)Z?W5UU>U6>/#I!?=VY?4>6II*QT]13(AU4OU X4WU:-S
M_-,C..8NB9!-B:=BJC'RN1>B&'M4Q+%'N(N5'XC1^ZVEG]4_9F&'24MIN64P
MX 6TJ0<PP+#YG.ZC@LVQ8SO,P2'R:!PBAGV)1.S#GX$(N!\ZU/-55V:\J+R)
MY3+Y5F54U&3':J39)H;N/6*9+C%N>NUV<?;JHT^;_.LQSI<7HP@<9 *3EB)H
M\#T?6^"&ZC#"1ZX3QH@YH%2*4 I$8A>[D><XH0.6.R9^B7O/B4[<I%P1@W,&
MYU81AFEP;HDX-^:AE+;O>XX(48!MBAC\BOQ V,C!U"=2.F% (AV R? "W)0K
M"<#LC6*^TLM/K\NZ;MKJ BO+#NW76(/<M2E^^]0A;D.4;L_4&K2;+%F!R)(P
M+X.;J(ZST?;985N@A;P67>.S;)\JNEVL;46FJAQET6[!NF6]][Y3W-+7+FRC
M7<RB79 A*\JI75;H3\Q<)Z;"179 .6@7 4%^1!P4>#&/0\<AL*$/^VI?FA".
M<K TI/!<4G"BB,8,J( *ZB,6"C"H&7-0Y :4$,9C(IV=?;8[H>3->AR/&R%E
MA-1,V/1,P]A@T_*Q*1S%IBCDD?2X!V**VXC9*HD@##D*A..[@2THB^1<8FIE
MI&#TE840@@P]C#D&J23="#'*,.(^"*F04L:XXU*'TIU]=]>]'UJY'D)J&_H0
M?==_R @)&)4XE[F%FUG=3$96)X5Y-Z\ %^];O"K,:\PNWD CV.0$303AG @6
M:R;8X[#;([V#G/)J7=7OXCC6$)P==SM9!\@-5K2 XUD\UP:K9\)J>M^@L'W.
MN.H,R)5!(:B-?%<(A 6S?5^X<:1B:]>27@K%[1[9&(I9*L4$KN32<V,4>)0A
M1F)E@JHN3![H:#:-N1/QG7U*2C;W2L2_?]ZQ1CEI1EHL7EH\4ULWW+]>W#^F
MV[N<<L98B.R02L0\Z>1% ",W(M0FS,4N6U.*,?K%"]"+'X%<"'F( A%CQ'QF
M(Q$P%X4QI90'A/NQ:IN.2S[F)0_?K[^_1M)B:4V)-^MD?!,Z"2_B&=O@!3@$
M*[\M+V0K2WY+;=5O8A6J!09"K/4S5A1U\:(I)]L;X#[7F=6+[M62SZQ>=&XF
M6/U5JZJ5FU''QIFSZF#U5>8W&F3:4F0RX>4;B4SA*#*M-KS\17(R'ZI]2M?<
MB,JK8(3&E-J@9RPR:7CM2]$=7HC6N;02)2K:$@9T)Z/\"!^D1]+Z+;..Z@K]
M"FVNF4YFMJ/<U1*[?BC\&_$DY9K!USZQ_94VU-)^$$E+J0O'K5,9=MM))Y'9
M03O)X*LC^+-U_AF6(8W>2= F9%W<&,UA_GCA/#'-CGT98>(@1D!?8#ZU$7<"
M!SD^EF$H0*?PW)U]0M>D>);A^LTQ  S7KP_7CZ6C.G80$1QA9',5B0M CWR?
MJ^-:'HJ <.+X;&<?,W\]N'ZK^K 5+7&GF P;J(&M<>VLC4'IU>MF"I!KLG,<
M ^!^3MMJ@ >=3CL)NAT1-&0]_2S:8!(8+'Z:[V:XI-YU]2BT?P:@:47"9TAI
M8H# D8,".Y (=M=U5<*62_!S-; EE=EZ\5BYK<6#U6MM!@^6A0?A*!YPET41
MCQWD,DP1P[:' AISQ'@D<"@\@8/XN;K92O!@&TI Y,K:JU#3%E.5*M^->S5"
M3,VJYR[-ZY%=R]-E)XBMGL@R!Y!+ROG('0I"!F$48Q^%CNLAQNP8^=SU46P[
MK@Q#)^;$4UV&[1+(LX45N'H61ZUY@0*#IP9/7]H6,'BZ^JR('$\]V$3?<PB*
MF>JW&!('"4((BD!R>L*E)(Z$#NAPW/L9$1L%I]I*V-,V)/P;);_W_P,_>D,>
M>E8H5?><@A_W_Q.T]_;[\S2WF=O,;=M^VQ*$M'[BFP2,_"1\6&P3);9/I;1$
MJ-P!HG4+R&BUT@Z\KY-:G0N9226W-7P*528C3EJB%2:B >.&#W2 S>[421?O
M86374]%$5VF6*+!_TY8-T0'Q_/8ZB3H7O83<H1L+5+<'MX@ !M'M3+]EA0O\
MX'(ZHZLQ_%.--E<MG( +*EQ/LH#!;4+&W"8T(B'U"!;R)\9\IW?713\W[TJ<
M2Q2TI?B%1 PS?",:U^(VV]D;68AFTD)C"S^^9M,I]B7IMEA6;^*R?JN<5(XJ
M!S6K_E?YY.!S^6N]<GA:LBJUP^GDMRYC/SRNG1Y_JAP=U,M'UFD=_JF6:_53
MZ_B]=?C70>U#^13F 5\<'_[]U_&GH_+)Z;__Q0GVWEKE+U\K];.UG^ ?20O
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M\@D2(5J)N"$&:?B(+ TX\GS8,\/U-@.]&&$I;+[2;/[H3)E"I4*EU5>92]L
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MDS>(:V=!+#&"2.0)"!:X561C4YDV)VPUI-*2C("U0'I;X=-X.*H=T-E7/8C
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M^#,>LMS40R"-DT'H/8?9SZ6N?L]SO]U,?9$X-Y,X9 $[:!*LPMJA:+1 G*B
M#-$680]*0VN&HV0;FTP^J&/B;+FOEV/B(;GT8:NR%'Y=&K_.(81HE<?.8$2E
MD0BHY9&5DB,:N&&<,NE3WBB&Z4-Y(B[RZE/R1+PXLKU#>%J.=YP74QD.XZA)
MR.A4UE6=6Q16N:X=])#/6"8<Y"M>:N?U(![;*ISAP)K*_=%1'$S(_K0"70^:
M6+/3\X.L:%[&YO=.;T*=ES'%P2"&B0;:ZH7]3*&MFD!E(^02E15; )=$>L*S
M.<LYQ8AC;9 Q)J($P!+6$%#>>@"7;<;,:CC.UP9:K@N?+[^F2N'S%>#S.5 J
M@,V)<AKI8,&(9(P@(#Q!@00C8 $DKW/6<)N;13MR[0-DJXY2MOPD#?C8GN;P
M<(F+/1PFF=+B=4.*(I:6*);X8M*O$ )SXY"*G '\X G9%".B1!,*.LE(:D$L
MD;:@BX'[$A9[+'Q]#QBD\/6=\O5\E$QI1XF2*-7Q;JD2  ^-47!6,&#X8"3)
M<$/>?H?AB@;*U@!S#,8QS#A$9IQ?3\LKLG( )!/F]W-J%%FU1%DE%K-_I2:*
M)H)@D4VR?QU-"M$@>)*8,&=Q+CRIR,.&V(H?9/TA2.'L.^7L^4A<,HH+9A")
M $"XEQ10"#=(@K&1/'8:)Y-1"-./=;/TJJ.0=SU@A0[ D$$\B;UQ\7S<_VE1
MBW+J!;PX=^FO:G3T8CP<];L3)VV12#>22#N+=5>$B$99RO-.2(PXDX U!%;(
MXB0YPY1C&38V&5\,MA1GQTJS\HI%7 H++X^%YT!%DM$&:3P2/M>I3QHCRYU&
MF'LMM&?>);JQR059C3H%3\FG,0TPW@I-K*VQLQJ'3UY/%DUMH-,BCVXFCQ;K
MIAA%$]",(:,$15P9A;14!&$E,/P/5V*NFZ(7B\*6_(U59>75!Q.%@7^>@><
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M719?NMNNL/B#LO@<J*5"2T<I19HQCC@8&,B97+C#6ZT=S75&89$2K=N</<)
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MWSU;+S@_:%0D8!18+O=KF4 V@/$AB#?$L41TKAA*VI@N;I4IKH^'WR]S :\
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MJ2:[EO/B0'EQY&T7L3.-MDR0=R,YLI,<J.J:(/@T3#6WL:U3UR:Y* N:6^N
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MEL4#[^X(O'T$CE;_"/S*(^W6T71@6E%C@]0>4JV1-D01:(F 1! 8Y-,YFKZ
M[^7*H_>F@I9[SV3F'F13M'EJW? 83+^P,";VT+N39)'[5&8YZ$\."V,A:_/,
MIOE<Y<O45\]%&]ZW_,-43UX1NE>*FZG_\N,=3^O:IL2:6SG@2\Y?<R"[@=QU
M2"/YZN-Q.OVJF#^K';SU&'4^7S$QV8RHK8RV59Y/>2J"MSDC9Z[,9F,9U-Q_
MY>DLB[?PF-\,W>;,7WY;)%07.;PO/G5W;Y]8Y*/V0P"="(#Z@(!Q-)K6!DMA
MB''8/J-*U+^:492&5#Q)<_*O2[/NLHJ7Y0-9Q9O4Z25R%-PT%UQE1LA1'9I,
M&N0\%8\,J R/\E9-FE$]**EXRL/1Q%K0J%A(#EG\BJZY3*)TV6EA5MG#U/$I
MU=?[BB+=5N0<175_/Y4L#C,_>6665K#7'SN0HA9GLWK#!I]K9J4LPP^Y#T8Q
ML,O2&!O<) G?3FQ=E!IO501(_.2BL@KC4T^GZC:Y8F=XDMR<;,F-"^:"QFNN
M73>2',ST2ZJ?+((A*9";^1_*-A_'$;7[>N::QBLUBWB227OH=>VDMC;"N E<
MDI$Z6]=F?+&_+/&JWE23WZ&_^7RZ&C?2P_YQ9>OG5!";MY?:&ZGWF<:;RU)X
M,@_HL$4^>EI46)?;6H/I1_==F?V1S.U<O%3*;]:"Q?!<F@5=E&+U:W%^NHYF
M>VAU#F]6GR6'#PTBU>Q/Y/SFRJ;)53UU<D>=8]OD"[Y:AJH$GQJ(LDSD"MFY
M5C[SQQZE6&5]+9L/56P7"TD7Y0C<DN<N*4-F!55C/SO5JTKEZV+;AL;/(E:S
M^K!&55B2K)IK:5ZW&DD0RQ^\M#HO>>J+9KN(2M>35AJ'Q6E$0=M<IY[GX%.S
M44CN2E26U.?JPG>C\HAK,WWQS7S;N*H$X=WFFYKBJE+:(@8P=^;5GWRK4S[R
M,9NY@)#V_LNY,@7)[R66[F8$C;;@GU&<RM<^34_<V9NB8&_2577-FX9VWR &
MK:,$!).JNBSD0%/F@ EQ\EETL ATS\<TK 2EER4EJT-#5'I95GJ5L#SY7>$H
M;\^SQ)Q\UAK'YAMUMGI21V%+7H!HOGD_+4IZ^V6.]Y5EL[4776%5R(?X^>AV
M;BO79<9$"KY=0*3??L3%*MNRT*:Q<I.X<OUV_>O<R.<M@P(C*_LCX6;?%>9>
M?<EZHQN-#_2P?UZE%,^LN,Q5-__F7-#T>]X74L_*<ON=92%<DI29P^LIN62<
M6"RJK+_Z<HWN"LM[!Y3I )-^7K_^M+(9RRZTO8F-MTHV=>J4,!X-!@5!F/.#
M:-:-SPH;^;B@\FATGOM>Q!:*DH%Q;I10AIZ3Z5WOI/,F5U43T!\6#6,R)5?:
M#=,Q1FICV4Q]G,\@JP]O"UZ1*BLI&_K+ NJY,/S-?'/#I7&-*^V7,D%H1N.8
MQ+F9;E.V:FJJ5I%]_*@%S9^2U_5;DOW?&S[73M7;^_TP15OC$O^9Z'.ZT$C>
M_P[VM4**"B6!H#H RHP $B(*""=<..BT-?CY[']91D 6DEY32I[\5C=7JGQ1
M_*$&D&F3(C?A0*J%G+TR=P"?N5N+-,AJH\SM/*O,^!2U2*P,U>>;5!BYS+1U
M^CTI\>VW@;;?P"=[.,K)'\=U D#.;*G*)N8/Q.>?I?D8I5-R,JGOO>SZ8/[Z
M-<E($[(KMI'FR7S>DN('JT/=(OVQ2M=,_$)5(M7Q+--UED,Z(TN<'0;6;5&7
MGBS7W\U-LEL73^Y'='.];_$TU@0B^9M1B%-&@NN=]?W 39;=>C%(4F;O7"E
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MI;"4VFJJ@Y/4<T^D%BQZA1XNL(W.UB-!0EH'D!>B3 2Y\\2/U3E'O7*FYBE
MBU[/17U\2K@]FW4SS/;,Q;FWB8@E]6\N68YSRD<NK\_'6/,$UOVA2Q:"O^@V
M99%3?<"8=KVB)C]W&8Z[UK+CFE*GWXW+TOB38;_0Z).)6YM7<>4$\5)BZ!FG
MFBM%-/3(""4)\]ZYK.*H4G%4J+CSMG^D!Y/_N_9^^]TE&M_6\__Q _=N-/X\
MF4\2?17Z/[P#YWX\6NNEP]!X-?CR0 !MG;\E^SBZ221(#*#S 5!-+5 .:F!(
M!%TI*((YT>GZ*_Q3(-ZM\/VM,$=6..H0$)Q80 -3(/%& P618PHCB:A9>[T]
MJK"X6N37"R\L,D)%0\@W:S#+_+&$+CF;.#5:]V[!FL09PI*"/^B1XEL]3M3Q
MDS_].'-)=W; ]N[['_N"0!HD0H!KZ@"5/MH!%GH M=<F,"A5>$8LXMM^&NV0
M23;/>UD,GJ31\9N>1 U)T8Y!-9@<9<E%-'I@R_*;Z*EF+NE**^LOE"YL<8],
M+1CW]P/?:,HP"]K,.YC1]TZ9BMFYG*E[V74KN4OQ$ZV^B^UKS''$?DIY2W.N
MU*DNVTD70RN/@(I$AL&L5* ^U%R/8QSDJJ'E\Y$]5YTZZ&9Z].7SUKKZ>D56
ME'.L)N4H\@>J0M)Z3.5$-28F-32*G\F/%7>K+I?_)PO3C^(:1_-V$N?P?>9#
M+""[ ^[M77NVSQTG@D7,9B0E@SB&@,)> LN,AYI3YNU"-K^75C%M:'1'&%7:
M2F&1=9QR9:,Y0%@;Z.?6( /G,_;9KIR<UG1D""FK%L?]S,P99MB2(UJ-GBY5
M2GM)?I9[HEW,2)H+E>J*\8U>@[VT65]IYQZHN$K*[6O2FE;ID_FL;.*/=6;G
MG9V57:-_W,RAO#C@NLPUG(^[N^:(EXXSW>R_'L[; %'>4W.X^%L;?&;S_4><
MU"3X.\,&I?.\OQ%W3>!&4U!>N78Z^,N#)KRUNP?WM>;!1/<=:*,H2+2/(.H3
M!R[ZE(XQ3YD5:Z_A!EYT,HY2*^OR".,FHG#+T$(G"O<A"O;'O@D.82\XX)!'
M]P)*"32Q$& 4""9$4XYM$@5TL2C<V*U<;QP<#MH,3/?= "#9*;OZ1V>D;.]N
M_=B'G*0U%P JBE,#$0,,) 8X2[V76G#D:-M(@0%+&*2GQK*X&3.IM9?0.:H,
M$432Y^.-%M+2B^+BGUR&ZN5]K$K^\FD:6?(VB^2;.A>T69=S5B??A.H:58<^
M5YW&-2^7,A;+E^/?UZSTJ:ROLAE>^F(R>'(14]';<3KNFY-I1:_O^B'>HWBO
MXGHM&$D7.DBV(^F3N3K)BQZO8"V=SW%(3V6*LLHW.=>A/,U/+*I%BD*C_+#N
M997;3_4S]^G1:)R*7;[Y3%@89SM%\(N:^ME<UI,6W?7HT-9!_K+P_-JS6].U
M%6OKA[KHJ16_5?2TFK79&N6,BYR;'-\N>23SBI;&9X'KC:;=HURV4O*_SZU&
M56E?77EV0)$,\-09,U'UE?SW1:97LC(7A[\XJB2 #?M\-I+YFIU9'5+)J-2(
M@.3)+@NS2KKC-"\S$N"GKN9UZD"SJ_+2R2VC*CDE9U9*,IH4],)G\;W<A6R]
M4,9,M56PZ.4.MF63[T2_4)6N-1/+H_:-I^#D^*(,G[HMJEZJ2!FB$B55Q)IQ
M$1=;-H9)OT@,JHND4\%5P1V8OGT8=7Q4M!V='V&[EVC.#AA5/1\*&;E"8=/U
MESW24IU]*@&FGW#*KS0&7K>7_@9.@PQ8<,J@\,)3;XBQ"%N%N%-*"JW5_OMK
M'E(E'Z'"A[B;_U:V3^^.I1;M0K*]N<?VC?*0,P,!) 0"RF@ RC$-(!2,8^J"
M5FKM]7#Q6"K'$&HHSCMF.=FMWO95,LYDEN2;.R]'/!Z4>UBKX#^S$)1UFD4&
M<<.&N3I*TM@3,EHMQHJB<)945&5T:-;(_KMOLH&NV!E[Y=.\_1'U?I@?Z<]J
M&G-[WF)^WQ8#Z(1^F=!_/6#[G'I">!3ZP)0"E$,+)"4",.6QT43'!6./?=K>
MK?7=K+6EPF,:$L<A$R#N7 C$'0P!2CQ&DI.X/.2:Y^XY+:>N^9MU36O@X&J>
MO'\?N^&K?S(I395VUX5%MG<MWB=,(QIG%IB,!,&GK RC@#):6(R-]<:UPR+.
M(V4$PO&GIXA@9144&,*X(D@P>>DA_0K'0"KYN'.>])4Q;#]7S"%UIGMJ<E(.
M.Z<M5TU5EQ^ZS_L2OO!G2N\RU2G5?)?E-8NLYD5JD9RQ?3SNY^:,LT!+-E;F
MZP>67J])9/3NS:??<K5$IOM)-1,K5"E1%(,7\9>3_N0PDY$UW/QL\!555(])
MS;#>GD4&V:K-XDK-DD0K-S^;\4+?L_E>&/W_XUWTKP_6'Y7RHR!3^KTGD%SO
MZK=O6+]-5[]^^V;UV-<OOK[2P%@5K4M;832&BT<'9:E.\\7'!:SFAIIR9*N=
M/A=US14]3>;#S^.Z;*DRBI:T66]^(W=A;1H'*6L_!P;C=<9%?+R(A_=TO9O[
M'WYL^YDQK-'.9.X>9<72PN6+:TTNN-C,>BGJG&8CO;)Z^F?-O7NNNO8'*;KS
M5^X,'&&]<V%*%V;S&]EGG$<7,SB +.?1A=$>*(8LL$1:S(E6S*KG<U);BD+O
M_8P_ZZF?Y)0!RQS;+$DS+XH\38K1WWOT:3NG'^^$FE2VG/;)(LW[\.2HIGE_
MN;$FNK/Y]C0U*3*(6P=4< A0*370W&K@K.(A"(V,-&NO1T._$%LJUGUV>%4N
M=-H2UDNVIOARHM\<CNHWRW:?F<U\%HV:D4REIFG]8='@OBY46R]8Y!:8Y-<;
MM"HY?M@\/SP^/)ND9I"#U&W&YIA[2>"8=J7/43QSI6X6XAQ1CW?4!V/O&RWO
MEU&PI':MPXH=R_GA*(<ZBZ/=W,;6C08#G<JZ4\^:XVG9#FZ8VA,^:J>9B (S
MSN _QZ,9!T 77ZOC:P>G^YHHKQ2U0,-\O&054(HS8.)K1G F2'A&FU.#1GI>
M)C)I+D*_]G9'O=]\[XT;'4<)7OV(V;M\)-<_*KKTQ9^)V>.T&;0ZGA]G4>J1
M:_G+TI8<-:A[@TY*=NULP>8N@B/7K[A2FQ:N3E.43^K*&%A*SBGLXAEK4-'-
M>8Z)?>0GY:G\H.^_^]F%\P7+F%IJ##B<#FK:@4G-^9UA-#>&.*NH6U-7BW'N
M<A5O4>2P7$E*NR0[*;L5#<2^ KXN#0C<.!);@ \S4A/-A:>&QO75/DB(B<.6
M"(RTWT=$K3T@<<UR'2(;EW:SN0/LKKO3O9\UI]NL%V9U(/M;"=G'AWM'>S^V
M__A\OK7YANV=[\'MKV]/]W;WV-8?VX,O?Z3K?<-;?VR=;WUJ0?;1N_Z7KV_A
ME]T([9N#K]M?/^*MW=_2YT_W\-_?]N*S[^SNG<;[_OC/N<5;'_=#X!1)"(&!
M!J5"9 .4#P0@J>-DJN#E8FL*XI2DF 5&#*:8*Q4P,CHM#9<JI-Y +3:"[;_?
M?MK=>KN]^ZGW9GLS0L3[OWI_O_GP^6UOZ^V;3Y__>IO?N[+"Y5)W=!G=WE6/
MV6H\H3R)VQ1&T"JJH9'*2HR5Y0H10@-:NU\MN7$*:YT)?[.)NF?RX!G)T9OO
MNC](.8?O1N-/T5'83;^_:'4[V,=2>!$Q&'#-"* 8.6 LIX!:!(T(6K)@E]E'
MC^ZTUOM>LVJH[,U9%&#E+-U1RO0KTF\+SM7B'+QP=^8.PY>^A5[=0);S/T7B
M<!W_'CL_!JE_@3Z>^%?5+[_&??AXH,]>]8=YD/E+O\[;FBE*G*F4HMM3[K5Y
MVRW>+@/(BFX@EDBT_GLZCO^[ZL9E>'DCAY?_/76+[Q&Z02"Y\&VX@7[RO2A#
M/_7-RQX6T7A9T3UL]["4X&M=]M]9'PJ=B%J7U/3_KI&UV;E-;B3_"A__Z*%Y
MGR[UEF\K7J%S]^X#+6RL^7CHEQSE&)W$:[C)OVK(*6?@DL'!-+2U:WUTR3P4
MIV\K-1-O:KK7Q);]DF?BCW%*(VW4 J>*Q$DW(XT9^9#3[U_RE+Q+3*E_)Z;4
MN5FX AJ-MM\.QJ.3H0/E@UKK?0B_EL;,='3\*HZ]EX,-O32*7Y\2FBYD0EY#
M0BZ<DAN(SBVF]397[Y[P23[AC74TY/_:FMC+/\G*J.2"5Y=5<FLT]"EC8?PM
M-7R,@[H.:E\Y!>W5NLG4P=YJ0=GR>?NO]C3=:(C-H64VVY4:VPUJ'PSW!D$%
M(264(A\4XU@PAX+AW$MDE]=N =(.%K7#0ZW@465[)M,SL6Y=D^^!/-&XTMX_
M_SOYLGM\M/-'_$ZZ_N[!CYW- [BU.3C:V[5L9W<[OO?Y=/N/=_VMS2^'7ZKO
M_.=_#\V1&^P<[=$O7]^B-):=S;=T9_/CZ<X_7PZWS[^Q+1S?VWT3/__^=/OH
MW> _Y^^G6WWXX\/NV^GVU[VS[=UO^] 0:BVEP&L2 +7< :FQ!(S#^(9D%FJ8
MNJR(=07)!<?9M]&/"CUOH"<=6G5HM2IH-:.&RH[1/'7-;SXB5ZKMNK)JJT.O
MZZ'7]N_SZ.6A\=YH!J#!(I5Z(2!#1*\@.6%6$\893AV*95SI7SOTZM"K0Z]K
MH5<*ZG3H=>?HU;*]G%<&6XD 4EP#JI &!B9"2>,D<E03+FV'7AUZK<385@"]
M9L@UCV.=AWB7*+73MK&<D$*9B%+40$"YM\ PRP&A4FN.@T^IG2OH(?YL_/U)
MQO9R$G7J%3\Y&:>RH7;#L7N)Q^*;3>92#'_20">L<TP)3KFAU#$L%=7>.J,=
M$UAZWX7$5A_PMA9"8MQ@:F500"C) +56 :VC>TF,)5)SPXQ!:Z\E6V="WA;O
M+L&<^[+*.NU>+>V^;@BIT^H;:74[5 0#]-93#A"! E L*%"0(\ (8L8)*P@*
MT8S!MS9A.I5^8)7^Y0GI="NPTNGTS72ZM5-CRX)RC@,!2=1I+1607ED ;;"*
M2Q6]%K/V6O$%E5Y([^NT>56T>064N8LS/(0R+\09#(2*&@*BK2W3!JV!EO$?
M(VC0W,E O<QF-X=LA?;H%Y5"E,,,=C1.-.%3WSO6J:%7JNHPHWM*)[H6VETW
M8/RTT8X1RUE@RCM"F6'*$.1@L,0HBXGF7;!A]5'OXT*P 3'&J0P8<$=00CT#
MM-$:<*JA%8%IA&ET2Y1:)PRN4'2U4^^GJ=Y=M.%>U+H=;;"64,.\ #YH!JCQ
M'BBD)&#40FP%$@3KJ-:=0C\QA;Y1K.&1-;J+-=Q*HUL;-;/0"&$P@*GG)\7.
M D6D!$1Q+J66# 6S]IK(1=_D^L&&3IU?WO[<!1L>0IO;P09(M*7(&\!E\(F%
M(0!)(0-0:6<#TD%RF\QNN1[5>X5VZ1>5U)![7Q0M,7+[[RKLD((-O41L%T?4
M93C<*^HQR)"TGA&"'34H,>LPXI ESB(5L:\+.JP^^GU>"#H8X232T3$)C"M
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MT3]1' 0/O< 28V+]VFNZSN&M^Z=WAR@O7KN['(@'UO96-,(R0RPV$E@84LN
M8$$B<HG:[AB45$ 6[BX3O=/W%8Y)/+;"=S&)VRGV7CN7$9F B0-1<66*26@@
M!3$ .T.T4%S$-Z,7T_4P?$+JO +:W,4D'D:;6S&)0)B&TB1MYHEC6C!@L+)
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M8 ,BEGBX]AI)M$X4[-3Z^:KU767_=!OU0VMT>Z/6 2&=2A!,@(!2C4#<G"F
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MT @Z:8!!E"2^-0>DM A !XWEGE*G[H[M^!*XZ;HV/+8%@WS4:J$LMSZQ)ZK
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MDJGH218+3Z1!_$@1<W0G;,@R;@+LX)/\Y@*.;:,V0'<EN:V)RMPNC[(RO_N
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M*/TFN;\B;E*7<#2;E&(E:011+(=]P5U#M_]SA0]038"J4"13:9";;GARPAJ
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MOF?E3]3/OF%E I4NYZ[@$O&< <=($9 CEF%L?(PB6VE6L<"K()L3:MIP 1;
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M/G\$RQ)AE]5"*.QI(#Q!>])Q(Z+P)C"96 RR8D6O ;FV)U@1\39HJQ72AB9
M+N!'5DB&M!,^$NU5\,"*#,.KC,VKYN%BERQ['DY4X<ISX4K%B9X'6<8Y4;(D
M1AD4PMAZQ*7(SF24(!VMD50(*C69&R>:([*\!8O1Y7EH92FZ!;LPMS1H HO5
M*ZZ]<-%K#_\/)#(3R?TC6RI.M,#(M3/!B1RA*7J<$&81D,LEC@RL ]#F0O*)
M424]SSX65.E5-:7*8V4IJBQ%BXXL,[&B"F >!S#CU(@Z[$&=,L"*5$0\6@NL
M2%.D#'>1)6*(<!E@E":K6C^ZAG1E,)J1' V\HRN#T6T0E@R)+EAGK>7>6QL2
M0)@14B5EB"<O28XJ>)H!GCY.\)\4K?*:*T F5VAN$FD6(_(D4)VL,9* YD;T
M9-:3RAY4V8,6'38J>]#SH,HXZ5%!"9%<0AY30!6L ]+::@033Z2DCC M*WO0
MR\AP.;KW_[G7Z=OF\F1362)\G%LVE<KFM,#H^&6"<W%AJ"71(V\813S!KF,$
M]RA;RI51,9C(5];%JJ)TE?-G*7"]M-6MG]5652'9PB)99>-Z1D ;IWM2 )SQ
M')9E;,KII#"RCEC$!$M4"A(U4?.W<;TDH-V03&8TL<4B9DH81BM,1J3?$(<_
MS!DP&?Y^:.$B>(.QVK+Q/Z>V61N$?K9L]SCV:S]R&LMAF.:U6L>#(-"0 T;A
M^^]E<4UX9LPQDO'6\$WEB*:>F62PXI9;)QFUDGCM"2PXFNX1E%> A;L;;=PX
MVE0AG'<',=<W=UC][)N+@25C#%)*!,2%#<AI!9IA\D8EH50*[+8(SAP./+%&
MUFH?8CMVRUP4P\P2/V*O?W/<?'M ;*^M(9&"#<D);%+BV!#CL;>.<NV"YB:*
M^Z=R?O22*G[\#:\ T%0F.8.EE871?K]* 8OHFUY0L"M]_*8X989RAK"T#A84
MCWFS44ARK3%A3A*E5]:IF-AE_E&#]5#$33:ZO0PS[4:NV3Y2[O='.?P%1L7V
M .^*A9<Q:;:EI1PG*6(N'6/<8@:+2QO).=-18V]TM;06:VF)^L=OAF.?J.%(
M2@Z*F?(66>X3*&9))96/;H-<65?3EA;L!D &SG,ZG'(+A$VN?UA\ *IULUF$
M==<Z/P;;;9EH(:^UV[>X!ZRA.1'JT453;G)DZBY7O.>;7CI?2/W[MUP(75N:
M*;#,B0H44.#L"Z<P['*8$$L=S1E5)[:Y8OQZ93J+T216@ *=2YXVW.**M!G%
M/C>QSCK=&OS=[<<N_&%;P)>'Z^VDF+U>[?0D\[+GH%35>GO*]0:ZVL=OW 3J
M1>0(AUR0R5B%-!$,:4QE G5+XA16UKF^:;V]J=12H[(5.M!NN].O^=-N%Q8?
M2$M.%E7+W_5S&B<@[H.<.&NU+R>7JDHI@I?JSO6,##E%3FX6NCN2<R?$9L$P
M+M.5Y5M.;%8K&R>9Q5X?S%MSCP[>A],UE5,JG'1Z17:EW[HYTR4\Y2J3PC^N
MI[P83 B^NL4Z4(9/^S??,A$._D+3ECG<M0$:^7G8O0IF_QZ1@YD[1C9!9W^S
MS3-[WEOYY_7E"6MS; S'7__F97Y+DLD[DT:.)9FDQ,CDB!21$.Z5M-Y)$Z(S
M% -_]6+EJ1/1?/:',9PV;TQ#4Z0U&-@)-G*VG$;_?"_;.=YT[IF+K6_<!V!A
MA" >@H$? +:6*8,2YM8ZHX74YK;<,PN#AANUWFFK-5![KIEC!AAG!].>$VC9
M81*EWITY9;*I313V^N?-'F/,FL+J(<EC.%LSY-[Y6&;*G2(>EI/F]N\$8V^\
MLQ2:7:K.WB^'T!M-H5._3$(XV'#FFSIGJ<9B6 <*#0I!U88E$&I%#81J9*Y&
MYM.E\>0=W)QM,%D1WLNY( OR]DMA.IZHRO:&AFSC^_=N_)X-E]LP0(UV#XAD
M44QL,$"-; CMG,(3PM@XO04/J&NEHZYEW5O4@M]+Y I@@K)!&:82C3P1JXDP
M7*44+!,"_KMWP>_*J>D!/@"=\YT/^VS_: OO;!Z+W<V/N'ZQPW>_;M']HPVV
MN[DO#CYL7>SNP36-,1^ H^VS@Z/0V-G[>+:[=\SKFQ]9SD.\OW?0V-GTO'[4
M/-[?VQ'P#HUI*9= *:4X: 8#2A*H1UXB)X1$H)52T(>)#1AG'P"IV:IF"UPC
M_$D\EYX6,Q8.8?_KR>9QAOE;**R\N8S6PP!SHHS6'.%RK"3IM5I<%4[.BI-C
M5=2U#(X0I1 67"!NE4,Z1(M8PHX&J;CCLBA&:N:5EFY9,'*6-F9YIZ5 C*GF
M7FP8-H1Z+I3AV":;I&?4*1&Y,(*6&>K)T-Q+YNKB="<L7&IA(TI8UL'H:W.&
M>F[$&/>N%-+#.H@)18$5X@0S8%;1(:PY)T);2JU96=<C@#%17*MB,A63F2.3
MF0N#0>P)*<REV6-00OT^FA^K\.E^^#3&:&@DALO(D/7"(TY-0BYZ@B2)CH&J
M1W'"N9+HJI%+H_;-*?=!\6Q5'C<O,LI]*/V,JB0(MQBV'N0<]:06KF+6>ML#
M'_0/W4ZO5]FXYH=TDPDTA=-:ZH 19\0A+KE$QC&*<*0,2Q,TSV'-=!4TNU4Q
MI2#7ZTF9\,8 X6;KS2-1878SSHVUH::"0F7*F2<<C!,?G"SP6XVX3T!\E"+(
M6DN0DQ++J 6QB@+Q@?W_;6337<XVYG3BN2Q4;P@!#R-[RYNT[Y<79WO9Q2[7
M+8IA\[1[Z>5>!BR/>EU>SE!%YN:'WI.9/P-FC&,;40P&(-Q@CAS'L-(595'K
MY(,0@-Z&K%)#)O![PKMD&5-^ODY)?PTL;H@!%9%[$B@8(W+$)BZ)<TAIFL_D
M  J,B_"#1R>\L=+('*/,U_C;*!6UG&V\,9O=^TXWQ481'=@=Y$MX:P:\E^=T
MC[3@#>;PM'L%]!7IFQ_23Z8[Q4:!7FX4TE@RT-N)0D90CVCPPI,4J28Y3)>(
M56$F#RON3_H66%]_G5#P&DC?%#2H:-\\P6",]N$(L\^U1L9KBCA+&%E" E)>
M*$X%U['(?6S6^*-35BTP'BQ[&U7$0HY8H%7$PD,/=J.6S /@&\4#, +BA'3.
M<Y_%WVC'JS2LKP'^)].P>A4D5@'G4F4:<84I<I$(E(PF2GM.77JZ-*S+XXU;
M&0D?A1.5H_ZRP,,8.V3&*<XT1E$'B;C&!CGK#%+,1FZ3@CF7Q>DN9951\%6X
MV[]D1M'*W?ZEY'XBF;$/,F@&/$!IBSA7V9U5.>2P!YGWAD<<LKN]7 AW^S?@
M4?\ZG>8?QB8JI_EE19DQ=N$4X8P K$0"4,.5M<@&;Y$&[*$\)".R[YC4JT8M
M4M'1MU 3,">AO#Q5BS[_WN^463?G:7L9C,R(/CB6PKXROCRG\:6<]8UVSNU>
M3/I>)W]4V62>$!;W)VPRD6DBF5:(^\ 1!TA$)G@*ZA=3F&G*:(Z.GIM-9F89
M?&&C_1.#R<)!\?VYXNP#L*0HNO#VJ;N!M#);S1-!QXAE4I$&1P2B*NE<'L$C
M*VE 201#J4M"83LGL]6RH><L;<ST4DL!)8MJ\IH9+VZRA$W/%U]9PNX-)>.6
M,,=ET@$+)"ACB$<)9 R6*OR)E>=14._U'"UA%?>IN,^R6M'N!K'+E)R5E>T)
M$6R,#$4?? PQ(*& $7'')'+,,42=U1%KDB()\[*R/1L;>@L.3P.=H,@C_[0.
M3Y71[06-;B/37%G7Y@V'?C)':TA YFU"C+F(N P466L\XDDGT!NQ"BQGZEF5
M1JU*(N?O\?3"^N'\4IN],88Y^P L*5PNO'5M!#$K,]H\H7+<C):,M0)04GN6
MDU@#:71,F%Q?+<J@HV6"E&E:)ZM!OG*8G*6-RHSV7&:TFX&ALI<]$6:,V\MX
M4)SD>")L?<X')#VRQ&?[.W N0@3SK+"78;4(GF,5FWD+;.8I[67S0:OK]C!2
M&<3F"E%CM ;FW@89.#*$<<2YM4CG6L5)) /?>,^\65FG9)6*1\<\/ANO>4-.
M:4_G@#:HN#AEBBICV6(8RVXX8ZAL:$^(H-\G;&C$*.!Q(B'*<N%M*2C2H!)F
M%5%*CV525,W1AC9_(5T.%[8G@Z.%0_:'GO/.9826%*@7WDQW-U97UKMY@O1X
M[":F4AN.D989FA/52!-N$>@C-E!GHTAN3M:[5P?0#_"2F]-;+P48+:K];V;$
MJ<R"3P1&XV9!;500P7)$.8L 1I(C'3E#+"IB*/$I!C-'LV#%ORK^M>2&Q2<E
M7I4CWG-@X!@A4[E(%, @"I;(7"]!(,T"14$8P$-B&6=B7G;'Q6%DA6'RG_V\
MZN#?T/BQ/H'P\.'P34;:/CKM]1OI?"#VZT71]LOW+]JYSWU/ !=%B[\U^O X
M?PU )NK0TR)'K6UT!X7G-WJ]TU8IH[._R0*-P$V 6;SOWF&L9=RR[?/::0_:
M[<,'?S1AB:+/_K#3A$\ZQ1C43F#V<S:W5B?$9HXO!I "I.G'XI:4Q^U',6Z=
M!"_1\<>#&WNU[V6M+@!C6+VU1K]7B_\Y;?3/ 8^O +-VTH376*OM33R_?& W
MW].%/QOMDU-H K"OUFWTCE'JQ@@?]F,WQSMWH4.K-1CI1HCM4#MOQ&98K?WH
M-.$A37CF:LW"QY=ATLW&CU@8J/,[#/J[5OLC>@N#47PX')Q#VZM9N+Y5)# ^
M;, K=L^OWO7DM.OADE@TW[/9"12@X$?QQ,NG776CUNC5"EY<@S>W-1 WN T:
M*]O-XED+MF]KJ=MI0=NN6?#WW)-&,4>V7X,MI=:#[C1M-\_&:%\;L(Q@#11]
M:=N<GC.WW3D!%EV\X6JVRI_%9C/_.W+C?_\_38GZ'0;DK#W2V7)2AHV?->"^
MO),VVC#9\.0\4L..P-Z6WV[T1=OE+E7NQO!AL0!&WO/ZH'1C,_Z Y9(;;D7;
MRWV?-GYY^@<+LUA>O>N=M-X#P Z62;K*4CIX89@X[T^[Y3U7JR@OGN*.DR*5
M*8Q1HW\(@YF'R%_I'+ *4C&BT?K#82]&)S1?_V7M\UJY#>QUB_<X+Q=C#9[[
M(R_86DP)7JL&4YFO!UF*PX58O%'1$3OH2IY\( [03.YB[E9QX56X/ZA!U^XN
M7^WZ][_D^SJG("3 )KI%CH"1H?EU9$RO9+8;3^"[G JV:'O0F_RDW-]B(8[?
M8D>G#)[AX+U&LT'"HH3! B@ V0OE"A\?X-S=<;$<ME]*\.#":\)<7HCBP# %
M#SZT/QJ=[F!M7(>HW'(!2,WSW*L\OIWV0)C'Y](W.[U\48; RYNOW0&_Y$?4
M;2_8_]3>V9.\X=1V;/<X7LYPR%,'-Y?S\[JWE+.!YHYLJ;J7+XV*(;@^#^.K
MYSJ472)2;)TT.^<Q2S!,>:LX3"Q62$83U\G+&?X(L$-X !987D7!FJ*I; B
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MBACQP-JP=,A%')&#O4>8%*F4P!SPX_7%UX([;\K4=MV'_OG-;4\S"N-'J M
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M<HN@X14Y-,ND0CEKT/VR!$V=XN?-]0,(OH9+%'] LA_%;OYZ+'_.E*.*X3L
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MT6I,9;.9E<E\M;GX4'_.5.:-Z&4^8(,M2=9SQI41FEOM11)4!J6HY"]%92K
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M'#./+'8>&6&DEDH*@+?I/IR5^>^U2/R+'D%6$O_4$C_&6#S'BB7/$#7:(:Z
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M))$QWH)RB95'UC"&+,6 _#$9SM2\#43S$*$7-BQ5 %H!Z$(<#U8 ^E('@P,
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MZ?(NWLU(=LO3RNTEW^R&7<P[8-Z 0$4N:.&X=>-:*]?WCCQ"@ZVJN/S:;C*
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M0Q_HD_Y4FPWY6VU\U],?)M/^M_[8&'[OCW3CY"%80)(2YT]9..\% 7T ]J(
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MBIZ0(S[!EYWUEDY1!7W./OT\0'/NDM)MWA5*$3Y5:'WRE2>',20Y0O6%N E
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M3\]-Q=\U/5\-QV&<KN-C- ]82Y&U<8Z6C\G@O+> 3AM5HO.H6G?361Y=GTI
M?WQZ;BK^I]">WE@7BDY@1$Z@6# 0D'YTWAF=%<N2M4Z0KJL]5Y^'=^';H@G
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M\,-UVZ<3VD"L!(E.@Q+60N31 -,E,^UUXC<K5!]1%S=>T*=JY0Y5PR;3VE3
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MJ>M=Q]J$&E:'#-%D :BS=4K*4GCGK%@O<[RU'@?=<V1#N30GS)U6.SF/+,H
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MKN>&: ?CJY5=OJ$;OL+5[FBJV>FHF4 O=$;P?_YI-,XX_NO/K(UZ7Y^/Q[3
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M23XHXYDV5N,A%F$<<A$P=QG<^S$<]<9L6$?FNW'4N6;"8%V1J<'H)'6=SU4
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MD*VFM7,=P3,K0-M KW**/,36=N@3-[GL6F,/]KE<1]R=- FYU9^X-A<>IOX
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ML2Q"#BK2KI](/)8<$12<7-DZ;3ZVMN?7@/?B&-9*51T87_>VW^5(LQ5>,V]
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M+05SD2LTN%)%P"/;]Z)G_VDD;J^2AJ'#6WCJ^B\13:YZ JP JJ%1N!3([HW
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M\UA[,7*ET'&R[.K<E>)J:S_CR*?2G$N,2*_PNEQY\(G[RHUV8FX=>%@&\IK
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MA9/,IMC<3MU-SE@<J$-UMVE6-A)\'^[.DK176TGS214O41./BM5*/+*D8T[
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M;SY5BS #),^T BW02<>-DT=!ENO:*(OA8TLH]<.WJX_M&KZMAK[8O[\3VM3
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M$OT9BVR#4:N- BQ8CF*,,?*,C'^\U9M]P$[DVV$_^>2,/,!Y)+G'P9:MZO%
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M'Q4+Y2\X,#+NWSAP^=\)]F^],8Z/? 6K9G 1[TX.CN%-9],A2/G@LJG^@(?
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MP;;.7N[^F3E=-SP@3I\)^GO8;#S /Q>3@0?(R.->;4,QH];3$-.?>@(M2J
M5V]@56U5E XOO\AA7:0=84L*U(U)YMA;KS3TGKH"?9^RJ?)"_94%N-^V")F]
MO#&5S4/_%#=;JO>&BH1U%%,/VWK/2NB_?RN1: 2\<U0929Z8Z[P2*RA6[VH.
MK^<3Q0.DXSC^" Y$C1I?,$*K"T;H=<$(&0IYE :WL/;HR\W/AU+ #/T:\&#$
MU97H;:)IA06WM_Q;EE.GXVXI6.8A^,+M@?3*<3!6R9P\,/\@S&+LD=MM"GKS
M]JZ6Y<&*FAU&%7F5@V6&![,\.T)9VHS:\WD<,/L@/. ['G"9'&,#"S8^$(8N
M2X_C 6%J?_31B(LIB6"J36W3T?I8+'9?7]4I]FA1*5[)8L_WOEPUD)N2B,BQ
M3VA$@P)+]U&57,:I@>W#)BT#J^W NK&Y9QE)796@I=5;UIN/Y@\6N4= ,5ZM
MCA8T-3D\T! <^4*U_9^X9*Z-,='M8M1YZX@TV\=5'5^YRG%C)9K"='V%XMCS
M!?'IS"=[QTSH 0,TY]9NWMI#JC@>!ZFVM+?@V(W1+?9@:J&2W, L^UCU_+6"
M#P^2,*D3WMT[-]ZV:_?S@>KQ .)N<,N?#4$> ZP)3HZQ_]D@Y31^>[R\@'RK
M8B__G2+Y)(=MC*(HI0/WHOM.XY+3$@-ZHZHI]"CX+#1WO$W-6B6_'+?OI;>[
MY-[_)Q[G)D+MW9:\!ZMJWJR"G9P)U">5_DF8,%*69?E;"^G:8#P@N>1L<A/T
M![73_A#<ED;4MB["!O>9[_^[(,6F9WJ>*F55NNSC)O6/WYLD-0&R)K9D09$P
MEM2XXBQLW@YPO%@)9]2]:SD'N@2UO@8*"3_52@.SQ""Y!CKNA 4%+\MK14A^
M?)33V2XAN8C(V^O_B;M3C4H.=BIXTSO)SUNH;L[M/A\*&PC]*$7FG:D=%IR:
MHRB^U5_=B1YN4X_*0<O#//RH%QH$,9.N*5B]X#%FN38!TG4QT1H+F/T=U8>*
M.[YOGG%^+HJVKP7NCY8>0S:GD"X%V1#$F=R )Z=H>::UJX.NC5[65.H'&9[<
MVJN+WF97PS.JC:KH"^TM^?HUWUA7C%O:;\R!J@X>\C2!O?DAL?:DF.&78V]5
MDNW3,5%2@HA-Y>K0KB[[-X%MFHLF'YC, T]\;XI&QF^,+X*S$'=+O01U#D';
MFV$T'G)?+*C\&+2K.9FRHBA?F&(:^]V9)0@<A.?TH<T3!S4\'0WTN$&&B[2'
M$K%N:TH894-3,FN])Y\CX\B3;OZ^M"59^(:F+Z'$O)@$@3K6*JXU7J5\P:T,
M1#=C-1;? +-/[[2(I2GE-1F2LZ9.#ZW8_?Q.A>O(/B%F#:CCF[5])W</#_ U
M'>>")6$=%B,HK("4T 6&N-;9VQ7E98-\=M=/00&I\%BD2Y2Y&]NU*R=N5ZL
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MJ+;CGZI(\EM3^A?6'S7 \F0\;AG;#"\2&)2V=* 3.7>:",\1Z)_]J9ZB&*A
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MHNBR5_IY@C[U/1E+1C*7.G(A&G$B,P53P_W]!7[;W[?!7JJ%:X4>"WMK#S#
MIZK79@KP@ #U/N'A':WUPD^?"2]=C?GV#7,E2K'0OTJOM'B@XG9#0^70EIT
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M[31'I\[?OX?R94P^1TU$F5 *D^KD2'Y6[%/EE)"R[<NSZH[GEJ?6L_LR(S;
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MJ''D9<F\'W1,O.<L3G]0F!3LN5>_PZ\Y$7Z5M=Q?W"3LC;_(U<BV%$V-ZP#
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MT ,A^])N>#?&CLQ:FQ[;2*DK01(?<R=_@B:1$R?IGF5@H]+5N:HJ_\KI!*D
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MG#D@R/0TJ$W6\]W[\Z@(]*W\-:7;[!\4T\AYI"1AG?($=+#@D#UQ<,H$^?M
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M MI0A<^HK%.!>.PLE".$ID1XY"5R!C%*!;[M'U0";2;I4@'= (JYUU^21?U
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M05%Q-\SJ(CR!'TD)!E,!N!W9E2GK"&?/"GQG675_WXN8^YO,(9_7;ZKV>ZB
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M.?9!%(40=\\B5T;JXO&#[O%#1F@V5]W<DQ>] RC>KL0L]0,AO-"#.$DQ1$G
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MM^K;0Y;A6GV@-R.?H0$=F)'VXP$:%931KV4%2EB'H5L70.4JC*N/"..&=%T
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M>6,7LD;*/E$/'5A91#RXP6RD:(>>V-E%/)Q'I#/:H>/U\2(=SNNP$^5@\/@
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MD,=&>3N.-3XU8FBWY46]+=<I?BRB1?:1ZY[\E^(QAH?B;NVA^'P9%!;!,1=
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MH_8A?!X'UK2&]:#3(?>,Y&F9E]66D0^%M!GI._@>!Z;WN@1X"U EH"Z@X=
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M1 3B.VJOU!((Q6O2";T\_!#W[H^I?8)_C)_:5U]948*IU "72%C*,99RN(
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M(H!B@P!1$E:$E*S".*2!Z(7V!+U >NLV.G-.97+;JUJ<,^PE<>E4^;T*>IR
MC@F_]B3;<665\OB+\^;7N@>R>YE;EYP>2.U4Y^TD$P&<B,\OM:97UDX$W6MN
M3G7;B(WGK9K4:Z7&;@@^>9ASU_CU[[/)\Z.^_LG'$S?<Q]G\OM4>6*4P&R)$
M:6 !J-0VKE=8 LZX!)0PQF I> 7]=Z4O,F5H@?O& U=$6K?1_5G[D/&5$YF9
MS;.5FL.5DT(.S#V_;.X\]KA[FY&N(V]74'^W+JC?FIO6F:SQ)EN[DUE_LOOU
MW(37!5PV-P$;Z+W-44^[ZYW/5=@&?!)X3^[.7S9"?UOW29#8V==/<\<+I B:
MO@OOG^=VP&9I4Y?2'5X1C215D")"['NNK)Q4 0&\<G4#1)0E0[2 ,"@+(]R$
MH;WDG/%UF:@-866SYUOK&M1O-LD7/[+G)_L[&]UD^D\[;>-%_='F,[,GY](B
M>Y[:66NU#[+QU,VM"Y2?[$B!ZY.(.?7<G>ITIOK8=EHUC;E:U?B>W8SBQGZ#
M'+4:/5X^SQ-JY<:CF;+=?9@!_;?#CP+H8+O\N#M%TNKAS:3-%^O=R^8C[??N
MVG77W&V(L\W[?[/7NHY\F+,JIR!G&KF.?!QP;2!0E2$*8H8$#](.[\K0H5%T
M^_3O+CK&*]Z.;];5U3Q[$O( 9J_'TX*=\YTM+UVGAH-$WN@.[#4.N][Y%M0>
M)Z3UCN<D%?EW96:_KXB.P=Y[D70]7L36U?6CVQ+[5WM(L7[5.6*K3RA&@AHD
ML#&@<JU<$:D,$!B6@%&>4R@DSZ57EV6OT89&_-OV.@IX>A:3L;0_&>T" 1NO
M+X*TU\^B[;&?E!+#CNEW![[5=D2V7O#<I$8O8,<G)8H];>I<A&;8AHTO.B?W
M9,[>I+]M%U]_=G96O"^*H=VE7<\W%5EW+9FL,O^@4 II O*BU ")0KJC6 FP
M+(R2LJ1&5WZ9?Z<'&E[ZW_426%M!6Z>VXM@0?C@**N.Z*I&$0$.W]933"@A-
M.&"(X8I(*C O_%]B*2#MY>WU\#E;"UPGP='G]90"G:[?2SO?M)69YY,L0Z *
M>1>E@*ROEU D=('OGW.(G'[Q'+VZQS?..0]V7S5G/QV[0<^7C;S]A"\6JV."
M/\>+45$52#O=E (1 1""$' ;Z@-,$(.4,HY*KT/GLR,-C11K^]:-P;/?G8VA
M#7J.HLHI(=RP D"L[6(ISQ405)7VGRHW3DFX,C L;3\)KCVE[W>)K.\90P*T
M.G[YA,$4<3!P!H)D^__'QNEYF_^,N_N[^><NB&Y(U'1JNY]-QO)ED[M-2U&4
M-"^!Q,38@!XR( I& -:.@0F6RN# ]D,'!QH:T6[Z$NK (\BC4/J10 J .N:
M#38N8]%9F?W>_K>3O/1SD*3K!'1XF+[[_IQT]D"7G].?OS#V:LIY38%S31D&
MJH#82450&W!A:!?W"#/!RD+E04W'=V\_M(=_;5UD"\1=[ )?_D,K'?<'(_YM
MWTF#PMV;O\U[_72SP<.?BBQAYHL?[G^N3^%//G&5TM=3]>W';+Y\T//'V^E/
MO6@*J$>P%!1"2$ N*]=+AMG5$]<EX 5U2M557HJ@=[K_T$-[T)W55TV:DMX8
M7Q=?+9SYP!KQF(TW#@06]OK/B1])=(-TUTN&&F3W_[,MNZ]JE&O3@;,]N_5
M.;Q..!BP5 7$_@/W6UD<#,A>R7'X'6+%N[<%5VJY/WMGUTIZW6"Z303EW_5(
MY$1!I0R@)90 *2Z P%4%*H15A:36B),P">^ T8?&:YO^ZN/6\&QN+0\5]0[!
MWX_ .D.U8P[;TU]:F5YWK;_*-H!OS$^I\QV!6C*U[Y"Q>];\CH!E7_D[YB9Q
MC/9)+Q9:K[NP?G)=6;_JJ?Z#3QQUCG)E8"$1!141)4#"Y(!J)($6)7(=$RH!
M@S(<SXPW--9JS+W:ZNX\T74]Q[RQ.7/16!B'G4/<C[42XM@Q3ZT@W#1M_M1
MV)J;/9R",)B8/(%)1$7G1NN5?#Q=?TTWOI=%"L@]SZ=UJKZ-R#Z._W0_K1N(
MPHH31R8"20(0SB&@,E<NA9KEBB!B?QTD&W=TJ*'1RMK2>L5A6EL#5>&. ^M'
M(6G@ZI@]=I%:F=E!^Z;S:*12>CL^4+_Z;F<=WE-U.W]%'$=<UXH)K5SZ6M<
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M]:.?4W">9II$('5,*A'X>-.'!P('F&*AY7]\G_W\W_;JAB3L#QMN.'7/7FC
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M:Y0)O4:TEX#T.M2]Z%[AS46OG]78?@,^VB%OU:BJ.*P$EZ#2RC(?K@B@J(!
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MGN@O>KG)T'N8W?#%#VO*S[%RC0A^JQO'K%/YVL1=UYI:+)9S+I<C@04ED%"
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M['!F_6+08<Q7QTR>(&7,N=N6Z6XY?)6MOP7.Y\1Y8YU.2\KTL6X,[3^+K%/
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M0]U&R*PV-:L_ENG6V)!<^J.X>@1 2=#J^-FO@;HS66-E5IN9?4@)5$CY00K
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MBE6U_E(!$-<,T(H*H$K)2D),SO*@_*C3PPWM+; G-+^7>1G?_?(,\#$GA9?
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M]_<7O73E%O?SV<^QLJ'!RV\+K6ZGMU-WZCJ>?K]V*EQU%#TBI<R14 @40F&
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MT&*=W0/8G];238)&P(O]&*0>@4\"H+H^-=DY8_W["J/361G^& 6$/PFPZBD
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M*EX"IJD$2 D"J"Y*@$5>222,A,9+<OG(_8?&\:T<7&UCMC(R5$%O%\'39)T
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M^BO=-!G5'^73KFW !\W&?/Y$%_?+_Y9T_59_3V8%ACB7' &E3'H?SC@@&$+
M>"8*E"A&D)L^E(\54Z-7_35#CC)07N#;A?.#0SHP_QK[@7&@:B)BE.\J'W[<
M1,;8R%@;4"*J#UBA]**\;!A7/*H/3"=*4KUNYA$.FLR=59NY\_7KO"SU:_"M
ME!_DVFB$T\_ZM[^L5V5I/OAAO>)2BG)&"YF1%%.0Y@H!F'(."L@*4&!*8"P8
M0L(JS<;?A*GQW+/ED9+2%%5SZW3F'A-A$5<.#N_0VP_'68,[H+43-]&S&^9#
ME2-1=4GKRN!SX!"Q#CX7(T6S@\V)6[S;"\[.6-COSN/%R;T\/XBA^]W)[8TC
MY'QVNQ5S/:7OS,R:YX7D628D08#* @*H8V= 4XB 4214+!6"Y%91\YE[3^T=
MT9@7M?;9,=,YT+IIOR<40V< V*)@S04=_IX)0TO)__7SZMN_Z:OJ"%3_\!QX
MGKO7*(]UAQ/M\]KU$?<'\<URHU<.;^<+N;ZC&_EYM?XQXQGA,:888)[K):PH
M!&!,98 E$HJ$8$R@]<-XYOY3>R!K$Z/*QJ@UTOZI/(?@]2>S)RX#/YUND#@]
MHAV.>SVFY^XWVJ/:X<S^X]KU,<\6M<TK^*TVIVU<^:#V=L)FC*,TR6(&$('Z
MC1H3"4@N4D!A$<>Y$@2+W.U0_.J8TSN\;DVNRTU-5^_YA0;@-V;;W_QJ8XX
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M8T(IST$1JQS Q*A+IH(!CG!>D"Q-B(*SI?QL%+,?[5<];E98?;-)_<T^L67
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MZ_]N?^Y_>_N-SA<F#GZ[6G^B"_E1U@O?7^A\.4L(RJ3"$G#]S@>0F#Y$*1.
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MD8Y +3UHQV76*@81VEB)NRNOA0H]7%0TD6C/J#B8+L?+[^_&$_QP?A9Q/J+
MRAFF/0@9*!KC=/+Y&,D1\CH;S-Q9K79"P]T5UT*!&2X*=I+@(+1_C)_&50C3
MY8=PAJ/LL; D,P@A&=FT+( <7PDN!EM\+$*I%@BXO>I:*+!#1\$.DAP$$@ZG
M:38G$[82_ G)'_=GY]/E_/O^+./(A&Q-)$Q[04ZQ*IR!"[P 9DON#QJ#D34
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M*@;?A,4XC6), AU!.@KGZT,+BD8+5U (YY+9F&UNG>!^D)!^J^RZ ,ON\AZ
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M_Z8U1AXY0C*UME5%.GV#(DL;I*Z=E;12'0[8>IRPQ@D$8D8DRR.46-\ME>3
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M/T!/XP()&8RG_<4!51T?$FL-G(L29)0B<$F[C;5_+C[( HG=-/],7<0F8A[
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MHGDKQL?)Z?>]7V^^W6YJ&4Y*[U8.O;H 1U^J[A97UCJ/I!8V)26 >25!Y2+
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M!9WK0?"U9/5?3&,#0.7=)QQWV4E6T,E>$H@08YV<Q2$(3>+T+D0*B(-VO#$
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MA5!7$T%O%)=,ER3UR7GM='M=PG[P+4W.2907S>?/OIPO+W?)XQ,MM>91:[3
MDJL7<S:#D[7O2++,.&F#:SXDH#T7 YU!N@GRGJ@CZD/5K\$6WA@0NLM;K+L?
MTN4@TP[MWU.C*X.*(F5![J'R&93E J(S$1BRF%D=QIU:.TD=CC.]X2V4@C5,
MQ!^K'9.K4EV":1I/QBN]W7&<I2V6'&0%V@5!#@%Y*#YI";Q$JX6,G)R"[OS%
MC>D=[CC433#UA+_7K08'%?J\O22 F'SHE<Z]BAERJ),58&N+$L5-@) 2!RNL
M11]=$JSU<\@M2>TWG=4]1KO3VVLX9=\>G.P?'WZLETA'[][\=G+XX>#DY"TN
MPWBR957O$Y_709WONM2WJ@"8?PH4CJ[(WI]-%[/).(?+V10?;[!THS7W"7T'
M;P?3*$V.7C*0C,MJXRALE3*"U4IS+WS*LO6=3A/"=Q\O19J98KYR8O=2.C\[
M7^4?:!>.TYA$HXTP)@<PF!SMK\C *VG 1$03D]&,M\[X/T]5SY4!+XZY^W.H
MFNIM<[OH+[;[%#_5-9M-8;DS[X/D>?)Y-E_6(M?K"0Z+42F6N=I".$5>XRE6
M&_Z8!+$PJZ+DR$/KYY'K4]?O\=P_-CO2XVLXN]>;*OVA5O94'WR'4WW+E7J:
MH_TTQ]W/TPY*:VV-@"1K,U6C%/C,$H&->2TPH0NMB]ZZFZ=][2@__GJWNL@C
MFSC:*#-H53>Q1-I=)B<P#',,@DDZ'SJ+:)ZF;; SM3=!RN,13$/%]!A1+^;+
MT7&MAMG[-EZ,R$+SZ&(&KNNL+1T0O' 1E.-2N$)RR6OM(?K4&TBB/UVCZ-:"
M_4*D&UW.=A7L$-#P*YY%G(^\+Y)\3 51UG'?UEH(O!1BG'->T":Y7B'Q.GBX
M6+(?1.R@K+OJWD)R/2O\U_%T?'9^=DFX-2AX0@/:U[%#N4@(%]U8&:I"/F',
M:^5RGU'YK45[5OHV*INUD%_?B@_?;A).SG@VVH&P0A/AV8.WOO8LRCIC,<7+
M%GO]UJ+]A%'-%+^U_ :00G_TR*,X 0\I5J3(S6:?)7'$!:MCU.GL"S'5$A3A
M0\[,6-:ZBOQYJOJ-O#MU&3I2S9#!]ML"R_GD_;C@B!6F!/,<DA6U WCFX)6@
MK1A2R"$P$<2+H>V:K($VAMH2">L";4NU# !I-^:PW)V^\C><Y'>S.?$VLC:+
M*"V"SK4K( \&G#866.2>.293<JWSW6L1UJ]QZQAM[54S +S]-IUCF-12R5_"
M>/I^ME@<36]F/U<^7QT\%7VJ4SS)MR!!>7!6R.P#P^):O[-_AJ1^J\4[QEA+
M=0SBPJ0R=%6,>QJ^O<$IEC$QXG)D(KL PM4!BUP;H+#508TOM)(4<?C6%NP1
M4OHML'X!/.TJ_@%8J1_U' ??PMEXNM+.1YR&R:I'\S0?3FDMVB0'WVH].!GA
M+*7(@D%6Q)1*P8'CV0'YKBK9'$QL_IY^0Q+70EUG<PR[/BD[5-< T/CAO ;,
M1^5';X_+P1R+$5?,J"($B.(I$L\\0 P^ YKBF*;@FK/FLRD>(V8MA'4VIK!C
MA+51P6NXKMT_>O]^[\W1\>K%_MXOQP<7 QEVN)9]YA,[:">U/@>#*KB*WF5O
M8P)N%+GR+-8Y*<6"H_.1)^NC;%X6/(B"J^LDT?YL0G\_N[@7O_GLG,CY,",K
M__!?G])7"R+DQQO%$3+.C/ :,J\7$;HV3DTB@_?9),:S]<TOM]MS\6<HZ-H$
MTX_?'?>"BYYO&_;K=3S.25G+[Q_"V<556]*\L.0RA?=UV%:0&KS-)-,<K7,B
M2+->0?8SEPX/K3V4N^=^L#!KJ)B^+ZSQR_D\?0X+W/LTQY5P[K+T=G86QM.1
M=#;'X@PXYD2=WA6(*>D@"A&9LX*A6*ND\+GK['4)ZN_><W>=S[I60-]3/O\/
M!5R+-^/9Q\]A?A:NK@JYXI9)"\S*4@?=<O"%1,0,%T4XY9Q3S_F/CWYZC]?@
MW6APUE*<?>/A8YB'3[/IZ0T?_9(+I5.(3'/0RM2A@(@4B#D+.I&G(%<O5]A:
MH'ATB1[OR;M'1AO!]GP(4;R>S]/R:'[99&%E4$/,J(0P$#@2O$W2$ TQH:5@
M+G*%!M=*_C]SWCRT]E"NR7OW;G96S#" M2JOO^!@<;GA4D$>0]:@1?*@/":(
M4; ZD!2-DLFKL%;?HO70=9^ _HZKW75Z'R ["KCOT^G&/JO=9;[B]/RJO"F*
M2,<,(P.J:F,"@PJ"5@RX-,2(9(ZOZ;,\OD;O4-A5>[/VHMP:$5]Q'F<-+,?1
M'U/"UN?QE]7V8,J29Y4*Q,!=;=I3P$NMB/1"4DF<66\;6(M;B_9[U3R@0VA[
M5?1\^OP@_')3\<@C[1L-*47: #E%\+0EP$B.0D>OHVM1'7QGV?[,RPZ*>TC]
M6TBQ[X.E#D$]JQ[_N_-I7OP:IN%B<UQ:Q!2D\BX6R"4BJ&(0O$':%MF:[$Q@
MANFU#I>GUQD  K;1W:P;00[@#K>!2;V^R8S:J61I2[%H#"B;,@1?*,XK7EIK
MF"/)-+[=:$E_OQ4P SGF>@?& #;%I;-XT3YLNKHP^GV\_+Q_OEC.SG!^.*WM
MQ<;33[7HD?Z_5A2-DA#")N=!^D!N*G+:]]QEX$QC"!DMRZW'X6Y!9M]#9_K"
MU+V6#-TJN->8X8K)7\?369VM<U5E].,$_(CS5-7^"=]\7XF=)$"B)WXO?H3\
MHU04UPA">0:*UWM1$SB@IM@[)9=D\\?(6Q/;;X)L,(A^&67W[<0^)N[?OI!J
MR"-#O&R].^):&:YB F%K/T=/8;X75M56M\JG4"PO92U_=NTE^PV2>P=BA_H9
M*NHN9OVL&IZE6K^Y(/Y&(FD18M'$21V55AQM)ZOH*Z2M%8RG<\/M!+R'5NW7
M<QTV]G;6TB <T@42 9^)B[?DNDQFJQ+2R[+ABVZWU5M)_SP?$W&'TX_S62+'
MI?;['KE0+]DH#'6Y"E2; I%%#\9&VFS1QQ);]TK<@=Q^Z\%[1_)+*_PU5/X>
M?OC[P<F/,:SO]@Z/_[[W_K>#7P_V3GX[OJBAO?$T:(>"X.T6ZJ E\L[\-BH?
MKJFN.F\#K]N'7E=0.O2>RT3P9D6""EY#+!0/J>2]XZX^Q6]M5YZB9^?)8QB7
MUQW$][Z24&L.Y=UL?A(F>)%/84H)GE%"T+'.0A4:@C06$BM"*^NYY:U;V:U!
M5K\Q?3.,W)O_U5@A SC&?Q0D7\^B7]U'U">+&G,!YNA\4)%9B HUF.RRUIP%
M=*WSIH^0TO.TN=8JG[67_P!@M'(W:.7KR_(:S9<'N%N<TD<N'OZKRWL0IY,Q
MWM 6S8G"_Z =1.X<Z,!J_"^]P]8VK27]/1N_%H":#42[ T#VK[,I?O\US/^!
ME[=K%W=JF9NDBI(0H\JU/2Y"M*Z SDD'$=%ET?H!TL.4](NV_I!Q-]FXNYH&
MD2'_[>1TCH%<EN_7I\XE+T;$P'0(M<>M!B5KM]O:/46G(HT/ILCUBO(V>9?_
M*#7]YK@' [M&ZAH$]$@<%,&-T_YL_J4F%/"V[W-53""X89PVDZL>CT(1P*=L
M@,=<I,]1E=@:A6L1UF^N>S" ;*_$06"3_&T<?YH^S95/2@3+(P5T]9$1XQR"
MB@H*Q\(P)&&P]1WA.G3UFPD?##*;JW 0P+PQ]^U.;'C-VW7^U:(K(3 &R*RJ
MCY(H4G0:(=L@2PDEF]BZ9=-&!/8\Z;KC6+L[70T@3KG+TAUAGLWFR]IIJ*;C
MWX0%!83"QHC294C:<%!:%?"A#FH0DD>FO4??>L[FIC0.Y1UU<[C,7E!WVV-S
MM@R3E\#F]?"97^:SQ>)VH[4W6.C@J-5.T003A)!@I*M5(5A=ZR" Z^B*ELZF
MV+J<K0GA0WDOUS.*.]#R\,WNHTS7_H'73*?"E<O$;PHE@B(6(5BI()$K9&)V
MM*M?V!:O1_A07N$,%=K;:WG7#I&GG2'\FN_;4AA)E4U@Q0,F&:KOKL 7*0"=
M%UG2OJ4CJF,0/T;;4,KH7QJG373U)RG(:#$V:YME^BC&>)&!64]>LZ=D&,M,
M@'>K8]QX^LI($,D%9Q&U\ZV=M?Y*,8[O- 8>R;H)K'8@/:_<>PDNU:DOEA<3
MG8RQ^8#!S2@<<('&)LC9K$!C)S4-P-=\)C^"\[.1LS[SX V$FJ53T@F(07'@
MR8N2@DZR>??YYZGJ-P#J"6P;J^-/<LS^$/>OJWLQ?($*R">7[./X75\&+W$4
M8V:9)\S@F*>PPWM&7P4#6H7 ?4I*-.^XW>51_..SWWQ_$R9AFO#D,^*2(J_S
M+^/IIXLTL=(JA6B)9Z7KC!R*MSS]"FAU?1K'A5MOXM0V/#]!UX"/W4U0<N]J
MI[5*!G#8WN#IQBY^-\=_GN,T?5_55*'1'J.BT\/7*"H[8HE.C7IYY1GQID)J
M?9VS!ED# 5DS+#P.MB:*&1+6'F+H\NJ5UBVVN !1%/)4/#DIGI'PA(C:Q"*L
M,:U#BC7(&@S6VD#A,:@UTLM H;8XKE[LG';GY2T\1\U+00.)U_;_UBB*BS0'
MIYD)0G,,S1];KT/70,#6"@QK@&TGS0P);6^^__CR;V/RJN?I\_?W]179Q1[U
MJ?A8NX"86BJGM0 GLP#KZ4M+$LVZ0V_M"<H&$KF^P%':2CU# MW-C72?O\LM
MJWW)-EA'(;HOH#!D"!(]L!"L=CRJ6#I[,[8.@0,Q>@T1LH[=:Z*N(6'Q</KE
M?+E828Q?%0CSY"V&!(Y+5E]DD/CT_]?>FS6Y=23I@N_S7]PF]N5ES%(46<T[
M%)-#LE2WGV"Q>%"83@)L(%,E]J^_'@!R92Y8XN $6-4/*BG)SN/+%Q[N'KX(
M#R)EK[@N1;$R%/)^)*<3G+4'P5-P.U CG8)+7#<^),08$J^[XTA$.JUVA2M@
MA;G(8G!T,1P!7**';H%QP;6/1CH%E]RP$K+DQ<C5F%HZ)[6Q/[K H&3'$]=6
MLM!ZG_(SY(Q;A#(NN/;12 _@>J))T7.GZ)@X8,E7/P(%Q%P;MU (5;0IG#5/
M<AS0=3P\J ;S_!LHH ,<-6UNP(Q!)E6GO).55BQJ,M5>U)40:#QYL+9Y<?[/
MWW:\$Z"&;#O>1;L=(/N)?E;E12:9"0BA!%"A2++S=/HSUYZA),_"-Q^#^+.W
M'>^$C.W:CG=14P=@VZYIT-J8<HQU:F]=3(V<XJ20 ^3@O'(AZ1!D8^RUZ_P\
MC5;D0Z#87HD=(/.9_FJ13+;()8@HJJS00)3D_KA<M+"\J.Q:7]<'ML.?1O?Q
M(1ALI*X.@+=5MRK31#@Z!>3)U+?%7)L1I0&A,],^8TP/-Q3\N^'X>&!LKL(>
M8'D3&#X2%OZX7/A5^/9@ F3Q113F VA>]XQP3R<P(*?_E"@X.AOR8$^[>](\
M+IR/^ AW!)5V .$ZP/[.UFMF,L^^UF>44L-")L'7_V1>,"VD,ZRDUEU#]RCH
MY.'C*-I_V"ZTORJZ&+[P*BSK.-KZ/Z__^VKZ9[C NPO5#=T=S*@ ,?H$M>,)
M?"H.?!"9CJ@GOZ.UK7N>HG&A=HBV'VYB:2?X#BS2X]P\4BT[P:"X9#*!-8+L
MO&*U[]X6*-P4ZT3R(6VUZ>Y@1#U"W,A[5!HB8BNP':J>+@S8IS_FB\O:*7)G
M>O*-S+).,B<>P<I,OF\=V^@DBT""=%I9YV5H71_P'#V=O.&.<4\V4U,'QF[K
M%N'$-7(E$E0&00E,X"5#0*F5H8@]HVM=E->TG7NXN3#-T+!O]_8NJNG"SJU=
MC\=,MI,I!E4,%&%3#? -71&9(O'HM%$B9%V:3[YXBIA>WGQ'BP0.55"S44,#
MMC!^^'C^X?7'S_]Y]O[7U__?W]]^J U[K^9?O\UG]1S/RX?%_!LN+K^'6:[>
MQFK)Q0'MBX=\KGGK8C/>&[4M7G_O P'^\NS.1V_,:2@L9^,U!.U5+9HBE]&1
M6T=NGBU1$A)]:Q_H1:+:C0Q\\E/KK%*R='"-]&"9E75(AX"@L@:>R,<-,AD1
M6S^X;4O;N#=P6]P\/2:PH7XZ\/R>Y.:7[S41ORK74,4&)U8A4UU!7,<K>E6P
MEG0S;:Q)DK>&W!9D]3('L"4>YL,JIV>\58:N5UXK31Z%C#4O0"S5=8_1DT];
MF%0B.^7H'\?"VRU9G5JW?:&P+=3VU$L'4+MAX6;LOW44)#G0T=%)C.0%!R-)
M6D(([Q+= :)U[/J A$XAM*^*Y^WDW0%<WF%8XA_SB_SVZ[?%_,]US?:&E<)<
M,4XIX,I0O!.] R<X!Z,<!>^&%RU;>YS/D#-NTFUH&+720P>0JF'4%?VZAR>#
M<6Z<EI:B<$V.:$IDJ*/.(*0IM;R@A.85[4^0,FYV8V@HM9!_!S!Z<[6832^O
M%D@B>C/]J_[;S2H;H5CFA8$0SE3O,D((04.R]>T.7>&V>;'1D]2,6Y,Q-)@:
M::$#/#TIJ3MI0U>82L:"4W7>:+()0MT3YM PK2VK4X".Y8*_ZV,1P;@1WWZJ
MZ1ELJZG(='0,MSQ[0%6(&V\CU.8T8"79Z R/TK1>F?8\19WZZ'OJ?UMX[:Z,
M#J!U9\3VKTA$I.E*3_3O%[A2V"QOUB2L?OXD\Q-1C&#1U=732/;;LSI A:)G
ME"*33,DG:%[_V(KV3F.!-G =1<']#%E_DI_W>#DQ&2TY%XQX"*SZL!%\81E*
MTB:I+&4NK6<I/T=/IX'$P&9S5T6<ZEMHBS'I6_W>H[QN'F40^LO/449FPT3,
M0 BL;?\YUF#$U__DWHH8LFQ=Y#SX,^:Z9. _\")ORE7>SR\_A,7E>?EUNOPV
M7X:+5?'"JZM%/=83GXQFY'2 E+7_QV0ZGCX+.J-12^D"9[FU][<;A9UZ@WMA
MZ/'RCD%TU8%S2+)+B'GYAJ1:F3LOOP42]PP7W^^Y!BP(ZY@N9+[K!); ZYP^
M7T 3.\'&(K)J/;9D2](Z=>V:8&\([70 NNLE N>S]1&:5FV=E_5)(R_4!YY#
MAL1%K3]PF;P/CD"'IZ#4R4C9>@[_LP1UZK,U 5@[31P:#S3:\O!R^#-!:8),
MPH!&@76JK:8HASFP19;$<T+;?&'8-G1UFA9N K/F>CF%A0]GKUY]_/OK7]^]
M/?OE[;NWG]^^_G2W7I""]L45$3T-<7JQ*53>.VC8]U/-XX@F/+<*+<+WFFBN
MO=2K#X>+VU)S+KVP03&P6.H+ARD4YBH.1@8;N-&$OM;-2,^0LZ_9JT"8;(1Z
M?D42OEK4AO%7]/>FJ59"YP]T[#;_]>GR*M<">,V4M+H$0._K%N#HH"Y- YY0
M&>LD2N9?PML^'QXY1F@$AFO+-KCH.W#37I/IF7]',G^KW.*=8WL=[#@L@9P
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MK9/W'TV@8V)$8"A,";QUS<)C=(S[OMKZMCE8TAVBY?H,":NL<@&TK_/_E4Y
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M7Z>S:75)+J=_X@.F5"V%9P*8J_48Q7,*A)$!$X8'LO&"F]:M^EL1-NX+T7!
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M=&EO;F]F<V5C+FAT;5!+ 0(4 Q0    ( /TZ:5;Q-Q_Y.P,  (\2   2
M          "  <T;  !F>3(P,C(Q,&ME>#(Q,2YH=&U02P$"% ,4    " #]
M.FE6A2 &>B (  #"*P  $@              @ $X'P  9GDR,#(R,3!K97@S
M,3$N:'1M4$L! A0#%     @ _3II5OS?V(A'"   G#   !(
M ( !B"<  &9Y,C R,C$P:V5X,S$R+FAT;5!+ 0(4 Q0    ( /TZ:584T-E'
MAP8  "HD   2              "  ?\O  !F>3(P,C(Q,&ME>#,R,2YH=&U0
M2P$"% ,4    " #].FE6+(N&!'EE P"<9!T $0              @ &V-@
M=G)D;BTR,#(R,3(S,2YH=&U02P$"% ,4    " #].FE6>N=UB- 2   >RP
M$0              @ %>G , =G)D;BTR,#(R,3(S,2YX<V102P$"% ,4
M" #].FE6EI;SX;,>  "-*0$ %0              @ %=KP, =G)D;BTR,#(R
M,3(S,5]C86PN>&UL4$L! A0#%     @ _3II5LR6UR ]:P  7:\$ !4
M         ( !0\X# '9R9&XM,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M /TZ:5;EQAV(8 H  $@+   4              "  ;,Y! !V<F1N+3(P,C(Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( /TZ:5;"D3FAJ:0  '+F   4
M      "  45$! !V<F1N+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( /TZ
M:59;C?*UQ_P  )&""@ 5              "  2#I! !V<F1N+3(P,C(Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " #].FE65#PFSO*5  #,PP8 %0
M    @ $:Y@4 =G)D;BTR,#(R,3(S,5]P<F4N>&UL4$L%!@     .  X I ,
' #]\!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
